

SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORSCross-Reference to Related Applications

- 5 This application is related to U.S. Provisional Application Serial No. 60/047,570 filed May 22, 1997 and U.S. Application Serial No. 09/083,670 filed May 22, 1998.

10 Field of the Invention

 This invention relates to a novel group of pyrazole compounds, compositions and methods for treating p38 kinase mediated disorders.

15 Background of the Invention

- Mitogen-activated protein kinases (MAP) is a family of proline-directed serine/threonine kinases that activate their substrates by dual phosphorylation. The kinases are activated by a variety of signals including nutritional and osmotic stress, UV light, growth factors, endotoxin and inflammatory cytokines. The p38 MAP kinase group is a MAP family of various isoforms, including p38 α , p38 β and p38 γ , and is responsible for phosphorylating and activating transcription factors (e.g. ATF2, CHOP and MEF2C) as well as other kinases (e.g. MAPKAP-2 and MAPKAP-3). The p38 isoforms are activated by bacterial lipopolysaccharide, physical and chemical stress and by pro-inflammatory cytokines, including tumor necrosis factor (TNF- α) and interleukin-1 (IL-1). The products of the p38 phosphorylation mediate the production of inflammatory cytokines, including TNF and IL-1, and cyclooxygenase-2.

- TNF- α is a cytokine produced primarily by activated monocytes and macrophages. Excessive or unregulated TNF production has been implicated in mediating a number of diseases. Recent studies indicate that TNF has a

10041976594US

causative role in the pathogenesis of rheumatoid arthritis. Additional studies demonstrate that inhibition of TNF has broad application in the treatment of inflammation, inflammatory bowel disease, multiple sclerosis and asthma.

TNF has also been implicated in viral infections, such as HIV, influenza virus, and herpes virus including herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus, human herpesvirus-6 (HHV-6), human herpesvirus-7 (HHV-7), human herpesvirus-8 (HHV-8), pseudorabies and rhinotracheitis, among others.

IL-8 is another pro-inflammatory cytokine, which is produced by mononuclear cells, fibroblasts, endothelial cells, and keratinocytes, and is associated with conditions including inflammation.

IL-1 is produced by activated monocytes and macrophages and is involved in the inflammatory response. IL-1 plays a role in many pathophysiological responses including rheumatoid arthritis, fever and reduction of bone resorption.

TNF, IL-1 and IL-8 affect a wide variety of cells and tissues and are important inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines by inhibition of the p38 kinase is of benefit in controlling, reducing and alleviating many of these disease states.

Various pyrazoles have previously been described. U.S. Patent No. 4,000,281, to Beiler and Binon, describes 4,5-aryl/heteroaryl substituted pyrazoles with antiviral activity against both RNA and DNA viruses such as myxoviruses, adenoviruses, rhinoviruses, and various viruses of the herpes group. WO 92/19615, published November 12, 1992, describes pyrazoles as novel fungicides. U. S. Patent No. 3,984,431, to Cueremy and Renault, describes derivatives of pyrazole-5-acetic acid

as having anti-inflammatory activity. Specifically, [1-isobutyl-3,4-diphenyl-1H-pyrazol-5-yl]acetic acid is described. U. S. Patent No. 3,245,093 to Hinsgen et al, describes a process for preparing pyrazoles. WO 83/00330, published February 3, 1983, describes a new process for the preparation of diphenyl-3,4-methyl-5-pyrazole derivatives. WO 95/06036, published March 2, 1995, describes a process for preparing pyrazole derivatives. US patent 5,589,439, to T. Goto, et al., describes tetrazole derivatives and their use as herbicides. EP 515,041 describes pyrimidyl substituted pyrazole derivatives as novel agricultural fungicides. Japanese Patent 4,145,081 describes pyrazolecarboxylic acid derivatives as herbicides. Japanese Patent 5,345,772 describes novel pyrazole derivatives as inhibiting acetylcholinesterase.

Pyrazoles have been described for use in the treatment of inflammation. Japanese Patent 5,017,470 describes synthesis of pyrazole derivatives as anti-inflammatory, anti-rheumatic, anti-bacterial and anti-viral drugs. EP 115640, published Dec 30, 1983, describes 4-imidazolyl-pyrazole derivatives as inhibitors of thromboxane synthesis. 3-(4-Isopropyl-1-methylcyclohex-1-yl)-4-(imidazol-1-yl)-1H-pyrazole is specifically described. WO 97/01551, published Jan 16, 1997, describes pyrazole compounds as adenosine antagonists. 4-(3-Oxo-2,3-dihydropyridazin-6-yl)-3-phenylpyrazole is specifically described. U.S. Patent No. 5,134,142, to Matsuo et al. describes 1,5-diaryl pyrazoles as having anti-inflammatory activity.

U.S. Patent No. 5,559,137 to Adams et al, describes novel pyrazoles (1,3,4,-substituted) as inhibitors of cytokines used in the treatment of cytokine diseases. Specifically, 3-(4-fluorophenyl)-1-(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole is described. WO 96/03385, published February 8, 1996,

describes 3,4-substituted pyrazoles, as having anti-

inflammatory activity. Specifically, 3-methylsulfonylphenyl-4-aryl-pyrazoles and 3-


5 aminosulfonylphenyl-4-aryl-pyrazoles are described.

Laszlo et al., Bioorg. Med. Chem. Letters, 8 (1998) 2689-2694, describes certain furans, pyrroles and pyrazolones, particularly 3-pyridyl-2,5-diaryl-pyrroles, as inhibitors of p38 kinase.

10 The invention's pyrazolyl compounds are found to show usefulness as p38 kinase inhibitors.

Description of the Invention

15 A class of substituted pyrazolyl compounds useful in treating p38 mediated disorders is defined by Formula IA:



wherein

R¹ is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino,


20

25

10061780-10001

alkenylamino, alkynylamino, arylamino, heterocyclylamino,
 alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
 arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
 alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
 5 heterocyclylsulfonyl, alkylaminoalkylene,
 alkylsulfonylalkylene, acyl, acyloxycarbonyl,
 alkoxycarbonylalkylene, aryloxycarbonylalkylene,
 heterocyclylloxycarbonylalkylene, alkoxycarbonylarylene,
 aryloxycarbonylarylene, heterocyclylloxycarbonylarylene,
 10 alkylcarbonylalkylene, arylcarbonylalkylene,
 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
 arylcarbonylarylene, heterocyclylcarbonylarylene,
 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 15 arylcarbonyloxyarylene, and
 heterocyclylcarbonyloxyarylene; or

R^1 has the formula



wherein:

- 20 i is an integer from 0 to 9;
 R^{25} is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkylcarbonylalkylene, arylcarbonylalkylene, and
 25 heterocyclylcarbonylaminoalkylene; and
 R^{26} is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxycarbonylalkylene, and alkylaminoalkyl; and
 R^{27} is selected from alkyl, cycloalkyl, alkynyl,
 30 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
 alkylaralkyl, aralkylarylene, alkylheterocyclyl,

alkylheterocyclylalkylene, alkylheterocyclylarylene,
 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
 alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
 aryloxyarylene, aralkoxyarylene,
 5 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
 alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
 alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl,
 alkylaminoalkylene, arylaminocarbonylalkylene,
 alkoxyarylaminoalkylene, aminocarbonylalkylene,
 10 arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
 arylcarbonylalkylene, alkoxycarbonylarylene,
 aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
 arylcarbonylarylene, alkylarylcarbonylarylene,
 alkoxycarbonylheterocyclylarylene,
 15 alkoxycarbonylalkoxylarylene,
 heterocyclylcarbonylalkylarylene, alkylthioalkylene,
 cycloalkylthioalkylene, alkylthioarylene,
 aralkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, arylsulfonylaminoalkylene,
 20 alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
 heterocyclylalkylene, alkylheterocyclylarylene,
 alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
 aryloxycarbonylarylene, arylcarbonylarylene,
 25 alkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, and alkylsulfonylarylene groups
 are optionally substituted with one or more radicals
 independently selected from alkyl, halo, haloalkyl,
 alkoxy, keto, amino, nitro, and cyano; or
 30 R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
 is selected from aralkyl, aralkoxyalkylene,
 heterocyclylalkylene, alkylheterocyclylalkylene,
 alkoxycarbonylalkylene, alkylthioalkylene, and
 aralkylthioalkylene; wherein said aralkyl and
 35 heterocyclyl groups are optionally substituted with one
 or more radicals independently selected from alkyl and

nitro; or

- R^{26} and R^{27} together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and
- R^2 is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy, heterocycliloxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl,

alkoxycarbonylalkyl, alkoxycarbonylalkylamino,
 alkoxycarbonylheterocyclyl,
 alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino,
 alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
 5 alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl,
 aralkythio, heterocyclylalkylthio, aminoalkoxy,
 cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
 alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein
 the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and
 10 cycloalkenyl groups are optionally substituted with one
 or more radicals independently selected from halo, keto,
 amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl,
 aralkyl, heterocyclylalkyl, epoxyalkyl,
 amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy,
 15 haloalkyl, alkylamino, alkynylamino,
 alkylaminoalkylamino, heterocyclylalkylamino,
 alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,
 arylsulfonyl, and aralkylsulfonyl; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 20 cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y^-$;
- $C(O)-$;
- $C(O)-(CH_2)_y^-$;
- 25 - $C(O)-O-(CH_2)_y^-$;
- $(CH_2)_y-C(O)-$;
- $O-(CH_2)_y-C(O)-$;
- $NR^{202}-$;
- $NR^{202}-(CH_2)_y^-$;
- 30 - $(CH_2)_y-NR^{202}-$;
- $(CH_2)_y-NR^{202}-(CH_2)_z^-$;
- $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z^-$;
- $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z^-$;
- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z^-$;
- 35 - $S(O)_x-(CR^{202}R^{203})_y^-$;
- $(CR^{202}R^{203})_y-S(O)_x^-$;

-S(O)_x-(CR²⁰²R²⁰³)_y-O-;

-S(O)_x-(CR²⁰²R²⁰³)_y-C(O)-;

-O-(CH₂)_y-;

-(CH₂)_y-O-;

5 -S-;

-O-;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from
the group consisting of hydrido, halogen, hydroxy,
10 carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,
cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,
aralkyl, heterocyclylalkylene, alkylcarbonyl,
hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,
haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,
15 alkoxycarbonyl, carboxyalkylcarbonyl,
alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,
alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,
alkylamino, aralkylamino, alkylaminoalkylene,
aminocarbonyl, alkylcarbonylamino,
20 alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,
alkylaminoalkylcarbonylamino,
aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino,
alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene,
alkylimidocarbonyl, amidino, alkylamidino,
25 aralkylamidino, guanidino, guanidinoalkylene, or
alkylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido,
alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6
30 wherein y + z is less than or equal to 6; and


z is 0, 1 or 2; or

R² is -NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene,
and R²⁰⁵ is aryl; or

R² is -C(NR²⁰⁶)R²⁰⁷ wherein R²⁰⁶ is selected from
35 hydrogen and hydroxy, and R²⁰⁷ is selected from alkyl,
aryl and aralkyl; or

10021780-120701

R² has the formula:



wherein:

j is an integer from 0 to 8; and

5 m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and


10 R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

15 R³³ is selected from hydrogen, alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁹R⁴⁰, wherein R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and


20 R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R² is -CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and

25 R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



- 5 groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, 10 aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloaryl amino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, 15 aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxy carbonyl, aryloxy carbonyl, heterocyclyl oxy carbonyl, alkoxy carbonylamino, alkoxyaryl amino, alkoxyaralkyl amino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, 20 aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxy carbonyl heterocyclylamino, nitro, 25 alkylaminocarbonyl, alkylcarbonylamino, haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or -NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and
- 30 R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein

R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; and

further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and

further provided that R⁴ is not methylsulfonylphenyl or aminosulfonylphenyl; and

further provided that R¹ is not methylsulfonylphenyl; or


a pharmaceutically-acceptable salt or tautomer thereof.

In a subclass of interest, R² is as defined above, and

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino,

alkenylamino, alkynylamino, arylamino, heterocyclylamino,
 alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
 arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
 alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
 5 heterocyclylsulfonyl, alkylaminoalkylene,
 alkylsulfonylalkylene, acyl, acyloxycarbonyl,
 alkoxycarbonylalkylene, aryloxycarbonylalkylene,
 heterocyclylloxycarbonylalkylene, alkylcarbonylalkylene,
 arylcarbonylalkylene, heterocyclylcarbonylalkylene,
 10 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 arylcarbonyloxyarylene, and
 heterocyclylcarbonyloxyarylene; or

R^1 has the formula



wherein:

i is an integer from 0 to 9;

R^{25} is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 20 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkylcarbonylalkylene, arylcarbonylalkylene, and
 heterocyclylcarbonylaminoalkylene; and


R^{26} is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 25 alkoxycarbonylalkylene, and alkylaminoalkyl; and

R^{27} is selected from alkyl, cycloalkyl, alkynyl,
 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
 30 alkylaralkyl, aralkylarylene, alkylheterocyclyl,
 alkylheterocyclylalkylene, alkylheterocyclylarylene,
 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
 alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,


aryloxyarylene, aralkoxyarylene,
 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
 alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
 alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl,
 5 alkylaminoalkylene, arylaminocarbonylalkylene,
 alkoxyarylaminoalkylene, aminocarbonylalkylene,
 arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
 arylcarbonylalkylene, alkoxycarbonylarylene,
 aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
 10 arylcarbonylarylene, alkylarylcarbonylarylene,
 alkoxycarbonylheterocyclylarylene,
 alkoxycarbonylalkoxylarylene,
 heterocyclylcarbonylalkylarylene, alkylthioalkylene,
 cycloalkylthioalkylene, alkylthioarylene,
 15 aralkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, arylsulfonylaminoalkylene,
 alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
 heterocyclylalkylene, alkylheterocyclylarylene,
 20 alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
 aryloxycarbonylarylene, arylcarbonylarylene,
 alkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, and alkylsulfonylarylene groups
 are optionally substituted with one or more radicals
 25 independently selected from alkyl, halo, haloalkyl,
 alkoxy, keto, amino, nitro, and cyano; or
 R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
 is selected from aralkyl, aralkoxyalkylene,
 heterocyclylalkylene, alkylheterocyclylalkylene,
 30 alkoxycarbonylalkylene, alkylthioalkylene, and
 aralkylthioalkylene; wherein said aralkyl and
 heterocyclyl groups are optionally substituted with one
 or more radicals independently selected from alkyl and
 nitro; or
 35 R^{26} and R^{27} together with the nitrogen atom to which
 they are attached form a heterocycle, wherein said

heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclalkylene, alkylheterocyclalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylsulfonyl, aralkoxy, heterocyclalkoxy, amino, alkylamino, alkenylamino,

5
10
15

20

25


30

a pharmaceutically-acceptable salt or tautomer thereof.

35

preferably do not include those substituted pyrazoles disclosed in WO98/52940 published on November 26, 1998.

A subclass of compounds useful in treating p38 mediated disorders is defined by Formula I:




wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene,

heterocyclylcarbonylalkylene, alkylcarbonylarylene,
 arylcarbonylarylene, heterocyclylcarbonylarylene,
 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 5 arylcarbonyloxyarylene, and
 heterocyclylcarbonyloxyarylene; or

R^1 has the formula



wherein:

10 i is an integer from 0 to 9;

R^{25} is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkylcarbonylalkylene, arylcarbonylalkylene, and
 15 heterocyclylcarbonylaminoalkylene; and

R^{26} is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxy carbonylalkylene, and alkylaminoalkyl; and

R^{27} is selected from alkyl, cycloalkyl, alkynyl,
 20 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
 alkylaralkyl, aralkylarylene, alkylheterocyclyl,
 alkylheterocyclylalkylene, alkylheterocyclylarylene,
 25 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
 alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
 aryloxyarylene, aralkoxyarylene,
 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
 alkoxy carbonylalkylene, alkoxy carbonyl heterocyclyl,
 30 alkoxy carbonyl heterocyclyl carbonylalkylene, aminoalkyl,
 alkylaminoalkylene, arylaminocarbonylalkylene,
 alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene,
 arylaminocarbonylalkylene, alkylaminocarbonylalkylene,

- arylcarbonylalkylene, alkoxycarbonylarylene,
 aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
 arylcarbonylarylene, alkylarylcarbonylarylene,
 alkoxycarbonylheterocyclylarylene,
 5 alkoxycarbonylalkoxylarylene,
 heterocyclylcarbonylalkylarylene, alkylthioalkylene,
 cycloalkylthioalkylene, alkylthioarylene,
 aralkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, arylsulfonylaminoalkylene,
 10 alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
 heterocyclylalkylene, alkylheterocyclylarylene,
 alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
 aryloxycarbonylarylene, arylcarbonylarylene,
 15 alkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, and alkylsulfonylarylene groups
 are optionally substituted with one or more radicals
 independently selected from alkyl, halo, haloalkyl,
 alkoxy, keto, amino, nitro, and cyano; or
 20 R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
 is selected from aralkyl, aralkoxyalkylene,
 heterocyclylalkylene, alkylheterocyclylalkylene,
 alkoxycarbonylalkylene, alkylthioalkylene, and
 aralkylthioalkylene; wherein said aralkyl and
 25 heterocyclyl groups are optionally substituted with one
 or more radicals independently selected from alkyl and
 nitro; or
 R^{26} and R^{27} together with the nitrogen atom to which
 they are attached form a heterocycle, wherein said
 30 heterocycle is optionally substituted with one or more
 radicals independently selected from alkyl, aryl,
 heterocyclyl, heterocyclylalkylene,
 alkylheterocyclylalkylene, aryloxyalkylene,
 alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
 35 alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
 alkoxycarbonylamino; wherein said aryl,

heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

- 5 R² is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, 10 aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, cycloalkyl, cycloalkenyl, alkoxy, heterocycliloxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxyalkyl, 15 carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxycarbonylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; 20 wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, 25 epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

$$\begin{array}{c} R^{30} \\ | \\ -C-(CH_2)_j- \\ | \\ R^{31} \end{array} \quad \left[\begin{array}{c} H \\ | \\ C \\ | \\ R^{34} \end{array} \right]_m - N \begin{array}{l} \diagup R^{32} \\ \diagdown R^{33} \end{array} \quad (III)$$

```


    j is an integer from 0 to 8; and
5    m is 0 or 1; and

```

10 R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

20 R³⁴ is selected from hydrogen, alkyl, aminocarbonyl,
alkylaminocarbonyl, and arylaminocarbonyl; or

R³ is selected from pyridinyl, pyrimidinyl,
25 quinolinyl, purinyl,



(V)

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfanyl, arylsulfanyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxycarbonyl, aryloxycarbonyl, heterocyclylloxycarbonyl, alkoxycarbonylamino, alkoxyaralkylamino, aminosulfanyl, aminosulfonyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or -NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and further provided R⁴ is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

10 Compounds of Formula I and/or IA would be useful for, but not limited to, the treatment of any disorder or disease state in a human, or other mammal, which is excacerbated or caused by excessive or unregulated TNF or p38 kinase production by such mammal. Accordingly, the
15 present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula I and/or IA or a pharmaceutically acceptable salt thereof.

20 Compounds of Formula I and/or IA would be useful for, but not limited to, the treatment of inflammation in a subject, as an analgesic in the treatment of pain including but not limited to neuropathic pain, and for use as antipyretics for the treatment of fever.

25 Compounds of the invention would be useful to treat arthritis, including but not limited to, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, gouty arthritis and other
30 arthritic conditions. Such compounds would be useful for the treatment of pulmonary disorders or lung inflammation, including adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, silicosis, and chronic pulmonary inflammatory disease. The compounds
35 are also useful for the treatment of viral and bacterial infections, including sepsis, septic shock, gram negative

sepsis, malaria, meningitis, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), pneumonia, and herpesvirus. The compounds are also useful for the treatment of bone resorption diseases, such as osteoporosis, endotoxic shock, toxic shock syndrome, reperfusion injury, autoimmune disease including graft vs. host reaction and allograft rejections, cardiovascular diseases including atherosclerosis, myocardial infarction, thrombosis, congestive heart failure, and cardiac reperfusion injury, renal reperfusion injury, liver disease and nephritis, and myalgias due to infection.

The compounds are also useful for the treatment of influenza, multiple sclerosis, leukemia, lymphoma, diabetes, systemic lupus erythematosus (SLE), neuroinflammation, ischemia including stroke and brain ischemia, brain trauma, brain edema, skin-related conditions such as psoriasis, eczema, burns, dermatitis, keloid formation, scar tissue formation, and angiogenic disorders. Compounds of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis. The compounds would also be useful in the treatment of ophthalmic diseases, such as retinitis, retinopathies, uveitis, ocular photophobia, and of acute injury to the eye tissue. Compounds of the invention also would be useful for treatment of angiogenesis, including neoplasia; metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas,

including invantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone; diabetic nephropathy and cardiomyopathy; and disorders of the female reproductive system such as endometriosis. The compounds of the invention may also be useful for preventing the production of cyclooxygenase-2.

Compounds of the invention would be useful for the prevention or treatment of benign and malignant tumors/neoplasia including cancer, such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamus cell and basal cell cancers, prostate cancer, renal cell carcimoma, and other known cancers that affect epithelial cells throughout the body.

The compounds of the invention also would be useful for the treatment of certain central nervous system disorders such as Alzheimer's disease and Parkinson's disease.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

The present compounds may also be used in co-therapies, partially or completely, in place of other conventional anti-inflammatories, such as together with steroids, cyclooxygenase-2 inhibitors, DMARD's, immunosuppressive agents, NSAIDs, 5-lipoxygenase inhibitors, LTB₄ antagonists and LTA₄ hydrolase inhibitors.

As used herein, the term "TNF mediated disorder"

refers to any and all disorders and disease states in which TNF plays a role, either by control of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disorder mediated by TNF.


As used herein, the term "p38 mediated disorder" refers to any and all disorders and disease states in which p38 plays a role, either by control of p38 itself, or by p38 causing another factor to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to p38, would therefore be considered a disorder mediated by p38.

As TNF- β has close structural homology with TNF- α (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, the synthesis of both TNF- α and TNF- β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise.

A preferred class of compounds consists of those compounds of Formula I wherein

R¹ is selected from hydrido, lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower heterocyclyl, lower cycloalkylalkylene, lower haloalkyl, lower hydroxyalkyl, lower aralkyl, lower alkoxyalkyl, lower mercaptoalkyl, lower alkylthioalkylene, amino, lower alkylamino, lower arylamino, lower alkylaminoalkylene, and lower heterocyclylalkylene; or

R¹ has the formula



wherein:

i is 0, 1 or 2; and

R²⁵ is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclalkyl, lower alkoxyalkylene, lower phenoxyalkylene, lower aminoalkyl, lower alkylaminoalkyl, lower phenoxyaminoalkyl, lower alkylcarbonylalkylene, lower phenoxycarbonylalkylene, and lower heterocyclcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkoxycarbonylalkylene, and lower alkylaminoalkyl; and

R²⁷ is selected from lower alkyl, lower cycloalkyl, lower alkynyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocycl, lower phenylalkyl, lower cycloalkylalkylene, lower cycloalkenylalkylene, lower cycloalkylarylene, lower cycloalkylcycloalkyl, lower heterocyclalkylene, lower alkylphenylene, lower alkylphenylalkyl, lower phenylalkylphenylene, lower alkylheterocycl, lower alkylheterocyclalkylene, lower alkylheterocyclphenylene, lower phenylalkylheterocycl, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl, lower alkoxyheterocycl, lower alkoxyalkoxyphenylene, lower phenoxyphenylene, lower phenylalkoxyphenylene, lower alkoxyheterocyclalkylene, lower phenoxyalkoxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylheterocycl, lower alkoxycarbonylheterocyclcarbonylalkylene, lower aminoalkyl, lower alkylaminoalkylene, lower phenylaminocarbonylalkylene, lower alkoxyphenylaminocarbonylalkylene, lower

5 alkylphenoxy carbonylphenylene, lower
phenyl carbonylphenylene, lower
alkylphenyl carbonylphenylene, lower
alkoxy carbonyl heterocyclylphenylene,
alkoxy carbonyl alkoxyphenylene, lower

15 phenylsulfonylaminoalkylene, lower
alkylsulfonylphenylene, lower
alkylaminosulfonylphenylene; wherein said lower alkyl,
lower cycloalkyl, aryl selected from phenyl, biphenyl and
naphthyl, lower heterocyclyl, lower phenylalkyl, lower

25 heterocyclcylthiophenylene, lower
phenylthioalkylphenylene, and lower
alkylsulfonylphenylene groups are optionally substituted
with one or more radicals independently selected from
lower alkyl, halo, lower haloalkyl, lower alkoxy, keto,


R²⁷ is -CHR⁴⁶R⁴⁷ wherein R⁴⁶ is lower alkoxycarbonyl, and R⁴⁷ is selected from lower phenylalkyl, lower phenylalkoxyalkylene, lower heterocyclalkylene, lower alkylheterocyclalkylene, lower alkoxycarbonylalkylene, lower alkylthioalkylene, and lower phenylalkylthioalkylene; wherein said phenylalkyl and

heterocyclcyl groups are optionally substituted with one or more radicals independently selected from lower alkyl and nitro; or

- 5 R^{26} and R^{27} together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, heterocyclcyl, heterocyclcylalkylene, lower
- 10 alkylheterocyclcylalkylene, lower phenoxyalkylene, lower alkoxyphenylene, lower alkylphenoxyalkylene, lower alkylcarbonyl, lower alkoxy carbonyl, lower phenylalkoxycarbonyl, lower alkylamino and lower alkoxy carbonylamino; wherein said aryl selected from
- 15 phenyl, biphenyl and naphthyl, lower heterocyclcylalkylene and lower phenoxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, lower alkyl and lower alkoxy; and
- 20 R^2 is selected from hydrido, halogen, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, lower haloalkyl, lower hydroxyalkyl, 5- or 6-membered heterocyclcyl, lower alkylheterocyclcyl, lower heterocyclcylalkyl, lower alkylamino, lower alkynylamino, phenylamino, lower heterocyclcylamino, lower
- 25 heterocyclcylalkylamino, lower phenylalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkylaminoalkylamino, lower cycloalkyl, lower alkenyl, lower alkoxy carbonylalkyl, lower cycloalkenyl, lower carboxyalkylamino, lower alkoxy carbonyl, lower
- 30 heterocyclcylcarbonyl, lower alkoxy carbonylheterocyclcyl, lower alkoxy carbonylheterocyclcylcarbonyl, alkoxy carbonylalkyl, lower alkoxyalkylamino, lower alkoxy carbonylaminoalkylamino, lower heterocyclcylsulfonyl, lower heterocyclcylloxy, and lower
- 35 heterocyclcylthio; wherein the aryl, heterocyclcyl, heterocyclcylalkyl, cycloalkyl, and cycloalkenyl groups

are optionally substituted with one or more radicals independently selected from halo, keto, lower alkyl, lower alkynyl, phenyl, 5- or 6-membered heterocyclyl, lower phenylalkyl, lower heterocyclylalkyl, lower epoxyalkyl, carboxy, lower alkoxy, lower aryloxy, lower phenylalkoxy, lower haloalkyl, lower alkylamino, lower alkylaminoalkylamino, lower alkynylamino, lower amino(hydroxyalkyl), lower heterocyclylalkylamino, lower alkylcarbonyl, lower alkoxy carbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, and phenylsulfonyl; or

R² has the formula:



wherein:

j is 0, 1 or 2; and

m is 0;

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R³³ is selected from hydrogen, alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁹R⁴⁰;


wherein R³⁵ is selected from alkyl, cycloalkyl, haloalkyl, alkenyl, aryl, heterocyclyl, aralkyl, arylcycloalkyl, cycloalkenylalkylene,

heterocyclylalkylene, alkylarylene, alkylheterocyclyl, arylarylene, arylheterocyclyl, alkoxy, alkenoxy, alkoxyalkylene, alkoxyaralkyl, alkoxyarylene,

- aryloxyalkylene, aralkoxyalkylene, cycloalkyloxyalkylene, alkoxycarbonyl, heterocyclylcarbonyl, alkylcarbonyloxyalkylene, alkylcarbonyloxyarylene, alkoxycarbonylalkylene, alkoxycarbonylarylene,
- 5 aralkoxycarbonylheterocyclyl, alkylcarbonylheterocyclyl, arylcarbonyloxyalkylarylene, and alkylthioalkylene; wherein said aryl, heterocyclyl, aralkyl, alkylarylene, arylheterocyclyl, alkoxyarylene, aryloxyalkylene, cycloalkoxyalkylene, alkoxycarbonylalkylene, and
- 10 alkylcarbonylheterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; or
- R^{35} is $CHR^{48}R^{49}$ wherein R^{48} is arylsulfonylamino or
- 15 alkylarylsulfonylamino, and R^{49} is selected from aralkyl, amino, alkylamino, and aralkylamino; or
- R^{35} is $-NR^{50}R^{51}$ wherein R^{50} is alkyl, and R^{51} is aryl; and
- wherein R^{36} is selected from alkyl, haloalkyl, aryl,
- 20 heterocyclyl, cycloalkylalkylene, alkylarylene, alkenylarylene, arylarylene, aralkyl, aralkenyl, heterocyclylheterocyclyl, carboxyarylene, alkoxyarylene, alkoxycarbonylarylene, alkylcarbonylaminoarylene, alkylcarbonylaminoheterocyclyl,
- 25 arylcarbonylaminoalkylheterocyclyl, alkylaminoarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, alkylsulfonylaralkyl, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, cycloalkylalkylene, aralkyl, alkylcarbonylaminoheterocyclyl, and
- 30 alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and
- wherein R^{37} is selected from hydrogen and alkyl; and
- 35 wherein R^{38} is selected from hydrogen, alkyl, alkenyl, aryl, heterocyclyl, aralkyl, alkylarylene,

arylcycloalkyl, arylarylene, cycloalkylalkylene,
 heterocyclylalkylene, alkylheterocyclylalkylene,
 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
 aryloxyarylene, arylcarbonyl, alkoxycarbonyl,
 5 alkoxycarbonylalkylene, alkoxycarbonylarylene,
 alkylcarbonylcarbonylalkylene, alkylaminoalkylene,
 alkylaminoaralkyl, alkylcarbonylaminoalkylene,
 alkylthioarylene, alkylsulfonylaralkyl, and
 aminosulfonylaralkyl; wherein said aryl, heterocyclyl,
 10 aralkyl, and heterocyclylalkylene groups are optionally
 substituted with one or more radicals independently
 selected from alkyl, halo, hydroxy, haloalkyl, alkoxy,
 haloalkoxy, keto, amino, nitro, and cyano; or
 R^{38} is $-CR^{52}R^{53}$ wherein R^{52} is alkoxycarbonyl, and R^{53}
 15 is alkylthioalkylene; or
 R^{37} and R^{38} together with the nitrogen atom to which
 they are attached form a heterocycle; and
 R^{39} and R^{40} have the same definition as R^{26} and R^{27} in
 claim 1; or
 20 R^2 is $-CR^{54}R^{55}$ wherein R^{54} is phenyl and R^{55} is hydroxy;
 or

R^2 is selected from the group consisting of



25

wherein

k is an integer from 0 to 3; and
 R^{56} is hydrogen or lower alkyl; and
 R^{57} is hydrogen or lower alkyl; or
 R^{56} and R^{57} form a lower alkylene bridge; and


R^{58} is selected from hydrogen, alkyl, aralkyl, aryl, heterocyclyl, heterocyclylalkyl, alkoxycarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, $-C(O)R^{59}$, $-SO_2R^{60}$, and $-C(O)NHR^{61}$;

5 wherein R^{59} is selected from alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, alkylarylene, aralkyl, alkylheterocyclyl, alkoxy, alkenoxy, aralkoxy, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl; wherein said aryl, heterocyclyl, and aralkyl groups are
10 optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

 wherein R^{60} is selected from alkyl, aryl,
15 heterocyclyl, alkylarylene, alkylheterocyclyl, aralkyl, heterocyclylheterocyclyl, alkoxyarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, and aralkyl groups are optionally
20 substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

 wherein R^{61} is selected from alkyl, aryl, alkylarylene, and alkoxyarylene; wherein said aryl group
25 is optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

30 R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, and



wherein R^{43} is selected from hydrogen, lower alkyl, lower aminoalkyl, lower alkoxyalkyl, lower alkenoxyalkyl and lower aryloxyalkyl; and

wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkylsulfonyl, aminosulfonyl, halo, lower alkyl, lower aralkyl, lower phenylalkenyl, lower phenylheterocyclyl, carboxy, lower alkylsulfinyl, cyano, lower alkoxy, amino, lower cycloalkylamino, lower alkylamino, lower alkenylamino, lower alkynylamino, lower aminoalkyl, arylamino, lower aralkylamino, nitro, halosulfonyl, lower alkylcarbonyl, lower alkoxyphenylalkylamino, lower alkylaminoalkylamino, lower hydroxyalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower phenylalkylheterocyclylamino, lower alkylaminocarbonyl, lower alkoxyphenylalkylamino, hydrazinyl, lower alkylhydrazinyl, or $-NR^{62}R^{63}$ wherein R^{62} is lower alkylcarbonyl or amino, and R^{63} is lower alkyl or lower phenylalkyl; and

R^4 is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, aryl selected from phenyl, biphenyl, and naphthyl, and 5- or 6- membered heterocyclyl; wherein the lower cycloalkyl, lower cycloalkenyl, aryl and 5-10 membered heterocyclyl groups of R^4 are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkylsulfonyl, lower alkylsulfinyl, halo, lower alkyl, lower alkynyl, lower alkoxy, lower aryloxy, lower aralkoxy, lower heterocyclyl, lower haloalkyl, amino, cyano, nitro, lower alkylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of particular interest consists of these compounds of Formula I wherein

- R^1 is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloroethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and
- R^2 is selected from hydrido, chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, phenyl, biphenyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxymethyl, hydroxyethyl, pyridinyl, isothiazolyl, isoxazolyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl, N-methylpiperazinyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-n-propylamino, N,N-dimethylamino, N-methyl-N-phenylamino, N-phenylamino, piperadinylamino, N-benzylamino, N-

A class of compounds of particular interest consists of these compounds of Formula I wherein

- R^1 is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloroethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and
- R^2 is selected from hydrido, chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, phenyl, biphenyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxymethyl, hydroxyethyl, pyridinyl, isothiazolyl, isoxazolyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl, N-methylpiperazinyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-n-propylamino, N,N-dimethylamino, N-methyl-N-phenylamino, N-phenylamino, piperadinylamino, N-benzylamino, N-

- propargylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, N,N-
- 5 dimethylaminoethylamino, N,N-dimethylaminopropylamino, morpholinylethylamino, morpholinylpropylamino, carboxymethylamino, methoxyethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, 1,1-dimethylethoxycarbonyl, 1,1-
- 10 dimethylethoxycarbonylaminoethylamino, 1,1-dimethylethoxycarbonylaminoethylamino, piperazinylcarbonyl, and 1,1-dimethylethoxycarbonylpiperazinylcarbonyl; wherein the aryl, heteroaryl, cycloalkyl and cycloalkenyl groups are
- 15 optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, isopropyl, tert-butyl, isobutyl, benzyl, carboxy, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl,
- 20 dimethylamino, methoxycarbonyl, ethoxycarbonyl, and 1,1-dimethylethylcarbonyl; or
- R^2 is $-CR^{54}R^{55}$ wherein R^{54} is phenyl and R^{55} is hydroxy; and
- R^3 is selected from pyridinyl, pyrimidinyl, and
- 25 purinyl; wherein R^3 is optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, aminosulfonyl, methyl, ethyl, isopropyl, tert-butyl, isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl,
- 30 aminocarbonyl, methylcarbonylamino, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, hydroxy, fluorophenylmethyl, fluorophenylethyl, chlorophenylmethyl, chlorophenylethyl,
- 35 fluorophenylethenyl, chlorophenylethenyl, fluorophenylpyrazolyl, chlorophenylpyrazolyl, carboxy,

methoxy, ethoxy, propyloxy, n-butoxy, methylamino, ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl, aminoethyl, N-methyl-N-phenylamino, phenylamino, 5 diphenylamino, benzylamino, phenethylamino, cyclopropylamino, nitro, chlorosulfonyl, amino, methylcarbonyl, methoxycarbonylamino, ethoxycarbonylamino, methoxyphenylmethylamino, N,N-dimethylaminoethylamino, hydroxypropylamino, 10 hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, 15 methylaminocarbonyl, ethylaminocarbonyl, methylcarbonyl, methoxyphenylmethylamino, hydrazinyl, 1-methylhydrazinyl, or $-NR^{62}R^{63}$ wherein R^{62} is methylcarbonyl or amino, and R^{63} is methyl, ethyl or phenylmethyl; and R^4 is selected from hydrido, cyclopropyl, cyclobutyl, 20 cyclopentyl, cyclohexyl, cyclopropylenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, 25 isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl 30 groups of R^4 are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, 35 fluoromethyl, difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Another class of compounds of particular interest
5 consists of these compounds of Formula I wherein

R¹ is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R² is selected from hydrido, methyl, ethyl, propyl,
10 phenyl, trifluoromethyl, methoxycarbonylethyl, N,N-dimethylamino, N-phenylamino, piperidinyl, piperazinyl, pyridinyl, N-methylpiperazinyl, and piperazinylamino; wherein the phenyl, piperidinyl, and pyridinyl groups are optionally substituted with one or more radicals
15 independently selected from fluoro, chloro, bromo, methyl, ethyl, and trifluoromethyl;

R³ is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³ is optionally substituted with one or more radicals independently selected from fluoro,
20 bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl;

R⁴ is selected from phenyl, quinolyl, biphenyl,
25 pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴ are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro,
30 bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

35


A class of compounds of specific interest consists

R¹ is hydrido or methyl;
R² is selected from hydrido, methyl or ethyl;
R³ is selected from pyridinyl, pyrimidinyl or
5 quinolinyl; wherein R³ is optionally substituted with one
or more radicals independently selected from fluoro,
bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl,
benzyl, phenethyl, acetyl, hydroxyl, methoxy,
dimethylamino, benzylamino, phenethylamino, aminomethyl,
10 amino, hydroxy, and methylcarbonyl;
R⁴ is selected from phenyl which is optionally
substituted with one or more radicals independently
selected from methylthio, fluoro, chloro, bromo, methyl,
ethyl, methoxy, ethoxy, phenoxy, benzyloxy,
15 trifluoromethyl, nitro, dimethylamino, and hydroxy; or
a pharmaceutically-acceptable salt or tautomer
thereof.

Still another class of compounds of particular interest consists of those compounds of Formula I wherein R^1 is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloroethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl,

hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and

R² has the formula:



5 wherein:

j is 0, 1 or 2; and

m is 0; and

R³⁰ and R³¹ are independently selected from hydrogen and lower alkyl;

10 R³² is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclalkyl, lower alkoxyalkylene, aryloxyalkylene, aminoalkyl, lower alkylaminoalkyl, lower phenylaminoalkyl, lower alkylcarbonylalkylene, lower phenylcarbonylalkylene, and
15 lower heterocyclcarbonylaminoalkylene;

R³³ is selected from hydrogen, lower alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁹R⁴⁰;

 wherein R³⁵ is selected from lower alkyl, lower cycloalkyl, lower haloalkyl, lower alkenyl, aryl selected
20 from phenyl, biphenyl and naphthyl, lower heterocycl, lower phenylalkyl, lower phenylcycloalkyl, lower cycloalkenylalkylene, lower heterocyclalkylene, lower alkylphenylene, lower alkylheterocycl, phenylphenylene, lower phenylheterocycl, lower alkoxy, lower alkenoxy,
25 lower alkoxyalkylene, lower alkoxyphenylalkyl, lower alkoxyphenylene, lower phenoxyalkylene, lower phenylalkoxyalkylene, lower cycloalkyloxyalkylene, lower alkoxycarbonyl, lower heterocyclcarbonyl, lower alkylcarbonyloxyalkylene, lower
30 alkylcarbonyloxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower phenylalkoxycarbonylheterocycl, lower

alkylcarbonylheterocyclyl, lower
 phenylcarbonyloxyalkylphenylene, and lower
 alkylthioalkylene; wherein said aryl selected from
 phenyl, biphenyl and naphthyl, lower heterocyclyl, lower
 5 phenylalkyl, lower alkylphenylene, lower
 phenylheterocyclyl, lower alkoxyphenylene, lower
 phenoxyalkylene, lower cycloalkoxyalkylene, lower
 alkoxycarbonylalkylene, and lower
 alkylcarbonylheterocyclyl groups are optionally
 10 substituted with one or more radicals independently
 selected from lower alkyl, halo, lower haloalkyl, lower
 alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano;
 or
 R^{35} is $CHR^{48}R^{49}$ wherein R^{48} is phenylsulfonylamino or
 15 lower alkylphenylsulfonylamino, and R^{49} is selected from
 lower phenylalkyl, amino, lower alkylamino, and lower
 phenylalkylamino; or
 R^{35} is $-NR^{50}R^{51}$ wherein R^{50} is lower alkyl, and R^{51} is
 aryl selected from phenyl, biphenyl and naphthyl; and
 20 wherein R^{36} is selected from lower alkyl, lower
 haloalkyl, aryl selected from phenyl, biphenyl and
 naphthyl, lower heterocyclyl, lower cycloalkylalkylene,
 lower alkylphenylene, lower alkenylphenylene,
 phenylphenylene, lower phenylalkyl, lower phenylalkenyl,
 25 lower heterocyclylheterocyclyl, carboxyphenylene, lower
 alkoxyphenylene, lower alkoxycarbonylphenylene, lower
 alkylcarbonylaminophenylene, lower
 alkylcarbonylaminoheterocyclyl, lower
 phenylcarbonylaminoalkylheterocyclyl, lower
 30 alkylaminophenylene, lower alkylamino, lower
 alkylaminophenylene, lower alkylsulfonylphenylene, lower
 alkylsulfonylphenylalkyl, and lower
 phenylsulfonylheterocyclyl; wherein said aryl selected
 from phenyl, biphenyl and naphthyl, lower heterocyclyl,
 35 lower cycloalkylalkylene, lower phenylalkyl, lower
 alkylcarbonylaminoheterocyclyl, and lower

alkylsulfonylphenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R^{37} is selected from hydrogen and lower alkyl; and


wherein R^{38} is selected from hydrogen, lower alkyl, lower alkenyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylcycloalkyl, phenylphenylene, lower cycloalkylalkylene, lower heterocyclalkylene, lower alkylheterocyclalkylene, lower phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower phenoxyphenylene, phenylcarbonyl, lower alkoxycarbonyl, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower alkylcarbonylcarbonylalkylene, lower alkylaminoalkylene, lower alkylaminophenylalkyl, lower alkylcarbonylaminoalkylene, lower alkylthiophenylene, lower alkylsulfonylphenylalkyl, and lower aminosulfonylphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, and lower heterocyclalkylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

R^{38} is $-CR^{52}R^{53}$ wherein R_{52} is lower alkoxycarbonyl, and R_{53} is lower alkylthioalkylene; or

R^{37} and R^{38} together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle;

R^{39} and R^{40} have the same definition as R^{26} and R^{27} in claim 2; or

R^2 is selected from the group consisting of



(VI)

(VII)

(VIII)

wherein

k is an integer from 0 to 2; and

5 R^{56} is hydrogen or lower alkyl; and

R^{57} is hydrogen or lower alkyl; and

10 R^{58} is selected from hydrogen, lower alkyl, lower phenylalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower heterocyclylalkyl, lower alkoxycarbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, lower phenylsulfonyl, $-\text{C}(\text{O})\text{R}^{59}$, $-\text{SO}_2\text{R}^{60}$, and $-\text{C}(\text{O})\text{NHR}^{61}$;

15 wherein R^{59} is selected from lower alkyl, lower haloalkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower alkylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower alkoxy, lower alkenoxy, lower phenylalkoxy, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl; wherein said
 20 aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, and lower phenylalkyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino,
 25 nitro, and cyano; and

wherein R^{60} is selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower alkylphenylene, lower alkylheterocyclyl, lower phenylalkyl, lower

5
10

15


20
25
30
35

Still another class of compounds of particular
35 interest consists of those compounds of Formula I wherein
R¹ is hydrido, methyl, ethyl, propargyl,

35 interest consists of those compounds of Formula I wherein
R¹ is hydrido, methyl, ethyl, propargyl,

hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R² has the formula:



5 wherein:

j is 0, 1 or 2; and

m is 0; and

R³⁰ is hydrogen; and

R³¹ is selected from hydrogen and lower alkyl; and

10 R³² is selected from hydrogen and lower alkyl; and

R³³ is selected from lower alkyl, -C(O)R³⁵, -C(O)OR³⁵,
-SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁹R⁴⁰;

wherein R³⁵ is selected from lower alkyl, lower
cycloalkyl, phenyl, lower heterocyclyl, lower

15 alkylphenylene, lower alkoxy, lower alkenoxy, lower
alkoxyalkylene, lower phenoxyalkylene, and lower
phenylalkoxyalkylene; wherein said phenyl and lower
phenoxyalkylene groups are optionally substituted with
one or more radicals independently selected from lower
20 alkyl, halo, and lower haloalkyl; and

wherein R³⁶ is selected from lower alkyl, phenyl,
lower heterocyclyl, lower alkylphenylene,
phenylphenylene, lower phenylalkyl, lower
alkylheterocyclyl, lower heterocyclylheterocyclyl, lower

25 alkoxyphenylene, and lower alkylamino; wherein said
phenyl and lower heterocyclyl groups are optionally
substituted with one or more radicals independently
selected from lower alkyl, halo, hydroxy, lower
haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino,
30 nitro, and cyano; and


wherein R³⁷ is hydrogen; and

wherein R³⁸ is selected from lower alkyl, phenyl, and

lower alkylphenylene;

wherein R^{39} and R^{40} have the same definition as R^{26} and R^{27} in claim 2; or

R^2 is selected from the group consisting of



(VI)

(VII)

(VIII)

wherein

k is an integer from 0 or 1; and

R^{56} is hydrogen; and

10 R^{57} is hydrogen; and

R^{58} is selected from $-C(O)R^{59}$ and $-SO_2R^{60}$;

15 wherein R^{59} is selected from lower alkyl, lower cycloalkyl, phenyl, lower alkylphenylene, and lower alkoxyalkylene; wherein said phenyl group is optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R^{60} is selected from lower alkyl; and

20 R^3 is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R^3 is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl; and

25 R^4 is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the

cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R^4 are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy,

5 benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

10 Still another class of compounds of specific interest consists of those compounds of Formula I wherein R^1 is hydrido or methyl; and

R^3 is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R^3 is optionally substituted with one
15 or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl; and

20 R^4 is selected from phenyl which is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

25 a pharmaceutically-acceptable salt or tautomer thereof.

In one embodiment of the present invention, the compounds of Formula I and/or 1A satisfy one or more of
30 the following conditions:

R^1 is hydrido or lower alkyl; more preferably, R^1 is hydrido or methyl; and still more preferably, R^1 is hydrido;

35 R^2 is hydrido or lower alkyl; more preferably, R^2 is hydrido or methyl; and still more preferably, R^2 is hydrido;

TOC-03-0001

R² comprises a piperidinyl, piperazinyl or cyclohexyl moiety;

R³ is substituted or unsubstituted pyridinyl; and preferably, the pyridinyl is a 4-pyridinyl; or

5 R⁴ is substituted or unsubstituted phenyl; and preferably, R⁴ is phenyl substituted with halo.

In addition, where R³ is substituted pyrimidinyl, preferably at least one R³ substituent is attached to the carbon atom positioned between two nitrogen atoms of the
10 pyrimidinyl ring.

A family of specific compounds of particular interest within Formula I and/or 1A consists of compounds, tautomers and pharmaceutically-acceptable
15 salts thereof as follows:

4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;
20 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-methyl-3-[4-(methylthio)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
25 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
30 4-[3-methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-[(1,1'-biphenyl)-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine;
35 4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine;

- 4- [3-methyl-5- [2- (phenylmethoxy) phenyl] -1H-pyrazol-4-yl]pyridine;
 2- [3-methyl-4- (4-pyridinyl) -1H-pyrazol-4-yl]phenol;
 3- [3-methyl-4- (4-pyridinyl) -1H-pyrazol-4-yl]phenol;
 5 1-hydroxy-4- (3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium;
 5- (4-fluorophenyl) -N, N-dimethyl-4- (4-pyridinyl) -1H-pyrazol-3-amine;
 5- (4-fluorophenyl) -N-phenyl-4- (4-pyridinyl) -1H-pyrazol-3-amine;
 10 4- [5- (4-fluorophenyl) -3-phenyl-1H-pyrazol-4-yl]pyridine;
 4- [5- (3-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-4-yl]pyridine;
 4- [3- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-5-yl]pyridine;
 15 4- (5-cyclohexyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
 4- [5- (3-fluoro-5-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
 4- [5- (3-methylphenyl) -3-propyl-1H-pyrazol-4-yl]pyridine;
 4- [(3-methyl-5-phenyl-1H-pyrazol-4-yl)methyl]pyridine;
 20 4- [3,5-bis (3-methylphenyl) -1H-pyrazol-4-yl]pyridine;
 4- [4-methyl-2- (2-trifluorophenyl) -1H-pyrazol-4-yl]pyridine;
 4- [3- (2-chlorophenyl) -5-methyl-1H-pyrazol-4-yl]pyridine;
 4- [5-methyl-3- (2,4-dimethylphenyl) -1H-pyrazol-4-yl]pyridine;
 25 4- [5- (4-chlorophenyl) -1,3-dimethyl-1H-pyrazol-4-yl]pyridine;
 4- [3- (3-fluoro-2-methylphenyl) -5-methyl-1H-pyrazol-4-yl]pyridine;
 30 4- [3- (3,5-dimethylphenyl) -5-methyl-1H-pyrazol-4-yl]pyridine;
 4- [3- (3,5-dimethoxyphenyl) -5-methyl-1H-pyrazol-4-yl]pyridine;
 4- [5-methyl-3- (3-nitrophenyl) -1H-pyrazol-4-yl]pyridine;
 35 N,N-dimethyl-4- [5-methyl-4- (4-pyridinyl) -1H-pyrazol-3-yl]benzenamine;

4- [3- (2,3-dihydrobenzofuran-5-yl) -5-methyl-1H-pyrazol-4-yl]pyridine;
4- [3- (4-bromophenyl) -5-methyl-1H-pyrazol-4-yl]pyridine;
4- [3- (2-fluorophenyl) -5-methyl-1H-pyrazol-4-yl]pyridine;
5 4- [3- (3-fluorophenyl) -5-methyl-1H-pyrazol-4-yl]pyridine;
4- [3-methyl-5- [3- (trifluoromethyl)phenyl] -1H-pyrazol-4-yl]pyridine;
4- (3-ethyl-4-phenyl-1H-pyrazol-4-yl)pyridine;
4- [5- (3-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
10 4- [3-ethyl-5- (3-methylphenyl) -1H-pyrazol-4-yl]pyridine;
4- [5- (3,4-difluorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
4- [5- (3-ethoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
4- [3-methyl-5- [4- (trifluoromethyl)phenyl] -1H-pyrazol-4-yl]pyridine;
15 4- [3-methyl-5- (3-thienyl) -1H-pyrazol-4-yl]pyridine;
4- [5- (2,4-dichlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
4- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
20 4- [5- (3-chloro-4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
ethyl 3- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazole-5-propanoate;
4- [3- (4-fluorophenyl) -1-methyl-pyrazol-4-yl]pyridine;
25 5- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5- [3-methyl-5- (3-methylphenyl) -1H-pyrazol-4-yl]pyrimidin-2-amine;
5- [3-methyl-5- (2-methylphenyl) -1H-pyrazol-4-yl]pyrimidin-2-amine;
30 5- [5- (4-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5- [5- (4-fluorophenyl) -3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
35 5- [5- (4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;

- 5- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 4- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 5 4- [5- (3-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 4- [5- (2-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 4- [5- (4-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 10 4- [5- (4-fluorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 4- [5- (4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 15 5- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl] -2-methoxypyridine;
- 2-methoxy-5- [3-methyl-5- (3-methylphenyl) -1H-pyrazol-4-yl]pyridine;
- 2-methoxy-5- [5- (4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 20 4- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl] -2-methoxypyridine;
- 2-methoxy-4- [3-methyl-5- (3-methylphenyl) -1H-pyrazol-4-yl]pyridine;
- 25 2-methoxy-4- [3-methyl-5- (2-methylphenyl) -1H-pyrazol-4-yl]pyridine;
- 4- [5- (4-chlorophenyl) -3-methyl-1H-pyrazol-4-yl] -2-methoxypyridine;
- 4- [5- (4-fluorophenyl) -3-methyl-1H-pyrazol-4-yl] -2-methoxypyridine;
- 30 2-methoxy-4- [3-methyl-5- (4-methylphenyl) -1H-pyrazol-4-yl]pyridine;
- 5- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
- 35 4- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

- 4- [5- (3-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-
ol;
4- [5- (2-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-
ol;
5 4- [5- (4-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-
ol;
4- [5- (4-fluorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-2-
ol;
4- [5- (4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridin-
10 2-ol;
5- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-methanamine;
4- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-methanamine;
15 4- [5- (3-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-methanamine;
4- [5- (2-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-methanamine;
4- [5- (4-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
20 2-methanamine;
4- [5- (4-fluorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-methanamine;
4- [5- (4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-methanamine;
25 5- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-carboxamide;
4- [5- (3-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-carboxamide;
4- [5- (3-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
30 2-carboxamide;
4- [5- (2-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-carboxamide;
4- [5- (4-chlorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-carboxamide;
35 4- [5- (4-fluorophenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-
2-carboxamide;

- 4- [5- (4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- 4- [5- (3-fluoro-4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 5 4- [5- (4-fluoro-3-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- [5- (4-chloro-3-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- [5- (2,3-dihydrobenzofuran-6-yl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 10 4- [5- (benzofuran-6-yl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- [5- (3-fluoro-5-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- [5- (3-chloro-5-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 15 4- [5- (1-cyclohexen-1-yl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- [5- (1,3-cyclohexadien-1-yl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 20 4- [5- (5,6-dihydro-2H-pyran-4-yl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- (5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine;
- 4- [5- (4-methoxy-3-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 25 4- [5- (3-methoxy-4-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- [5- (3-methoxy-5-methylphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 4- [5- (3-furyl) -3-methyl-1H-pyrazol-4-yl]pyridine;
- 30 2-methyl-4- (3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
- 2-methoxy-4- (3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
- methyl 4- (3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxylate;
- 4- (3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxamide;
- 35 1- [4- (3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-2-

pyrazol-3-amine monohydrate;
1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-
1H-pyrazol-3-yl]-1-piperazinecarboxylate;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
5 yl]piperazine trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
methylpiperazine;
1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-
1H-pyrazol-3-yl]-1-piperazinecarboxylate;
10 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
yl]piperazine trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
yl]piperazine;
N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-
15 pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine,
trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
(phenylmethyl)piperazine;
4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-
20 yl]pyrimidine, dihydrochloride;
1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(4-
pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate;
N-[5-[4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-
1,3-propanediamine, trihydrochloride monohydrate;
25 1,1-dimethylethyl [2-[[5-(4-chlorophenyl)-4-(4-
pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]carbamate;
1,1-dimethylethyl 4-[5-(4-chlorophenyl)-1-(2-
hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-
piperazinecarboxylate;
30 1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-
pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-
pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
35 ethylpiperazine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-

- 1,2-ethanediamine;
- 4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
- 4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
- 5 4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine;
- 4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine;
- 4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine;
- 10 4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
- 4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine;
- 4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
- 15 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
- 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
- 4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
- 20 1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
- Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate;
- 25 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid;
- 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
- 4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine
- 30 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid;
- 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol;
- 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine;
- 35 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-

- 1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate;
 4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine;
 4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
 4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-
 5 yl]pyridine;
 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-
 yl]pyridine;
 4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-
 yl]pyridine;
 10 4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-
 yl]pyridine;
 4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-
 yl]pyridine;
 4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-
 15 yl]pyridine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
 3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-
 20 ethanol;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
 pyridinyl]amino]-1-butanol;
 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-
 25 yl]pyridine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
 pyridinecarbonitrile;
 4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-
 yl]ethyl]morpholine;
 30 3-(4-fluorophenyl)-1-methyl- α -phenyl-4-(4-pyridinyl)-1H-
 pyrazole-5-methanol;
 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
 morpholineethanamine;
 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone
 35 hydrazone;
 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-

- 2-pyridinamine;
 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine;
 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide;
 Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid;
 4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(1,3-benzodioxol-5-yl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine;
 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine;
 4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 2-methyl-4-[1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 2-methyl-4-[1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
 4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
 4-[1-methyl-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
 4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine;

- 4- [3- (4-bromophenyl) -1H-pyrazol-4-yl]pyridine;
4- [3- (3,4-difluorophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine;
4- [3- (4-bromophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine;
5 (E) -4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2- (2-phenyleth-
enyl)pyridine;
(S) -4- [3- (4-chlorophenyl) -1H-pyrazol-4-yl] -N- (2-methylbut-
yl) - 2-pyridinamine;
4- [3- (4-chlorophenyl) -1H-pyrazol-4-yl] -N- [(4-methoxy-
10 phenyl)methyl] - 2-pyridinamine;
N- [4- [3- (4-chlorophenyl) -1H-pyrazol-4-yl] -2-pyridinyl] -
2-pyridinemethanamine;
N- [4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinyl] -
2-pyridinemethanamine;
15 2-fluoro-4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl]pyridine;
4- [3- (4-iodophenyl) -1H-pyrazol-4-yl]pyridine;
4- [3- (4-iodophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine;
4- [1-methyl-3- [4- (trifluoromethyl)phenyl] -1H-pyrazol-4-yl]
pyridine;
20 N- [1- (4-fluorophenyl) ethyl] -4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinamine;
N- [(3-fluorophenyl)methyl] -4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinamine;
4- [3- (4-fluorophenyl) -1-methyl-1H-pyrazol-4-yl] -2- (1-
25 methylhydrazino)pyridine;
2-fluoro-4- [3- (4-fluorophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine;
4- [3- (3,4-difluorophenyl) -1H-pyrazol-4-yl] -2-fluoropyridine;
30 4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -3-methylpyridine;
4- [3- (4-fluorophenyl) -1-methyl-1H-pyrazol-4-yl] -3-methylpyridine;
4- [3- (3,4-difluorophenyl) -1-methyl-1H-pyrazol-4-yl] -2-fluoropyridine;
35 3- (4-fluorophenyl) -N,N-dimethyl-4- (4-pyridinyl) -1H-pyrazole-1-ethanamine;

- 2- [2- (4-fluorophenyl) ethyl] -4- [3- (4-fluorophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine;
 4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N- [1- (phenylmethyl) -4-piperidinyl] -2-pyridinamine;
 5 N' - [4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinyl] -N,N-dimethyl-1,2-ethanediamine;
 2,4-bis[3- (4-fluorophenyl) -1H-pyrazol-4-yl]pyridine;
 N- [4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinyl] -4-morpholineethanamine;
 10 3- (4-fluorophenyl) -4- (2-fluoro-4-pyridinyl) -1H-pyrazole-1-ethanol;
 4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N- [2- (1H-imidazol-1-yl) ethyl] -2-pyridinamine;
 4- [2- [3- (4-fluorophenyl) -4- (2-fluoro-4-pyridinyl) -1H-pyrazol-1-yl] ethyl] morpholine;
 15 (E) -3- (4-fluorophenyl) -4- [2- [2- (4-fluorophenyl) ethenyl] -4-pyridinyl] -1H-pyrazole-1-ethanol;
 3- (4-fluorophenyl) -4- (2-fluoro-4-pyridinyl) -N,N-dimethyl-1H-pyrazole-1-ethanamine;
 20 3- (4-fluorophenyl) -4- [2- [2- (4-fluorophenyl) ethyl] -4-pyridinyl] -1H-pyrazole-1-ethanol;
 4- [1- [2- (dimethylamino) ethyl] -3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N,N-dimethyl-2-pyridinamine;
 4- [1- [2- (dimethylamino) ethyl] -3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N- [(4-fluorophenyl) methyl] -2-pyridinamine;
 25 3- (4-fluorophenyl) -4- [2- [2- (4-fluorophenyl) ethyl] -4-pyridinyl] -N,N-dimethyl-1H-pyrazole-1-ethanamine;
 N- [(4-fluorophenyl) methyl] -4- [3 (or 5) - (4-fluorophenyl) -1- [2- (4-morpholinyl) ethyl] -1H-pyrazol-4-yl] -2-pyridinamine;
 30 4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N-4-piperidinyl-2-pyridinamine;
 N,N-diethyl-3- (4-fluorophenyl) -4- (2-fluoro-4-pyridinyl) -1H-pyrazole-1-ethanamine;
 35 4- [1- [2- (diethylamino) ethyl] -3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N- [(4-fluorophenyl) methyl] -2-pyridinamine;

- 2-[[4-[3-(4-(fluorophenyl)-1H-pyrazol-4-yl)]-2-pyridinyl]amino]ethanol;
 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)]-2-pyridinyl]amino]ethanol;
 5 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl)]-2-pyridinyl]amino]-1-propanol;
 3-(4-fluorophenyl)-4-[2-[[4-(fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
 5-(4-fluorophenyl)-4-[2-[[4-(fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
 10 N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine;
 N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine;
 15 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholinepropanamine;
 N'-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-1,3-propanediamine;
 5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
 20 3-(4-fluorophenyl)-4-[2-[[4-(fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
 5-(4-fluorophenyl)-4-[2-[[4-(fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol;
 25 4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline;
 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine methyl ester;
 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine;
 30 4-[3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine;
 4-[5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine;
 4,4'-(1H-pyrazole-3,4-diyl)bis[pyridine];
 35 4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine;
 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-

piperidinamine;
2-Chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone
5 hydrazone;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine;
10 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine;
N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine;
15 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine;
N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide;
Ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate;
20 4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine;
25 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-cyclopropylpiperazine;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate;
methyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate,
30 monohydrate;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate;
4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, monosodium salt dihydrate;
35 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-

(methylsulfonyl)piperazine, monohydrate;
1- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1- (2-propynyl) -1H-
pyrazol-3-yl]piperazine, trihydrochloride monohydrate;
4- [3- (4-fluorophenyl) -5- (1H-imidazol-4-yl) -1- (4-
5 methoxyphenyl) -1H-pyrazol-4-yl]pyridine;
4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N-2-propynyl-2-
pyrimidinamine;
N- (2-fluorophenyl) -4- [3- (4-fluorophenyl) -1H-pyrazol-4-
yl] -2-pyrimidinamine;
10 4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N- (2-
methoxyphenyl) -2-pyrimidinamine;
1- [5- (3-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-
methylpiperazine;
N- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-
15 piperidinamine, trihydrochloride;
N- [5- (4-fluorophenyl) -4- (pyridinyl) -1H-pyrazol-3-yl] -1-
methyl-4-piperidinamine;
ethyl 4- [[5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-
3-yl] amino] -1-piperidinecarboxylate, monohydrate;
20 1- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-
(2-methoxyphenyl)piperazine;
1- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-
phenylpiperazine;
N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
25 methyl-4-piperidinamine;
1- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-
(2-propynyl)piperazine;
1- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-
yl]piperazine;
30 1,1-dimethylethyl [3- [[5- (4-chlorophenyl) -4- (2-
[(phenylmethyl) amino] -4-pyridinyl-1H-pyrazol-3-
yl] amino] propyl] carbamate;
1,1-dimethylethyl 4- [5- (4-chlorophenyl) -4- (2-fluoro-4-
pyridinyl) -1H-pyrazol-3-yl] -1-piperazinecarboxylate;
35 ethyl 4- [[5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-
3-yl] amino] -1-piperidinecarboxylate;

- 1- (4-chlorophenyl) -2- (1,3-dithietan-2-ylidene) -2- (4-pyridinyl) ethanone;
- 4- [3- (4-fluorophenyl) -5- [(1-methyl-4-piperidinyl)methyl] -1H-pyrazol-4-yl]pyridine;
- 5 1,1-dimethylethyl 4- [[5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]carbonyl] -1-piperazinecarboxylate;
- 1- [[5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]methyl] -4-methylpiperazine;
- 1- [[5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]methyl] -4-piperazine;
- 10 4- [3- (4-fluorophenyl) -5- (4-piperidinylmethyl) -1H-pyrazol-4-yl]pyridine;
- N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -3H-pyrazol-3-yl] -4-piperidineamine, trihydrochloride, monohydrate;
- 15 N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-N,1-dimethyl-4-piperidinamine, dihydrate
- 1- [2- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]ethyl]piperazine;
- 1- [2- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]ethyl] -4-methylpiperazine;
- 20 1- [2- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]ethyl]piperazine;
- 1- [2- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]ethyl] -4-methylpiperazine;
- 25 1- [[5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]methyl]piperazine;
- 1- [[5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl]methyl] -4-methylpiperazine;
- 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-piperazineethanol;
- 30 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-piperazineethanamine;
- 4- [5- [4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-piperazineethanol;
- 35 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-piperazineethanamine;

- 1 - [5 - (4-chlorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
3,5-dimethylpiperazine;
4 - [5 - (4-chlorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
1,2,6-trimethylpiperazine;
5 1 - [5 - (4-fluorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
3,5-dimethylpiperazine;
4 - [5 - (4-fluorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
1,2,6-trimethylpiperazine;
1 - [5 - (4-chlorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -3-
10 methylpiperazine;
4 - [5 - (4-chlorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
1,2-dimethylpiperazine;
1 - [5 - (4-fluorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -3-
methylpiperazine;
15 4 - [5 - (4-fluorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
1,2-dimethylpiperazine;
5 - (4-chlorophenyl) -4 - (4-pyridinyl) -N-3-pyrrolidinyl-1H-
pyrazol-3-amine;
5 - (4-chlorophenyl) -N - (1-methyl-3-pyrrolidinyl) -4 - (4-
20 pyridinyl) -1H-pyrazol-3-amine;
5 - (4-fluorophenyl) -4 - (4-pyridinyl) -N-3-pyrrolidinyl-1H-
pyrazol-3-amine;
5 - (4-fluorophenyl) -N - (1-methyl-3-pyrrolidinyl) -4 - (4-
pyridinyl) -1H-pyrazol-3-amine;
25 1 - [5 - (4-chlorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -3-
pyrrolidinamine;
1 - [5 - (4-chlorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
N,N-dimethyl-3-pyrrolidinamine;
1 - [5 - (4-fluorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -3-
30 pyrrolidinamine;
1 - [5 - (4-fluorophenyl) -4 - (4-pyridinyl) -1H-pyrazol-3-yl] -
N,N-dimethyl-3-pyrrolidinamine;
5 - (4-chlorophenyl) -N - [(1-ethyl-2-pyrrolidinyl)methyl] -4 -
(4-pyridinyl) -1H-pyrazol-3-amine;
35 5 - (4-fluorophenyl) -N - [(1-ethyl-2-pyrrolidinyl)methyl] -4 -
(4-pyridinyl) -1H-pyrazol-3-amine;

- N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -3-piperidinamine;
- N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-methyl-3-piperidinamine;
- 5 N- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -3-piperidinamine;
- N- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-methyl-3-piperidinamine;
- 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-piperazinemethanol;
- 10 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-piperazinemethanamine;
- 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-methyl-2-piperazinemethanol;
- 15 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-methyl-2-piperazinemethanamine;
- 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-piperazinemethanol;
- 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-piperazinemethanamine;
- 20 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-methyl-2-piperazinemethanol;
- 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-methyl-2-piperazinemethanamine;
- 25 4- [3- (4-chlorophenyl) -5- (4-methyl-1-piperazinyl) -1H-pyrazol-4-yl] -N-methyl-2-pyrimidinamine;
- 4- [3- (4-fluorophenyl) -5- (4-methyl-1-piperazinyl) -1H-pyrazol-4-yl] -N-methyl-2-pyrimidinamine;
- 1- [[5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] methyl] -4-piperidinol;
- 30 1- [[5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] methyl] -4-piperidinol;
- 4- [3- (4-chlorophenyl) -5- (4-methyl-1-piperazinyl) -1H-pyrazol-4-yl] pyrimidine;
- 35 4- [3- (4-fluorophenyl) -5- (4-methyl-1-piperazinyl) -1H-pyrazol-4-yl] pyrimidine;


- 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-
piperazinecarboxylic acid;
ethyl 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-
3-yl] -2-piperazinecarboxylate;
- 5 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
methyl-2-piperazinecarboxylic acid;
ethyl 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-
yl] -1-methyl-2-piperazinecarboxylate;
- 10 4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
methyl-2-piperazinecarboxamide;
4- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-
piperazinecarboxamide;
- 15 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-
piperazinecarboxylic acid;
ethyl 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-
yl] -2-piperazinecarboxylate;
- 20 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -2-
piperazinecarboxamide;
4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
methyl-2-piperazinecarboxylic acid;
- 25 4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
methyl-2-piperazinecarboxylate;
4- [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
methyl-2-piperazinecarboxamide;
- 30 N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
ethyl-4-piperidinamine;
N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
(phenylmethyl) -4-piperidinamine;
- 35 1-acetyl-N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-
pyrazol-3-yl] -4-piperidinamine;
N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
(2-propynyl) -4-piperidinamine;
- N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
cyclopropyl-4-piperidinamine;
- N- [5- (4-chlorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -1-
(methoxyacetyl) -4-piperidinamine;

- N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methylethyl)-4-piperidinamine;
- N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-propyl-4-piperidinamine;
- 5 ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate;
- 5-(4-fluorophenyl)-N-methyl-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
- (β R)- β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;
- 10 (β S)- β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;
- (β S)- β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;
- 15 (β R)- β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;
- N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
- N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl-1,2-ethanediamine;
- 20 N-(1-ethyl-4-piperidinyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
- 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)-2-pyridinamine;
- 25 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl-1-butanol;
- (2S)-2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-1-pentanol;
- N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-1,4-pentanediamine;
- 30 (2R)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;
- N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl-1,4-pentanediamine;
- 35 (2S)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;

- 1-[5-(3,4-dichlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]-2-pyridinamine;
 5 N,N-diethyl-N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,2-ethanediamine;
 4-[3-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-yl]pyridine, monohydrochloride;
 8-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-
 10 1,4-dioxo-8-azaspiro[4.5]decane;
 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinone;
 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinol;
 15 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,3,6-hexahydropyridine;
 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-4-piperidinamine, trihydrochloride;
 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
 20 piperidinamine, trihydrochloride;
 4-[3-(4-fluorophenyl)-5-(4-(1-pyrrolidinyl)-1-piperidinyl)-1H-pyrazol-4-yl]pyridine, trihydrochloride;
 ethyl 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-piperidinecarboxylate;
 25 1-methyl-4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;
 1-[5-(3,4-difluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;
 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
 30 yl]morpholine;
 N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,4-pentanediamine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[3-(2-methyl-1-piperidinyl)propyl]-2-pyridinamine;
 35 ethyl 4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;

- N,N-diethyl-N'-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine;
 N1,N1,-diethyl-N4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-pentanediamine;
 5 N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-1-piperazinepropanamine (2E)-2-butenedioate (1:1);
 N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
 N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl-1,3-propanediamine;
 10 N,N,N''-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-1,3-propanediamine;
 15 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1,2-propanediol;
 trans-4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanol;
 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanone; and
 20 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-diethyl-4-piperidinamine, trihydrochloride.

- Within Formula I there is another subclass of
 25 compounds of high interest represented by Formula IX:



wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower heterocyclyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkynylamino, lower heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, and lower alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R² is -CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy; and

R⁴ is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, lower cycloalkyldienyl, 5- or 6-membered heterocyclyl, and aryl selected from phenyl, biphenyl, naphthyl; wherein R⁴ is optionally substituted at a substitutable position with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower

alkylthio, lower alkylamino, nitro, hydroxy; and

R^5 is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or $-NR^{62}R^{63}$ wherein R^{62} is lower alkylcarbonyl or amino, and R^{63} is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula IX

R^1 is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethyl-


ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R^4 is selected from cyclohexyl, cyclohexenyl, cyclohexadienyl, phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R^4 is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R^5 is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or - $NR^{62}R^{63}$ wherein R^{62} is methylcarbonyl or amino, and R^{63} is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula I there is another subclass of compounds of high interest represented by Formula X:



(X)

wherein

5 Z represents a carbon atom or a nitrogen atom; and
 R¹ is selected from lower alkyl, lower hydroxyalkyl,
 lower alkynyl, lower aminoalkyl and lower
 alkylaminoalkyl; and

 R² is selected from hydrido, lower alkyl, aryl
 10 selected from phenyl, biphenyl, and naphthyl, 5- or 6-
 membered heterocyclyl selected from piperidinyl,
 piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower
 haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl,
 lower alkylamino, lower alkylaminoalkyl, phenylamino,
 15 lower aralkyl, lower aralkylamino, lower
 alkylaminoalkylamino, lower aminoalkyl, lower
 aminoalkylamino, lower alkynylamino, lower
 heterocyclylamino, lower heterocyclylalkyl, lower
 heterocyclylalkylamino, lower alkylheterocyclyl, lower
 20 carboxycycloalkyl, lower carboxyalkylamino, lower
 alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino,
 lower heterocyclylcarbonyl, lower
 alkoxycarbonylheterocyclyl, and lower
 alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and
 25 heteroaryl groups are optionally substituted with one or

more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxy carbonyl; or

R^2 is $-CR^{54}R^{55}$ wherein R^{54} is phenyl and R^{55} is hydroxy; and

R^4 is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl;

wherein R^4 is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

R^5 is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxy carbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxy carbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or $-NR^{62}R^{63}$ wherein R^{62} is lower alkylcarbonyl or amino, and R^{63} is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula X

R^1 is selected from methyl, ethyl, hydroxyethyl and propargyl; and


R^2 is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonyl ethyl,

- ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino,
- 5 piperadinylamino, dimethylaminoethylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyll, piperazinyl, imidazolyl, morpholinyl, pyridinyl, N-methylpiperazinyl, carboxymethylamino, methoxyethylamino, (1,1-
- 10 dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, and 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl,
- 15 piperidinyll, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-
- 20 dimethyl)ethoxycarbonyl; and
- R^4 is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R^4 is optionally substituted with one or more radicals
- 25 independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and
- R^5 is selected from fluoro, chloro, bromo, methyl,
- 30 fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino,
- 35 hydroxyethylamino, propargylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino,

piperidinylamino, pyridinylmethylamino,
 phenylmethylpiperidinylamino, aminomethyl,
 cyclopropylamino, amino, hydroxy, methylcarbonyl,
 ethoxycarbonylamino, methoxyphenylmethylamino,
 5 phenylmethylamino, fluorophenylmethylamino,
 fluorophenylethylamino, methylaminocarbonyl,
 methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -
 $\text{NR}^{62}\text{R}^{63}$ wherein R^{62} is methylcarbonyl or amino, and R^{63} is
 methyl or benzyl; or

10 a pharmaceutically-acceptable salt or tautomer
 thereof.

Within Formula I there is another subclass of
 compounds of high interest represented by Formula XI:



15

wherein

Z represents a carbon atom or a nitrogen atom; and

R^1 is selected from lower alkyl, lower hydroxyalkyl,
 lower alkynyl, lower aminoalkyl and lower
 20 alkylaminoalkyl; and

R^2 is selected from hydrido, lower alkyl, aryl
 selected from phenyl, biphenyl, and naphthyl, 5- or 6-
 membered heterocyclyl selected from piperidinyl,
 piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower
 25 haloalkyl, lower hydroxyalkyl, lower alkoxyalkyl,

- lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkynylamino, lower
- 5 heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylcarbonyl, lower
- 10 alkoxycarbonylheterocyclyl, and lower alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower
- 15 alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or
- R^2 is $-CR^{54}R^{55}$ wherein R^{54} is phenyl and R^{55} is hydroxy; and
- 20 R^4 is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl; wherein R^4 is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and
- 25 R^5 is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower
- 30 arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower
- 35 alkoxyaralkylamino, hydrazinyl, and lower

alkylhydrazinyl, or $-NR^{62}R^{63}$ wherein R^{62} is lower alkylcarbonyl or amino, and R^{63} is lower alkyl or lower phenylalkyl; or

5 a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula XI

10 R^1 is selected from methyl, ethyl, hydroxyethyl and propargyl; and

15 R^2 is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, 20 methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl, 25 piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1- 30 dimethyl)ethoxycarbonyl;

R^4 is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R^4 is 35 optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy,

100430-10701

benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

- R⁵ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl or benzyl; or
- a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula IX wherein

- Z represents a carbon atom or a nitrogen atom; and
- R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aminoalkyl and lower alkylaminoalkyl; and
- R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower

5 alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino,
lower heterocyclylcarbonyl, lower
alkoxycarbonylheterocyclyl, and lower

alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or

alkylaminoalkylamino, lower alkynylamino, lower

15 R² is -CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy;
and

20 haloalkyl, lower alkylthio, lower alkylamino, nitro,
hydroxy; and

25 aralkylamino, lower alkoxycarbonyl, lower alkylamino,
lower alkylcarbonyl, lower aralkenyl, lower

30 heterocyclylalkylamino, lower aralkylheterocyclylamino,
lower alkylaminocarbonyl, lower alkylcarbonyl, lower
alkoxyaralkylamino, hydrazinyl, and lower

35 phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer

thereof.

A class of compounds of specific interest consists of those compounds of Formula IX wherein

5 R^1 is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl;

R^2 is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, 10 imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl, 20 piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; 25

R^4 is phenyl that is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, 30 dimethylamino, and hydroxy; and

R^5 is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, 35 methylamino, dimethylamino, 2-methylbutylamino,

ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Another class of compounds of specific interest consists of those compounds of Formula IX wherein

Z represents a carbon atom or a nitrogen atom;

and

R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl and lower alkynyl; and

R² is selected from hydrido and lower alkyl; and

R⁴ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more halo radicals; and

R⁵ is selected from hydrido, halo and alkylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of specific interest consists of those compounds of Formula IX wherein;

Z represents a carbon atom; and

R¹ is selected from hydrido, methyl, hydroxyethyl, propargyl; and

R^2 is hydrido; and

R^4 is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

R^5 is selected from hydrido, fluoro, and 1-methylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds of specific interest consists of those compounds of Formula IX wherein

Z represents a carbon atom; and

R^1 is selected from hydrido and methyl; and


R^2 is hydrido; and

R^4 is selected from phenyl that is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

R^5 is selected from hydrido and fluoro; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula IXA:



wherein

Z represents a carbon atom or a nitrogen atom; and

R^1 is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R^2 is selected from hydrido, lower alkylamino, lower alkynylamino, arylamino, lower aralkylamino, lower heterocyclylalkylamino, lower aminoalkylamino, lower alkylaminoalkylamino, lower hydroxyalkylamino, lower carboxyalkylamino, and lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, wherein the aryl group is optionally substituted with one or more radicals independently selected from halo, keto, lower alkyl, aralkyl, carboxy, lower alkoxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R^2 is R^{200} -heterocyclyl- R^{201} or R^{200} -cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y$ -;
- NR^{202} -;
- $NR^{202}-(CH_2)_y$ -;
- $(CH_2)_y-NR^{202}$ -;
- $O-(CH_2)_y$ -;
- $(CH_2)_y-O$ -;
- S -;
- O -;

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, aryl, heterocyclyl, lower aralkyl, lower heterocyclylalkylene, lower alkylcarbonyl, lower hydroxyalkylcarbonyl, lower cycloalkylcarbonyl,

arylcarbonyl, haloarylcarbonyl, lower alkoxy, lower
 alkoxyalkylene, lower alkoxyarylene, lower
 alkoxycarbonyl, lower carboxyalkylcarbonyl, lower
 alkoxyalkylcarbonyl, lower heterocyclylalkylcarbonyl,
 5 lower alkylsulfonyl, lower alkylsulfonylalkylene, amino,
 lower aminoalkyl, lower alkylamino, lower aralkylamino,
 lower alkylaminoalkylene, aminocarbonyl, lower
 alkylcarbonylamino, lower alkylcarbonylaminoalkylene,
 lower alkylaminoalkylcarbonyl, lower
 10 alkylaminoalkylcarbonylamino, lower
 aminoalkylcarbonylaminoalkyl, lower alkoxycarbonylamino,
 lower alkoxyalkylcarbonylamino, lower
 alkoxycarbonylaminoalkylene, lower alkylimidocarbonyl,
 amidino, lower alkylamidino, lower aralkylamidino,
 15 guanidino, lower guanidinoalkylene, and lower
 alkylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido,
 lower alkyl, aryl and lower aralkyl; and

y is 0, 1, 2 or 3; and

20 R^4 is selected from aryl selected from phenyl,
 biphenyl, naphthyl, wherein said aryl is optionally
 substituted at a substitutable position with one or more
 radicals independently selected from halo, lower alkyl,
 lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl,
 25 lower alkylthio, lower alkylamino, nitro, and hydroxy;
 and

R^5 is selected from hydrido, halo, amino, cyano,
 aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower
 aminoalkyl, lower aralkyl, lower aralkyloxy, lower
 30 aralkylamino, lower alkoxycarbonyl, lower alkylamino,
 lower hydroxyalkylamino, lower alkylcarbonyl, lower
 aralkenyl, lower arylheterocyclyl, carboxy, lower
 cycloalkylamino, lower hydroxycycloalkylamino, lower
 alkoxycarbonylamino, lower alkoxyaralkylamino, lower
 35 alkylaminoalkylamino, lower heterocyclylamino, lower
 heterocyclylalkylamino, lower aralkylheterocyclylamino,

5

10

25

30

35

morpholinylpropylamino, piperidinylmethylamino,
 piperidinylethylamino, piperidinylpropylamino,
 piperazinylmethylamino, piperazinylethylamino,
 piperazinylpropylamino, carboxymethylamino,
 5 carboxyethylamino, methoxyethylamino, ethoxyethylamino,
 ethoxymethylamino, (1,1-
 dimethyl)ethylcarbonylaminoethylamino, and (1,1-
 dimethyl)ethylcarbonylaminoethylamino, wherein the
 phenyl, morpholinyl, piperidinyl, and piperazinyl groups
 10 are optionally substituted with one or more radicals
 independently selected from fluoro, chloro, bromo, keto,
 methyl, ethyl, trifluoromethyl, benzyl, methoxy, ethoxy,
 methoxycarbonyl, ethoxycarbonyl and (1,1-
 dimethyl)ethoxycarbonyl; and
 15 R^2 is R^{200} -piperidinyl- R^{201} , R^{200} -piperazinyl- R^{201} , or
 R^{200} -cyclohexyl- R^{201} wherein:
 R^{200} is selected from:
 - $(CR^{202}R^{203})_y-$;
 - $NR^{202}-$;
 20 -S-;
 -O-;
 or R^{200} represents a bond;
 R^{201} represents one or more radicals selected from
 the group consisting of hydrido, chloro, fluoro, bromo,
 25 iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl,
 butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl,
 hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl,
 chloromethyl, chloroethyl, chloropropyl, chlorobutyl,
 fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl,
 30 cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
 ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl,
 butynyl, phenyl, benzyl, piperidinyl, piperazinyl,
 morpholinyl, piperidinylmethylene, piperazinylmethylene,
 morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy,
 35 methoxymethylene, methoxyethylene, methoxypropylene,
 ethoxyethylene, ethoxypropylene, propoxyethylene,

propoxypropylene, methoxyphenylene, ethoxyphenylene,
 propoxyphenylene, methylcarbonyl, ethylcarbonyl,
 propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl,
 cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl,
 5 chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl,
 hydroxyethylcarbonyl, hydroxypropylcarbonyl,
 carboxymethylcarbonyl, carboxyethylcarbonyl,
 carboxypropylcarbonyl, methoxymethylcarbonyl,
 methoxyethylcarbonyl, methoxypropylcarbonyl,
 10 ethoxymethylcarbonyl, ethoxyethylcarbonyl,
 ethoxypropylcarbonyl, propoxymethylcarbonyl,
 propoxyethylcarbonyl, propoxypropylcarbonyl,
 methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
 propoxyphenylcarbonyl, piperidinylmethylcarbonyl,
 15 piperazinylmethylcarbonyl, morpholinylcarbonyl,
 methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene,
 amino, aminomethyl, aminoethyl, aminopropyl, N-
 methylamino, N,N-dimethylamino, N-ethylamino, N,N-
 diethylamino, N-propylamino, N,N-dipropylamino,
 20 phenylamino, benzylamino, methylaminomethylene,
 ethylaminomethylene, methylaminoethylene,
 ethylaminoethylene, aminocarbonyl, methylcarbonylamino,
 ethylcarbonylamino, methylaminomethylcarbonyl,
 ethylaminomethylcarbonyl, methylcarbonylaminoethylene,
 25 ethylcarbonylaminoethylene,
 aminomethylcarbonylaminoethylmethylene,
 methoxycarbonylamino, ethoxycarbonylamino,
 methoxymethylcarbonylamino, methoxyethylcarbonylamino,
 ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
 30 methoxycarbonylaminoethylene,
 ethoxycarbonylaminoethylene, methylimidocarbonyl,
 ethylimidocarbonyl, amidino, methylamidino,
 methylamidino, benzylamidino, guanidino,
 guanidinomethylene, guanidinoethylene, and
 35 methylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido,

methyl, ethyl, propyl, butyl, phenyl and benzyl; and
y is 0, 1 or 2; and


R⁴ is phenyl, wherein said phenyl is optionally
substituted with one or more radicals independently
5 selected from methylthio, fluoro, chloro, bromo, iodo,
methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy,
trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo,
iodo, hydroxy, methyl, ethyl, propyl, benzyl,
10 fluorophenylethyl, fluorophenylethenyl,
fluorophenylpyrazolyl, cyano, carboxy, methoxy,
methoxycarbonyl, aminocarbonyl, acetyl, methylamino,
dimethylamino, 2-methylbutylamino, ethylamino,
dimethylaminoethylamino, hydroxyethylamino,
15 hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino,
imidazolylamino, morpholinylethylamino, (1-ethyl-2-
hydroxy)ethylamino, piperidinylamino,
20 pyridinylmethylamino, phenylmethylpiperidinylamino,
aminomethyl, cyclopropylamino, amino, hydroxy,
ethoxycarbonylamino, methoxyphenylmethylamino,
phenylmethylamino, fluorophenylmethylamino,
fluorophenylethylamino, methylaminoethylamino,
25 dimethylaminoethylamino, methylaminopropylamino,
dimethylaminopropylamino, methylaminobutylamino,
dimethylaminobutylamino, methylaminopentylamino,
dimethylaminopentylamino, ethylaminoethylamino,
diethylaminoethylamino, ethylaminopropylamino,
30 diethylaminopropylamino, ethylaminobutylamino,
diethylaminobutylamino, ethylaminopentylamino,
methylaminocarbonyl, methylcarbonyl, ethylcarbonyl,
hydrazinyl, and 1-methylhydrazinyl, or -NR⁶²R⁶³ wherein R⁶²
is methylcarbonyl or amino, and R⁶³ is methyl or benzyl;
35 or

a pharmaceutically-acceptable salt or tautomer

thereof.

Within Formula IXA there is another subclass of compounds of interest represented by Formula XA:



5

wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from hydrido, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-butylamino, N-propargylamino, N-phenylamino, N-benzylamino, aminoethylamino, aminopropylamino, aminobutylamino, methylaminoethylamino, dimethylaminoethylamino, ethylaminoethylamino, diethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, piperidinylmethylamino, piperidinylethylamino, piperidinylpropylamino, piperazinylmethylamino, piperazinylethylamino, and piperazinylpropylamino, wherein the phenyl, morpholinyl, piperidinyl, and piperazinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl,

25

trifluoromethyl, benzyl, and methoxy; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from hydrido, methylaminopropylamino,

dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, wherein the phenyl and morpholinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, methyl, ethyl, and methoxy; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is selected from hydrido, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, and morpholinylpropylamino; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethylaminobutylamino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹ is selected hydrido; and


R² is selected from hydrido, dimethylaminopropylamino, diethylaminopropylamino, morpholinylethylamino, and morpholinylpropylamino; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula XA:



(XA)

R¹ is selected from hydrido, methyl, ethyl,
5 hydroxyethyl and propargyl; and

R² is R²⁰⁰-piperidinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

-(CR²⁰²R²⁰³)_y-;

-NR²⁰²-;

10 -S-;

-O-;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from
the group consisting of hydrido, chloro, fluoro, bromo,
15 iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl,
butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl,
hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl,
chloromethyl, chloroethyl, chloropropyl, chlorobutyl,
fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl,
20 cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl,
butynyl, phenyl, benzyl, piperidinyl, piperazinyl,
morpholinyl, piperidinylmethylene, piperazinylmethylene,
morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy,
25 methoxymethylene, methoxyethylene, methoxypropylene,

ethoxyethylene, ethoxypropylene, propoxyethylene,
propoxypropylene, methoxyphenylene, ethoxyphenylene,
propoxyphenylene, methylcarbonyl, ethylcarbonyl,
propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl,
5 cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl,
chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl,
hydroxyethylcarbonyl, hydroxypropylcarbonyl,
carboxymethylcarbonyl, carboxyethylcarbonyl,
carboxypropylcarbonyl, methoxymethylcarbonyl,
10 methoxyethylcarbonyl, methoxypropylcarbonyl,
ethoxymethylcarbonyl, ethoxyethylcarbonyl,
ethoxypropylcarbonyl, propoxymethylcarbonyl,
propoxyethylcarbonyl, propoxypropylcarbonyl,
methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
15 propoxyphenylcarbonyl, piperidinylmethylcarbonyl,
piperazinylmethylcarbonyl, morpholinylcarbonyl,
methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene,
amino, aminomethyl, aminoethyl, aminopropyl, N-
methylamino, N,N-dimethylamino, N-ethylamino, N,N-
20 diethylamino, N-propylamino, N,N-dipropylamino,
phenylamino, benzylamino, methylaminomethylene,
ethylaminomethylene, methylaminoethylene,
ethylaminoethylene, aminocarbonyl, methylcarbonylamino,
ethylcarbonylamino, methylaminomethylcarbonyl,
25 ethylaminomethylcarbonyl, methylcarbonylaminoethylene,
ethylcarbonylaminoethylene,
aminomethylcarbonylaminoethylmethylene,
methoxycarbonylamino, ethoxycarbonylamino,
methoxymethylcarbonylamino, methoxyethylcarbonylamino,
30 ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
methoxycarbonylaminoethylene,
ethoxycarbonylaminoethylene, methylimidocarbonyl,
ethylimidocarbonyl, amidino, methylamidino,
methylamidino, benzylamidino, guanidino,
35 guanidinomethylene, guanidinoethylene, and
methylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

5 R^4 is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R^5 is selected from hydrido, fluoro, chloro, bromo,
10 hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino,
15 hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino,
20 aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino,
25 dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino,
30 diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl;
or

a pharmaceutically-acceptable salt or tautomer thereof.

35

A subclass of compounds of particular interest

consists of those compounds of Formula XA wherein:

R^1 is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is R^{200} -piperidinyl- R^{201} wherein:

5 R^{200} is selected from:

methylene;

- NR^{202} -;

-S-;

-O-;

10 or R^{200} represents a bond;

R^{201} represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, hydroxy, carboxy, keto, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, fluoromethyl, fluororoethyl, fluoropropyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, methoxymethyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl, propoxypropyl, methoxyphenyl, ethoxyphenyl, propoxyphenyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-benzylamino, methylaminomethylene, aminocarbonyl, methoxycarbonylamino, ethoxycarbonylamino,

15
20
25
30
35

or methylsulfonylamino; and

R²⁰² is selected from hydrido, methyl, ethyl, phenyl and benzyl; and

5 R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

10 R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, 15 cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, 20 ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

30

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is R²⁰⁰-piperidinyl-R²⁰¹ wherein:

35 R²⁰⁰ is selected from:

methylene;

-NR²⁰²-;

-S-;

-O-;

or R²⁰⁰ represents a bond;

5 R²⁰¹ represents one or more radicals selected from
the group consisting of hydrido, hydroxy, methyl, ethyl,
propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl,
methoxymethyl, methoxyethyl, methoxypropyl, ethoxyethyl,
ethoxypropyl, propoxyethyl, propoxypropyl, methoxyphenyl,
10 ethoxyphenyl, propoxyphenyl, methylcarbonyl,
ethylcarbonyl, propylcarbonyl, hydroxymethylcarbonyl,
hydroxyethylcarbonyl, carboxymethylcarbonyl,
carboxyethylcarbonyl, methoxymethylcarbonyl,
methoxyethylcarbonyl, ethoxymethylcarbonyl,
15 ethoxyethylcarbonyl, methoxyphenylcarbonyl,
ethoxyphenylcarbonyl, methylsulfonyl, ethylsulfonyl,
amino, aminomethyl, aminoethyl, aminopropyl, N-
methylamino, N,N-dimethylamino, N-ethylamino, N,N-
diethylamino, N-propylamino, N,N-dipropylamino, N-
20 benzylamino, methylaminomethylene, aminocarbonyl,
methoxycarbonylamino, and ethoxycarbonylamino; and
 R²⁰² is selected from hydrido, methyl phenyl and
benzyl; and

 R⁴ is phenyl, wherein said phenyl is optionally
25 substituted with one or more radicals independently
selected from fluoro, chloro, methyl, and methoxy; and

 R⁵ is selected from hydrido, methylamino,
dimethylamino, 2-methylbutylamino, ethylamino,
dimethylaminoethylamino, hydroxypropylamino,
30 hydroxyethylamino, hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino, (1-
ethyl-2-hydroxy)ethylamino, aminomethyl,
cyclopropylamino, amino, dimethylaminoethylamino,
35 dimethylaminopropylamino, dimethylaminobutylamino,
dimethylaminopentylamino, diethylaminoethylamino,

FOIA b 7 - DEXTER

diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

5

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R^1 is hydrido; and

R^2 is R^{200} -piperidinyl- R^{201} wherein:

10

R^{200} is selected from:

methylene;

- NR^{202} -;

-S-;

-O-;

15

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from the group consisting of hydrido, methyl, methoxyethyl, methylcarbonyl, hydroxymethylcarbonyl, methoxymethylcarbonyl, methylsulfonyl, amino, N,N-dimethylamino, and N,N-diethylamino; and

20

R^{202} is selected from hydrido and methyl; and

R^4 is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and


25

R^5 is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

30

Within Formula IXA there is another subclass of compounds of interest represented by Formula XA:



R^1 is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is R^{200} -piperazinyl- R^{201} wherein:

5 R^{200} is selected from:

- $(CR^{202}R^{203})_y$;

- NR^{202} -;

-S-;

-O-;

10 or R^{200} represents a bond;

R^{201} represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, butynyl, phenyl, benzyl, piperidinyll, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene,

15
20
25

- propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, methylimidocarbonyl, ethylimidocarbonyl, amidino, methylamidino, methylamidino, benzylamidino, guanidino, guanidinomethylene, guanidinoethylene, and methylsulfonylamino; and
- R^{202} and R^{203} are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

TOZ001 08272001

R^2 is R^{200} -piperazinyl- R^{201} wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y$ -;

- NR^{202} -;

5 - S -;

- O -;

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from
the group consisting of hydrido, chloro, fluoro, bromo,
10 hydroxy, carboxy, keto, methyl, ethyl, propyl,
hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-
1,1-dimethyl)ethyl, chloromethyl, chloroethyl,
chloropropyl, fluoromethyl, fluoroethyl, fluoropropyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
15 ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl,
phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl,
piperidinylmethylene, piperazinylmethylene,
morpholinylmethylene, methoxy, ethoxy, propoxy,
methoxymethylene, methoxyethylene, ethoxyethylene,
20 methoxyphenylene, ethoxyphenylene, methylcarbonyl,
ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl,
cyclobutylcarbonyl, cyclopentylcarbonyl,
cyclohexylcarbonyl, benzoyl, chlorobenzoyl,
fluorobenzoyl, hydroxymethylcarbonyl,
25 hydroxyethylcarbonyl, hydroxypropylcarbonyl,
carboxymethylcarbonyl, carboxyethylcarbonyl,
carboxypropylcarbonyl, methoxymethylcarbonyl,
methoxyethylcarbonyl, methoxypropylcarbonyl,
ethoxymethylcarbonyl, ethoxyethylcarbonyl,
30 ethoxypropylcarbonyl, propoxymethylcarbonyl,
propoxyethylcarbonyl, propoxypropylcarbonyl,
methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
propoxyphenylcarbonyl, piperidinylmethylcarbonyl,
piperazinylmethylcarbonyl, morpholinylcarbonyl,
35 methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene,
amino, aminomethyl, aminoethyl, aminopropyl, N-

- methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene,
- 5 ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminoethylmethylene,
- 10 methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, and methylsulfonylamino;
- 15 and
- R^{202} and R^{203} are independently selected from hydrido, methyl, ethyl, phenyl and benzyl; and
- y is 0, 1 or 2; and
- R^4 is phenyl, wherein said phenyl is optionally
- 20 substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and
- R^5 is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy,
- 25 methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-
- 30 ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino,
- 35 methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino,

methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, 5 ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or
a pharmaceutically-acceptable salt or tautomer thereof.

- 10 A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:
 R^1 is hydrido; and
 R^2 is R^{200} -piperazinyl- R^{201} wherein:
 R^{200} is selected from:
 15 methylene;
 $-NR^{202}-$;
 $-S-$;
 $-O-$;
 or R^{200} represents a bond;
 20 R^{201} represents one or more radicals selected from the group consisting of hydrido, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethynyl, propynyl, propargyl, phenyl, benzyl, piperidinyl, piperazinyl, and morpholinyl; and
 25 R^{202} is selected from hydrido, methyl, ethyl, phenyl and benzyl; and
 y is 0, 1 or 2; and
 R^4 is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently
 30 selected from fluoro, chloro, methyl, and methoxy; and
 R^5 is selected from hydrido, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, 35 hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-

1003380-190704

ethyl-2-hydroxy)ethylamino, aminomethyl,
 cyclopropylamino, amino, dimethylaminoethylamino,
 dimethylaminopropylamino, dimethylaminobutylamino,
 dimethylaminopentylamino, diethylaminoethylamino,
 5 diethylaminopropylamino, diethylaminobutylamino, and
 diethylaminopentylamino; or
 a pharmaceutically-acceptable salt or tautomer
 thereof.

10 A subclass of compounds of high interest consists of
 those compounds of Formula XA wherein:

R^1 is hydrido; and

R^2 is R^{200} -piperazinyl- R^{201} wherein:

R^{200} is selected from:

15 methylene;

- NR^{202} -;

-S-;

-O-;

or R^{200} represents a bond;

20 R^{201} represents one or more radicals selected from
 the group consisting of hydrido, methyl, cyclopropyl,
 propargyl, and benzyl; and


R^{202} is selected from hydrido and methyl; and

25 R^4 is phenyl, wherein said phenyl is optionally
 substituted with one or more radicals independently
 selected from fluoro, chloro, methyl, and methoxy; and

R^5 is selected from hydrido, hydroxypropylamino,
 hydroxycyclohexylamino, and diethylaminoethylamino; or

30 a pharmaceutically-acceptable salt or tautomer
 thereof.

Within Formula IA there is another subclass of
 compounds of interest represented by Formula XA:



R^1 is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is R^{200} -cyclohexyl- R^{201} wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y$ -;

- NR^{202} -;

-S-;

-O-;

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, butynyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene,

- propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylamino, aminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, methylimidocarbonyl, ethylimidocarbonyl, amidino, methylamidino, methylamidino, benzylamidino, guanidino, guanidinomethylene, guanidinoethylene, and methylsulfonylamino; and
- R^{202} and R^{203} are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is R^{200} -cyclohexyl- R^{201} wherein:

R^{200} is selected from:

$-(CR^{202}R^{203})_y-$;

$-NR^{202}-$;

5 $-S-$;

$-O-$;

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from
the group consisting of hydrido, chloro, fluoro, bromo,
10 hydroxy, carboxy, keto, methyl, ethyl, propyl,
hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-
1,1-dimethyl)ethyl, chloromethyl, chloroethyl,
chloropropyl, fluoromethyl, fluoroethyl, fluoropropyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl,
15 benzyl, piperidinyl, piperazinyl, morpholinyl,
piperidinylmethylene, piperazinylmethylene,
morpholinylmethylene, methoxy, ethoxy, propoxy,
methoxymethylene, methoxyethylene, methoxypropylene,
ethoxyethylene, ethoxypropylene, propoxyethylene,
20 propoxypropylene, methoxyphenylene, ethoxyphenylene,
propoxyphenylene, methylcarbonyl, ethylcarbonyl,
propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl,
cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl,
chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl,
25 hydroxyethylcarbonyl, hydroxypropylcarbonyl,
carboxymethylcarbonyl, carboxyethylcarbonyl,
carboxypropylcarbonyl, methoxymethylcarbonyl,
methoxyethylcarbonyl, methoxypropylcarbonyl,
ethoxymethylcarbonyl, ethoxyethylcarbonyl,
30 ethoxypropylcarbonyl, propoxymethylcarbonyl,
propoxyethylcarbonyl, propoxypropylcarbonyl,
methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
propoxyphenylcarbonyl, piperidinylmethylcarbonyl,
piperazinylmethylcarbonyl, morpholinylcarbonyl,
35 methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene,
amino, aminomethyl, aminoethyl, aminopropyl, N-

ethylaminopropylamino, diethylaminopropylamino,
ethylaminobutylamino, diethylaminobutylamino,
ethylaminopentylamino, methylaminocarbonyl,
methylcarbonyl, and ethylcarbonyl; or

5 a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

10 R^1 is hydrido; and

R^2 is R^{200} -cyclohexyl- R^{201} wherein:

R^{200} is selected from:

methylene;

- NR^{202} -;

15 -S-;

-O-;

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from

the group consisting of hydrido, amino, aminomethyl,

20 aminoethyl, aminopropyl, N-methylamino, N,N-

dimethylamino, N-ethylamino, N,N-diethylamino, N-

propylamino, N,N-dipropylamino, phenylamino, benzylamino,

methylaminomethylene, ethylaminomethylene,

methylaminoethylene, ethylaminoethylene, aminocarbonyl,

25 methylcarbonylamino, ethylcarbonylamino,

methylaminomethylcarbonyl, ethylaminomethylcarbonyl,

methylcarbonylaminomethylene,

ethylcarbonylaminomethylene,

aminomethylcarbonylaminocarbonylmethylene,

30 methoxycarbonylamino, ethoxycarbonylamino,

methoxymethylcarbonylamino, methoxyethylcarbonylamino,

ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,

methoxycarbonylaminomethylene, and

ethoxycarbonylaminomethylene; and

35 R^{202} is selected from hydrido, methyl, phenyl and benzyl; and

R⁵ is selected from hydrido, methylamino,

dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethylaminobutylamino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R^2 is R^{200} -cyclohexyl- R^{201} wherein:

R^{200} is selected from:

methylene;

-NR²⁰² - ;

-S-;

-O-;

or R^{200} represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of amino, aminomethyl, N,N-dimethylamino, and N-isopropylamino; and

R²⁰² is selected from hydrido and methyl; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, hydroxypropylamino,


hydroxycyclohexylamino, and diethylaminoethylamino; or
a pharmaceutically-acceptable salt or tautomer
thereof.

5 Within Formula IA is another subclass of compounds
of interest wherein:

 R¹ is selected from hydrido, hydroxy, alkyl,
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl,
heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene,
10 heterocyclylalkylene, haloalkyl, haloalkenyl,
haloalkynyl, hydroxyalkyl, hydroxyalkenyl,
hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl,
arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl,
alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl,
15 heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl,
alkylthioalkylene, alkenylthioalkylene,
alkylthioalkenylene, amino, aminoalkyl, alkylamino,
alkenylamino, alkynylamino, arylamino, heterocyclylamino,
alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
20 arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
heterocyclylsulfonyl, alkylaminoalkylene,
alkylsulfonylalkylene, acyl, acyloxycarbonyl,
alkoxycarbonylalkylene, aryloxycarbonylalkylene,
25 heterocycliloxy carbonylalkylene, alkoxycarbonylarylene,
aryloxy carbonylarylene, heterocycliloxy carbonylarylene,
alkylcarbonylalkylene, arylcarbonylalkylene,
heterocyclylcarbonylalkylene, alkylcarbonylarylene,
arylcarbonylarylene, heterocyclylcarbonylarylene,
30 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
arylcarbonyloxyarylene, and
heterocyclylcarbonyloxyarylene; or

 R¹ has the formula

TOC22T 0342001



wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocycl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocycl, alkylheterocyclalkylene, alkylheterocyclarylene, aralkylheterocycl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocycl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocycl, alkoxycarbonylheterocyclcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclarylene, alkoxycarbonylalkoxyarylene, heterocyclcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene,

aralkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, arylsulfonylaminoalkylene,
 alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
 5 heterocyclylalkylene, alkylheterocyclylarylene,
 alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
 aryloxycarbonylarylene, arylcarbonylarylene,
 alkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, and alkylsulfonylarylene groups
 10 are optionally substituted with one or more radicals
 independently selected from alkyl, halo, haloalkyl,
 alkoxy, keto, amino, nitro, and cyano; or

R^{27} is $-\text{CHR}^{28}\text{R}^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
 is selected from aralkyl, aralkoxyalkylene,
 15 heterocyclylalkylene, alkylheterocyclylalkylene,
 alkoxycarbonylalkylene, alkylthioalkylene, and
 aralkylthioalkylene; wherein said aralkyl and
 heterocyclyl groups are optionally substituted with one
 or more radicals independently selected from alkyl and
 20 nitro; or

R^{26} and R^{27} together with the nitrogen atom to which
 they are attached form a heterocycle, wherein said
 heterocycle is optionally substituted with one or more
 radicals independently selected from alkyl, aryl,
 25 heterocyclyl, heterocyclylalkylene,
 alkylheterocyclylalkylene, aryloxyalkylene,
 alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
 alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
 alkoxycarbonylamino; wherein said aryl,
 30 heterocyclylalkylene and aryloxyalkylene radicals are
 optionally substituted with one or more radicals
 independently selected from halogen, alkyl and alkoxy;
 and


R^2 is selected from mercapto,
 35 heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl,
 N-alkyl-N-alkynyl-amino, aminocarbonylalkylene,

- alkylcarbonylaminoalkylene,
 aminoalkylcarbonylaminoalkylene,
 alkylaminoalkylcarbonylamino, aminoalkylthio,
 alkylaminocarbonylalkylthio,
 5 alkylaminoalkylaminocarbonylalkylthio, cyanoalkylthio,
 alkenylthio, alkynylthio, carboxyalkylthio,
 alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl,
 alkoxycarbonylalkylamino, alkoxycarbonylaminoalkylene,
 alkoxycarbonylaminoalkoxy, aralkythio,
 10 heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy,
 carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy,
 and heterocyclylalkyloxy; wherein the aryl, heterocyclyl,
 heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are
 optionally substituted with one or more radicals
 15 independently selected from halo, keto, amino, alkyl,
 alkenyl, alkynyl, aryl, heterocyclyl, aralkyl,
 heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl)
 carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl,
 alkylamino, alkynylamino, alkylaminoalkylamino,
 20 heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl,
 alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or
 R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 cycloalkyl- R^{201} wherein:
 R^{200} is selected from:
 25 - $(CR^{202}R^{203})_y-$;
 -C(O)-;
 -C(O)-(CH₂)_y-;
 -C(O)-O-(CH₂)_y-;
 -(CH₂)_y-C(O)-;
 30 -O-(CH₂)_y-C(O)-;
 -NR²⁰²-;
 -NR²⁰²-(CH₂)_y-;
 -(CH₂)_y-NR²⁰²-;
 -(CH₂)_y-NR²⁰²-(CH₂)_z-;
 35 -(CH₂)_y-C(O)-NR²⁰²-(CH₂)_z-;
 -(CH₂)_y-NR²⁰²-C(O)-(CH₂)_z-;


- $-(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;
 $-S(O)_x-(CR^{202}R^{203})_y-$;
 $-(CR^{202}R^{203})_y-S(O)_x-$;
 $-S(O)_x-(CR^{202}R^{203})_y-O-$;
5 $-S(O)_x-(CR^{202}R^{203})_y-C(O)-$;
 $-O-(CH_2)_y-$;
 $-(CH_2)_y-O-$;
 $-S-$;
 $-O-$;
10 or R^{200} represents a bond;
 R^{201} represents one or more radicals selected from
the group consisting of hydrido, halogen, hydroxy,
carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,
cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,
15 aralkyl, heterocyclylalkylene, alkylcarbonyl,
hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,
haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,
alkoxycarbonyl, carboxyalkylcarbonyl,
alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,
20 alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,
alkylamino, aralkylamino, alkylaminoalkylene,
aminocarbonyl, alkylcarbonylamino,
alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,
alkylaminoalkylcarbonylamino,
25 aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino,
alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene,
alkylimidocarbonyl, amidino, alkylamidino,
aralkylamidino, guanidino, guanidinoalkylene, or
alkylsulfonylamino; and
30 R^{202} and R^{203} are independently selected from hydrido,
alkyl, aryl and aralkyl; and
y and z are independently 0, 1, 2, 3, 4, 5 or 6
wherein y + z is less than or equal to 6; and
z is 0, 1 or 2; or
35 R^2 is $-NHCR^{204}R^{205}$ wherein R^{204} is alkylaminoalkylene,
and R^{205} is aryl; or

R^2 is $-C(NR^{206})R^{207}$ wherein R^{206} is selected from hydrogen and hydroxy, and R^{207} is selected from alkyl, aryl and aralkyl; and

R^3 is selected from pyridinyl, pyrimidinyl,
 5 quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl,
 10 purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy,
 15 carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloaryl amino,
 20 heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyaryl amino, alkoxyaralkyl amino,
 25 aminosulfinyl, aminosulfonyl, alkylsulfonylamino,


alkylaminoalkylamino, hydroxyalkylamino, aralkylamino,
 aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino,
 alkylheterocyclylamino, heterocyclylalkylamino,
 alkylheterocyclylalkylamino, aralkylheterocyclylamino,
 5 heterocyclylheterocyclylalkylamino,
 alkoxycarbonylheterocyclylamino, nitro,
 alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl,
 aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl,
 alkylhydrazinyl, arylhydrazinyl, or $-NR^{44}R^{45}$ wherein R^{44} is
 10 alkylcarbonyl or amino, and R^{45} is alkyl or aralkyl; and
 R^4 is selected from hydrido, alkyl, alkenyl, alkynyl,
 cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
 R^4 is optionally substituted with one or more radicals
 independently selected from halo, alkyl, alkenyl,
 15 alkynyl, aryl, heterocyclyl, alkylthio, arylthio,
 alkylthioalkylene, arylthioalkylene, alkylsulfinyl,
 alkylsulfinylalkylene, arylsulfinylalkylene,
 alkylsulfonyl, alkylsulfonylalkylene,
 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
 20 aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
 alkoxycarbonyl, aryloxy carbonyl, haloalkyl, amino, cyano,
 nitro, alkylamino, arylamino, alkylaminoalkylene,
 arylaminoalkylene, aminoalkylamino, and hydroxy; or
 a pharmaceutically-acceptable salt or tautomer
 25 thereof.

Within Formula IA is another subclass of compounds
 of interest wherein:

R^1 is selected from hydrido, hydroxy, alkyl,
 30 cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl,
 heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene,
 heterocyclylalkylene, haloalkyl, haloalkenyl,
 haloalkynyl, hydroxyalkyl, hydroxyalkenyl,
 hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl,
 35 arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl,
 alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl,

heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl,
 alkylthioalkylene, alkenylthioalkylene,
 alkylthioalkenylene, amino, aminoalkyl, alkylamino,
 alkenylamino, alkynylamino, arylamino, heterocyclylamino,
 5 alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
 arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
 alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
 heterocyclylsulfonyl, alkylaminoalkylene,
 alkylsulfonylalkylene, acyl, acyloxy carbonyl,
 10 alkoxy carbonylalkylene, aryloxy carbonylalkylene,
 heterocyclyloxy carbonylalkylene, alkoxy carbonylarylene,
 aryloxy carbonylarylene, heterocyclyloxy carbonylarylene,
 alkyl carbonylalkylene, aryl carbonylalkylene,
 heterocyclyl carbonylalkylene, alkyl carbonylarylene,
 15 aryl carbonylarylene, heterocyclyl carbonylarylene,
 alkyl carbonyloxyalkylene, aryl carbonyloxyalkylene,
 heterocyclyl carbonyloxyalkylene, alkyl carbonyloxyarylene,
 aryl carbonyloxyarylene, and
 heterocyclyl carbonyloxyarylene; or

20 R^1 has the formula



wherein:

i is an integer from 0 to 9;

25 R^{25} is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkyl carbonylalkylene, aryl carbonylalkylene, and
 heterocyclyl carbonylaminoalkylene; and

30 R^{26} is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxy carbonylalkylene, and alkylaminoalkyl; and

R^{27} is selected from alkyl, cycloalkyl, alkynyl,
 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,

5
10
15
20
25
30

aralkylthioalkylene; wherein said aralkyl and heterocyclcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

5 R^{26} and R^{27} together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclcyl, heterocyclcylalkylene,
 10 alkylheterocyclcylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxy carbonyl, aralkoxycarbonyl, alkylamino and alkoxy carbonylamino; wherein said aryl, heterocyclcylalkylene and aryloxyalkylene radicals are
 15 optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R^2 is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclcyl, haloalkyl,
 20 hydroxyalkyl, aralkyl, alkylheterocyclcyl, heterocyclcylalkyl, heterocyclcylheterocyclcyl, heterocyclcylalkylheterocyclcyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino, heterocyclcylamino, heterocyclcylalkylamino, aralkylamino,
 25 N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene,
 30 aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy, heterocyclcylloxy, alkylthio, cyanoalkylthio, alkenylthio,
 35 alkynylthio, carboxyalkylthio, arylthio, heterocyclcylthio, alkoxy carbonylalkylthio, alkylsulfinyl,

alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl,
 alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl,
 carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl,
 alkoxycarbonylalkyl, alkoxycarbonylalkylamino,
 5 alkoxycarbonylheterocyclyl,
 alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino,
 alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
 alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl,
 aralkylthio, heterocyclylalkylthio, aminoalkoxy,
 10 cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
 alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein
 the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and
 cycloalkenyl groups are optionally substituted with one
 or more radicals independently selected from halo, keto,
 15 amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl,
 aralkyl, heterocyclylalkyl, epoxyalkyl,
 amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy,
 haloalkyl, alkylamino, alkynylamino,
 alkylaminoalkylamino, heterocyclylalkylamino,
 20 alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,
 arylsulfonyl, and aralkylsulfonyl; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- 25 - $(CR^{202}R^{203})_y-$;
 - $C(O)-$;
 - $C(O)-(CH_2)_y-$;
 - $C(O)-O-(CH_2)_y-$;
 - $(CH_2)_y-C(O)-$;
 30 - $O-(CH_2)_y-C(O)-$;
 - $NR^{202}-$;
 - $NR^{202}-(CH_2)_y-$;
 - $(CH_2)_y-NR^{202}-$;
 - $(CH_2)_y-NR^{202}-(CH_2)_z-$;
 35 - $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;
 - $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;

5

10

15

20

25


30

35

R² is -NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene, and R²⁰⁵ is aryl; or

R^2 is $-C(NR^{206})R^{207}$ wherein R^{206} is selected from hydrogen and hydroxy, and R^{207} is selected from alkyl, aryl and aralkyl; or

R^2 has the formula:



wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

10 R^{30} and R^{31} are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

15 R^{32} is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R^{33} is selected from hydrogen, alkyl, $-C(O)R^{35}$,


20 $-C(O)OR^{35}$, $-SO_2R^{36}$, $-C(O)NR^{37}R^{38}$, and $-SO_2NR^{39}R^{40}$, wherein

R^{35} , R^{36} , R^{37} , R^{38} , R^{39} and R^{40} are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and


R^{34} is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

25 R^2 is $-CR^{41}R^{42}$ wherein R^{41} is aryl, and R^{42} is hydroxy; and

R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



groups are substituted with one or more radicals independently selected from keto, haloarylamino, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxyarylamino, alkylsulfonylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, alkylheterocyclylalkylamino, heterocyclylheterocyclylalkylamino, and alkoxycarbonylheterocyclylamino; and

R^4 is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R^4 is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,

nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer thereof.

5


Within Formula IA is another subclass of compounds of interest wherein:

R^1 is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclioxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfanyl, alkenylsulfanyl, alkynylsulfanyl, arylsulfanyl, heterocyclylsulfanyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclioxyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclioxyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R^1 has the formula

35

TOCOT-0342001



wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl,
 5 heterocyclalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkylcarbonylalkylene, arylcarbonylalkylene, and
 heterocyclalkylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl,
 10 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxyalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl,
 aryl, heterocycl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 15 cycloalkylcycloalkyl, heterocyclalkylene, alkylarylene,
 alkylaralkyl, aralkylarylene, alkylheterocycl,
 alkylheterocyclalkylene, alkylheterocyclarylene,
 aralkylheterocycl, alkoxyalkylene, alkoxyarylene,
 alkoxyaralkyl, alkoxyheterocycl, alkoxyalkoxyarylene,
 20 aryloxyarylene, aralkoxyarylene,
 alkoxyheterocyclalkylene, aryloxyalkoxyarylene,
 alkoxyalkylene, alkoxyalkylheterocycl,
 alkoxyalkylheterocyclalkylene, aminoalkyl,
 alkylaminoalkylene, arylaminocarbonylalkylene,
 25 alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene,
 arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
 arylcarbonylalkylene, alkoxyalkylarylene,
 aryloxyalkylarylene, alkylaryloxyalkylarylene,
 arylcarbonylarylene, alkylarylcarbonylarylene,
 30 alkoxyalkylheterocyclarylene,
 alkoxyalkylalkoxyalkylarylene,
 heterocyclalkylalkylarylene, alkylthioalkylene,
 cycloalkylthioalkylene, alkylthioarylene,

R²⁷ is -CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R² is selected from hydrido, halogen, mercapto,
35 alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl,
hydroxyalkyl, aralkyl, alkylheterocyclyl,

heterocyclylalkyl, heterocyclylheterocyclyl,
heterocyclylalkylheterocyclyl, alkylamino, alkenylamino,
alkynylamino, arylamino, aryl(hydroxyalkyl)amino,
heterocyclylamino, heterocyclylalkylamino, aralkylamino,
5 N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl,
aminoalkylamino, aminocarbonylalkylene,
arylaminoalkylene, alkylaminoalkylene, arylaminoarylene,
alkylaminoarylene, alkylaminoalkylamino,
alkylcarbonylaminoalkylene,
10 aminoalkylcarbonylaminoalkylene,
alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl,
aminoalkylthio, alkylaminocarbonylalkylthio,
alkylaminoalkylaminocarbonylalkylthio, alkoxy,
heterocyclyoxy, alkylthio, cyanoalkylthio, alkenylthio,
15 alkynylthio, carboxyalkylthio, arylthio,
heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl,
alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl,
alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl,
carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl,
20 alkoxycarbonylalkyl, alkoxycarbonylalkylamino,
alkoxycarbonylheterocyclyl,
alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino,
alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl,
25 aralkylthio, heterocyclylalkylthio, aminoalkoxy,
cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein
the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and
cycloalkenyl groups are optionally substituted with one
30 or more radicals independently selected from halo, keto,
amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl,
aralkyl, heterocyclylalkyl, epoxyalkyl,
amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy,
haloalkyl, alkylamino, alkynylamino,
35 alkylaminoalkylamino, heterocyclylalkylamino,
alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,

arylsulfonyl, and aralkylsulfonyl; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- 5 - $(CR^{202}R^{203})_y-$;
- $C(O)-$;
- $C(O)-(CH_2)_y-$;
- $C(O)-O-(CH_2)_y-$;
- $(CH_2)_y-C(O)-$;
- 10 - $O-(CH_2)_y-C(O)-$;
- $NR^{202}-$;
- $NR^{202}-(CH_2)_y-$;
- $(CH_2)_y-NR^{202}-$;
- $(CH_2)_y-NR^{202}-(CH_2)_z-$;
- 15 - $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;
- $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;
- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;
- $S(O)_x-(CR^{202}R^{203})_y-$;
- $(CR^{202}R^{203})_y-S(O)_x-$;
- 20 - $S(O)_x-(CR^{202}R^{203})_y-O-$;
- $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;
- $O-(CH_2)_y-$;
- $(CH_2)_y-O-$;
- $S-$;
- 25 - $O-$;

or R^{200} represents a bond;

- R^{201} represents one or more radicals selected from
- the group consisting of hydrido, halogen, hydroxy,
- carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,
- 30 cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,
- aralkyl, heterocyclylalkylene, alkylcarbonyl,
- hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,
- haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,
- alkoxycarbonyl, carboxyalkylcarbonyl,
- 35 alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,
- alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,

alkylamino, aralkylamino, alkylaminoalkylene,
aminocarbonyl, alkylcarbonylamino,
alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,
alkylaminoalkylcarbonylamino,

- 5 aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino,
alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene,
alkylimidocarbonyl, amidino, alkylamidino,
aralkylamidino, guanidino, guanidinoalkylene, or
alkylsulfonylamino; and

- 10 R^{202} and R^{203} are independently selected from hydrido,
alkyl, aryl and aralkyl; and


y and z are independently 0, 1, 2, 3, 4, 5 or 6
wherein y + z is less than or equal to 6; and

z is 0, 1 or 2; or

- 15 R^2 is $-NHCR^{204}R^{205}$ wherein R^{204} is alkylaminoalkylene,
and R^{205} is aryl; or

R^2 is $-C(NR^{206})R^{207}$ wherein R^{206} is selected from
hydrogen and hydroxy, and R^{207} is selected from alkyl,
aryl and aralkyl; or

- 20 R^2 has the formula:



wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

- 25 R^{30} and R^{31} are independently selected from hydrogen,
Alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene,
aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl,
alkoxyalkyl, and alkylcarbonyloxyalkyl; and

- R^{32} is selected from hydrogen, alkyl, aralkyl,
30 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
alkylcarbonylalkylene, arylcarbonylalkylene, and

heterocyclylcarbonylaminoalkylene;

R^{33} is selected from hydrogen, alkyl, $-C(O)R^{35}$,
 $-C(O)OR^{35}$, $-SO_2R^{36}$, $-C(O)NR^{37}R^{38}$, and $-SO_2NR^{39}R^{40}$, wherein
 R^{35} , R^{36} , R^{37} , R^{38} , R^{39} and R^{40} are independently


5 selected from hydrocarbon, heterosubstituted hydrocarbon
 and heterocyclyl; and

R^{34} is selected from hydrogen, alkyl, aminocarbonyl,
 alkylaminocarbonyl, and arylaminocarbonyl; or


R^2 is $-CR^{41}R^{42}$ wherein R^{41} is aryl, and R^{42} is hydroxy;

10 and

R^3 is selected from maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,




15 wherein the R^3 maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,



groups are optionally substituted with one or more
 radicals independently selected from halo, keto, alkyl,
 aralkyl, aralkenyl, arylheterocyclyl, carboxy,
 20 carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio,
 alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl,
 aralkoxy, heterocyclylalkoxy, amino, alkylamino,
 alkenylamino, alkynylamino, cycloalkylamino,
 cycloalkenylamino, arylamino, haloarylamino,
 25 heterocyclylamino, aminocarbonyl, cyano, hydroxy,

- hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene,
 aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy,
 alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl,
 alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino,
 5 aminosulfinyl, aminosulfonyl, alkylsulfonylamino,
 alkylaminoalkylamino, hydroxyalkylamino, aralkylamino,
 aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino,
 alkylheterocyclylamino, heterocyclylalkylamino,
 alkylheterocyclylalkylamino, aralkylheterocyclylamino,
 10 heterocyclylheterocyclylalkylamino,
 alkoxycarbonylheterocyclylamino, nitro,
 alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl,
 aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl,
 alkylhydrazinyl, arylhydrazinyl, or $-NR^{44}R^{45}$ wherein R^{44} is
 15 alkylcarbonyl or amino, and R^{45} is alkyl or aralkyl; and
 R^4 is selected from hydrido, alkyl, alkenyl, alkynyl,
 cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
 R^4 is optionally substituted with one or more radicals
 independently selected from halo, alkyl, alkenyl,
 20 alkynyl, aryl, heterocyclyl, alkylthio, arylthio,
 alkylthioalkylene, arylthioalkylene, alkylsulfinyl,
 alkylsulfinylalkylene, arylsulfinylalkylene,
 alkylsulfonyl, alkylsulfonylalkylene,
 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
 25 aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
 alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
 nitro, alkylamino, arylamino, alkylaminoalkylene,
 arylaminoalkylene, aminoalkylamino, and hydroxy;
 provided that R^3 is other than maleimidyl or
 30 pyridonyl having the structures:




(IV)

(V)

respectively, wherein R^{43} is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; or

- 5 a pharmaceutically-acceptable salt or tautomer thereof.

Another group of compounds of interest consists of compounds of Formula IB:



wherein:

R^1 has the same definition as previously set forth in the description of compounds of Formula IA. In another embodiment, R^1 is selected from hydrido, alkyl, hydroxyalkyl and alkynyl. In still another embodiment, R^1 is hydrido;

R^2 is selected from at least one of the following four categories:

(1) piperidinyl substituted with one or more substituents selected from hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl, wherein said hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl substituents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein

said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or one or more substituents selected from hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl, wherein said hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl substituents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy. In another embodiment, R² is piperidinyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, hydroxyalkylcarbonyl, hydroxyalkenylcarbonyl, and hydroxyalkynylcarbonyl; or one or more substituents selected from optionally substituted hydroxycycloalkyl and hydroxycycloalkylcarbonyl. In still another embodiment, R² is piperidinyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, hydroxyalkenyl, alkoxyalkylene, alkoxyalkenylene, hydroxyalkylcarbonyl, and hydroxyalkenylcarbonyl, and hydroxycycloalkylcarbonyl. In still another

embodiment, R^2 is piperidinyl substituted with at least one substituent selected from optionally substituted lower hydroxyalkyl, lower hydroxyalkylcarbonyl and hydroxycycloalkylcarbonyl.

5 In still another embodiment, R^2 is piperidinyl substituted with 2-hydroxyacetyl, 2-hydroxypropionyl, 2-hydroxy-2-methylpropionyl, 2-hydroxy-2-phenylacetyl, 3-hydroxypropionyl, 2-hydroxy-3-methylbutyryl, 2-hydroxyisocaprotyl, 2-hydroxy-3-phenylpropionyl, 2-hydroxy-3-imidazolylpropionyl, 10 1-hydroxy-1-cyclohexylacetyl, 2-hydroxy-1-cyclohexylacetyl, 3-hydroxy-1-cyclohexylacetyl, 4-hydroxy-1-cyclohexylacetyl, 1-hydroxy-1-cyclopentylacetyl, 2-hydroxy-1-cyclopentylacetyl, 3-hydroxy-1-cyclopentylacetyl, 2-hydroxy-2-cyclohexylacetyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, methoxymethylene, methoxyethylene, methoxypropylene, methoxyisopropylene, ethoxymethylene, 20 ethoxyethylene, ethoxypropylene, and ethoxyisopropylene. In each of the above embodiments, when R^2 is piperidinyl, the piperidinyl ring may be substituted with at least one substituent attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the 25 distal nitrogen heteroatom of the piperidine ring. In each of the above embodiments, the piperidinyl ring may be monosubstituted at the distal nitrogen; and

30 (2) cyclohexyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, alkylaminoalkylene and cycloalkylamino. In another embodiment, R^2 is cyclohexyl substituted with one or more substituents 35 selected from optionally substituted lower hydroxyalkyl, lower alkylaminoalkylene and

cycloalkylamino. In still another embodiment, R^2 is cyclohexyl substituted with one or more substituents selected from optionally substituted lower hydroxyalkyl, lower dialkylaminoalkylene and cycloalkylamino. In still another embodiment, R^2 is cyclohexyl substituted with one or more substituents selected from hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, methylaminomethylene, methylaminoethylene, methylaminopropylene, ethylaminomethylene, ethylaminoethylene, ethylaminopropylene, propylaminomethylene, propylaminoethylene, propylaminopropylene, dimethylaminomethylene, dimethylaminoethylene, dimethylaminopropylene, diethylaminomethylene,

5

10


11

1002430-10704

and di-isobutylamino. In each of the above
embodiments, when R² is cyclohexyl, the cyclohexyl
ring may be substituted with at least one
substituent attached to the 4-position carbon atom
of the cyclohexyl ring heteroatom of the piperidine
ring. In each of the above embodiments, the
cyclohexyl ring may be monosubstituted at the 4-
position carbon atom; and


(4) piperidinylamino substituted with one or
more alkynyl substituents. In another embodiment, R²
is piperidinylamino substituted with optionally
substituted lower alkynyl. In still another
embodiment, R² is piperidinylamino substituted with
optionally substituted ethynyl, propynyl and
butynyl. In still another embodiment, R² is
piperidinylamino substituted with optionally
substituted propargyl. In still another embodiment,
R² is 4-propargylpiperidinylamino. In each of the
above embodiments, when R² is piperidinylamino, the
piperidinyl ring may be substituted with at least
one substituent attached to the distal nitrogen
heteroatom or to a carbon ring atom adjacent to the
distal nitrogen heteroatom of the piperidine ring.
In each of the above embodiments, the piperidinyl
ring may be monosubstituted at the distal nitrogen;
and

R³ is selected from pyridinyl, pyrimidinyl,
quinolinyl, purinyl, maleimidyl, pyridonyl,
thiazolyl, thiazolylalkyl, thiazolylamino,



wherein the R³ pyridinyl, pyrimidinyl, quinolinyl,
purinyl, maleimidyl, pyridonyl, thiazolyl,

thiazolylalkyl, thiazolylamino,





groups may be optionally substituted with one or
 5 more substituents independently selected from
 hydrogen, aryl, alkylamino, alkylthio, alkyloxy,
 aryloxy, arylamino, arylthio, aralkoxy, wherein said
 aryl, alkylamino, alkylthio, alkyloxy, aryloxy,
 arylamino, arylthio, aralkoxy substituents may be
 10 optionally substituted with one or more alkylene,
 alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto,
 amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl,
 alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and
 heteroaralkoxy. In another embodiment, R³ is
 15 optionally substituted pyridinyl or pyrimidinyl. In
 still another embodiment, R³ is unsubstituted
 pyridinyl or pyrimidinyl; and

R⁴ is selected from hydrido, alkyl, alkenyl,
 alkynyl, cycloalkyl, cycloalkenyl, aryl, and
 20 heterocyclyl, wherein R⁴ is optionally substituted
 with one or more substituents independently selected
 from halo, haloalkyl, haloalkoxy, alkoxy, cyano,
 hydroxy, alkyl, alkenyl, and alkynyl, wherein said
 haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy,
 25 alkyl, alkenyl, and alkynyl substituents may be
 optionally substituted with one or more alkylene,
 alkenylene, alkynylene, hydroxy, halo, haloalkyl,
 alkoxy, keto, amino, nitro, cyano, alkylsulfonyl,
 alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy,
 30 heterocyclyl, and heteroaralkoxy. In another
 embodiment, R⁴ is selected from optionally
 substituted cycloalkyl, cycloalkenyl, aryl, and
 heterocyclyl. In still another embodiment, R⁴ is





optionally substituted phenyl. In still another embodiment, R⁴ is phenyl optionally substituted at a substitutable position with one or more radicals independently selected from chloro, fluoro, bromo and iodo. In still another embodiment, R⁴ is phenyl optionally substituted at the meta or para position with one or more chloro radicals; or

a pharmaceutically-acceptable salt or tautomer thereof. Within each of the above embodiments, R² may be located at the 3-position of the pyrazole ring with R⁴ located at the 5-position of the pyrazole ring. Alternatively, R² may be located at the 5-position of the pyrazole ring with R⁴ located at the 3-position of the pyrazole ring.




Still another group of compounds of interest consists of the compounds, their tautomers and their pharmaceutically acceptable salts, of the group consisting of:





147




148




400439-40704





;



;



;



The term "hydrido" denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH₂-) radical. Where used, either alone or within other terms such as "haloalkyl", "alkylsulfonyl", "alkoxyalkyl" and "hydroxyalkyl", "cyanoalkyl" and "mercaptoalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like. The term

"alkenyl" embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The terms "alkenyl" and "lower alkenyl", embrace radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations. The term "alkynyl" embraces linear or branched radicals having at least one carbon-carbon triple bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about six carbon atoms. Examples of alkynyl radicals include propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butyne and 1-pentynyl. The term "cycloalkyl" embraces saturated carbocyclic radicals having three to about twelve carbon atoms. The term "cycloalkyl" embraces saturated carbocyclic radicals having three to about twelve carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkylalkylene" embraces alkyl radicals substituted with a cycloalkyl radical. More preferred cycloalkylalkylene radicals are "lower cycloalkylalkylene" which embrace lower alkyl radicals substituted with a lower cycloalkyl radical as defined above. Examples of such radicals include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl. The term "cycloalkenyl" embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. Cycloalkenyl radicals that are partially unsaturated carbocyclic radicals that contain

two double bonds (that may or may not be conjugated) can be called "cycloalkyldienyl". More preferred cycloalkenyl radicals are "lower cycloalkenyl" radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl and cyclohexenyl. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having one to six carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms "alkoxy" and "alkyloxy" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy.

The term "alkoxyalkyl" embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkylene, acyl, carboxy, and aralkoxycarbonyl. The term "heterocyclyl" embraces saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, which can also be called "heterocyclyl", "heterocycloalkenyl" and "heteroaryl" correspondingly, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and

1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. Heterocyclyl radicals may include a pentavalent nitrogen, such as in tetrazolium and pyridinium radicals. The term "heteroaryl" embraces unsaturated heterocyclyl radicals. Examples of heteroaryl radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyll, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g., 1,2,4- thiadiazolyl, 1,3,4- thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated

condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term "heterocycle" also embraces radicals where heterocyclyl radicals are fused with aryl or cycloalkyl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said "heterocyclyl group" may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino, alkylthio and alkylamino. The term "heterocyclylalkylene" embraces heterocyclyl-substituted alkyl radicals. More preferred heterocyclylalkylene radicals are "lower heterocyclylalkylene" radicals having one to six carbon atoms and a heterocyclyl radicals. The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. The term "alkylthioalkylene" embraces radicals containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkylene radicals are "lower alkylthioalkylene" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkylene radicals include methylthiomethyl. The term "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms, attached to a divalent $-S(=O)-$ radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term "sulfonyl", whether used alone or linked to other terms

such as "alkylsulfonyl", "halosulfonyl" denotes a divalent radical, $-\text{SO}_2-$. "Alkylsulfonyl" embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The term "halosulfonyl" embraces halo radicals attached to a sulfonyl radical. Examples of such halosulfonyl radicals include chlorosulfonyl, and bromosulfonyl. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" denote $\text{NH}_2\text{O}_2\text{S}-$. The term "acyl" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. Examples of such alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, and radicals formed from succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, mandelic, pantothenic, β -hydroxybutyric, galactaric and galacturonic acids. The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", denotes $-(\text{C}=\text{O})-$. The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes $-\text{CO}_2\text{H}$. The term "carboxyalkyl" embraces alkyl radicals substituted with a carboxy radical. More preferred are "lower carboxyalkyl" which embrace lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl. The term "alkoxycarbonyl" means a radical containing an alkoxy

radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are "lower alkoxy carbonyl" radicals with alkyl portions having one to six carbons. Examples of such lower alkoxy carbonyl (ester) radicals include substituted or unsubstituted methoxy carbonyl, ethoxy carbonyl, propoxy carbonyl, butoxy carbonyl and hexyloxy carbonyl. The term "alkoxy carbonyl alkyl" embraces alkyl radicals substituted with a alkoxy carbonyl radical as defined above. More preferred are "lower alkoxy carbonyl alkyl" radicals with alkyl portions having one to six carbons. Examples of such lower alkoxy carbonyl alkyl radicals include substituted or unsubstituted methoxy carbonyl methyl, ethoxy carbonyl methyl, methoxy carbonyl-ethyl and ethoxy carbonyl ethyl. The term "alkyl carbonyl", includes radicals having alkyl, hydroxy alkyl, radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted methyl carbonyl, ethyl carbonyl, propyl carbonyl, butyl carbonyl, pentyl carbonyl, hydroxy methyl carbonyl, hydroxy ethyl carbonyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenyl methyl, triphenyl methyl, phenyl ethyl, and diphenyl ethyl. The aryl in said aralkyl may be additionally substituted with one or more substituents selected independently from halo, alkyl, alkoxy, haloalkyl, haloalkoxy, amino and nitro. The terms benzyl and phenyl methyl are interchangeable. The term "heterocyclyl alkylene" embraces saturated and partially unsaturated heterocyclyl-substituted alkyl radicals (also can be called heterocycloalkyl alkylene and heterocycloalkenyl alkylene correspondingly), such as pyrrolidinyl methyl, and heteroaryl-substituted alkyl radicals (also can be called heteroaryl alkylene), such as pyridyl methyl, quinolyl methyl, thienyl methyl, furyl ethyl, and quinolyl ethyl. The heteroaryl in said heteroaralkyl

may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy. The term "aryloxy" embraces aryl radicals attached through an oxygen atom to other radicals. The term "aralkoxy" embraces aralkyl radicals attached through an oxygen atom to other radicals. The term "aminoalkyl" embraces alkyl radicals substituted with amino radicals. More preferred are "lower aminoalkyl" radicals. Examples of such radicals include aminomethyl, aminoethyl, and the like. The term "alkylamino" denotes amino groups which are substituted with one or two alkyl radicals. Preferred are "lower alkylamino" radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be monosubstituted N-alkylamino or disubstituted N,N-alkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like. The term "arylamino" denotes amino groups which are substituted with one or two aryl radicals, such as N-phenylamino. The "arylamino" radicals may be further substituted on the aryl ring portion of the radical. The term "aminocarbonyl" denotes an amide group of the formula -C(=O)NH₂. The term "alkylaminocarbonyl" denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are "N-alkylaminocarbonyl" and "N,N-dialkylaminocarbonyl" radicals. More preferred are "lower N-alkylaminocarbonyl" and "lower N,N-dialkylaminocarbonyl" radicals with lower alkyl portions as defined above. The term "alkylcarbonylamino" embraces amino groups which are substituted with one alkylcarbonyl radicals. More preferred alkylcarbonylamino radicals are "lower alkylcarbonylamino" having lower alkylcarbonyl radicals as defined above attached to amino radicals. The term "alkylaminoalkylene" embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical.


The "hydrocarbon" moieties described herein are organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Preferably, these moieties comprise 1 to 20 carbon atoms.

The heterosubstituted hydrocarbon moieties described herein are hydrocarbon moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, sulfur, or a halogen atom. These substituents include lower alkoxy such as methoxy, ethoxy, butoxy; halogen such as chloro or fluoro; ethers; acetals; ketals; esters; heterocyclyl such as furyl or thienyl; alkanoxy; hydroxy; protected hydroxy; acyl; acyloxy; nitro; cyano; amino; and amido.

The additional terms used to describe the substituents of the pyrazole ring and not specifically defined herein are defined in a similar manner to that illustrated in the above definitions. As above, more preferred substituents are those containing "lower" radicals. Unless otherwise defined to contrary, the term "lower" as used in this application means that each alkyl radical of a pyrazole ring substituent comprising one or more alkyl radicals has one to about six carbon atoms; each alkenyl radical of a pyrazole ring substituent comprising one or more alkenyl radicals has two to about six carbon atoms; each alkynyl radical of a pyrazole ring substituent comprising one or more alkynyl radicals has two to about six carbon atoms; each cycloalkyl or cycloalkenyl radical of a pyrazole ring substituent comprising one or more cycloalkyl and/or cycloalkenyl radicals is a 3 to 8 membered ring cycloalkyl or

cycloalkenyl radical, respectively; each aryl radical of a pyrazole ring substituent comprising one or more aryl radicals is a monocyclic aryl radical; and each heterocyclyl radical of a pyrazole ring substituent comprising one or more heterocyclyl radicals is a 4-8 membered ring heterocyclyl.

The present invention comprises the tautomeric forms of compounds of Formulae I and IX (as well as the compounds of Formulae (IA and IXA)). As illustrated below, the pyrazoles of Formula I and I' are magnetically and structurally equivalent because of the prototropic tautomeric nature of the hydrogen:



The present invention also comprises compounds of Formula I, IA, IX, IXA, X, XA and XI having one or more asymmetric carbons. It is known to those skilled in the art that those pyrazoles of the present invention having asymmetric carbon atoms may exist in diastereomeric, racemic, or optically active forms. All of these forms are contemplated within the scope of this invention. More specifically, the present invention includes enantiomers, diastereomers, racemic mixtures, and other mixtures thereof.

The present invention comprises a pharmaceutical composition for the treatment of a TNF mediated disorder, a p38 kinase mediated disorder, inflammation, and/or arthritis, comprising a therapeutically-effective amount

of a compound of Formula I and/or IA, or a therapeutically-acceptable salt or tautomer thereof, in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The present invention further encompasses substituted pyrazoles that specifically bind to the ATP binding site of p38 kinase. Without being held to a particular theory, applicants hypothesize that these substituted pyrazoles interact with p38 kinase as set forth below. As the substituent at the 3-position of the pyrazole ring approaches the ATP binding site of p38 kinase, a hydrophobic cavity in the p38 kinase forms around the 3-position substituent at the binding site. This hydrophobic cavity is believed to form as the 3-position substituent binds to a specific peptide sequence of the enzyme. In particular, it is believed to bind to the sidechains of Lys₅₂, Glu₆₉, Leu₇₃, Ile₈₂, Leu₈₄, Leu₁₀₁ and the methyl group of the Thr₁₀₃ sidechain of p38 kinase at the ATP binding site (wherein the numbering scheme corresponds to the numbering scheme conventionally used for ERK-2). Where the 3-position substituent is aryl or heteroaryl, such aryl or heteroaryl may be further substituted. It is hypothesized that such ring substituents may be beneficial in preventing hydroxylation or further metabolism of the ring.

The substituent at the 4-position of the pyrazole ring is one that is a partial mimic of the adenine ring of ATP, although it may be further elaborated. Preferably, it is a planar substituent terminated by a suitable hydrogen bond acceptor functionality. It is hypothesized that this acceptor hydrogen bonds to the backbone N-H of the Met₁₀₆ residue while one edge of this substituent is in contact with bulk solvent.


Substitution at the 5-position of the pyrazole ring is well tolerated and can provide increased potency and selectivity. It is hypothesized that such substituents

extend out in the direction of the bulk solvent and that suitable polar functionality placed at its terminus can interact with the sidechain of Asp¹⁰⁹, leading to increased potency and selectivity.

Similarly, substitution on the nitrogen atom at the 1- or 2-position of the pyrazole ring is well tolerated and can provide increased potency. It is hypothesized that a hydrogen substituent attached to one of the ring nitrogen atoms is hydrogen bonded to Asp₁₆₅. Preferably, the nitrogen atom at the 2-position is double bonded to the carbon atom at the 3-position of the pyrazole while the nitrogen atom at the 1-position of the pyrazole is available for substitution with hydrogen or other substituents.

The 5-position substituent and the 1- or 2-position substituent of the pyrazole can be selected so as to improve the physical characteristics, especially aqueous solubility and drug delivery performance, of the substituted pyrazole. Preferably, however, these substituents each have a molecular weight less than about 360 atomic mass units. More preferably, these substituents each have a molecular weight less than about less than about 250 atomic mass units. Still more preferably, these substituents have a combined molecular weight less than about 360 atomic mass units.

A class of substituted pyrazoles of particular interest consists of those compounds having the formula:



wherein

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R² is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical that binds with p38 kinase at said ATP binding site of p38 kinase; and

R³ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality; and

R⁴ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units;

provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and further provided R⁴ is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

In this embodiment of the invention, one or more of R¹, R², R³ and R⁴ preferably are selected from the corresponding groups of the compounds of Formula I and/or IA. More preferably, R³ is an optionally substituted pyridinyl or pyrimidinyl, R⁴ is a halo substituted phenyl, and R¹ and R² have the definitions set forth immediately above.

A class of substituted pyrazoles of particular interest consists of those compounds of Formula XI wherein

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R² is a hydrocarbyl, heterosubstituted hydrocarbyl or

400430 120704


heterocyclyl radical wherein said radical binds with Lys₅₂, Glu₆₉, Leu₇₃, Ile₈₂, Leu₈₄, Leu₁₀₁, and Thr₁₀₃ sidechains at said ATP binding site of p38 kinase, said radical being substantially disposed within a hydrophobic cavity formed during said binding by p38 kinase at the ATP binding site; and

R³ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality that hydrogen bonds with the N-H backbone of Met₁₀₆ of p38 kinase; and

R⁴ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units.

The present invention also comprises a therapeutic method of treating a TNF mediated disorder, a p38 kinase mediated disorder, inflammation and/or arthritis in a subject, the method comprising treating a subject having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Formula I and/or IA.


For example, in one embodiment the present invention comprises a therapeutic method of treating a TNF mediated disorder, a p38 kinase mediated disorder, inflammation and/or arthritis in a subject, the method comprising treating a subject having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Formula I



wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocycliloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocycliloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula



wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl,

heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R^{26} is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxy carbonylalkylene, and alkylaminoalkyl; and

R^{27} is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxy carbonylalkylene, alkoxy carbonyl heterocyclyl, alkoxy carbonyl heterocyclyl carbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxy carbonylarylene, aryloxy carbonylarylene, alkylaryloxy carbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxy carbonyl heterocyclylarylene, alkoxy carbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxy carbonylarylene, arylcarbonylarylene,

alkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or


R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29} is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R^{26} and R^{27} together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R^2 is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, cycloalkyl, cycloalkenyl, alkoxy, heterocycliloxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxyalkyl,

carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² has the formula:



wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;


R³³ is selected from hydrogen, alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁹R⁴⁰, wherein R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently

selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and


R^{34} is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R^2 is $-CR^{41}R^{42}$ wherein R^{41} is aryl, and R^{42} is hydroxy; and

R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,



, and



(IV)

(V)

wherein R^{43} is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxy carbonyl, aryloxy carbonyl, heterocyclylalkoxy carbonyl, alkoxy carbonylamino, alkoxy aralkylamino, aminosulfinyl, aminosulfonyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl,

arylhidrazinyl, or $-NR^{44}R^{45}$ wherein R^{44} is alkylcarbonyl or amino, and R^{45} is alkyl or aralkyl; and

R^4 is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R^4 is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R^3 is not 2-pyridinyl when R^4 is a phenyl ring containing a 2-hydroxy substituent and when R^1 is hydrido; further provided R^2 is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R^4 is hydrido; and further provided R^4 is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

The present invention also is directed to the use of the compounds of Formula I and/or IA in the preparation of medicaments useful in the treatment and/or prophylaxis of p38 kinase mediated conditions and disorders.


Also included in the family of compounds of Formulae I and/or IA are the pharmaceutically-acceptable salts and prodrugs thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-

acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formulae I and/or IA may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclyl, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, *p*-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, β -hydroxybutyric, galactaric and galacturonic acid.

Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I and/or IA include metallic salts and organic salts. More preferred metallic salts include, but are not limited to appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts and other physiological acceptable metals. Such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, tromethamine, diethylamine, *N,N'*-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (*N*-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formulae I and/or IA by reacting, for example, the appropriate acid or base with the compound of Formulae I and/or IA.

The present invention additionally comprises a class

of compounds defined by Formula XX:




(XX)

wherein R³ and R⁴ are as defined for the compounds of Formulae I and/or IA. Also included in the family of compounds of Formula XX are the pharmaceutically-acceptable salts and prodrugs thereof.

The compounds of Formula XX are useful as intermediates in the preparation of the compounds of Formulae I and/or IA. In addition, the compounds of Formula XX themselves have been found to show usefulness as p38 kinase inhibitors. These compounds are useful for the prophylaxis and treatment of the same p38 kinase mediated disorders and conditions as the compounds of formulae I and/or IA. Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula XX or a pharmaceutically acceptable salt or prodrug thereof.

The present invention further comprises a pharmaceutical composition for the treatment of a TNF mediated disorder, a p38 kinase mediated disorder, inflammation, and/or arthritis, comprising a therapeutically-effective amount of a compound of Formula XX, or a therapeutically-acceptable salt or prodrug thereof, in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.


The compounds of the invention can be prepared according to the following procedures of Schemes I-XXIX wherein R^1 , R^2 , R^3 , R^4 , R^5 and Ar^1 are as previously defined for the compounds of Formula I, IX, X and XI except where expressly noted.



Scheme I shows the synthesis of pyrazole 5 by two routes. Condensation of the pyridylmethyl ketone 1 with aldehyde 2 in the presence of a base, such as piperidine, in a solvent, such as toluene or benzene, either in the absence or the presence of acetic acid at reflux, provides the α,β -unsaturated ketone 3. In route 1, ketone 3 is first converted to epoxide 4, such as by treatment with hydrogen peroxide solution at room temperature, in the presence of base such as sodium hydroxide. Treatment of epoxide 4 with hydrazine in ethanol or other suitable solvent at a temperature ranging up to reflux, yields pyrazole 5. In route 2, ketone 3 is condensed directly with tosyl hydrazide in the presence of an acid such as acetic acid, at reflux,

to provide pyrazole 5. Alternatively, the intermediate tosyl hydrazone 6 may be isolated, conversion of it to pyrazole 5 is effected by treatment with a base, such as potassium hydroxide, in a suitable solvent, such as ethylene glycol, at a temperature ranging from 25 °C up to 150 °C.

SCHEME II



Scheme II shows the synthesis of pyrazole 12 of the present invention. The treatment of pyridine derivative 7 with ester 8 in the presence of a base, such as sodium bis(trimethylsilyl)amide, in a suitable solvent, such as tetrahydrofuran, gives ketone 9. Treatment of ketone 9 or a hydrohalide salt of ketone 9 with a halogenating agent, such as bromine, N-bromosuccinimide or N-chlorosuccinimide, in suitable solvents, such as acetic acid, methylene chloride, methanol, or combinations thereof, forms the α -halogenated ketone 10 (wherein X is halo). Examples of suitable hydrohalide salts include

the hydrochloride and hydrobromide salts. Reaction of haloketone 10 with thiosemicarbazide 11 (where R^6 and R^7 can be hydrido, lower alkyl, phenyl, heterocyclyl and the like or where R^6 and R^7 form a heterocyclyl ring optionally containing an additional heteroatom) provides pyrazole 12. Examples of suitable solvents for this reaction are ethanol and dimethylformamide. The reaction may be carried out in the presence or absence of base or acid at temperatures ranging from room temperature to 100 °C.


Thiosemicarbazides which are not commercially available may be conveniently prepared by one skilled in the art by first reacting an appropriate amine with carbon disulfide in the presence of a base, followed by treatment with an alkylating agent such as methyl iodide. Treatment of the resultant alkyl dithiocarbamate with hydrazine results in the desired thiosemicarbazide. This chemistry is further described in E. Lieber and R.C. Orlowski, J. Org. Chem., Vol. 22, p. 88 (1957). An alternative approach is to add hydrazine to appropriately substituted thiocyanates as described by Y. Nomoto et al., Chem. Pharm. Bull., Vol. 39, p.86 (1991). The Lieber and Nomoto publications are incorporated herein by reference.

Where Compound 12 contains a second derivatizable nitrogen atom, a wide range of substituents may be placed on that atom by methods known to those skilled in the art. For example, in cases where R^6 and R^7 together with the nitrogen atom to which they are attached comprise a piperazine ring, the distal nitrogen of that ring may be, for example, (i) methylated by reaction with formic acid and formaldehyde; (ii) propargylated by reaction with propargyl bromide in a suitable solvent such as dimethylformamide in the presence of a suitable base such as potassium carbonate; (iii) acylated or sulfonylated by reaction with a suitable acyl or sulfonyl derivative in

pyridine; or (iv) cyclopropanated by reaction with [1(1-ethoxycyclopropyl)oxy]trimethylsilane using sodium cyanoborohydride in the presence of acetic acid.

Additionally, one of the nitrogen atoms of the pyrazole ring optionally may be alkylated by reaction with an alkyl halide, such as propargyl bromide, in the presence of a strong base such as sodium hydride.


SCHEME III



Scheme III shows the synthesis of pyrazole 19 in more general form by three routes. In Route 1, ketone 13 is condensed with hydrazine 14 to give the substituted hydrazide 16, which is then reacted with acyl halide or anhydride 17 at low temperature to provide acyl hydrazone 18. Upon heating at a temperature up to 200°C, acyl hydrazone 18 is converted to pyrazole 19. In Route 2, acyl hydrazone 18 is formed directly by reaction of ketone 13 with acyl hydrazone 15, formed by reaction of hydrazine with a carboxylic acid ester, at room


temperature. Heating acyl hydrazone 18 as above then provides pyrazole 19. In Route 3, ketone 13 is treated with acyl hydrazide 15 at a suitable temperature, ranging from room temperature to about 200 °C, to give pyrazole 19 directly. Alternatively, this condensation may be carried out in an acidic solvent, such as acetic acid, or in a solvent containing acetic acid.

SCHEME IV



Synthetic Scheme IV describes the preparation of pyrazole 19.

SCHEME V



X = halyl, alkyl


R¹ = Me, CH₂CH₂OH

R⁴ = cyclopropyl, 4-pyridyl,
4-imidazolyl

Scheme V shows the two step synthesis of the 3-substituted 4-pyridyl-5-arylpirazoles **33** of the present invention by cyclization of hydrazone dianions with carboxylates. In step 1, the reaction of substituted pyridylmethyl ketones **31** (prepared, for example, as later described in Scheme IX) with hydrazines in the presence of solvents such as ethanol gives ketohydrazones **32**. Examples of suitable hydrazines include, but are not limited to, phenylhydrazine and p-methoxyphenylhydrazine. In step 2, the hydrazones **32** are treated with two equivalents of a base such as sodium bis(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran to generate dianions. This reaction may be carried out at temperatures of about 0 °C or lower. In the same step, the dianions then are condensed with esters such as methyl isonicotinate, methyl cyclopropanecarboxylate, to give the desired pyrazoles

33. It may be necessary to treat the product from this step with a dehydrating agent, such as a mineral acid, to produce the target pyrazole in some instances.

SCHEME VI



R^3 = heteroaryl

R^4 = substituted or unsubstituted phenyl

X = lower alkyl, lower alkenyl or aryl

Scheme VI shows an alternative method for synthesizing pyrazoles which are unsubstituted at the 5 position of the ring. In accordance with this method, a heteroarylmethyl ketone 34 is synthesized by first treating a heteroarylmethane with a strong base such as lithium hexamethyldisilazide or lithium diisopropylamide. Examples of suitable heteroarylmethanes are 4-methylpyridine, 4-methylpyrimidine, 2,4-dimethylpyridine, 2-chloro-4-methylpyrimidine, 2-chloro-4-methylpyridine and 2-fluoro-4-methylpyridine. The resulting heteroarylmethyl lithium species is then reacted with a substituted benzoate ester to produce ketone 34. Examples of suitable benzoate esters are methyl and ethyl p-fluorobenzoate and ethyl and methyl p-chlorobenzoate. Ketone 34 is converted to the aminomethylene derivative 35 by reaction with an aminomethylenating agent such as dimethylformamide dimethyl acetal or tert-butoxybis(dimethylamino)methane. Ketone 35 is converted to pyrazole 36 by treatment with hydrazine.


A modification of this synthetic route serves to regioselectively synthesize pyrazole 38 which contains a substituted nitrogen at position 1 of the ring. Ketone 34 is first converted to hydrazone 37 by reaction with the appropriate substituted hydrazine. Examples of suitable hydrazines are N-methylhydrazine and N-(2-hydroxyethyl)hydrazine. Reaction of hydrazone 37 with an aminomethylenating agent produces pyrazole 38. Examples of suitable aminomethylenating agents include dimethylformamide dimethyl acetal and tert-butoxybis(dimethylamino)methane.

In cases where the R³ substituent of pyrazoles 36 and 38 bears a leaving group such as a displaceable halogen, subsequent treatment with an amine produces an amino-substituted heteroaromatic derivative. Examples of such amines include benzylamine, cyclopropylamine and ammonia.

The leaving group may also be replaced with other nucleophiles such as mercaptides and alkoxides. Examples of substitutable R^3 groups include, but are not limited to, 2-chloropyridinyl and 2-bromopyridinyl groups.


202011 03:1200

SCHEME VII





Scheme VII describes the preparation of derivatives from pyrazole 5 (prepared in accordance with Scheme I) when $R^2 = \text{CH}_3$. Oxidation of pyrazole 5 gives carboxylic acid 39, which is then reduced to hydroxymethyl compound 40, or coupled with amine $\text{NR}^{10}\text{R}^{11}$ (wherein R^{10} and R^{11} are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur) to form amide 41 followed by reduction to generate amine derivative 42.

SCHEME VIII







Scheme VIII illustrates the synthesis of pyrazoles 44 and 45 from pyrazole 43. The alkylation of the ring nitrogen atoms of pyrazole 43 can be accomplished using conventional techniques. Treatment of pyrazole 43 with an appropriate base (for example, sodium hydride) followed by treatment with an alkyl halide (for example, CH_3I) yields a mixture of isomers 44 and 45.

SCHEME IX



"desoxybenzoïn"





Scheme IX illustrates the synthesis of 3-aryl-4-pyridyl-pyrazoles of the present invention. Benzoate 46 is reacted with pyridine 47 in the presence of a strong base, such as an alkali metal hexamethyldisilazide (preferably sodium hexamethyldisilazide or lithium hexamethyldisilazide), in a suitable solvent, such as tetrahydrofuran, to give desoxybenzoin 48. Desoxybenzoin 48 is then converted to ketone 49 by treatment with an excess of dimethylformamide dimethyl acetal. Ketone 49 is then reacted with hydrazine hydrate in a suitable solvent such as ethanol to yield pyrazole 50. In Scheme IX, R¹² represents one or more radicals independently selected from the optional substituents previously defined for R⁴. Preferably, R¹² is hydrogen, alkyl, halo, trifluoromethyl, methoxy or cyano, or represents methylenedioxy.



The 3-aryl-4-pyrimidinyl-pyrazoles of the present invention can be synthesized in the manner of Scheme IX by replacing pyridine 47 with the corresponding pyrimidine. In a similar manner, Schemes X through XVII can be employed to synthesize 3-aryl-4-pyrimidinyl-pyrimidines corresponding to the 3-aryl-4-pyrimidinyl-pyrazoles shown in those schemes.


52

Schemes XI through XVIII illustrate further modifications that can be made to Scheme IX to synthesize other 3-aryl-4-pyridyl-pyrazoles having alternative substituents.


SCHEME XI**SCHEME XII**

In Scheme XII, X is chloro, fluoro or bromo; R^{13} is, for example, hydrogen, alkyl, phenyl, aralkyl, heteroarylalkyl, amino or alkylamino; and R^{20} is, for example, hydrogen or alkyl.


SCHEME XIIISCHEME XIV

SCHEME XV

In Scheme XV, n is 1, 2, 3, 4 or 5; and R^{14} and R^{15} are independently selected from, for example, hydrogen, alkyl or aryl, or together with the nitrogen atom to which they are attached form a 4-7 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.


SCHEME XVI

In Scheme XVI, R^{16} is selected, for example, from hydrogen, alkyl and phenyl.

SCHEME XVII

In Scheme XVII, R^{17} is selected, for example, from alkyl, phenylalkyl and heterocyclalkyl.


SCHEME XVIII



Compounds wherein the 2-position of the pyridine ring is substituted by a carboxyl group or a carboxyl derivative may be synthesized according to the procedures outline in Scheme XVIII. The starting pyridyl pyrazole 67 is converted to the 2-cyano derivative 68 by first conversion to its pyridine N-oxide by reaction with an oxidizing agent such as m-chloroperoxybenzoic acid.

Treatment of the pyridine N-oxide with trimethylsilyl cyanide followed by dimethylcarbamoyl chloride produces the 2-cyano compound **68**. Compound **68** is converted to its carboxamide **69** by reaction with hydrogen peroxide in the presence of a suitable base. Examples of suitable bases include potassium carbonate and potassium bicarbonate. Carboxamide **69** is converted to its methyl ester **70** by reaction with dimethylformamide dimethyl acetal in methanol. The ester **70** is converted to its carboxylic acid **71** by saponification. Typical saponification conditions include reaction with a base such as sodium hydroxide or potassium hydroxide in a suitable solvent such as ethanol or ethanol and water or methanol and water or the like. Ester **70** is also convertible to substituted amide **72** by treatment with a desired amine, such as methylamine at a suitable temperature. Temperatures may range from room temperature to 180°C. In Scheme XVIII, R¹⁸ and R¹⁹ are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.

SCHEME XIX



The synthesis of compound **77**, wherein the amino group is extended two methylene units from the pyrazole


ring is illustrated in Scheme XIX above. Reaction of pyrazole 73 with a protecting reagent such as 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) in the presence of a base such as sodium hydride yields protected pyrazole 74. This reaction results in a mixture of regioisomers wherein the 2-(trimethylsilyl)-ethoxymethyl (SEM) group may be attached to either of the nitrogen atoms of the pyrazole ring. Alternatively, protecting reagents such as 2-methoxyethoxymethyl chloride (MEMCl) also may be used.

Reaction of compound 74 with a suitable derivative of dimethyl formamide, followed by exposure to water, leads to aldehyde 75. Examples of suitable derivatives of dimethylformamide include tert.-butoxybis(dimethylamino)methane and dimethylformamide dimethyl acetal. One skilled in the art will understand that this leads to the formation of a reactive vinyl amine as an intermediate. The reaction may be carried out in the reagent itself or in the presence of dimethylformamide as solvent. Suitable reaction temperatures range from about 50 °C to about 153 °C. The contacting of the intermediate vinyl amine with water may be carried out in solution in a suitable solvent such as methanol, ethanol, acetone, or dioxane. Alternatively, a solution of the vinyl amine in a suitable solvent may be contacted with hydrated silica gel.

Aldehyde 75 may be reductively aminated to amine 76 by reaction with the desired amine in the presence of a reducing agent. Typical reducing agents include sodium cyanoborohydride, sodium borohydride or hydrogen in the presence of a catalyst, such as a palladium/carbon catalyst or a Raney nickel catalyst, either at atmospheric pressure or in a pressurized system. An acid catalyst such as acetic acid or dilute hydrochloric acid may also be employed. The reaction may be run at ambient temperature or may be heated.

Pyrazole 77 is obtained by removal of the pyrazole nitrogen protecting group. The deprotection reaction employed will depend upon the specific protecting group removed. A 2-(trimethylsilyl)ethoxymethyl group can be removed, for example, by reaction of amine 76 with tetrabutylammonium fluoride while a 2-methoxyethoxymethyl group can be removed, for example, by acid hydrolysis.

100430-4034
100430-4034


SCHEME XX

Scheme XX shows the syntheses of pyrazole 82 and its derivatives 83 and 85. A substituted 4-picoline 78 is condensed with ethyl ester derivative 79 in the presence of a base such as lithium diisopropylamide to give ketone derivative 80. An example of a suitable picoline is 4-picoline. Suitable ethyl ester derivatives include ethyl 4-piperidinylacetate (Compound 79, $n = 1$). Ester 79 may be synthesized, for example, by hydrogenation of ethyl 4-pyridylacetate and protection of the resulting piperidine nitrogen as the tert.-butoxycarbonyl (Boc) derivative by reaction with tert.-butoxycarbonyl chloride. The hydrogenation may be carried out, for example, at pressures from atmospheric to 100 psi. Suitable catalysts include 5% platinum on carbon. The presence of an acid such as hydrochloric acid may also improve reaction performance.

Treatment of 80 with a substituted benzaldehyde provides unsaturated ketone 81. Pyrazole 82 may be synthesized by treatment of 81 with *p*-toluenesulfonylhydrazide in the presence of acetic acid. During this reaction, the protecting tert.-butoxycarbonyl group is removed. Derivatization of pyrazole 82 by appropriate methods as described in Scheme II for analogous piperazine derivatives gives various pyrazole derivatives 83.

Alternatively, unsaturated ketone 81 can be converted to pyrazole 84 by first reaction with hydrogen peroxide in the presence of sodium or potassium hydroxide, followed by reaction with hydrazine. Using trifluoroacetic acid, the tert.-butoxycarbonyl group may be removed from pyrazole 84 to give pyrazole 82.

Alternatively, the tert.-butoxycarbonyl group of 84 may be reduced with a reagent such as lithium aluminum hydride to provide the methyl derivative 85.

SCHEME XXI

Scheme XXI shows the synthesis of pyrazoles 92. Treatment of compound 86 with ester 87 in the presence of a base, such as sodium bis(trimethylsilyl)amide, in a suitable solvent such as tetrahydrofuran, gives ketone 88. Substituent R^3 is typically heteroaryl, preferably pyridinyl or pyrimidinyl, and more preferably 4-pyridinyl. Substituent R^4 is typically aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkyl or aralkyl, and is preferably a substituted phenyl. R^{103} can be, for example, lower alkyl.


Treatment of ketone 88 with carbon disulfide, dibromomethane, and a base such as potassium carbonate in a suitable solvent such as acetone gives dithietane 89. Other suitable bases include, but are not limited to, carbonates such as sodium carbonate, tertiary amines such as triethylamine or diazabicycloundecane (DBU), and alkoxides such as potassium tert-butoxide. Other suitable solvents include, but are not limited to, low molecular weight ketones, methyl ethyl ketone, tetrahydrofuran, glyme, acetonitrile, dimethylformamide, dimethylsulfoxide, dichloromethane, benzene, substituted benzenes and toluene.

Dithietane 89 may be reacted with an appropriate amine, with or without heating, in an acceptable solvent such as toluene or acetonitrile to make thioamide 90. Thioamide 90 is treated with hydrazine or a substituted hydrazine in an appropriate solvent such as tetrahydrofuran or an alcohol, with or without heating, to produce pyrazole 92 and/or its tautomer.

Alternatively, thioamide 90 can be reacted with an alkyl halide or a sulphonic acid ester to yield substituted thioamide 91. Substituted thioamide 91 is treated with hydrazine or a substituted hydrazine in an appropriate solvent such as tetrahydrofuran or an alcohol, with or without heating, to produce pyrazole 92 or its tautomer.

R^{104} and R^{105} can be independent radicals or can form a heterocyclyl ring that is optionally substituted and/or contains an additional heteroatom.


TOGETHER 03/03/00




Scheme XXII shows the synthesis of substituted 5-

amino pyrazoles 98 and 99. Desoxybenzoin 93 (prepared, for example, as illustrated in Scheme IX, supra, or Example C-1, infra) is reacted with an aminomethylenating agent, such as N,N-dimethylformamide dimethyl acetal, to form aminomethylene ketone 94. Aminomethylene ketone 94 is converted to isoxazole 95 by treatment with a hydroxylamine in a suitable solvent such as ethanol. Isoxazole 95 is treated with a base, such as dilute aqueous sodium hydroxide, to form cyanoketone 96. Cyanoketone 96 is then reacted with a chlorinating agent, such as phosphorous trichloride, to form a vinyl chloride which is then treated with hydrazine hydrate (or a substituted hydrazine hydrate) to form amino pyrazole 97. Amino pyrazole 97 can be reacted further with a variety of alkyl halides, such as methyl bromoacetate, bromoacetonitrile, and chloroethylamine, to form the appropriate mono- or disubstituted, cyclic or acyclic amino pyrazole 98. Typical R^{106} and R^{107} substituents include, for example, hydrogen and alkyl. In addition, amino pyrazole 97 can be reacted further with a variety of acylating agents, such as benzyliminodiacetic acid and N,N-dimethylglycine, to give the corresponding mono- or disubstituted, cyclic or acyclic amide or imide 99. Typical R^{108} and R^{109} substituents include, for example, hydrogen, alkyl and acyl.

SCHEME XXIII




Scheme XXIII shows the synthesis of sulfoxide/sulfone **103**. Ketone **100**, wherein X is preferably halo such as fluoro or chloro, in a solvent, such as tetrahydrofuran, is treated with a suitable base, such as sodium hydride or potassium t-butoxide, to yield an enolate intermediate. The enolate intermediate is reacted with carbon disulfide and then alkylated with an appropriate alkylating agent, such as methyl iodide, benzyl bromide, or trimethylsilylchloride, to form dithioketene acetal **101**. Dithioketene acetal **101** can be cyclized to pyrazole **102** using hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in a suitable solvent, such as tetrahydrofuran or ethanol. Pyrazole **102** is then treated with an oxidizing agent, such as potassium peroxymonosulfate, ammonium persulfate, or 3-chloroperoxybenzoic acid, to generate sulfoxide **103** (n=1) and/or sulfone **103** (n=2).

SCHEME XXIV


Scheme XXIV shows the synthesis of pyrazole **106**. Dithioketene acetal **104** in a suitable solvent, such as toluene, is combined with a secondary amine, wherein Z is preferably S or $-NCH_3$, and heated to about 80-110 °C. After the solution has been heated for several hours, any insoluble bis substituted material may be removed by filtration. Mono substituted product **105** is then reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in a solvent, such as tetrahydrofuran or ethanol, at ambient up to reflux temperatures, to form pyrazole **106**.

SCHEME XXV




Scheme XXV shows the synthesis of pyrazole **109**. Dithietane **107** is added to a solution of a sodium or potassium alkoxide in tetrahydrofuran. The alkoxide may be generated by treating an alcohol, in tetrahydrofuran, with a suitable base, such as sodium hydride, sodium hexamethyldisilazide, or potassium hexamethyldisilazide. The reaction mixture is stirred from 4 to 72 hours at room temperature. The resulting thionoester **108** is reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in ethanol, methanol, or tetrahydrofuran at room temperature for about 2-18 hours to generate pyrazole **109**.


SCHEME XXVI




Scheme XXVI shows the synthesis of pyrazole **112**. To dithietane **107** in a suitable solvent, such as toluene, is added an amine, such as thiomorpholine and heated to about 80-110 °C, to form thioamide **110**. Thioamide **110** may be isolated or used directly in the next reaction step. To thioamide **110** in tetrahydrofuran is added a suitable base, such as potassium t-butoxide, and the resulting thiol anion alkylated with iodomethane to form alkylated thioamide **111**. Alkylated thioamide **111** can be cyclized with hydrazine (or substituted hydrazine), in a solvent, such as tetrahydrofuran or ethanol, to generate pyrazole **112**.

SCHEME XXVII

Scheme XXVII shows the synthesis of pyrazole 114. Dithietane 107 in a suitable solvent, such as tetrahydrofuran or ethanol, is reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), at room temperature up to the reflux temperature of the solvent to generate thiopyrazole 113. The thiol group of thiopyrazole 113 may be alkylated with a variety of alkylating agents, such as alkyl halides or Michael acceptors, including, but not limited to, methyl chloroacetate, ethyl acrylate, and benzyl bromide, in the presence of a suitable base such as potassium carbonate, sodium ethoxide or triethylamine, in a solvent such as dimethylformamide or ethanol to generate pyrazole 114.

SCHEME XXVIII

Scheme XXVIII shows the synthesis of pyrazole 117. Pyrazoles containing acid labile amine protecting groups, such as pyrazole 115, may be treated with a suitable acid catalyst, such as trifluoroacetic acid in dichloromethane or HCl in ethanol or dioxane to yield amine 116. Amine 116 can then be acylated or alkylated by methods known to one of ordinary skill in the art, such as reacting amine 116 with a reagent such as acetyl chloride or methyl iodide in the presence of a suitable base, such as potassium carbonate or triethylamine. In addition, N-methylation can be performed directly, using formaldehyde and formic acid in ethanol/water at reflux to give pyrazole 117 wherein R¹¹⁴ is methyl.

SCHEME XXIX

Scheme XXIX shows the synthesis of pyrazole 120. Pyrazoles containing base labile esters, such as pyrazole 118, may be treated with a suitable base, such as, sodium hydroxide to generate free acid 119. Acid 119 can then be aminated by methods known to one of ordinary skill in the art, such as treating acid 119 with a suitable coupling reagent, such as 1-(3-dimethylaminopropyl)3-ethylcarbodiimide hydrochloride or O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate, with or without catalysts, such as 1-hydroxybenzotriazole or N-hydroxysuccinimide, and an appropriate amine. In addition, amidation can be performed directly, by treating the methyl ester with an appropriate amine, for example N-methylpiperazine, in a suitable solvent such as dimethylformamide or methanol, at a temperature from room temperature up to reflux to generate pyrazole 120.


The following examples contain detailed descriptions of the methods of preparation of compounds of Formulas I, IA, XI, X, XI, and XX. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned structures. In some cases, the assigned structures were confirmed by nuclear Overhauser effect (NOE) experiments.

The following abbreviations are used:

HCl - hydrochloric acid
MgSO₄ - magnesium sulfate
Na₂SO₄ - sodium sulfate
NaIO₄ - sodium periodate
NaHSO₃ - sodium bisulfite
NaOH - sodium hydroxide
KOH - potassium hydroxide
P₂O₅ - phosphorus pentoxide
Me - methyl
Et - ethyl
MeOH - methanol
EtOH - ethanol
HOAc (or AcOH) - acetic acid
EtOAc - ethyl acetate
H₂O - water
H₂O₂ - hydrogen peroxide
CH₂Cl₂ - methylene chloride
K₂CO₃ - potassium carbonate
KMnO₄ - potassium permanganate
NaHMDS - sodium hexamethyldisilazide
DMF - dimethylformamide
EDC - 1-(3-dimethylaminopropyl)3-ethylcarbodiimide

hydrochloride
 HOBT - 1-hydroxybenzotriazole
 mCPBA - 3-chloroperoxybenzoic acid
 Ts - tosyl
 TMSCN - trimethylsilyl cyanide
 Me₂NCOCl - N,N-dimethylcarbamoyl chloride
 SEM-Cl - 2-(trimethylsilyl)ethoxymethyl chloride
 h - hour
 hr - hour
 min - minutes
 THF - tetrahydrofuran
 TLC - thin layer chromatography
 DSC - differential scanning calorimetry
 b.p. - boiling point
 m.p. - melting point
 eq - equivalent
 RT - room temperature
 DMF DMA - dimethylformamide dimethyl acetal
 TBAF - tetrabutylammonium fluoride
 Boc - tert.-butoxycarbonyl
 DBU - diazabicycloundecane
 DMF(OMe)₂ - N,N-dimethylformamide dimethyl acetal
 Et₃N - triethylamine
 TMSCl - trimethylsilylchloride
 TFA - trifluoroacetic acid
 TBTU - O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium
 tetrafluoroborate
 psi - pounds per square inch
 ESHRMS - electron spray high resolution mass spectroscopy

Example A-1



4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 4-(3-fluoro-4-methoxyphenyl)-3-pyridyl-3-butene-2-one


A solution of 4-pyridylacetone (1.0 g, 7.4 mmol), 3-fluoro-*p*-anisaldehyde (1.25 g, 8.1 mmol), and piperidine (0.13 g, 1.5 mmol) in toluene (50 ml) was heated to reflux. After 18 hours, the reaction was cooled to room temperature and the solvent was removed under reduced pressure. The crude product (3.0 g) was purified by column chromatography (silica gel, 65:35 ethyl acetate/hexane) to give 4-(3-fluoro-4-methoxyphenyl)-3-pyridyl-3-butene-2-one as a pale yellow solid (1.60 g, 80%).

Step 2: Preparation of 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 3-pyridyl-4-(3-fluoro-4-methoxyphenyl)-3-butene-2-one (step 1) (0.99 g, 3.65 mmol) in acetic acid (25 ml), *p*-toluenesulfonyl hydrazide (0.68 g, 3.65 mol) was added. The reaction solution was heated to reflux for 6 hours. Acetic acid was removed by distillation from the reaction solution. The resulting residue was diluted with CH₂Cl₂ (150 ml), washed with H₂O (2x100 ml), dried (Na₂SO₄), filtered, and concentrated. The crude product (1.5 g) was purified by chromatography (silica gel, ethyl acetate) to give 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine as a pale yellow solid (213 mg, 20.7%): Anal. Calc'd for C₁₆H₁₄N₃O_F·0.1 H₂O: C, 67.41; H, 5.02; N, 14.74. Found:

C, 67.37; H, 4.88; N, 14.35.

Example A-2



4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)
pyridine

Step 1: Preparation of 4-pyridylacetone

4-Pyridylacetone was prepared according to the method of Ippolito et al, U.S. Patent 4,681,944.

Step 2: Preparation of 4-phenyl-3-(4-pyridyl)-3-buten-2-one

Using the procedure of Example A-1, step 1, 4-pyridylacetone (step 1) (1 g, 7.4 mmol) was condensed with benzaldehyde (790 mg, 7.4 mmol) in benzene (15 mL) containing piperidine (50 mg) at reflux. The desired 4-phenyl-3-(4-pyridyl)-3-buten-2-one (1.3 g, 78 %) was obtained as a crystalline solid: m. p. 101-103 °C. Anal. Calc'd for C₁₅H₁₃NO (223.28): C, 80.69; H, 5.87; N, 6.27. Found: C, 80.59; H, 5.79; N, 6.18.


Step 3: Preparation of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone

Using the procedure of Example A-1, step 2, a solution of 4-phenyl-3-(4-pyridyl)-3-buten-2-one (step 2) (1.25 g, 5.6 mmol) in methanol (20 ml) was treated with 30% aqueous hydrogen peroxide (1 ml) in the presence of sodium hydroxide (230 mg, 5.7 mmol). The crude product was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (270 mg, 20%).

Step 4: Preparation of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine

Using the procedure of Example A-1, step 3, a solution of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 3) (250 mg, 1 mmol) in ethanol (15 ml) was treated with anhydrous hydrazine (50 mg, 1.5 mmol) and heated to reflux for 4 hours. The crude product was purified by chromatography (silica gel, 1:1 acetone/hexane). The product was recrystallized from ethyl acetate and hexane to give 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (81 mg, 35%) as a crystalline solid: m. p. 212-214 °C. Anal. Calc'd for $C_{15}H_{13}N_3$ (235.29): C, 76.57; H, 5.57; N, 17.86. Found: C, 76.49; H, 5.42; N, 17.39.

Example A-3



4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one

A solution of 4-pyridylacetone (Example A-5, step 1) (0.75 g, 5.56 mmol), o-tolualdehyde (0.73 g, 5.56 mmol) and piperidine (100 mg) in toluene (50 ml) was heated to reflux. Water generated during the reaction was removed by a Dean-Stark trap. After heating at reflux for 5 hours, the reaction mixture was stirred at room temperature for 15 hours. The mixture was concentrated to an orange color oily residue. The crude ketone was purified by chromatography to give 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one: Anal. Calc'd for $C_{16}H_{15}NO$ (237.30): C, 80.98; H, 6.37; N, 5.90. Found: C, 80.78; H, 6.61; N, 5.85.


Step 2: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone

To a solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3-buten-2-one (step 1) (1.0g, 4.2 mmol) in methyl alcohol (18 ml), a solution of H₂O₂ (30% by wt.) (0.95 g, 8.4 mmol) and sodium hydroxide (0.18 g 4.6 mmol) in water (4 ml) was added. The reaction was stirred at room temperature for 70 hours. After methyl alcohol was removed, water (25 ml) and ethyl acetate (100 ml) were added and the two phase mixture was stirred for 30 minutes. The layers were separated, and the aqueous layer was washed with ethyl acetate (100 ml). The combined organic layer was dried with Na₂SO₄, filtered and concentrated to give an oil. 4-(2-Methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone was isolated from the oil residue by chromatography.

Step 3: Preparation of 4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine

A solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 2) (0.11 g, 0.434 mmol) and hydrazine hydrate (0.043 g, 0.868 mmol) in ethyl alcohol (50 ml) was heated at reflux for 20 hours. The solvent was removed and the resulting residue was purified by chromatography to give 4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₆H₁₅N₃ (249.32): C, 77.08; H, 6.06; N, 16.85. Found: C, 76.66; H, 5.91; N, 16.84.


Example A-4



4-[5-methyl-3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine

By following the method of Example A-3 and substituting *p*-fluorobenzaldehyde for *o*-tolualdehyde, the titled compound was prepared: Anal. Calc'd for $C_{15}H_{12}N_3F + 0.1 H_2O$: (249.32): C, 70.63; H, 4.82; N, 16.47. Found: C, 70.63; H, 4.78; N, 16.40.


Example A-5



4-[5-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine

By following the method of Example A-3 (with one minor modification: in Step 2, the preparation of the intermediate epoxide was accomplished at 0-10 °C for 1 hour, and the reaction was quenched by being partitioned between water, containing 2 eq. sodium bisulfite, and ethyl acetate) and substituting *p*-tolualdehyde for *o*-tolualdehyde, the titled product was isolated: Anal. Calc'd for $C_{16}H_{15}N_3$ (249.32): C, 77.08; H, 6.06; N, 16.85. Found: C, 76.97; H, 6.09; N, 16.90.


Example A-6



4-[5-methyl-3-[4-(methylthio)phenyl]-
1H-pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting 4-(methylthio)benzaldehyde for *p*-tolualdehyde, the titled product was prepared: Anal. Calc'd for $C_{16}H_{15}N_3S$ (281.38): C, 68.30; H, 5.37; N, 14.93. Found: C, 68.34; H, 5.09; N, 14.78.


Example A-7



4-[3-[4-chlorophenyl]-5-methyl-1H-
pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting *p*-chlorobenzaldehyde for *p*-tolualdehyde, the titled product was obtained. Anal. Calc'd for $C_{15}H_{12}N_3Cl$ (269.77): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.43; H, 4.44; N, 15.78.


Example A-8



4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting *m*-tolualdehyde for *p*-tolualdehyde, the titled product was obtained: Anal. Calc'd for $C_{16}H_{15}N_3 + 0.2H_2O$: C, 75.98; H, 6.14; N, 16.61. Found: C, 76.06; H, 6.05; N, 16.38.

Example A-9




4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting 2,5-dimethylbenzaldehyde for *p*-tolualdehyde, the titled product was obtained: Anal. Calc'd for $C_{17}H_{17}N_3 + 0.1H_2O$: C, 77.01; H, 6.54; N, 15.85. Found: C, 76.96; H, 6.81; N, 15.51.

Cc1c(C2=CC=CC=C2C3OC3)c4n[nH]4C5=CC=CC=C5N=C6

4-Pyridylacetone (1.5 g, 12 mmol), piperonal (1.6 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene (30 mL) and heated for 2 hours at reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature, and ethyl acetate was added to precipitate a solid, which was collected on a filter plate (1.25 g). A sample (500 mg) of this solid was heated with p-toluensulfonyl hydrazide (348 mg, 1.81 mmol) in acetic acid (5 mL) at 80 °C for 1 hour. The reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature and the solvent was evaporated. The residue was dissolved in ethyl acetate, washed with 5% aqueous potassium carbonate, and water. The organic layer was dried (MgSO₄), filtered and evaporated to obtain a yellow solid. This solid was triturated with methylene chloride, yielding 4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine which was collected on a filter plate (220 mg, 42% yield). Anal. Calc'd for C₁₆H₁₃N₃O₂: C, 68.81; H, 4.69; N, 15.04. Found: C, 68.02; H, 4.54; N, 14.76. MS (M⁺H): 280 (base peak).


Example A-11



4-[3-methyl-5-(4-phenoxyphenyl)-
1H-pyrazol-4-yl]pyridine

4-Pyridylacetone (1.5 g, 12 mmol), 4-phenoxybenzaldehyde 92.1 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene (30 mL) and heated for 2 hours at reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature and ethyl acetate was added to precipitate a solid, which was collected on a filter plate. A sample (223 mg) of this solid was heated with p-toluensulfonyl hydrazide (348 mg, 1.81 mmol) in ethylene glycol with potassium hydroxide (77 mg) at 110 °C for 0.5 hour. The work up procedure was the same as that in Example A-10. 4-[3-Methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine was obtained (100 mg, 66% yield): Anal. Calc'd for $C_{21}H_{17}N_3O + 0.1 H_2O$: C, 76.62; H, 5.27; N, 12.76. Found: C, 76.37; H, 5.19; N, 12.64. MS (M^+H): 328 (base peak).

Example A-12




4-[5-[(1,1'-biphenyl)-4-yl]-3-methyl
1H-pyrazol-4-yl]pyridine

The same procedure as for the preparation of Example A-10 was used, substituting 4-formylbiphenyl in place of piperonal, to give 4-[5-[(1,1'-biphenyl)-4-yl]-3-methyl-

1H-pyrazol-4-yl]pyridine as a white solid: MS (M^+H): 312 (base peak).


Example A-13



4-[3-methyl-5-[3-(phenoxyphenyl)-
1H-pyrazol-4-yl]pyridine


The same procedure for the preparation of Example A-10 was used, substituting 3-phenoxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine as a white solid.

Example A-14




4-[3-methyl-5-[3-(benzyloxyphenyl)-
1H-pyrazol-4-yl]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 3-benzyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(benzyloxyphenyl)-1H-pyrazol-4-yl]pyridine as a white solid: MS (M^+H): 342 (base peak).

Example A-15


4-[3-methyl-5-[2-(phenylmethoxy)-
phenyl]-1H-pyrazol-4-yl]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 2-benzyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[2-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine. MS (M^+H): 342 (base peak).

Example A-16

2-[3-methyl-4-(4-pyridinyl)-1H-
pyrazol-4-yl]phenol


The same procedure for the preparation of Example A-10 was used, substituting 2-hydroxybenzaldehyde in place of piperonal, to give 2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M^+H): 252 (base peak).

Example A-17

3-[3-methyl-4-(4-pyridinyl)-1H-
pyrazol-4-yl]phenol

The same procedure for the preparation of Example A-10 was used, substituting 3-hydroxybenzaldehyde in place of piperonal, to give 3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M⁺H): 252 (base peak).


Example A-18



1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium

To a solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (Example A-2) (2.06 g, 8.76 mmol) in a mixture of CH₂Cl₂ (10 mL) and MeOH (20 mL), was added 3-chloroperoxybenzoic acid (57~86%) (2.65 g, 8.76 mmol). The reaction was stirred at room temperature for 2h, quenched with K₂CO₃ solution (25%, 15 mL), and concentrated. The resulting residue was partitioned between EtOAc (2.0 L) and H₂O (500 mL). The organic layer was separated, washed with H₂O (500 mL), dried over MgSO₄, filtered and concentrated to give 1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium (1.12 g, 54.5%): MS (M⁺H): 252 (base peak).

Example A-19



5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

Step 1: Preparation of 1-fluoro-4-(4'-pyridylacetyl)benzene

To a solution of sodium bis(trimethylsilyl)amide (200 mL, 1.0 M in THF) at 0 °C was added a solution of 4-picoline (18.6 g, 0.20 mol) in dry THF (200 mL) over 30 minutes. The reaction mixture was stirred at 0-10 °C for another 30 minutes, then was added to a solution of ethyl 4-fluorobenzoate (16.8 g, 0.10 mol) in dry THF (200 mL) at such a rate that the internal temperature didn't exceed 15 °C. After the addition, the resulting yellow suspension was stirred at room temperature for 3 hours. Water (600 mL) was added and the aqueous phase was extracted with ethyl acetate (3 X 200 mL). The combined organic layers were washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give 1-fluoro-4-(4'-pyridylacetyl)benzene (19.9 g, 92 %) as an oil which solidified upon standing: m.p.: 90-91 °C; Anal. Calc'd for $C_{13}H_{10}FNO$: C, 72.55; H, 4.68; N, 6.51. Found: C, 72.07; H, 4.66; N, 6.62.


Step 2: Preparation of 1-fluoro-4-(4'-pyridylbromoacetyl)benzene

To a solution of 1-fluoro-4-(4'-pyridylacetyl)benzene (step 1) (10.0 g, 0.046 mol) in acetic acid (200 mL) was added a solution of bromine (8.2 g, 0.052 mol) in acetic acid (20 mL) dropwise. The reaction mixture was stirred at room temperature overnight. After the solvent was removed, the residue was triturated with ethyl acetate. A yellow solid formed, which was filtered and air-dried to give 1-fluoro-4-(4'-pyridylbromoacetyl)benzene (14.5 g). The compound was used in next step without further purification.

Step 3: Preparation of 5-(4-fluorophenyl)-N, N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

A mixture of 1-fluoro-4-(4'-pyridylbromoacetyl)-benzene (step 2) (3.8 g, 0.01 mol) and 4,4-dimethylamino-3-thiosemicarbazide (1.2 g, 0.01 mol) in ethanol (10 mL) was heated at reflux for 30 minutes. The dark green solution was cooled and poured into water (100 mL). The aqueous phase was extracted with methylene chloride (100 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The resulting residue was purified by chromatography (silica gel, ethyl acetate) to give 0.3 g 5-(4-fluorophenyl)-N, N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine (0.3 g, 11 %) as a light yellow solid: m.p.: 245-247 °C. Anal. Calc'd for $C_{16}H_{15}FN_4$: C, 68.07; H, 5.36; N, 19.84. Found: C, 68.00; H, 5.37; N, 19.61.


Example A-20



5-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

5-(4-Fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine was prepared by the same procedure as described for Example A-19: m.p. 218-219 °C. Anal. Calc'd for $C_{20}H_{15}FN_4 + 0.1 H_2O$: C, 72.33; H, 4.61; N, 16.87. Found: C, 72.16; H, 4.56; N, 16.77.

Example A-21



4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine


Step 1: Preparation of 1-fluoro-4-(4'-pyridylacetyl)benzene N-benzoylhydrazone

To a solution of benzoic hydrazide (1.36 g, 0.01 mol) in THF (20 mL) was added 1-fluoro-4-(4'-pyridylacetyl)benzene (2.15 g, 0.011 mol) in one portion followed by a drop of conc. HCl. The reaction mixture was stirred at room temperature overnight. There was white precipitate formed, which was filtered, washed with ether and air-dried to give 1-fluoro-4-(4'-pyridylacetyl)benzene N-benzoylhydrazone (2.90 g, 79 %) as a mixture of cis and trans (ratio, 1:9) isomers.

Step 2: Preparation of 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine

1-Fluoro-4-(4'-pyridylacetyl)benzene N-benzoylhydrazone (step 1) (0.50 g, 1.5 mmol) was heated at 180 °C under N₂ for 15 minutes, then cooled. The resulting solid was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine (0.25 g, 53 %) as a pale yellow solid: m.p.: 265-267 °C. Anal. Calc'd for C₂₀H₁₄FN₃ + 0.25 H₂O: C, 75.10; H, 4.57; N, 13.14. Found: C, 74.98; H, 4.49; N, 12.87.

Example A-22



4-[5-(3-methylphenyl)-3-(trifluoromethyl)-
1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 3-(4'-pyridylacetyl)toluene

3-(4'-Pyridylacetyl)toluene was prepared by the same method as described for Example A-19, step 1 in 70% yield.


Step 2: Preparation of trifluoroacetyl hydrazide

A mixture of ethyl trifluoroacetate (14.2 g, 0.10 mol) and hydrazine hydrate (5.54 g, 0.11 mol) in ethanol (25 mL) was heated at reflux for 6 hours. Solvent was removed and the resulting residue was dried in vacuum to give trifluoroacetyl hydrazide (12.3 g, 96 %) as a clear oil which solidified upon standing.

Step 3: Preparation of 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

A mixture of 3-(4'-pyridylacetyl)toluene (2.11 g, 0.01 mol) and trifluoroacetyl hydrazide (step 2) (1.0 g, 0.01 mol) was heated at 200 °C under N₂ for 15 minutes. The crude residue was purified by chromatography (silica gel, 35:65 ethyl acetate/hexane) to give 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine (0.56 g) as a white solid: m.p. 237-239 °C. Anal. Calc'd for C₁₆H₁₂F₃N₃: C, 63.36; H, 3.99; N, 13.85. Found: C, 63.6; H, 4.00; N, 13.70.


Example A-23



4-[3-(4-fluorophenyl)-4-(4-pyridinyl)-
1H-pyrazol-5-yl]pyridine

A mixture of 1-fluoro-4-(4'-pyridylacetyl)benzene (1.0 g, 4.6 mmol) and isonicotinic hydrazide (0.63 g, 4.6 mmol) in THF (25 mL) was heated to dissolution and then evaporated to dryness. The resulting solid was heated first to 140 °C, which caused a phase change, and subsequently melted on further heating until 180 °C whereupon a solid crystallized out. The reaction was immediately cooled, diluted with 10 % HCl (50 mL) and washed with chloroform. The aqueous layer was neutralized with bicarbonate and a tan colored solid was precipitated out. The solid was purified by treatment with activated carbon (Darco®) in boiling MeOH (100 mL), followed by filtration and concentration, to give 4-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]pyridine (1.05 g, 69 %) as a shiny tan solid: m.p. 304 °C (DSC). Mass (MH⁺) 137 (100%). Anal. Calc'd for C₁₉H₁₃N₄F.1/4H₂O: C, 71.13; H, 4.24; N, 17.46. Found: C, 70.88; H, 3.87; N, 17.38.

Example A-24



4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl]pyridine


Step 1: Preparation of 4-cyclohexyl-3-pyridyl-3-butene-2-one

4-Cyclohexyl-3-pyridyl-3-butene-2-one was prepared by the method of Example A-1, step 1 by replacing of 3-fluoro-*p*-anisaldehyde with cyclohexanecarboxaldehyde.

Step 2: Preparation of 4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine

4-(5-Cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine was prepared by the method for Example A-1, step 2, by replacing 4-(3-fluoro-4-methoxyphenyl)-3-pyridyl-3-butene-2-one with 4-cyclohexyl-3-pyridyl-3-butene-2-one (step 1): Anal. Calc'd for $C_{15}H_{19}N_3$: C, 73.56; H, 7.98; N, 17.16. Found: C, 73.72; H, 7.91; N, 19.98.

Example A-25



4-{5-(3-Fluoro-5-methoxyphenyl)-3-methyl-3-methyl-1H-pyrazol-4-yl}pyridine was prepared by the method of Example A-1, steps 1 and 2 by replacing 3-fluoro-*p*-anisaldehyde with 3-fluoro-*m*-anisaldehyde: Anal. Calc'd for $C_{16}H_{14}N_3OF$: C, 67.83; H, 4.98; N, 14.83. Found: C, 67.68, H, 4.92; N, 14.92.

The following examples (No 26-55) listed in Table 1 were prepared by the procedures described above:

TABLE 1

| No A- | R ¹ | R ² | R ³ | R ⁴ | m.p. or DSC(°C) | Anal.Calc'd Formula | Anal. Calc'd (calcd/found) | | |
|----------|------------------|----------------------------------|----------------|------------------|--------------------|--|----------------------------|---------------|-----------------|
| | | | | | | | C | H | N |
| 26 | H | | | | 185-186 | C ₁₈ H ₁₉ N ₃ | 77.95/ 77.51 | 6.90/ 6.93 | 15.15/ 14.73 |
| 27 | H | -CH ₃ | | | 142-144 | C ₁₆ H ₁₅ N ₃ | 75.71/ 75.69 | 6.16/ 6.11 | 16.55/ 16.49 |
| 28 | H | | | | 240-242 | C ₂₂ H ₁₉ N ₃ .0.25H ₂ O | 80.09/ 79.74 | 5.96/ 5.90 | 12.74/ 13.01 |
| 29 | H | | | -CH ₃ | 228.8 | C ₁₆ H ₁₂ N ₃ F ₃ | 63.36/ 63.28 | 3.99/ 3.73 | 13.85/ 13.69 |
| 30 | H | -CH ₃ | | | 189.6 | C ₁₅ H ₁₂ N ₃ Cl .0.15H ₂ O | 66.13/ 65.98 | 4.55/ 4.31 | 15.42/ 15.74 |
| 31 | H | -CH ₃ | | | 171.6 | C ₁₇ H ₁₇ N ₃ .0.2H ₂ O | 76.49/ 76.69 | 6.57/ 6.53 | 15.74/ 15.61 |
| 32 | -CH ₃ | -CH ₃ | | | 88.6 | C ₁₆ H ₁₄ N ₃ Cl | 67.72/ 67.35 | 4.97/ 5.29 | 14.81/ 15.02 |
| 33 | H | -CH ₃ | | | 188.8 | C ₁₆ H ₁₄ N ₃ F | 71.89/ 71.72 | 5.28/ 5.45 | 15.72/ 15.77 |
| 34 | H | -CH ₃ | | | 215.7 | C ₁₇ H ₁₇ N ₃ | 77.54/ 77.24 | 6.51/ 6.80 | 15.96/ 15.71 |
| 35 | H | -CH ₃ | | | 201.4 | C ₁₇ H ₁₇ N ₃ O ₂ .0.25H ₂ O | 68.10/ 67.92 | 5.88/ 5.65 | 14.01/ 13.65 |
| 36 | H | | | | 210.7 | C ₁₅ H ₁₂ N ₄ O ₂ .0.25H ₂ O | 63.26/ 63.59 | 4.42/ 4.39 | 19.67/ 19.31 |
| 37 | H | -CH ₃ | | | 252.5 | C ₁₇ H ₁₈ N ₄ | 73.35/ 72.61 | 6.52/ 6.79 | 20.13/ 19.59 |
| 38 | H | | | -CH ₃ | 196.3 | C ₁₇ H ₁₅ N ₃ O | 73.63/ 73.43 | 5.45/ 5.46 | 15.15/ 15.19 |
| 39 | H | | | -CH ₃ | 252.8 | C ₁₅ H ₁₂ N ₃ Br | 57.34/ 57.09 | 3.85/ 3.79 | 13.37/ 13.06 |
| 40 | H | | | -CH ₃ | 198.5 | C ₁₅ H ₁₂ N ₃ F | 71.13/ 71.23 | 4.78/ 5.01 | 16.59/ 16.76 |
| 41 | H | -CH ₃ | | | 225.6 | C ₁₅ H ₁₂ N ₃ F ₃ | 71.13/ 70.74 | 4.78/ 4.66 | 16.59/ 16.44 |
| 42 | H | -CH ₃ | | | 219.5 | C ₁₆ H ₁₂ F ₃ N ₃ | 63.36/ 63.19 | 3.99/ 4.07 | 13.85/ 13.38 |
| 43 | H | -CH ₂ CH ₃ | | | 227.7 | C ₁₆ H ₁₅ N ₃ .0.1H ₂ O | 76.53/ 76.53 | 6.10/ 6.20 | 16.73/ 16.49 |

| No A- | R ¹ | R ² | R ³ | R ⁴ | m.p. or DSC(°C) | Anal.Calc'd Formula | Anal. Calc'd (calcd/found) | | |
|----------|--------------------|-------------------------------|----------------|----------------|--------------------|--|----------------------------|---------------|-----------------|
| | | | | | | | C | H | N |
| 44 | H | $\cdot\text{CH}_3$ | | | 175.6 | $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}$.15H ₂ O | 71.70/ 71.92 | 5.75/ 5.76 | 15.68/ 15.29 |
| 45 | H | $\cdot\text{CH}_2\text{CH}_3$ | | | — | $\text{C}_{17}\text{H}_{19}\text{N}_3$ | 77.54/ 77.13 | 6.51/ 6.28 | 15.96/ 15.69 |
| 46 | H | $\cdot\text{CH}_3$ | | | 412.1 | $\text{C}_{15}\text{H}_{11}\text{N}_3\text{F}_2$ | 66.42/ 66.12 | 4.09/ 3.86 | 15.49/ 15.25 |
| 47 | H | $\cdot\text{CH}_3$ | | | 168.5 | $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}$.15H ₂ O | 72.40/ 72.39 | 6.18/ 5.87 | 14.90/ 14.50 |
| 48 | H | $\cdot\text{CH}_3$ | | | 211.2 | $\text{C}_{16}\text{H}_{12}\text{N}_3\text{F}_3$.0.2H ₂ O | 62.62/ 62.64 | 4.07/ 4.06 | 13.69/ 13.35 |
| 49 | H | $\cdot\text{CH}_3$ | | | — | $\text{C}_{13}\text{H}_{11}\text{N}_3\text{S}$ | 64.71/ 64.44 | 4.59/ 4.58 | 17.41/ 17.27 |
| 50 | H | $\cdot\text{CH}_3$ | | | 189.2 | $\text{C}_{15}\text{H}_{11}\text{N}_3\text{Cl}_2$ | 59.23/ 59.22 | 3.65/ 3.24 | 13.81/ 13.81 |
| 51 | H | $\cdot\text{CH}_3$ | | | 211.7 | $\text{C}_{15}\text{H}_{12}\text{N}_3\text{Cl}$.15H ₂ O | 66.13/ 66.33 | 4.55/ 4.62 | 15.42/ 15.05 |
| 52 | H | $\cdot\text{CH}_3$ | | | 219.8 | $\text{C}_{16}\text{H}_{14}\text{N}_3\text{Cl}$ | 64.11/ 63.85 | 4.71/ 4.69 | 14.02/ 13.93 |
| 53 | H | | | | 163.4 | $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_2\text{Cl}$ | 64.32/ 63.98 | 4.83/ 5.08 | 11.84/ 11.80 |
| 54 | $\cdot\text{CH}_3$ | | | H | — | $\text{C}_{15}\text{H}_{12}\text{N}_3\text{F}$.0.2H ₂ O | 70.15/ 70.18 | 4.86/ 4.60 | 16.35/ 16.47 |
| 55 | H | | | H | — | $\text{C}_{14}\text{H}_{10}\text{N}_3\text{F}$ | 70.28/ 69.97 | 4.21/ 3.84 | 17.56/ 17.53 |

The following pyrazoles could be prepared by the procedures described above:

- Example A-56 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
- Example A-57 5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
- Example A-58 5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
- Example A-59 5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
- Example A-60 5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
- Example A-61 5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
- Example A-62 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- Example A-63 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- Example A-64 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- Example A-65 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- Example A-66 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- Example A-67 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- Example A-68 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- Example A-69 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
- Example A-70 2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
- Example A-71 2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-72 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-

4-yl]-2-methoxypyridine;

Example A-73 2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;

Example A-74 2-methoxy-4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;

Example A-75 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;

Example A-76 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;

Example A-77 2-methoxy-4-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;

Example A-78 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

Example A-79 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

Example A-80 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

Example A-81 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

Example A-82 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

Example A-83 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

Example A-84 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;

Example A-85 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;

Example A-86 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;

Example A-87 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;

Example A-88 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;

Example A-89 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;

Example A-90 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-

- 4-yl]pyridine-2-methanamine;
- Example A-91 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
- Example A-92 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- Example A-93 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- Example A-94 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- Example A-95 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- Example A-96 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- Example A-97 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- Example A-98 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- Example A-99 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-100 4-[5-(4-fluoro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-101 4-[5-(4-chloro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-102 4-[5-(2,3-dihydrobenzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-103 4-[5-(benzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-104 4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-105 4-[5-(3-chloro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-106 4-[5-(1-cyclohexylen-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-107 4-[5-(1,3-cyclohexadien-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
- Example A-108 4-[5-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-

1H-pyrazol-4-yl]pyridine;

Example A-109 4-(5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine;

Example A-110 4-[5-(4-methoxy-3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

Example A-111 4-[5-(3-methoxy-4-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

Example A-112 4-[5-(3-methoxy-5-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

Example A-113 4-[5-(3-furanyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

Example A-114 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;

Example A-115 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;

Example A-116 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxylate;

Example A-117 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxamide;

Example A-118 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-2-yl]ethanone;

Example A-119 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-2-amine;

Example A-120 3-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;

Example A-121 3-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;

Example A-122 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxylate;

Example A-123 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxamide;

Example A-124 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-3-yl]ethanone;

Example A-125 3-bromo-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;

Example A-126 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-

pyrazol-2-yl)pyridin-3-amine;

Example A-127 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;

Example A-128 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;

Example A-129 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;

Example A-130 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;

Example A-131 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;

Example A-132 4-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-5-phenyl-1H-pyrazole;

Example A-133 3-methyl-5-phenyl-4-(3-thienyl)-1H-pyrazole;

Example A-134 4-(3-furanyl)-3-methyl-5-phenyl-1H-pyrazole;

Example A-135 3-methyl-5-phenyl-4-(2-thienyl)-1H-pyrazole;

Example A-136 4-(2-furanyl)-3-methyl-5-phenyl-1H-pyrazole;

Example A-137 4-(3-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;

Example A-138 4-(3-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;

Example A-139 4-(5-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;

Example A-140 4-(5-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;

Example A-141 3-methyl-5-phenyl-4-(5-thiazolyl)-1H-pyrazole;

Example A-142 3-methyl-4-(5-oxazolyl)-5-phenyl-1H-pyrazole;


Example A-143 2-methyl-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;

Example A-144 4-(1-methyl-3-phenyl-1H-pyrazol-4-


yl)pyridine;
 Example A-145 4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
 Example A-146 2-methyl-4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
 Example A-147 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
 Example A-148 4-[3-(4-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
 Example A-149 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
 Example A-150 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
 Example A-151 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-methylpyridine;
 Example A-152 4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 Example A-153 4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine; and
 Example A-154 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]-2-methylpyridine.

The compounds of Examples A-155 through A-172 were synthesized in accordance with the chemistry described above (particularly Scheme II) and illustrated by many of the previously disclosed Examples by selection of the corresponding starting reagents:


Example A-155




5-(4-chlorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 261 °C. Anal. Calc'd for $C_{20}H_{15}ClN_4$ + 0.25 H_2O (MW 351.32): C, 68.38, H, 4.30, N, 15.95. Found: C, 68.25, H, 4.41, N, 15.74.

Example A-156

5-(4-chlorophenyl)-N-methyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 260 °C. Anal. Calc'd for $C_{15}H_{13}ClN_4$ + 0.125 H_2O (MW 287.00): C, 62.77, H, 4.57, N, 19.52. Found: C, 62.78, H, 4.33, N, 19.22.


Example A-157

5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine dihydrate: DSC 230 °C. Anal. Calc'd for $C_{16}H_{15}ClN_4$ + 2 H_2O (MW 334.81): C, 57.40, H, 4.52, N, 16.73. Found: C, 57.72, H, 4.85, N, 16.54.

Example A-158


5-(3-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227 °C. Anal. Calc'd for $C_{16}H_{15}FN_4 + 0.125 H_2O$ (MW 284.57): C, 67.53, H, 5.31, N, 19.69. Found: C, 67.60, H, 5.20, N, 19.84.

Example A-159




N,N-dimethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 222 °C. Anal. Calc'd for $C_{17}H_{18}N_4 + 0.25 H_2O$ (MW 282.86): C, 72.19, H, 6.41, N, 19.81. Found: C, 71.99, H, 6.46, N, 19.90.

Example A-160




N-methyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 226 °C. Anal. Calc'd for $C_{16}H_{16}N_4 + 0.125 H_2O$ (MW 266.58): C, 72.09, H, 6.05, N, 21.02. Found: C, 72.12, H, 6.12, N, 20.83.

Example A-161




N-ethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227 °C. Anal. Calc'd for $C_{17}H_{18}N_4 + 0.125 H_2O$ (MW 280.61): C, 72.77, H, 6.47, N, 19.97. Found: C, 72.63, H, 6.40, N, 19.73.

Example A-162




N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 234 °C. Anal. Calc'd for $C_{19}H_{22}N_4$ (MW 306.41): C, 74.48, H, 7.24, N, 18.29. Found: C, 74.12, H, 7.18, N, 18.13.


Example A-163




5-(4-chlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: m.p. 260-261°C. Anal. Calc'd for $C_{18}H_{19}ClN_4$ (MW 326.83): C, 66.15, H, 5.86, N, 17.14. Found: C, 66.03, H, 5.72, N, 17.23.^[

Example A-164

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine: DSC 279 °C. Anal. Calc'd for $C_{18}H_{17}ClN_4O$ + 0.25 H_2O (MW 345.32): C, 62.61, H, 4.96, N, 16.23. Found: C, 62.52, H, 4.77, N, 16.52.


Example A-165

5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 244 °C. Anal. Calc'd for $C_{17}H_{17}ClN_4$ + 0.125 H_2O (MW 315.06): C, 64.81, H, 5.44, N, 17.78. Found: C, 64.94, H, 5.43, N, 17.78.


Example A-166

Isolated as 5-(4-chlorophenyl)-N-(phenylmethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine hydrate (2:1): DSC 237 °C. Anal. Calc'd for $C_{21}H_{17}ClN_4$ + 0.5 H_2O (MW 369.86): C, 68.20, H, 4.63, N, 15.15. Found: C, 68.09, H, 4.55, N,

15.15.


Example A-167

Isolated as 5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine monohydrate: DSC 223 °C. Anal. Calc'd for $C_{17}H_{17}ClN_4O + H_2O$ (MW 346.82): C, 58.87, H, 4.94, N, 16.15. Found: C, 58.59, H, 4.79, N, 16.02.


Example A-168

1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate: DSC 251 °C. Anal. Calc'd for $C_{23}H_{26}ClN_5O$ (MW 439.95): C, 62.79, H, 5.96, N, 15.92. Found: C, 62.40, H, 5.82, N, 15.82.

T02021-0842001


Example A-169

Isolated as 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: DSC 99 °C. Anal. Calc'd for $C_{18}H_{18}ClN_4 + 3 HCl$ (MW 449.21): C, 48.13, H, 4.71, N, 15.59. Found: C, 47.76, H, 5.07, N, 15.51.


Example A-170

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine: m.p. 247-249 °C. Anal. Calc'd for $C_{19}H_{20}ClN_5 + 0.75 H_2O$ (MW 367.33): C, 62.12, H, 5.49, N, 19.06. Found: C, 62.45, H, 5.86, N, 19.32.

Example A-171



1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate: m.p. 243-244 °C. Anal. Calc'd for $C_{23}H_{26}FN_5O_2 + 0.5 CH_3CH_2CO_2CH_2CH_3$ (MW 467.55): C, 64.22, H, 6.47, N, 14.98. Found: C, 63.90, H, 6.47, N, 14.78.



1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: m.p. 204-206 °C. Anal. Calc'd for $C_{18}H_{18}FN_5 + 3 HCl + 0.5 H_2O$ (MW 441.77): C, 48.94, H, 4.79, N, 15.85. Found: C, 48.66, H, 4.88, N, 15.50.

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine: m.p. 264-265 °C. Anal. Calc'd for $C_{18}H_{18}ClN_5 + 0.125 H_2O$ (MW 342.08): C, 63.20, H, 5.30, N, 20.47. Found: C, 63.04, H, 5.36, N, 20.33.


Additional compounds that were synthesized in accordance with the chemistry described in Scheme II by selection of the corresponding starting reagents further

include the compounds disclosed in Table 2.


1002430 1002430

TABLE 2


| Example | General Procedure | Formula | Microanalysis | | | | | | DSC |
|---------|----------------------|--|---------------|---------|--------|---------|--------|---------|------|
| | | | C calc | C found | H calc | H found | N calc | N found | |
| A-173 | Sch. II | C ₂₄ H ₂₅ CIN ₆ •3HCl•1.5H ₂ O | 50.63 | 50.58 | 4.96 | 5.03 | 14.76 | 14.68 | 182 |
| A-174 | Sch. II | C ₂₅ H ₂₄ CIN ₅ •0.125H ₂ O | 69.47 | 69.33 | 5.60 | 5.56 | 16.20 | 16.11 | 259 |
| A-175 | Sch. II | C ₁₇ H ₁₇ FN ₆ •1.25H ₂ O | 48.64 | 48.45 | 4.56 | 4.86 | 20.02 | 20.24 | 82 |
| A-176 | Sch. II | C ₂₂ H ₂₆ CIN ₅ O ₂ | 61.75 | 61.57 | 6.12 | 6.04 | 16.37 | 16.34 | 217 |
| A-177 | Sch. II | C ₁₇ H ₁₈ CIN ₅ •3HCl•H ₂ O | 44.85 | 44.96 | 4.65 | 4.87 | 15.38 | 15.17 | 220 |
| A-178 | Sch. II | C ₂₁ H ₂₄ CIN ₅ O ₂ •0.125H ₂ O | 60.61 | 60.51 | 5.81 | 5.81 | 16.83 | 16.64 | 232 |
| A-179 | Sch. II | C ₂₅ H ₃₀ CIN ₅ O ₃ | 62.04 | 61.76 | 6.25 | 6.25 | 14.47 | 14.37 | 220 |
| A-180 | Sch. II | C ₂₂ H ₂₅ FN ₆ O ₂ •0.5H ₂ O | 60.96 | 60.86 | 5.81 | 6.21 | 19.39 | 19.47 | N.D. |
| A-181 | Sch. II | C ₂₂ H ₂₅ ClFN ₅ O ₂ | 59.26 | 58.98 | 5.65 | 5.55 | 15.71 | 15.36 | 210 |
| A-182 | Sch. II | C ₂₀ H ₂₂ CIN ₅ •0.75H ₂ O | 62.98 | 62.97 | 5.81 | 5.64 | 18.36 | 17.83 | 271 |
| A-183 | Sch. II | C ₁₆ H ₁₉ Cl ₄ N ₅ •3HCl | 45.41 | 45.37 | 4.53 | 4.74 | | | 120 |

Example A-173


N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride

Example A-174


1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)piperazine

Example A-175


Isolated as 4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine, dihydrochloride

Example A-176


1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate

Example A-177


Isolated as N-[5-[4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride monohydrate

Example A-178

1,1-dimethylethyl [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]carbamate


Example A-179

1,1-dimethylethyl 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

Example A-180


1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

Example A-181




1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]aminopropyl]carbamate

Example A-182




1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethylpiperazine

Example A-183


N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine

The compounds of Examples A-184 through A-189 were synthesized in accordance with the chemistry described above (particularly in Schemes I and IV) and illustrated by the previously disclosed Examples by selection of the corresponding starting reagents:

Example A-184


4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{15}H_{11}F_2N_3$: C, 66.42; H, 4.09; N, 15.49. Found: C, 66.20; H, 3.94; N, 15.16; m.p. 236.67 °C.

Example A-185




4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{17}H_{17}N_3$: C, 77.54; H, 6.51; N, 15.96. Found; C, 77.16; H, 6.27; N, 15.69. m.p. (DSC): 189.25 °C.

Example A-186



4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{16}H_{14}ClN_3 \cdot 0.1$ mole H_2O : C, 67.15; H, 4.91; N, 14.33. Found: C, 66.95; H, 5.00; N, 14.36. DSC: 176.18 °C.


Example A-187



4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{18}H_{19}N_3 \cdot 0.1$ mole H_2O : C,


77.44; H, 6.93; N, 15.05. Found: C, 77.39; H, 6.94; N, 14.93. m.p. (DSC): 192.66 °C.

Example A-188



4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{17}H_{16}ClN_2 \cdot 0.4M$ EtOAc: C, 67.08; H, 5.81; N, 12.62. Found: C, 67.40; H, 6.15; N, 12.34.


Example A-189



4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{17}H_{14}FN_3$: C, 73.1; H, 5.05; N, 15.04. Found: C, 73.23; H, 4.89; N, 14.63; m.p.: 239-240 °C.

The compound of Example A-190 was synthesized in accordance with the chemistry described above (particularly in Scheme III) and illustrated by the previously disclosed Examples by selection of the corresponding starting reagents:

Example A-190




4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

This compound was prepared by the same procedure as described for Example A-22 by replacing 3-(4'-pyridylacetyl)toluene with 1-fluoro-4-(4'-pyridylacetyl)benzene (prepared as set forth in Example A-19).

Anal. Calc'd for $C_{15}H_9F_4N_3$: C, 58.64; H, 2.95; N, 13.68. Found: C, 58.57; H, 3.07; N, 13.31. m.p. (DSC): 281.94 °C.


The compounds of Examples A-191 through A-198 were synthesized in accordance with the chemistry described above (particularly in Scheme V) by selection of the corresponding starting reagents:

Example A-191



4-[5-(cyclopropyl)-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone



1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone


To a solution of 4-fluorobenzoyl-4'-pyridinyl methane (8.60 g, 0.04 mol) and methyl hydrazine (2.14 g, 0.044 mol) in 50 mL of ethanol was added two drops of concentrated sulfuric acid. The reaction mixture was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium carbonate solution, washed with brine, and dried over magnesium sulfate. The filtrate was concentrated and the crude product was recrystallized from diethyl ether and hexane to afford 7.5 g of a yellow solid product (77% yield), 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone.

Step 2: Preparation of 4-[5-(cyclopropyl-3-(4-(fluorophenyl))-1-methyl-1H-pyrazol-4-yl]pyridine

To a solution of sodium hexamethyldisilazide (5.5 mL, 1.0 M in THF) at 0 °C was added a solution of the compound prepared in step 1 (0.67 g, 0.0028 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.34 g, 0.0034 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and


filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane/acetone, 10:9:1) to give 0.45 g of product, 4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl)]pyridine, as a light yellow solid (55% yield), mp: 129-130 °C; ^1H NMR (CDCl_3): δ 8.53 (m, 2H), 7.32 (m, 2H), 7.14 (m, 2H), 6.97 (m, 2H), 4.00 (s, 3H), 1.83 (m, 1H), 0.95 (m, 2H), 0.36 (m, 2H); Anal. Calc'd For $\text{C}_{18}\text{H}_{16}\text{FN}_3$: C, 73.70; H, 5.50; N, 14.32. Found: C, 73.63; H, 5.57; N, 14.08.

Example A-192



5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone




1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone

To a flask containing hydroxyethyl hydrazine (3.4 g, 0.04 mol) at 80 °C was added 4-fluorobenzoyl-4'-pyridinyl methane (8.6 g, 0.04 mol) portionwise. The yellow oil was stirred at this temperature overnight. The cooled

reaction mixture was dissolved with hot ethyl acetate and then triturated with hexane to give 8.9 g of product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone, as a yellow crystal (81%), mp: 122-123 °C.


Step 2: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]hydrazone



1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone
[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]hydrazone

To a solution of the 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone prepared in step 1 (2.73 g, 0.01 mol) and (1,1-dimethylethyl)dimethylsilyl chloride (1.5 g, 0.01 mol) in 25 mL of DMF was added imidazole portionwise. The reaction mixture was stirred at room temperature overnight. Water was added and extracted with ethyl acetate, the organic layer was washed with water, washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to give 3.8 g of crude product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]hydrazone, as a yellow oil that was used in the next step without further purification.

Step 3: 5-cyclopropyl-1-[2-[[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl]-3,4-diphenyl-1H-pyrazole




5-cyclopropyl-1-[2-[[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl]-3,4-diphenyl-1H-pyrazole

To a solution of sodium hexamethyldisilazide (4.2 mL, 1.0 M in THF) at 0 °C was added a solution of the compound prepared in step 2 (0.78 g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.27 g, 0.0026 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 0.30 g of product, 5-cyclopropyl-1-[2-[[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl]-3,4-diphenyl-1H-pyrazole, as a light yellow oil (35% yield), ¹H NMR (CDCl₃): δ 8.53 (m, 2H), 7.32 (m, 2H), 7.14 (d, *J* = 5.6 Hz, 2H), 6.97 (m, 2H), 4.47 (t, *J* = 4.8 Hz, 2H), 4.14 (t, *J* = 4.8 Hz, 2H), 1.93 (m, 1H), 0.95 (m, 2H), 0.87 (s, 9H), 0.41 (m, 2H); Anal. Calc'd For C₂₅H₃₂FN₃OSi: C, 68.61; H, 7.37; N, 9.60. Found: C, 68.39; H, 7.81; N, 9.23.

Step 4: Preparation of 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 3 (0.27 g, 0.00062 mol) in 5 mL of THF was added tetrabutylammonium fluoride (1.9 mL of 1.0 M THF solution) at room temperature. After 1 hour, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 9:1) to give 0.16 g of product, 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a pale yellow solid, mp: 155-157 °C; ¹H NMR (CDCl₃): δ 8.53 (br s, 2H), 7.32 (m, 2H), 7.14 (d, *J* = 5.6 Hz, 2H), 6.97 (m, 2H), 4.42 (t, *J* = 4.8 Hz, 2H), 4.14 (t, *J* = 4.8 Hz, 2H), 1.83 (m, 1H), 0.93 (m, 2H), 0.35 (m, 2H); Anal. Calc'd For C₁₉H₁₈FN₃O: C, 70.57; H, 5.61; N, 12.99. Found: C, 70.46; H, 5.87; N, 12.84.


Example A-193



3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of sodium hexamethyldisilazide (7.4 mL, 1.0 M in THF) at 0 °C was added a solution of the compound prepared in step 2 of Example A-192 (1.25 g, 0.0034 mol) in 15 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl 4-(2-


Example A-194



4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone

To a solution of 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (0.28 g, 0.0006 mol) in 5 mL of acetic acid was added 3 mL of 48% hydrobromic acid. The reaction mixture was heated at reflux for 3 hour. The cooled mixture was then treated with water, basified with ammonium hydroxide and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (MeOH/CH₂Cl₂/NH₄OH, 5:94:1) to give 0.07 g of product, 4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone, as a yellow solid (32% yield), mp: 250-251 °C; ¹H NMR (DMSO-d₆): δ 11.74 (s, 1H), 8.45 (d, *J* = 5.0 Hz, 2H), 7.35 (m, 3H), 7.16 (m, 2H), 7.03 (d, *J* = 5.0 Hz, 2H), 6.37 (s, 1H), 6.05 (d, *J* = 5.2 Hz, 1H), 5.0 (m, 1H), 4.13 (m, 2H), 3.81 (m, 2H); Anal. Calc'd for C₂₁H₁₇FN₄O₂•0.2 H₂O: C, 66.06; H, 4.65; N, 14.67. Found: C, 66.31; H, 4.49; N, 14.27.


Example A-195



1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone

1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone was obtained as a byproduct of the reaction of Example A-194 in the form of a yellow solid (38% yield), mp: 220-221 °C; ^1H NMR (CDCl_3): δ 8.50 (m, 2H), 7.39 (m, 3H), 7.02 (m, 4H), 6.59 (m, 1H) 6.08 (dd, $J = 1.4, 5.2$ Hz, 1H), 4.52 (t, $J = 6.0$ Hz, 2H), 4.43 (t, $J = 6.0$ Hz, 2H), 2.04 (s, 3H); Anal. Calc'd for $\text{C}_{23}\text{H}_{19}\text{FN}_4\text{O}_3 \cdot 0.3 \text{ H}_2\text{O}$: C, 65.46; H, 4.63; N, 13.28. Found: C, 65.09; H, 4.64; N, 12.99.

Example A-196




Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate

To a solution of sodium hexamethyldisilazide (17.0 mL, 1.0 M in THF) at 0 °C was added a solution of the

compound prepared in step 1 of Example A-192 (1.37 g, 0.005 mol) in 20 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of diethyl 1,2-cyclopropanedicarboxylate (1.12 g, 0.006 mol) in 10 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 2 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 0.18 g of product, ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate, as a light yellow oil (35% yield), ^1H NMR (CDCl_3): δ 8.55 (m, 2H), 7.32 (m, 2H), 7.11 (m, 2H), 6.97 (m, 2H), 4.38 (m, 2H), 4.16 (m, 4H), 2.47 (m, 1H), 1.53 (m, 2H), 1.26 (t, $J=7.0$ Hz, 3H), (m, 2H), 0.90 (m, 2H); Anal. Calc'd for $\text{C}_{22}\text{H}_{22}\text{FN}_3\text{O}_3 \cdot 0.25 \text{ H}_2\text{O}$: C, 66.07; H, 5.67; N, 10.51 Found: C, 65.89; H, 5.80; N, 9.95.

Example A-197




2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid

To a solution of ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate prepared in accordance with Example A-196 (0.21 g, 0.00045 mol) in 10 mL of methanol


was added a solution of sodium hydroxide (0.09 g, 0.0022 mol) in 2 mL of water. The reaction mixture was stirred at reflux for 6 hours. After the solvent was removed, the residue was dissolved with 10 mL of 1N HCl and stirred for 30 minutes. The pH was then adjusted to 5-6 by addition of 1N sodium hydroxide solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium and filtered. The filtrate was concentrated and the crude was purified by recrystallization from ethanol and ether to give 0.1 g of product, 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid, as a white solid (60% yield), mp: 253-255 °C; ¹H NMR (CD₃OD): δ 8.46 (m, 2H), 7.32 (m, 2H), 7.25 (m, 2H); 7.04 (m, 2H), 4.39 (t, J = 5.0 Hz, 2H), 4.03 (m, 2H), 2.60 (m, 1H), 1.51 (m, 2H), 0.97 (m, 2H); Anal. Calc'd For C₂₀H₁₈FN₃O₃: C, 65.39; H, 4.94; N, 11.44. Found: C, 64.92; H, 4.77; N, 11.20.

Example A-198



3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol


Step 1: Preparation of methyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate



methyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate

To a suspension of sodium hydride (1.0 g, 0.025 mol) in 50 mL of DMF was added methyl 4-imidazolecarboxylate (2.95 g, 0.023 mol) portionwise at room temperature. The mixture was stirred at room temperature for 0.5 hours. Then SEM-Cl (4.17 g, 0.025 mol) was added dropwise over 5 minutes. The reaction mixture was stirred for 4 hours and quenched by adding water. The aqueous phase was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 4.0 g of the major regioisomer as a clear oil.

Step 2: Preparation of 4-[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-(4-fluorophenyl)-5-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-4-yl]-1H-pyrazol-4-yl]pyridine



4-[1-[2[[[(1,1-dimethylethyl)dimethylsilyl]-oxy]ethyl]-3-(4-fluorophenyl)-5-[1-[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-4-yl]-1H-pyrazol-4-yl]pyridine

To a solution of sodium hexamethyldisilazide (4.5 mL, 1.0 M in THF) at 0 °C under Ar was added a solution of the compound prepared in step 2 of Example A-192 (0.8

g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of the compound prepared in step 1 of the present Example (0.54 g, 0.0021 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 1 hour. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 0.98 g of product as a light yellow oil which solidified upon standing (91% yield), mp: 79-80 °C; ¹H NMR (CDCl₃): δ 8.48 (d, *J* = 6.0 Hz, 2H), 7.68 (d, *J* = 1.3 Hz, 1H), 7.38 (d, *J* = 6.0 Hz, 2H), 7.10 (m, 2H), 7.00 (m, 2H), 6.93 (d, *J* = 1.3 Hz, 1H), 5.25 (s, 2H), 4.53 (t, *J* = 6.0 Hz, 2H), 4.12 (t, *J* = 6.0 Hz, 2H), 3.84 (t, *J* = 8.0 Hz, 2H), 0.92 (t, *J* = 8.0 Hz, 2H), 0.84 (s, 9H), 0.021 (s, 18H); Anal. Calc'd For C₃₁H₄₄FN₅O₂Si₂: C, 62.70; H, 7.47; N, 11.79. Found: C, 62.98; H, 7.74; N, 11.88.


Step 3: Preparation of 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 2 of the present Example (0.54 g, 0.001 mol) in 10 mL of THF was added a solution of tetrabutylammonium fluoride (1.0 M in THF). After the mixture was heated at reflux for 3 hours, the solvent was removed and the residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified on silica gel (methylene chloride/methanol, 95:5) to give 0.22 g of the product, 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a white solid (63% yield), mp: 227-228 °C; ¹H NMR (DMSO-d₆): δ 8.45 (m, 2H), 7.83 (s,

1H), 7.35 (m, 2H), 7.15 (m, 4H), 7.09 (s, 1H), 5.20 (br s, 1H), 4.32 (s, 2H), 3.81 (m, 2H); Anal. Calc'd For $C_{19}H_{16}FN_5O$: C, 65.32; H, 4.62; N, 20.05. Found: C, 64.98; H, 4.55; N, 19.79.

The compound of Example A-199 was synthesized in accordance with the chemistry described above (particularly in Scheme VI) by selection of the corresponding starting reagents:

Example A-199




4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine

Anal. Calc'd for $C_{15}H_{12}N_3Cl$ (269.74): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.57; H, 4.15; N, 15.54. m.p. (DSC): 198.17 °C.

The compounds of Examples A-200 through A-202 were synthesized in accordance with the chemistry described above (particularly in Scheme VII) by selection of the corresponding starting reagents:


Example A-200



5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid

A mixture of 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine prepared as set forth in Example A-4 (5.83 g, 24.0909 mmol) and potassium permanganate (7.6916 g, 48.1818 mmol) in water (7.5 ml) and tert-butanol (10 ml) was heated at reflux for 6 hours (or until all the potassium permanganate was consumed). The mixture was then stirred at room temperature overnight and then diluted with water (150 ml). Manganese dioxide was removed from the mixture by filtration. The filtrate was extracted with ethyl acetate to remove unreacted starting material. The aqueous layer was acidified with 1N HCl to increase the pH to about 6. A white precipitate formed, was collected by filtration, washed with water, and dried in a vacuum oven to give 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid (isolated as the monohydrate salt) (2.9777 g, 43.7 %). Anal. Calc'd for $C_{15}H_{10}N_3FO_2 \cdot H_2O$ (283 + 18): C, 59.80; H, 4.01; N, 13.95; Found: C, 59.48; H, 3.26; N, 13.65. MS (MH^+): 284 (base peak).

Example A-201




5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol

To a suspension of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.526 g, 2.0 mmol) in dry THF (15 ml) at reflux under nitrogen, a


solution of 1N lithium aluminum hydride in THF (4.0 ml, 4.0 mmol) was added dropwise over 15 minutes. A precipitate formed. The mixture was boiled for an additional hour. Excess lithium aluminum hydride was then decomposed by cautiously adding a solution of 4N potassium hydroxide in water (0.5 ml). Upon hydrolysis, a white salt precipitated. After the addition was complete, the mixture was heated at reflux for 15 minutes. The hot solution was filtered by suction through a Buchner funnel, and remaining product was extracted from the precipitate by refluxing with THF (15 ml) for 1 hour, followed again by suction filtration. The combined filtrates were concentrated under reduced pressure. The resulting residue was taken into ethyl acetate, washed with water and brine, dried over MgSO_4 to give a crude product (0.45 g). Recrystallization of the crude product from methanol gave 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol (0.2808 g, 56.5%). DSC: 260.26 °C; Anal. Calc'd for $\text{C}_{15}\text{H}_{12}\text{N}_3\text{FO}$ (269): C, 66.91; H, 4.49; N, 15.60; Found: C, 66.07; H, 4.63; N, 15.20. MS (MH^+): 270 (base peak).

Example A-202



1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine

Step 1: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate




To a solution of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.9905 g, 3.5 mmol) and 1-hydroxybenzotriazole (0.4824 g, 3.57 mmol) in DMF (20 ml) at 0 °C under nitrogen, 1-(3-dimethylaminopropyl)3-ethylcarbodiimide hydrochloride (0.6984 g, 3.57 mmol, Aldrich Chemical Co.) was added. The solution was stirred at 0 °C under nitrogen for 1 hour then 1-butoxycarbonylpiperazine (0.6585 g, 3.5 mmol) was added followed by N-methylmorpholine (0.40 ml, 3.6 mmol). The reaction was stirred from 0 °C to room temperature overnight. After 19 hours, the solvent was removed under reduced pressure, and resulting residue was diluted with ethyl acetate, washed with saturated NaHCO₃ solution, water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure to give a crude product (1.7595 g). 1,1-Dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (1.2372 g, 78.4%) was obtained by chromatography. Anal. Calc'd for C₂₄H₂₆N₅O₃F. (451): C, 63.85; H, 5.80; N, 15.51; Found: C, 63.75; H, 5.71; N, 15.16. MS (MH⁺): 452 (base peak).

Step 2: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine bis(trifluoroacetate), monohydrate


A solution of the compound prepared in step 1 (0.1804 g, 0.4 mmol) in methylene chloride (1.0 ml) and TFA (0.3 ml) was stirred at room temperature under nitrogen for 2 hours. The solvent was removed under reduced pressure and TFA was chased by methylene chloride and methanol. The resulting colorless oily residue was dried in a vacuum oven overnight to give 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine (isolated as the bis(trifluoroacetate), monohydrate salt) (0.2400g, 100%) as a white solid. Anal. Calc'd for $C_{19}H_{18}N_5O \cdot 2CF_3COOH \cdot H_2O$ (351 + 228 + 18): C, 46.24; H, 3.71; N, 11.72; Found: C, 45.87; H, 3.43; N, 11.45. MS (MH^+): 352 (base peak).

The compounds of Examples A-203 through A-206 were synthesized in accordance with the chemistry described above (particularly in Scheme VIII) by selection of the corresponding starting reagents:

Example A-203



4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine




4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine


A 60% dispersion of sodium hydride (41 mg, 0.00172 moles) (prewashed with hexane) in mineral oil (69 mg) was added with 5 ml of dioxane to a stirred solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (200 mg, 0.00086 moles) (prepared as set forth in Example A-2) in 50 ml of dioxane. After 3 hours a solution of CH_3I (122 mg, 0.00086 mole) in 10 ml dioxane was added and the mixture was stirred at room temperature for 20 hours. The mixture was concentrated to a solid. The products were partitioned between water (15 ml) and ethyl acetate (50 ml). The organic layer was dried over Na_2SO_4 , filtered and concentrated to a solid. The products were purified and separated by radial chromatography. NMR (NOE experiments) showed that the first component off the column (the minor component) was 4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine, and the second material off the column was 4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine.

Major isomer (4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine): m.p.: 94-99 °C. Anal. calc'd for $\text{C}_{16}\text{H}_{15}\text{N}_3 \cdot 0.1\text{MH}_2\text{O}$: C, 77.08; H, 6.06; N, 16.85. Found: C, 76.59; H, 5.70; N, 16.62

Example A-204



4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine




4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine (the compound of Example A-32)

4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine and 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl)pyridine (prepared as set forth in Example A-7).


Major Isomer (4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine): Anal. calc'd for $C_{16}H_{14}N_3Cl$ (283.76): C, 67.72; H, 4.97; N, 14.81; Found: C, 67.45; H, 4.71; N, 14.63. m.p. (DSC): 190.67 °C.

Minor Isomer (4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine): m.p.: 82-88 °C. Anal. calc'd for $C_{16}H_{14}N_3Cl$: C, 67.72; H, 4.97; N, 14.81; Found: C, 67.56; H, 4.96; N, 14.73.

Example A-205



4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine




4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine


4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine and 4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-methylphenyl)-5-ethyl-1H-pyrazol-4-yl)pyridine (prepared as set forth in Example A-45).

Major Isomer (4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for $C_{18}H_{19}NO_3 \cdot 0.45$ MH_2O : C, 75.73; H, 7.03; N, 14.77. Found: C, 76.03; H, 6.87; N, 14.28.

Minor Isomer (4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for $C_{18}H_{19}NO_3 \cdot 0.30$ MH_2O : C, 76.46; H, 6.99; N, 14.86. Found: C, 76.58; H, 6.98; N, 14.63.


Example A-206

4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{17}H_{16}N_3Cl$ (297.79): C, 68.57; H, 5.42; N, 14.11. Found: C, 68.33; H, 5.27; N, 14.08; m.p. (DSC) 164.36 °C.

Example A-207

4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{17}H_{16}N_3Cl$ (297.79): C, 68.57; H, 5.42; N, 14.11. Found: C, 68.25; H, 5.36; N, 13.74; m.p. (DSC) 153.46 °C.

The compounds of Examples A-208 and A-209 were prepared in accordance with the chemistry described above (particularly in Scheme IX):

Example A-208

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 4-fluorobenzoyl-4'-pyridyl methane

To a mixture of 4-picoline (32.6 g, 0.35 moles) and ethyl-4-fluorobenzoate (50.45g, 0.3 moles), maintained at 20 °C, was added lithium bis(trimethylsilylamide) (600 mL (1M)) in a steady but rapid stream so as to maintain ambient temperature. The initial yellow solution turned into a suspension which was then stirred for an additional 2 hours. Toluene (250 mL) was added and the mixture cooled to 0 °C. The reaction mixture was quenched with concentrated HCl at 0 °C to lower the pH to about 7. The organic layer was separated and the aqueous layer re-extracted with of toluene (100 mL). The organic layer was dried (sodium sulfate) and concentrated, to furnish a yellow solid which on trituration with hexanes (200 mL) provided the pure desoxybenzoin, 4-fluorobenzoyl-4'-pyridyl methane, in 90% yield (58g). ¹H NMR was consistent with the proposed structure.

Step 2:


To a suspension of the desoxybenzoin prepared in step 1 (30g, 0.14 moles) in tetrahydrofuran (50 mL) was added dimethylformamide dimethyl acetal (50 mL) and the mixture stirred at ambient temperature for two days. The solution was then concentrated to dryness and the solid paste obtained was triturated with hexanes (150 mL) to furnish a yellow solid which was of sufficient purity (as determined by NMR) and was used for the next step without additional purification. Yield: 33.9 g (90%). ¹H NMR was consistent with the proposed structure.

Step 3:

The vinyl amine prepared in step 2 (33.9g, 0.1255 moles) was dissolved in 125 mL of ethanol and cooled to 0 °C. Hydrazine hydrate (8.0g of anhydrous or 16.0g. of hydrate, 0.25 moles) was then added in one portion. The mixture was stirred well and allowed to warm up to

ambient temperature for a total reaction time of 3 hours. The mixture was concentrated and taken up in 200 mL of chloroform. After washing with water (100 mL), the organic layer was extracted with 150 mL of 10% HCl. The water layer was then treated with 0.5 g of activated charcoal at 70 °C for 10 minutes, filtered through celite and neutralized cautiously to pH 7 - 8 with vigorous stirring and cooling (20% sodium hydroxide was used). The fine off-white precipitate was filtered and dried to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine. Yield: 27.3g. (91%). Mass spectrum: $m/z = 240$. ^1H NMR was consistent with the proposed structure. Anal. calc'd for $\text{C}_{14}\text{H}_{10}\text{FN}_3$: C, 70.28; H, 4.21; N, 17.56. Found: C, 70.11; H, 4.33; N, 17.61.

Example A-209




4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine

This compound was prepared by the same procedure described for Example A-208 using the corresponding starting reagents.

Anal. Calc'd for $\text{C}_{14}\text{H}_{10}\text{ClN}_3$: C, 65.76; H, 3.94; N, 16.43. Found: C, 65.22; H, 3.91; N, 16.50. m.p. (DSC): 208.46 °C.

The compounds of Examples A-210 and A-211 illustrate were prepared in accordance with the chemistry described above (particularly in Scheme X):


Example A-210

3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

The desoxybenzoin prepared in step 1 of Example A-208, 4-fluorobenzoyl-4'-pyridyl methane, (12.7g, 0.059 moles) was mixed with 90% hydroxyethyl hydrazine (5.3g, 0.062 moles) in 30 mL of ethanol containing 0.5 mL of acetic acid in a 500 mL Erlenmeyer flask. After gentle boiling (1 hour), a small sample was evacuated at high vacuum and examined by ¹H NMR to confirm completion of hydrazone formation. On cooling to ambient temperature, the reaction mass solidified to a yellow cake. DMF dimethylacetal (36 mL, 0.27 moles) was then added and the mixture heated to 80°C for 10min, at which point all the solids dissolved and a clear yellow viscous solution was obtained. The reaction mixture was immediately allowed to cool slowly to 25 °C, and water (20 mL) was added dropwise with stirring, at which point a cloudy yellow oily suspension was obtained. The solution was now warmed to approximately 50-60 °C, whereupon the solution turned clear yellow. Slow cooling to ambient temperature with stirring (a crystal seed if available speeds up the process) results in a copious formation of crystals. Suction filtration followed by washing with 10% ethanol-water (50 mL), followed by drying, furnishes 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol as a light yellow crystalline solid. Re-heating the filtrate to clarity as before, followed by cooling, yields additional product. The third and fourth recovery from

the mother liquor on standing overnight furnishes the remaining 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol. Total yield: {12.3 + 3.3 + 0.4 + 0.4} = 16.4g. (97.6%). Mass spectrum, m/z = 284. ^1H NMR was consistent with the proposed structure. Anal. calc'd for $\text{C}_{16}\text{H}_{14}\text{FN}_3\text{O}$ + H_2O : C, 63.78; H, 5.35; N, 13.95. Found: C, 63.55; H, 5.07; N, 13.69.

Example A-211




3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol

This compound was prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 4-methyl-pyrimidine.

The compound of Example A-212 was prepared in accordance with the chemistry of Scheme XI:

Example A-212




4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

The vinyl amine prepared in Step 2 of Example A-208 (5.0g, 0.0185 moles) was taken up in ethanol (75mL) and

cooled to 0 °C. Methyl hydrazine (1.7g, 0.037 moles) in ethanol (75mL) was added in one portion while maintaining the temperature at 0 to 10 °C. After 3 hours at ambient temperature the solvent was removed and the residue taken up in methylene chloride (150 mL) and water (100 mL). The organic layer was separated, dried and concentrated to provide the crude regio-isomeric mixture as a light tan colored solid (80:20 by NMR in favor of the title compound). The crude isomeric mixture was taken up in 10% HCl (100 mL) and washed with methylene chloride (100 mL) and the water layer treated with activated charcoal (0.5g). After filtration through Celite, the solution was neutralized with sodium hydroxide (20%) to pH 8 with good stirring and cooling. The cream colored precipitate was filtered, washed with water and dried. The solid (5 g) was dissolved in hot 10% heptane/toluene (70 mL) and allowed to cool slowly, first to ambient temperature and then to 15 °C. Scratching the sides of the flask starts the crystallization process. After 2 hours of standing, the solids formed were filtered, washed with cold 50% toluene/heptane (25 mL) followed by hexane (25 mL) and dried to yield the pure title compound. ¹H NMR confirmed the structure (including regiochemistry using NOE experiments). Yield: 2.1g. (45%). Mass spectrum, m/z = 254 (base peak). Anal. calc'd for C₁₅H₁₂FN₃ + 0.2 H₂O: C, 70.15; H, 4.86; N, 16.4. Found: C, 70.18; H, 4.6; N, 16.47.

The compound of Example A-213 was prepared in accordance with the chemistry of Scheme XII:

Example A-213




2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol

An intimate mixture of 2-fluoro-pyridinyl pyrazole (0.2g, (prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 2-fluoro-4-methylpyridine) and (R,S)-2-amino-1-butanol (4 fold molar excess) was heated to 210-220 °C in a sealed vial for 1.5 hours. After cooling to 100 °C the vial was cautiously opened and 5 mL of toluene and 5 mL of water were added and stirred well for 1 hour. The solid obtained, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol, was suction-filtered and washed with an additional 5 mL of water followed by toluene and dried. Yield: 190mg. (71%). Mass spectrum, $m/z = 343$. ^1H NMR was consistent with the proposed structure.

The compound of Example A-214 was prepared in accordance with the chemistry of Scheme XIII:

Example A-214




4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (2.7 g, 10.67 mmol) (prepared in accordance with Example A-212) in acetic acid (30 mL) and DMF (13 mL) was added bromine (19.5 g, 122.0 mmol).. The solution was heated at 80 °C overnight. TLC indicated that the reaction was complete. The mixture was quenched slowly with K_2CO_3 (25g). When pH was about 5, a precipitate was formed. The precipitate was washed with water (50mL x 5) to give 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (1.24g, 35%): mp 174.38°C; Mass spectrum m/z = 332, 334; 1H NMR was consistent with the proposed structure. Anal. Calc'd for $C_{15}H_{11}N_3FBr \cdot 0.2 H_2O$: C, 53.66; H, 3.42; N, 12.51. Found: C, 53.58; H, 3.12; N, 12.43.

The compound of Example A-215 was prepared in accordance with the chemistry of Scheme XIV:

Example A-215



4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile

Step 1:


To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (4.3g, 17.97 mmol) (prepared in accordance with Example A-208) in methanol (100 mL) was added 3-chloroperoxybenzoic acid (5.44 g in 57 % purity, 17.97 mmol). The solution was stirred at 25 °C for overnight. The mixture was concentrated. K_2CO_3 (10%, 100 mL) was added to the residue. A precipitate was formed, filtered and washed with water (30 mL x 3) to give the corresponding N-oxide (3.764g, 81.66%).

Step 2:

To a suspension of the N-oxide prepared in step 1 (0.40 g, 1.567 mmol) in DMF (5 mL) was added trimethylsilyl cyanide (0.3 mL, 2.25 mmol). The mixture was stirred for 15 minutes at 25 °C. Dimethylcarbonyl chloride (0.8 mL, 8.69 mmol) was added. The mixture was stirred at 25 °C for 2 hours. TLC indicated that the starting materials were gone. The mixture was partitioned into ethyl acetate:water (100 mL:20 mL). The organic layer was washed with K_2CO_3 (10%, 20 mL), water (50 mL), brine (50 mL), dried over $MgSO_4$, filtered and concentrated to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile (0.23 g, 56 % yield): mp 209.22 °C ; Mass spectrum (chemical ionization): m/z =

265; ^1H NMR was consistent with the proposed structure. Anal. Calc'd for $\text{C}_{15}\text{H}_9\text{N}_4\text{F} \cdot 0.2 \text{ H}_2\text{O}$: C, 67.26; H, 3.54; N, 20.92. Found: C, 67.44; H, 3.40; N, 20.69.

The compound of Example A-216 was prepared in accordance with the chemistry of Scheme XV:



4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine

Step 1:

3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (prepared in accordance with Example A-210) (10.0 g, 0.0353 moles) was suspended in pyridine (100 mL) and cooled to 0 °C. Methane sulfonyl chloride (4.4 g, 0.0388 moles) was added slowly while maintaining the temperature at 0 °C. After stirring overnight at 10 °C, chilled water (100 mL) and methylene chloride (150 mL) was added and the two layers separated. The water layer was re-extracted with 100 mL of methylene chloride and the organic layer dried and concentrated to a paste. After drying at high vacuum, a light tan colored cake was obtained which was triturated with ether (75 mL), filtered and dried to furnish a cream colored solid in 79% yield (10.1g). ^1H NMR was consistent with the proposed structure. The compound was used as such for step 2.


Step 2:

The mesylate prepared in step 1 (5.0 g, 0.0138

moles) was dissolved in an eight fold excess of morpholine (9.6 g, 0.11 moles) in methanol (50 mL) and heated at reflux for 3 to 4 hours. After an NMR sample confirmed completion, the mixture was concentrated and taken up in methylene chloride (150 mL) and washed with water (100 mL) and then with 75 mL of 5% HCl. The water layer was neutralized to pH 8 and extracted with methylene chloride (100 mL). On drying and concentration a light yellow pasty solid was obtained which was triturated with 25 mL of ether to furnish a solid. Recrystallization from toluene/hexane provided 4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine as a solid. Yield: 4.5g (86%). Mass spectrum, $m/z = 353$. ^1H NMR was consistent with the proposed structure. Anal. calc'd for $\text{C}_{20}\text{H}_{21}\text{FN}_4\text{O}$: C, 68.16; H, 6.01; N, 15.90. Found: C, 68.20; H, 6.21; N, 15.80.

The compound of Example A-217 was prepared in accordance with the chemistry of Scheme XVI:

Example A-217




3-(4-fluorophenyl)-1-methyl- α -phenyl-4-(4-pyridinyl)-1H-pyrazole-5-methanol

To solid magnesium (60 mg, 5 mmol) under nitrogen was added a solution of 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (450 mg, 1.35 mmol) (prepared in accordance with Example A-214) in tetrahydrofuran (7 mL). The mixture was heated at 40 °C

for 2 hours. Benzaldehyde (1 mL) was added. The mixture was heated to 45 °C for 2 hours. It was quenched with HCl (10 mL, 1N) and washed with ethyl acetate. The aqueous acid layer was basified and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over MgSO₄, filtered and concentrated to give a residue. The residue was purified with a silica gel column to give the title compound (59 mg, 12% yield). MS: m/z = 360 (M+1); ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₂₂H₁₈N₂OF•0.6EtOAc: C, 71.1; H, 5.6; N, 10.2; Found: C, 70.9; H, 5.47; N, 10.2.

The compound of Example A-218 was prepared in accordance with the chemistry described above (particularly Scheme XVII):

Example A-218




N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine

The starting desoxybenzoin prepared in step 1 of Example A-208, 4-fluorobenzoyl-4'-pyridyl methane, (1.0 g, 0.0046 moles) was dissolved in 10 mL of DMF and cooled to -10 °C (dry ice-aqueous isopropanol). N-chlorosuccinimide (0.62 g, 0.0046 moles) was added in one portion while maintaining the temperature at -10 °C. After 5 minutes the thiosemicarbazide (0.0046 moles) was added in one portion at 0 °C and allowed to warm to ambient temperature slowly over 1 hour. After stirring overnight, the solvent was removed at high vacuum and


water and toluene (25 mL each) added and stirred well. The toluene layer was separated and the water layer (starting pH of 5.5) treated with bicarbonate to pH 8. The fine precipitate formed was filtered and washed with water, toluene and ether. A final trituration with ether (25 mL) furnished an off white solid, N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine, which was re-filtered and dried. Yield: 0.95g. (56%). Mass Spec. m/z: 368 (base peak). Anal. Calc'd for $C_{20}H_{22}FN_5O$. C, 65.38; H, 6.04; N, 19.06. Found: C, 64.90; H, 5.92; N, 18.67.

Example A-219



4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone hydrazone


Step 1: Preparation of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethenamine



4-Methyl-2-bromopyridine (1.0 g, 5.8 mmol) and t-butoxybis(dimethylamino)methane (5 ml) were heated to 150 °C for 16 hours. 4-Methyl-2-bromopyridine was prepared as set forth in B. Adger et al., J. Chem. Soc., Perkin Trans. 1, pp. 2791-2796 (1988), which is incorporated herein by reference. The contents were evaporated and the residue dissolved in ethyl acetate and washed with


water. The organic layer was dried over magnesium sulfate and solvent removed in vacuo to give 1.0 g of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethenamine as an oil suitable for use in step 2.

Step 2: Preparation of (Z)-2-(2-bromo-4-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one



The product from step 1 (1.0 g, 4.4 mmol) was dissolved in methylene chloride (15 ml). Triethylamine (900 mg, 8.8 mmol) was added at 0 °C, followed by the addition of 3-chlorobenzoyl chloride (350 mg, 4.5 mmol). The mixture was stirred under nitrogen for 16 hours. Solvent was evaporated in vacuo and the residue was dissolved in ether (25 ml), stirred with magnesium sulfate (500 mg) and silica gel (500mg), and filtered. Ether was evaporated and the residue was chromatographed on silica gel using mixtures of acetone and methylene chloride as eluents to give 670 mg of the product, (Z)-2-(2-bromo-4-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one, as a glass which was used in step 3 without further purification.


Step 3: Preparation of 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine



A solution of the product from step 2 (650 mg, 1.8 mmol) and hydrazine monohydrate (100 mg) in ethanol (10 ml) was refluxed for 24 hours. Solvent was evaporated and the residue was chromatographed on silica gel using mixtures of ethyl acetate and toluene as eluents to give 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine (190 mg, 31%) as an oil: Anal. Calc'd for $C_{14}H_9BrClN_3$: C, 50.25; H, 2.71; N, 12.56. Found: C, 50.10; H, 2.60; N, 12.40.

Continued elution with mixtures of ethyl acetate and methanol gave 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone hydrazone (190 mg, 36%) as a crystalline solid: m.p. 163-164 °C.; MS (M+H) = 286. Anal. Calc'd for $C_{14}H_{12}N_5Cl$: C, 58.85; H, 4.23; N, 24.51. Found: C, 58.53; H, 4.28; N, 24.87.

Example A-220




4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (150 mg, 0.5 mmol) in benzylamine (5 ml) was heated at 175 °C for six hours. After cooling, excess benzylamine was removed by high vacuum distillation and ethyl acetate added to the residue. After washing the organic phase with water and drying over magnesium sulfate, the solvent was removed in vacuo and the residue chromatographed on silica gel using mixtures of ethyl acetate and toluene to give 4-[3-(3-

chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine (110 mg, 61%) as a solid, m.p. 179-180 °C.

Anal. Calc'd For $C_{21}H_{17}ClN_4$: C, 69.90; H, 4.75; N, 15.53.
Found: C, 69.69; H, 4.81; N, 15.11.

Example A-221




4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (250 mg, 0.75 mmol) in phenethylamine (5 ml) was heated at 175 °C for six hours under a nitrogen atmosphere. The excess amine was distilled off under high vacuum and the residue was dissolved in ethyl acetate and washed with water. After drying over magnesium sulfate and removal of solvent, the residue was chromatographed on silica gel with mixtures of ethyl acetate and toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine (230 mg, 81%) as a solid, m.p. 185-186 °C.

Anal. Calc'd For $C_{22}H_{19}ClN_4$: C, 70.49; H, 5.11; N, 14.95. Found: C, 70.29; H, 5.15; N, 14.66.

Example A-222




4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (300 mg, 0.9 mmol) in ethylamine (3.5 ml) and ethanol (5 ml) as heated at 150 °C in a sealed tube for 9 hours. The solvent was removed in vacuo and the residue chromatographed on silica gel with 70 ethyl acetate/30 toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine (125 mg, 46%) as a solid, m.p. 186-187 °C.

Anal. Calc'd For $C_{16}H_{15}ClN_4$: C, 64.32; H, 7.06; N, 18.75.
Found: C, 64.42; H, 7.01; N, 18.45.

The compounds of Examples A-223 through A-226 were synthesized in accordance with the chemistry described above (particularly in Scheme XVIII) by selection of the corresponding starting reagents:

Example A-223



4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide

Step 1:

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (prepared as set forth in Example A-208) (8.8 g, 0.037 mol) in methylene chloride was added m-chloroperoxybenzoic acid (mCPBA) in one portion at room temperature. After stirring for 16 hours, solvent was removed and the residue was treated with saturated sodium bicarbonate solution. The precipitate was filtered, air-dried to give 8.2 g of a product as a white solid (87%), mp: 207-209°C.

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile


To a solution of the product of step 1 (5.1 g, 0.02 mol) in 20 mL of DMF was added trimethylsilyl cyanide (2.5 g, 0.025 mol), followed by a solution of N, N-dimethylcarbamoyl chloride (2.7 g, 0.025 mol) in 5 mL of DMF at room temperature. After stirring overnight, the reaction mixture was basified by 200 mL of 10% potassium carbonate water solution. The aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude

was triturated with hexane and filtered to give 4.3 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile (90%) as a pale yellow solid, mp: 238-239°C.

Step 3: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide:

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile from step 2 (0.45 g, 0.0017 mol) in 10 mL of DMSO was added hydrogen peroxide (0.24 mL of 30% aqueous solution, 1.7 mmol) and potassium carbonate (0.04 g, 0.4 mmol) at 0°C. The mixture was stirred for 1 hour while allowing it to warm to room temperature. Water was added and the precipitate was collected by filtration and air-dried to give 0.32 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide as a white solid (67% yield), mp: 230-231 °C. Anal. Calc'd for $C_{15}H_{11}FN_4O$: C, 63.83; H, 3.93; N, 19.85. Found C, 63.42; H, 3.66; N, 19.58.

Example A-224




Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide prepared as set forth in Example A-223 (2.9 g, 0.01 mol) in 50 mL of methanol was added N,N-dimethylformamide dimethyl acetal (3.67 g, 0.03

mol) dropwise. The reaction mixture was stirred at room temperature overnight and heated at reflux for 4 hours. After cooling, the precipitate was collected by filtration and air-dried to give 2.0 g of methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate as a white solid (69% yield), mp: 239-241°C. Anal. Calc'd for $C_{16}H_{12}FN_3O_2$: C, 64.64; H, 4.07; N, 14.13. Found: C, 64.36; H, 4.10; N, 14.27.

Example A-225



4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide

A mixture of methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate prepared as set forth in Example A-224 (0.45 g, 1.5 mmol) and 20 mL of methylamine (40% aqueous solution) was heated at 120°C in a sealed tube for 16 hours. After cooling, water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to afford 0.4 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide as a white solid, mp: 88-89°C. Anal. Calc'd for $C_{16}H_{13}FN_4O + 0.4 H_2O$: C, 63.32; H, 4.58; N, 18.46. Found C, 63.10; H, 4.62; N, 18.35.

TABLE 3


| Example | General Procedure | MS M+1 | Microanalysis | | | | | | | |
|---------|----------------------|-----------|---------------|---------|--------|---------|--------|---------|----------------|----------------|
| | | | C calc | C found | H calc | H found | N calc | N found | water added | EtOAc added |
| | | | | | | | | | | |
| A-227 | IX | 240 | 69 | 69 | 4.3 | 4.6 | 17.2 | 16.8 | 0.25 | |
| A-228 | IX | 266 | 65.69 | 65.69 | 4.41 | 4.33 | 15.32 | 14.98 | | |
| A-229 | XI | 254 | 70.6 | 70.6 | 4.8 | 4.5 | 16.5 | 16.3 | 0.1 | |
| A-230 | IX | 256 | 65.76 | 65.48 | 3.94 | 3.78 | 16.43 | 16.52 | | |
| A-231 | XI | 280 | 64.18 | 63.95 | 4.39 | 4.31 | 13.86 | 13.90 | | |
| A-232 | XI | 271 | 66.79 | 66.79 | 4.48 | 4.24 | 15.58 | 15.32 | | |
| A-233 | XI | 284 | 66.9 | 66.8 | 5 | 5 | 14.6 | 14.9 | 0.2 | |
| A-234 | XI | 270 | 65.9 | 65.6 | 4.6 | 4.6 | 15.4 | 15.4 | 0.2 | |
| A-235 | XI | 264 | 77 | 76.7 | 6.5 | 6.5 | 15.8 | 15.7 | 0.1 | |
| A-236 | IX | 221 | 75.38 | 75.44 | 5.06 | 5.1 | 18.84 | 19 | 0.1 | |
| A-237 | IX | 290 | 61.52 | 61.67 | 3.58 | 3.51 | 14.35 | 14.32 | | |
| A-238 | XI | 304 | 63.36 | 63.28 | 3.99 | 3.91 | 13.85 | 13.83 | | |
| A-239 | IX | 258 | 65.37 | 65.39 | 3.53 | 3.52 | 16.33 | 16.31 | | |
| A-240 | IX | 274 | 61.44 | 61.14 | 3.31 | 3.01 | 15.35 | 14.95 | | |
| A-241 | IX | 300 | 56.02 | 55.99 | 3.36 | 3.26 | 14.00 | 14.01 | | |
| A-242 | XI | 272 | 66.42 | 66.41 | 4.09 | 4.04 | 15.49 | 15.32 | | |
| A-243 | XI | 314 | 57.34 | 57.22 | 3.85 | 3.68 | 13.37 | 13.27 | | |
| A-244 | IX | 342 | 76.39 | 76.16 | 4.81 | 4.51 | 12.31 | 12.05 | 0.25 | |
| A-245 | XII | 341 | 64.89 | 64.65 | 6.36 | 6.17 | 15.93 | 15.82 | 0.6 | |
| A-246 | XII | 391 | 66.08 | 66.18 | 5.04 | 5.56 | 14.01 | 12.26 | 0.5 | |
| A-247 | XII | 362 | 64.46 | 64.16 | 4.65 | 4.34 | 18.79 | 18.65 | 0.6 | |
| A-249 | XII | 258 | 64.91 | 64.84 | 3.58 | 3.63 | 16.22 | 15.98 | 0.1 | |

| | | | | | | | | | | |
|-------|-------------|-----|-------|-------|------|------|-------|-------|------|-----|
| A-250 | IX | 348 | 48.44 | 48.07 | 2.9 | 2.82 | 12.1 | 12.01 | | |
| A-251 | XI | 362 | 49.88 | 49.89 | 3.35 | 3.51 | 11.63 | 11.54 | | |
| A-252 | XI | 304 | 63.36 | 63.34 | 3.99 | 3.96 | 13.85 | 13.81 | | |
| A-253 | XII | 377 | 68.24 | 68.17 | 5 | 4.71 | 14.47 | 14.34 | 0.6 | |
| A-254 | XII | 363 | 66.31 | 66.12 | 4.77 | 4.31 | 14.73 | 14.6 | 1 | |
| A-215 | XIV | 265 | 67.3 | 67.4 | 3.5 | 3.4 | 20.9 | 20.7 | 0.2 | |
| A-255 | XII | 298 | 64.63 | 64.64 | 5.42 | 5.41 | 23.55 | 23.32 | | |
| A-256 | XI | 272 | 66.42 | 66.58 | 4.09 | 4.26 | 15.49 | 14.78 | | |
| A-257 | IX | 276 | 60.11 | 60.4 | 3.06 | 3.18 | 15.02 | 14.73 | 0.25 | |
| A-258 | IX | 254 | | | | | | | | |
| A-259 | XI | 268 | 71.89 | 71.63 | 5.28 | 5.24 | 15.72 | 15.84 | | |
| A-260 | X | 290 | 62.28 | 62.41 | 3.48 | 3.48 | 14.53 | 14.51 | | |
| A-261 | X, XV | 311 | 69.26 | 69.2 | 6.2 | 6.25 | 17.95 | 17.89 | 0.1 | |
| A-262 | XI | 376 | 72.71 | 72.5 | 5.17 | 4.98 | 11.06 | 10.99 | 0.25 | |
| A-263 | XII | 428 | 70.81 | 70.59 | 6.28 | 6.45 | 15.88 | 15.08 | 0.75 | |
| A-264 | XII | 326 | 63.79 | 63.76 | 6.39 | 6.09 | 20.66 | 20.45 | 0.75 | |
| A-265 | IX | 400 | 66.18 | 66.77 | 4.1 | 4.23 | 16.78 | 15.83 | 1 | |
| A-266 | XII | 368 | 62.32 | 62.38 | 6.28 | 6.5 | 18.17 | 17.56 | 1 | |
| A-267 | XI | 302 | 62.66 | 62.85 | 4.47 | 4.34 | 13.7 | 13.53 | 0.4 | |
| A-268 | XII | 349 | 62.9 | 63.2 | 5.2 | 4.8 | 22.7 | 22.5 | 0.75 | 0.1 |
| A-269 | XI, XV | 371 | 61.85 | 61.84 | 5.71 | 5.24 | 14.42 | 14.17 | 1 | |
| A-270 | XI, XV | 404 | 70.66 | 70.7 | 4.82 | 4.61 | 10.3 | 10.15 | 0.25 | |
| A-271 | XI, XV | 329 | 65.8 | 65.3 | 5.5 | 5.6 | 17.1 | 16.8 | | |
| A-272 | XI | 406 | 69.95 | 70.13 | 5.35 | 5.28 | 10.14 | 9.89 | 0.5 | |
| A-273 | XI | 354 | 66.9 | 67.2 | 6.9 | 6.6 | 19.1 | 18.7 | 0.2 | 0.1 |
| A-274 | XI, XII, XV | 434 | 63.6 | 63.1 | 6.3 | 5.8 | 14.4 | 14 | 2 | 0.2 |

FOOTNOTES


| | | | | | | | | | | |
|-------|----------------|-----|-------|-------|------|------|-------|-------|------|-----|
| A-275 | XI, XV | 433 | 70.44 | 70.74 | 6.18 | 6.3 | 12.64 | 12.05 | 0.6 | |
| A-276 | XI, XII, XV | 476 | 65.9 | 66.2 | 6.1 | 6.1 | 13.3 | 13.6 | 0.5 | 0.5 |
| A-277 | XII | 338 | 61.11 | 63.02 | 6.48 | 6.39 | 18.75 | 16.61 | | |
| A-278 | XI, XV | 357 | 64.2 | 63.8 | 6.5 | 6 | 15 | 14.8 | 1 | |
| A-279 | XI, XII, XV | 462 | 67.4 | 67.1 | 6.7 | 6.2 | 13.6 | 13.7 | 0.6 | 0.5 |
| A-280 | XII | 299 | 61.27 | 61.47 | 5.37 | 5.11 | 17.86 | 17.21 | 0.9 | |
| A-281 | XII | 313 | 64.63 | 64.94 | 5.55 | 5.63 | 17.73 | 17.48 | 0.2 | |
| A-282 | XII | 313 | 64.63 | 64.81 | 5.55 | 5.43 | 17.73 | 17.38 | 0.3 | |
| A-283 | XI, XII | 407 | 67.2 | 67 | 5 | 5.2 | 13.6 | 13.2 | 0.25 | |
| A-284 | XI, XV | 339 | 70 | 70.3 | 6.9 | 6.9 | 16.3 | 16.2 | 0.25 | |
| A-285 | XI, XII, XV | 476 | 68.2 | 68.5 | 5.7 | 6.2 | 14.7 | 13.6 | | |
| A-286 | XVII | 382 | 59.77 | 59.69 | 6.81 | 6.56 | 16.6 | 16.65 | 2.25 | |
| A-287 | XVII | 340 | 56.07 | 56.26 | 7.31 | 7.1 | 17.21 | 17.27 | 3.75 | |
| A-288 | XVII | 293 | 69.42 | 69.4 | 4.52 | 4.6 | 19.05 | 19.09 | 0.1 | |
| A-289 | XI, XII | 407 | 68 | 67.5 | 5 | 4.5 | 13.8 | 13.5 | | |
| A-290 | XI, XII | 407 | 64 | 64.5 | 5.3 | 4.9 | 13 | 12.4 | 1.4 | |
| A-291 | IX | 290 | 74.7 | 74.9 | 4.2 | 4.2 | 14.5 | 14.5 | | |
| A-292 | XVII | 326 | 61.22 | 61.46 | 4.77 | 4.53 | 16.8 | 16.97 | 0.4 | |
| A-293 | XVII | 313 | 55.75 | 55.98 | 4.85 | 4.02 | 16.25 | 16.37 | 1.8 | |
| A-294 | XI | 278 | 73.6 | 73.2 | 4.4 | 4.2 | 15.2 | 15 | | |
| A-295 | XI | 278 | 67.9 | 67.7 | 4.9 | 4.3 | 14 | 13.7 | 1.3 | |
| A-296 | IX | | 70.3 | 70.4 | 4.5 | 4.7 | 25.2 | 25.4 | | |
| A-297 | IX | | 57.9 | 57.7 | 3.1 | 2.9 | 14.5 | 14.5 | | |

Example A-227




4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine

Example A-228




4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine


Example A-229




4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-230


4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine

Example A-231


4-[3-(1,3-benzodioxol-5-yl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-232


4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-233


4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine and 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine

Example A-234


4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine and 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-235


2-methyl-4-[1-methyl-3 (or 5) - (3-methylphenyl) -1H-pyrazol-4 -yl]pyridine

Example A-236


4-(3-phenyl-1H-pyrazol-4-yl)pyridine

Example A-237


4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine

Example A-238


4-[1-methyl-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine

Example A-239


4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine

Example A-240


4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine

Example A-241


4-[3-(4-bromophenyl)-1H-pyrazol-4-yl]pyridine

Example A-242


4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-243

4-[3-(4-bromophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-244


(E)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-phenylethenyl)pyridine

Example A-245

S


(S)-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-methylbutyl)-2-pyridinamine

Example A-246




4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyridinamine

Example A-247




N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine

Example A-248




N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine


Anal Calc'd: C, 41.12; H, 3.58; N, 9.22. Found: C, 41.74; H, 5.05; N, 11.11.

Example A-249


2-fluoro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine


Example A-250

4-[3-(4-iodophenyl)-1H-pyrazol-4-yl]pyridine


Example A-251

4-[3-(4-iodophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine


Example A-252

Example A-256


2-fluoro-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-257


4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine

Example A-258


4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine

Example A-259


4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methylpyridine

Example A-260


4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-fluoropyridine

Example A-261


3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine

Example A-262

2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine


Example A-263

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]-2-pyridinamine

Example A-264


N' - [4 - [3 - (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinyl] -
N,N-dimethyl-1,2-ethanediamine

Example A-265




2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine

Example A-266




N - [4 - [3 - (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinyl] -4-
morpholineethanamine

Example A-267




3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanol

Example A-268




4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]-2-pyridinamine

Example A-269




4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine

Example A-270




(E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-4-pyridinyl]-1H-pyrazole-1-ethanol

Example A-271




3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-N,N-dimethyl-1H-pyrazole-1-ethanamine

Example A-272




3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-1H-pyrazole-1-ethanol

Example A-273




4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine

Example A-274




4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine


Example A-275




3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine

Example A-276


N-[(4-fluorophenyl)methyl]-4-[3-(or 5)-(4-fluorophenyl)-1-[[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine

Example A-277


4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl-2-pyridinamine

Example A-278


N,N-diethyl-3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanamine

Example A-279


4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine

Example A-280


2-[[4-[3-(4-(fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol

Example A-281


2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol

Example A-282


3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-propanol

Example A-283


3 (or 5) - (4-fluorophenyl) - 4 - [2 - [[(4-fluorophenyl)methyl]amino] - 4-pyridinyl] - 1H-pyrazole-1-ethanol

Example A-284


N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine

Example A-285


N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine

Example A-286


N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholinepropanamine

Example A-287


N'-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-1,3-propanediamine

Example A-288


5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

Example A-289


3-(4-fluorophenyl)-4-[2-[[4-(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol

Example A-290


5-(4-fluorophenyl)-4-[2-[[4-(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol

Example A-291


4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline

Example A-292

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine methyl ester


Example A-293

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine

Example A-294


4-[3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine

Example A-295




4-[5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine

Example A-296




4,4'-(1H-pyrazole-3,4-diyl)bis[pyridine]

Example A-297



4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine


Example A-298



N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]
-4-piperidinamine


The pyrimidine-substituted compounds of Examples A-299 through A-312 were synthesized in accordance with the chemistry described in Schemes I-XVIII by selection of the corresponding starting reagents:

Example A-299




2-Chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

Step 1:



A mixture of 2,6-dichloro-4-methylpyrimidine (5.0 g, 0.031 mol), triethylamine (6.23 g, 0.062 mol) and catalytic amount of 5% Pd/C in 100 mL of THF was hydrogenated on a Parr apparatus under 40 psi at room temperature. After 0.5 hour, the catalyst was filtered and the filtrate was concentrated. The crude was purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 2.36 g of product as a pale yellow crystal (50% yield); mp: 47-49 °C.

Step 2: Preparation of 2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone




2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone

To a solution of lithium diisopropylamide (generated from BuLi (0.045 mol) and diisopropylamine (0.048 mol) in THF) at -78 °C was added a solution of the compound prepared in step 1 (5.5 g, 0.037 mol) in THF slowly over 30 minutes. After 1 hour, a solution of ethyl 4-fluorobenzoate (7.62 g, 0.045 mol) in THF was added and the reaction mixture was stirred overnight and allowed to warm up to room temperature. Water was added and the aqueous phase was extracted with ethyl acetate. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 4.78 g of a yellow solid (51% yield), mp: 112-113 °C.

1004480-1004

Step 3: Preparation of (E)-2-(2-chloro-4-pyrimidinyl)-3-(dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one




(E)-2-(2-chloro-4-pyrimidinyl)-3-(dimethylamino)-
1-(4-fluorophenyl)-2-propen-1-one

A mixture of the compound prepared in step 2 (4.7 g, 0.017 mol) in 100 mL of dimethylformamide dimethyl acetal was stirred at room temperature overnight. Excess dimethylformamide dimethyl acetal was removed under vacuum to give 4.5 g of crude product as a thick brown oil, which was used without further purification.


Step 4: Preparation of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

A solution of the compound prepared in step 3 (4.4 g) and hydrazine hydrate (0.82 g, 0.014 mol) was stirred at room temperature for 6 hours. The yellow precipitate was collected by filtration and air-dried to give 1.85 g of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine as a yellow solid, mp: 204-205 °C; Anal. Calc'd for $C_{13}H_8ClFN_4$: C, 56.84; H, 2.94; N, 20.40; Cl, 12.91. Found: C, 56.43; H, 2.76; N, 20.02; Cl, 12.97.


Example A-300

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone
hydrazone

A solution of the compound prepared in step 3 of Example A-299 (1.5 g) and hydrazine hydrate (5mL) in ethanol was heated at reflux overnight. After the reaction mixture was cooled, the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified by recrystallization from ethyl acetate and hexane to give 0.5 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone, as a pale yellow solid (38% yield), mp: 149-150 °C; Anal. Calc'd for $C_{13}H_{11}FN_6$: C, 57.77; H, 4.10; N, 31.10. Found: C, 57.70; H, 4.31; N, 30.73.

Example A-301

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-
2-pyrimidinamine

Step 1: Preparation of


A solution of the compound prepared in step 2 of Example A-299 (3.0 g, 0.02 mol) and *tert*-butylbis(dimethylamino)methane (10.45 g, 0.06 mol) in 40 mL of DMF was stirred at 110 °C overnight. After the solvent was removed under vacuum, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by recrystallization from ethyl acetate and hexane to give 1.23 g of a yellow solid product (32% yield), mp: 76-77 °C; Anal. Calc'd for C₁₀H₁₆N₄: C, 62.47; H, 8.39; N, 29.14. Found: C, 62.19; H, 8.58; N, 29.02.

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine

To a solution of the compound prepared in step 1 of the present Example (1.2 g, 0.0064 mol) and triethylamine (0.65 g, 0.0064 mol) in 10 mL of toluene was added 4-fluorobenzoyl chloride dropwise. The mixture was heated at reflux for 10 hours and the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude (1.6 g) was then dissolved in 50 mL of ethanol. The solution was treated with hydrazine hydrate (0.36 g, 0.006 mol) and the mixture was heated at reflux for 2 hours. After ethanol was removed, the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was


concentrated and the crude was purified by chromatography on silica gel (ethyl acetate/hexane, 1:1) to give 0.6 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine, as a yellow solid (33% yield), mp: 155-156 °C; Anal. Calc'd for $C_{15}H_{14}FN_5$: C, 63.59; H, 4.98; N, 24.72. Found: C, 63.32; H, 4.92; N, 24.31.

Example A-302




4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

A suspension of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 (0.3 g, 0.0011 mol) in 10 mL of methylamine (40% water solution) was heated in a sealed tube at 100 °C overnight. The mixture was then cooled to room temperature and the precipitate was filtered, air-dried to give 0.2 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine, as a white solid (68% yield), mp: 217-218 °C; Anal Calc'd for $C_{14}H_{12}FN_5$: C, 62.45; H, 4.49; N, 26.01. Found: C, 62.58; H, 4.36; N, 25.90.

Example A-303

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine

This compound was synthesized by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in benzylamine overnight. The product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine, was obtained as a white solid in 95% yield; mp: 216-217 °C; Anal. Calc'd for $C_{20}H_{16}FN_5$: C, 69.55; H, 4.67; N, 20.28. Found: C, 69.73; H, 4.69; N, 19.90.


Example A-304

N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

This compound was synthesized by stirring 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 with excess cyclopropylamine in methanol at 50 °C for 12 hours. The

product, N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, was obtained as a white solid in 26% yield, mp: 203-204 °C; Anal. Calc'd for $C_{16}H_{14}FN_5$: C, 65.07; H, 4.78; N, 23.71. Found: C, 64.42; H, 4.82; N, 23.58.


Example A-305



4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine

This compound was synthesized by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in 4-methoxybenzylamine overnight. The product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine, was obtained as a off-white solid in 80% yield, mp: 183-185 °C; Anal. Calc'd for $C_{21}H_{18}FN_5O$: C, 67.19; H, 4.83; N, 18.66. Found: C, 67.01; H, 5.11; N, 18.93.


Example A-306



4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

A solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine prepared in accordance with Example A-305 (0.35 g, 0.00093 mol) in 15 mL of trifluoroacetic acid was heated at reflux for 16 hours. Solvent was removed and the residue was partitioned between ethyl acetate and 1 N ammonia hydroxide. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate) to give 0.14 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, as a pale yellow solid (59% yield), mp: 273-274 °C; Anal. Calc'd for $C_{13}H_{10}FN_5 \cdot 0.25 H_2O$: C, 60.11; H, 4.07; N, 26.96. Found: C, 60.15; H, 3.82; N, 26.38.

Example A-307




N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide

To a mixture of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine prepared in accordance with Example A-303 (0.15 g, 0.00043 mol), DMAP (0.027 g, 0.00022 mol) and acetic anhydride (0.066 g, 0.00066 mol) in 10 mL of THF was added triethylamine

(0.053 g, 0.00052 mol). The solution was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated NaHCO_3 , washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was triturated with ether to give 0.1 g of product, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide, as a white solid (60% yield), mp: 176-178 °C; Anal. Calc'd for $\text{C}_{22}\text{H}_{18}\text{FN}_5$: C, 68.21; H, 4.68; N, 18.08. Found: C, 67.67; H, 4.85; N, 17.79.

Example A-308




Ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine prepared in accordance with Example A-306 (0.26 g, 0.001 mol) in 5 mL of pyridine was added ethyl chloroformate dropwise. After the addition, the clear solution was stirred at room temperature for 6 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was triturated with ether to give 0.15 g of product, ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-

pyrimidinyl]carbamate, as a white solid (46% yield), mp: 163-165 °C; Anal. Calc'd for $C_{16}H_{14}FN_5O_2$: C, 58.71; H, 4.31; N, 21.04. Found: C, 59.22; H, 4.51; N, 21.66.

Example A-309




4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared by the same procedure as described for Example A-208 except that 1-methyl-3-(4'-pyrimidinylacetyl) benzene (prepared as set forth in Step 1 of Example A-19 from 4-methyl-pyrimidine and methyl 3-methylbenzoate) was used in place of 4-fluorobenzoyl-4-pyridinyl methane.

Anal. Calc'd for $C_{14}H_{12}N_4$ (236.27): C, 71.17; H, 5.12; N, 23.71. Found C, 70.67; H, 5.26; N, 23.53. m.p. (DSC): 151.67 °C.

Example A-310




4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place

of the pyridine starting material.

Anal. Calc'd for $C_{13}H_9N_4Cl \cdot 0.25MH_2O$: C, 59.78; H, 3.67; N, 21.45. Found: C, 59.89; H, 3.32; N, 21.56. m.p. (DSC): 218.17 °C.

Example A-311




4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for $C_{13}H_9N_4F$ (240.24): C, 64.99; H, 3.78; N, 23.22. Found: C, 64.78; H, 3.75; N, 23.31. m.p. (DSC): 168.58 °C.

Example A-312



4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of


the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for $C_{13}H_9N_4F$ (240.24): C, 64.99; H, 3.78; N, 23.32. Found: C, 64.94; H, 3.56; N, 23.44. m.p. (DSC): 191.47 °C.


TOGETHER

Example A-313

The compound 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine was prepared in accordance with general synthetic Scheme VII:




Step 1: Preparation of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate



A mixture of 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine (5.8 g, 24.0909 mmol; prepared as set forth in Example A-4) and potassium permanganate (7.6916 g, 48.1818 mmol) in water (7.5 mL) and *tert*-butanol (10 mL) was heated to reflux at 95 to 100 °C for 6 hours (or until all the potassium permanganate was consumed) and stirred at room temperature overnight. The mixture was diluted with water (150 mL) and filtered to remove manganese dioxide. The aqueous filtrate (pH >10) was extracted with ethyl acetate to remove unreacted starting material. The aqueous layer was acidified with 1N HCl to a pH of about 6.5. A white precipitate was formed. This precipitate was collected by filtration, dried in air, and then dried in a vacuum oven overnight at 50 °C to give 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate (2.7677 g, 40.6 %). The remaining product (0.21 g, 3.1%) was isolated from the

mother liquid by reverse phase chromatography. The total isolated yield of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate was 43.7 %. Anal. Calc'd for $C_{15}H_{10}N_3FO_2 \cdot H_2O$: C, 59.80; H, 4.01; N, 13.95; Found: C, 59.48; H, 3.26; N, 13.65. MS (MH^+): 284 (base peak).

Step 2: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate



In a solution of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate (0.9905 g, 3.5 mmol) from step 1 and 1-hydroxybenzotriazole hydrate (0.4824 g, 3.57 mmol) in dimethylformamide (20 mL) at 0 °C under N_2 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6983 g, 3.57 mmol) was added. The solution was stirred at 0 °C under N_2 for 1 hour, then was added 1-tert.-butoxycarbonylpiperazine (0.6585 g, 3.5 mmol) followed by N-methyl morpholine (0.40 mL, 3.6 mmol). The reaction was stirred from 0 °C to room temperature overnight. The reaction mixture was diluted with ethyl acetate and saturated $NaHCO_3$ solution, extracted. The organic layer was washed with water and brine, and dried over $MgSO_4$. After filtration, the solvent was removed under reduced pressure, and crude product was obtained (1.7595 g). The desired product 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (1.2375 g, 78.4 %) was isolated by chromatography (silica gel, 10:90

isopropyl alcohol/toluene). Anal. Calc'd for $C_{24}H_{26}N_5FO_3$: C, 63.85; H, 5.80; N, 15.51; Found: C, 63.75; H, 5.71; N, 15.16. MS (MH^+): 452 (base peak).


5 Step 3: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine

To a suspension of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-
 10 1-piperazinecarboxylate (0.451 g, 1.0 mL) in dry tetrahydrofuran (8 mL), 1.0N $LiAlH_4$ in tetrahydrofuran (2.5 mL, 2.5 mmol) was added dropwise at such a rate as to maintain reflux over 15 minutes. Upon the addition, the suspension became a clear light yellow solution,
 15 which was kept boiling for an additional 1.5 hours. Excess $LiAlH_4$ was decomposed by cautious addition of a solution of KOH (0.5611 g, 10.0mmol) in water (3.5 mL). Upon hydrolysis, a white salt precipitated. After the addition was completed, the mixture was heated to reflux
 20 for 1 hour. The hot solution was filtered by suction through a buchner funnel. Any remaining product was extracted from the precipitate by refluxing with tetrahydrofuran (10mL) for 1 hour, followed again by suction filtration. The combined filtrates were
 25 concentrated under reduced pressure to give a crude residue, which was then diluted with ethyl acetate and washed with water and brine. The organic layer was dried over $MgSO_4$. After filtration, the solvent was removed under reduced pressure, and a crude product was obtained.
 30 The desired product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine (0.1509 g, 50.1 %) was obtained by chromatography (silica gel, 70:30:1 methanol/ethyl acetate/ NH_4OH). Anal. Calc'd for $C_{20}H_{22}N_5F \cdot 0.6H_2O$: C, 66.32; H, 6.46; N, 19.33; Found: C, 66.31; H, 5.96; N, 18.83. MS (MH^+): 352 (base peak).
 35


100490-1004

Example A-314

The compound 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine was prepared in accordance with general synthetic Scheme VII:



Step 1: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate



A solution of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (0.6349 g; 1.4077 mmol; prepared as set forth in step 2 of Example A-313) in methylene chloride (3.5 mL) and TFA (1.1 mL, 14.077 mmol) was stirred at room temperature under N₂ for 2 hours. The solvents were removed under reduced pressure, and TFA was chased by methylene chloride and methanol. The resulting colorless oily residue was triturated with methanol. The resulting solid was collected by filtration and dried in a vacuum oven overnight to give the desired product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate (0.7860 g, 96.4%).

Anal. Calc'd for C₁₉H₁₈N₅OF·2TFA·H₂O: C, 46.24; H, 3.71; N, 11.72; Found: C, 45.87; H, 3.43; N, 11.45. MS (MH⁺): 352

(base peak) .

Step 2: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine


5

By following the method of Example A-313, step 3 and substituting of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate (prepared in step 1 of this Example) for 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate, the title product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine was obtained. Anal. Calc'd for $C_{19}H_{20}N_5F \cdot 0.75H_2O$: C, 65.03, H, 6.18, N, 19.96. Found: C, 65.47, H, 5.83, N, 19.35. MS (MH^+): 338 (base peak) .

Example A-315


20

The compound 4-[3-(4-fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine was prepared in accordance with general synthetic Scheme XX:




Step 1: Preparation of ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate

25



Ethyl 4-pyridyl acetate was converted to 2-(4-piperidinyl) ethyl acetate hydrochloride by hydrogenation (60 psi H₂) catalyzed by 5% Pt/C at 40 °C in ethanol and HCl solution. To a solution of 2-(4-piperidinyl)ethyl acetate hydrochloride (21.79g, 0.105mol) in tetrahydrofuran (500 mL) at 0 °C, triethylamine (32.06 mL, 0.230 mL) was added followed by di-tert-butylidicarbonate (23.21g, 0.105mol). The reaction mixture was stirred under N₂ from 0 °C to room temperature overnight. After removing tetrahydrofuran, the reaction mixture was diluted with ethanol, washed with saturated NaHCO₃, 10 % citric acid, water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure. The resulting oily product was dried under vacuum to give ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate (27.37 g, 95.9 %). The structure of this product was confirmed by NMR.


Step 2: Preparation of 1,1-dimethylethyl 4-[2-oxo-3-(4-pyridinyl)propyl]-1-piperidinecarboxylate



To a solution of diisopropylamide (6.15 mL, 43.91 mmol) in dry tetrahydrofuran (40 mL) at 0 °C was added 2.5 M butyl lithium solution in hexane (16.22 mL, 40.53 mmol) dropwise over 10 minutes. After the addition, the lithium diisopropylamide solution was stirred at 0 °C for 20 minutes, then cooled to -78 °C. 4-Picoline (3.98 mL, 40.53 mmol) was added to the above lithium diisopropylamide solution under N₂ dropwise over 10 minutes. The resulting solution was stirred at -78 °C under N₂ for 1.5 hours, then transferred into a suspension


of anhydrous cerium chloride (10.0 g, 40.53 mmol) in tetrahydrofuran (40 mL) at -78 °C under N₂. The mixture was stirred at -78 °C under N₂ for 2 hours, then a solution of ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate (from step 1 of this Example) (10.98 g, 40.53 mmol) in tetrahydrofuran (40 mL) was added slowly for 1 hour. The mixture was stirred under N₂ from -78 °C to room temperature overnight. The reaction was quenched with water, diluted with ethyl acetate, and washed with a pH 7 buffer. The organic layer was washed with water and brine. After filtration, the solvent was removed under reduced pressure to give a crude product mixture. The desired product 1,1-dimethylethyl 4-[2-oxo-3-(4-pyridinyl)propyl]-1-piperidinecarboxylate (3.19 g, 25%) was isolated by chromatography (silica gel, 50:50 - 75:25- 100:0 ethyl acetate/hexane).

Step 3: Preparation of 1,1-dimethylethyl 4-[4-(4-fluorophenyl)-2-oxo-3-(4-pyridinyl)-3-butenyl]-1-piperidinecarboxylate




1,1-Dimethylethyl 4-[4-(4-fluorophenyl)-2-oxo-3-(4-pyridinyl)-3-butenyl]-1-piperidinecarboxylate was prepared by the same method as described for step 1 of Example A-1 by replacing 4-pyridylacetone and 3-fluoro-p-anisaldehyde with the ketone of step 2 of the present Example and 4-fluorobenzaldehyde, respectively.

Step 4: Preparation of 1,1-dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate



1,1-Dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate was prepared by the same method as described for step 3 of Example A-2 by replacing 4-phenyl-3-(4-pyridyl)-3-butene-2-one with the α,β unsaturated ketone of step 3 of the present Example.

Step 5: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate




To a solution of 1,1-dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate prepared in step 4 of this Example (3.45 g, 7.8409 mmol) in ethanol (15 mL), anhydrous hydrazine (0.50 mL, 15.6818 mmol) was added. The reaction was heated to reflux overnight. The reaction solution was cooled to room temperature and ethanol was removed under reduced pressure. The resulting residue was taken into ethyl acetate, washed with water and brine, and dried over MgSO_4 . After filtration the solvent

was removed under reduced pressure. The crude residue was purified by chromatography (silica gel, 2:1 - 1:1 - 1:2 hexane/ethyl acetate) to give 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4,5-dihydro-4-hydroxy-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate (1.9187 g, 53.9%). This intermediate (1.8611 g, 4.0993 mmol) was dissolved in dry methylene chloride (40 mL) and treated with Martin sulfurane dehydrating reagent (4.13 g, 6.1490 mmol). The reaction solution was stirred at room temperature under N₂ overnight, then diluted with ethyl acetate, washed with 1N sodium hydroxide solution, water and brine, dried over MgSO₄. After filtration the solvents were removed. The resulting crude product mixture was purified by flash chromatography (silica gel, 2:1 - 1:1 - 1:2 Hexane/ethyl acetate) to give 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate (0.6964 g, 39 %).

20 Step 6: Preparation of 4-[3-(4-fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine

4-[3-(4-Fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine was prepared using the same method as described for Example A-314, step 1 by replacing 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate with the pyrazole of step 5 of the present Example. Anal. Calc'd for C₂₀H₂₁N₄F·2TFA·1.25H₂O: C, 49.11; H, 4.38; N, 9.54; Found: C, 48.74; H, 4.02; N, 9.57. MS (MH⁺): 337 (base peak).


Example A-316



4-[3-(4-fluorophenyl)-5-[(1-methyl-4-piperidinyl)methyl]-
 5 1H-pyrazol-4-yl]pyridine was prepared by the same method
 as described for step 3 of Example A-313 by replacing
 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-
 1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate with
 the pyrazole of step 5 of the present Example. Anal.
 10 Calc'd for $C_{21}H_{23}N_4F \cdot 0.2 H_2O$: C, 71.24; H, 6.66; N, 15.82;
 Found: C, 71.04; H, 6.54; N, 15.56. MS (MH^+): 351 (base
 peak).

Example A-317

15 The compound 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-
 1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate was
 prepared in accordance with general synthetic Scheme II:




20 2-(4-Pyridyl)-1-(4-fluorophenyl)ethanone
 hydrochloride (5.9g, 0.023 moles) was dissolved in a
 methylene chloride/methanol solution (70/15) at room
 temperature and N-chlorosuccinimide (3.25g, 0.024 moles)
 was added as a solid. The mixture was stirred at room
 25 temperature for 2.5 hours.
 N-methylpiperazinylthiosemicarbazide (4.1g, 0.023 moles)
 was added as a solid and the mixture was stirred for 3

days at room temperature. The mixture was diluted with 100 mL of methylene chloride and washed with saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO_4) and solvent removed using a rotary evaporator. The residue was treated with ethyl acetate with stirring while cooling in an ice bath. The solid formed was filtered and recrystallized from ethyl acetate with a small amount of methanol to give 1.7g (22%) of 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate. Anal. Calc'd. for $\text{C}_{19}\text{H}_{20}\text{FN}_5 \cdot 2\text{H}_2\text{O}$: C, 61.11; H, 6.48; N, 18.75. Found: C, 60.59; H, 6.41; N, 18.44. M.p. (DSC) 262-264 °C; $\text{MH}^+ = 338$.

Example A-318

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine, trihydrochloride monohydrate was prepared in accordance with general synthetic Scheme VII:



To a mixture of sodium hydride (30 mg, 1.5 mmol) in dimethylformamide (25 mL) stirred under a nitrogen atmosphere at room temperature was added 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonylpiperazinyl)pyrazole (500 mg, 1.1 mmol; prepared as set forth in Example A-169). After stirring for 1 hour, propargyl bromide (225 mg, 1.5 mmol, 80% solution in toluene) was added. After stirring for an


additional 2 hour at room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was dried with MgSO_4 , filtered and concentrated in vacuo. The residue was

5 chromatographed on silica gel using 70% ethyl acetate/hexane as the eluent to give 110 mg of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonyl-piperazinyl)pyrazole (24%), m. p. 204-205 °C. Anal. Calc'd. for $\text{C}_{26}\text{H}_{28}\text{ClN}_5\text{O}_2$: C, 65.33; H, 5.90; N, 14.65.
10 Found: C, 65.12; H, 5.81; N, 14.70.

A solution of HCl in methanol (5 mL) was generated by addition of acetyl chloride (200 mg) to methanol while cooling (5 °C). 3-(4-Chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonylpiperazinyl)pyrazole (100 mg, 0.2
15 mmol) prepared above was added and the reaction stirred in the cold for one hour. The reaction mixture was concentrated in vacuo and the residue azeotroped with toluene to give 100 mg of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine,
20 trihydrochloride monohydrate (90%), m.p.=231-233 °C (dec.). Anal. Calc'd. for $\text{C}_{21}\text{H}_{20}\text{N}_5\text{Cl} \cdot 3\text{HCl} \cdot \text{H}_2\text{O}$: C, 49.92; H, 4.99; N, 13.86. Found: C, 49.71; H, 4.89; N, 13.61.

Example A-319


25 The compound methyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate, monohydrate was prepared in accordance with general synthetic Scheme II:



5 Methyl chloroformate (55 mg) was added to a solution
 of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)
 pyrazole (200 mg, 0.54 mmol; prepared as set forth in
 Example A-169) and 4-dimethylaminopyridine (5 mg) in
 pyridine (10 mL). The mixture was stirred at room
 temperature for 3 hours. Additional methyl chloroformate
 (30 mg) was added and stirring was continued for 24
 10 hours. The solvent was removed in vacuo. The residue
 was treated with water and extracted with ethyl acetate.
 After drying the organic layer (MgSO₄), the solvent was
 blown down to a volume of 10 mL and refrigerated. The
 resultant crystalline solid was filtered and air dried to
 15 give 103 mg (48%) of methyl 4-[5-(4-chlorophenyl)-4-(4-
 pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate,
 monohydrate, mp 264-265 °C. Anal. Calc'd. for
 C₂₀H₂₀ClN₅O₂·H₂O: C, 57.76; H, 5.33; N, 16.84. Found: C,
 57.98; H, 4.89; N, 16.44.

Example A-320


20 The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-
 1H-pyrazol-3-yl]-4-(methanesulfonyl)piperazine,
 monohydrate was prepared in accordance with general
 25 synthetic Scheme II:




5 A solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)pyrazole (200 mg; 0.54 mmol; prepared as set forth in Example A-169), methanesulfonyl chloride (75 mg) and 4-dimethylaminopyridine (5 mg) in pyridine was stirred at room temperature for 3 hours. The solvent was removed in vacuo and the residue was treated with water. The resultant crystalline solid was filtered, air dried
 10 and recrystallized from methanol and water to give 118 mg (37%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)piperazine, monohydrate, m.p. 245-248 °C. Anal. Calc'd. for C₁₉H₂₀ClN₅SO₂·H₂O: C, 52.35; H, 5.09; N, 16.07. Found: C, 52.18; H, 5.31; N,
 15 16.00.

Example A-321

The compounds 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate, and 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, monosodium salt dihydrate, were prepared in accordance with general synthetic Scheme II:



and



5


A solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperziny)pyrazole (200 mg; 0.54 mmol; prepared as set forth in Example A-169), succinic anhydride (60 mg, 0.55 mmol) and 4-dimethylaminopyridine (5 mg) was stirred at room temperature for 24 hours. The solvent was removed in vacuo and the residue treated with methanol and water (1:1). The resultant crystalline solid was filtered and air dried to give 170 mg (58%) of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-gamma-oxo-1-piperazinebutanoic acid, dihydrate, m. p. 281-283 °C (dec.). Anal. Calc'd. for $C_{22}H_{22}ClN_5O_3 \cdot 2H_2O$: C, 55.52; H, 5.51; N, 14.72. Found: C, 55.11; H, 5.20; N, 14.44.

A slurry of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-gamma-oxo-1-piperazinebutanoic acid, dihydrate (150 mg, 0.31 mmol) from above in methanol (10 mL) was treated with a solution of sodium hydroxide (12

mg, 0.31 mmol) in methanol (2 mL). The reaction was stirred at room temperature for 15 minutes until dissolution was completed. The solvent was removed in vacuo. The residue was treated with tetrahydrofuran and filtered and air dried to give 150 mg (97%) of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]- γ -oxo-1-piperazinebutanoic acid, monosodium salt dihydrate as a solid. Anal. Calc'd. for $C_{22}H_{21}ClN_5O_3Na \cdot 2H_2O$: C, 53.07; H, 5.06; N, 14.07. Found: C, 52.81; H, 5.11; N, 13.90.

Example A-322

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-cyclopropylpiperazine was prepared in accordance with general synthetic Scheme II:




To a solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)pyrazole (1.95g; 5.8 mmol; prepared as set forth in Example A-169) and acetic acid (3.6 g, 60 mmol) containing 5A molecular sieves (6 g) was added [(1-ethoxycyclopropyl)oxy]trimethylsilane (6 g, 35 mmol). After stirring for 5 minutes, sodium cyanoborohydride (1.7 g, 26 mmol) was added and the mixture was refluxed under a nitrogen atmosphere for 6 hours. The reaction mixture was filtered hot and the filtrate concentrated in vacuo. Water (50 mL) was added and the solution made basic with 2N sodium hydroxide. The resultant gel was extracted with dichloroethane and the combined organic extracts dried ($MgSO_4$). Evaporation again yielded a gel which was treated with hot methanol. Upon cooling, the product crystallized to give 1.4 g (63%) of 1-[5-(4-

chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-cyclopropylpiperazine, m. p. 264-265 °C. Anal. Calc'd. for $C_{21}H_{22}ClN_5 \cdot 1.5 H_2O$: C, 61.99; H, 6.19; N, 17.21. Found: C, 62.05; H, 5.81; N, 16.81.

5

Example A-323

The compound 4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine was prepared in accordance with general synthetic Scheme V:



10

To a suspension of sodium hydride (1.0 g, 0.025 mol) in 50 mL of dimethylformamide was added methyl 4-imidazolecarboxylate (2.95 g, 0.023 mol) portionwise at room temperature. The mixture was stirred at room temperature for 0.5 hour. Then 2-(trimethylsilyl)ethoxymethyl chloride (4.17 g, 0.025 mol) was added dropwise over 5 minutes. The reaction mixture was stirred for 4 hours and quenched by cautiously adding water. The aqueous phase was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel using ethyl acetate/hexane (8:2) as the eluent to give 4.0 g of the major regioisomer as a clear oil.

15

20

25

To a solution of 4-fluorobenzoyl-4'-pyridyl methane (8.6 g, 0.04 mol, prepared as set forth in Step 1 of Example A-208) in 150 mL of ethanol was added p-methoxyphenylhydrazine hydrochloride (7.34 g, 0.042 mol), followed by triethylamine (4.05 g, 0.04 mol). The reaction mixture was refluxed for 16 hours. After the

30

removal of solvent, the residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over MgSO_4 and filtered. The filtrate was concentrated and the crude residue was purified by

5 recrystallization from ethyl acetate and hexane to give 8.45 g of the product hydrazone as a yellow solid. To a solution of sodium hexamethyldisilazide (9 mL of 1.0 M tetrahydrofuran solution, 0.009 mol) was added a solution

10 of this hydrazone (1.35 g, 0.004 mol) in 10 mL of dry tetrahydrofuran at 0 °C. After stirring for 30 minutes at this temperature, a solution of the regioisomer prepared above (1.1 g, 0.0042 mol) in 5 mL of dry tetrahydrofuran was added dropwise. The reaction mixture


15 was stirred for 3 hours at room temperature. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified by

20 chromatography on silica gel using ethyl acetate as the eluent to give 0.74 g of the desired product as an orange solid (34%). Deprotection of the above solid by using tetrabutylammonium fluoride afforded 0.37 g of 4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine as a yellow solid (75%), mp:

25 124-126 °C. Anal. Calc'd. for $\text{C}_{24}\text{H}_{18}\text{FN}_5\text{O} \cdot 0.5 \text{H}_2\text{O}$: C, 68.56; H, 4.55; N, 16.66. Found: C, 68.44; H, 4.39; N, 16.00.

Example A-324


30 The compound 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-2-propynyl-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:



A mixture of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine (0.28 g; 0.001 mol; prepared as
 5 set forth in Example A-299) and 10 mL propargylamine was heated at reflux for 16 hour. Excess amine was removed
 in vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was washed with
 and ethyl acetate. The organic layer was washed with brine, dried over MgSO_4 and filtered. The filtrate was
 10 concentrated and the residue purified by chromatography on silica gel using ethyl acetate/hexane (1:1) as the
 eluent to give 0.21 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-2-propynyl-2-pyrimidinamine as a pale yellow
 solid (68% yield), mp: 186-187 °C. Anal. Calc'd. for
 15 $\text{C}_{16}\text{H}_{12}\text{FN}_5$: C, 65.52; H, 4.12; N, 23.88. Found: C, 64.99;
 H, 4.15; N, 23.91.

Example A-325


The compound N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine was
 20 prepared in accordance with general synthetic Scheme XII:



A mixture of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine (0.37 g; 0.0013 mol; prepared as set forth in Example A-299), 7 mL of 2-fluoroaniline and 2 drops of methanol was heated at 180 °C in a sealed tube for 16 hours. Excess amine was removed by vacuum distillation and the residue was treated with ethyl acetate to give 0.35 g of N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine as a yellow solid (77%), mp: 239-240 °C. Anal. Calc'd. for $C_{19}H_{13}F_2N_5$: C, 65.33; H, 3.75; N, 20.05. Found: C, 64.95; H, 3.80; N, 19.77.

Example A-326


The compound 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:



4-[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)-2-pyrimidinamine was synthesized in 41% yield using the same method described for the preparation of N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine in Example A-325 using 2-methoxyaniline in place of 2-fluoroaniline; mp: 265 °C (dec.). Anal. Calc'd. for $C_{20}H_{16}FN_5O$: C, 66.47; H, 4.46; N, 19.38. Found: C, 66.70; H, 4.53; N, 19.20.

Example A-327

The compound 1-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine was prepared in accordance with general synthetic Scheme II:




1-[5-(3-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine was synthesized in 12% yield as a pale yellow solid using the same method described for the preparation of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine in Example A-170 using 2-(4-pyridyl)-1-(3-chlorophenyl)ethanone in place of 2-(4-pyridyl)-1-(4-chlorophenyl)ethanone; mp: 229-231 °C. Anal. Calc'd. for $C_{19}H_{20}ClN_5 \cdot 0.4 H_2O$: C, 63.21; H, 5.81; N, 19.40. Found: C, 62.85; H, 5.57; N, 19.77.

Additional aminopyrazole compounds that were synthesized in accordance with the chemistry described in Scheme II by selection of the corresponding starting reagents include the compounds disclosed in Table 3-1 below.

TABLE 3-1

| | EXAMPLE | FORMULA | MW | Theoretical | | | | Found | | DSC (mp) |
|----|---------|--|--------|-------------|------|-------|-------|-------|-------|-------------|
| | | | | C | H | N | C | H | N | |
| 5 | A-328 | C ₁₈ H ₁₈ ClN ₅ ·1/8H ₂ O | 342.08 | 63.20 | 5.30 | 20.47 | 63.04 | 5.36 | 20.33 | 199°C |
| | A-329 | C ₂₃ H ₃₃ ClN ₆ O ₂ | 533.08 | 65.34 | 6.24 | 15.77 | 64.98 | 6.11 | 15.58 | (168-171°C) |
| | A-330 | C ₂₃ H ₂₅ ClN ₅ O ₂ | 457.94 | 60.33 | 5.50 | 15.29 | 59.97 | 5.52 | 15.17 | (253-255°C) |
| | A-331 | C ₂₂ H ₂₄ ClN ₅ O ₂ | 425.92 | 62.04 | 5.68 | 16.44 | 61.64 | 5.94 | 16.29 | (273-275°C) |
| 10 | A-332 | C ₁₉ H ₂₃ Cl ₄ N ₅ ·H ₂ O | 481.26 | 47.42 | 4.82 | 14.35 | 47.66 | 5.11 | 13.74 | (217-219°C) |
| | A-333 | C ₂₁ H ₂₀ ClN ₅ ·2.5H ₂ O | 422.92 | 59.64 | 4.77 | 16.56 | 59.67 | 4.88 | 15.96 | (247°C) (d) |
| | A-334 | C ₂₀ H ₂₂ ClN ₅ ·1/4H ₂ O | 372.39 | 64.51 | 5.96 | 18.81 | 64.79 | 5.97 | 18.95 | 242°C |
| | A-335 | C ₂₄ H ₂₂ ClN ₅ ·3/4H ₂ O | 429.44 | 67.13 | 5.16 | 16.31 | 67.04 | 5.31 | 16.32 | 230°C |
| | A-336 | C ₂₅ H ₂₄ ClN ₅ O·1/4H ₂ O | 450.46 | 66.66 | 5.37 | 15.55 | 66.64 | 5.11 | 15.69 | (270-271°C) |
| | A-337 | C ₂₂ H ₂₄ FN ₅ O ₂ ·H ₂ O | 427.48 | 61.81 | 5.66 | 16.38 | 61.88 | 5.96 | 16.41 | 249°C |
| 15 | A-338 | C ₂₀ H ₂₂ FN ₅ ·1/2H ₂ O | 360.44 | 66.65 | 6.15 | 19.43 | 66.74 | 6.59 | 19.37 | 241°C |
| | A-339 | C ₁₉ H ₂₀ FN ₅ ·3HCl·1/2H ₂ O | 455.79 | 50.07 | 5.09 | 15.30 | 49.87 | 5.47 | 15.30 | (237-239°C) |

Example A-328




5

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine


10

Example A-329




15


1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-[(phenylmethyl)amino]-4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate

Example A-330

5 1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(2-fluoro-
4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

Example A-331


15 ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-
pyrazol-3-yl]amino]-1-piperidinecarboxylate

Example A-332

20


N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-3H-pyrazol-3-yl]-4-piperidineamine, trihydrochloride, monohydrate

Example A-333




The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine was prepared in accordance with general synthetic Scheme II. To a suspension of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine (92 mg, 0.27 mmole) in 2 mL of dimethylformamide was added 75 mg (0.54 mmole) of anhydrous potassium carbonate and then 60 microliters of 80% propargyl bromide solution in toluene (containing 64 mg, 0.54 mmole). The resulting mixture was stirred for 30 minutes and then partitioned between ethyl acetate and water. The aqueous layer was further extracted with ethyl acetate, and the combined organic extracts filtered through silica gel using 10% methanol-ethyl acetate as eluent to give, after evaporation of the appropriate fractions, 34 mg of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine as a pale yellowish solid, m.p. 247 °C (decomp.). Anal. Calc'd. for $C_{21}H_{20}ClN_5 \cdot 2.5H_2O$ (MW 422.92): C, 59.64, H, 4.77, N, 16.56. Found: C, 59.67, H, 4.88, N, 15.96.

Example A-334



5 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine

Example A-335




10


1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-phenylpiperazine

15


Example A-336



20 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-methoxyphenyl)piperazine


Example A-337

5 Ethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate, monohydrate

Example A-338

10

N-[5-(4-fluorophenyl)-4-(pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine

Example A-339

15

20 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine, trihydrochloride

Example A-340

The compound of Example A-170 was also synthesized in the following manner. 1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine (12.2g, 36 mmol, prepared as set forth in Example A-169), 88% formic acid (20 mL), and formaldehyde (37% formalin solution; 44g, 540 mmol) were combined and stirred at 60 °C for 16 hours under a nitrogen atmosphere. Excess solvent was removed on the rotary evaporator and the residue was dissolved in water (150 mL). The pH was adjusted to 8-9 by addition of solid sodium bicarbonate. The resulting precipitate was filtered and air dried. It was then treated with hot methanol (400 mL), filtered and blown down to a volume of 75 mL, cooled and filtered. After drying in a vacuum oven at 80 °C overnight, there was obtained 8.75g (68%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, m. p. 262-264 °C. Anal. Calc'd. for $C_{19}H_{20}N_5Cl$: C, 64.49; H, 5.70; N, 19.79. Found: C, 64.04; H, 5.68; N, 19.63.

The compounds of Examples A-341 through A-345 were synthesized, for example, in accordance with the chemistry described in Scheme XXI by selection of the corresponding starting reagents.

Example A-341


The compound of Example A-170 was also synthesized in the following manner:

Step 1: Preparation of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone

To a solution of 2-(4-pyridyl)-1-(4-chlorophenyl)ethanone (70.0 g, 0.3 mol) prepared in a similar manner as the compound of Step 1 of Example A-19, dibromomethane (200 mL) and carbon disulfide (25.9 g, 0.34 mol) in acetone (800 mL) was added potassium

carbonate (83.0 g, 0.6 mol). The reaction mixture was stirred at room temperature for 24 hours. An additional two equivalents of potassium carbonate and one equivalent of carbon disulfide was added and the stirring was continued for another 24 hours. Solvent was removed and the residue was partitioned between dichloromethane and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was stirred with 1000 mL of a mixture of ethyl acetate and ether (1:9) to give 78.4 g of pure product, 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone, as a yellow solid (82%), mp: 177-179 °C. Anal. Calc'd. for $C_{15}H_{10}ClNOS_2$: C, 56.33; H, 3.15; N, 4.38. Found: C, 55.80; H, 2.84; N, 4.59.

Step 2: Preparation of 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine




A mixture of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (78.3 g, 0.24 mol) and 1-methylpiperazine (75.0 g, 0.73 mol) in 800 mL of toluene was heated at reflux for 2 hours. Solvent and excess 1-methylpiperazine was removed under vacuum and the residue was triturated with a mixture of ethyl acetate and ether (1:3) to give 53.0 g of product, 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine, as yellow crystals (60%), mp: 149-151 °C. Anal. Calc'd. for $C_{19}H_{20}ClN_3OS$: C, 61.03; H, 5.39; N, 11.24. Found: C, 60.74; H, 5.35; N, 11.14.

Step 3: Preparation of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

To a suspension of 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine (52.0 g, 0.14 mol) in 500 mL of dry tetrahydrofuran was added anhydrous hydrazine (8.9 g, 0.28 mol) dropwise. The reaction mixture was stirred at room temperature for 16 hours. The pale yellow precipitate was filtered and recrystallized from hot methanol to give 30.2 g of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine as a white powder (60%), mp: 267-268 °C. Anal. Calc'd. for $C_{19}H_{20}ClN_5$: C, 64.49; H, 5.70; N, 19.79. Found: C, 64.89; H, 5.55; N, 19.99.

Example A-342




1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine

A mixture of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (3.2 g, 0.01 mol; prepared as set forth in Step 1 of Example A-341) and 2,6-dimethylpiperazine (3.43 g, 0.03 mol) in 35 mL of toluene was heated at reflux for 12 hours. Toluene and excess 2,6-dimethylpiperazine were then removed under vacuum and the crude thiamide produced was used without purification. A solution of the crude thiamide and

anhydrous hydrazine (0.65 g, 0.02 mol) in 40 mL of dry tetrahydrofuran was stirred at room temperature overnight. After the removal of tetrahydrofuran, the residue was stirred with a mixture of ethyl acetate and ammonium hydroxide for one hour. The precipitate was filtered and air dried to give 1.6 g of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine as a white solid (43% overall yield), mp: 236-238°C. Anal. Calc'd. for $C_{20}H_{22}ClN_5 \cdot 0.25H_2O$: C, 64.51; H, 6.09; N, 18.81; Cl, 9.52. Found: C, 64.28; H, 5.85; N, 18.70; Cl, 9.67.

Example A-343



1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine

1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine was prepared according to the same procedure set forth above in Example A-342 except that 2-methylpiperazine was used in place of 2,6-dimethylpiperazine (4% overall yield), mp: 235-237°C. Anal. Calc'd. for $C_{19}H_{20}ClN_5 \cdot 0.75H_2O$: C, 62.12; H, 5.90; N, 19.06. Found: C, 62.23; H, 5.53; N, 18.80.

Example A-344

The compound of Example A-317 was also synthesized in the following manner:

Step 1: Preparation of 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone


To a solution of 4-fluorobenzoyl-4'-pyridyl methane
 5 (70.0 g, 0.3 mol, prepared as set forth in Step 1 of
 Example A-208) and dibromomethane (125 mL) was added
 solid anhydrous potassium carbonate (55.0 g, 0.4 mol)
 portionwise over five minutes. Carbon disulfide (17 g,
 0.22 mol) was added dropwise over 15 minutes at room
 10 temperature. After stirring for 16 hours under a
 nitrogen atmosphere, the reaction was incomplete.
 Additional carbon disulfide (15 g) was added and the
 reaction mixture was stirred for an additional 24 hours.
 The reaction mixture was filtered and the potassium
 15 carbonate was washed on the filter with methylene
 chloride. The filtered solid was dissolved in water and
 extracted with methylene chloride. The extract was
 combined with the filtrate and dried over magnesium
 sulfate. The drying agent was filtered and the filtrate
 20 concentrated in vacuo. The residue was treated with
 ethyl acetate/ether (1:1), filtered and air dried to give
 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-
 fluorophenyl)-ethanone (26 g, 86%) as a solid, m.p. 182-
 183 °C; Anal. Calc'd. for $C_{15}H_{10}FNOS_2$: C, 59.39; H, 3.32;
 25 N, 4.62. Found: C, 59.18; H, 3.41; N, 4.49.

Step 2: Preparation of 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate

A mixture of the 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone (3 g,
 0.01 mol) prepared in Step 1 and 1-methylpiperazine (3 g,
 0.03 mol) in 30 mL of toluene was refluxed under a
 nitrogen atmosphere for three hours. The mixture was
 35 cooled and solvent was removed under vacuum. The residue
 was dissolved in dry tetrahydrofuran (30 mL) and

anyhydrous hydrazine (640 mg, 0.02 mol) was added. The reaction mixture was stirred at room temperature for 16 hours and the resulting precipitate was filtered. The precipitate was warmed in methanol and a few drops of concentrated ammonium hydroxide were added. The mixture was filtered hot and the filtrate blown down to half the volume. As the filtrate cooled, a product crystallized and was filtered to give 1.5 g (42%) of 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate, mp: 238-240 °C; Anal. Calc'd. for $C_{19}H_{20}FN_5 \cdot 2H_2O$: C, 61.11; H, 65.48; N, 18.75. Found: C, 60.79; H, 6.21; N, 18.98.

Example A-345



N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate

Step 1: Preparation of 1-methyl-4-methylaminopiperidine

A mixture of 1-methyl-4-piperidone (20 g, 0.18 mol) in methanol:tetrahydrofuran (100 mL, 1:1) and methyl amine (2 M in tetrahydrofuran, 3 mole excess) was placed in a Parr shaker with 5% Pd/C and hydrogenated for two hours at 60 psi and 70°C. The catalyst was filtered and the filtrate concentrated on the rotary evaporator. The crude material was distilled at 44-45°C at 0.3 mm Hg to give 20 g (87%) of 1-methyl-4-methylaminopiperidine. Anal. Calc'd for $C_7H_{16}N_2$: C, 65.57; H, 12.58; N, 21.85. Found: C, 65.49; H, 12.44; N: 21.49.

Step 2: Preparation of N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate

5


A solution of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (3.2 g, 0.01 mol; prepared as set forth in Step 1 of Example A-341) and 1-methyl-4-methylaminopiperidine (3.8 g, 0.03 mol) in 30 mL of toluene refluxed for six hours under nitrogen. The mixture was cooled and solvent was removed under vacuum. The residue was dissolved in dry tetrahydrofuran (30 mL) and anhydrous hydrazine (650 mg, 0.02 mol) was added. The reaction mixture was stirred at room temperature under nitrogen for 16 hours. The resulting precipitate was filtered and warmed in methanol and a few drops of concentrated ammonium hydroxide. The mixture was filtered hot and the filtrate blown down to half the volume. As the filtrate cooled, a product separated and was filtered to give 395 of pure N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate, m.p. 260-261°C. Anal. Calc'd for $C_{21}H_{24}ClN_5 \cdot 2H_2O$: C, 60.35; H, 6.75; N, 16.76. Found: C, 59.89; H, 6.56; N: 16.40.

Additional compounds of the present invention that were prepared according to one or more of above reaction schemes (particularly Schemes IX through XVIII) are disclosed in Table 3-2. The specific synthesis scheme or schemes as well as the mass spectroscopy and elemental analysis results for each compound also are disclosed in Table 3-2.


TABLE 3-2

| Example | General | MS | Microanalysis | | | | | | | | | |
|---------|---------|-----|---------------|--------|---------|--------|---------|-------------|-------------|-------------------------|---------------|-----------|
| | | | C Found | H Calc | H Found | N Calc | N Found | Water Added | EtOAc Added | CHCl ₃ Added | Toluene Added | HCl Added |
| A-346 | XII | | | | | | | | | | | |
| A-347 | XII | 329 | 59.33 | 5.65 | 5.47 | 15.55 | 15.41 | 0.8 | 0.2 | | | |
| A-348 | XII | 439 | 68.46 | 8.04 | 8.48 | 19.16 | 16.17 | | | | | |
| A-349 | XII | 397 | 61.85 | 7.79 | 7.52 | 17.45 | 17.39 | 1.3 | 0.7 | | | |
| A-350 | XII | 449 | 66.29 | 7.60 | 7.68 | 17.84 | 17.00 | 1.25 | | | | |
| A-351 | XII | 352 | 68.36 | 6.31 | 7.31 | 19.93 | 17.17 | | | | | |
| A-352 | XII | 366 | 69.02 | 6.62 | 6.59 | 19.16 | 18.22 | | | | | |
| A-353 | XII | 430 | 69.26 | 7.40 | 6.91 | 18.36 | 14.87 | | | | | |
| A-354 | XII | 355 | 70.48 | 6.80 | 7.15 | 13.99 | 13.91 | | | | 0.5 | |
| A-355 | XII | 341 | 66.73 | 6.29 | 6.77 | 16.04 | 15.78 | | 0.1 | | | |
| A-356 | XVII | 410 | 63.42 | 6.00 | 6.06 | 16.81 | 16.63 | 0.4 | | | | |
| A-357 | XVII | 392 | 54.37 | 5.91 | 6.32 | 13.78 | 14.68 | 0.4 | | | | |
| A-358 | XII | 394 | 70.20 | 7.17 | 7.68 | 17.80 | 16.58 | | | | | |
| A-359 | XVII | 396 | 69.21 | 7.68 | 8.01 | 17.55 | 17.61 | 0.2 | | | | |
| A-360 | XVII | 366 | 50.81 | 5.97 | 5.80 | 14.11 | 14.00 | 1.2 | | | | 3 |
| A-361 | XII | 389 | 71.12 | 5.45 | 5.64 | 14.42 | 12.90 | | | | | |
| A-362 | XII | 375 | 70.57 | 5.12 | 5.39 | 14.96 | 13.90 | | | | | |
| A-363 | XII | 389 | 71.12 | 5.45 | 5.58 | 14.42 | 13.09 | | | | | |
| A-364 | XVII | 368 | 68.31 | 7.15 | 7.49 | 18.97 | 18.93 | 0.1 | | | | |
| A-365 | XVII | 338 | 48.72 | 5.47 | 5.45 | 14.95 | 14.79 | 1.2 | | | | 3 |
| A-366 | XII | 397 | 56.34 | 7.31 | 7.03 | 17.92 | 17.89 | 2 | | | | 1 |


| | | | | | | | | | | | | |
|-------|------|-----------|-------|-------|------|-------|-------|-------|------|------|--|---|
| A-367 | XVII | 321 | 70.25 | 69.83 | 5.43 | 5.62 | 17.25 | 17.82 | 0.25 | | | |
| A-368 | XII | 313 | 64.66 | 64.28 | 5.73 | 5.62 | 16.76 | 16.93 | | 0.25 | | |
| A-369 | XII | 412 | 66.76 | 66.60 | 7.36 | 7.61 | 16.93 | 16.74 | 0.1 | | | |
| A-370 | XII | 313 | 64.66 | 64.36 | 5.73 | 5.59 | 16.76 | 16.82 | | 0.25 | | |
| A-371 | XVII | | 63.78 | 63.63 | 6.37 | 6.09 | 17.71 | 17.24 | 1 | | | |
| A-372 | XII | | 68.63 | 68.80 | 7.26 | 7.53 | 17.40 | 17.14 | 0.5 | | | |
| A-373 | XVII | 389 | 58.10 | 57.99 | 5.00 | 4.88 | 17.83 | 17.48 | 0.25 | | | |
| A-374 | XII | 354 | 67.97 | 67.23 | 6.84 | 6.81 | 19.81 | 19.38 | | | | |
| A-375 | XII | 366 | 68.18 | 68.06 | 6.67 | 6.80 | 18.93 | 18.56 | 0.25 | | | |
| A-376 | XII | 375 | 70.57 | 68.19 | 5.12 | 6.06 | 14.96 | 13.13 | | | | |
| A-377 | XII | 396 | 64.14 | 64.44 | 6.99 | 6.78 | 16.02 | 16.02 | | 0.35 | | |
| A-378 | XVII | 337 | 66.42 | 66.44 | 5.22 | 4.91 | 16.31 | 16.27 | 0.4 | | | |
| A-379 | XVII | 339 | 62.76 | 62.80 | 6.04 | 5.43 | 15.41 | 15.17 | 1.4 | | | |
| A-380 | XVII | 381 | 63.31 | 63.40 | 5.19 | 5.82 | 14.06 | 13.84 | 1 | | | 1 |
| A-381 | XVII | 307 | 70.57 | 69.69 | 4.94 | 5.00 | 18.29 | 17.68 | | | | |
| A-382 | XVII | | | | | | | | | | | |
| A-383 | XVII | | | | | | | | | | | |
| A-384 | 320 | 55.4 8 | 53.44 | 5.64 | 5.00 | 17.03 | 21.60 | | | | | |
| A-385 | XI | 280 | 52.65 | 52.51 | 5.98 | 5.17 | 10.83 | 11.12 | | | | 1 |
| A-386 | XII | 351 | 64.96 | 64.77 | 5.82 | 5.34 | 14.85 | 15.03 | 1 | 0.1 | | |
| A-387 | XII | 353 | 65.29 | 65.62 | 6.32 | 6.14 | 14.64 | 14.47 | 0.7 | 0.2 | | |
| A-388 | | 394 | 54.93 | 55.34 | 6.21 | 6.79 | 13.93 | 14.01 | | | | 3 |

Example A-346

- 5 N- [4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-
pyridinyl] -4-methyl-1-piperazinepropanamine (2E) -2-
butenedioate (1:1)


Example A-347

- 10 3- [[4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-
pyridinyl] amino] -1,2-propanediol;

Example A-348


N,N,N'-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-1,3-propanediamine;

5

Example A-349

N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl-1,3-propanediamine;


10

Example A-350


15

N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;

20

Example A-351


5 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)-2-pyridinamine;

Example A-352


10

N-(1-ethyl-4-piperidinyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;

15

Example A-353

5 N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl-1,2-ethanediamine;


Example A-354

10

(2S)-2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-1-pentanol;


15

Example A-355



5 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl-1-butanol;


Example A-356



10 ethyl 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-piperidinecarboxylate;


15

Example A-357



5 4-[3-(4-fluorophenyl)-5-(4-(1-pyrrolidinyl)-1-piperidinyl)-1H-pyrazol-4-yl]pyridine, trihydrochloride;

Example A-358




10

N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;


15

Example A-359




N1,N1,-diethyl-N4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-pentanediamine;

Example A-360




1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-4-piperidinamine, trihydrochloride;

Example A-361




(βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;

Example A-362



5 (βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;

Example A-363




10

 (βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol;

15


Example A-364



N,N-diethyl-N' - [5- (4-fluorophenyl) -4- (4-pyridinyl) -
1H-pyrazol-3-yl] -1,3-propanediamine;

Example A-365


5



1 - [5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-
yl] -4-piperidinamine, trihydrochloride;


10

Example A-366




15

N1,N1-diethyl-N4 - [4 - [3 - (4-fluorophenyl) -1H-pyrazol-
4-yl] -2-pyrimidinyl] -1,4-pentanediamine;

Example A-367


5 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,3,6-hexahydropyridine;

Example A-368

10

(2R)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;


15

Example A-369

N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl-1,4-pentanediamine;

Example A-370


5



(2S)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol;

10

Example A-371




15

ethyl 4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;


400430-1000

Example A-372



- 5 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[3-(2-methyl-1-piperidinyl)propyl]-2-pyridinamine;


Example A-373



- 10 1-[5-(3,4-dichlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;


15

Example A-374



- 5 N,N-diethyl-N' - [4 - [3 - (4-fluorophenyl) - 1H-pyrazol-4-yl] - 2-pyridinyl] - 1,2-ethanediamine;

Example A-375




10

- 4 - [3 - (4-fluorophenyl) - 1H-pyrazol-4-yl] - N - [2 - (1-piperidinyl)ethyl] - 2-pyridinamine;


15

Example A-376



5 (βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol;


Example A-377



10


N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,4-pentanediamine;

Example A-378




5 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinone;

Example A-379




10

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinol;

Example A-380


5 8-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-dioxaspiro[4.5]decane;

Example A-381

10


5-(4-fluorophenyl)-N-methyl-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;

15

Example A-382


20 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine;

Example A-383




5 1-[5-(3,4-difluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;

Example A-384




10 1-methyl-4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;

Example A-385




20 4-[3-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-yl]pyridine, monohydrochloride;

Example A-386




5 trans-4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanol;

Example A-387




10

4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanone;


Example A-388

5 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-diethyl-4-piperidinamine, trihydrochloride;

Example A-389

10 1-[5-(3-tolyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine:


15 Step 1. Preparation of 1-tolyl-2-(4-pyridyl)ethanone



20 Methyl 3-methylbenzoate (6.0 g, 40 mmol), tetrahydrofuran (50 mL), and 4-picoline (4.1 g, 44 mmol) were stirred at -78 °C under an atmosphere of nitrogen.

Sodium (bis)trimethylsilylamide 1.0 M in tetrahydrofuran (88 mL, 88 mmol) was added dropwise. The mixture was allowed to warm to room temperature, stirred for 16 hours and then was poured into saturated aqueous sodium bicarbonate solution. The mixture was then extracted with ethyl acetate (3 X 50 mL). The combined organics were washed with brine (2 X 50 mL), dried over magnesium sulfate, and concentrated. The product was recrystallized from ethyl acetate/hexane to yield a light yellow solid (5.7 g, 67%), mp 118.0-119.0 °C; ¹H NMR (acetone-d₆/300 MHz) 8.50 (m, 2H), 7.90 (m, 2H), 7.44 (m, 2H), 7.29 (m, 2H), 4.45 (s, 2H), 2.41 (s, 3H); ESHRMS *m/z* 212.1067 (M+H, C₁₄H₁₃NO requires 212.1075); Anal. Calc'd for C₁₄H₁₃NO: C, 79.59; H, 6.20; N, 6.63. Found: C, 79.54; H, 6.30; N, 6.56.


Step 2. Preparation of 1-(3-tolyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridyl)ethanone



1-tolyl-2-(4-pyridyl)ethanone (4.22 g, 20 mmol), acetone (100 mL), potassium carbonate (8.3 g, 60 mmol), carbon disulfide 4.56 g, 60 mmol), and dibromomethane (10.43 g, 60 mmol) were stirred at room temperature for 16 hours. Water (100 mL) was added and the mixture was extracted with ethyl acetate (3 X 50 mL). The combined organic extracts were washed with brine (2 X 50 mL), dried over magnesium sulfate and concentrated. This crude material was purified by either flash column chromatography eluting with ethyl acetate:hexane or crystallization from ethyl acetate/hexane to yield a

yellow solid (4.8 g, 80%), mp 178.6-179.2 °C; ¹H NMR (acetone-d₆/300 MHz) 8.47 (m, 2H), 7.08 (m, 6H), 4.37 (s, 2H), 2.21 (s, 3H); ESHRMS *m/z* 300.0521 (M+H, C₁₆H₁₃NOS₂ requires 300.0517); Anal. Calc'd for C₁₆H₁₃NOS₂: C, 64.18; H, 4.38; N, 4.68. Found: C, 64.08; H, 4.25; N, 4.62.

Step 3. Preparation of 1-[3-(3-tolyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine



10

The dithietane compound from step 2 above (3.0 g, 10 mmol), N-methylpiperazine (5.0 g, 50 mmol), and toluene (50 mL) were refluxed using a Dean-Stark apparatus for one to three hours. The reaction was allowed to cool to room temperature and was concentrated to dryness under high vacuum. This thick, oily material was crystallized from ethyl acetate / hexane (2.9 g, 82%), mp 124.8-125.8 °C; ¹H NMR (acetone-d₆/300 MHz) 8.57 (m, 2H), 7.75 (m, 2H), 7.54 (m, 2H), 7.37 (m, 2H) 6.54 (s, 1H), 4.27 (m, 2H), 4.19 (m, 1H), 3.83 (m, 1H), 2.47-2.28 (m, 6H), 2.22 (s, 3H), 2.17 (m, 1H); ESHRMS *m/z* 354.1669 (M+H, C₂₀H₂₃N₃OS requires 354.1640); Anal. Calc'd for C₂₀H₂₃N₃OS: C, 67.96; H, 6.56; N, 11.89. Found: C, 67.79; H, 6.66; N, 11.88.


20

Step 4. Preparation of 1-[5-(3-tolyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

The thioamide compound from step 3 above (1.06 g, 3 mmol), tetrahydrofuran (50 mL), and hydrazine (15 mL, 15 mmol, 1.0 M) in tetrahydrofuran were stirred at room temperature for 16 hours. A white solid was collected by filtration. Purification when necessary was by trituration or recrystallization (0.98 g, 97%), mp 261.9-262.0 °C; ¹H NMR (DMSO-d₆/300 MHz) 12.6 (brs, 1H), 8.42 (m, 2H), 7.2 (m, 4H), 7.12 (s, 1H), 7.0 (m, 1H), 2.86 (m, 4H), 2.34 (m, 4H) 2.25 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 334.2049 (M+H, C₂₀H₂₃N₅ requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅: C, 72.04; H, 6.95; N, 21.00. Found: C, 71.83; H, 7.06; N, 20.83.


Additional dithietanes and pyrazoles that were synthesized by selection of the corresponding starting reagents in accordance with the chemistry described in Scheme XXI and further illustrated in Example 389 above include compounds A-390 through A-426 disclosed below.

Example A-390



mp 185.3-185.4 °C; ¹H NMR (acetone-d₆/300 MHz) 8.49 (m, 2H), 7.31 (m, 4H), 7.09 (m, 2H), 4.39 (s, 2H); ESHRMS m/z 319.9981 (M+H, C₁₅H₁₀ClNOS₂ requires 319.9971); Anal. Calc'd for C₁₅H₁₀ClNOS₂: C, 56.33; H, 3.15; N, 4.38. Found: C, 56.47; H, 3.13; N, 4.44.


Example A-391



5 1-(4-chloro-3-methylphenyl)-2-1,3-dithietan-2-ylidene-2-pyridin-4-yl-ethanone


mp 164.0-165.0 °C; ¹H NMR (acetone-d₆/300 MHz) 8.49 (m, 2H), 7.25 (m, 2H), 7.0 (m, 3H), 4.38 (s, 2H), 2.24 (s, 3H); ESHRMS *m/z* 334.0130 (M+H, C₁₆H₁₂ClNOS₂ requires 334.0127); Anal. Calc'd for C₁₆H₁₂ClNOS₂: C, 57.56; H, 3.62; N, 4.20. Found: C, 57.68; H, 3.67; N, 4.17.

Example A-392



15 mp 126.5-126.6 °C; ¹H NMR (acetone-d₆/300 MHz) 8.40 (m, 2H), 7.17 (m, 2H), 7.0 (m, 4H), 4.39 (s, 2H), 2.85 (s, 3H); ESHRMS *m/z* 300.0483 (M+H, C₁₆H₁₃NOS₂ requires 300.0517); Anal. Calc'd for C₁₆H₁₃NOS₂: C, 64.18; H, 4.38; N, 4.68. Found: C, 64.05; H, 4.27; N, 4.59.

Example A-393




5

mp 159.6-159.7 °C; ^1H NMR (acetone- d_6 /300 MHz) 8.52 (m, 2H), 7.6 (m, 1H), 7.50 (s, 1H), 7.21 (m, 2H), 7.13 (m, 2H), 4.40 (s, 2H); ESHRMS m/z 363.9503 (M+H, $\text{C}_{15}\text{H}_{10}\text{BrNOS}_2$ requires 363.9465); Anal. Calc'd for $\text{C}_{15}\text{H}_{10}\text{BrNOS}_2$: C, 49.46; H, 2.77; N, 3.84. Found: C, 49.51; H, 2.68; N, 3.74.

10

Example A-394




15

mp 198.8-198.9 °C; ^1H NMR (acetone- d_6 /300 MHz) 8.45 (m, 2H), 7.05 (m, 3H), 6.95 (m, 1H), 6.82 (m, 1H), 4.29 (s, 2H), 2.14 (s, 3H), 2.08 (s, 3H); ESHRMS m/z 314.0691 (M+H, $\text{C}_{17}\text{H}_{15}\text{NOS}_2$ requires 314.0673).

20


Example A-395



5 mp 182.6-183.0 °C. ^1H NMR (acetone- d_6 /300 MHz) 8.50 (m, 2H), 7.42 (d, 2H, $J = 8.5$ Hz), 7.23 (d, 2H, $J = 8.5$ Hz), 7.10 (m, 2H), 4.40 (s, 2H). ESHRMS m/z 370.0173 (M+H, $\text{C}_{16}\text{H}_{10}\text{F}_3\text{NO}_2\text{S}_2$ requires 370.0183).


10

Example A-396



15 mp 193.3-193.4 °C. ^1H NMR (acetone- d_6 /300 MHz) 8.49 (m, 2H), 7.69 (d, 2H, $J = 8.2$ Hz), 7.46 (d, 2H, $J = 8.2$ Hz), 7.01 (m, 2H), 4.43 (s, 2H). ESHRMS m/z 311.0327 (M+H, $\text{C}_{16}\text{H}_{10}\text{N}_2\text{O}_2\text{S}_2$ requires 311.0313).

Example A-397




20

mp 191.5-192.5 °C; ¹H NMR (CDCl₃/ 300 MHz) 8.55 (dd, 2H, *J* = 4.6, 1.6 Hz), 7.4 (m, 1H), 7.09-7.03 (m, 3H), 6.67 (d, 1H, *J* = 8.7 Hz), 4.17 (s, 2H), 3.86 (s, 3H); ESHRMS *m/z* 350.0090 (M+H, C₁₆H₁₂ClNO₂S₂ requires 350.0076);

5 Anal. Calc'd. for C₁₆H₁₂ClNO₂S₂: C, 54.93; H, 3.60; N, 4.00; Cl, 10.13; S, 18.33. Found: C, 54.74; H, 3.60; N, 3.89; Cl, 10.45; S, 18.32.


Example A-398



mp 172.1-173.1 °C; ¹H NMR (CDCl₃ / 300 MHz) 8.51 (dd, 2H, *J* = 4.4, 1.6 Hz), 7.23-7.21 (m, 4H), 7.04 (dd, 2H, *J* = 4.6, 1.6 Hz), 4.17 (s, 2H), 1.25 (s, 9H); ESHRMS *m/z* 342.1004 (M+H, C₁₉H₁₉NOS₂ requires 342.0986); Anal.

15 Calc'd for C₁₉H₁₉NOS₂: C, 66.83; H, 5.61; N, 4.10; S, 18.78. Found: C, 66.97; H, 5.89; N, 4.02; S, 18.64.

Example A-399




mp 203.0-204.1 °C; ¹H NMR (CDCl₃ / 300 MHz) 8.52 (dd, 2H, *J* = 4.4, 1.6 Hz), 7.29 (d, 1H, *J* = 6.8 Hz), 7.28 (d, 1H, *J* = 7.0 Hz), 7.05 (dd, 2H, *J* = 4.4, 1.6 Hz), 6.70 (d, 1H, *J* = 6.8 Hz), 6.69 (d, 1H, *J* = 6.8 Hz), 4.17 (s, 2H), 3.79 (s, 3H); ESHRMS *m/z* 316.0475 (M+H, C₁₆H₁₃NO₂S₂

25

requires 316.0466); Anal. Calc'd. for $C_{16}H_{13}NO_2S_2$: C, 60.93; H, 4.15; N, 4.44; S, 20.33. Found: C, 60.46; H, 4.17; N, 4.37; S, 19.84.

5


Example A-400



mp 209.1-215.1 °C; 1H NMR ($CDCl_3$ / 300 MHz) 8.50 (dd, 2H, $J = 4.4, 1.6$ Hz), 7.20 (d, 2H, $J = 8.0$ Hz), 7.03-6.99 (m, 4H), 4.18 (s, 2H), 2.30 (s, 3H); ESHRMS m/z 300.0517 ($M+H$, $C_{16}H_{13}NOS_2$ requires 300.0517); Anal. Calc'd. for $C_{16}H_{13}NOS_2$: C 64.18; H, 4.38; N, 4.69; S, 21.42. Found: C, 64.02; H, 4.62; N, 4.54; S, 21.24.

15


Example A-401



mp 257.6-257.7 °C; 1H NMR ($CDCl_3$ / 300 MHz) 8.51 (dd, 2H, $J = 4.4, 1.6$ Hz), 7.57 (d, 2H, $J = 8.5$ Hz), 7.27-6.99 (m, 4H), 4.18 (s, 2H); ESHRMS m/z 411.9348 ($M+H$, $C_{15}H_{10}NIOS_2$ requires 411.9327); Anal. Calc'd. for $C_{15}H_{10}NIOS_2$: C, 43.81; H, 2.45; N, 3.41. Found: C, 43.71; H, 2.27; N, 3.41.


25

Example A-402




5 mp 197.3-202.2 °C; ¹H NMR (CDCl₃ / 300 MHz) 8.53 (dd, 2H, *J* = 4.4, 1.6 Hz), 7.26 (d, 2H, *J* = 9.3 Hz), 7.09 (dd, 2H, *J* = 4.4, 1.6 Hz), 6.43 (d, 2H, *J* = 9.3 Hz), 4.14 (s, 2H), 2.97 (s, 6H); ESHRMS *m/z* 329.0789 (M+H, C₁₇H₁₆N₂OS₂ requires 329.0782); Anal. Calc'd. for C₁₇H₁₆N₂OS₂: C, 62.17; H, 4.91; N, 8.53; S, 19.53. Found: C, 61.93; H, 5.12; N, 8.46; S, 19.26.

Example A-403



15 mp 176.6-176.7 °C; ¹H NMR (CDCl₃ / 300 MHz) 8.51 (dd, 2H, *J* = 4.4, 1.6 Hz), 7.29-7.22 (m, 4H), 7.03 (dd, 2H, *J* = 4.4, 1.6 Hz), 6.64 (dd, 1H, *J* = 17.5, 10.9 Hz), 5.76 (d, 1H, *J* = 17.7 Hz), 5.31 (d, 1H, *J* = 10.9 Hz), 4.19 (s, 2H); ESHRMS 312.0513 (M+H, C₁₇H₁₃NOS₂ requires 312.0517); Anal. Calc'd. for C₁₇H₁₃NOS₂: C, 65.56; H, 4.21; N, 4.50. Found: C, 65.75; H, 4.11; N, 4.46.


Example A-404



5 mp 174.8-175.0 °C; ^1H NMR (CDCl_3 / 300 MHz) 8.50 (dd, 2H, $J = 4.4, 1.6$ Hz), 7.23-7.20 (m, 4H), 7.03 (dd, 2H, $J = 4.6, 1.6$ Hz), 4.17 (s, 2H), 2.59 (q, 2H, $J = 7.6$ Hz), 1.17 (t, 3H, $J = 7.7$ Hz); ESHRMS m/z 314.0677 ($\text{M}+\text{H}$, $\text{C}_{17}\text{H}_{15}\text{NOS}_2$ requires 314.0673); Anal. Calc'd. for

10 $\text{C}_{17}\text{H}_{15}\text{NOS}_2$: C, 65.14; H, 4.82; N, 4.47. Found: C, 64.90; H, 4.62; N, 4.45.


Example A-405



15 mp 167.1-167.5 °C; ^1H NMR (CDCl_3 / 300 MHz) 8.52 (dd, 1H, $J = 4.4, 1.6$ Hz), 7.33 (d, 1H, $J = 8.3$ Hz), 7.02-7.00 (m, 3H), 6.87-6.83 (m, 1H), 4.19 (s, 2H), 2.28 (s, 3H); ESHRMS m/z 379.9577 ($\text{M}+\text{H}$, $\text{C}_{16}\text{H}_{12}\text{BrNOS}_2$ requires 379.9622); Anal. Calc'd. for $\text{C}_{16}\text{H}_{12}\text{BrNOS}_2$: C, 50.80; H, 3.20; N, 3.70. Found: C, 50.69; H, 3.19; N, 3.71.


20

Example A-406



5 mp 168.6-168.7 °C; ¹H NMR (CDCl₃/300 MHz) 8.54 (dd, 2H, *J* = 4.6, 1.8 Hz), 7.68-7.62 (m 2H), 7.43-7.39 (m, 1H), 7.33-7.28 (m, 1H), 6.99 (dd, 2H, *J* = 4.4, 1.6 Hz), 4.22 (s, 2H); ESHRMS *m/z* 311.0330 (M+H, C₁₆H₁₀N₂OS₂ requires 311.0313); Anal. Calc'd. for C₁₆H₁₀N₂OS₂: C, 61.91; H, 3.25; N, 9.02. Found: C, 61.45; H, 3.18; N, 8.91.

Example A-407




15 1-[5-(3-methyl-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

20 mp 236.7-239.3 °C; ¹H NMR (DMSO-d₆/300 MHz) 12.6 (brs, 1H), 8.45 (m, 2H), 7.41 (m, 1H), 7.26 (m, 3H), 7.0 (m, 1H), 2.86 (m, 4H), 2.35 (m, 4H), 2.27 (s, 3H), 2.16 (s, 3H); ESHRMS *m/z* 368.4653 (M+H, C₂₀H₂₂ClN₅ requires 368.1642).

25


Example A-408



1- [5- (2-tolyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-methylpiperazine.

mp 244.0-244.2 °C; ¹H NMR (acetone-d₆/300 MHz) 11.6 (brs, 1H), 8.35 (m, 2H), 7.35 (m, 2H), 7.25 (m, 4H), 3.05 (m, 4H), 2.47 (m, 4H), 2.25 (s, 3H), 2.00 (s, 3H); ESHRMS *m/z* 334.2018 (M+H, C₂₀H₂₃N₅ requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅: C, 72.04; H, 6.95; N, 21.00. Found: C, 72.03; H, 7.00; N, 20.85.


Example A-409



1- [5- (3-bromophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-methylpiperazine.

mp 222.5-223.4 °C; ¹H NMR (acetone-d₆/300 MHz) 11.8 (brs, 1H), 8.51 (m, 2H), 7.55 (m, 2H), 7.34 (m, 4H), 3.0 (m, 4H), 2.41 (m, 4H), 2.22 (s, 3H); ESHRMS *m/z* 398.0982 (M+H, C₁₉H₂₀BrN₅ requires 398.0980).


Example A-410



5 1-[5-(3,4-dimethylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 270.9-272.7 °C; ¹H NMR (DMSO-d₆/300 MHz) 12.5 (brs, 1H), 8.41 (m, 2H), 7.24 (m, 2H), 7.26 (m, 3H), 7.10 (m, 2H), 6.92 (m, 1H), 2.86 (m, 4H), 2.38 (m, 4H), 2.21 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 348.2183 (M+H, C₂₁H₂₅N₅ requires 348.2188).

Example A-411




15 1-[5-(4-trifluoromethoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

20 mp 221.0-221.2 °C; ¹H NMR (DMSO-d₆/300 MHz) 12.7 (brs, 1H), 8.45 (m, 2H), 7.38 (s, 4H), 7.24 (m, 2H), 2.86 (m, 4H), 2.34 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 404.1698 (M+H, C₂₀H₂₀F₃N₅O requires 404.1698).

25


Example A-412



5 1-[5-(4-cyanophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp > 300 °C; ¹H NMR (DMSO-d₆/300 MHz) 12.8 (brs, 1H), 8.47 (m, 2H), 7.83 (m, 2H), 7.42 (m, 2H), 2.88 (m, 4H), 2.39 (m, 4H), 2.20 (s, 3H); ESHRMS *m/z* 345.1848 (M+H, C₂₀H₂₀N₆ requires 345.1828).

Example A-413




15

1-[5-(3-chloro-4-methoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

20 mp 272.7-276.4 °C; ¹H NMR (DMSO-d₆/300 MHz) 8.44 (dd, 2H, *J* = 4.6, 1.6 Hz), 7.32-7.13 (m, 5H), 3.84 (s, 3H), 2.90-2.85 (m, 4H), 2.38-2.35 (m, 4H), 2.16 (s, 3H); ESHRMS *m/z* 384.1580 (M+H C₂₀H₂₂ClN₅O requires 384.1591).

25


Example A-414



5 1-[5-(4-tert-butylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 243.6-244.3 °C; ¹H NMR (DMSO-d₆/300 MHz) 8.44
10 (dd, 2H, *J* = 4.6, 1.6, Hz), 7.40 (d, 2H, *J* = 8.3 Hz),
7.28-7.18 (m, 4H), 2.90-2.85 (m, 4H), 2.38-2.34 (m, 4H),
2.16 (s, 3H), 1.26 (s, 9H); ESHRMS *m/z* 376.2491 (M+H,
C₂₃H₂₉N₅ requires 376.2501).

Example A-415




15 1-[4-(4-methoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.
20

mp 259.0-260.2 °C; ¹H NMR (DMSO-d₆/300 MHz) 8.53
(dd, 2H, *J* = 4.4, 1.6 Hz), 7.24 (dd, 2H, *J* = 4.4, 1.6
Hz), 7.18 (d, 2H, *J* = 8.9 Hz), 6.94 (d, 2H, *J* = 8.9 Hz),

3.75 (s, 3H), 2.90-2.85 (m, 4H), 2.39-2.35 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 350.1991 ($M+H$, $C_{20}H_{23}N_5O$ requires 350.1981); Anal. Calc'd. for $C_{20}H_{23}N_5O + 3.93\%H_2O$: C, 66.04; H, 6.81; N, 19.25. Found: C, 66.01; H, 6.62; N, 19.32.

Example A-416




10 1-[5-(4-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 243.0-246.8 °C; 1H NMR (DMSO- d_6 /300 MHz) 8.41 (dd, 2H, $J = 4.6, 1.6$ Hz), 7.24 (m, 6H), 2.91-2.86 (m, 4H), 2.40-2.35 (m, 4H), 2.29 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 334.2041 ($M+H$, $C_{20}H_{23}N_5$ requires 334.2032); Anal. Calc'd for $C_{20}H_{23}N_5 + 4.09\%H_2O$: C, 69.10; H, 7.13; N, 20.14. Found: C, 69.10; H, 7.08; N, 20.13.

20

Example A-417




25

1- [5- (4-iodophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-methylpiperazine.

mp 265.2-265.8 °C; ¹H NMR (CD₃OD/300 MHz) 8.41 (dd, 2H, *J* = 4.6, 1.6 Hz), 7.76-7.74 (m, 2H), 7.41-7.39 (m, 2H), 7.08-7.05 (m, 2H), 3.08-3.04 (m, 4H), 2.61-2.58 (m, 4H), 2.35 (s, 3H); ESHRMS *m/z* 446.0847 (M+H, C₁₉H₂₀IN₅ requires 446.0842); Anal. Calc'd. for C₁₉H₂₀IN₅ + 12.09%H₂O: C, 44.60; H, 5.39; N, 13.69. Found: C, 44.50; H, 4.56; N, 13.66.


Example A-418



1- [5- (4-ethenylphenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl] -4-methylpiperazine.

mp >300 °C; ¹H NMR (CD₃OD/300 MHz) 8.49 (dd, 2H, *J* = 4.6, 1.6 Hz), 7.47-7.44 (m, 4H), 7.26 (d, 2H, *J* = 8.4 Hz), 6.75 (dd, *J* = 17.7, 11.1 Hz), 5.83 (d, 1H, *J* = 17.5 Hz), 5.28 (d, 1H, *J* = 11.1 Hz), 3.07-3.03 (m, 4H), 2.58-2.53 (m, 4H), 2.31 (s, 3H); ESHRMS *m/z* 346.2034 (M+H, C₂₁H₂₃N₅ requires 346.2032); Anal. Calc'd. for C₂₁H₂₃N₅ + 2.83%H₂O: C, 70.95; H, 6.84; N, 19.70. Found: C, 70.97; H, 6.49; N, 19.54.


Example A-419



5 1-[5-(4-ethylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 221.6-222.6 °C; ¹H NMR (CD₃OD/300 MHz) 8.38 (dd, 2H, *J* = 4.6, 1.6 Hz), 7.44-7.40 (m, 2H), 7.26-7.19 (m, 4H), 3.06-3.02 (m, 4H), 2.66 (q, 2H, *J* = 7.5 Hz), 2.59-2.54 (m, 4H), 2.32 (s, 3H), 1.23 (t, 3H, *J* = 7.5 Hz); ESHRMS *m/z* 348.2188 (M+H, C₂₁H₂₅N₅ requires 348.2188); Anal. Calc'd for C₂₁H₂₅N₅ + 2.59%H₂O: C, 70.71; H, 7.35; N, 19.63. Found: C, 70.76; H, 7.40; N, 19.46.

Example A-420




20 1-[5-(4-bromo-3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 294.7 °C decomp.; ¹H NMR (CD₃OD/300 MHz) 8.41 (dd, 2H, *J* = 4.6, 1.6 Hz), 7.55 (d, 1H, *J* = 8.2 Hz), 7.45-7.42 (m, 2H), 7.27-7.25 (m, 1H), 7.00-6.97 (m 2H),


3.08-3.03 (m, 4H), 2.59-2.54 (m, 4H), 2.35 (s, 3H), 2.31 (s, 3H); ESHRMS m/z 412.1124 (M+H, $C_{20}H_{22}BrN_5$ requires 412.1137).

5

Example A-421

10 1-[5-(4-dimethylaminophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp >300 °C (decomposed); 1H NMR (CD_3OD / 300 MHz)
 8.37 (d, 2H, $J = 4.6$ Hz), 7.44 (d, 2H, $J = 4.8$ Hz), 7.12, (d, 2H, $J = 8.9$ Hz), 6.73 (d, 2H, $J = 8.7$ Hz), 3.04-3.02
 15 (m, 4H), 2.96 (s, 6H), 2.54-2.49 (m, 4H), 2.31 (s, 3H);
 ESHRMS m/z 363.2266 (M+H, $C_{21}H_{26}N_6$ requires 363.22972).


Example A-422

20

1-[5-(3-cyanophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 223.4-224.3 °C; ¹H NMR (CD₃OD / 300 MHz) 8.44 (dd, 2H, J= 4.6, 1.4 Hz), 7.75-7.69 (m, 2H), 7.56-7.54 (m, 2H), 7.40-7.38 (m, 2H), 3.05-3.03 (m, 4H), 2.54-2.49 (m, 4H), 2.53 (s, 3H); ESHRMS m/z 345.1840 (M+H, C₂₀H₂₀N₆ requires 345.1828).

Example A-423




10 1-[5-(4-thiomethoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

15 mp 275.6-281.9 °C; ¹H NMR (CD₃OD / 300 MHz) 8.44-8.40 (m, 2H), 7.46-7.41 (m, 2H), 7.28-7.23 (m, 4H), 3.04-3.00 (m, 4H), 2.59-2.53 (M, 4H), 2.48 (s, 3H), 2.31 (s, 3H); ESHRMS m/z 366.1777 (M+H, C₂₀H₂₃N₅S requires 366.1752).

20


Example A-424



1- [5- (3-trifluoromethylphenyl) -4- (4-pyridinyl-1H-pyrazol-3-yl) -4-methylpiperazine.

mp 212.6-213.7 °C; ¹H NMR (CD₃OD / 300 MHz) 8.43 (d, 2H, *J* = 4.8 Hz), 7.69-7.56 (m, 4H), 7.41 (s, 2H), 3.07-3.04 (m, 4H), 2.56-2.53 (m, 4H), 2.32 (s, 3H); ESHRMS *m/z* 388.1764 (M+H, C₂₀H₂₀F₃N₅ requires 388.1749).


Example A-425



1- [5- (4-trifluoromethylphenyl) -4- (4-pyridinyl-1H-pyrazol-3-yl) -4-methylpiperazine.

mp 240.5 °C (decomposed); ¹H NMR (CD₃OD / 300 MHz) 8.43 (dd, 2H, *J* = 4.6, 1.6 Hz), 7.70-7.67 (m, 2H), 7.51-7.48 (m, 2H), 7.42-7.38 (m, 2H), 3.09-3.04 (m, 4H), 2.59-2.53 (m, 4H), 2.31 (s, 3H); ESHRMS *m/z* 388.1768 (M+H, C₂₀H₂₀F₃N₅ requires 388.1749).


Example A-426



1- [5- (2-thienyl) -4- (4-pyridinyl-1H-pyrazol-3-yl)] -4-methylpiperazine.

mp 199.7 °C (decomposed); ¹H NMR (CD₃OD / 300 MHz)
 8.44 (d, 2H, *J* = 5.8 Hz), 7.47 (d, 2H, *J* = 5.6 Hz), 7.13
 - 7.07 (m, 3H), 3.04-3.00 (m, 4H), 2.53-2.49 (m, 4H),
 2.30 (s, 3H); ESHRMS *m/z* 326.1454 (M+H, C₁₇H₁₉N₅S
 requires 326.1439).

Example A-427



Step 1: Preparation of 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propene-1-one

A solution of 4-chlorophenyl-2-(pyridin-4-yl)ethan-1-one (20.0 g, 86.4 mmol) and N,N-dimethylformamide dimethylacetal (57.6 mL, 0.43 mole) was heated at 100 °C for 3 ½ hours. The reaction mixture was concentrated in vacuo, and the residue crystallized from methyl butyl ether to give 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (22.80 g, 93%). ¹H NMR (CDCl₃/300 MHz) δ 8.52 (d, 2H), 7.38 (d, 2H), 7.29 (d, 2H), 7.08 (d, 2H), 2.83 (s, 6H).

Step 2: Preparation of 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole

A solution of 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (22.80 g, 79.7 mmol), hydroxylamine hydrochloride (18.01 g, 0.26 mole), and 150

mL ethanol was heated to reflux for 30 minutes. The reaction mixture was then cooled to room temperature and concentrated *in vacuo*. The residue was dissolved in 1N hydrochloric acid and then treated with an aqueous saturated solution of sodium bicarbonate. The precipitates were collected by filtration, washed with water and ethanol, and dried to yield 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole (20.50 g, 93%). m.p. 120.8-120.9 °C. ¹H NMR (CDCl₃/CD₃OD/300 MHz) δ 8.53 (d, 2H), 8.46 (s, 1H), 7.51 (d, 2H), 7.41-7.34 (m, 4H). ESLRMS *m/z* 257 (M+H). ESHRMS *m/z* 257.0457 (M+H, C₁₄H₉N₂OCl requires 257.0482).

Step 3: Preparation of 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile:


A solution of 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole (20.5 g, 79.9 mmol) and 150 mL of a 1N sodium hydroxide solution was stirred at 60 °C for 1 hour. The reaction mixture was cooled to room temperature and adjusted to pH 6 with concentrated hydrochloric acid. The precipitates were filtered, washed with water and ethanol, and dried to give 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (20.0 g, quantitative yield). m.p. 225.4-234.9 °C. ¹H NMR (CDCl₃/CD₃OD/300 MHz) δ 8.12 (brs, 2H), 7.73-7.59 (m, 5H), 7.30 (d, 3H). ESLRMS *m/z* 257 (M+H). ESHRMS *m/z* 257.0481 (M+H, C₁₄H₉N₂OCl requires 257.0482).

Step 4: 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole

A solution of 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (3.50 g, 13.6 mmol) in 40 mL acetonitrile and phosphorous trichloride (14.2 mL, 163 mmol) was stirred at 100 °C for 5 hours. The reaction

mixture was concentrated in vacuo, and the residue taken up in toluene and concentrated again. The residue was then taken up in ethanol (150 mL) and treated with anhydrous hydrazine (1.71 mL, 54.4 mmol). The reaction mixture was heated to reflux for 3 hours, cooled, and concentrated in vacuo. The residue was triturated with a mixture of ethanol and dichloromethane (1:4), and filtered. The solid was washed with the ethanol/dichloromethane mixture, and dried to give 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (2.0 g, 54%): m.p. >300 °C. ¹H NMR (DMSO/300 MHz) δ 8.40 (d, 2H), 7.40 (d, 2H), 7.29 (d, 2H), 7.11 (d, 2H), 5.05 (s, 2H). ESLRMS m/z 271 (M+H). ESHRMS m/z 271.0752 (M+H, C₁₄H₁₁N₄Cl requires 271.0750).


Example A-428



A solution of 1,1'-carbonyldiimidazole (1.19 g, 7.38 mmol) and N-benzyliminodiacetic acid (0.824 g, 3.69 mmol) in dimethylformamide was heated at 75 °C for 30 minutes. To this mixture the 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (1.0 g, 3.69 mmol) was added, and heating was continued at 75 °C overnight. The white solid was filtered, was washed with diethyl ether, methylene chloride, 5% methanol/methylene chloride, and ethanol, and was dried to give the desired imide as an

off-white solid (0.9 g, 53%): m.p. >300 °C. ¹H NMR (DMSO/300 MHz) δ 8.53 (m, 2H), 7.5 (d, 2H), 7.44- 7.16 (m, 7H), 6.98 (m, 2H), 3.64 (m, 4H), 3.48 (m, 2H). ESLRMS m/z 458 (M+H). ESHRMS m/z 458.1380 (M+H, C₂₅H₂₀N₅O₂Cl requires 458.1384).


Example A-429



Methyl 2-([3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino)acetate

A solution of 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (1.0 g, 3.7 mmol) in dimethylformamide (30 mL) was heated to 95 °C and methyl bromo acetate (0.34 mL, 3.7 mmol) was added dropwise. The resulting solution was stirred at 95 °C for 4 hours, cooled, and concentrated *in vacuo* to an orange viscous oil (1.79 g). A portion of this product mixture (1.20 g) was crystallized from ethanol and diethyl ether to give methyl 2-([3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino)acetate as a bright yellow solid (805 mg): m.p. 195.4-196.8 °C. ¹H NMR (CD₃OD/300 MHz) δ 8.49 (d, 2H), 7.68 (d, 2H), 7.44 (m, 4H), 5.37 (s, 2H), 3.84 (s, 3H). ESLRMS m/z 343 (M+H). ESHRMS m/z 343.0975 (M+H, C₁₇H₁₆N₄O₂Cl requires 343.0962).

Example A-430




5 Lithium 2-{[3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate

To a solution of methyl 2-{[3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate (500 mg, 1.5
 10 mmol) in 15 mL of methanol and 5 mL of water was added lithium hydroxide (189 mg, 4.5 mmol). The reaction mixture was stirred at room temperature for 5 hours. The solvent was removed in vacuo, and the residue taken up in ethanol. The precipitate was filtered and washed with
 15 methanol, and the filtrate was concentrated to give lithium 2-{[3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate as a yellow/orange solid (479 mg, 95%). mp >300 °C. ¹H NMR (CD₃OD/300 MHz) δ 8.06 (d, 2H), 7.43 (d, 2H), 7.37 (m, 4H), 3.34 (s, 2H). ESLRMS m/z 329 (M+H), 335 (M+Li), 351 (M+Na). ESHRMS m/z 329.0772 (M+H, C₁₆H₁₄N₄O₂Cl requires 329.0805).


20

Example A-431




The above 4-chlorophenylketone was prepared according to the procedure used in Step 1 of Example C-1, infra, substituting methyl 4-chlorobenzoate for ethyl 4-fluorobenzoate. Yield; (74 %), yellow solid, mp = 95.5-97.3 °C; ¹H-NMR (DMSO-d₆/300 MHz) 8.57 (br d, 2H), 7.92 (d, 2H), 7.46 (d, 2H), 7.20 (d, 2H), 4.28 (s, 2H); ESLRMS m/z 232 (M+H).

Example A-432




To the ketone (1.0gm, 4.7 mmol) from Step 1 of Example C-1, infra, in anhydrous tetrahydrofuran (10 mL) was added 1M potassium t-butoxide in tetrahydrofuran (10 mL, 10 mmol). The reaction mixture was stirred for 15 minutes at room temperature, then carbon disulfide (0.31 mL, 5.1 mmol) was added. After several minutes, methyl iodide (0.64 mL, 10.3 mmol) was added and the reaction allowed to stir for 4 hours. The reaction mixture was diluted with saturated sodium bicarbonate solution (25 mL) and extracted twice with ethyl acetate (35 mL). The combined ethyl acetate layers were washed with water (25 mL) and brine (25mL). The organic solution was dried (MgSO₄), filtered and concentrated to an orange oil. The oil solidified on standing. Yield 1.4 gm (94%), mp 80.2-82.1 °C; ¹H-NMR (CDCl₃/300 MHz) 8.59 (d, 2H), 7.96 (m, 2H), 7.38 (m, 2H), 7.14 (m, 2H), 2.33 (s, 3H), 2.23 (s, 3H); Anal. Calc'd for C₁₆H₁₄FNOS₂: C, 60.16; H, 4.42; N, 4.39; S, 20.08. Found: C, 59.89; H, 4.09; N, 4.31; S, 20.14.

Example A-433



5 The above compound was prepared in a manner
 analogous to Example A-432 starting with the product of
 Example A-431. Crude yield: 100 %; mp 87.6-88.2 °C; ¹H-
 NMR (CDCl₃/300 MHz) 8.60 (d, 2H), 7.87 (d, 2H), 7.44 (d,
 2H), 7.37 (m, 2H), 2.33 (s, 3H), 2.22 (s, 3H); ESHRMS m/z
 10 336.0297 (M+H, C₁₆H₁₅ClNOS₂ requires 336.0283); Anal.
 Calc'd for C₁₆H₁₄ClNOS₂: C, 57.22; H, 4.20; N, 4.17.
 Found: C, 57.44; H, 3.97; N, 4.04.


Example A-434



15 To the compound of Example A-432 (1.4 gm, 4.4 mmol)
 in ethanol (15 mL) was added 1M hydrazine in acetic acid
 20 (5 mL, 5 mmol). The reaction was stirred at room
 temperature for 18 hours. No reaction had occurred, so
 additional hydrazine hydrate (1.08 mL, 22 mmol) was added
 and the reaction heated to reflux for 6 hours. The
 product began to precipitate from the reaction mixture.
 25 The reaction was cooled to room temperature and water was
 added to precipitate the product. The solid was
 collected by suction filtration and air dried. Yield:
 675 mg (53%). The product was recrystallized from
 ethanol: 494 mg; mp 249.9-249.9 °C; ¹H-NMR (DMSO-d₆/300


MHz) 13.51 (br s, 1H), 8.50 (d, 2H), 7.34 (m, 2H), 7.23 (m, 2H), 7.16 (m, 2H), 2.43 (s, 3H); ESHRMS m/z 286.0807 (M+H, $C_{15}H_{13}FN_3S$ requires 286.0814); Anal. Calc'd for $C_{15}H_{12}FN_3S$: C, 63.14; H, 4.24; N, 14.73. Found: C, 63.01; H, 4.43; N, 14.81.

Example A-435



The above compound was made in an analogous manner to Example A-434 starting with the compound of Example A-433. Yield: 750 mg (33%); mp 250.2-250.2 °C; 1H NMR (DMSO- d_6 /300 MHz) 13.57 (br s, 1H), 8.51 (m, 2H), 7.45 (br s, 2H), 7.32 (m, 2H), 7.17 (m, 2H), 2.43 (s, 3H); ESHRMS m/z 302.0537 (M+H, $C_{15}H_{13}ClN_3S$ requires 302.0518); Anal. Calc'd for $C_{15}H_{12}ClN_3S$: C, 59.70; H, 4.01; N, 13.92. Found: C, 59.56; H, 3.96; N, 13.96.

Example A-436




3-(4-fluorophenyl)-4-(methylsulfinyl)-4-pyridin-4-yl-1H-pyrazole

To the compound of Example A-434 (150 mg, 0.52 mmol) in ethanol (15 mL) was added ammonium persulfate (450 mg, 1.97 mmol). The reaction mixture was stirred at ambient

temperature. After several hours an additional amount of ammonium persulfate (450 mg) was added. The reaction mixture was monitored by TLC (silica) using 5% methanol in dichloromethane as the eluting solvent. When the
 5 stating material had been consumed, the reaction mixture was quenched with saturated sodium bicarbonate (25 mL) and extracted with ethyl acetate (2 x 25 mL). The ethyl acetate layers were combined, washed with brine (25 mL) and dried (MgSO₄). Filtration and concentration produced
 10 a white solid. The solid was triturated with diethyl ether, collected by suction filtration, and air dried. Yield 150 mg (96%), mp 262.9-262.9 °C; ¹H NMR (DMSO-d₆/300 MHz) 14.22 (br s, 1H), 8.56 (d, 2H), 7.42-7.23 (br m, 6H), 2.94 (s, 3H); Anal. Calc'd for C₁₅H₁₂FN₃OS·0.25
 15 H₂O: C, 58.91; H, 4.12; N, 13.74; Found: C, 58.88; H, 4.17; N, 13.39.

Example A-437




20 3-(4-fluorophenyl)-5-(methylsulfonyl)-4-pyridin-4-yl-1H-pyrazole

25 To the compound of Example A-434 (285 mg, 1 mmol) in ethanol (10 mL) was added potassium peroxymonosulfate (2.45 gm, 4 mmol) and water (5 mL). The reaction mixture was stirred at ambient temperature. After 6 hours the reaction mixture was diluted with water (20 mL) and
 30 extracted with ethyl acetate (2 x 30 mL). The ethyl acetate layers were combined, washed with brine (25 mL) and dried (MgSO₄). The ethyl acetate did not efficiently extract the product from the aqueous phase, so the

aqueous layer was saturated with sodium chloride and extracted with acetonitrile (50 mL). The acetonitrile solution was dried (MgSO_4), filtered, and combined with the filtered ethyl acetate solution. The solvents were evaporated and the resulting solid was triturated with a small amount of acetonitrile, collected by suction filtration, and air dried. Yield: 203 mg (64 %); mp 297.1-300 °C; ^1H NMR ($\text{DMSO-d}_6/300\text{ MHz}$) 14.37 (br s, 1H), 8.54 (m, 2H), 7.29 (m, 6H), 3.26 (s, 3H); Anal. Calc'd for $\text{C}_{15}\text{H}_{12}\text{FN}_3\text{O}_2\text{S}$: C, 56.77; H, 3.81; N, 13.24. Found: C, 56.52; H, 4.03; N, 13.11.


Example A-438



To the compound of Example A-432 (638 mg, 2 mmol) in toluene (6 mL) was added thiomorpholine (502 μL , 5 mmol). The reaction mixture was heated to between 80 and 110 °C. After about three hours the bis-thiomorpholine substituted product began to precipitate from the reaction mixture. When the dithioketene acetal had been completely consumed, the reaction mixture was cooled to room temperature and the insoluble bis-thiomorpholine compound removed by filtration. To the toluene solution was added hydrazine hydrate (1 mL) and sufficient ethanol to create a homogeneous solution. The reaction mixture was then stirred at room temperature for 72 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and extracted twice with water (25 mL) and once with brine (25 mL). The organic solution was dried (MgSO_4), filtered and concentrated to a reddish solid. The solid was triturated with acetonitrile, collected by suction


filtration, and dried in-vacuo. The solid was then suspended in acetonitrile and heated to reflux. Ethyl acetate was then added until the solid almost completely dissolved. A small amount of ethanol was then added and the homogeneous yellow solution concentrated until a solid began to form. Allow to cool to room temperature. Collected a white solid by suction filtration. Yield: 63 mg, (7%); ^1H NMR (DMSO- d_6 /300 MHz) 12.65 (br s, 1H), 8.45 (d, 2H), 7.27 (m, 6H), 3.14 (m, 4H), 2.63 (m, 4H). ESLRMS m/z 341 (M+H); ESHRMS m/z 341.1241 (M+H, $\text{C}_{18}\text{H}_{18}\text{FN}_4\text{S}$ requires 341.1236).

Example A-439




The above compound was prepared in a similar manner to Example A-438 starting with the appropriate dithioketene acetal and N-methylpiperazine. A white solid was obtained, mp 270.2-270.7 °C; ^1H NMR (DMSO- d_6 /300 MHz) 12.7 (br s, 1H), 8.47 (m, 2H), 7.57 (m, 2H), 7.21 (m, 2H), 2.85 (m, 4H), 2.34 (m, 4H) 2.15 (s, 3H); ESHRMS 398.0993 (M+H, $\text{C}_{19}\text{H}_{21}\text{BrN}_5$ requires 398.0980).

Example A-440




To N-(2-hydroxyethyl)morpholine (363 uL, 3 mmol) in anhydrous tetrahydrofuran (7 mL), under nitrogen, was added 1M sodium hexamethyldisilamide (3 mL, 3 mmol) in tetrahydrofuran at ambient temperature. The reaction mixture was stirred for 15 minutes, then the dithietane prepared as set forth in Step 1 of Example A-341 (636mg, 2 mmol) was added as a solid. The reaction mixture gradually became dark orange. After about 18 hours at ambient temperature, the reaction was quenched with saturated sodium bicarbonate solution (30 mL) and extracted twice with ethyl acetate (30 mL). The organic solutions were combined and washed with saturated NaCl solution (20 mL), then dried (MgSO_4), filtered, and concentrated to an orange oil. The oil was taken up in methanol (10 mL) and reconcentrated to remove any remaining ethyl acetate. The oil was then taken up in methanol (5 mL) and anhydrous hydrazine (69 uL) was added. The reaction mixture was allowed to stir at ambient temperature 18 hours, then quenched with saturated sodium bicarbonate solution (30 mL) and extracted twice with ethyl acetate (30 mL). The organic solutions were combined and washed with water (20 mL) and saturated NaCl solution (20 mL), then dried (MgSO_4), filtered, and concentrated to an orange semi-solid. The solid was triturated with acetonitrile (5 mL), collected by suction filtration, washed with acetonitrile and dried in-vacuo. Yield: off-white solid, 114 mg (14.8%); mp 198.9-199.9 °C; $^1\text{H-NMR}$ (DMSO-d_6 /300 MHz) 12.61 (br s, 1H), 8.41 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.21 (d, 2H), 4.33 (t, 2H), 3.54 (m, 4H), 2.70 (t, 2H), 2.44 (m, 4H); ESHRMS m/z 385.1444 ($\text{M}+\text{H}$, $\text{C}_{20}\text{H}_{22}\text{ClN}_4\text{O}_2$ requires 385.1431).

Example A-441



5 The above compound was prepared in an analogous manner to that of Example A-440, starting with 4-hydroxy-N-t-boc piperidine. Recrystallized from acetone/methanol. Yield: white solid 263 mg (29%); mp 230.1-231.8 °C; ¹H-NMR (DMSO-d₆/300 MHz) 12.61 (br s, 1H), 8.42 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.20 (d, 2H), 4.88 (m, 1H), 3.52 (m, 2H), 3.30 (m, 2H), 1.93 (m, 2H), 1.65 (m, 2H), 1.39 (s, 9H); Anal. Calc'd for C₂₄H₂₇ClN₄O₃: C, 63.36; H, 5.98; N, 12.31; Found: C, 63.34; H, 5.97; N, 12.22.


Example A-442



20 Example A-441 (130 mg, 0.28 mmol) was treated with concentrated HCl (0.5 mL) in ethanol (5 mL) for two hours. The solvent was removed in-vacuo and the resulting residue dissolved in ethanol and reconcentrated twice. The resulting solid was triturated with
25 acetonitrile to afford a white solid. Yield: 119 mg (91%) tri-hydrochloride salt; mp 220.6-222.1 °C; ¹H-NMR (DMSO-d₆/300 MHz) 13.25 (br s, 1H), 9.10 (br s, 2H), 8.67 (d, 2H), 7.75 (d, 2H), 7.60 (d, 2H), 7.50 (d, 2H), 5.04


(m, 1H), 3.17 (br d, 4H), 2.21 (m, 2H), 2.03 (m, 2H);
 Anal. Calc'd for $C_{19}H_{19}ClN_4O \cdot 3 HCl$: C, 49.16; H, 4.78; N, 12.07. Found: C, 49.24; H, 4.72; N, 12.02.

5

Example A-443

The above compound was prepared in a manner
 10 analogous to Example A-440 starting with (+/-)3-
 hydroxytetrahydrofuran. Recrystallized from ethanol.
 Yield: white crystalline solid, 57 mg (8%); mp >300 °C;
 1H -NMR (DMSO- d_6 /300 MHz) 12.65 (br s, 1H), 8.42 (d, 2H),
 7.52 (d, 2H), 7.38 (d, 2H), 7.18 (d, 2H), 5.28 (m, 1H),
 15 3.86 (m, 2H), 3.82 (m, 1H), 3.75 (m, 1H), 2.26-2.01 (br
 m, 2H); Anal. Calc'd for $C_{18}H_{16}ClN_3O_2$: C, 63.25; H, 4.72;
 N, 12.29. Found: C, 63.12; H, 4.51; N, 12.31.


20

Example A-444

The above compound was prepared in a manner
 analogous to Example A-440 starting with p-methoxybenzyl
 25 alcohol. Yield: off-white solid, 252 mg (21%); mp =229.1-
 229.2 °C; 1H -NMR (acetone- d_6 /300 MHz) 11.62 (br s, 1H),
 8.40 (br s, 2H), 7.76 (s, 2H), 7.39 (m, 4H), 7.30 (br s,
 2H), 6.87 (d, 2H), 5.27 (s, 2H), 3.77 (s, 3H); Anal.

Calc'd for $C_{22}H_{18}ClN_3O_2 \cdot 0.25 H_2O$: C, 66.67; H, 4.70; N, 10.60. Found: C, 66.79; H, 4.95; N, 10.54.

Example A-445




5

The above compound was prepared in a manner analogous to Example A-440 starting with N-tert-butoxycarbonyl-ethanolamine. Recrystallized from ethyl acetate/methanol. Yield: white solid, 75 mg (4 %); mp >300 °C; 1H -NMR (DMSO- d_6 /300 MHz) 12.60 (br s, 1H), 8.38 (d, 2H), 7.53 (d, 2H), 7.38 (d, 2H), 7.22 (d, 2H), 7.02 (t, 1H), 4.20 (t, 2H), 3.34 (m, 2H), 1.36 (s, 9H); ESHRMS m/z 415.1551 (M+H, $C_{21}H_{24}ClN_4O_3$ requires 415.1537)

15

Example A-446




The above compound was prepared in a manner analogous to Example A-440 starting with methanol. Yield: off-white solid, 119 mg (14 %); mp = 265.3-265.3 °C; 1H -NMR (DMSO- d_6 /300 MHz) 12.61 (br s, 1H), 8.41 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.17 (d, 2H), 3.90 (s, 3H); ESHRMS m/z 286.0766 (M+H, $C_{15}H_{13}ClN_3O$ requires 286.0747); Anal. Calc'd for $C_{15}H_{12}ClN_3O \cdot 0.25 H_2O$: C, 62.08; H, 4.34; N, 14.48. Found: C, 62.24; H, 4.11; N,

25

14.16.

Example A-447




5

To the dithietane of Step 1 of Example A-341 (638 mg, 2 mmol) in toluene (15 mL) was added thiomorpholine (800 uL, 8 uL). The reaction mixture was heated to reflux for 6 hours, then cooled to room temperature and diluted with toluene (20 mL). The reaction mixture was then extracted twice with water (20 mL) and brine (20 mL). The organic solution was dried (MgSO₄), filtered, and concentrated to an oil. Hexane was added to the residue and heated to reflux, then decanted. The oil became semi-solid. The semi-solid was dissolved in tetrahydrofuran (10 mL) and potassium t-butoxide 1M in tetrahydrofuran (2 mL, 2 mmol) was added. This was followed by iodomethane (125 uL, 2 mmol). The reaction was stirred at room temperature for 1 hour, then quenched with water (20 mL). The reaction mixture was extracted with ethyl acetate (2 x 30 mL). The organic layers were pooled, washed with brine (20 mL) and dried (MgSO₄). Filtration and concentration produced an oil which was chased once with toluene to remove any ethyl acetate. The residue was dissolved in ethanol (10 mL) and hydrazine hydrate (97 uL, 2 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours then partitioned between ethyl acetate and saturated sodium bicarbonate solution (30 mL each). The layers were separated and the aqueous layer extracted again with ethyl acetate (30 mL). The combined organic

layers were washed with brine (20 mL) and dried (MgSO_4). Filtration and concentration produced an orange residue which was triturated with acetonitrile to generate a tan solid. Yield: 295 mg (43%); mp $>300^\circ\text{C}$; ^1H NMR ($\text{DMSO}-d_6/300\text{ MHz}$) 12.70 (br s, 1H), 8.47 (d, 2H), 7.46 (d, 2H), 7.26 (m, 4H), 3.13 (m, 4H), 2.62 (m, 4H); ESHRMS m/z 357.0942 ($\text{M}+\text{H}$, $\text{C}_{18}\text{H}_{18}\text{ClN}_4\text{S}$ requires 357.0941); Anal. Calc'd for $\text{C}_{18}\text{H}_{17}\text{ClN}_4\text{S}$: C, 60.58; H, 4.80; N, 15.70. Found: C, 60.32; H, 4.96; N, 15.60.

Example A-448




3-(4-chlorophenyl)-5-[(1-methylpiperidin-4-yl)-oxy]-4-pyridin-4-yl-1H-pyrazole

The compound of Example A-441 (455 mg, 1.5 mmol) was combined with 98% formic acid (6 mL) and heated to 100°C . After three hours, 37% formaldehyde (1.22 mL, 15 mmol) was added and the reaction was heated for an additional five hours at 100°C . The reaction mixture was allowed to cool to room temperature and filtered. The solution was diluted with water (15 mL) and extracted once with ethyl acetate (30 mL). The aqueous solution was then basified with 2.5 N sodium hydroxide to pH 8. The cloudy mixture was then extracted twice with 1:1 tetrahydrofuran:ethyl acetate (30 mL). The organic layers were pooled and washed once with brine (25 mL), dried (MgSO_4), filtered and concentrated to an oil which solidified on standing. The solid was triturated with

acetonitrile and collected by suction filtration. The solid was suspended in ethanol:water 2:1 (15 mL) and 1 mL of concentrated HCl was added. The solution was allowed to stir at room temperature for one hour, then
 5 filtered and concentrated. The residue was combined with ethanol (10 mL) and reconcentrated twice. The resulting solid was triturated with acetonitrile (10 mL) containing a small amount of ethanol (0.5 mL) to remove some colored impurities. The solid was collected by suction
 10 filtration, washed with acetonitrile and dried in-vacuo. Yield: 490 mg (88 %); mp 255.9-256.8 °C; ¹H NMR (D₂O/DMSO-d₆/NaOD/300 MHz) 7.93 (d, 2H), 7.09 (s, 4H), 7.00 (d, 2H), 4.42 (m, 1H), 2.26 (br m, 2H,) 2.12 (br m, 2H), 1.92 (s, 3H), 1.68 (br m, 2 H), 1.57 (br m, 2H);
 15 ESLRMS m/z 369 (M+H).

Example A-449




20 To the compound of Example C-1, infra, (4'-fluoro-1-(4-pyridyl)acetophenone, 14.0 g, 0.065 mol) in anhydrous tetrahydrofuran (200 mL) was added dropwise potassium t-butoxide (1M in tetrahydrofuran, 150 mL). The mixture
 25 was stirred 30 minutes. Carbon disulfide (4.2 mL, 0.07 mol) in tetrahydrofuran (25 mL) was added dropwise and stirred 15 minutes. 2-Bromomethyl-1,3-dioxolane (25.0 g, 0.15 mol) in tetrahydrofuran (25 mL) was added dropwise and contents were refluxed 10 hours. The mixture was
 30 allowed to cool and partitioned between ethyl acetate and

water. The ethyl acetate layer was dried over MgSO_4 and concentrated in vacuo leaving a red oil (29.3 g).

Chromatography on silica gel eluting with 25% ethyl acetate/hexanes gave the desired compound as a red oil, (5.5 g, 18% yield). ^1H NMR (CDCl_3) 8.62-8.52 (m, 2H); 8.07-7.95 (m, 2H); 7.48-7.40 (m, 2H); 7.20-7.05 (m, 2H); 5.15-5.05 (m, 1H); 4.98-4.90 (m, 1H); 4.00-3.77 (m, 8H); 3.08 (d, $J = 6$ Hz, 2H); 3.03 (d, $J = 6$ Hz, 2H); ESHRMS m/z 464.0966 ($\text{M}+\text{H}$, $\text{C}_{22}\text{H}_{23}\text{FNO}_5\text{S}_2$ requires 464.1001); Anal.

Calc'd for: $\text{C}_{22}\text{H}_{22}\text{FNO}_5\text{S}_2$ (0.1 H_2O): C, 56.79; H, 4.81; N, 3.01. Found: C, 56.45; H, 4.71; N, 3.02.


Example A-450



To the compound of Example C-1, *infra*, (4'-fluoro-1-(4-pyridyl)acetophenone, 7.0 g, 0.0325 mol) in anhydrous tetrahydrofuran (200 mL) was added dropwise potassium *t*-butoxide (1M in tetrahydrofuran, 75 mL). The mixture was stirred 30 minutes. Carbon disulfide (2.1 mL, 0.035 mol) in tetrahydrofuran (25 mL) was added dropwise and stirred 15 minutes. 4-Methoxybenzyl chloride (10.2 mL, 0.075 mol) in tetrahydrofuran (10 mL) was added dropwise and contents were stirred overnight. The contents were partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO_4 and concentrated in vacuo leaving a red oil (19.1 g). Chromatography on silica gel eluting with 25% ethyl acetate/hexanes gave the desired as a white solid (11.8 g, 68% yield). Recrystallization from ethyl acetate/hexanes gave the desired as colorless crystals: mp 118.5 - 120.6 $^{\circ}\text{C}$; ^1H

NMR (CDCl₃) 8.43 (d, *J* = 7 Hz, 2H); 7.62-7.52 (m, 2H);
 7.20-6.72 (m, 12H); 3.98 (d, *J* = 6 Hz, 4H); 3.83 (s, 3H);
 3.81 (s, 3H); ESHRMS *m/z* 532.1408 (M+H, C₃₀H₂₇FN₃O₃S₂
 requires 532.1416); Anal. Calc'd for: C₃₀H₂₆FN₃O₃S₂ (0.5
 5 H₂O): C, 66.65; H, 5.03; N, 2.59. Found: C, 66.34; H,
 4.96; N, 2.55.

Example A-451




10

The compound of Example A-449 (4.0 g, 9.2 mmol) and
 hydrazine monohydrate (2.2 mL, 46 mmol) were refluxed in
 ethanol (100 mL) for three hours. The mixture was
 15 allowed to cool and stand overnight. A yellow
 precipitate was filtered to give the desired product as a
 yellow solid, (1.34 g, 41% yield); mp 202.1-205.4°C; ¹H
 NMR (DMSO-d₆) 13.5 (br s, 1H); 8.55-8.45 (m, 2H); 7.40-
 7.12 (m, 6H); 5.01 (s, 1H); 3.92-3.70 (m, 4H); 3.13 (s,
 20 2H); ESHRMS *m/z* 358.1025 (M+H, C₁₈H₁₇FN₃O₂S requires
 358.1025); Anal. Calc'd for: C₁₈H₁₆FN₃O₂S: C, 60.49; H,
 4.51; N, 11.76. Found: C, 60.26; H, 4.55 N, 11.87.


400430-130304

Example A-452



5 The above compound was prepared similarly to the compound of Example A-451 starting with the compound prepared in Example A-450. The desired product was obtained as a white solid (2.15 g, 49% yield); mp 214.7-215.8 °C; ¹H NMR (DMSO-d₆ + approx. 10%TFA) 8.70 (d, 2H); 7.60 (d, 2H); 7.42-7.38 (m, 2H); 7.30-7.20 (m, 2H); 6.70 (d, 2H); 4.10 (s, 2H); 3.68 (s, 3H); ESHRMS m/z 392.1225 (M+H, C₂₂H₁₉FN₃OS requires 392.1232); Anal. Calc'd for: C₂₂H₁₈FN₃OS: C, 67.50; H, 4.63; N, 10.73. Found: C, 67.46; H, 4.67 N, 10.77.


Example A-453



20 The compound prepared in step 1 of Example A-341 (50 g, 0.156 mol) and anhydrous hydrazine (25 mL, 0.8 mol) were refluxed in ethanol (500 mL) for five hours. The mixture was allowed to cool and the precipitate filtered to afford the desired product as a yellow-orange solid (21.8 g). The filtrate was diluted with water (200 mL) and a second crop was obtained as a yellow-orange solid

(18.0 g). The pH of the filtrate was adjusted to pH 8 with 3N HCl and the precipitated solid filtered to give more desired as a yellow-orange solid (2.0 g). The product was obtained in 93% yield. mp 266.3-268.9°C; ¹H NMR (DMSO-d₆) 13.80 (br, 1H); 12.20 (br s, 1H); 8.32 (s, 4H); 7.50-7.30 (m, 4H); ESHRMS m/z 288.0358 (M+H, C₁₄H₁₁ClN₃S requires 288.0362); Anal. Calc'd for: C₁₄H₁₀ClN₃S (0.4 H₂O): C, 57.01; H, 3.69; N, 14.25. Found: C, 56.95; H, 3.50 N, 14.14.

Example A-454




The above compound was prepared similarly to the compound of Example A-453. mp 261.3-263.9°C; ¹H NMR (DMSO-d₆) 11.55 (br s, 1H); 8.25-8.13 (m, 2H); 7.61-7.50 (m, 2H); 7.36-7.20 (m, 2H); 7.19-7.05 (m, 2H); ESHRMS m/z 272.0691 (M+H, C₁₄H₁₁FN₃S requires 272.0657); Anal. Calc'd for: C₁₄H₁₀FN₃S (0.25 H₂O): C, 60.97; H, 3.84; N, 15.24. Found: C, 61.05; H, 3.64 N, 15.12.

Example A-455

To the compound prepared in Example A-453 (100 mg, 0.35 mmol) in methanol (2 mL) was added 0.5 M sodium methoxide (0.7 mL, 0.35 mmol). The mixture was stirred for 15 minutes and filtered to remove some small particles. The filtrate was concentrated in vacuo, dissolved in water and concentrated in vacuo leaving the desired product as a white solid. ¹H NMR (DMSO-d₆) 11.60 (br s, 1H); 8.20 (d, 2H); 7.60-7.50 (m, 2H); 7.40-7.20 (m, 4H); Anal. Calc'd for: C₁₄H₉ClN₃NaS (2.5 H₂O): C,

47.40; H, 3.98; N, 11.84. Found: C, 47.39; H, 3.33; N, 11.50.

Example A-456




[3-(4-chlorophenyl)-4-pyridin-4-yl-1H-pyrazole-5-yl]thio]acetonitrile

- 10 To the compound prepared in Example A-453 (584 mg, 2.0 mmol) and bromoacetonitrile (140 μ L, 2.0 mmol) in dimethylformamide (5 mL) was added anhydrous potassium carbonate (276 mg, 2.0 mmol). The contents were stirred overnight, then partitioned between ethyl acetate and
- 15 water. The ethyl acetate layer was dried over MgSO_4 and concentrated in vacuo leaving a tan solid. The solid was triturated with methanol and filtered to give the desired as a off-white solid (369 mg, 56% yield). mp 230.0-230.5°C; ^1H NMR ($\text{DMSO}-d_6$) 13.90 (br s, 1H); 8.58 (d, 2H);
- 20 7.60-7.13 (m, 6H); 4.10 (s, 2H); ESHRMS m/z 327.0482 ($\text{M}+\text{H}$, $\text{C}_{16}\text{H}_{12}\text{ClN}_4\text{S}$ requires 327.0471); Anal. Calc'd for: $\text{C}_{16}\text{H}_{11}\text{ClN}_4\text{S}$ ($0.3 \text{ H}_2\text{O}$): C, 57.85, H, 3.52; N, 16.87. Found C, 57.88; H, 3.31; N, 16.77.

25


Example A-457



The above compound was prepared similarly to the


compound of Example A-456 except that when the contents were partitioned between ethyl acetate and water, an insoluble solid was filtered to give the desired product as a white solid (2.16 g). A second crop (1.68 g) of
 5 desired product gave a total yield of 61%. mp 192.8-195.2°C; ¹H NMR (DMSO-d₆ + approximately 10%TFA) 9.80 (d, 2H); 7.80 (d, 2H); 7.52-7.34 (m, 4H); 3.92 (s, 2H); 3.57 (s, 3H); ESHRMS m/z 360.05735 (M+H, C₁₇H₁₄ClN₃O₂S requires 360.05732); Anal. Calc'd for: C₁₇H₁₄ClN₃O₂S (0.25 H₂O): C, 56.05, H, 4.01; N, 11.53. Found C, 56.10; H, 3.72; N, 11.51.

Example A-458



15 The compound prepared in Example A-453 (1.2 g, 4.2 mmol), potassium carbonate (630 mg, 4.6 mmol), N-tert-butoxycarbonyl-4-bromo piperidine (1.2 g, 4.5 mmol) were
 20 heated in dimethylformamide (15 mL) at 105 °C for three hours. Contents were allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄ and concentrated in vacuo. The
 25 residue was triturated with ethyl acetate and filtered to give the desired as a white solid (1.2 g, 61% yield). mp 220.9-221.0°C; ¹H NMR (DMSO-d₆) 13.70 (br, 1H); 8.60-8.50 (m, 2H); 7.58-7.10 (m, 6H); 3.80-3.60 (m, 2H); 3.40-3.20 (m, 1H); 3.00-2.63 (m, 2H); 2.00-1.53 (m, 2H); 1.50-1.05 (m, 2H); 1.40 (s, 9H); ESHRMS m/z 471.1605 (M+H, C₂₄H₂₈ClN₄OS requires 471.1622); Anal. Calc'd for: C₂₄H₂₇ClN₄OS (0.5 H₂O): C, 60.05; H, 5.88; N, 11.67.
 30 Found: C, 60.04; H, 5.57; N, 11.31.


Example A-459



5 3-(4-chlorophenyl)-5-[(piperidin-4-yl)-thio]-4-pyridin-4-yl-1H-pyrazole

10 The compound prepared in Example A-458 (5.0 g, 11 mmol), and TFA (30 mL) were mixed in methylene chloride (50 mL) and stirred overnight. The mixture was concentrated in vacuo leaving a pale yellow oil which was dissolved in water. The pH was adjusted with 2.5 N sodium hydroxide to pH 9, precipitating a white solid which was filtered to give the desired product as a white solid (3.7 g, 93% yield). mp 211.1-211.2°C; ¹H NMR (DMSO-*d*₆) 13.80 (br, 1H); 8.55 (d, 2H); 8.40 (br, 1H); 7.50-7.15 (m, 6H); 3.50-3.00 (m, 3H); 3.00-2.80 (m, 2H); 2.05-1.80 (m, 2H); 1.65-1.42 (m, 2H); ESHRMS *m/z* 371.1103 (M+H, C₁₉H₂₀ClN₄S requires 371.1097); Anal. 15 Calc'd for: C₁₉H₁₉ClN₄S (H₂O): C, 58.68; H, 5.44; N, 14.41. Found: C, 58.86; H, 5.28; N, 14.25.


Example A-460



25 To 1-(2-chloroethyl)pyrrolidine hydrochloride (306 mg, 1.8 mmol) in methanol (10 mL) was added 0.5 M sodium methoxide (7.0 mL, 3.6 mmol). The mixture was stirred 10

minutes and the compound of Example A-453 (500 mg, 1.8 mmol) added. The contents were refluxed one hour, allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO_4 and concentrated in vacuo leaving a light amber solid. The solid was recrystallized from methanol (15 mL) to give the desired product as a white solid (213 mg, 33% yield). mp 189.9-190.1°C; ^1H NMR ($\text{DMSO}-d_6$) 13.65 (br, 1H); 8.52 (d, 2H); 7.42 (d, 2H); 7.38-7.10 (m, 4H); 3.10-2.93 (m, 2H); 2.63-2.51 (m, 2H); 2.38 (br s, 4H); 1.70-1.52 (m, 4H); ESHRMS m/z 385.1262 ($\text{M}+\text{H}$, $\text{C}_{20}\text{H}_{22}\text{ClN}_4\text{S}$ requires 385.1254); Anal. Calc'd for: $\text{C}_{20}\text{H}_{21}\text{ClN}_4\text{S}$: C, 62.41, H, 5.50; N, 14.56. Found C, 62.22; H, 5.62; N, 14.48.


Example A-461



Method A: The compound prepared in Example A-457 (1.3 g, 3.6 mmol) in methanol (10 mL), 2.5N sodium hydroxide (4 mL) and water (10 mL) were stirred overnight. The mixture was concentrated in vacuo to remove the methanol and the aqueous solution left was made acidic to pH 6 with 3N HCl, precipitating a solid. The solid was extracted into ethyl acetate, dried over MgSO_4 and concentrated in vacuo leaving light tan crystals (205 mg). Brine was added to the aqueous layer precipitating more solid. The solid did not extract into ethyl acetate, but was filtered to give more desired product as a light tan powder (529 mg). Total yield was 61% yield. ^1H NMR ($\text{DMSO}-d_6 + 10\%\text{TFA}$) 8.80 (d, 2H); 7.83 (d, 2H); 7.55-7.35 (m, 4H); 3.87 (s, 2H).


Method B: The compound prepared in Example A-457 (3.8 g, 11 mmol) and 3N HCl (30 mL) were refluxed for three hours. The mixture was allowed to cool and concentrated in vacuo. The residue was mixed with CH₃CN (50 mL). Upon standing overnight, pale yellow crystals grew and were filtered to give the desired product as the HCl salt (2.9 g, 69% yield). ¹H NMR (DMSO-d₆) 8.79 (d, 2H); 7.75 (d, 2H); 7.51-7.38 (m, 4H); 3.88 (s, 2H); ESHRMS m/z 346.0435 (M+H, C₁₇H₁₆ClN₄OS requires 346.0417); Anal. Calc'd for: C₁₆H₁₂ClN₃O₂S (HCl, 0.5 H₂O): C, 49.12; H, 3.61; N, 10.74. Found: C, 49.36; H, 3.48; N, 10.72.

Example A-462



The compound prepared in Example A-457 (400 mg, 11 mmol) and a 2M solution of methyl amine in tetrahydrofuran (25 mL) were refluxed for three hours. The mixture was stirred overnight at room temperature before filtering to give the desired as a light amber solid (335 mg, 85 % yield). mp 284.0-288.4°C; ¹H NMR (DMSO-d₆) 13.58 (br, 1H); 8.60-8.45 (m, 2H); 7.98 (br s, 1H); 7.55-7.12 (m, 6H); 3.60 (s, 2H); 2.46 (s, 3H); ESHRMS m/z 359.0733 (M+H, C₁₇H₁₆ClN₄OS requires 359.0745); Anal. Calc'd for: C₁₇H₁₅ClN₄OS: C, 56.90; H, 4.21; N, 15.61. Found: C, 56.74; H, 4.11; N, 15.17.

Example A-463




5 The compound prepared in Example A-457 (415 mg, 12 mmol) and N, N-dimethylaminopropylamine were refluxed in methanol (25 mL) for three hours. The mixture was stirred overnight at room temperature before concentrating in vacuo leaving a solid. The solid was

10 trituated with ethyl acetate and filtered to give the desired as a white solid (256 mg, 50 % yield). mp 168.8-169.5°C; ¹H NMR (DMSO-d₆) 13.80 (br, 1H); 8.55-8.50 (m, 2H); 8.02 (t, 1H); 7.50-7.40 (m, 6H); 3.61 (s, 2H); 3.30-2.98 (m, 2H); 2.14-2.10 (m, 2H); 2.04 (s, 6H); 1.50-1.40

15 (m, 2H); ESHRMS m/z 430.1472 (M+H, C₂₁H₂₅ClN₁₂OS requires 430.1468); Anal. Calc'd for: C₂₁H₂₄ClN₅OS (0.5 H₂O): C, 57.46; H, 5.74; N, 15.95. Found: C, 57.71; H, 5.56; N, 16.12.

Example A-464




20 To the compound prepared in Example A-458 (1.0 g, 2.1 mmol) in methylene chloride (25 mL) was added meta-chloroperbenzoic acid (425 mg, 2.1 mmol). The mixture was stirred 15 minutes and chromatographed on silica gel (20 g) eluting with ethyl acetate. The desired product precipitated out of the ethyl acetate elutant upon

25


standing and was filtered to give the desired product as a white solid (958 mg, 93% yield). mp 215.8-215.9°C; ^1H NMR (DMSO- d_6) 14.34 (br s, 1H); 8.57-8.54 (m, 2H); 7.51-7.25 (m, 6H); 4.00-3.82 (m, 2H); 3.60-3.40 (m, 1H); 2.85-2.70 (m, 2H); 2.10-1.95 (m, 1H); 1.56-1.10 (m, 3H); 1.36 (s, 9H); ESHRMS m/z 487.1580 ($M+H$, $C_{17}H_{16}ClN_4OS$ requires 487.1571); Anal. Calc'd for: $C_{24}H_{27}ClN_{12}O_3S$: C, 59.19; H, 5.59; N, 11.50. Found: C, 59.00; H, 5.76; N, 11.46.

Example A-465




To the compound prepared in Example A-458 (320 mg, 0.68 mmol) in ethanol (5 mL) was added an aqueous solution of potassium peroxydisulfate (420 mg, 0.68 mmol). The mixture was stirred two hours and extracted into ethyl acetate which was dried over $MgSO_4$ and concentrated in vacuo leaving a white solid. The solid was triturated with methanol and filtered to give the desired as a white solid (90 mg, 26% yield). mp 228.0-230.8°C; ^1H NMR (DMSO- d_6) 8.61 (d, 2H); 7.48 (d, 2H); 7.31-7.20 (m, 4H); 4.05-3.90 (m, 2H); 3.54-3.35 (m, 1H); 2.85-2.60 (m, 2H); 1.92-1.80 (m, 2H); 1.48-1.25 (m, 2H); 1.32 (s, 9H); ESHRMS m/z 503.1541 ($M+H$, $C_{24}H_{27}ClN_4O_4S$ requires 503.1520); Anal. Calc'd for: $C_{24}H_{27}ClN_4O_4S$ (H_2O): C, 56.30; H, 5.51; N, 10.94. Found: C, 56.41; H, 5.78; N, 10.54.

Example A-466



5 The above compound was prepared similarly to the
 compound of Example A-464. After chromatography the
 solid obtained was recrystallized from CH₃CN to give the
 desired product as white crystals (64 mg, 33% yield). mp
 189.5-189.5°C; ¹H NMR (DMSO-d₆) 14.28 (br s, 1H); 8.50
 10 (d, 2H); 7.40-7.20 (m, 4H); 7.20-7.05 (m, 4H); 6.85 (d,
 2H); 4.41 (s, 2H); 3.70 (s, 3H); ESHRMS m/z 408.1168
 (M+H, C₂₂H₁₉FN₃O₂S requires 408.1182); Anal. Calc'd for:
 C₂₂H₁₈FN₃O₂S: C, 64.85; H, 4.45; N, 10.31. Found: C,
 64.44; H, 4.34; N, 10.70.


Example A-467



20 To the compound prepared in Example A-466 (1.2 g,
 2.5 mmol) in methylene chloride (50 mL) was added *meta*-
 chloroperbenzoic acid (1.0 g, 5.0 mmol). The mixture was
 stirred 1.5 hours and filtered a white solid (620 mg)

which was inorganic salts. The filtrate was chromatographed on silica gel (20 g) eluting with ethyl acetate to give the desired product as a white solid (98 mg, 9% yield). mp 241.9-242.0°C; ¹H NMR (DMSO-d₆) 8.48-8.40 (m, 2H); 7.33-6.80 (m, 10H); 4.55 (s, 2H); 3.72 (s, 3H); ESHRMS m/z 424.1143 (M+H, C₂₄H₂₇ClN₄O₄S requires 424.1131); Anal. Calc'd for: C₂₂H₁₈FN₃O₃S: C, 62.40; H, 4.28; N, 9.92. Found: C, 62.14; H, 4.42; N, 9.68.


Example A-468



3-(4-chlorophenyl)-5-[(1-methylpiperidin-4-yl)-thio]-4-pyridin-4-yl-1H-pyrazole

The compound prepared in Example A-458 (5.0 g, 0.01 mol) and formic acid (96%, 7 mL) were heated at 100 °C for one hour. The mixture was allowed to cool to about 50 °C and formaldehyde (37%, 13 mL) was added. The contents were heated at 80 °C for two hours. The contents were allowed to cool, diluted with water (200 mL) and made basic to pH 11 with 2.5N sodium hydroxide, precipitating a white solid. The solid was filtered and recrystallized from methanol to give the desired as a white solid (174 mg, 33% yield). mp 227.7-227.7°C; ¹H NMR (DMSO-d₆) 13.70 (br s, 1H); 8.56-8.48 (m, 2H); 7.50-7.15 (m, 6H); 3.10-2.92 (m, 1H); 2.63-2.50 (m, 2H); 2.05 (s, 3H); 1.95-1.65 (m, 4H); 1.50-1.30 (m, 2H); ESHRMS m/z 385.1233 (M+H, C₂₀H₂₂ClN₄S requires 385.1254); Anal. Calc'd for: C₂₀H₂₁ClN₄S: C, 62.41; H, 5.50; N, 14.56. Found: C, 62.40; H, 5.80; N, 14.61.

Example A-469




5 3-(4-chlorophenyl)-5-[(2-methoxyethyl)-thio]-4-pyridin-4-yl-1H-pyrazole

10 The above compound was prepared similarly to the compound of Example A-456 using bromoethyl methyl ether except contents were heated at 70 °C for one hour before partitioning between ethyl acetate and water. The crude product was recrystallized from methanol/ethyl acetate to give the desired product as a white solid (210 mg, 35% yield). mp 189.2-190.2°C; ¹H NMR (DMSO-d₆) 8.60-8.45 (m, 2H); 7.60-7.10 (m, 6H); 3.60-2.85 (m, 7H); ESHRMS m/z 346.0799) M+H, C₁₇H₁₇ClN₃OS requires 346.0781); Anal. Calc'd for: C₁₇H₁₆ClN₃OS (H₂O): C, 58.73; H, 4.70; N, 12.09. Found: C, 58.67; H, 4.86; N, 12.03.

20


Example A-470



25 The above compound was prepared similarly to the compound of Example A-456 using 2-chloromethylbenzimidazole except contents were heated at 70 °C for one hour before partitioning between ethyl acetate and water. An insoluble solid was filtered from the two layers and triturated with methanol to give the


desired product as a light amber solid (292 mg, 40%
 yield). mp 257.7-257.7°C; ¹H NMR (DMSO-d₆) 13.75 (br s,
 1H); 12.30 (br s, 1H); 8.55-8.30 (m, 2H); 7.65-6.90 (m,
 10H); 4.40 (br s, 2H); ESHRMS m/z 418.0895 (M+H,
 5 C₂₂H₁₇ClN₅S requires 418.0893); Anal. Calc'd for:
 C₂₂H₁₆ClN₅S (0.75 H₂O): C, 61.25; H, 4.09; N, 16.23.
 Found: C, 61.27; H, 3.90; N, 15.92.

Example A-471



The above compound was prepared similarly to the
 compound of Example A-456 using DL-*alpha*-bromo-*beta*-(5-
 15 imidazolyl)propionic acid except the mixture was heated
 at 70 °C for one hour. The mixture contained an
 insoluble solid which was diluted with water and the pH
 was adjusted with 3N HCl to pH 7. The mixture was
 filtered and triturated with methanol to give the desired
 20 product as a white solid (1.5 g, 81% yield). mp 163.0-
 165.5°C; ¹H NMR (DMSO-d₆ + approx. 10%TFA) 8.92 (d, 1H);
 8.83-8.75 (m, 2H); 7.80 (d, 2H); 7.55-7.30 (m, 5H); 4.20-
 4.05 (m, 1H); 3.25-3.00 (m, 2H). ESHRMS m/z 426.0799
 (M+H, C₂₀H₁₇ClN₅O₂S requires 426.0791); Anal. Calc'd for:
 25 C₂₀H₁₆ClN₅O₂S (1.8 H₂O): C, 52.41 H, 4.31; N, 15.28.
 Found: C, 52.68; H, 4.58; N, 15.37.


Example A-472



5 To the compound prepared in Example A-453 (264 mg, 0.9 mmol) and α -methylenebutylolactone (0.08 mL, 0.9 mmol) in ethanol was added a drop of triethylamine. The mixture was stirred overnight. The resulting solid was filtered and triturated with methanol to give the desired

10 product as a pale yellow solid (181 mg, 51% yield). mp 224.2-225.9°C; ^1H NMR (DMSO- d_6 + approx. 10%TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.53-7.33 (m, 4H); 4.30-4.05 (m, 2H); 3.50-3.40 (m, 1H); 3.15-2.90 (m, 2H); 2.32-2.20 (m, 1H) 2.10-1.90 (m, 1H); ESHRMS m/z 386.0760 (M+H, $\text{C}_{19}\text{H}_{17}\text{ClN}_3\text{O}_2\text{S}$ requires 386.0730); Anal. Calc'd for: $\text{C}_{19}\text{H}_{16}\text{ClN}_3\text{O}_2\text{S}$: C, 59.14 H, 4.18; N, 10.89. Found: C, 58.97; H, 4.21; N, 10.96.

Example A-473




20 The above compound was prepared similarly to the compound of Example A-456 using 2-bromomethyl-1,3-dioxolane except the mixture was heated at 80°C for two

25 hours. The mixture was diluted with water and filtered to give a white solid (502 mg). The solid was recrystallized from ethanol to give the desired product as off-white crystals (280 mg, 43% yield). mp 197.0-

198.2°C; ^1H NMR (DMSO- d_6) 13.60 (br s, 1H); 8.60-8.45 (m, 2H); 7.60-7.10 (m, 6H); 5.15-4.85 (m, 1H); 3.95-3.62 (m, 4H); 3.40-2.95 (m, 2H); ESHRMS m/z 374.0741 (M+H, $\text{C}_{18}\text{H}_{17}\text{ClN}_3\text{O}_2\text{S}$ requires 374.0730); Anal. Calc'd for: $\text{C}_{18}\text{H}_{16}\text{ClN}_3\text{O}_2\text{S}$: C, 57.83 H, 4.31; N, 11.24. Found: C, 57.69; H, 4.41; N, 11.15.

Example A-474




10

The above compound was prepared similarly to the compound of Example A-456 using 2-(2-bromoethoxy)tetrahydro-2H-pyran except that the mixture was heated at 80 °C for four hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO_4 and concentrated in vacuo leaving a solid (737 mg). The solid was recrystallized from ethanol to give the desired product as pale yellow crystals (281 mg, 39% yield). mp 163.2-163.5°C; ^1H NMR (DMSO- d_6) 13.80-13.70 (m, 1H), 8.60-8.42 (br s, 1H); 7.60-7.10 (m, 6H); 4.60-4.30 (m, 1H); 3.90-2.90 (m, 6H); 1.70-1.20 (m, 6H); ESHRMS m/z 416.1200 (M+H, $\text{C}_{21}\text{H}_{23}\text{ClN}_3\text{O}_2\text{S}$ requires 416.1198); Anal. Calc'd for: $\text{C}_{21}\text{H}_{22}\text{ClN}_3\text{O}_2\text{S}$: C, 60.64 H, 5.33; N, 10.10. Found: C, 60.49; H, 5.71; N, 9.96.

25


1004801904

Example A-475



5 The above compound was prepared similarly to the
 compound of Example A-456 using 4-bromobutyronitrile
 except the mixture was heated at 55 °C for one hour. The
 mixture was diluted with water (75 mL) and filtered to
 give a white solid (567 mg). The solid was
 10 recrystallized from methanol to give the desired product
 as white crystals (333 mg, 54% yield). mp 216.7-216.9°C;
¹H NMR (DMSO-d₆ + approx. 10%TFA) 8.80-8.75 (m, 2H);
 7.83-7.75 (m, 2H); 7.50-7.35 (m, 4H); 3.10-3.00 (m, 2H);
 2.60-2.45 (m, 2H); 1.95-1.80 (m, 2H); ESHRMS m/z
 15 355.0818 (M+H, C₁₈H₁₆ClN₄S requires 355.0784); Anal.
 Calc'd for: C₁₈H₁₅ClN₄S (0.5 H₂O): C, 59.42 H, 4.43; N,
 15.40. Found: C, 59.64; H, 4.11; N, 15.44.

Example A-476




20 The compound prepared in Example A-461 (416 mg, 1.1
 mmol), morpholine (4 mL), O-benzotriazol-1-yl-N,N,N',N'-
 25 tetramethyluronium tetrafluoroborate (481 mg, 1.5 mmol)
 and dimethylformamide (10 mL) were stirred overnight.
 The mixture was diluted with water (75 mL) and the
 resulting solid was filtered (363 mg). The solid was
 recrystallized from ethanol to give the desired product

as a white solid (219 mg, 48% yield). mp 215.4-215.5°C;
¹H NMR (DMSO-d₆) 13.70-13.60 (m, 1H); 8.60-8.50 (m, 2H);
 7.50-7.10 (m, 6H); 3.93-3.80 (m, 2H); 3.60-3.20 (m, 8H);
 ESHRMS m/z 415.0995 (M+H, C₂₀H₂₀ClN₄O₂S requires 415.1001);

5 Anal. Calc'd for: C₂₀H₁₉ClN₄O₂S: C, 57.90 H, 4.62; N,
 13.50. Found: C, 57.87; H, 4.86; N, 13.53.

Example A-477




10

The above compound was prepared similarly to the
 compound of Example A-456 using 2-bromopropionitrile
 except the mixture was heated at 70 °C for one hour. The
 15 mixture was diluted with water (75 mL) and filtered to
 give an off-white solid (662 mg). The solid was
 recrystallized from methanol to give the desired product
 as a white solid (220 mg, 37% yield). mp 211.1-212.8°C;
¹H NMR (DMSO-d₆ + approx. 10%TFA) 8.87-8.80 (m, 2H);
 20 7.90-7.80 (m, 2H); 7.55-7.45 (m, 6H); 4.42 (q, 1H); 1.50
 (d, 3H); ESHRMS m/z 341.0628 (M+H, C₁₈H₁₆ClN₄S requires
 341.0628); Anal. Calc'd for: C₁₇H₁₃ClN₄S: C, 59.91 H,
 3.84; N, 16.44. Found: C, 59.64; H, 4.01; N, 16.18.

25


Example A-478



The above compound was prepared similarly to the


compound of Example A-456 using propargyl bromide. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (577 mg). The solid was triturated with methanol to give the desired product as a white solid (388 mg, 68% yield). mp 212.7-213.2°C; ¹H NMR (DMSO-d₆ + approx. 10%TFA) 8.80 (d, *J* = 6.8 Hz, 2H); 7.82 (d, *J* = 6.8 Hz, 2H); 7.50-7.35 (m, 4H); 3.81 (d, *J* = 2.6 Hz, 2H); 3.05 (t, *J* = 2.6 Hz, 1H); ESHRMS *m/z* 326.0533 (M+H, C₁₇H₁₃ClN₃S requires 326.0519); Anal. Calc'd for: C₁₇H₁₂ClN₃S (0.2 H₂O): C, 61.98 H, 3.79; N, 12.76. Found: C, 61.89; H, 3.45; N, 12.67.

Example A-479




The above compound was prepared similarly to the compound of Example A-456 using allyl bromide. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (509 mg). The solid was recrystallized from methanol to give the desired product as a pale yellow solid (187 mg, 33% yield). mp 207.3-208.1°C; ¹H NMR (DMSO-d₆ + approx. 10%TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.50-7.30 (m, 4H); 5.90-5.70 (m, 1H); 5.10-4.95 (m, 2H); 3.62 (d, 2H); ESHRMS *m/z* 328.0693 (M+H, C₁₇H₁₅ClN₃S requires 328.0675); Anal. Calc'd for: C₁₇H₁₄ClN₃S (0.1 H₂O): C, 61.94 H, 4.34; N, 12.75. Found: C, 61.83; H, 4.21; N, 12.76.

Example A-480



- 5 The above compound was prepared similarly to the compound of Example A-456 using 2-bromoethylamine except two equivalents of potassium carbonate were used. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (509 mg). The solid was
- 10 recrystallized from methanol to give the desired product as a pale yellow solid (262 mg, 45% yield). mp 186.8-187.8°C; ¹H NMR (DMSO-d₆ + approx. 10%TFA) 8.85-8.75 (m, 2H); 8.90 (br s, 2H); 8.85-8.75 (m, 2H); 7.55-7.35 (m, 4H); 3.30-3.00 (m, 4H); ESHRMS m/z 331.0779 (M+H,
- 15 C₁₆H₁₆ClN₄S requires 331.0784); Anal. Calc'd for: C₁₆H₁₅ClN₄S (0.5 H₂O): C, 56.55; H, 4.75; N, 16.49. Found: C, 56.28; H, 4.38; N, 16.20.


Example A-481



- 20 The above compound was prepared similarly to the compound of Example A-456 using 3-(2-bromoethyl)indole.
- 25 The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (752 mg). The solid was triturated with methanol to give the desired product as a white solid (682 mg, 91% yield). mp 211.9-213.2°C; ¹H NMR (DMSO-d₆ + approx. 10%TFA) 10.80 (s, 1H); 8.72 (d,


2H); 7.71 (d, 2H); 7.55-7.35 (m, 5H); 7.29 (d, 1H); 7.12-6.88 (m, 3H); 3.40-3.30 (m, 2H); 3.05-2.95 (m, 2H); ESHRMS m/z 431.1095 (M+H, $C_{24}H_{20}ClN_4S$ requires 431.1097); Anal. Calc'd for: $C_{24}H_{19}ClN_4S$ (0.15 H_2O): C, 66.47 H, 4.49; N, 12.92. Found: C, 66.44; H, 4.51; N, 12.84.

Example A-482




The compound of Example A-464 (464 mg, 0.95 mmol) and TFA (8 mL) were mixed in methylene chloride (10 mL) and stirred overnight. The mixture was concentrated in vacuo and the residue was partitioned between ether and water. The aqueous layer was made basic to pH 10 with 2.5N sodium hydroxide and extracted with ethyl acetate (2 x 100 mL). Upon standing overnight, a solid precipitated from the aqueous layer and was filtered to give the desired product as a white solid (183 mg, 50% yield). mp 189.1-190.8°C; 1H NMR (DMSO- d_6 + approx. 10%TFA) 8.85 (d, 2H); 8.80-8.60 (m 1H); 8.45-8.25 (m, 1H); 7.90 (d, 2H); 7.55-7.30 (m, 4H); 3.65-3.20 (m 3H); 3.10-2.80 (m 2H); 2.20-2.00 (m, 1H); 1.90-1.50 (m, 3H); ESHRMS m/z 387.1032 (M+H, $C_{19}H_{20}ClN_4OS$ requires 387.1046); Anal. Calc'd for: $C_{19}H_{20}ClN_4OS$ (2 H_2O): C, 53.96 H, 5.48; N, 13.25. Found: C, 53.75; H, 4.99; N, 13.21.

Example A-483




5 The above compound was prepared similarly to the
 compound of Example A-456 using 3-bromopropionitrile.
 The mixture was diluted with water (75 mL) and extracted
 into ethyl acetate, which was dried over MgSO_4 and
 concentrated in vacuo leaving an orange waxy solid (523
 10 mg). The solid was dissolved in CH_3CN and filtered
 through a pad of silica gel and eluted with ethyl acetate
 to give a white solid. The solid was triturated with
 ethyl acetate and filtered to give the desired product as
 a white solid (76 mg, 13% yield). mp 205.7-206.5°C; ^1H
 15 NMR ($\text{DMSO}-d_6$ + approx. 10%TFA) 8.80 (d, 2H); 7.80 (d,
 2H); 7.55-7.35 (m, 4H); 3.30-3.20 (m, 2H); 2.90-2.80 (m,
 2H); ESHRMS m/z 341.0639 ($\text{M}+\text{H}$, $\text{C}_{19}\text{H}_{20}\text{ClN}_4\text{OS}$ requires
 341.0628); Anal. Calc'd for: $\text{C}_{17}\text{H}_{13}\text{ClN}_4\text{S}$ ($0.25 \text{ H}_2\text{O}$): C,
 59.13 H, 3.94; N, 16.22. Found: C, 59.03; H, 3.93; N,
 20 15.90.

Example A-484



A solution of 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (200 mg, 0.74 mmol) and toluene sulfonyl chloride (564 mg, 2.94 mmol, prepared as set forth in Example A-427) in pyridine (5 mL) was stirred at 100 °C for two days. The mixture was concentrated in vacuo to a brown residue. The residue was chromatographed on a silica gel column eluting with 10% methanol/dichloromethane. The fractions containing the desired product were combined and concentrated to a yellow solid which was washed with diethyl ether and filtered to afford 78 mg (25%) of the desired sulfonamide as a white solid. m.p. 284.3-284.4 °C. ¹H NMR (DMSO/300 MHz) δ 13.33 (brs, 0.8H), 9.94 (brs, 0.75H), 8.48 (brs, 1.75H), 8.22 (brs, 0.3H), 7.63 (d, 1.7H), 7.47 (d, 1.85H), 7.24 (m, 6.45H), 7.02 (brs, 0.25H), 6.81 (brs, 0.20H). ESLRMS m/z 425 (M+H). ESHRMS m/z 425.0848 (M+H, C₂₁H₁₈N₄ClS requires 425.0839).

Example A-485




20


1-[cyclohexyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine.

mp >300 °C (decomposed). ¹H NMR (CD₃OD / 300 MHz) 8.50 (d, 2H, J = 6.0 Hz), 7.51 (d, 2H, J = 5.8 Hz), 2.99-2.93, (m, 4H), 2.52-2.48 (m, 4H), 3.04-3.02 (m, 4H), 2.96 (s, 3H), 2.54-2.49 (m, 1H), 2.31-2.26 (m, 4H), 1.84-1.33 (m, 10H). FABLRMS m/z 326 (M+H).


Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:




4-[3-(4-chlorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine ;




1-[5-(4-bromophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine ;




1-[4-(4-pyridinyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]piperazine ;




4-[5-(1-piperazinyl)-4-(4-pyridinyl)-
-1H-pyrazol-3-yl]benzonitrile ;




1-[5-(4-ethynylphenyl)-4-(4-pyridinyl)-
-1H-pyrazol-3-yl]piperazine ;




5-(4-fluorophenyl)-4-
(4-pyridinyl)-N-3-pyrrolidinyl-
1H-pyrazol-3-amine ;




5-(4-chlorophenyl)-4-
(4-pyridinyl)-N-3-pyrrolidinyl-
1H-pyrazol-3-amine ;



N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine ;




3-(4-fluorophenyl)-5-(1-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol ;




3-(4-chlorophenyl)-5-(1-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol ;


457




4-[2-aminoethyl]-2-(4-fluoro
phenyl)-4,5,6,7-tetrahydro-
3-(4-pyridinyl)pyrazolo
[1,5-a]pyrimidin-6-ol ;




4-[2-aminoethyl]-2-(4-chloro
phenyl)-4,5,6,7-tetrahydro-
3-(4-pyridinyl)pyrazolo
[1,5-a]pyrimidin-6-ol ;




3-(4-chlorophenyl)-4-(4-pyrimidinyl)-
1H-pyrazole-1-ethanol ;




5-(4-fluorophenyl)-4-(4-pyrimidinyl)-
1H-pyrazole-3-ethanamine ;



5-(4-chlorophenyl)-4-(4-pyrimidinyl)-
1H-pyrazole-3-ethanamine ;




4-[3-(4-fluorophenyl)-5-(4-piperidinyl)-
1H-pyrazol-4-yl]pyrimidine ;




4-[3-(4-chlorophenyl)-5-(4-piperidinyl)-
1H-pyrazol-4-yl]pyrimidine ;

459




N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-
2-pyrimidinyl]acetamide

;




N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-
2-pyrimidinyl]acetamide

;



N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-
2-pyrimidinyl]propanamide


;




N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-
2-pyrimidinyl]propanamide

;


1003390-19001
Total: 03/2001




6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-purine ;




6-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-1H-purine ;




N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide ;




N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)propanamide ;



N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)propanamide;




1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine;




5

1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine;

400480-1004




1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine;




5

1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine;




10 1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]piperazine;

100480 03/2001




1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine;






5


4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol;




10

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine;







1 - [5 - (4 - fluorophenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - yl] - 3,5 - dimethylpiperazine;




5 4 - [5 - (4 - fluorophenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - yl] - 1,2,6 - trimethylpiperazine;




4 - [5 - (4 - chlorophenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - yl] - 1,2 - dimethylpiperazine;




1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine;




- 5 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine;




5-(4-chlorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine;




- 10 5-(4-chlorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;




5-(4-fluorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine;



- 5 5-(4-fluorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;




1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine;




10


1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine;



1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine;




5 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine;




5-(4-chlorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine;


10




5-(4-fluorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine;




5 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine;




N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine;



10 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine;




N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine;



5


4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol;




10

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine;


10024780-100701




4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol;




- 5 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine;




4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol;




4 - [5 - (4 - fluorophenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - yl] - 2 - piperazinemethanamine;




5 4 - [5 - (4 - fluorophenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - yl] - 1 - methyl - 2 - piperazinemethanol;




4 - [5 - (4 - fluorophenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - yl] - 1 - methyl - 2 - piperazinemethanamine;




4 - [3 - (4-chlorophenyl) - 5 - (4-methyl-1-piperazinyl) - 1H-pyrazol-4-yl] - N-methyl-2-pyrimidinamine;




5 4 - [3 - (4-fluorophenyl) - 5 - (4-methyl-1-piperazinyl) - 1H-pyrazol-4-yl] - N-methyl-2-pyrimidinamine;




1 - [[5 - (4-chlorophenyl) - 4 - (4-pyridinyl) - 1H-pyrazol-3-yl]methyl] - 4-piperidinol;




1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl-4-piperidinol;




5 4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine;




4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine;




4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic acid;




5 ethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate;




4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylic acid;




10 ethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate;




4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxamide;




- 5 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide;




4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic acid;




ethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate;




- 5 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide;




4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylic acid;




ethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate;




- 5 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxamide;




- 10 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-ethyl-4-piperidinamine;




N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(benzyl)-4-piperidinamine;




- 5 1-acetyl-N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine;




N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-propynyl)-4-piperidinamine;




N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-cyclopropyl-4-piperidinamine;




- 5 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)-4-piperidinamine;






N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methylethyl)-4-piperidinamine;




N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-propyl-4-piperidinamine;




5 ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate;






;




; and



5

Additional compounds of specific interest include the compounds of Tables 3-3, 3-4, 3-5 and 3-6:

TABLE 3-3



| | R ² | R ⁵ | R ¹² |
|----|----------------|-----------------------------|-----------------|
| 5 | 4-piperidinyl | methyl | m- or p-fluoro |
| | 4-piperidinyl | ethyl | m- or p-fluoro |
| | 4-piperidinyl | amino | m- or p-fluoro |
| | 4-piperidinyl | methylamino | m- or p-fluoro |
| | 4-piperidinyl | dimethylamino | m- or p-fluoro |
| 10 | 4-piperidinyl | ethylamino | m- or p-fluoro |
| | 4-piperidinyl | diethylamino | m- or p-fluoro |
| | 4-piperidinyl | propylamino | m- or p-fluoro |
| | 4-piperidinyl | dipropylamino | m- or p-fluoro |
| | 4-piperidinyl | hydroxyethylamino | m- or p-fluoro |
| 15 | 4-piperidinyl | 1-hydroxy-1,1-dimethylethyl | m- or p-fluoro |
| | 4-piperidinyl | methoxyethylamino | m- or p-fluoro |
| | 4-piperidinyl | methyl | m- or p-chloro |
| | 4-piperidinyl | ethyl | m- or p-chloro |
| | 4-piperidinyl | amino | m- or p-chloro |
| 20 | 4-piperidinyl | methylamino | m- or p-chloro |
| | 4-piperidinyl | dimethylamino | m- or p-chloro |
| | 4-piperidinyl | ethylamino | m- or p-chloro |
| | 4-piperidinyl | diethylamino | m- or p-chloro |
| | 4-piperidinyl | propylamino | m- or p-chloro |
| 25 | 4-piperidinyl | dipropylamino | m- or p-chloro |
| | 4-piperidinyl | hydroxyethylamino | m- or p-chloro |
| | 4-piperidinyl | 1-hydroxy-1,1-dimethylethyl | m- or p-chloro |
| | 4-piperidinyl | methoxyethylamino | m- or p-chloro |
| | 4-piperidinyl | methyl | m- or p-methyl |
| 30 | 4-piperidinyl | ethyl | m- or p-methyl |
| | 4-piperidinyl | amino | m- or p-methyl |
| | 4-piperidinyl | methylamino | m- or p-methyl |
| | 4-piperidinyl | dimethylamino | m- or p-methyl |

1002180-100201

| | | | |
|----|---------------|-----------------------------|----------------|
| 5 | 4-piperidinyl | ethylamino | m- or p-methyl |
| | 4-piperidinyl | diethylamino | m- or p-methyl |
| | 4-piperidinyl | propylamino | m- or p-methyl |
| | 4-piperidinyl | dipropylamino | m- or p-methyl |
| | 4-piperidinyl | hydroxyethylamino | m- or p-methyl |
| 10 | 4-piperidinyl | 1-hydroxy-1,1-dimethylethyl | m- or p-methyl |
| | 4-piperidinyl | methoxyethylamino | m- or p-methyl |
| | 4-piperazinyl | methyl | m- or p-fluoro |
| | 4-piperazinyl | ethyl | m- or p-fluoro |
| | 4-piperazinyl | amino | m- or p-fluoro |
| 15 | 4-piperazinyl | methylamino | m- or p-fluoro |
| | 4-piperazinyl | dimethylamino | m- or p-fluoro |
| | 4-piperazinyl | ethylamino | m- or p-fluoro |
| | 4-piperazinyl | diethylamino | m- or p-fluoro |
| | 4-piperazinyl | propylamino | m- or p-fluoro |
| 20 | 4-piperazinyl | dipropylamino | m- or p-fluoro |
| | 4-piperazinyl | hydroxyethylamino | m- or p-fluoro |
| | 4-piperazinyl | 1-hydroxy-1,1-dimethylethyl | m- or p-fluoro |
| | 4-piperazinyl | methoxyethylamino | m- or p-fluoro |
| | 4-piperazinyl | methyl | m- or p-chloro |
| 25 | 4-piperazinyl | ethyl | m- or p-chloro |
| | 4-piperazinyl | amino | m- or p-chloro |
| | 4-piperazinyl | methylamino | m- or p-chloro |
| | 4-piperazinyl | dimethylamino | m- or p-chloro |
| | 4-piperazinyl | ethylamino | m- or p-chloro |
| 30 | 4-piperazinyl | diethylamino | m- or p-chloro |
| | 4-piperazinyl | propylamino | m- or p-chloro |
| | 4-piperazinyl | dipropylamino | m- or p-chloro |
| | 4-piperazinyl | hydroxyethylamino | m- or p-chloro |
| | 4-piperazinyl | 1-hydroxy-1,1-dimethylethyl | m- or p-chloro |
| 35 | 4-piperazinyl | methoxyethylamino | m- or p-chloro |
| | 4-piperazinyl | methyl | m- or p-methyl |
| | 4-piperazinyl | ethyl | m- or p-methyl |
| | 4-piperazinyl | amino | m- or p-methyl |
| | 4-piperazinyl | methylamino | m- or p-methyl |
| 40 | 4-piperazinyl | dimethylamino | m- or p-methyl |
| | 4-piperazinyl | ethylamino | m- or p-methyl |
| | 4-piperazinyl | diethylamino | m- or p-methyl |
| | 4-piperazinyl | propylamino | m- or p-methyl |
| | 4-piperazinyl | dipropylamino | m- or p-methyl |

4001300 4001

| | | | |
|----|-----------------|-----------------------------|----------------|
| | 4-piperazinyl | hydroxyethylamino | m- or p-methyl |
| | 4-piperazinyl | 1-hydroxy-1,1-dimethylethyl | m- or p-methyl |
| | 4-piperazinyl | methoxyethylamino | m- or p-methyl |
| 5 | aminocyclohexyl | methyl | m- or p-fluoro |
| | aminocyclohexyl | ethyl | m- or p-fluoro |
| | aminocyclohexyl | amino | m- or p-fluoro |
| | aminocyclohexyl | methylamino | m- or p-fluoro |
| | aminocyclohexyl | dimethylamino | m- or p-fluoro |
| 10 | aminocyclohexyl | ethylamino | m- or p-fluoro |
| | aminocyclohexyl | diethylamino | m- or p-fluoro |
| | aminocyclohexyl | propylamino | m- or p-fluoro |
| | aminocyclohexyl | dipropylamino | m- or p-fluoro |
| | aminocyclohexyl | hydroxyethylamino | m- or p-fluoro |
| | aminocyclohexyl | 1-hydroxy-1,1-dimethylethyl | m- or p-fluoro |
| 15 | aminocyclohexyl | methoxyethylamino | m- or p-fluoro |
| | aminocyclohexyl | methyl | m- or p-chloro |
| | aminocyclohexyl | ethyl | m- or p-chloro |
| | aminocyclohexyl | amino | m- or p-chloro |
| | aminocyclohexyl | methylamino | m- or p-chloro |
| 20 | aminocyclohexyl | dimethylamino | m- or p-chloro |
| | aminocyclohexyl | ethylamino | m- or p-chloro |
| | aminocyclohexyl | diethylamino | m- or p-chloro |
| | aminocyclohexyl | propylamino | m- or p-chloro |
| | aminocyclohexyl | dipropylamino | m- or p-chloro |
| 25 | aminocyclohexyl | hydroxyethylamino | m- or p-chloro |
| | aminocyclohexyl | 1-hydroxy-1,1-dimethylethyl | m- or p-chloro |
| | aminocyclohexyl | methoxyethylamino | m- or p-chloro |
| | aminocyclohexyl | methyl | m- or p-methyl |
| | aminocyclohexyl | ethyl | m- or p-methyl |
| 30 | aminocyclohexyl | amino | m- or p-methyl |
| | aminocyclohexyl | methylamino | m- or p-methyl |
| | aminocyclohexyl | dimethylamino | m- or p-methyl |
| | aminocyclohexyl | ethylamino | m- or p-methyl |
| | aminocyclohexyl | diethylamino | m- or p-methyl |
| 35 | aminocyclohexyl | propylamino | m- or p-methyl |
| | aminocyclohexyl | dipropylamino | m- or p-methyl |
| | aminocyclohexyl | hydroxyethylamino | m- or p-methyl |
| | aminocyclohexyl | 1-hydroxy-1,1-dimethylethyl | m- or p-methyl |
| | aminocyclohexyl | methoxyethylamino | m- or p-methyl |

1006480-4004
T0602F-082F200F

Still other compounds of specific interest include those compounds of Table 3-3 modified as follows:

(1) The 4-piperidiny1 moiety is replaced with a 1-, 2- or 3-piperidiny1 moiety; and/or

(2) The 4-piperidiny1, 3-piperidiny1, 2-piperidiny1 or piperaziny1 ring is substituted at a nitrogen ring atom with methyl, ethyl, isopropyl, cyclopropyl, propargyl, benzyl, hydroxyethyl, methoxyethyl, or methoxyacetyl; and/or


(3) The 1-piperidiny1 ring is substituted at a carbon ring atom with methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, cyclopropylamino, propargylamino, benzylamino, hydroxyethylamino, methoxyethylamino, or

methoxyacetylamino; and/or

(4) The amino group of the aminocyclohexyl is replaced with methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, methoxyethylamino, or methoxyacetylamino; and/or

(5) A linking group selected from the group consisting of methylene, -S-, -O-, and -NH- separates the piperidiny1, piperaziny1 or cyclohexyl moiety from the pyrazole nucleus.


TABLE 3-4



| R ⁴ | R ³ | R ²⁰⁰ | R ²⁰¹ |
|----------------|----------------|------------------|------------------|
| 4-pyridyl | 4-methylphenyl | H | O |
| 4-pyridyl | 4-methylphenyl | CH ₃ | O |
| 4-pyrimidyl | 4-methylphenyl | H | O |
| 4-pyrimidyl | 4-methylphenyl | CH ₃ | O |
| 4-pyridyl | 4-methylphenyl | H | S |
| 4-pyridyl | 4-methylphenyl | CH ₃ | S |


| | | | | |
|----|-------------|----------------|-----------------|---|
| | 4-pyrimidyl | 4-methylphenyl | H | S |
| | 4-pyrimidyl | 4-methylphenyl | CH ₃ | S |
| | 4-pyridyl | 3-methylphenyl | H | O |
| | 4-pyridyl | 3-methylphenyl | CH ₃ | O |
| 5 | 4-pyrimidyl | 3-methylphenyl | H | O |
| | 4-pyrimidyl | 3-methylphenyl | CH ₃ | O |
| | 4-pyridyl | 3-methylphenyl | H | S |
| | 4-pyridyl | 3-methylphenyl | CH ₃ | S |
| | 4-pyrimidyl | 3-methylphenyl | H | S |
| 10 | 4-pyrimidyl | 3-methylphenyl | CH ₃ | S |

TABLE 3-5



| | R ⁴ | n | X |
|----|------------------------------|---|-------------------|
| 15 | 4-chlorophenyl | 1 | S |
| | 4-chlorophenyl | 2 | SO |
| | 4-chlorophenyl | 2 | SO ₂ |
| | 4-chlorophenyl | 2 | CH ₂ |
| | 4-chlorophenyl | 2 | CHCH ₃ |
| 20 | 4-chlorophenyl | 2 | CHOH |
| | 4-chlorophenyl | 1 | CH ₂ |
| | 4-chlorobenzyl | 2 | NCH ₃ |
| | 2-chlorophenyl | 2 | NCH ₃ |
| | 3,4-methylenedioxyphenyl | 2 | NCH ₃ |
| 25 | cyclohexyl | 2 | NCH ₃ |
| | 2-thienyl | 2 | NCH ₃ |
| | 5-chloro-2-thienyl | 2 | NCH ₃ |
| | 4-propynylphenyl | 2 | NCH ₃ |
| | 4-methylsulfoxylphenyl | 2 | NCH ₃ |
| 30 | 4-methylsulfonylphenyl | 2 | NCH ₃ |
| | 2-(1-methyl-5-chloro)indolyl | 2 | NCH ₃ |

TABLE 3-6



| R ⁴ | R ³ | R ⁴⁰⁰ |
|----------------|----------------|----------------------------------|
| p-Cl phenyl | 4-pyridyl | —SO ₂ CH ₃ |
| p-Cl phenyl | 4-pyridyl | —CH ₂ CN |
| p-Cl phenyl | 4-pyridyl | —CH ₂ — |
| p-Cl phenyl | | H |

5

BIOLOGICAL EVALUATION**p38 Kinase Assay**Cloning of human p38a:

The coding region of the human p38a cDNA was obtained by PCR-amplification from RNA isolated from the human monocyte cell line THP.1. First strand cDNA was synthesized from total RNA as follows: 2 μ g of RNA was annealed to 100 ng of random hexamer primers in a 10 μ l reaction by heating to 70 °C for 10 minutes followed by 2 minutes on ice. cDNA was then synthesized by adding 1 μ l of RNasin (Promega, Madison WI), 2 μ l of 50 mM dNTP's, 4 μ l of 5X buffer, 2 μ l of 100 mM DTT and 1 μ l (200 U) of Superscript II TM AMV reverse transcriptase. Random primer, dNTP's and Superscript TM reagents were all purchased from Life-Technologies, Gaithersburg, MA. The reaction was incubated at 42 °C for 1 hour. Amplification of p38 cDNA was performed by aliquoting 5 μ l of the reverse transcriptase reaction into a 100 μ l

PCR reaction containing the following: 80 μ l dH₂O, 2 μ l 50 mM dNTP's, 1 μ l each of forward and reverse primers (50 pmol/ μ l), 10 μ l of 10X buffer and 1 μ l ExpandTM polymerase (Boehringer Mannheim). The PCR primers incorporated Bam HI sites onto the 5' and 3' end of the amplified fragment, and were purchased from Genosys. The sequences of the forward and reverse primers were 5'-GATCGAGGATTCATGTCTCAGGAGAGGCCCA-3' and 5'-GATCGAGGATTCTCAGGACTCCATCTCTTC-3' respectively. The PCR amplification was carried out in a DNA Thermal Cycler (Perkin Elmer) by repeating 30 cycles of 94 °C for 1 minute, 60 °C for 1 minute and 68 °C for 2 minutes. After amplification, excess primers and unincorporated dNTP's were removed from the amplified fragment with a WizardTM PCR prep (Promega) and digested with Bam HI (New England Biolabs). The Bam HI digested fragment was ligated into BamHI digested pGEX 2T plasmid DNA (PharmaciaBiotech) using T-4 DNA ligase (New England Biolabs) as described by T. Maniatis, *Molecular Cloning: A Laboratory Manual*, 2nd ed. (1989). The ligation reaction was transformed into chemically competent *E. coli* DH10B cells purchased from Life-Technologies following the manufacturer's instructions. Plasmid DNA was isolated from the resulting bacterial colonies using a Promega WizardTM miniprep kit. Plasmids containing the appropriate Bam HI fragment were sequenced in a DNA Thermal Cycler (Perkin Elmer) with PrismTM (Applied Biosystems Inc.). cDNA clones were identified that coded for both human p38a isoforms (Lee et al. Nature 372, 739). One of the clones which contained the cDNA for p38a-2 (CSBP-2) inserted in the cloning site of pGEX 2T, 3' of the GST coding region was designated pMON 35802. The sequence obtained for this clone is an exact match of the cDNA clone reported by Lee et al. This expression plasmid allows for the production of a GST-p38a fusion protein.

Expression of human p38a:

GST/p38a fusion protein was expressed from the plasmid pMON 35802 in *E. coli*, strain DH10B (Life Technologies, Gibco-BRL). Overnight cultures were grown in Luria Broth (LB) containing 100 mg/ml ampicillin. The next day, 500 ml of fresh LB was inoculated with 10 ml of overnight culture, and grown in a 2 liter flask at 37 °C with constant shaking until the culture reached an absorbance of 0.8 at 600 nm. Expression of the fusion protein was induced by addition of isopropyl b-D-thiogalactoside (IPTG) to a final concentration of 0.05 mM. The cultures were shaken for three hours at room temperature, and the cells were harvested by centrifugation. The cell pellets were stored frozen until protein purification.

Purification of p38 Kinase- α :

All chemicals were from Sigma Chemical Co. unless noted. Twenty grams of *E. coli* cell pellet collected from five 1 L shake flask fermentations was resuspended in a volume of PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.3) up to 200 ml. The cell suspension was adjusted to 5 mM DTT with 2 M DTT and then split equally into five 50 ml Falcon conical tubes. The cells were sonicated (Ultrasonics model W375) with a 1 cm probe for 3 X 1 minutes (pulsed) on ice. Lysed cell material was removed by centrifugation (12,000 x g, 15 minutes) and the clarified supernatant applied to glutathione-sepharose resin (Pharmacia).

Glutathione-Sephadex Affinity Chromatography:

Twelve ml of a 50% glutathione sepharose-PBS suspension was added to 200 ml clarified supernatant and incubated batchwise for 30 minutes at room temperature. The resin was collected by centrifugation (600 x g, 5 min) and washed with 2 x 150 ml PBS/1% Triton X-100,

followed by 4 x 40 ml PBS. To cleave the p38 kinase from the GST-p38 fusion protein, the glutathione-sepharose resin was resuspended in 6 ml PBS containing 250 units thrombin protease (Pharmacia, specific activity > 7500 units/mg) and mixed gently for 4 hours at room temperature. The glutathione-sepharose resin was removed by centrifugation (600 x g, 5 min) and washed 2 x 6 ml with PBS. The PBS wash fractions and digest supernatant containing p38 kinase protein were pooled and adjusted to 0.3 mM PMSF.

Mono Q Anion Exchange Chromatography:

The thrombin-cleaved p38 kinase was further purified by FPLC-anion exchange chromatography. Thrombin-cleaved sample was diluted 2-fold with Buffer A (25 mM HEPES, pH 7.5, 25 mM beta-glycerophosphate, 2 mM DTT, 5% glycerol) and injected onto a Mono Q HR 10/10 (Pharmacia) anion exchange column equilibrated with Buffer A. The column was eluted with a 160 ml 0.1 M-0.6 M NaCl/Buffer A gradient (2 ml/minute flowrate). The p38 kinase peak eluting at 200 mM NaCl was collected and concentrated to 3-4 ml with a Filtron 10 concentrator (Filtron Corp.).

Sephacryl S100 Gel Filtration Chromatography:

The concentrated Mono Q- p38 kinase purified sample was purified by gel filtration chromatography (Pharmacia HiPrep 26/60 Sephacryl S100 column equilibrated with Buffer B (50 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM DTT, 5% glycerol)). Protein was eluted from the column with Buffer B at a 0.5 ml/minute flowrate and protein was detected by absorbance at 280 nm. Fractions containing p38 kinase (detected by SDS-polyacrylamide gel electrophoresis) were pooled and frozen at -80 °C. Typical purified protein yields from 5 L *E. coli* shake flasks fermentations were 35 mg p38 kinase.

4002130-10704

In Vitro Assay

The ability of compounds to inhibit human p38 kinase alpha was evaluated using two in vitro assay methods. In the first method, activated human p38 kinase alpha phosphorylates a biotinylated substrate, PHAS-I (phosphorylated heat and acid stable protein-insulin inducible), in the presence of gamma ^{32}P -ATP (^{32}P -ATP). PHAS-I was biotinylated prior to the assay and provides a means of capturing the substrate which is phosphorylated during the assay. p38 Kinase was activated by MKK6. Compounds were tested in 10 fold serial dilutions over the range of 100 μM to 0.001 μM using 1% DMSO. Each concentration of inhibitor was tested in triplicate.

All reactions were carried out in 96 well polypropylene plates. Each reaction well contained 25 mM HEPES pH 7.5, 10 mM magnesium acetate and 50 μM unlabeled ATP. Activation of p38 was required to achieve sufficient signal in the assay. Biotinylated PHAS-I was used at 1-2 μg per 50 μl reaction volume, with a final concentration of 1.5 μM . Activated human p38 kinase alpha was used at 1 μg per 50 μl reaction volume representing a final concentration of 0.3 μM . Gamma ^{32}P -ATP was used to follow the phosphorylation of PHAS-I. ^{32}P -ATP has a specific activity of 3000 Ci/mmol and was used at 1.2 μCi per 50 μl reaction volume. The reaction proceeded either for one hour or overnight at 30 $^{\circ}\text{C}$.

Following incubation, 20 μl of reaction mixture was transferred to a high capacity streptavidin coated filter plate (SAM-streptavidin-matrix, Promega) prewetted with phosphate buffered saline. The transferred reaction mix was allowed to contact the streptavidin membrane of the Promega plate for 1-2 minutes. Following capture of biotinylated PHAS-I with ^{32}P incorporated, each well was washed to remove unincorporated ^{32}P -ATP three times with 2M NaCl, three washes of 2M NaCl with 1% phosphoric, three washes of distilled water and finally a single wash

of 95% ethanol. Filter plates were air dried and 20 μ l of scintillant was added. The plates were sealed and counted. Results are shown in Table 4.

A second assay format was also employed that is based on p38 kinase alpha induced phosphorylation of EGFRP (epidermal growth factor receptor peptide, a 21 mer) in the presence of ^{33}P -ATP. Compounds were tested in 10 fold serial dilutions over the range of 100 μ M to 0.001 μ M in 10% DMSO. Each concentration of inhibitor was tested in triplicate. Compounds were evaluated in 50 μ l reaction volumes in the presence of 25 mM Hepes pH 7.5, 10 mM magnesium acetate, 4% glycerol, 0.4% bovine serum albumin, 0.4mM DTT, 50 μ M unlabeled ATP, 25 μ g EGFRP (200 μ M), and 0.05 uCi gamma ^{33}P -ATP. Reactions were initiated by addition of 0.09 μ g of activated, purified human GST-p38 kinase alpha. Activation was carried out using GST-MKK6 (5:1,p38:MKK6) for one hour at 30 $^{\circ}\text{C}$ in the presence of 50 μ M ATP. Following incubation for 60 minutes at room temperature, the reaction was stopped by addition of 150 μ l of AG 1X8 resin in 900 mM sodium formate buffer, pH 3.0 (1 volume resin to 2 volumes buffer). The mixture was mixed three times with pipetting and the resin was allowed to settle. A total of 50 μ l of clarified solution head volume was transferred from the reaction wells to Microlite-2 plates. 150 μ l of Microscint 40 was then added to each well of the Microlite plate, and the plate was sealed, mixed, and counted.

TABLE 4

| Example | p38 kinase IC50 (μ M) |
|---------|-------------------------------|
| 1 | 4.6 |
| 2 | 1.5 |
| 8 | <0.1 |
| 16 | 3.8 |
| 23 | 1.5 |
| 25 | 2.6 |
| 26 | 0.7 |

| | | |
|----|-----|------|
| | 28 | 0.3 |
| | 33 | 2.5 |
| | 34 | 8.0 |
| | 36 | 12.1 |
| 5 | 38 | 0.8 |
| | 39 | 1.1 |
| | 40 | 1.3 |
| | 42 | 0.3 |
| | 43 | <0.1 |
| 10 | 44 | <0.1 |
| | 45 | <0.1 |
| | 46 | <0.1 |
| | 47 | 3.2 |
| | 48 | 1.8 |
| 15 | 50 | 2.3 |
| | 51 | <0.1 |
| | 52 | 0.1 |
| | 53 | 0.9 |
| | 54 | 0.7 |
| 20 | 55 | 6.4 |
| | 143 | <0.1 |

TNF Cell Assays

25 Method of Isolation of Human Peripheral Blood Mononuclear Cells:

Human whole blood was collected in Vacutainer tubes containing EDTA as an anticoagulant. A blood sample (7 ml) was carefully layered over 5 ml PMN Cell Isolation Medium (Robbins Scientific) in a 15 ml round bottom centrifuge tube. The sample was centrifuged at 450-500 x g for 30-35 minutes in a swing out rotor at room temperature. After centrifugation, the top band of cells were removed and washed 3 times with PBS w/o calcium or magnesium. The cells were centrifuged at 400 x g for 10 minutes at room temperature. The cells were resuspended in Macrophage Serum Free Medium (Gibco BRL) at a concentration of 2 million cells/ml.

40 LPS Stimulation of Human PBMs:

PBM cells (0.1 ml, 2 million/ ml) were co-incubated with 0.1 ml compound (10-0.41 μ M, final concentration) for 1 hour in flat bottom 96 well microtiter plates.

400430-1204
T0202T 081200T

Compounds were dissolved in DMSO initially and diluted in TCM for a final concentration of 0.1% DMSO. LPS (Calbiochem, 20 ng/ml, final concentration) was then added at a volume of 0.010 ml. Cultures were incubated overnight at 37 °C. Supernatants were then removed and tested by ELISA for TNF-a and IL1-b. Viability was analyzed using MTS. After 0.1 ml supernatant was collected, 0.020 ml MTS was added to remaining 0.1 ml cells. The cells were incubated at 37 °C for 2-4 hours, then the O.D. was measured at 490-650 nM.

Maintenance and Differentiation of the U937 Human Histiocytic Lymphoma Cell Line:

U937 cells (ATCC) were propagated in RPMI 1640 containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine (Gibco). Fifty million cells in 100 ml media were induced to terminal monocytic differentiation by 24 hour incubation with 20 ng/ml phorbol 12-myristate 13-acetate (Sigma). The cells were washed by centrifugation (200 x g for 5 min) and resuspended in 100 ml fresh medium. After 24-48 hours, the cells were harvested, centrifuged, and resuspended in culture medium at 2 million cells/ml.

LPS Stimulation of TNF production by U937 Cells:

U937 cells (0.1 ml, 2 million/ml) were incubated with 0.1 ml compound (0.004-50 µM, final concentration) for 1 hour in 96 well microtiter plates. Compounds were prepared as 10 mM stock solutions in DMSO and diluted in culture medium to yield a final DMSO concentration of 0.1% in the cell assay. LPS (E coli, 100 ng/ml final concentration) was then added at a volume of 0.02 ml. After 4 hour incubation at 37°C, the amount of TNF-α released in the culture medium was quantitated by ELISA. Inhibitory potency is expressed as IC50 (µM). Results of these TNF Cell Assays are shown in Table 5.

1002430-100704
1002430-100704

TNF Inhibition: Human Whole Blood Assay

Human peripheral blood is obtained in heparinized tubes. A 190 μ L aliquot of blood is placed in each well of a 96 well u-bottom plate. A compound or control
5 vehicle (phosphate buffered saline with dimethylsulfoxide and ethanol) is added to the blood in 10 μ L aliquots for serial dilutions providing final concentrations of 25, 5, 1 and 0.25 μ M. The final dimethylsulfoxide and ethanol concentrations are 0.1% and 1.5%, respectively. After
10 one hour of incubation at 37 °C, 10 mL of lipopolysaccharide (*Salmonella typhosa*, Sigma) in phosphate buffered saline is added resulting in a final concentration of 10 mg/mL. After four to five hours of incubation at 37 °C, the supernatants are harvested and
15 assayed at 1:10 or 1:20 dilutions for human TNF using ELISA.

FOI b7E b7F b7G b7H b7I b7J b7K b7L b7M b7N b7O b7P b7Q b7R b7S b7T b7U b7V b7W b7X b7Y b7Z

TABLE 5

| | Example | Human PBM Assay | U937 Cell Assay |
|----|---------|-----------------|-----------------|
| | | IC50 (μ M) | IC50 (μ M) |
| 5 | 1 | 0.5 | |
| | 2 | 1.6 | 0.578 |
| | 4 | 0.1 | 0.222 |
| | 5 | | 0.274 |
| | 7 | 0.2 | 0.201 |
| 10 | 8 | <0.1 | |
| | 9 | 0.4 | |
| | 10 | 0.7 | 1.687 |
| | 12 | 8.5 | |
| | 13 | 4.8 | |
| 15 | 14 | 1.2 | |
| | 17 | 1.1 | |
| | 19 | 0.3 | 0.484 |
| | 20 | | 1.089 |
| | 21 | | 0.077 |
| 20 | 22 | 3.2 | |
| | 24 | 8.2 | |
| | 26 | <0.1 | 0.029 |
| | 27 | 2.7 | |
| | 28 | 0.1 | |
| 25 | 29 | 2.2 | |
| | 30 | 2.6 | |
| | 31 | 0.8 | 1.053 |
| | 32 | | 2.696 |
| | 33 | 0.4 | |
| 30 | 34 | 0.5 | |
| | 35 | 0.7 | |
| | 36 | 1.4 | |
| | 37 | 1.5 | 0.099 |
| | 38 | 0.2 | 0.208 |
| 35 | 39 | 0.7 | 0.244 |
| | 40 | 0.4 | |
| | 41 | 1.0 | |
| | 42 | 0.7 | |
| | 43 | <0.1 | 0.243 |
| 40 | 44 | 0.4 | 0.477 |
| | 45 | <0.1 | 0.04 |
| | 46 | | 0.329 |
| | 47 | | 2.359 |
| | 48 | 2.2 | 0.522 |
| 45 | 49 | 6.8 | |
| | 50 | 0.9 | |
| | 51 | | 0.074 |
| | 54 | 0.2 | 0.13 |
| | 55 | <0.1 | 0.228 |
| | 143 | | 0.301 |

400480-120701

Rat Assay

The efficacy of the novel compounds in blocking the production of TNF also was evaluated using a model based on rats challenged with LPS. Male Harlan Lewis rats [Sprague Dawley Co.] were used in this model. Each rat weighed approximately 300 g and was fasted overnight prior to testing. Compound administration was typically by oral gavage (although intraperitoneal, subcutaneous and intravenous administration were also used in a few instances) 1 to 24 hours prior to the LPS challenge. Rats were administered 30 μ g/kg LPS [salmonella typhosa, Sigma Co.] intravenously via the tail vein. Blood was collected via heart puncture 1 hour after the LPS challenge. Serum samples were stored at -20 °C until quantitative analysis of TNF- α by Enzyme Linked-Immuno-Sorbent Assay ("ELISA") [Biosource]. Additional details of the assay are set forth in Perretti, M., et al., Br. J. Pharmacol. (1993), 110, 868-874, which is incorporated by reference in this application.

Mouse Assay

Mouse Model Of LPS-Induced TNF Alpha Production:

TNF alpha was induced in 10-12 week old BALB/c female mice by tail vein injection with 100 ng lipopolysaccharide (from S. Typhosa) in 0.2 ml saline. One hour later mice were bled from the retroorbital sinus and TNF concentrations in serum from clotted blood were quantified by ELISA. Typically, peak levels of serum TNF ranged from 2-6 ng/ml one hour after LPS injection.

The compounds tested were administered to fasted mice by oral gavage as a suspension in 0.2 ml of 0.5% methylcellulose and 0.025% Tween 20 in water at 1 hour or 6 hours prior to LPS injection. The 1 hour protocol allowed evaluation of compound potency at Cmax plasma levels whereas the 6 hour protocol allowed estimation of

compound duration of action. Efficacy was determined at each time point as percent inhibition of serum TNF levels relative to LPS injected mice that received vehicle only.

- Additional results obtained using the above-
- 5 described assays are set forth in Table 6 below. p38 assay and U937 cell assay results are expressed as IC_{50} (μ m). Mouse-LPS assay results are expressed as percent inhibition.

400430-10001

500
TABLE 6

| Example | p38 ¹ | p38 ² | U937 | mLPS | mLPS | mLPS |
|---------|------------------|------------------|--------|------|---------|-----------|
| | | | | 8h | 6h dose | 1h, 30mpk |
| A-212 | 0.49 | 0.74 | 0.0967 | 20 | 10 | 93 |
| A-208 | 0.104 | 0.049 | 0.1896 | 98 | 30 | 97 |
| A-227 | | 0.06 | | | | 96 |
| A-228 | 0.76 | 0.339 | 0.4173 | 32 | 30 | 92 |
| A-229 | | 1.4 | 0.4622 | 76 | | 91 |
| A-230 | 0.42 | 0.178 | | | | 96 |
| A-231 | | 0.174 | 0.3225 | 86 | 30 | 94 |
| A-232 | | 0.048 | | | | 96 |
| A-233 | | 0.044 | | | | 53 |
| A-234 | | 0.103 | | | | |
| A-235 | | 0.104 | | | | 56 |
| A-236 | | 0.237 | | | | 94 |
| A-237 | | 0.093 | 0.087 | | | 60 |
| A-238 | | 0.177 | 0.4016 | | | |
| A-239 | | 0.034 | | 51 | 30 | 87 |
| A-240 | | 0.961 | | 78 | 30 | 85 |
| A-241 | | 0.338 | | 79 | 30 | 87 |
| A-242 | | 0.047 | | 95 | 30 | 87 |
| A-243 | | 0.729 | | | | 82 |
| A-244 | | 0.099 | | | | |
| A-245 | | <.001 | 0.0337 | | | 65 |
| A-246 | 0.403 | 0.592 | 0.4952 | | | |
| A-247 | | <0.01 | 0.166 | | | |
| A-249 | | 0.432 | | 73 | 30 | 86 |
| A-250 | | 2.873 | | | | |
| A-251 | | 0.637 | | 32 | | 87 |
| A-252 | | 0.774 | 1.197 | 48 | 30 | 75 |
| A-253 | | <.001 | 0.0044 | | | 61 |
| A-254 | | 0.081 | 0.1411 | | | |
| A-215 | | 2.34 | 0.2976 | 38 | 30 | 80 |
| A-256 | | 0.813 | 0.4562 | | | |
| A-257 | 1.081 | <.01 | 0.5167 | | | |
| A-213 | | 0.22 | | | | 57 |
| A-258 | | 0.48 | 1.2083 | | | 68 |
| A-259 | | 0.17 | 0.7574 | | | 62 |
| A-210 | 0.16 | | 0.1983 | 85 | 30 | 93 |
| A-260 | | 0.23 | 1.2821 | 47 | 30 | 79 |
| A-214 | | 0.06 | 1.4006 | | | 70 |
| A-261 | | 0.008 | 0.2542 | 48 | 30 | 92 |
| A-216 | | 0.018 | 1.8287 | 27 | 30 | 91 |
| A-262 | | <0.1 | 0.3267 | | | 45 |
| A-263 | <0.01 | <0.1 | 0.5434 | | | 49 |

FOUO 034200

| Example | p38 ¹ | p38 ² | U937 | mLPS | mLPS | mLPS |
|---------|------------------|------------------|--------|------|---------|-----------|
| | | | | 8h | 6h dose | 1h, 30mpk |
| A-264 | | | 0.2594 | | | 61 |
| A-265 | | <0.1 | 0.6016 | | | 32 |
| A-266 | | | 0.5393 | | | 0 |
| A-267 | | 0.43 | 2.6681 | | | 80 |
| A-268 | | <0.01 | 0.0074 | | | 11 |
| A-217 | 0.697 | | 0.3486 | | | 9 |
| A-269 | | | >10 uM | | | 51 |
| A-270 | | 0.015 | 0.3466 | | | 53 |
| A-271 | | 0.216 | 4.2144 | | | 68 |
| A-272 | 0.073 | | 0.583 | | | -8 |
| A-273 | 6.98 | | >10 | | | 43 |
| A-274 | <0.1 | | 0.92 | 21 | 30 | |
| A-275 | 10.14 2 | | >10 | | | |
| A-276 | 0.176 | | 0.45 | -24 | 30 | |
| A-277 | 0.026 | | | 33 | 30 | |
| A-278 | 0.285 | | 2.3 | 62 | 30 | |
| A-279 | 0.005 | | 0.7 | 64 | 30 | |
| A-280 | 0.134 | | | 15 | 30 | |
| A-281 | 0.053 | | | 22 | 30 | |
| A-218 | 0.044 | | | 18 | 30 | |
| A-282 | 0.045 | | 0.0973 | 30 | 30 | |
| A-283 | <0.1 | | 0.7998 | -20 | 30 | |
| A-284 | 0.98 | | 0.5088 | -1 | | |
| A-285 | <0.1 | | 0.1795 | 11 | 30 | |
| A-286 | 0.057 | | 0.09 | 29 | 30 | |
| A-287 | 0.041 | | 0.27 | -24 | 30 | |
| A-288 | 0.017 | | 0.3 | 40 | 30 | |
| A-289 | <0.1 | | 0.14 | 44 | 30 | |
| A-290 | | | 6.0191 | 4 | 30 | |
| A-291 | 0.388 | | 1.1309 | 36 | 30 | |
| A-292 | 1.15 | | >10 | | | |
| A-293 | 0.73 | | | | | |
| A-294 | 0.015 | | 0.5 | 61 | 30 | |
| A-295 | 7.66 | | >10 | 94 | 30 | |
| A-296 | 26 | | | | | |
| A-297 | 0.52 | | 0.17 | 89 | 30 | |

¹ p38 α in vitro assay results based on PHAS-I assay procedure

² p38 α in vitro assay results based on EGFRP assay procedure

1002130 120704
FOI 08/22/2004

Induction And Assessment Of Collagen-Induced Arthritis In Mice:

Arthritis was induced in mice according to the procedure set forth in J.M. Stuart, Collagen Autoimmune Arthritis, Annual Rev. Immunol. 2:199 (1984), which is incorporated herein by reference. Specifically, arthritis was induced in 8-12 week old DBA/1 male mice by injection of 50 μ g of chick type II collagen (CII) (provided by Dr. Marie Griffiths, Univ. of Utah, Salt Lake City, UT) in complete Freund's adjuvant (Sigma) on day 0 at the base of the tail. Injection volume was 100 μ l. Animals were boosted on day 21 with 50 μ g of CII in incomplete Freund's adjuvant (100 μ l volume). Animals were evaluated several times each week for signs of arthritis. Any animal with paw redness or swelling was counted as arthritic. Scoring of arthritic paws was conducted in accordance with the procedure set forth in Wooley et al., Genetic Control of Type II Collagen Induced Arthritis in Mice: Factors Influencing Disease Susceptibility and Evidence for Multiple MHC Associated Gene Control., Trans. Proc., 15:180 (1983). Scoring of severity was carried out using a score of 1-3 for each paw (maximal score of 12/mouse). Animals displaying any redness or swelling of digits or the paw were scored as 1. Gross swelling of the whole paw or deformity was scored as 2. Ankylosis of joints was scored as 3. Animals were evaluated for 8 weeks. 8-10 animals per group were used.

Preparation And Administration Of Compounds:

The compounds tested on mice having collagen-induced arthritis were prepared as a suspension in 0.5% methylcellulose (Sigma, St. Louis, MO), 0.025% Tween 20 (Sigma). The compound suspensions were administered by oral gavage in a volume of 0.1 ml b.i.d. Administration began on day 20 post collagen injection and continued

400480-10001

daily until final evaluation on day 56. Scoring of arthritic paws was conducted as set forth above. Assay results are set forth in Table 7.

5

TABLE 7

| <u>Compound</u> | <u>% Inhibition of Arthritis</u> |
|-----------------|----------------------------------|
| A-210 | 58.5 @ 15 mpk |
| A-172 | 49.3 @ 100 mpk |
| A-189 | 51.6 @ 30 mpk |
| 10 A-208 | 97.5 @ 60 mpk |
| A-208 | 75.0 @ 60 mpk |

Additional results for selected compounds obtained using the above-described assays are set forth in Tables 8, 9 and 10 below:

15

TABLE 8

| <u>Example</u> | <u>Rat LPS Assay % Inhibition (Dose in mg/kg)</u> | <u>TNF Inhibition-Human Whole Blood Assay (μM)</u> | <u>p38α Kinase Assay IC₅₀ in μM (% DMSO)</u> |
|------------------|---|---|--|
| A-313, Step 1 | | | 1.34 (1) |
| A-313, Step 3 | 96.0 (20.0) | 0.12 | 0.036 (1) 0.37 (10) |
| 20 A-314, Step 1 | | | 0.85 (1) 0.37 (10) |
| A-314, Step 2 | 0 (1.0) 53.0 (5.0) 85.0 (20.0) | 0.47 | 0.032 (10) |
| A-315 | | 1.75 | 0.049 (10) |
| A-317 | 58.0 (3.0) 10.0 (3.0) 69.0 (10.0) | 0.45 | 0.07 (10) 0.11 (10) |
| 25 A-318 | 54.0 (3.0) | 0.167 | 0.29 (1) 0.58 (10) 0.37 (10) 0.6 (10) |
| A-319 | 62.0 (3.0) | >25.0 | 6.06 (1) 0.13 (10) |

T0202T-084T200T

| | | | | |
|----|--|---|-------|--|
| 5 | A-320 | 1.0 (3.0) | | 0.27 (1) 0.05 (10) 0.15 (10) |
| | A-321 (dihydrate) | | >25.0 | 0.77 (1) |
| | A-321 (monosodium salt dihydrate) | 14.0 (3.0) | | |
| | A-322 | 51.5 (3.0) | 4.2 | 0.15 (10) 0.25 (10) |
| | A-323 | 40.0 (30.0) 54.0 (30.0) | | 0.39 (10) |
| 10 | A-324 | 44.0 (3.0) | | 0.08 (10) |
| | A-325 | 25.0 (3.0) 11.0 (30.0) | 0.057 | 0.021 (1) <0.1 (10) |
| | A-326 | 0 (10.0) | >25.0 | 0.97 (10) |
| | A-327 | 83.0 (20.0) | 0.18 | 0.15 (10) |
| | A-328 | | | 0.012 (1) |
| 15 | A-331 | 13.0 (20.0) | | >100 (1) 0.64 (10) |
| | A-332 | 33.0 (1.0) 26.0 (3.0) 25.0 (5.0) -85.0 (10.0) | 0.45 | 0.04 (1) 0.04 (10) 0.015 (10) <0.1 (10) |
| | A-333 | 69.0 (5.0) | 0.585 | 0.052 (10) |
| | A-334 | 95.0 (20.0) 57.0 (5.0) 36.0 (1.0) | 0.22 | 0.07 (10) |
| | A-335 | | >25.0 | 89.9 (10) |
| 20 | A-336 | | | 1.16 (10) |
| | A-337 | | >25.0 | 1.35 (10) |
| | A-338 | | 0.059 | 0.018 (10) |
| | A-339 | | 0.056 | 0.052 (10) |
| | A-342 | 98.0 (20.0) | 0.31 | 0.012 (10) |
| 25 | A-343 | 96.0 (20.0) | | 0.016 (10) |

104031 034200

TABLE 9

| Example | Rat LPS Assay % Inhibition (Dose in mg/kg) | TNF Inhibition- Human Whole Blood Assay (μ M) | p38 α Kinase Assay IC ₅₀ in μ M (10% DMSO) |
|---------|--|--|---|
| A-350 | 65 (20) | | |
| A-351 | 0 (20) | 0.49 | 0.27 |
| A-352 | 36 (20) | 9.8 | 0.13 |
| A-353 | 49 (20) | 5.3 | 0.037 |
| A-354 | 0 (20) | 25 | 0.22 |
| A-355 | 0 (20) | 0.095 | 0.05 |
| A-356 | 73 (20) | 5.3 | <0.01 |
| A-357 | 74 (20) | 0.25 | 0.12 |
| A-358 | 71 (20) | 4 | 0.23 |
| A-359 | 70 (20) | 1 | 0.3 |
| A-360 | 95 (20) 14 (5) 0 (1) | 0.5 | 0.06 |
| A-361 | 9 (20) | 1 | |
| A-362 | 0 (20) | 5.5 | 0.69 |
| A-363 | 6 (20) | 25 | 1.5 |
| A-364 | 79 (20) | 0.255 | 0.49 |
| A-365 | 95 (20) 50 (5) 12 (1) | 0.057 | 0.032 |
| A-366 | 92 (20) DR: 6 (1) 45 (5) 97 (20) | 0.29 | 0.041 0.06 0.04 |
| A-368 | 88 (20) DR: 28 (1) 41 (5) 97 (20) | 0.66 | 0.042 |
| A-369 | 94 (20) 52 (5) | 0.84 | 0.019 0.011 0.0027 |
| A-370 | 90 (20) 46 (5) | 1.92 | 0.16 |

| | | | | |
|----|-------|--|------|-----------------|
| 5 | A-371 | 52 (20) | 25 | 7.9 |
| | A-372 | 56 (20) | 21 | 0.53 |
| | A-374 | 88 (20) 0 (5) 3 (1) | 0.31 | 0.38 |
| | A-375 | 43 (20) | 28% | 2.3 |
| | A-376 | 24 (20) | 1 | 0.032 |
| 10 | A-377 | 84 (20) DR: 32 (1) 67 (5) 96 (20) | 0.67 | 0.004 0.0019 |
| | A-378 | 73 (10) | 49% | 6.2 |
| | A-379 | 61 (10) | 44% | 0.19 |
| | A-380 | 85 (30) 62 (10) 33 (3) | 32% | 0.85 |
| | A-385 | | | 0.18 1.25 |
| 15 | A-386 | 91 (20) | 0.16 | 0.016 |
| | A-387 | 83 (20) | 0.11 | 0.005 |
| | A-388 | 97 (20) 67 (5) | 0.34 | 0.21 |
| | | | | |

TABLE 10

| Example | Rat LPS Assay % Inhibition (Dose in mg/kg @ 4.0 hours) | TNF Inhibition- Human Whole Blood Assay (μ M) | p38 α Kinase Assay IC ₅₀ (μ M) (10% DMSO; @ 1.0 hour) |
|---------|---|--|--|
| 20 | | | |
| | A-389, Step 4 | 55.0 (5.0) 94.0 (20.0) | 0.16 |
| | A-389, Step 1 | | 1.72 |
| 25 | A-390 | >25.0 | 15.1 |
| | A-391 | 53.0 (20.0) | >25.0 4.83 |

| | | | | |
|----|-------|---------------------------|-------|-------|
| 5 | A-392 | | | 29.7 |
| | A-393 | | | 2.32 |
| | A-394 | | | 9.11 |
| | A-395 | | | >100 |
| | A-397 | | | 30.0 |
| 10 | A-398 | | >25.0 | 45.6 |
| | A-399 | | | 22.9 |
| | A-400 | | >25.0 | 4.77 |
| | A-401 | | | 21.2 |
| | A-402 | | | 28.9 |
| 15 | A-403 | | >25.0 | 4.89 |
| | A-404 | | >25.0 | 4.13 |
| | A-405 | | >25.0 | 4.85 |
| | A-406 | | >25.0 | 7.24 |
| | A-407 | 21.0 (5.0) 82.0 (20.0) | 3.86 | 0.18 |
| 20 | A-408 | 20.0 (5.0) 49.0 (20.0) | 11.7 | 5.59 |
| | A-409 | 41.0 (5.0) 89.0 (20.0) | 5.27 | 0.21 |
| | A-410 | 11.0 (5.0) 0 (20.0) | | 0.21 |
| | A-411 | 40.0 (5.0) 0 (20.0) | | 3.37 |
| | A-412 | 0 (5.0) 0 (20.0) | | 2.15 |
| 25 | A-413 | 45.0 (5.0) 85.0 (20.0) | 6.51 | 0.91 |
| | A-414 | 3.0 (5.0) 14.0 (20.0) | 11.2 | 9.51 |
| | A-415 | 17.0 (5.0) 84.0 (84.0) | | 0.51 |
| | A-416 | | 5.07 | 0.041 |
| | A-417 | 40.0 (5.0) 70.0 (20.0) | 12.0 | 0.19 |
| | A-418 | | | 0.12 |

| | | | | |
|----|-------|---|-------|-------|
| 5 | A-419 | 24.0 (5.0) 58.0 (10.0) | | 1.31 |
| | A-420 | 47.0 (5.0) 91.0 (20.0) | | 0.32 |
| | A-427 | 56.0 (5.0) 77.0 (20.0) | 24.1 | 0.19 |
| | A-428 | | 0.68 | 0.4 |
| | A-429 | | | 56.3 |
| 10 | A-430 | | | >100 |
| | A-434 | | | 5.84 |
| | A-435 | 10.0 (1.0) 0 (5.0) 14.0 (20.0) | >25.0 | 0.35 |
| | A-436 | | 4.61 | 2.81 |
| | A-437 | | >25.0 | 7.76 |
| 15 | A-438 | 49.0 (20.0) | >25.0 | 0.56 |
| | A-439 | 58.0 (5.0) 93.0 (20.0) | 5.63 | 0.15 |
| | A-440 | | | |
| | A-441 | 14.0 (5.0) 62.0 (20.0) | >25.0 | 1.21 |
| | A-442 | 51.0 (1.0) 56.0 (5.0) 92.0 (20.0) | 0.16 | 0.022 |
| 20 | A-443 | | 4.89 | 0.47 |
| | A-444 | | | 6.99 |
| | A-445 | | >25.0 | 1.08 |
| | A-446 | | 3.38 | 0.9 |
| | A-447 | | >25.0 | 0.77 |
| 25 | A-448 | 73.0 (5.0) 97.0 (20.0) | 0.12 | 0.084 |
| | A-449 | | | 59.0 |
| | A-450 | | | >100 |
| | A-451 | | 15.0 | 0.078 |
| | A-452 | | 0.24 | 2.87 |
| | A-454 | | | 8.41 |

FOOTING - 08'x20'

| | | | | |
|----|--------------|---|-------|-------|
| 5 | A-453 | | | 10.2 |
| | A-455 | | | 12.9 |
| | A-456 | 36.0 (1.0) 48.0 (5.0) 53.0 (20.0) | 0.98 | 0.12 |
| | A-457 | | >25.0 | 0.4 |
| | A-458 | | >25.0 | 8.7 |
| 10 | A-459 | 0 (1.0) 54.0 (5.0) 80.0 (20.0) | 0.26 | 0.027 |
| | A-459 (salt) | | 0.28 | 0.1 |
| | A-460 | | 8.91 | 1.84 |
| | A-461 | | | 30.6 |
| | A-462 | | >25.0 | 1.66 |
| 15 | A-463 | | >25.0 | 1.66 |
| | A-464 | | | >100 |
| | A-465 | | | >100 |
| | A-466 | | | 20.1 |
| | A-467 | | | 21.4 |
| 20 | A-468 | 46.0 (1.0) 50.0 (5.0) 94.0 (20.0) | | 0.3 |
| | A-469 | 51.0 (5.0) 68.0 (20.0) | 7.17 | 0.095 |
| | A-470 | | | 10.4 |
| | A-471 | | | 4.92 |
| | A-472 | | >25.0 | 0.39 |
| 25 | A-473 | 58.0 (20.0) | 0.56 | 0.17 |
| | A-474 | 59.0 (20.0) | 1.47 | 0.11 |
| | A-475 | | 5.11 | 0.28 |
| | A-476 | 35.0 (20.0) | 0.97 | 1.01 |
| | A-477 | | | 0.34 |
| | A-478 | | 0.49 | 0.18 |
| | A-479 | | 2.97 | 0.072 |
| | A-480 | | 0.16 | 0.11 |

FOOTNOTES: 08-1-2007

| | | | |
|-------|-------------|-------|------|
| A-481 | | >25.0 | 0.2 |
| A-482 | 15.0 (20.0) | 0.69 | 1.62 |
| A-483 | | 0.51 | 0.3 |

5 Also embraced within this invention is a class of
pharmaceutical compositions comprising the active
compounds of this invention in association with one or
more non-toxic, pharmaceutically-acceptable carriers
and/or diluents and/or adjuvants (collectively referred
10 to herein as "carrier" materials) and, if desired, other
active ingredients. The active compounds of the present
invention may be administered by any suitable route,
preferably in the form of a pharmaceutical composition
adapted to such a route, and in a dose effective for the
15 treatment intended. The active compounds and composition
may, for example, be administered orally, intravascularly
(IV), intraperitoneally, subcutaneously, intramuscularly
(IM) or topically. For oral administration, the
pharmaceutical composition may be in the form of, for
20 example, a tablet, hard or soft capsule, lozenges,
dispensable powders, suspension or liquid. The
pharmaceutical composition is preferably made in the form
of a dosage unit containing a particular amount of the
active ingredient. Examples of such dosage units are
25 tablets or capsules. The active ingredient may also be
administered by injection (IV, IM, subcutaneous or jet)
as a composition wherein, for example, saline, dextrose,
or water may be used as a suitable carrier. The pH of
the composition may be adjusted, if necessary, with
30 suitable acid, base, or buffer. Suitable bulking,
dispersing, wetting or suspending agents, including
mannitol and PEG 400, may also be included in the
composition. A suitable parenteral composition can also
include a compound formulated as a sterile solid
35 substance, including lyophilized powder, in injection
vials. Aqueous solution can be added to dissolve the

40024780-120704

compound prior to injection. The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the inflammation or inflammation related disorder, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 1000 mg, preferably in the range of about 7.0 to 350 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most preferably between about 0.5 to 30 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day. For disorders of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active

1002430-120701

ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane. The transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others. The choice of suitable oils or fats for the formulation

is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The anti-inflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered *per os*, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active

4002130-130701

compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and
5 suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil,
10 cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

All patent documents listed herein are incorporated
15 by reference.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

20 [PAGES 515-529 INTENTIONALLY OMITTED]

4006150-100704

515 – 529

MISSING AT THE TIME OF PUBLICATION

10024780-100204

Description of parallel array synthesis methodology utilized to prepare compounds of Examples B-i, B-ii, and B-iii.

5

Scheme B-1 describes the parallel array reaction blocks that were utilized to prepare compounds of Examples B-0001 through B-1574, and by analogy could also be used to prepare compounds of Examples B-1575 through B-2269.

- 10 Parallel reactions were performed in multi-chamber reaction blocks. A typical reaction block is capable of performing 48 parallel reactions, wherein a unique compound is optionally prepared in each reaction vessel B1. Each reaction vessel B1 is made of either
- 15 polypropylene or pyrex glass and contains a frit B2 toward the base of the vessel. Each reaction vessel is connected to the reaction block valve assembly plate B3 via leur-lock attachment or through a threaded connection. Each vessel valve B4 is either opened or
- 20 closed by controlling the leur-lock position or by the opening or closing of levers B5 within a valve assembly plate row. Optionally, solutions can be either drained or maintained above the vessel frits by leaving the valves in the opened position and controlling the back
- 25 pressure beneath the valve assembly plate by control of inert gas flow through the inert gas inlet valve B6. The parallel reactions that are performed in these reaction blocks are allowed to progress by incubation in a jacketed, temperature controlled shaking station.
- 30 Temperature control of the reaction chambers is effected by passing a heat-transfer liquid through jacketed aluminum plates that make contact with the reaction block

10034780-120701


mantle B7. Mixing is effected at the shaking station by either vertical orbital shaking of the up-right reaction block or by lateral shaking of the reaction block tilted on its side.

5

Functionalized resins are optionally added to each reaction vessel B1 during the course of reaction or at the conclusion of the reaction. These functionalized resins enable the rapid purification of each reaction vessel product. Vacuum filtration of the reaction block apparatus by opening of the vacuum valve B8 allows purified products to be separated from resin-sequestered non-product species. Valve B8 is located on the bottom reaction block chamber B10 which houses the quadrant collection vial racks B11. The desired products are obtained as filtrates in unique collection vials B9. Removal of solvent from these collection vials affords desired products.

20

FOUO 100-100000



Scheme B-2 illustrates the various utilizations of functionalized resins to purify reaction vessel products B22 prior to filtration from the fritted vessels B1 into collection vials B9. Said functionalized resins perform as 1) resin-bound reagents B12, which give rise to resin-bound reagent byproducts B13; 2) sequestrants B14 or B15 of excess solution-phase reactants B16 or B17, respectively. Solution-phase reactants B16 and B17 contain inherent reactive functionality $-rf_1$ and $-rf_2$

which enable their chemoselective sequestration by the complementary reactive functionality $-Cr_f1$ and $-Cr_f2$, attached to resins B14 and B15; 3) sequestrants B18 of solution-phase byproducts B19. Byproduct B19 contains

5 molecular recognition functionality $-mr_2$, which enables its chemoselective sequestration by the complementary functionality $-Cmr_2$, attached to resin B18; 4) reaction-quenching resins B20 which give rise to quenched resins B21. Resin B20 contains functionality $-Q$ which mediates

10 reaction quenching (for instance, proton transfer) of product B22 to form a desired isolable form of product B22. Upon performing reaction quench, the resin B20 is converted to resin B21 wherein $-q$ represents the spent functionality on resin B21 ; 5) sequestrants B23 of

15 chemically-tagged reagents B24 and their corresponding reagent byproducts B25. The soluble reagent B24 contains a bifunctional chemical group, $-tag$, which is inert to the reaction conditions but is used to enable the post-reaction sequestration of B24 by the complementary

20 functionality $-Ctag$ attached to resin B23. Additionally, the soluble reagent byproduct B25, formed during the course of reaction, contains the same chemical function $-tag$ that also enables its sequestration by resin B23. Additionally, some reactants B16, particularly

25 sterically-hindered reactants and/or electron deficient nucleophiles, contain poorly sequestrable functionality ($rf1$ in this case is a poorly sequestable functionality). These poorly sequestable reactants B16 can be transformed *in situ* to more robustly sequestrable species B27 through

30 their reaction with sequestration-enabling-reagents B26. B26 contain highly reactive, complementary functionality Cr_f1 which reacts with B16 to form B27 *in situ*. The

10021780-100201

bifunctional molecular recognition functionality, mr , contained within B26 is also present on the *in situ* derivatized B27. Both B26 and B27 are sequestered by the complementary molecular recognition functionality

5 attached to resin B28. By analogy, some reactions contain poorly sequestable byproducts B19, wherein the molecular recognition functionality mr_2 in this case is not able to mediate the direct sequestration of B19 by the complementary functionality attached to resin B18.


10 Similar use of the bifunctional sequestration-enabling-reagent B29 transforms B19 into the more readily sequesterable species B30. The imparted molecular recognition functionality, mr , present in B30 is readily sequestered by the complementary functionality, Cmr ,

15 attached to resin B31. In some reactions, multiple sequestration resins are utilized simultaneously to perform reaction purifications. Even resins containing incompatible (mutually reactive) functional groups can be used simultaneously because these resins scavenge

20 complementary functionalized solution phase reactants, reagents, or byproducts from solution phase faster than resin cross-neutralization. Similarly, resins containing mutually reactive or neutralizing reaction-quenching functionality are able to quench solution phase

25 reactants, products, or byproducts faster than resin cross-neutralization.

FOUO - 0342001



Scheme B3 describes the modular robotics laboratory environment that was utilized to prepare compounds of Examples B0001 through Bxxxx. Chemicals that are utilized in the robotics laboratory are weighed and then dissolved or suspended into solvents at Station #1 (Automated Chemistry Prep Station). Thus, solutions or suspensions of known molarity are prepared for use at the other robotics workstations. Station #1 also optionally bar-code labels each chemical solution so that its identity can be read by bar-code scanning at this and other robotics workstations.

Reactions are initiated at the modular Stations #2 and #2 DUP. Station #2DUP is defined as a duplicate of Station #2 and is used to increase capacity within the robotics laboratory. A reaction block is mounted at Station #2 or #2 DUP. Also, racks containing reactants, reagents, solvents, and resin slurries are also mounted at Station #2 or #2 DUP. Under the control of a chemical

informatics mapping file, reactions are initiated by the transfer of reactant solutions, reagent solutions, solvents, and/or resin slurries into each mounted reaction block vessel. The transfer of known volumes of solutions, suspensions, or solvents is mediated by syringes which control a one-up septum piercing/argon purging cannula, a wide-bore resin slurry-despensing cannula, or by a six-up cannula which can simultaneously deliver volumes to a row of six reaction vessels. The reaction block and/or chemical solution racks may be optionally cooled below room temperature during the chemical solution transfer operations. After the transfer of chemical solutions and solvents has been performed by Station#2 or #2DUP, incubation of the reaction block may occur while the reaction block is mounted at the robot station. Preferably, however, the reaction block is removed after all volume transfers are complete and the reaction block is brought to ambient temperature. The reaction block is transferred off-line to either a vertical- or lateral shaking Incubator Station #5.

The Automated weighing/archival Station #3 performs the functions of weighing empty collection vials (to obtain tare weights of collection vials) and also performs the functions of weighing collection vials containing filtered, purified products (to obtain gross weights of collection vials). After product-containing collection vials have been weighed (gross weight determinations) at workstation #3, the collection vial products are optionally redissolved into an organic solvent at workstation #3. Transfer of solvents is accomplished with syringes which control a mounted one-up septum-piercing/argon purging cannula. Each product-containing

10024780-130704

collection vial is prepared as a solution of known molarity as directed and recorded by the chemical informatics system. These product solutions may be subsequently mounted at Station #2 or #2DUP for subsequent reaction steps or taken to Station #7 or #7DUP for analytical processing.

Rapid solvent evaporation of product-containing collection vials is accomplished by mounting the collection racks at Savant Automated Solvent Evaporation Stations #4, #4 DUP, or #4 TRIP, wherein #4DUP and #4TRIP are defined as a duplicate and a triplicate of Station #4 to increase the capacity for solvent removal within the robotics laboratory. Commercially available solvent removal stations were purchased from the Savant Company (model # SC210A speedvac unit equipped with model # RVT4104 vapor trap and model # VN100 vapornet cryopump).

Stations #7 and #7DUP perform analytical processing functions. Station #7DUP is defined as a duplicate of Station #7 to increase capacity within the robotics laboratory. Product-containing collection racks are mounted at either of these stations. Each product-containing collection vial is then prepared as a solution of known molarity as directed and recorded by the chemical informatics mapping file. Optionally, this dissolution function is performed by prior processing of the collection vial rack at Station #3 as described above. Station#7 or #7DUP, under the control of the chemical informatics mapping file, transfers aliquots of each product vial into unique and identifiable microtiter plate wells that are utilized to perform analytical determinations.

One such microtiter plate is prepared at Station #7 or #7DUP for subsequent utilization at the Automated HPLC/Mass Spectrometer Station #8 or #8DUP. Station #8DUP is a duplicate of Station #8 to increase the analytical capacity of the robotics laboratory. Stations #8 and #8DUP are commercially available benchtop LC/Mass spec units purchased from Hewlett Packard (model HP1100 HPLC connected to HP1100 MSD (G1946A) mass spectrometer; this unit is also equipped with a model# G1322A solvent degasser, model # G1312A binary pump, a model # G1316A column heater, and a model # G1315A diode array detector. The HP unit has been interfaced with a commercially available autosampler rack (Gilson Company # 215 autosampler). Station #8 or #8DUP is utilized for the determination of product purity and identity by performing high performance liquid chromatography (HPLC) and companion atmospheric pressure chemi-ionization (APCI) or electrospray mass spectrometry for molecular weight determination.

Another microtiter plate is prepared at Station #7 or #7DUP for subsequent utilization at a commercially available flow-probe Varian NMR spectrometer Station #10 (Varian Instruments flow probe NMR, 300 MHz, interfaced with a commercially available Gilson 215 autosampler). Proton, ¹³-Carbon, and/or ¹⁹-Fluorine NMR spectra are determined at this Station #10.

Other microtiter plates are optionally mounted at Station #7 or #7DUP for the purpose of preparing product-containing plates for biological assays. Aliquots of product-containing collection vials are transferred to these biological assay microtiter plates under the control of the chemical informatics mapping file. Identity and amount of each transferred product is

10021780-120704
FOZET-08472007


recorded by the chemical informatics system for retrieval by biologists who perform the biological assaying of products.

- 5 The Fourier Transfrom InfraRed (FT-IR) Spectrometer Station #11 is utilized to analyze resins for the identity of organic functional groups chemically attached to these resins. The resins, as mentioned above, contain chemical functionality utilized as reagents, chemoselective sequestrants, or reaction quenching media for the workup and purification of the crude product mixtures contained within reaction block vessels. The robotics laboratory utilizes a commercially available FT-IR spectrometer purchased from Nicolet Instruments (model # MagnaIR 560 interfaced with an InspectIR microscope for resin mounting and positioning).

Scheme B-3

- 20 The lines interconnecting the modular Stations denote the transfer of chemical racks, reaction blocks, and/or collection vial racks from one modular Station to another.

10024780-120704



The ChemLib IT system is a composite of software running on the client's desktop and software running on a remote server.

The ChemLib IT system is a client/server software application developed to support and document the data handling flow in the robotics laboratory described above. This IT system integrates the chemist with the robotics synthesis laboratory and manages the data generated by this processes.

The software running on the server warehouses all the electronic data for the robotics chemistry unit. This

server, a Silicon Graphics IRIX station v6.2, runs the database software, Oracle 7 v7.3.3.5.0, that warehouses the data. Connection from the client's desktop to the server is provided by Oracle's TCP/IP Adapter v2.2.2.1.0 and SQL*Net v2.2.2.1.0A. SQL*Net is Oracle's network interface that allows applications running on the client's desktop to access data in Oracles' database.

The client's desktop is Microsoft Windows 95. The ChemLib IT system client software is composed of Omnis7 v3.5 and Microsoft Visual C++ v5.0. This composition on the client side is what is herein referred to as ChemLib. ChemLib communicates with the server for its data via Oracle's PL/SQL v2.3.3.4.0. These PL/SQL calls within ChemLib creates a network socket connection to Oracle's SQL*Net driver and the TCP/IP Adapter thereby allowing access to the data on the server.

A "library" is defined as a composite number of wells, where each well defines a single compound. ChemLib defines a library in a module called the *Electronic Spreadsheet*. The *Electronic Spreadsheet* is then a composite of n-number of wells containing the components that are required to synthesize the compound that exist in each these well(s).

The chemist begins by populating the *Electronic Spreadsheet* with those components required for the compound synthesis. The identity and the availability of these components are defined in the *Building Block Catalog* module of ChemLib. The *Building Block Catalog* is a catalog of a listing of all reagents, solvents, peripherals available in the robotics laboratory. Upon selecting the components for each compound we also

declare the quantity of each component to be utilized. The quantity of each component can be identified by its molarity and volumetric amounts (ul) or by it's solid state form (mg). Therefore a well in the *Electronic Spreadsheet* defines a compound that is identified by its components and the quantity of each of these components.

The assembly or the synthesis of these components for each compound in the *Electronic Spreadsheet* is defined in the *WS Sequence* module of ChemLib. The *Define WS Sequence* module identifies the synthesis steps to be performed at the robotics workstations and any activities to be performed manually or off-line from the robotics workstation. With this module we identify which components from the *Electronic Spreadsheet* and the activity that should be performed with this component in the robotics laboratory. In the *Define WS Sequence* module the chemist chooses from a list of activities to be performed in the robotics laboratory and assembles them in the order in which they are to occur. The ChemLib system takes these set of activities identified, and with the component data in the *Electronic Spreadsheet* assembles and reformats these instructions into terminology for the robotics workstation use. This robotics terminology is stored in a 'sequence' file on a common server that is accessible by the robotics workstation.

The robotics workstation performs the synthesis in a reaction block apparatus as described. Each well in the *Electronic Spreadsheet* is tracked and mapped to a unique location in the reaction block apparatus on the robotics workstation. The compound or product synthesized at the

10024380-120701

robotics workstation in the reaction block is then captured into collection vials.

5 The collection vials are first tarred then grossed on the robotics workstation after collecting their products from the reaction block. These weights (tare and gross) are recorded into the ChemLib system with the *Tare/Gross Session* module. The *Tare/Gross Session* module then calculates the product or compound yields and its final
10 mass.

Preparation of the compound for analytical analysis and screening is defined by the *Analytical WS Setup* module in ChemLib. The *Analytical WS Setup* module identifies the
15 dilution factor for each well in the *Electronic Spreadsheet*, based on the compound's product yield and the desired molar concentration. This identifies the quantity, in uL, to be transferred at the robotics workstation, to a specific location on the MTP
20 (microtiter plate) to be sent for analysis and/or biological assaying. The mass spectrometric and HPLC results for each well are recorded and scored into the ChemLib system.

25 The *Dilute/Archive WS* module further identifies each compound by mapping the compound's well from the *Electronic Spreadsheet* to a specific MX block location for long term storage and archival as part of the registration process.

30

All communications between ChemLib and the robotics workstations are by ASCII files. These files are placed on a server by the ChemLib system that is accessible by

1002430-12001
1002430-12001


the robotics workstations. Reports generated by the robotics workstations are also placed on the server where the ChemLib system can read these files to record the data generated. Each robotics workstation consists of robotics hardware by Bohdan Automation, Inc. Mundelein, Illinois, and a PC currently running Microsoft Windows for Workgroup v3.11 and Ethernet software. The robotics workstation PC is logged into the network for one-way communication that allows the workstation to access the server for file access only.

General Scheme B4

Scaffold C-i with a primary amine functionality contained within the R^4 substituent is reacted in spatially addressed, parallel array reaction block vessels with excess of electrophiles R^J-Q wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R^J-Q includes acid chlorides, alkyl chloroformates, sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-i with R^J-Q is effected in the presence of a tertiary amine base at room temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent. As illustrated in Scheme B-4 the products of the general formulae B-i are isolated in purified form by addition of a carbonyl-functionalized resin B32 which covalently sequesters any unreacted primary amine scaffold C-i as resin-bound adduct B35, and also by the addition of a primary amine-functionalized resin B33 which covalently sequesters any remaining electrophile R^J-Q from each reaction mixture as

1004301 08472007

resin-bound adduct B34. Resin B33 also sequesters the HQ byproduct from the reaction mixture by proton transfer from solution-phase Base-HQ. Incubation at room temperature, filtration, rinsing of the resin cake, and concentration of the filtrates affords purified products B-i filtered away from resin-bound adducts B32, B33, B34, B35, and B36.




10

Scheme B-5 specifically illustrates the derivatization of the primary amine-containing scaffold **C1** to afford the desired products **B-i** in a parallel array synthesis format. In a parallel array synthesis reaction block, individual reaction products are prepared in each of multiple reaction block vessels in a spatially

addressed format. A solution of the desired primary amine-containing scaffold C1 (limiting amount,) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0 fold stoichiometric excess solution of
5 N-methylmorpholine in DMF. To each reaction vessel is then added the electrophiles: either a 2.0 fold stoichiometric excess when R^J-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^J-Q is a sulfonyl chloride, or a 1.25 fold
10 stoichiometric excess when R^J-Q is an isocyanate. Excess electrophiles and N-methylmorpholine were used to effect more rapid and/or more complete conversion of scaffold C1 to products B-0001-B-0048 compared to reactions that do not utilize stoichiometric excesses of electrophiles and
15 N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-3 h. Each reaction vessel is then charged with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 and the aldehyde-functionalized resin B32. The
20 resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles R^J-Q and any unreacted scaffold amine C1 are removed from the reaction
25 medium as insoluble adducts B34 and B37 respectively. In addition the N-methylmorpholine hydrochloride salt formed during the course of the reaction is also neutralized to its free base form by proton transfer reaction to the amine-functionalized resin B33. Simple filtration of the
30 insoluble resin- adducts B32, B33, B34, B36, and B37, rinsing of the resin cake with dichloroethane, and evaporation of the filtrates affords the desired products B-i in purified form.


T0202T-0827200T



Scheme B-6 illustrates a general synthetic method involving the parallel array reaction of a scaffold **C-ii** containing a secondary amine functionality within the definition of the R^4 substituent. Each reaction vessel is charged with the secondary amine-containing scaffold **C-ii**, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R^L-Q into each vessel, wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R^L-Q includes acid chlorides, alkyl chloroformates,


10024380-120704

sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-ii with R^L-Q is effected in the presence of tertiary amine base at room temperature or elevated
5 temperature in a mixture of a polar aprotics solvent and/or a halogenated solvent. After solution-phase reactions have progressed to afford crude product mixtures in each vessel, the products
B-ii are isolated in purified form by the addition of the
10 isocyanate-functionalized resin B38 which covalently sequesters remaining secondary amine scaffold C-ii as resin-bound adduct B39, and also by the addition of the primary amine-functionalized resin B33 which covalently sequesters remaining electrophile R^L-Q from each reaction
15 vessel as resin-bound adducts B40. Resin B33 also sequesters the HQ byproduct in each vessel as B36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, either simultaneously or sequentially, followed by filtration, rinsing, and
20 concentration of the filtrates affords purified products B-ii filtered away from resin-adducts B33, B36, B38, B39, and B40.




Scheme B-7 illustrates the conversion of the secondary-amine containing scaffold **C-2** to the desired products **B-ii**. In a parallel array synthesis reaction block, individual reaction products are prepared in each of 48 multiple reaction block vessels. A solution of the scaffold **C-2** (limiting amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophile $\text{R}^{\text{L}}\text{-Q}$ as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when $\text{R}^{\text{L}}\text{-Q}$ is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when $\text{R}^{\text{L}}\text{-Q}$ is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when $\text{R}^{\text{L}}\text{-Q}$ is an isocyanate. The reaction mixtures are incubated at

ambient temperature for 2-6 h. Each reaction vessel is then charged with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 and the isocyanate-functionalized resin B32. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles R^L-Q and unreacted scaffold amine C-2 are removed from the reaction medium as insoluble adducts B40 and B39, respectively. Resin B33 also sequesters the HQ byproduct in each vessel as B36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, followed by filtration and rinsing with solvent mixtures of DMF and/or DCE, affords purified product solutions in collection vials filtered away from resin-adducts B33, B36, B38, B39, and B40. Concentration of filtrates affords purified products B-ii.




- 5 Scheme B-8 illustrates another general synthetic method involving the parallel array reaction of a scaffold **C-ii** containing a secondary amine functionality within the definition of the R^4 substituent. Each reaction vessel is charged with the secondary amine-containing scaffold **C-ii**, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R^L-Q into each vessel. Reaction of scaffold **C-ii** with R^L-Q is effected in the presence of tertiary amine base at room temperature or elevated temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent.
- 10
- 15

Excess electrophiles and N-methylmorpholine are used to effect more rapid and/or more complete conversion of scaffold C-ii to products B-ii compared to reactions that do not utilize stoichiometric excesses of electrophiles and N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-8 h. Each reaction vessel is then charged with the sequestration-enabling reagent phenylsulfonylisocyanate B41. This reagent B41 reacts with remaining secondary amine scaffold C-ii, converting C-ii to the *in situ*-derivatized compound B42. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 sequesters the solution-phase species R^L-Q , HQ, B41, and B42 as the resin-bound adducts B40, B36, B44, and B43, respectively. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin- adducts B33, B36, B40, B43 and B44 and subsequent rinsing of the vessel resin-bed with DMF and/or DCE affords filtrates containing the purified products B-ii. Concentration of the filtrates affords the purified products B-ii.



Scheme B-9 illustrates the method of Scheme B-8 using scaffold C-2. A solution of the scaffold C-2 (limiting

amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophile R^L-Q as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when R^L-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^L-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R^L-Q is an isocyanate. The reaction mixtures are incubated at ambient temperature for 2-6 h. After solution-phase reactions have progressed to afford crude product mixtures, each reaction vessel is then charged with a dichloroethane solution of the sequestration-enabling reagent phenylsulfonylisocyanate B41. This reagent B41 reacts with remaining secondary amine scaffold C-2, converting C-2 to the *in situ*-derivatized compound B45. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 sequesters the solution-phase species R^L-Q , HQ, B41, and B45 as the resin-bound adducts B40, B36, B44, and B46, respectively. The resin-charged reaction block is shaken vertically for 20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin- adducts B33, B36, B40, B44, and B46 and subsequent rinsing of the vessel resin-bed with DCE affords filtrates containing the purified products B-ii. Concentration of the filtrates affords the purified products B-ii.




5

Another general method for the parallel array reaction block synthesis is illustrated in Scheme B-10 for the derivatization of the carboxylic acid-containing scaffold

20

Scheme B-10




Scheme 'B-11 illustrates the conversion of the acid containing scaffold C-49 to the desired amide products B-iii in a parallel synthesis format. A limiting amount of the scaffold C-49 is added as a solution in dimethylformamide to each reaction vessel containing the polymer bound carbodiimide reagent B48 (5 fold stoichiometric excess). A solution of pyridine (4 fold stoichiometric excess) in dichloromethane is added to this slurry, followed by addition of an excess amount of a dimethylformamide solution of a unique amine B47 (1.5 fold stoichiometric excess) to each vessel. The parallel reaction block is then agitated vertically on an orbital shaker for 16-18 h at ambient temperature and filtered to separate the solution phase product mixture away from resin-bound reagent B48 and resin-bound reagent byproduct B49. The resulting solutions (filtrates) containing a mixture of the desired amide products B-iii, excess amines B47 and any unreacted acid containing scaffold C-49, are treated with tetrafluorophthalic anhydride B50. B50 converts the excess amines B47 in each filtrate vessel to its respective sequestrable half acid form B51. After two h incubation time, an excess of the amine-functionalized resin B33 and dichloromethane solvent are added to each reaction vessel. The amine-containing resin B33 converts B51, any remaining B50, and any remaining C-49 to their resin-bound adducts B52, B53, and B55, respectively. The resin-charged reaction block is shaken vertically for 16 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin- adducts B33, B52, B53, and B55 and subsequent rinsing of the vessel resin-bed with

dimethylformamide affords filtrates containing the purified products B-iii. Concentration of the filtrates affords the purified products B-iii.

5

1002130-10204

Scheme B-11



Although Schemes B-1 through B-11 describe the use of parallel array chemical library technology to prepare compounds of general formulae **B-i**, **B-ii**, and **B-iii**, it is noted that one with ordinary skill in the art of classical synthetic organic chemistry would be able to prepare **B-i**, **B-ii**, and **B-iii** by conventional means (one compound prepared at a time in conventional glassware and purified by conventional means such as chromatography and/or crystallization).

A general synthesis of pyridylpyrazole scaffolds **C-i**, **C-ii**, and **C-iii** is depicted in Scheme C-1.

Step A: Picoline is treated with a base chosen from but not limited to n-butyllithium (n-BuLi), lithium di-isopropylamide (LDA), lithium hexamethyldisilazide (LiHMDS), potassium t-butoxide (tBuOK), or sodium hydride (NaH) in an organic solvent such as tetrahydrofuran (THF), diethyl ether, t-butyl methyl ether, t-BuOH or dioxane from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of ester **B56**. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from -20 °C to 120 °C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone **B57** is isolated as a crude solid which can be purified by crystallization and/or chromatography.

Step B: A solution of the pyridyl monoketone **B57** in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, diethyl ether, t-butyl methyl ether, or t-BuOH from -78 °C to 50 °C for a period of time from ranging from 10 minutes to 3 hours. An appropriately substituted activated ester or acid halide derived from $R^4\text{-CO}_2\text{H}$ is then added as a solution in THF, ether, or dioxane to the monoketone anion of **B57** while the temperature is maintained between -50 °C and 50 °C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to three hours. The resulting pyridyl diketone intermediate **B58** is utilized without purification in Step C.

Step C: The solution containing the pyridyl diketone **B58** is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H_2SO_4 , HCl, or HNO_3 . The temperature during this step is maintained between -20 °C and room temperature. Hydrazine or hydrazine hydrate was then added to the mixture while maintaining the temperature between -20 °C and 40 °C for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole **C-i** or **C-ii** is obtained as a crude solid which is purified by chromatography or crystallization.


Step: D In some cases the pyridyl pyrazole **C-i** or **C-ii** is alkylated with $\text{Q-C(R}^A\text{)}-(\text{CH}_2)_n\text{CO}_2\text{alkyl}$ wherein Q is halogen. **C-i** or **C-ii** is treated with a base chosen from NaH, NaOEt, KOtBu, or NEt_3 in an organic solvent such as THF, methylene chloride, dioxane, or DMF at temperatures

between -20 °C and 150 °C and reaction times between 30 minutes and 12 hours. The resulting alkylated pyridyl pyrazole ester is then hydrolyzed to the acid by treatment with NaOH or LiOH in aqueous/alcohol solvent mixtures or in THF/water solvent mixtures. Alternatively, the ester function is removed by treatment with an organic or inorganic acid if the alkyl residue is t-butyl. Acidification, followed by extraction with an organic solvent affords C-iii which may be purified by chromatography or crystallography. In some cases, regioisomeric alkylated products C-iv are also formed. The desired C-iii can be separated away from C-iv by chromatographic purification or by fractional crystallization.

15

FOUO 1002180 120701

Scheme C-1



5 A synthesis of pyridylpyrazole scaffold C-1 is depicted in Scheme C-2.

Step A:

Picoline is added to a solution of LiHMDS in THF at room temperature over a time period ranging from 30 minutes to 1 hour. The resulting solution is stirred for an additional 30 minutes to 1 hour at room temperature.

5 This solution is then added to neat ethyl p-fluorobenzoate **B60** at room temperature over 1-2 h. The mixture is then allowed to stir at room temperature for 16-24 h. Equal portions of water and ethyl acetate are then added to the reaction and the mixture is partitioned

10 in an extraction funnel. The organic layer is dried, filtered, and evaporated to give an oily solid. Hexanes are then added and the solid is filtered and washed with cold hexanes leaving the pyridyl monoketone **B61** for use in Step B.

15 Step B:

The pyridyl monoketone **B61** is added as a solution in THF to a flask maintained at room temperature which contains t-BuOK in a THF/ t-BuOH cosolvent. A yellow precipitate forms and stirring at room temperature is continued for

20 1-3 h. After this time, N-Cbz-protected glycine N-hydroxysuccinimide **B62** is added dropwise at room temperature as a solution in THF over 1-3 h. This solution, containing crude diketone **B63**, is used directly in Step C.

25 Step C:.. The solution from step C is treated with water and the pH is adjusted to between 6 and 7 with acetic acid. Hydrazine hydrate is then added dropwise to the mixture as a solution in water over 30 minutes to 1h at room temperature. Water and ethyl acetate are then added

30 to the flask and the mixture is then partitioned in a separatory funnel. The organic layer is dried, filtered, and evaporated to give a crude oil which is purified by


silica gel chromatography, giving rise to purified C-1Cbz.

Step: D

- 5 The Cbz protecting group contained in compound C-1Cbz is cleaved using hydrogen gas under pressure and Pd-C in methanol solvent. The resulting amine C-1 is obtained by filtration and concentration.

10024780 120704

Scheme C-2



A number of pyridyl pyrazole scaffolds of type C-v are prepared as shown in Scheme C-3.

Step A: Picoline is treated with a base chosen from but not limited to *n*-BuLi, LDA, LiHMDS, *t*BuOK, or NaH in an organic solvent such as THF, ether, *t*-BuOH or dioxane from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of an appropriately activated ester analog of a carboxylic acid $\text{CbzNR}^{\text{H}}-(\text{CH}_2)_n\text{CR}^{\text{F}}(\text{R}^{\text{G}})-\text{CO}_2\text{H}$ or $\text{BocNR}^{\text{H}}-(\text{CH}_2)_n\text{CR}^{\text{F}}(\text{R}^{\text{G}})-\text{CO}_2\text{H}$, preferably but not limited to the N-hydroxysuccinimide **B64**. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from -20 °C to 120 °C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone **B65** is isolated as a crude solid which can be purified by crystallization and/or chromatography.


Step B: A solution of the pyridyl monoketone **B65** in ether, THF, *t*BuOH, or dioxane is added to a base chosen from but not limited to *n*-BuLi, LDA, LiHMDS, *t*BuOK, or NaH contained in hexane, THF, ether, dioxane, or *t*BuOH from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The anion sometimes precipitates as a yellow solid. An appropriately substituted activated ester such as the N-hydroxysuccinimide **B66** is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between -50 °C and 50 °C. The resulting mixture is allowed to stir at the specified temperature for a period of time from ranging from 5 minutes to 3 hours. The resulting pyridyl diketone intermediate **B67** is utilized without further purification in Step C.

Step C: The solution containing the pyridyl diketone **B67** is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between -20 °C and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between -20 °C and 40 °C for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole **C-vBoc** or **C-vCbz** is obtained as a crude solid which is purified by chromatography or crystallization.

Step: D

The carbamate protecting groups from **C-vBoc** or **C-vCbz** are removed to afford the scaffolds **C-v** containing either a free primary amine (R^H is hydrogen) or a free secondary amine (R^H not equal to hydrogen). The Boc protecting carbamate groups are cleaved utilizing 1:1 trifluoroacetic acid (TFA)/methylene chloride at room temperature for several hours. The CBZ carbamate protecting groups are cleaved using hydrogen gas under pressure and Pd-C in an alcoholic solvent. The resulting amines **C-v** are then optionally crystallized or purified by chromatography.

Scheme C-3



The synthesis of scaffolds C-vi is accomplished as shown in Scheme C-4.

5


Step A:

A Boc protected pyridylpyrazole B68 is treated with benzaldehyde in methylene chloride at room temperature in the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine B69 is used in step B without further purification.

Step B:

15 The pyridylpyrazole imine B69 is dissolved in THF and stirred under nitrogen at temperatures ranging from -78 to -20 °C. A base such as LDA, *n*-BuLi, or LiHMDS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two-five equivalents of an alkylating agent R^F-Q are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give C-vi.

30




5

The synthesis of maleimide-containing scaffolds **C-vii** is accomplished as shown in Scheme C-5.

The maleimide pyrazole scaffolds **C-vii** are synthesized as depicted in scheme C-5. Condensation reaction of a primary amine $\text{H}_2\text{N-R}$ with a maleic anhydride **B70** that is substituted at position 3 with either a bromo, chloro, or triflate group generates compound **B71**. The formed maleimide derivative **B71** then reacts with an acetophenone derivative **B72** in the presence of a $\text{Pd}(0)$


catalyst and base to afford compound **B73**. The methylene position of **B73** is then acylated with an acid anhydride **B74** or an activated acid ester **B75**, forming the di-ketone derivative **B76**. The di-ketone **B76** condenses with hydrazine to afford the desired maleimide pyrazole scaffold **C-vii**.



10

Scheme C-6 illustrates the synthesis of the maleimide pyrazole scaffold **C-63** wherein R^4 is hydrogen. The synthesis starts with the condensation reaction of bromomaleic anhydride **B77** with 2, 4-dimethoxybenzylamine in acetic acid and acetic anhydride, giving rise to intermediate **B78**. The maleimide **B78** is then treated with 4'-fluoroacetophenone in the presence of catalytic amount


$\text{Pd}_2(\text{dba})_3$ and sodium *t*-butoxide to form the fluoroacetophenone substituted maleimide **B79**. The **B79** is treated with *tert*-butoxybis(dimethylamino)methane to yield the α -ketoenamine **B80**. The α -ketoenamine **B80** is condensed with hydrazine to form the maleimide pyrazole skeleton **B81**. The 2, 4-dimethoxybenzyl group protecting group is optionally removed with ceric ammonium nitrate (CAN) to give compound **C-63**.









10

Scheme C-7 illustrates the synthesis of maleimide-containing scaffolds **C-64** and **C-65**. These scaffolds **C-49** and **C-50** are synthesized according to the general methods

illustrated in Scheme C-5 and exemplified with the utilization of N-hydroxysuccinimides **B82** and **B83** to afford the maleimide-containing pyrazoles **B86** and **B87**, respectively. Optional removal of the 2,4-dimethoxybenzyl groups with CAN and subsequent removal of the Boc-protecting groups with trifluoroacetic acid (TFA) affords the scaffolds **C-64** and **C-65**.



The various functionalized resins and sequestration-enabling-reagents utilized to prepare and purify parallel reaction mixtures are more fully described below, including their commercial source or literature reference to their preparation.



5

10

Experimental procedure for the parallel synthesis of a series of amides, carbamates, ureas and sulfonamides B-0001 through B-0048 from scaffold C-1.

15

Examples B-0001 through B-0048


To each reaction vessel (polypropylene syringe tubes fitted with a porous frit, closed at the bottom) of a parallel reaction apparatus was added 200 uL of dimethylformamide. A stock solution of the scaffold amine C-1 in dimethylformamide (0.1 M, 500 uL) was added to each reaction vessel followed by the addition of a stock solution of N-methylmorpholine in dimethylformamide (1.0 M., 200 uL). A stock solution of each of the electrophiles was then added to the appropriate reaction vessels: a) 500 uL of a 0.2 M solution of the acid chlorides in dichloroethane or b) 500 uL of a 0.2 M solution of the chloroformates in dichloroethane or c) 313 uL of a 0.2 M solution of the isocyanates in dichloroethane or d) 375 uL of a 0.2 M solution of the sulfonyl chlorides in dichloroethane. The parallel reaction apparatus was then orbitally shaken (Labline Benchtop orbital shaker) at 200 RPM at ambient

10061380-120701





















temperature (23-30 °C) for a period of 2-3 h, under a gentle flow of nitrogen. At this time each reaction vessel was treated with approximately 250 mg of polyamine resin **B33** (4.0 meq N/g resin) and approximately 100 mg of polyaldehyde resin **B32** (2.9 mmol/g resin). Each reaction vessel was diluted with 1 mL dimethylformamide and 1 mL dichloroethane and the orbital shaking was continued at 200 RPM for a period of 14-20 h at ambient temperature. Each reaction vessel was then opened and the desired solution phase products separated from the insoluble quenched byproducts by filtration and collected in individual conical vials. Each vessel was rinsed twice with dichloroethane (1 mL) and the rinsings were also collected. The solutions obtained were then evaporated to dryness in a Savant apparatus (an ultracentrifuge equipped with high vacuum, scalable temperature settings and a solvent trap to condense the volatile solvent vapors). The resulting amide, carbamate, urea and sulfonamide products were then weighed and characterized. The yields and analytical data for the products obtained using this method are shown below.





















25





















30























| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0001 | | | 85 | 397 | 398 |
| B-0002 | | | 94 | 412 | 413 |
| B-0003 | | | 91 | 340 | 341 |
| B-0004 | | | 79 | 368 | 369 |
| B-0005 | | | 92 | 498 | 499 |
| B-0006 | | | 92 | 416 | 417 |
| B-0007 | | | 86 | 450 | 451 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0008 |  |  | 86 | 448 | 449 |
| B-0009 |  |  | 83 | 368 | 369 |
| B-0010 |  |  | 86 | 338 | 339 |
| B-0011 |  |  | 92 | 402 | 403 |
| B-0012 |  |  | 74 | 442 | 443 |
| B-0013 |  |  | 91 | 446 | 447 |
| B-0014 |  |  | 84 | 352 | 353 |
| B-0015 |  |  | 94 | 380 | 381 |
| B-0016 |  |  | 89 | 440 | 441 |
| B-0017 |  |  | 83 | 498 | 499 |



| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0018 |  |  | 24 | 439 | 440 |
| B-0019 |  |  | 89 | 474 | 475 |
| B-0020 |  |  | 90 | 440 | 441 |
| B-0021 |  |  | 85 | 386 | 387 |
| B-0022 |  |  | 35 | 417 | 418 |
| B-0023 |  |  | 94 | 397 | 398 |
| B-0024 |  |  | 87 | 417 | 418 |
| B-0025 |  |  | 5 | 354 | - |
| B-0026 |  |  | 87 | 426 | 427 |
| B-0027 |  |  | 89 | 350 | 351 |

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0028 |  |  | 92 | 456 | 457 |
| B-0029 |  |  | 89 | 428 | 429 |
| B-0030 |  |  | 37 | 498 | 499 |
| B-0031 |  |  | 18 | 407 | 408 |
| B-0032 |  |  | 86 | 462 | 463 |
| B-0033 |  |  | 3 | 352 | - |
| B-0034 |  |  | 92 | 446 | 447 |
| B-0035 |  |  | 28 | 569 | 570 |
| B-0036 |  |  | 93 | 416 | 417 |
| B-0037 |  |  | 91 | 422 | 423 |

583

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0038 |  |  | 84 | 390 | 393 |
| B-0039 |  |  | 87 | 402 | 403 |
| B-0040 |  |  | 92 | 416 | 417 |
| B-0041 |  |  | 75 | 444 | 445 |
| B-0042 |  |  | 54 | 390 | 391 |
| B-0043 |  |  | 80 | 396 | 397 |
| B-0044 |  |  | 81 | 310 | 311 |
| B-0045 |  |  | 91 | 408 | 409 |
| B-0046 |  |  | 25 | 464 | 465 |
| B-0047 |  |  | 88 | 430 | 431 |

PCT/US99/26007

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0048 |  |  | 95 | 414 | 415 |

5

10

By analogy to the procedure identified above for the preparation of Examples B0001-B0048, the following examples B-0049 through B-1573 were prepared.


15

20

25

30





















TOX-0001-1573



Example#

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0049 | | | 85 | 414 | 415 |
| B-0050 | | | 9 | 458 | 459 |
| B-0051 | | | 91 | 426 | 427 |
| B-0052 | | | 79 | 407 | 408 |
| B-0053 | | | 92 | 407 | 408 |
| B-0054 | | | 92 | 363 | 364 |
| B-0055 | | | 86 | 505 | 506 |

Example#

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0056 |  |  | 86 | 487 | 488 |
| B-0057 |  |  | 83 | 394 | 395 |
| B-0058 |  |  | 86 | 462 | 463 |
| B-0059 |  |  | 92 | 466 | 467 |
| B-0060 |  |  | 74 | 456 | 457 |
| B-0061 |  |  | 35 | 458 | 459 |
| B-0062 |  |  | 94 | 458 | 459 |
| B-0063 |  |  | 87 | 372 | 373 |
| B-0064 |  |  | 5 | 394 | 395 |
| B-0065 |  |  | 87 | 420 | 395 |





















100480 084F2001

Example#

R²R^J

%Yield

Calcd.
Mass SpecObserved
Mass Spec
(M+H)





















| | | | | | |
|--------|---|---|----|-----|-----|
| B-0066 |  |  | 89 | 350 | 351 |
| B-0067 |  |  | 92 | 386 | 387 |
| B-0068 |  |  | 89 | 432 | 433 |
| B-0069 |  |  | 37 | 390 | 391 |
| B-0070 |  |  | 18 | 432 | 433 |
| B-0071 |  |  | 86 | 440 | 441 |
| B-0072 |  |  | 3 | 432 | 433 |
| B-0073 |  |  | 92 | 450 | 451 |
| B-0074 |  |  | 28 | 390 | 391 |
| B-0075 |  |  | 93 | 402 | 403 |

Example#





















R²R¹

%Yield



Calcd.
Mass SpecObserved
Mass Spec
(M+H)

| | | | | | |
|--------|---|---|----|-----|-----|
| B-0076 |  |  | 91 | 400 | 401 |
| B-0077 |  |  | 84 | 382 | 383 |
| B-0078 |  |  | 87 | 396 | 397 |
| B-0079 |  |  | 92 | 364 | 365 |
| B-0080 |  |  | 75 | 447 | 448 |
| B-0081 |  |  | 54 | 370 | 371 |
| B-0082 |  |  | 80 | 430 | 431 |
| B-0083 |  |  | 81 | 382 | 383 |
| B-0084 |  |  | 91 | 464 | 465 |
| B-0085 |  |  | 25 | 462 | 463 |

Example#















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0086 |  |  | 88 | 432 | 433 |
| B-0087 |  |  | 95 | 416 | 417 |
| B-0088 |  |  | | 438 | 439 |
| B-0089 |  |  | | 336 | 337 |
| B-0090 |  |  | | 444 | 445 |
| B-0091 |  |  | | 368 | 369 |
| B-0092 |  |  | | 506 | 507 |
| B-0093 |  |  | | 436 | 437 |
| B-0094 |  |  | | 461 | 462 |
| B-0095 |  |  | | 408 | 409 |

Example#

| | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|--------|---|---|--------|---------------------|--------------------------------|
| B-0096 |  |  | | 410 | 411 |





















T06031" 03/F2007

Example#

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0097 |  |  | 14 | 486 | 487 |
| B-0098 |  |  | 8 | 465 | - |
| B-0099 |  |  | 75 | 464 | 465 |
| B-0100 |  |  | 72 | 388 | 389 |
| B-0101 |  |  | 23 | 408 | 409 |
| B-0102 |  |  | 37 | 487 | 488 |
| B-0103 |  |  | 11 | 492 | 493 |





















100480 4004

Example#

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0104 |  |  | 59 | 426 | 427 |
| B-0105 |  |  | 79 | 360 | 361 |
| B-0106 |  |  | 56 | 374 | 375 |
| B-0107 |  |  | 33 | 346 | 347 |
| B-0108 |  |  | 12 | 466 | 467 |
| B-0109 |  |  | 65 | 450 | 451 |
| B-0110 |  |  | 55 | 458 | 459 |
| B-0111 |  |  | 41 | 458 | 459 |
| B-0112 |  |  | 19 | 467 | 468 |
| B-0113 |  |  | 78 | 453 | 454 |

10024780-10004

Example#





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0114 |  |  | 14 | 453 | 454 |
| B-0115 |  |  | 33 | 453 | |
| B-0116 |  |  | 11 | 459 | 487 |
| B-0117 |  |  | 77 | 438 | 439 |
| B-0118 |  |  | 52 | 422 | 423 |
| B-0119 |  |  | 82 | 434 | 435 |
| B-0120 |  |  | 49 | 422 | 423 |
| B-0121 |  |  | 64 | 414 | 415 |
| B-0122 |  |  | 87 | 501 | 502 |
| B-0123 |  |  | 100 | 450 | 451 |

Example#





















R²R¹

%Yield

Calcd.
Mass SpecObserved
Mass Spec
(M+H)



| | | | | | |
|--------|---|---|-----|-----|-----|
| B-0124 |  |  | 87 | 456 | 457 |
| B-0125 |  |  | 45 | 472 | 473 |
| B-0126 |  |  | 100 | 476 | 477 |
| B-0127 |  |  | 100 | 433 | 434 |
| B-0128 |  |  | 100 | 482 | - |
| B-0129 |  |  | 96 | 480 | 481 |
| B-0130 |  |  | 93 | 468 | 469 |
| B-0131 |  |  | 90 | 468 | 469 |
| B-0132 |  |  | 78 | 436 | 437 |
| B-0133 |  |  | 76 | 426 | 427 |

Example#















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0134 |  |  | 87 | 444 | 445 |
| B-0135 |  |  | 67 | 476 | 477 |
| B-0136 |  |  | 100 | 570 | - |
| B-0137 |  |  | 35 | 480 | 481 |
| B-0138 |  |  | 60 | 500 | - |
| B-0139 |  |  | 73 | 585 | 586 |
| B-0140 |  |  | 62 | 434 | 459 |
| B-0141 |  |  | 100 | 483 | 484 |
| B-0142 |  |  | 90 | 444 | 445 |
| B-0143 |  |  | 61 | 492 | 493 |





















Publ. 08/2/2004

Example#

| | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|--------|---|---|--------|---------------------|--------------------------------|
| B-0144 |  |  | 49 | 448 | 449 |





















100480-109
100480-109





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0145 |  |  | 48 | 433 | 434 |
| B-0146 |  |  | 32 | 415 | 416 |
| B-0147 |  |  | 67 | 471 | 472 |
| B-0148 |  |  | 79 | 465 | - |
| B-0149 |  |  | 65 | 353 | 354 |
| B-0150 |  |  | 53 | 465 | 466 |
| B-0151 |  |  | 68 | 401 | 402 |



| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0152 |  |  | 39 | 383 | - |
| B-0153 |  |  | 96 | 427 | 428 |
| B-0154 |  |  | 44 | 459 | 460 |
| B-0155 |  |  | 74 | 479 | 480 |
| B-0156 |  |  | 44 | 459 | 460 |
| B-0157 |  |  | 72 | 415 | 416 |
| B-0158 |  |  | 96 | 445 | 446 |
| B-0159 |  |  | 97 | 411 | 412 |
| B-0160 |  |  | 49 | 417 | 418 |
| B-0161 |  |  | 93 | 459 | 460 |

1002480 1002480















[illegible]





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0172 |  |  | 62 | 471 | 472 |
| B-0173 |  |  | 40 | 455 | 456 |
| B-0174 |  |  | 92 | 405 | 406 |
| B-0175 |  |  | 96 | 387 | 388 |
| B-0176 |  |  | 25 | 415 | 416 |
| B-0177 |  |  | 100 | 397 | 398 |
| B-0178 |  |  | 34 | 429 | 430 |
| B-0179 |  |  | 72 | 429 | 430 |
| B-0180 |  |  | 91 | 463 | 464 |
| B-0181 |  |  | 100 | 463 | 464 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0182 |  |  | 50 | 447 | 448 |
| B-0183 |  |  | 22 | 455 | 456 |
| B-0184 |  |  | 63 | 465 | 466 |
| B-0185 |  |  | 65 | 471 | 472 |
| B-0186 |  |  | 42 | 429 | 430 |
| B-0187 |  |  | 62 | 481 | 482 |
| B-0188 |  |  | 98 | 439 | 440 |
| B-0189 |  |  | 21 | 453 | 454 |
| B-0190 |  |  | 57 | 417 | 418 |
| B-0191 |  |  | 24 | 477 | 478 |

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0192 |  |  | 35 | 455 | 456 |





FOUO# 082 F2004

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0193 |  |  | 42 | 378 | 379 |
| B0194 |  |  | 65 | 365 | 366 |
| B-0195 |  |  | 93 | 587 | 588 |
| B-0196 |  |  | 82 | 365 | 366 |
| B-0197 |  |  | 100 | 587 | 588 |
| B-0198 |  |  | 86 | 373 | 374 |
| B-0199 |  |  | 81 | 373 | 374 |















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0200 |  |  | 78 | 373 | 374 |
| B-0201 |  |  | 95 | 352 | 353 |
| B-0202 |  |  | 100 | 416 | 417 |
| B-0203 |  |  | 69 | 354 | 355 |
| B-0204 |  |  | 93 | 340 | 341 |
| B-0205 |  |  | 94 | 354 | 355 |
| B-0206 |  |  | 79 | 424 | 425 |
| B-0207 |  |  | 82 | 326 | 327 |
| B-0208 |  |  | 88 | 378 | 379 |
| B-0209 |  |  | 83 | 362 | 363 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0210 |  |  | 100 | 364 | 365 |
| B-0211 |  |  | 60 | 325 | 326 |
| B-0212 |  |  | 79 | 339 | 340 |
| B-0213 |  |  | 71 | 353 | 354 |
| B-0214 |  |  | 77 | 311 | 312 |
| B-0215 |  |  | 24 | 353 | 354 |
| B-0216 |  |  | | 339 | 340 |
| B-0217 |  |  | | 381 | 382 |
| B-0218 |  |  | | 365 | 366 |
| B-0219 |  |  | | 401 | 402 |





















T06031-08212001

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0220 |  |  | | 415 | 416 |
| B-0221 |  |  | | 367 | 368 |





















FOUO: 08212001

















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0222 |  |  | 96 | 486 | 487 |
| B-0223 |  |  | 100 | 465 | 466 |
| B-0224 |  |  | 75 | 486 | 509a |
| B-0225 |  |  | 100 | 442 | 443 |
| B-0226 |  |  | 88 | 482 | 483 |
| B-0227 |  |  | 73 | 482 | 483 |
| B-0228 |  |  | 37 | 452 | - |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0229 |  |  | 100 | 476 | 477 |
| B-0230 |  |  | 94 | 476 | 477 |
| B-0231 |  |  | 100 | 460 | 461 |
| B-0232 |  |  | 90 | 440 | 441 |
| B-0233 |  |  | 99 | 476 | 477 |
| B-0234 |  |  | 100 | 486 | 487,489 |
| B-0235 |  |  | 89 | 486 | 487,489 |
| B-0236 |  |  | 100 | 476 | 477 |
| B-0237 |  |  | 100 | 476 | 477 |
| B-0238 |  |  | 92 | 438 | - |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0239 |  |  | 100 | 442 | 443 |
| B-0240 |  |  | 100 | 442 | 443 |
| B-0241 |  |  | 100 | 476 | 477 |
| B-0242 |  |  | 100 | 460 | 461 |
| B-0243 |  |  | 87 | 456 | 457 |
| B-0244 |  |  | 100 | 436 | 437 |
| B-0245 |  |  | 100 | 422 | 423 |
| B-0246 |  |  | 100 | 452 | 453 |
| B-0247 |  |  | 100 | 476 | 477 |
| B-0248 |  |  | 73 | 468 | - |





















R¹





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0249 |  |  | 100 | 516 | 517,519 |
| B-0250 |  |  | 72 | 458 | - |
| B-0251 |  |  | 100 | 427 | 428 |
| B-0252 |  |  | 100 | 450 | 451 |
| B-0253 |  |  | 100 | 472 | 473 |
| B-0254 |  |  | 100 | 433 | 434 |
| B-0255 |  |  | 84 | 547 | 548 |
| B-0256 |  |  | 100 | 484 | 507a |
| B-0257 |  |  | 85 | 534 | 535 |
| B-0258 |  |  | 100 | 491 | 492 |



| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0259 |  |  | 100 | 554 | 555 |
| B-0260 |  |  | 91 | 500 | 501 |
| B-0261 |  |  | 100 | 486 | 487 |
| B-0262 |  |  | 100 | 481 | 482 |
| B-0263 |  |  | 100 | 554 | 555 |
| B-0264 |  |  | 75 | 375 | 376 |
| B-0265 |  |  | 71 | 459 | 460 |
| B-0266 |  |  | 100 | 412 | 413 |

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0267 |  |  | 100 | 386 | 387 |
| B-0268 |  |  | 89 | 406 | 407 |
| B-0269 |  |  | 84 | 386 | 387 |
| B-0270 |  |  | 92 | 440 | 441 |
| B-0271 |  |  | 98 | 428 | 429 |
| B-0272 |  |  | 57 | 498 | 499 |
| B-0273 |  |  | 100 | 440 | 441 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0274 |  |  | 94 | 397 | 398 |
| B-0275 |  |  | 90 | 422 | 423 |
| B-0276 |  |  | 100 | 408 | 409 |
| B-0277 |  |  | 88 | 408 | 409 |
| B-0278 |  |  | 100 | 426 | 427 |
| B-0279 |  |  | 54 | 440 | 441 |
| B-0280 |  |  | 79 | 414 | 415 |
| B-0281 |  |  | 82 | 458 | 459 |
| B-0282 |  |  | 89 | 426 | 427 |
| B-0283 |  |  | 90 | 458 | 459 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0284 |  |  | 100 | 458 | 459 |
| B-0285 |  |  | 94 | 458 | 459 |
| B-0286 |  |  | 100 | 458 | 459 |
| B-0287 |  |  | 96 | 458 | 459 |
| B-0288 |  |  | 100 | 458 | 459 |
| B-0289 |  |  | 96 | 406 | 407 |
| B-0290 |  |  | 96 | 386 | 387 |
| B-0291 |  |  | 95 | 440 | 441 |
| B-0292 |  |  | 94 | 390 | 391 |
| B-0293 |  |  | 100 | 408 | 409 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0294 |  |  | 100 | 440 | 441 |
| B-0295 |  |  | 91 | 408 | 409 |
| B-0296 |  |  | 96 | 426 | 427 |
| B-0297 |  |  | 88 | 390 | 391 |
| B-0298 |  |  | 95 | 408 | 409 |
| B-0299 |  |  | 90 | 408 | 409 |
| B-0300 |  |  | 95 | 406 | 407 |
| B-0301 |  |  | 99 | 450 | 451,453 |
| B-0302 |  |  | 94 | 440 | 441 |
| B-0303 |  |  | 100 | 378 | 379 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0304 |  |  | 100 | 391 | 392 |





















100489-1307
102021-082200F



| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0305 |  |  | 70 | 326 | 327 |
| B-0306 |  |  | 59 | 340 | 341 |
| B-0307 |  |  | 59 | 354 | 355 |
| B-0308 |  |  | 60 | 368 | 369 |
| B-0309 |  |  | 61 | 352 | 353 |
| B-0310 |  |  | 61 | 366 | 367 |
| B-0311 |  |  | 65 | 356 | 357 |

| Example# | R ² | R ³ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0312 |  |  | 75 | 342 | 343 |
| B-0313 |  |  | 68 | 356 | 357 |
| B-0314 |  |  | 31 | 370 | 371 |
| B-0315 |  |  | 61 | 384 | 385 |
| B-0316 |  |  | 75 | 368 | 369 |
| B-0317 |  |  | 62 | 366 | 367 |
| B-0318 |  |  | 52 | 388 | 389 |
| B-0319 |  |  | 53 | 424 | 425 |
| B-0320 |  |  | 50 | 424 | 425 |
| B-0321 |  |  | 54 | 442 | 443 |


| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0322 |  |  | 64 | 474 | 475 |
| B-0323 |  |  | 58 | 474 | 475 |
| B-0324 |  |  | 60 | 422 | 423 |
| B-0325 |  |  | 64 | 422 | 423 |
| B-0326 |  |  | 58 | 422 | 423 |
| B-0327 |  |  | 63 | 378 | 379 |
| B-0328 |  |  | 68 | 389 | 390 |
| B-0329 |  |  | 63 | 362 | 363 |
| B-0330 |  |  | 48 | 376 | 377 |
| B-0331 |  |  | 66 | 424 | 425 |

| Example# | R ² | R ⁴ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0332 |  |  | 61 | 442 | 443 |
| B-0333 |  |  | 60 | 458 | 459 |
| B-0334 |  |  | 55 | 502 | 503 |
| B-0335 |  |  | 60 | 454 | 455 |
| B-0336 |  |  | 100 | 500 | 501 |
| B-0337 |  |  | 65 | 458 | - |
| B-0338 |  |  | 69 | 502 | 503 |
| B-0339 |  |  | 69 | 454 | - |
| B-0340 |  |  | 77 | 492 | 493 |
| B-0341 |  |  | 64 | 458 | 459 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0342 |  |  | 41 | 438 | - |
| B-0343 |  |  | 63 | 430 | 431 |
| B-0344 |  |  | 96 | 464 | 465 |
| B-0345 |  |  | 62 | 507 | 508 |
| B-0346 |  |  | 56 | 497 | 498 |
| B-0347 |  |  | 61 | 341 | 342 |
| B-0348 |  |  | 3 | 367 | - |
| B-0349 |  |  | 57 | 403 | 404 |
| B-0350 |  |  | 57 | 481 | 482 |
| B-0351 |  |  | 31 | 355 | 356 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0352 |  |  | 51 | 397 | 398 |

4002180-120701



























| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0353 | | | 71 | 382 | 383 |
| B-0354 | | | 35 | 512 | 513 |
| B-0355 | | | 37 | 352 | 353 |
| B-0356 | | | 57 | 404 | 405 |
| B-0357 | | | 88 | 366 | 367 |
| B-0358 | | | 88 | 410 | 411 |
| B-0359 | | | 100 | 324 | 325 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0360 |  |  | 56 | 364 | 365 |
| B-0361 |  |  | 70 | 350 | 351 |
| B-0362 |  |  | 100 | 464 | 465 |
| B-0363 |  |  | 73 | 512 | 513 |
| B-0364 |  |  | 88 | 377 | 378 |
| B-0365 |  |  | 70 | 396 | 397 |
| B-0366 |  |  | 100 | 354 | 355 |
| B-0367 |  |  | 71 | 416 | 417 |
| B-0368 |  |  | 86 | 454 | 455 |
| B-0369 |  |  | 40 | 440 | 441 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0370 |  |  | 94 | 364 | 365 |
| B-0371 |  |  | 88 | 460 | 461 |
| B-0372 |  |  | 69 | 430 | 431 |
| B-0373 |  |  | 100 | 430 | 431 |
| B-0374 |  |  | 75 | 400 | 401 |
| B-0375 |  |  | 74 | 386 | 387 |
| B-0376 |  |  | 53 | 378 | 379 |
| B-0377 |  |  | 71 | 387 | 388 |
| B-0378 |  |  | 69 | 387 | 388 |
| B-0379 |  |  | 66 | 387 | 388 |





















T02021-08412001

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|--|--|--------|---------------------|--------------------------------|
| B-0380 |  |  | 85 | 416 | 417 |
| B-0381 |  |  | 93 | 430 | 431 |
| B-0382 |  |  | 84 | 382 | 383 |
| B-0383 |  |  | 74 | 583 | 584 |
| B-0384 |  |  | 63 | 438 | 439 |

















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0385 |  |  | 83 | 440 | 441 |
| B-0386 |  |  | 99 | 422 | 423 |
| B-0387 |  |  | 47 | 388 | 389 |
| B-0388 |  |  | 100 | 448 | 449 |
| B-0389 |  |  | 71 | 436 | 437 |
| B-0390 |  |  | 100 | 458 | 459 |
| B-0391 |  |  | 45 | 414 | 415 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0392 |  |  | 100 | 440 | 441 |
| B-0393 |  |  | 75 | 388 | 389 |
| B-0394 |  |  | 92 | 402 | 403 |
| B-0395 |  |  | 87 | 374 | 375 |
| B-0396 |  |  | 86 | 360 | 361 |
| B-0397 |  |  | 81 | 452 | 453 |
| B-0398 |  |  | 88 | 428 | 429 |
| B-0399 |  |  | 99 | 436 | 437 |
| B-0400 |  |  | 82 | 482 | 483 |
| B-0401 |  |  | 94 | 367 | 368 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0402 |  |  | 73 | 325 | 326 |
| B-0403 |  |  | 91 | 415 | 416 |
| B-0404 |  |  | 41 | 379 | 380 |
| B-0405 |  |  | 88 | 395 | 396 |
| B-0406 |  |  | 100 | 419 | 420 |
| B-0407 |  |  | 52 | 353 | 354 |
| B-0408 |  |  | 83 | 339 | 340 |
| B-0409 |  |  | 74 | 415 | 416 |
| B-0410 |  |  | 100 | 419 | 420 |
| B-0411 |  |  | 94 | 429 | 430 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0412 |  |  | 91 | 365 | 366 |
| B-0413 |  |  | 79 | 367 | 368 |
| B-0414 |  |  | 85 | 429 | 430 |
| B-0415 |  |  | 82 | 401 | 402 |
| B-0416 |  |  | 93 | 429 | 430 |
| B-0417 |  |  | 97 | 429 | 430 |
| B-0418 |  |  | 100 | 419 | 420 |
| B-0419 |  |  | 100 | 431 | 432 |
| B-0420 |  |  | 36 | 381 | 382 |
| B-0421 |  |  | 96 | 353 | 354 |

400480 400480







| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0422 |  |  | 100 | 461 | 462 |
| B-0423 |  |  | 100 | 406 | 407 |
| B-0424 |  |  | 76 | 366 | 367 |
| B-0425 |  |  | 21 | 368 | 369 |
| B-0426 |  |  | 100 | 354 | 355 |
| B-0427 |  |  | 100 | 379 | 380 |
| B-0428 |  |  | 100 | 379 | 380 |
| B-0429 |  |  | 86 | 368 | 369 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0430 |  |  | 51 | 500 | 501 |
| B-0431 |  |  | 76 | 479 | 480 |
| B-0432 |  |  | 90 | 500 | 501 |
| B-0433 |  |  | 96 | 456 | 457 |
| B-0434 |  |  | 75 | 496 | 497 |
| B-0435 |  |  | 52 | 496 | 497 |
| B-0436 |  |  | 73 | 506 | |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0437 |  |  | 19 | 466 | |
| B-0438 |  |  | 100 | 490 | 491 |
| B-0439 |  |  | 67 | 464 | 465 |
| B-0440 |  |  | 96 | 472 | 473 |
| B-0441 |  |  | 87 | 472 | 473 |
| B-0442 |  |  | 72 | 481 | 482 |
| B-0443 |  |  | 66 | 473 | 474 |
| B-0444 |  |  | 80 | 515 | 516 |
| B-0445 |  |  | 94 | 490 | 491 |
| B-0446 |  |  | 84 | 464 | 465 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0447 |  |  | 89 | 470 | 471 |
| B-0448 |  |  | 100 | 490 | 491 |
| B-0449 |  |  | 100 | 474 | 475 |
| B-0450 |  |  | 100 | 447 | 448 |
| B-0451 |  |  | 100 | 454 | 455 |
| B-0452 |  |  | 95 | 496 | 497 |
| B-0453 |  |  | 100 | 490 | 491 |
| B-0454 |  |  | 100 | 500 | 501 |
| B-0455 |  |  | 96 | 500 | 501 |
| B-0456 |  |  | 89 | 494 | 495 |





















FOUOET 08472004











| Example# | R ² | R ³ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0457 |  |  | 93 | 482 | 483 |
| B-0458 |  |  | 100 | 490 | 491 |
| B-0459 |  |  | 100 | 490 | 491 |

400430-1004
10/20/01 08/20/01















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0460 |  |  | 93 | 450 | 451 |
| B-0461 |  |  | 84 | 452 | 453 |
| B-0462 |  |  | 96 | 456 | 457 |
| B-0463 |  |  | 66 | 456 | 457 |
| B-0464 |  |  | 69 | 490 | 491 |
| B-0465 |  |  | 86 | 490 | 491 |
| B-0466 |  |  | 78 | 474 | 475 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0467 |  |  | 78 | 470 | 471 |
| B-0468 |  |  | 91 | 450 | 451 |
| B-0469 |  |  | 85 | 436 | 437 |
| B-0470 |  |  | 99 | 466 | 467 |
| B-0471 |  |  | 100 | 490 | 491 |
| B-0472 |  |  | 37 | 482 | 483 |
| B-0473 |  |  | 92 | 462 | 463 |
| B-0474 |  |  | 99 | 530 | 532 |
| B-0475 |  |  | 55 | 472 | 473 |
| B-0476 |  |  | 89 | 441 | 442 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0477 |  |  | 79 | 464 | 465 |
| B-0478 |  |  | 92 | 486 | 487 |
| B-0479 |  |  | 97 | 447 | 448 |
| B-0480 |  |  | 75 | 561 | 562 |
| B-0481 |  |  | 74 | 498 | 499 |
| B-0482 |  |  | 57 | 548 | 549 |
| B-0483 |  |  | 83 | 505 | 506 |
| B-0484 |  |  | 100 | 568 | 569 |
| B-0485 |  |  | 100 | 495 | 496 |
| B-0486 |  |  | 100 | 426 | 427 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|--|--|--------|---------------------|--------------------------------|
| B-0487 |  |  | 32 | 389 | 390 |
| B-0488 |  |  | 100 | 568 | 569 |
| B-0489 |  |  | 91 | 500 | 501 |
| B-0490 |  |  | 40 | 473 | 474 |
| B-0491 |  |  | 73 | 514 | 515 |



100480-100491


| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0492 |  |  | 89 | 400 | 401 |
| B-0493 |  |  | 100 | 420 | 421 |
| B-0494 |  |  | 100 | 400 | 401 |
| B-0495 |  |  | 100 | 454 | 455 |
| B-0496 |  |  | 100 | 442 | 443 |
| B-0497 |  |  | 50 | 512 | 513 |
| B-0498 |  |  | 100 | 454 | 455 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0499 |  |  | 98 | 411 | 412 |
| B-0500 |  |  | 100 | 436 | 437 |
| B-0501 |  |  | 100 | 422 | 423 |
| B-0502 |  |  | 100 | 422 | 423 |
| B-0503 |  |  | 92 | 440 | 441 |
| B-0504 |  |  | 67 | 454 | 455 |
| B-0505 |  |  | 68 | 428 | 429 |
| B-0506 |  |  | 98 | 472 | 473 |
| B-0507 |  |  | 82 | 440 | 441 |
| B-0508 |  |  | 99 | 472 | 473 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0509 |  |  | 100 | 472 | 473 |
| B-0510 |  |  | 96 | 472 | 473 |
| B-0511 |  |  | 100 | 472 | 473 |
| B-0512 |  |  | 100 | 472 | 473 |
| B-0513 |  |  | 100 | 472 | 473 |
| B-0514 |  |  | 100 | 420 | 421 |
| B-0515 |  |  | 100 | 400 | 401 |
| B-0516 |  |  | 100 | 454 | 455 |
| B-0517 |  |  | 100 | 404 | 405 |
| B-0518 |  |  | 99 | 422 | 423 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0519 |  |  | 100 | 454 | 455 |
| B-0520 |  |  | 98 | 422 | 423 |
| B-0521 |  |  | 99 | 440 | 441 |
| B-0522 |  |  | 88 | 404 | 405 |
| B-0523 |  |  | 100 | 422 | 423 |
| B-0524 |  |  | 100 | 422 | 423 |
| B-0525 |  |  | 100 | 420 | 421 |
| B-0526 |  |  | 100 | 464 | 465 |
| B-0527 |  |  | 100 | 454 | 455 |
| B-0528 |  |  | 100 | 392 | 393 |











| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0529 |  |  | 94 | 405 | 406 |

















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0530 | | | 67 | 382 | 383 |
| B-0531 | | | 66 | 512 | 513 |
| B-0532 | | | 37 | 352 | 353 |
| B-0533 | | | 56 | 404 | 405 |
| B-0534 | | | 100 | 366 | 367 |
| B-0535 | | | 100 | 410 | 411 |
| B-0536 | | | 41 | 324 | 325 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0537 |  |  | 100 | 364 | 365 |
| B-0538 |  |  | 29 | 350 | 351 |
| B-0539 |  |  | 70 | 464 | 465 |
| B-0540 |  |  | 50 | 512 | 513 |
| B-0541 |  |  | 61 | 377 | 378 |
| B-0542 |  |  | 61 | 396 | 397 |
| B-0543 |  |  | 59 | 354 | 355 |
| B-0544 |  |  | 45 | 416 | 417 |
| B-0545 |  |  | 100 | 454 | 455 |
| B-0546 |  |  | 44 | 440 | 441 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0547 |  |  | 64 | 364 | 365 |
| B-0548 |  |  | 89 | 460 | 461 |
| B-0549 |  |  | 100 | 430 | 431 |
| B-0550 |  |  | 100 | 430 | 431 |
| B-0551 |  |  | 81 | 400 | 401 |
| B-0552 |  |  | 38 | 386 | 387 |
| B-0553 |  |  | 31 | 378 | 379 |
| B-0554 |  |  | 100 | 387 | 388 |
| B-0555 |  |  | 66 | 387 | 388 |
| B-0556 |  |  | 32 | 387 | 388 |





















| Example# | R ² | R ³ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|--|--------|---------------------|--------------------------------|
| B-0557 |  |  | 70 | 416 | 417 |
| B-0558 |  |  | 57 | 430 | 431 |
| B-0559 |  |  | 74 | 382 | 383 |
| B-0560 |  |  | 36 | 583 | 584 |
| B-0561 |  |  | 51 | 438 | 439 |

















4003480-10704
FOI 0842001















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0562 |  |  | 88 | 440 | 441 |
| B-0563 |  |  | 68 | 422 | 423 |
| B-0564 |  |  | 47 | 388 | 389 |
| B-0565 |  |  | 100 | 448 | 449 |
| B-0566 |  |  | 76 | 436 | 437 |
| B-0567 |  |  | 99 | 458 | 459 |
| B-0568 |  |  | 45 | 414 | 415 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0569 |  |  | 88 | 440 | 441 |
| B-0570 |  |  | 61 | 388 | 389 |
| B-0571 |  |  | 58 | 402 | 403 |
| B-0572 |  |  | 75 | 374 | 375 |
| B-0573 |  |  | 72 | 360 | 361 |
| B-0574 |  |  | 97 | 452 | 453 |
| B-0575 |  |  | 71 | 428 | 429 |
| B-0576 |  |  | 88 | 436 | 437 |
| B-0577 |  |  | 72 | 482 | 483 |
| B-0578 |  |  | 89 | 367 | 368 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0579 |  |  | 100 | 325 | 326 |
| B-0580 |  |  | 75 | 415 | 416 |
| B-0581 |  |  | 44 | 379 | 380 |
| B-0582 |  |  | 75 | 395 | 396 |
| B-0583 |  |  | 80 | 419 | 420 |
| B-0584 |  |  | 57 | 353 | 354 |
| B-0585 |  |  | 83 | 339 | 340 |
| B-0586 |  |  | 71 | 415 | 416 |
| B-0587 |  |  | 100 | 419 | 420 |
| B-0588 |  |  | 94 | 429 | 430 |







| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0589 |  |  | 78 | 365 | 366 |
| B-0590 |  |  | 82 | 367 | 368 |
| B-0591 |  |  | 72 | 429 | 430 |
| B-0592 |  |  | 82 | 401 | 402 |
| B-0593 |  |  | 88 | 429 | 430 |
| B-0594 |  |  | 100 | 429 | 430 |
| B-0595 |  |  | 99 | 419 | 420 |
| B-0596 |  |  | 93 | 431 | 432 |
| B-0597 |  |  | 40 | 381 | 382 |
| B-0598 |  |  | 93 | 353 | 354 |















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0599 |  |  | 100 | 461 | 462 |
| B-0600 |  |  | 98 | 406 | 407 |
| B-0601 |  |  | 66 | 366 | 367 |
| B-0602 |  |  | 25 | 368 | 369 |
| B-0603 |  |  | 90 | 354 | 355 |
| B-0604 |  |  | 86 | 379 | 380 |
| B-0605 |  |  | 87 | 379 | 380 |
| B-0606 |  |  | 72 | 368 | 369 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0607 |  |  | 34 | 500 | 501 |
| B-0608 |  |  | 100 | 479 | 480 |
| B-0609 |  |  | 82 | 500 | 501 |
| B-0610 |  |  | 100 | 456 | 457 |
| B-0611 |  |  | 76 | 496 | 497 |
| B-0612 |  |  | 69 | 496 | 497 |
| B-0613 |  |  | 61 | 506 | |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0614 |  |  | 18 | 466 | |
| B-0615 |  |  | 100 | 490 | 491 |
| B-0616 |  |  | 77 | 464 | 465 |
| B-0617 |  |  | 93 | 472 | 473 |
| B-0618 |  |  | 84 | 472 | 473 |
| B-0619 |  |  | 71 | 481 | 482 |
| B-0620 |  |  | 89 | 473 | 474 |
| B-0621 |  |  | 68 | 515 | 516 |
| B-0622 |  |  | 70 | 490 | 491 |
| B-0623 |  |  | 92 | 464 | 465 |











| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0624 |  |  | 98 | 470 | 471 |
| B-0625 |  |  | 96 | 490 | 491 |
| B-0626 |  |  | 100 | 474 | 475 |
| B-0627 |  |  | 100 | 447 | 448 |
| B-0628 |  |  | 64 | 454 | 455 |
| B-0629 |  |  | 100 | 496 | 497 |
| B-0630 |  |  | 85 | 490 | 491 |
| B-0631 |  |  | 75 | 500 | 501 |
| B-0632 |  |  | 83 | 500 | 501 |
| B-0633 |  |  | 58 | 494 | 495 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0634 |  |  | 63 | 482 | 483 |
| B-0635 |  |  | 95 | 490 | 491 |
| B-0636 |  |  | 100 | 490 | 491 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0637 |  |  | 91 | 450 | 451 |
| B-0638 |  |  | 96 | 436 | 437 |
| B-0639 |  |  | 100 | 456 | 457 |
| B-0640 |  |  | 100 | 456 | 457 |
| B-0641 |  |  | 88 | 490 | 491 |
| B-0642 |  |  | 99 | 490 | 491 |
| B-0643 |  |  | 92 | 474 | 475 |





















| Example# | R ² | R ⁴ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0644 |  |  | 100 | 470 | 471 |
| B-0645 |  |  | 92 | 450 | 451 |
| B-0646 |  |  | 100 | 436 | 437 |
| B-0647 |  |  | 90 | 466 | 467 |
| B-0648 |  |  | 94 | 490 | 491 |
| B-0649 |  |  | 57 | 482 | |
| B-0650 |  |  | 82 | 462 | 463 |
| B-0651 |  |  | 100 | 530 | 531 |
| B-0652 |  |  | 53 | 472 | |
| B-0653 |  |  | 84 | 441 | 442 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0654 |  |  | 92 | 464 | 465 |
| B-0655 |  |  | 100 | 486 | 487 |
| B-0656 |  |  | 98 | 447 | 448 |
| B-0657 |  |  | 85 | 561 | 562 |
| B-0658 |  |  | 92 | 498 | 499 |
| B-0659 |  |  | 46 | 548 | 549 |
| B-0660 |  |  | 80 | 505 | 506 |
| B-0661 |  |  | 100 | 568 | 569 |
| B-0662 |  |  | 98 | 495 | 496 |
| B-0663 |  |  | 74 | 426 | 427 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|--|--------|---------------------|--------------------------------|
| B-0664 |  |  | 30 | 389 | 390 |
| B-0665 |  |  | 100 | 568 | 569 |
| B-0666 |  |  | 93 | 500 | 501 |
| B-0667 |  |  | 54 | 473 | 474 |
| B-0668 |  |  | 66 | 514 | 515 |



400430-10701
FOUO-08/2004

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0669 |  |  | 65 | 400 | 401 |
| B-0670 |  |  | 45 | 420 | 421 |
| B-0671 |  |  | 43 | 400 | 401 |
| B-0672 |  |  | 45 | 454 | 455 |
| B-0673 |  |  | 41 | 442 | 443 |
| B-0674 |  |  | 16 | 512 | 513 |
| B-0675 |  |  | 39 | 454 | 455 |


| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0676 |  |  | 34 | 411 | 412 |
| B-0677 |  |  | 46 | 436 | 437 |
| B-0678 |  |  | 37 | 422 | 423 |
| B-0679 |  |  | 34 | 422 | 423 |
| B-0680 |  |  | 60 | 440 | 441 |
| B-0681 |  |  | 31 | 454 | 455 |
| B-0682 |  |  | 37 | 428 | 429 |
| B-0683 |  |  | 46 | 472 | 473 |
| B-0684 |  |  | 50 | 440 | 441 |
| B-0685 |  |  | 44 | 472 | 473 |

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0686 |  |  | 66 | 472 | 473 |
| B-0687 |  |  | 57 | 472 | 473 |
| B-0688 |  |  | 52 | 472 | 473 |
| B-0689 |  |  | 42 | 472 | 473 |
| B-0690 |  |  | 34 | 472 | 473 |
| B-0691 |  |  | 52 | 420 | 421 |
| B-0692 |  |  | 41 | 400 | 401 |
| B-0693 |  |  | 56 | 454 | 455 |
| B-0694 |  |  | 38 | 404 | 405 |
| B-0695 |  |  | 43 | 422 | 423 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0696 |  |  | 57 | 454 | 455 |
| B-0697 |  |  | 51 | 422 | 423 |
| B-0698 |  |  | 59 | 440 | 441 |
| B-0699 |  |  | 46 | 404 | 405 |
| B-0700 |  |  | 47 | 422 | 423 |
| B-0701 |  |  | 46 | 422 | 423 |
| B-0702 |  |  | 43 | 420 | 421 |
| B-0703 |  |  | 57 | 464 | 465 |
| B-0704 |  |  | 44 | 454 | 455 |
| B-0705 |  |  | 33 | 392 | 393 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0706 |  |  | 35 | 405 | 406 |

















1003490-10001
10/02/01 08:22001




| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0707 | | | 76 | 516 | 517 |
| B-0708 | | | 61 | 498 | 499 |
| B-0709 | | | 37 | 464 | 465 |
| B-0710 | | | 76 | 524 | 525 |
| B-0711 | | | 75 | 512 | 513 |
| B-0712 | | | 91 | 534 | 535 |
| B-0713 | | | 42 | 490 | 491 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0724 |  |  | 75 | 401 | 402 |
| B-0725 |  |  | 83 | 491 | 492 |
| B-0726 |  |  | 24 | 455 | 456 |
| B-0727 |  |  | 67 | 471 | 472 |
| B-0728 |  |  | 89 | 495 | 496 |
| B-0729 |  |  | 38 | 429 | 430 |
| B-0730 |  |  | 76 | 415 | 416 |
| B-0731 |  |  | 60 | 491 | 492 |
| B-0732 |  |  | 86 | 495 | 496 |
| B-0733 |  |  | 81 | 505 | 506 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0734 |  |  | 87 | 441 | 442 |
| B-0735 |  |  | 83 | 443 | 444 |
| B-0736 |  |  | 91 | 505 | 506 |
| B-0737 |  |  | 9 | 477 | - |
| B-0738 |  |  | 87 | 505 | 506 |
| B-0739 |  |  | 82 | 505 | 506 |
| B-0740 |  |  | 85 | 495 | 496 |
| B-0741 |  |  | 68 | 507 | 508 |
| B-0742 |  |  | 14 | 457 | - |
| B-0743 |  |  | 77 | 429 | 430 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0744 |  |  | 86 | 537 | 538 |
| B-0745 |  |  | 82 | 482 | 483 |
| B-0746 |  |  | 74 | 442 | 443 |
| B-0747 |  |  | 83 | 444 | 445 |
| B-0748 |  |  | 94 | 430 | 431 |
| B-0749 |  |  | 100 | 455 | 456 |
| B-0750 |  |  | 100 | 455 | 456 |
| B-0751 |  |  | 48 | 444 | 445 |

































| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0752 | | | 84 | 516 | 517 |
| B-0753 | | | 67 | 498 | 499 |
| B-0754 | | | 31 | 464 | 465 |
| B-0755 | | | 85 | 524 | 525 |
| B-0756 | | | 77 | 512 | 513 |
| B-0757 | | | 57 | 534 | 535 |
| B-0758 | | | 36 | 490 | 491 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0759 |  |  | 79 | 516 | 517 |
| B-0760 |  |  | 53 | 464 | 465 |
| B-0761 |  |  | 50 | 478 | 479 |
| B-0762 |  |  | 60 | 450 | 451 |
| B-0763 |  |  | 75 | 436 | 437 |
| B-0764 |  |  | 43 | 528 | 529 |
| B-0765 |  |  | 75 | 504 | 505 |
| B-0766 |  |  | 67 | 512 | 513 |
| B-0767 |  |  | 43 | 558 | 559 |
| B-0768 |  |  | 78 | 443 | 444 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0769 |  |  | 76 | 401 | 402 |
| B-0770 |  |  | 57 | 491 | 492 |
| B-0771 |  |  | 14 | 455 | 456 |
| B-0772 |  |  | 72 | 471 | 472 |
| B-0773 |  |  | 100 | 495 | 496 |
| B-0774 |  |  | 41 | 429 | 430 |
| B-0775 |  |  | 91 | 415 | 416 |
| B-0776 |  |  | 64 | 491 | 492 |
| B-0777 |  |  | 90 | 495 | 496 |
| B-0778 |  |  | 19 | 505 | 506 |











| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0779 |  |  | 79 | 441 | 442 |
| B-0780 |  |  | 40 | 443 | 444 |
| B-0781 |  |  | 93 | 505 | 506 |
| B-0782 |  |  | 57 | 477 | 478 |
| B-0783 |  |  | 99 | 505 | 506 |
| B-0784 |  |  | 100 | 505 | 506 |
| B-0785 |  |  | 92 | 495 | 496 |
| B-0786 |  |  | 91 | 507 | 508 |
| B-0787 |  |  | 15 | 457 | 458 |
| B-0788 |  |  | 48 | 429 | 430 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0789 |  |  | 91 | 537 | 538 |
| B-0790 |  |  | 93 | 482 | 483 |
| B-0791 |  |  | 76 | 442 | 443 |
| B-0792 |  |  | 96 | 444 | 445 |
| B-0793 |  |  | 54 | 430 | 431 |
| B-0794 |  |  | 100 | 455 | 456 |
| B-0795 |  |  | 100 | 455 | 456 |
| B-0796 |  |  | 94 | 444 | 445 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0797 |  |  | 90 | 458 | 459 |
| B-0798 |  |  | 90 | 588 | 589 |
| B-0799 |  |  | 82 | 428 | 429 |
| B-0800 |  |  | 92 | 480 | 481 |
| B-0801 |  |  | 82 | 442 | 443 |
| B-0802 |  |  | 95 | 486 | 487 |
| B-0803 |  |  | 89 | 400 | 401 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0804 |  |  | 87 | 440 | 441 |
| B-0805 |  |  | 100 | 426 | 427 |
| B-0806 |  |  | 99 | 540 | 541 |
| B-0807 |  |  | 96 | 588 | 589 |
| B-0808 |  |  | 82 | 453 | 454 |
| B-0809 |  |  | 92 | 472 | 473 |
| B-0810 |  |  | 98 | 430 | 431 |
| B-0811 |  |  | 88 | 492 | 493 |
| B-0812 |  |  | 81 | 530 | 531 |
| B-0813 |  |  | 98 | 516 | 517 |











| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0814 |  |  | 100 | 440 | 441 |
| B-0815 |  |  | 100 | 536 | 537 |
| B-0816 |  |  | 99 | 506 | 507 |
| B-0817 |  |  | 98 | 506 | 507 |
| B-0818 |  |  | 86 | 476 | 477 |
| B-0819 |  |  | 90 | 462 | 463 |
| B-0820 |  |  | 91 | 454 | 455 |
| B-0821 |  |  | 69 | 463 | 464 |
| B-0822 |  |  | 79 | 463 | 464 |
| B-0823 |  |  | 79 | 463 | 464 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|--|--------|---------------------|--------------------------------|
| B-0824 |  |  | 82 | 492 | 493 |
| B-0825 |  |  | 100 | 506 | 507 |
| B-0826 |  |  | 97 | 458 | 459 |
| B-0827 |  |  | 100 | 659 | 660 |
| B-0828 |  |  | 97 | 514 | 515 |


| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0829 |  |  | 63 | 458 | 459 |
| B-830 |  |  | 70 | 588 | 589 |
| B-0831 |  |  | 100 | 428 | 429 |
| B-0832 |  |  | 81 | 480 | 481 |
| B-0833 |  |  | 73 | 442 | 443 |
| B-0834 |  |  | 79 | 486 | 487 |
| B-0835 |  |  | 5 | 400 | 401 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0836 |  |  | 28 | 440 | 441 |
| B-0837 |  |  | 81 | 426 | 427 |
| B-0838 |  |  | 84 | 540 | 541 |
| B-0839 |  |  | 80 | 588 | 589 |
| B-0840 |  |  | 71 | 453 | 454 |
| B-0841 |  |  | 55 | 472 | 473 |
| B-0842 |  |  | 71 | 430 | 431 |
| B-0843 |  |  | 68 | 492 | 493 |
| B-0844 |  |  | 61 | 530 | 531 |
| B-0845 |  |  | 84 | 516 | 517 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0846 |  |  | 87 | 440 | 441 |
| B-0847 |  |  | 86 | 536 | 537 |
| B-0848 |  |  | 79 | 506 | 507 |
| B-0849 |  |  | 81 | 506 | 507 |
| B-0850 |  |  | 69 | 476 | 477 |
| B-0851 |  |  | 83 | 462 | 463 |
| B-0852 |  |  | 77 | 454 | 455 |
| B-0853 |  |  | 87 | 463 | 464 |
| B-0854 |  |  | 73 | 463 | 464 |
| B-0855 |  |  | 92 | 463 | 464 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0856 |  |  | 75 | 492 | 493 |
| B-0857 |  |  | 86 | 506 | 507 |
| B-0858 |  |  | 84 | 458 | 459 |
| B-0859 |  |  | 80 | 659 | 660 |
| B-0860 |  |  | 94 | 514 | 515 |


1004180-100701























| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0861 | | | 84 | 583 | 584 |
| B-0862 | | | 96 | 475 | 476 |
| B-0863 | | | 69 | 423 | 424 |
| B-0864 | | | 86 | 437 | 438 |
| B-0865 | | | 62 | 395 | - |
| B-0866 | | | 81 | 421 | 422 |
| B-0867 | | | 100 | 535 | 536 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0868 |  |  | 89 | 583 | 584 |
| B-0869 |  |  | 100 | 448 | 449 |
| B-0870 |  |  | 100 | 425 | 426 |
| B-0871 |  |  | 100 | 487 | 488 |
| B-0872 |  |  | 78 | 501 | 502 |
| B-0873 |  |  | 78 | 471 | 472 |
| B-0874 |  |  | 92 | 475 | 476 |
| B-0875 |  |  | 37 | 458 | 459 |
| B-0876 |  |  | 69 | 507 | 508 |
| B-0877 |  |  | 70 | 445 | 446 |


| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0878 |  |  | 91 | 431 | 432 |
| B-0879 |  |  | 92 | 511 | 512 |
| B-0880 |  |  | 89 | 410 | 411 |
| B-0881 |  |  | 84 | 490 | 491 |
| B-0882 |  |  | 85 | 500 | 501 |
| B-0883 |  |  | 85 | 424 | 425 |
| B-0884 |  |  | 86 | 532 | 533 |























| Example# | R ² | R ^j | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0885 | | | 51 | 583 | - |
| B-0886 | | | 97 | 475 | - |
| B-0887 | | | 29 | 423 | 424 |
| B-0888 | | | 82 | 437 | 438 |
| B-0889 | | | 93 | 395 | 396 |
| B-0890 | | | 91 | 421 | 422 |
| B-0891 | | | 43 | 535 | 536 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0892 |  |  | 62 | 583 | 584 |
| B-0893 |  |  | 95 | 448 | 449 |
| B-0894 |  |  | 100 | 425 | 426 |
| B-0895 |  |  | 76 | 487 | 488 |
| B-0896 |  |  | 62 | 501 | 502 |
| B-0897 |  |  | 80 | 471 | 472 |
| B-0898 |  |  | 79 | 475 | 476 |
| B-0899 |  |  | 70 | 458 | 459 |
| B-0900 |  |  | 62 | 507 | 508 |
| B-0901 |  |  | 43 | 445 | 446 |















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0902 |  |  | 93 | 431 | 432 |
| B-0903 |  |  | 100 | 511 | 512 |
| B-0904 |  |  | 95 | 410 | 411 |
| B-0905 |  |  | 89 | 490 | 491 |
| B-0906 |  |  | 69 | 500 | 501 |
| B-0907 |  |  | 28 | 424 | 425 |
| B-0908 |  |  | 64 | 532 | 533 |




| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-0909 | | | 83 | 542 | 543 |
| B-0910 | | | 80 | 434 | 435 |
| B-0911 | | | 91 | 382 | 383 |
| B-0912 | | | 100 | 396 | 397 |
| B-0913 | | | 94 | 354 | 355 |
| B-0914 | | | 95 | 380 | 381 |
| B-0915 | | | 98 | 494 | 495 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0916 |  |  | 84 | 542 | 543 |
| B-0917 |  |  | 79 | 407 | 408 |
| B-0918 |  |  | 89 | 384 | 385 |
| B-0919 |  |  | 91 | 446 | 447 |
| B-0920 |  |  | 99 | 460 | 461 |
| B-0921 |  |  | 84 | 430 | 431 |
| B-0922 |  |  | 81 | 434 | 435 |
| B-0923 |  |  | 76 | 417 | 418 |
| B-0924 |  |  | 70 | 466 | 467 |
| B-0925 |  |  | 64 | 404 | 405 |





















1003480-10034





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0926 |  |  | 47 | 390 | 391 |
| B-0927 |  |  | 89 | 470 | 471 |
| B-0928 |  |  | 53 | 369 | 370 |
| B-0929 |  |  | 100 | 449 | 450 |
| B-0930 |  |  | 14 | 459 | 460 |
| B-0931 |  |  | 41 | 383 | 384 |
| B-0932 |  |  | 94 | 491 | 492 |























| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|------------------|--------------------------|
| B-0933 | | | 48 | 447 | 448 |
| B-0934 | | | 44 | 429 | 430 |
| B-0935 | | | 33 | 485 | 486 |
| B-0936 | | | 30 | 479 | - |
| B-0937 | | | 68 | 367 | 368 |
| B-0938 | | | 72 | 479 | 480 |
| B-0939 | | | 76 | 415 | 416 |

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-0940 |  |  | 36 | 397 | 398 |
| B-0941 |  |  | 41 | 441 | 442 |
| B-0942 |  |  | 27 | 473 | 474 |
| B-0943 |  |  | 55 | 493 | 494 |
| B-0944 |  |  | 53 | 473 | 474 |
| B-0945 |  |  | 82 | 429 | 430 |
| B-0946 |  |  | 100 | 459 | 460 |
| B-0947 |  |  | 60 | 425 | 426 |
| B-0948 |  |  | 100 | 431 | 432 |
| B-0949 |  |  | 98 | 473 | 474 |



| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-0950 |  |  | 64 | 419 | 420 |
| B-0951 |  |  | 100 | 469 | 470 |
| B-0952 |  |  | 61 | 469 | 470 |
| B-0953 |  |  | 67 | 425 | 426 |
| B-0954 |  |  | 62 | 431 | 432 |
| B-0955 |  |  | 39 | 461 | 462 |
| B-0956 |  |  | 66 | 429 | 430 |
| B-0957 |  |  | 93 | 429 | 430 |
| B-0958 |  |  | 86 | 365 | 366 |
| B-0959 |  |  | 73 | 451 | 452 |















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-0960 |  |  | 98 | 485 | 486 |
| B-0961 |  |  | 100 | 469 | 470 |
| B-0962 |  |  | 100 | 419 | 420 |
| B-0963 |  |  | 83 | 401 | 402 |
| B-0964 |  |  | 38 | 429 | 430 |
| B-0965 |  |  | 90 | 411 | 412 |
| B-0966 |  |  | 76 | 443 | 444 |
| B-0967 |  |  | 100 | 443 | 444 |
| B-0968 |  |  | 100 | 477 | 478 |
| B-0969 |  |  | 77 | 477 | 478 |



















1004801-08472001



















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-0970 |  |  | 38 | 461 | 462 |
| B-0971 |  |  | 95 | 469 | 470 |
| B-0972 |  |  | 98 | 479 | 480 |
| B-0973 |  |  | 96 | 485 | 486 |
| B-0974 |  |  | 74 | 443 | 444 |
| B-0975 |  |  | 100 | 495 | 496 |
| B-0976 |  |  | 70 | 453 | 454 |
| B-0977 |  |  | 100 | 467 | 468 |
| B-0978 |  |  | 91 | 431 | 432 |
| B-0979 |  |  | 54 | 491 | 492 |















100480 0842004















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-0980 |  |  | 65 | 469 | 470 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0981 |  |  | 78 | 382 | 383 |
| B-0982 |  |  | 82 | 512 | 513 |
| B-0983 |  |  | 94 | 352 | 353 |
| B-0984 |  |  | 81 | 404 | 405 |
| B-0985 |  |  | 84 | 366 | 367 |
| B-0986 |  |  | 80 | 410 | 411 |
| B-0987 |  |  | 85 | 324 | 325 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0988 |  |  | 91 | 364 | 365 |
| B-0989 |  |  | 88 | 350 | 351 |
| B-0990 |  |  | 68 | 464 | 465 |
| B-0991 |  |  | 86 | 512 | 513 |
| B-0992 |  |  | 79 | 377 | 378 |
| B-0993 |  |  | 81 | 396 | 397 |
| B-0994 |  |  | 100 | 354 | 355 |
| B-0995 |  |  | 75 | 416 | 417 |
| B-0996 |  |  | 65 | 454 | 455 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-0997 |  |  | 64 | 440 | 441 |
| B-0998 |  |  | 81 | 364 | 365 |
| B-0999 |  |  | 79 | 460 | 461 |
| B-1000 |  |  | 84 | 430 | 431 |
| B-1001 |  |  | 78 | 430 | 431 |
| B-1002 |  |  | 85 | 400 | 401 |
| B-1003 |  |  | 83 | 386 | 387 |
| B-1004 |  |  | 87 | 378 | 379 |
| B-1005 |  |  | 57 | 387 | 388 |

















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1006 |  |  | 80 | 387 | 388 |
| B-1007 |  |  | 54 | 387 | 388 |
| B-1008 |  |  | 64 | 416 | 417 |
| B-1009 |  |  | 81 | 430 | 431 |
| B-1010 |  |  | 81 | 382 | 383 |
| B-1011 |  |  | 66 | 583 | 584 |
| B-1012 |  |  | 69 | 438 | 439 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1013 |  |  | 53 | 440 | 441 |
| B-1014 |  |  | 61 | 422 | 423 |
| B-1015 |  |  | 47 | 388 | 389 |
| B-1016 |  |  | 74 | 448 | 449 |
| B-1017 |  |  | 63 | 436 | 437 |
| B-1018 |  |  | 82 | 458 | 459 |
| B-1019 |  |  | 41 | 414 | 415 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1020 |  |  | 100 | 440 | 441 |
| B-1021 |  |  | 100 | 388 | 389 |
| B-1022 |  |  | 74 | 402 | 403 |
| B-1023 |  |  | 76 | 374 | 375 |
| B-1024 |  |  | 73 | 360 | 361 |
| B-1025 |  |  | 100 | 452 | 453 |
| B-1026 |  |  | 95 | 428 | 429 |
| B-1027 |  |  | 98 | 436 | 437 |
| B-1028 |  |  | 100 | 482 | 483 |
| B-1029 |  |  | 98 | 367 | 368 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1030 |  |  | 88 | 325 | 326 |
| B-1031 |  |  | 97 | 415 | 416 |
| B-1032 |  |  | 64 | 379 | 380 |
| B-1033 |  |  | 83 | 395 | 396 |
| B-1034 |  |  | 67 | 419 | 420 |
| B-1035 |  |  | 73 | 353 | 354 |
| B-1036 |  |  | 79 | 339 | 340 |
| B-1037 |  |  | 78 | 415 | 416 |
| B-1038 |  |  | 100 | 419 | 420 |
| B-1039 |  |  | 95 | 429 | 430 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1040 |  |  | 91 | 365 | 366 |
| B-1041 |  |  | 88 | 367 | 368 |
| B-1042 |  |  | 78 | 429 | 430 |
| B-1043 |  |  | 79 | 401 | 402 |
| B-1044 |  |  | 93 | 429 | 430 |
| B-1045 |  |  | 100 | 429 | 430 |
| B-1046 |  |  | 94 | 419 | 420 |
| B-1047 |  |  | 100 | 431 | 432 |
| B-1048 |  |  | 58 | 381 | 382 |
| B-1049 |  |  | 97 | 353 | 354 |







| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1050 |  |  | 100 | 461 | 462 |
| B-1051 |  |  | 88 | 406 | 407 |
| B-1052 |  |  | 82 | 366 | 367 |
| B-1053 |  |  | 21 | 368 | |
| B-1054 |  |  | 98 | 354 | 355 |
| B-1055 |  |  | 100 | 379 | 380 |
| B-1056 |  |  | 85 | 379 | 380 |
| B-1057 |  |  | 30 | 368 | 369 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1058 |  |  | 35 | 500 | 501 |
| B-1059 |  |  | 77 | 479 | 480 |
| B-1060 |  |  | 37 | 500 | 501 |
| B-1061 |  |  | 86 | 456 | 457 |
| B-1062 |  |  | 58 | 496 | 497 |
| B-1063 |  |  | 59 | 496 | 497 |
| B-1064 |  |  | 58 | 506 | - |





















10034780-100347801





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1065 |  |  | 24 | 466 | - |
| B-1066 |  |  | 100 | 490 | 491 |
| B-1067 |  |  | 74 | 464 | 465 |
| B-1068 |  |  | 79 | 472 | 473 |
| B-1069 |  |  | 97 | 472 | 473 |
| B-1070 |  |  | 54 | 481 | 482 |
| B-1071 |  |  | 67 | 473 | 474 |
| B-1072 |  |  | 35 | 515 | 516 |
| B-1073 |  |  | 100 | 490 | 491 |
| B-1074 |  |  | 100 | 464 | 465 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1075 |  |  | 100 | 470 | 471 |
| B-1076 |  |  | 93 | 490 | 491 |
| B-1077 |  |  | 100 | 474 | 475 |
| B-1078 |  |  | 80 | 447 | 448 |
| B-1079 |  |  | 85 | 454 | 455 |
| B-1080 |  |  | 100 | 496 | 497 |
| B-1081 |  |  | 100 | 490 | 491 |
| B-1082 |  |  | 100 | 500 | 501 |
| B-1083 |  |  | 93 | 500 | 501 |
| B-1084 |  |  | 81 | 494 | 495 |











| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1085 |  |  | 93 | 482 | 483 |
| B-1086 |  |  | 92 | 490 | 491 |
| B-1087 |  |  | 100 | 490 | 491 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1088 |  |  | 97 | 450 | 451 |
| B-1089 |  |  | 100 | 436 | 437 |
| B-1090 |  |  | 100 | 456 | 457 |
| B-1091 |  |  | 100 | 456 | 457 |
| B-1092 |  |  | 96 | 490 | 491 |
| B-1093 |  |  | 100 | 490 | 491 |
| B-1094 |  |  | 100 | 474 | 475 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1095 |  |  | 81 | 470 | 471 |
| B-1096 |  |  | 77 | 450 | 451 |
| B-1097 |  |  | 100 | 436 | 437 |
| B-1098 |  |  | 93 | 466 | 467 |
| B-1099 |  |  | 100 | 490 | 491 |
| B-1100 |  |  | 47 | 482 | - |
| B-1101 |  |  | 64 | 462 | 463 |
| B-1102 |  |  | 98 | 530 | 531 |
| B-1103 |  |  | 65 | 472 | - |
| B-1104 |  |  | 88 | 441 | 442 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1105 |  |  | 100 | 464 | 465 |
| B-1106 |  |  | 91 | 486 | 487 |
| B-1107 |  |  | 96 | 447 | 448 |
| B-1108 |  |  | 55 | 561 | 562 |
| B-1109 |  |  | 100 | 498 | 499 |
| B-1110 |  |  | 73 | 548 | 549 |
| B-1111 |  |  | 94 | 505 | 506 |
| B-1112 |  |  | 100 | 568 | 569 |
| B-1113 |  |  | 100 | 495 | 496 |
| B-1114 |  |  | 73 | 426 | 427 |





















100180-4001





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|--|--|--------|------------------|--------------------------|
| B-1115 |  |  | 30 | 389 | 390 |
| B-1116 |  |  | 100 | 568 | 569 |
| B-1117 |  |  | 83 | 500 | 501 |
| B-1118 |  |  | 55 | 473 | - |
| B-1119 |  |  | 70 | 514 | 515 |



100438 100438 100438


| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1120 |  |  | 84 | 400 | 401 |
| B-1121 |  |  | 86 | 420 | 421 |
| B-1122 |  |  | 90 | 400 | 401 |
| B-1123 |  |  | 100 | 454 | 455 |
| B-1124 |  |  | 91 | 442 | 443 |
| B-1125 |  |  | 50 | 512 | 513 |
| B-1126 |  |  | 85 | 454 | 455 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1127 |  |  | 93 | 411 | 412 |
| B-1128 |  |  | 87 | 436 | 437 |
| B-1129 |  |  | 78 | 422 | 423 |
| B-1130 |  |  | 96 | 422 | 423 |
| B-1131 |  |  | 84 | 440 | 441 |
| B-1132 |  |  | 77 | 454 | 455 |
| B-1133 |  |  | 62 | 428 | 429 |
| B-1134 |  |  | 91 | 472 | 473 |
| B-1135 |  |  | 85 | 440 | 441 |
| B-1136 |  |  | 82 | 472 | 473 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1137 |  |  | 95 | 472 | 473 |
| B-1138 |  |  | 100 | 472 | 473 |
| B-1139 |  |  | 100 | 472 | 473 |
| B-1140 |  |  | 92 | 472 | 473 |
| B-1141 |  |  | 100 | 472 | 473 |
| B-1142 |  |  | 88 | 420 | 421 |
| B-1143 |  |  | 90 | 400 | 401 |
| B-1144 |  |  | 87 | 454 | 455 |
| B-1145 |  |  | 93 | 404 | 405 |
| B-1146 |  |  | 90 | 422 | 423 |





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1147 |  |  | 100 | 454 | 455 |
| B-1148 |  |  | 87 | 422 | 423 |
| B-1149 |  |  | 87 | 440 | 441 |
| B-1150 |  |  | 90 | 404 | 405 |
| B-1151 |  |  | 82 | 422 | 423 |
| B-1152 |  |  | 85 | 422 | 423 |
| B-1153 |  |  | 90 | 420 | 421 |
| B-1154 |  |  | 78 | 464 | 465 |
| B-1155 |  |  | 79 | 454 | 455 |
| B-1156 |  |  | 95 | 392 | 393 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1157 |  |  | 81 | 405 | 406 |



























| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|---------------------|--------------------------------|
| B-1158 | | | 54 | 396 | 397 |
| B-1159 | | | 42 | 526 | 527 |
| B-1160 | | | 27 | 366 | 367 |
| B-1161 | | | 58 | 418 | 419 |
| B-1162 | | | 62 | 380 | 381 |
| B-1163 | | | 58 | 424 | 425 |
| B-1164 | | | 67 | 338 | 339 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1165 |  |  | 66 | 378 | 379 |
| B-1166 |  |  | 65 | 364 | 365 |
| B-1167 |  |  | 64 | 478 | 479 |
| B-1168 |  |  | 76 | 526 | 527 |
| B-1169 |  |  | 70 | 391 | 392 |
| B-1170 |  |  | 76 | 410 | 411 |
| B-1171 |  |  | 82 | 368 | 369 |
| B-1172 |  |  | 73 | 430 | 431 |
| B-1173 |  |  | 74 | 468 | 469 |
| B-1174 |  |  | 83 | 454 | 455 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1175 |  |  | 76 | 378 | 379 |
| B-1176 |  |  | 96 | 474 | 475 |
| B-1177 |  |  | 94 | 444 | 445 |
| B-1178 |  |  | 90 | 444 | 445 |
| B-1179 |  |  | 57 | 414 | 415 |
| B-1180 |  |  | 75 | 400 | 401 |
| B-1181 |  |  | 66 | 392 | 393 |
| B-1182 |  |  | 74 | 401 | 402 |
| B-1183 |  |  | 62 | 401 | 402 |
| B-1184 |  |  | 51 | 401 | 402 |





















FOUOEF 082FE004

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|--|--|--------|---------------------|--------------------------------|
| B-1185 |  |  | 90 | 430 | 431 |
| B-1186 |  |  | 86 | 444 | 445 |
| B-1187 |  |  | 74 | 396 | 397 |
| B-1188 |  |  | 76 | 597 | 598 |
| B-1189 |  |  | 60 | 452 | 453 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1190 |  |  | 44 | 454 | 455 |
| B-1191 |  |  | 47 | 436 | 437 |
| B-1192 |  |  | 50 | 402 | 403 |
| B-1193 |  |  | 62 | 462 | 463 |
| B-1194 |  |  | 49 | 450 | 451 |
| B-1195 |  |  | 61 | 472 | 473 |
| B-1196 |  |  | 52 | 428 | 429 |

TOC001-08212001

















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1197 |  |  | 54 | 454 | 455 |
| B-1198 |  |  | 44 | 402 | 403 |
| B-1199 |  |  | 67 | 416 | 417 |
| B-1200 |  |  | 45 | 388 | 389 |
| B-1201 |  |  | 52 | 374 | 375 |
| B-1202 |  |  | 100 | 466 | 467 |
| B-1203 |  |  | 91 | 442 | 443 |
| B-1204 |  |  | 100 | 450 | 451 |
| B-1205 |  |  | 83 | 496 | 497 |
| B-1206 |  |  | 97 | 381 | 382 |

| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1207 |  |  | 100 | 339 | 340 |
| B-1208 |  |  | 90 | 429 | 430 |
| B-1209 |  |  | 69 | 393 | 394 |
| B-1210 |  |  | 35 | 409 | 410 |
| B-1211 |  |  | 100 | 433 | 434 |
| B-1212 |  |  | 83 | 367 | 368 |
| B-1213 |  |  | 78 | 353 | 354 |
| B-1214 |  |  | 68 | 429 | 430 |
| B-1215 |  |  | 65 | 433 | 434 |
| B-1216 |  |  | 91 | 443 | 444 |















100480 08212001

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1217 |  |  | 99 | 379 | 380 |
| B-1218 |  |  | 92 | 381 | 382 |
| B-1219 |  |  | 74 | 443 | 444 |
| B-1220 |  |  | 67 | 415 | 416 |
| B-1221 |  |  | 14 | 443 | 444 |
| B-1222 |  |  | 19 | 443 | 444 |
| B-1223 |  |  | 71 | 433 | 434 |
| B-1224 |  |  | 100 | 445 | 446 |
| B-1225 |  |  | 75 | 395 | 396 |
| B-1226 |  |  | 58 | 367 | 368 |





















1004180-100704





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1227 |  |  | 98 | 475 | 476 |
| B-1228 |  |  | 71 | 420 | 421 |
| B-1229 |  |  | 85 | 380 | 381 |
| B-1230 |  |  | 10 | 382 | - |
| B-1231 |  |  | 66 | 368 | 369 |
| B-1232 |  |  | 100 | 393 | 394 |
| B-1233 |  |  | 96 | 393 | 394 |
| B-1234 |  |  | 66 | 382 | 383 |







1004380-130704















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1235 |  |  | 50 | 514 | 515 |
| B-1236 |  |  | 100 | 493 | 494 |
| B-1237 |  |  | 91 | 514 | 515 |
| B-1238 |  |  | 100 | 470 | 471 |
| B-1239 |  |  | 71 | 510 | 511 |
| B-1240 |  |  | 27 | 510 | 511 |
| B-1241 |  |  | 73 | 520 | |





















100480 0822001





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1242 |  |  | 26 | 480 | 481 |
| B-1243 |  |  | 100 | 504 | |
| B-1244 |  |  | 52 | 478 | 479 |
| B-1245 |  |  | 100 | 486 | 487 |
| B-1246 |  |  | 56 | 486 | 487 |
| B-1247 |  |  | 43 | 495 | 496 |
| B-1248 |  |  | 61 | 487 | 488 |
| B-1249 |  |  | 32 | 529 | 530 |
| B-1250 |  |  | 56 | 504 | 505 |
| B-1251 |  |  | 58 | 478 | 479 |











| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1252 |  |  | 98 | 484 | 485 |
| B-1253 |  |  | 59 | 504 | 505 |
| B-1254 |  |  | 100 | 488 | 489 |
| B-1255 |  |  | 96 | 461 | |
| B-1256 |  |  | 79 | 468 | 469 |
| B-1257 |  |  | 63 | 510 | 511 |
| B-1258 |  |  | 100 | 504 | 505 |
| B-1259 |  |  | 95 | 514 | 515 |
| B-1260 |  |  | 92 | 514 | 515 |
| B-1261 |  |  | 98 | 508 | 509 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1262 |  |  | 97 | 496 | 497 |
| B-1263 |  |  | 100 | 504 | 505 |
| B-1264 |  |  | 100 | 504 | 505 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1265 |  |  | 100 | 464 | 465 |
| B-1266 |  |  | 79 | 466 | 451 |
| B-1267 |  |  | 100 | 470 | 471 |
| B-1268 |  |  | 87 | 470 | 471 |
| B-1269 |  |  | 100 | 504 | 505 |
| B-1270 |  |  | 100 | 504 | 505 |
| B-1271 |  |  | 56 | 488 | 489 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1272 |  |  | 98 | 484 | 485 |
| B-1273 |  |  | 90 | 464 | 465 |
| B-1274 |  |  | 87 | 450 | 451 |
| B-1275 |  |  | 94 | 480 | 481 |
| B-1276 |  |  | 100 | 504 | 505 |
| B-1277 |  |  | 60 | 496 | 511 |
| B-1278 |  |  | 68 | 476 | 477 |
| B-1279 |  |  | 100 | 544 | 545 |
| B-1280 |  |  | 68 | 486 | - |
| B-1281 |  |  | 98 | 455 | 456 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1282 |  |  | 100 | 478 | 479 |
| B-1283 |  |  | 58 | 500 | 501 |
| B-1284 |  |  | 58 | 461 | 462 |
| B-1285 |  |  | 65 | 575 | 576 |
| B-1286 |  |  | 87 | 512 | 513 |
| B-1287 |  |  | 79 | 562 | 563 |
| B-1288 |  |  | 100 | 519 | 520 |
| B-1289 |  |  | 77 | 582 | 583 |
| B-1290 |  |  | 100 | 509 | 510 |
| B-1291 |  |  | 91 | 440 | 441 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|--|--|--------|---------------------|--------------------------------|
| B-1292 |  |  | 35 | 403 | 404 |
| B-1293 |  |  | 73 | 582 | 583 |
| B-1294 |  |  | 49 | 514 | 515 |
| B-1295 |  |  | 48 | 487 | - |
| B-1296 |  |  | 76 | 528 | 529 |















FOUO 1004801





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1297 |  |  | 62 | 447 | 448 |
| B-1298 |  |  | 66 | 452 | 453 |
| B-1299 |  |  | 65 | 479 | 431 |
| B-1300 |  |  | 71 | 444 | 445 |
| B-1301 |  |  | 100 | 472 | 473 |
| B-1302 |  |  | 75 | 410 | 411 |
| B-1303 |  |  | 74 | 424 | 425 |





















4004180-130704





















| Example# | R ² | R ^J | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1304 |  |  | 11 | 430 | 431 |
| B-1305 |  |  | 2 | 424 | - |
| B-1306 |  |  | 30 | 433 | 434 |
| B-1307 |  |  | 100 | 522 | 523 |
| B-1308 |  |  | 100 | 508 | 509 |
| B-1309 |  |  | 100 | 448 | 449 |
| B-1310 |  |  | 26 | 430 | 431 |
| B-1311 |  |  | 45 | 397 | 398 |
| B-1312 |  |  | 14 | 507 | 508 |
| B-1313 |  |  | 67 | 450 | 451 |



| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1314 |  |  | 69 | 444 | 445 |
| B-1315 |  |  | 57 | 450 | 451 |
| B-1316 |  |  | 75 | 393 | 394 |
| B-1317 |  |  | 100 | 461 | 462 |
| B-1318 |  |  | 31 | 450 | 451 |
| B-1319 |  |  | 23 | 464 | 465 |
| B-1320 |  |  | 59 | 512 | 513 |


| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1321 |  |  | 63 | 414 | 415 |
| B-1322 |  |  | 45 | 434 | 435 |
| B-1323 |  |  | 53 | 414 | 415 |
| B-1324 |  |  | 32 | 468 | 469 |
| B-1325 |  |  | 45 | 456 | 457 |
| B-1326 |  |  | 50 | 526 | 527 |
| B-1327 |  |  | 55 | 468 | 469 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1328 |  |  | 29 | 425 | 426 |
| B-1329 |  |  | 67 | 450 | 451 |
| B-1330 |  |  | 59 | 436 | 437 |
| B-1331 |  |  | 45 | 436 | 437 |
| B-1332 |  |  | 81 | 454 | 455 |
| B-1333 |  |  | 23 | 468 | 469 |
| B-1334 |  |  | 53 | 442 | 443 |
| B-1335 |  |  | 81 | 486 | 487 |
| B-1336 |  |  | 69 | 454 | 455 |
| B-1337 |  |  | 67 | 486 | 487 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1338 |  |  | 39 | 486 | 487 |
| B-1339 |  |  | 61 | 486 | 487 |
| B-1340 |  |  | 49 | 486 | 487 |
| B-1341 |  |  | 55 | 486 | 487 |
| B-1342 |  |  | 51 | 486 | 487 |
| B-1343 |  |  | 72 | 434 | 435 |
| B-1344 |  |  | 52 | 414 | 415 |
| B-1345 |  |  | 43 | 468 | 469 |
| B-1346 |  |  | 40 | 418 | 419 |
| B-1347 |  |  | 67 | 436 | 437 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1348 |  |  | 39 | 468 | 469 |
| B-1349 |  |  | 68 | 436 | 437 |
| B-1350 |  |  | 73 | 454 | 455 |
| B-1351 |  |  | 54 | 418 | 419 |
| B-1352 |  |  | 77 | 436 | 437 |
| B-1353 |  |  | 66 | 436 | 437 |
| B-1354 |  |  | 58 | 434 | 435 |
| B-1355 |  |  | 77 | 478 | 479 |
| B-1356 |  |  | 50 | 468 | 469 |
| B-1357 |  |  | 36 | 406 | 407 |















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1358 |  |  | 39 | 419 | 420 |











































| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|----------------|----------------|--------|------------------|--------------------------|
| B-1359 | | | 95 | 552 | 553 |
| B-1360 | | | 77 | 444 | 445 |
| B-1361 | | | 100 | 392 | 393 |
| B-1362 | | | 85 | 406 | 407 |
| B-1363 | | | 100 | 364 | 365 |
| B-1364 | | | 99 | 390 | 391 |
| B-1365 | | | 92 | 504 | 505 |





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1366 |  |  | 100 | 552 | 553 |
| B-1367 |  |  | 100 | 417 | 418 |
| B-1368 |  |  | 86 | 394 | 395 |
| B-1369 |  |  | 100 | 456 | 457 |
| B-1370 |  |  | 100 | 470 | 471 |
| B-1371 |  |  | 77 | 440 | 441 |
| B-1372 |  |  | 100 | 444 | 445 |
| B-1373 |  |  | 42 | 427 | 428 |
| B-1374 |  |  | 60 | 476 | 477 |
| B-1375 |  |  | 94 | 414 | 415 |





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1376 |  |  | 87 | 400 | 401 |
| B-1377 |  |  | 100 | 480 | 481 |
| B-1378 |  |  | 95 | 379 | 380 |
| B-1379 |  |  | 93 | 459 | 460 |
| B-1380 |  |  | 89 | 469 | 470 |
| B-1381 |  |  | 84 | 393 | 394 |
| B-1382 |  |  | 85 | 501 | 502 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1383 |  |  | 46 | 416 | 417 |
| B-1384 |  |  | 56 | 432 | 433 |
| B-1385 |  |  | 59 | 426 | 427 |
| B-1386 |  |  | 50 | 427 | 428 |
| B-1387 |  |  | 12 | 427 | 428 |
| B-1388 |  |  | 66 | 504 | 505 |
| B-1389 |  |  | 48 | 460 | 461 |















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1390 |  |  | 44 | 494 | 495 |
| B-1391 |  |  | 50 | 456 | 457 |
| B-1392 |  |  | 47 | 451 | 452 |
| B-1393 |  |  | 44 | 444 | 445 |
| B-1394 |  |  | 52 | 460 | 461 |
| B-1395 |  |  | 77 | 440 | 441 |
| B-1396 |  |  | 58 | 451 | 452 |
| B-1397 |  |  | 64 | 460 | 461 |
| B-1398 |  |  | 65 | 504 | 505 |
| B-1399 |  |  | 50 | 494 | 495 |





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1400 |  |  | 74 | 440 | 441 |
| B-1401 |  |  | 76 | 462 | 463 |
| B-1402 |  |  | 65 | 462 | 463 |
| B-1403 |  |  | 64 | 445 | 446 |
| B-1404 |  |  | 70 | 512 | 513 |
| B-1405 |  |  | 57 | 512 | 513 |
| B-1406 |  |  | 73 | 512 | 513 |
| B-1407 |  |  | 80 | 512 | 513 |
| B-1408 |  |  | 2 | 512 | 513 |
| B-1409 |  |  | 62 | 512 | 513 |





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1410 |  |  | 42 | 512 | 513 |
| B-1411 |  |  | 19 | 462 | 463 |
| B-1412 |  |  | 74 | 462 | 463 |
| B-1413 |  |  | 75 | 494 | 495 |
| B-1414 |  |  | 68 | 462 | 463 |
| B-1415 |  |  | 48 | 462 | 463 |
| B-1416 |  |  | 48 | 494 | 495 |
| B-1417 |  |  | 57 | 494 | 495 |
| B-1418 |  |  | 49 | 494 | 495 |
| B-1419 |  |  | 39 | 494 | 495 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1420 |  |  | 72 | 378 | 379 |
| B-1421 |  |  | 74 | 406 | 407 |
| B-1422 |  |  | 68 | 394 | 395 |
| B-1423 |  |  | 57 | 408 | 409 |
| B-1424 |  |  | 77 | 422 | 423 |
| B-1425 |  |  | 26 | 408 | 409 |
| B-1426 |  |  | 41 | 406 | 407 |
| B-1427 |  |  | 37 | 404 | 405 |
| B-1428 |  |  | 60 | 456 | 457 |
| B-1429 |  |  | 2 | 418 | 419 |





















100498 0842001



| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1430 |  |  | 61 | 442 | 443 |
| B-1431 |  |  | 64 | 428 | 429 |
| B-1432 |  |  | 71 | 429 | 430 |
| B-1433 |  |  | 74 | 462 | 463 |
| B-1434 |  |  | 88 | 466 | 467 |
| B-1435 |  |  | 75 | 481 | 482 |
| B-1436 |  |  | 71 | 504 | 505 |















| Example# | R ² | R ⁴ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1437 |  |  | 63 | 468 | 469 |
| B-1438 |  |  | 78 | 502 | 503 |
| B-1439 |  |  | 70 | 545 | 546 |
| B-1440 |  |  | 62 | 535 | 536 |
| B-1441 |  |  | 82 | 608 | |
| B-1442 |  |  | 79 | 555 | 556 |
| B-1443 |  |  | 28 | 513 | 514 |
| B-1444 |  |  | 75 | 522 | 523 |
| B-1445 |  |  | 74 | 526 | 527 |
| B-1446 |  |  | 70 | 570 | 571 |





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1447 |  |  | 73 | 506 | 507 |
| B-1448 |  |  | 76 | 530 | 531 |
| B-1449 |  |  | 82 | 530 | 531 |
| B-1450 |  |  | 83 | 530 | 531 |
| B-1451 |  |  | 74 | 530 | 531 |
| B-1452 |  |  | 76 | 530 | 531 |
| B-1453 |  |  | 73 | 530 | 531 |
| B-1454 |  |  | 81 | 498 | 499 |
| B-1455 |  |  | 83 | 498 | 499 |
| B-1456 |  |  | 78 | 498 | 499 |





















| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1457 |  |  | 74 | 496 | 497 |
| B-1458 |  |  | 82 | 540 | 541 |
| B-1459 |  |  | 80 | 476 | 477 |
| B-1460 |  |  | 78 | 530 | 531 |
| B-1461 |  |  | 82 | 487 | 488 |
| B-1462 |  |  | 71 | 540 | 541 |
| B-1463 |  |  | 78 | 546 | 547 |
| B-1464 |  |  | 83 | 480 | 481 |
| B-1465 |  |  | 84 | 496 | 497 |
| B-1466 |  |  | 80 | 540 | 541 |





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1467 |  |  | 79 | 476 | 477 |
| B-1468 |  |  | 79 | 530 | 531 |
| B-1469 |  |  | 75 | 487 | 488 |
| B-1470 |  |  | 80 | 480 | 481 |
| B-1471 |  |  | 74 | 496 | 497 |
| B-1472 |  |  | 75 | 540 | 541 |
| B-1473 |  |  | 77 | 476 | 477 |
| B-1474 |  |  | 81 | 530 | 531 |
| B-1475 |  |  | 70 | 487 | 488 |
| B-1476 |  |  | 54 | 540 | 541 |

| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1477 |  |  | 79 | 546 | 547 |





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1478 |  |  | 87 | 394 | 395 |
| B-1479 |  |  | 41 | 504 | 505 |
| B-1480 |  |  | 87 | 451 | 452 |
| B-1481 |  |  | 18 | 416 | 417 |
| B-1482 |  |  | 77 | 427 | 428 |
| B-1483 |  |  | 74 | 406 | 407 |
| B-1484 |  |  | 82 | 422 | 423 |

| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1485 |  |  | 85 | 460 | 461 |
| B-1486 |  |  | 64 | 406 | 407 |
| B-1487 |  |  | 71 | 392 | 393 |
| B-1488 |  |  | 82 | 427 | 428 |
| B-1489 |  |  | 87 | 444 | 445 |
| B-1490 |  |  | 81 | 462 | 463 |
| B-1491 |  |  | 87 | 462 | 463 |
| B-1492 |  |  | 69 | 364 | 365 |
| B-1493 |  |  | 53 | 417 | 418 |
| B-1494 |  |  | 17 | 426 | 427 |

| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1495 |  |  | 79 | 460 | 461 |
| B-1496 |  |  | 80 | 444 | 445 |
| B-1497 |  |  | 82 | 460 | 461 |
| B-1498 |  |  | 72 | 378 | 379 |
| B-1499 |  |  | 70 | 432 | 433 |
| B-1500 |  |  | 68 | 390 | 391 |
| B-1501 |  |  | 63 | 394 | 395 |
| B-1502 |  |  | 78 | 408 | 409 |
| B-1503 |  |  | 55 | 404 | 405 |
| B-1504 |  |  | 39 | 418 | 419 |



| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1505 |  |  | 69 | 540 | 541 |
| B-1506 |  |  | 69 | 462 | 463 |
| B-1507 |  |  | 70 | 496 | 497 |
| B-1508 |  |  | 65 | 480 | 481 |
| B-1509 |  |  | 56 | 414 | 415 |
| B-1510 |  |  | 62 | 400 | 401 |
| B-1511 |  |  | 30 | 468 | 469 |
| B-1512 |  |  | 50 | 476 | 477 |
| B-1513 |  |  | 44 | 540 | 541 |
| B-1514 |  |  | 42 | 530 | 531 |





















FOUOBT-08412001





















| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1515 |  |  | 68 | 496 | 497 |
| B-1516 |  |  | 27 | 429 | 430 |
| B-1517 |  |  | 92 | 466 | 467 |
| B-1518 |  |  | 33 | 379 | 380 |
| B-1519 |  |  | 50 | 393 | 394 |
| B-1520 |  |  | 82 | 435 | 436 |
| B-1521 |  |  | 86 | 509 | 510 |
| B-1522 |  |  | 12 | 405 | 406 |
| B-1523 |  |  | 59 | 459 | 460 |
| B-1524 |  |  | 81 | 459 | 460 |





















PAGE INTENTIONALLY LEFT BLANK





















100430 10704



| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|---------------------|--------------------------------|
| B-1525 |  |  | 57 | 419 | 420 |

| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1533 |  |  | 84 | 476 | 477 |
| B-1534 |  |  | 72 | 422 | 423 |
| B-1535 |  |  | 78 | 408 | 409 |
| B-1536 |  |  | 77 | 443 | 444 |
| B-1537 |  |  | 86 | 460 | 461 |
| B-1538 |  |  | 74 | 478 | 479 |
| B-1539 |  |  | 85 | 478 | 479 |
| B-1540 |  |  | 71 | 380 | 381 |
| B-1541 |  |  | 71 | 433 | 434 |
| B-1542 |  |  | 89 | 442 | 443 |

| Example# | R ² | R ⁴ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1543 |  |  | 82 | 476 | 477 |
| B-1544 |  |  | 76 | 460 | 461 |
| B-1545 |  |  | 77 | 476 | 477 |
| B-1546 |  |  | 76 | 394 | 395 |
| B-1547 |  |  | 58 | 448 | 449 |
| B-1548 |  |  | 83 | 406 | 407 |
| B-1549 |  |  | 67 | 410 | 411 |
| B-1550 |  |  | 37 | 424 | 425 |
| B-1551 |  |  | 55 | 420 | 421 |
| B-1552 |  |  | 23 | 434 | 435 |

| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1553 |  |  | 83 | 556 | 557 |
| B-1554 |  |  | 84 | 478 | 479 |
| B-1555 |  |  | 93 | 512 | 513 |
| B-1556 |  |  | 83 | 496 | 497 |
| B-1557 |  |  | 62 | 430 | 431 |
| B-1558 |  |  | 45 | 416 | 417 |
| B-1559 |  |  | 67 | 484 | 485 |
| B-1560 |  |  | 16 | 492 | 493 |
| B-1561 |  |  | 84 | 556 | 557 |
| B-1562 |  |  | 74 | 546 | 547 |

| Example# | R ² | R ¹ | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1563 |  |  | 72 | 512 | 513 |
| B-1564 |  |  | 57 | 445 | 446 |
| B-1565 |  |  | 64 | 482 | 483 |
| B-1566 |  |  | 71 | 395 | 396 |
| B-1567 |  |  | 54 | 409 | 410 |
| B-1568 |  |  | 76 | 451 | 452 |
| B-1569 |  |  | 70 | 525 | 526 |
| B-1570 |  |  | 79 | 421 | 422 |
| B-1571 |  |  | 60 | 475 | 476 |
| B-1572 |  |  | 77 | 475 | 476 |

| Example# | R ² | R ^L | %Yield | Calcd. Mass Spec | Observed Mass Spec (M+H) |
|----------|---|---|--------|------------------|--------------------------|
| B-1573 |  |  | 65 | 435 | 436 |

T02021 084T004

5

10

Proton NMR data for selected members from Examples B-0001 through B-1573 are shown in the following table.

15

20

25

30

40021380-180701

| Plate ID | ¹ H NMR(solvent), d ppm |
|----------|---|
| B-0120 | (DMF-d7) d 8.53(bd, J = 4.99Hz, 2H), 7.44-7.24(m, 11H), 4.41(s, 2H), 4.31(br, 2H) |
| B-0224 | (DMF-d7) d 8.56(bd, J = 4.98Hz, 2H), 7.78-7.69(m, 4H), 7.39-7.19(m, 6H), 4.23(br, 2H) |
| B-0235 | (DMF-d7) d 8.47(br, 2H), 7.91-7.75(m, 3H), 7.57-7.53(m, 1H), 7.38-7.34(m, 2H), 7.21-7.13(m, 4H), 4.20(br, 2H) |
| B-0244 | (CDCl3/CD3OD) d 8.38(d, J = 5.38 Hz, 1H), 7.62-7.32(m, 9H), 7.04-6.95(m, 4H), 6.86-6.80(m, 2H), 4.52(q, J = 6.96 Hz, 1H), 1.40(d, J = 6.88 Hz, 3H) |
| B-0256 | (DMF-d7) d 8.45(bd, J = 2.85, 2H), 7.87(br s, 4H), 7.76-7.75(m, 2H), 7.53-7.33(m, 5H), 7.18-7.13(br, 4H) |
| B-0426 | (DMF-d7), 1.32(br, 3H), 1.67(br, 3H), 4.17(br, 2H), 5.12(br, 1H), 7.50(m, 6H), 8.77(m, 2H), 13.54(br, 1H). |
| B-0438 | (DMSO), 1.14(t, J = 6.9 Hz, 3H), 4.54(m, 1H), 6.99(br, 2H), 7.21(br, 4H), 7.45(s, 1H), 7.61(q, J = 8.7 Hz, 2H), 8.52(d, J = 5.2 Hz, 2H). |
| B-0466 | (DMF-d7), 1.61(brd, J = 30.6 Hz, 3H), 4.61 (br, 1H), 7.25(m, 6H), 7.65(m, 3H), 8.59(br, 2H), 13.34(brd, J = 34.8 Hz, 1H). |
| B-0473 | (CD3OD), 1.53(d, J = 7.2 Hz, 3H), 4.59(q, J = 7.2 Hz, 1H), 6.88(d, J = 4 Hz, 1H), 7.09(m, 3H), 7.15(dd, J = 4.4, 1.6 Hz, 2H), 7.26(m, 2H), 8.46(d, J = 6.0 Hz, 2H). |
| B-0477 | (DMF), 1.80(br, 3H), 2.35(s, 1H), 4.98(br, 1H), 7.38(m, 6H), 7.85(m, 2H), 8.45(br, 1H), 8.75(d, J = 6.0 Hz, 2H). |
| B-0479 | (Methanol-d4), 1.57(d, J = 5.6 Hz, 3H), 4.74(br, 1H), 7.23(m, 4H), 7.60(m, 2H), 7.81(m, 4H), 8.67(br, 2H). |
| B-0487 | (DMF), 1.78(s, 3H), 2.76(br, 6H), 4.85(br, 1H), 7.42(br, 2H), 7.54(br, 2H), 7.66(br, 3H), 8.82(s, 2H). |
| B-0566 | (CD3OD), 1.38(d, J = 7.2 Hz, 3H), 4.15(br, 2H), 4.50(br, 1H), 7.04(br, 2H), 7.18(br, 2H), 7.30(m, 7H), 8.45(m, 2H). |
| B-0569 | (CD3OD), 1.56(br, 3H), 4.66(q, J = 6.7 Hz, 1H), 7.17(m, 8H), 7.56(m, 2H), 8.47(s, 2H). |
| B-0574 | (Methanol-d4), 1.49(br, 3H), 3.86(br, 3H), 4.60(br, 1H), 6.92(br, 2H), 7.19(br, 2H), 7.31(br, 2H), 7.76(m, 4H), 8.60(br, 2H). |
| B-0639 | (DMF-d7), 1.58(brd, J = 30.0 Hz, 3H), 4.62(br, 1H), 7.25(m, 6H), 7.60(m, 4H), 8.59(br, 2H), 13.30(brd, J = 12.3 Hz). |
| B-0643 | 7.18(m, 2H), 7.32(dd, J = 6.0, 4.4 Hz, 1H), 7.70(dd, J = 9.0, 5.8Hz, 1H), 8.43(dd, J = 4.8, 3.2 Hz, 2H). |
| B-0650 | (CD3OD), 1.58(br, 3H), 4.62(q, J = 6.6 Hz, 1H), 6.93(br, 1H), 7.17(m, 5H), 7.31(br, 2H), 8.51(br, 2H). |
| B-0656 | (CDCl3/CD3OD) d 8.48 (d, J = 5.30 Hz, 2H), 7.72-7.59(m, 4H), 7.14-7.10(m, 2H), 7.03-6.97(m, 4H), 4.60(q, J = 7.57Hz, 1H), 1.43(d, J = 7.26Hz, 3H) |
| B-0663 | (CD3OD), 1.52(d, J = 6.8 Hz, 3H), 3.75(s, 3H), 7.21(m, 2H), 7.42(m, 2H), 7.57(s, 1H), 7.76(s, 1H), 7.98(br, 2H), 8.76(br, 2H). |
| B-1165 | Hz, 2H), 3.06(m, 1H), 3.43(q, J = 6.1 Hz, 2H), 7.02(m, 2H), 7.14(m, 2H), 7.41(m, 2H), 8.59(d, J = 5.6 Hz, 2H). |
| B-1169 | = 1.6 Hz, 1H), 7.04(t, J = 8.6 Hz, 2H), 7.14(m, 2H), 7.36(m, 2H), 8.39(d, J = 1.8 Hz, 1H), 8.60(m, 2H). |
| B-1171 | 6.83(br, 1H), 7.02(t, J = 8.7 Hz, 2H), 7.15(d, J = 5.6 Hz, 2H), 7.40(m, 2H), 8.59(d, J = 5.0 Hz, 2H). |

| Plate ID | ¹ H NMR(solvent), d ppm |
|----------|--|
| B-1179 | (CDCl ₃), 1.94(br, 2H), 2.53(s, 3H), 2.85(t, J = 6.2 Hz, 2H), 3.65(br, 2H), 6.15(br, 1H), 7.04(m, 3H), 7.22(m, 3H), 7.41(br, 4H), 8.60(br, 2H). |
| B-1183 | (CDCl ₃), 2.00(br, 2H), 2.85(br, 2H), 3.64(br, 2H), 7.03(br, 3H), 7.17(br, 2H), 7.36(br, 2H), 7.66(br, 2H), 8.60(br, 2H), 8.77(br, 2H). |
| B-1194 | (DMSO), 1.76(br, 2H), 2.66(br, 2H), 2.91(br, 2H), 4.30(s, 2H), 7.18(br, 5H), 7.35(m, 6H), 8.54(d, J = 5.8 Hz, 2H). |
| B-1200 | (DMSO), 1.17(br, 3H), 1.76(br, 2H), 2.71(br, 2H), 2.97(br, 4H), 7.18(br, 4H), 7.36(br, 2H), 8.54(br, 2H). |
| B-1206 | (DMSO), 1.03(s, 6H), 1.68(br, 2H), 2.63(br, 2H), 3.00(br, 2H), 3.65(br, 1H), 5.69(m, 2H), 7.16(br, 4H), 7.35(br, 2H), 8.54(br, 2H). |
| B-1216 | (DMSO), 1.75(m, 2H), 2.14(s, 6H), 2.66(br, 2H), 3.10(br, 2H), 7.04(br, 3H), 7.18(br, 4H), 7.35(m, 2H), 7.47(br, 1H), 8.54(d, J = 4.8 Hz, 2H). |
| B-1226 | (DMF), 1.25(br, 3H), 2.01(br, 2H), 3.35(br, 4H), 6.20(s, 1H), 6.30(s, 1H), 7.42(br, 4H), 7.65(br, 2H), 8.77(s, 2H). |
| B-1360 | (DMSO-d ₆), 1.80(br, 4H), 2.82(br, 1H), 2.94(br, 1H), 3.10(br, 1H), 3.60(br, 1H), 4.54(br, 1H), 7.18(m, 4H), 7.30(m, 4H), 7.46(m, 2H), 8.54(br, 2H). |
| B-1361 | (DMSO-d ₆), 0.99(br, 6H), 1.73(br, 4H), 2.89(br, 2H), 3.03(m, 1H), 4.04(br, 2H), 4.44(m, 1H), 7.18(m, 4H), 7.30(m, 2H), 8.57(d, J = 4.64 Hz, 2H). |
| B-1363 | (DMSO-d ₆), 1.78(br, 4H), 2.01(s, 3H), 2.89(br, 1H), 3.05(br, 1H), 3.34(br, 1H), 3.85(br, 1H), 4.48(br, 1H), 7.12(br, 2H), 7.21(br, 2H), 7.30(br, 2H), 8.69(br, 2H). |
| B-1364 | (CDCl ₃), 0.78(dd, J = 3.0, 2.9 Hz, 2H), 1.00(s, 2H), 1.78(m, 1H), 1.86(b, 4H), 2.64(m, 1H), 2.99(m, 1H), 3.16(m, 1H), 4.33(br, 1H), 4.70(br, 1H), 6.99(m, 2H), 7.14(s, 2H), 7.29(m, 2H), 8.64(s, 2H). |
| B-1368 | (CDCl ₃), 1.89(s, 4H), 2.65(m, 1H), 2.96(m, 1H), 3.06(m, 1H), 3.43(s, 3H), 3.93(d, J = 13.2 Hz, 1H), 4.09(d, J = 13.5 Hz, 1H), 4.18(d, J = 13.5 Hz, 1H), 4.68(d, J = 12.4 Hz, 1H), 7.60(m, 2H), 7.12(s, 2H), 7.26(m, 2H), 8.63(s, 2H). |

5

10


By analogy to the procedure identified above for the
preparation of Examples B0001-B0048, the following
15 examples B-1574 through B-2269 are prepared.

20

25

30

FOUO - 4001

























Examples B-1574 through B-1597 are prepared from Scaffold C-27













Example#

R²


R¹

| | | | | | |
|--------|--|--|--|--|--|
| B-1574 | | | | | |
| B-1575 | | | | | |
| B-1576 | | | | | |
| B-1577 | | | | | |
| B-1578 | | | | | |
| B-1579 | | | | | |
| B-1580 | | | | | |

| | | | | | |
|--------|---|---|--|--|--|
| B-1581 |  |  | | | |
| B-1582 |  |  | | | |
| B-1583 |  |  | | | |
| B-1584 |  |  | | | |
| B-1585 |  |  | | | |
| B-1586 |  |  | | | |
| B-1587 |  |  | | | |
| B-1588 |  |  | | | |
| B-1589 |  |  | | | |
| B-1590 |  |  | | | |
| B-1591 |  |  | | | |

| | | | | | |
|--------|--|--|--|--|--|
| B-1592 |  |  | | | |
| B-1593 |  |  | | | |
| B-1594 |  |  | | | |
| B-1595 |  |  | | | |
| B-1596 |  |  | | | |
| B-1597 |  |  | | | |

FOUO - 08/2001



Examples B-1598 through B-1621 are prepared from Scaffold C-28

Example#

R²















R¹


| | | | | | |
|--------|--|--|--|--|--|
| B-1598 | | | | | |
| B-1599 | | | | | |
| B-1600 | | | | | |
| B-1601 | | | | | |
| B-1602 | | | | | |
| B-1603 | | | | | |
| B-1604 | | | | | |

Example#

 R^2 R^1

| | | | | | |
|--------|--|--|--|--|--|
| B-1605 | | | | | |
| B-1606 | | | | | |
| B-1607 | | | | | |
| B-1608 | | | | | |
| B-1609 | | | | | |
| B-1610 | | | | | |
| B-1611 | | | | | |
| B-1612 | | | | | |
| B-1613 | | | | | |
| B-1614 | | | | | |

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-1615 |  |  | | | |
| B-1616 |  |  | | | |
| B-1617 |  |  | | | |
| B-1618 |  |  | | | |
| B-1619 |  |  | | | |
| B-1620 |  |  | | | |
| B-1621 |  |  | | | |























Examples B-1622 through B-1645 are prepared from Scaffold C-38

Example#

R²















R¹


| | | | | | |
|--------|--|--|--|--|--|
| B-1622 | | | | | |
| B-1623 | | | | | |
| B-1624 | | | | | |
| B-1625 | | | | | |
| B-1626 | | | | | |
| B-1627 | | | | | |
| B-1628 | | | | | |

| Example# | R ² | R ⁴ | | | |
|----------|---|---|--|--|--|
| B-1629 |  |  | | | |
| B-1630 |  |  | | | |
| B-1631 |  |  | | | |
| B-1632 |  |  | | | |
| B-1633 |  |  | | | |
| B-1634 |  |  | | | |
| B-1635 |  |  | | | |
| B-1636 |  |  | | | |
| B-1637 |  |  | | | |
| B-1638 |  |  | | | |

Example#

 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1639 |  |  | | | |
| B-1640 |  |  | | | |
| B-1641 |  |  | | | |
| B-1642 |  |  | | | |
| B-1643 |  |  | | | |
| B-1644 |  |  | | | |
| B-1645 |  |  | | | |























Examples B-1646 through B-1669 are prepared from Scaffold C-39

| Example# | R ² | R ¹ | | | |
|----------|----------------|----------------|--|--|--|
| B-1646 | | | | | |
| B-1647 | | | | | |
| B-1648 | | | | | |
| B-1649 | | | | | |
| B-1650 | | | | | |
| B-1651 | | | | | |
| B-1652 | | | | | |















Example#


 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1653 |  |  | | | |
| B-1654 |  |  | | | |
| B-1655 |  |  | | | |
| B-1656 |  |  | | | |
| B-1657 |  |  | | | |
| B-1658 |  |  | | | |
| B-1659 |  |  | | | |
| B-1660 |  |  | | | |
| B-1661 |  |  | | | |
| B-1662 |  |  | | | |

Example#

 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1663 |  |  | | | |
| B-1664 |  |  | | | |
| B-1665 |  |  | | | |
| B-1666 |  |  | | | |
| B-1667 |  |  | | | |
| B-1668 |  |  | | | |
| B-1669 |  |  | | | |























Examples B-1670 through B-1693 are prepared from Scaffold C-65















Example#


R²

R¹

| | | | | | |
|--------|--|--|--|--|--|
| B-1670 | | | | | |
| B-1671 | | | | | |
| B-1672 | | | | | |
| B-1673 | | | | | |
| B-1674 | | | | | |
| B-1675 | | | | | |
| B-1676 | | | | | |

| Example# | R ² | R ^L | | | |
|----------|---|---|--|--|--|
| B-1677 |  |  | | | |
| B-1678 |  |  | | | |
| B-1679 |  |  | | | |
| B-1680 |  |  | | | |
| B-1681 |  |  | | | |
| B-1682 |  |  | | | |
| B-1683 |  |  | | | |
| B-1684 |  |  | | | |
| B-1685 |  |  | | | |
| B-1686 |  |  | | | |

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-1687 |  |  | | | |
| B-1688 |  |  | | | |
| B-1689 |  |  | | | |
| B-1690 |  |  | | | |
| B-1691 |  |  | | | |
| B-1692 |  |  | | | |
| B-1693 |  |  | | | |























Examples B-1694 through B-1717 are prepared from Scaffold C-66


| Example# | R ² | R ^L | | | |
|----------|----------------|----------------|--|--|--|
| B-1694 | | | | | |
| B-1695 | | | | | |
| B-1696 | | | | | |
| B-1697 | | | | | |
| B-1698 | | | | | |
| B-1699 | | | | | |
| B-1700 | | | | | |

Example#

 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1701 |  |  | | | |
| B-1702 |  |  | | | |
| B-1703 |  |  | | | |
| B-1704 |  |  | | | |
| B-1705 |  |  | | | |
| B-1706 |  |  | | | |
| B-1707 |  |  | | | |
| B-1708 |  |  | | | |
| B-1709 |  |  | | | |
| B-1710 |  |  | | | |

10024380-10024



Examples B-1718 through B-1741 are prepared from Scaffold C-69

Example#





















R²

R^L

| | | | | | |
|--------|--|--|--|--|--|
| B-1718 | | | | | |
| B-1719 | | | | | |
| B-1720 | | | | | |
| B-1721 | | | | | |
| B-1722 | | | | | |
| B-1723 | | | | | |
| B-1724 | | | | | |















Example#


 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1725 |  |  | | | |
| B-1726 |  |  | | | |
| B-1727 |  |  | | | |
| B-1728 |  |  | | | |
| B-1729 |  |  | | | |
| B-1730 |  |  | | | |
| B-1731 |  |  | | | |
| B-1732 |  |  | | | |
| B-1733 |  |  | | | |
| B-1734 |  |  | | | |

Example#

 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1735 |  |  | | | |
| B-1736 |  |  | | | |
| B-1737 |  |  | | | |
| B-1738 |  |  | | | |
| B-1739 |  |  | | | |
| B-1740 |  |  | | | |
| B-1741 |  |  | | | |



Examples B-1742 through B-1765 are prepared from Scaffold C-70

Example#

R²





















R¹

| | | | | | |
|--------|--|--|--|--|--|
| B-1742 | | | | | |
| B-1743 | | | | | |
| B-1744 | | | | | |
| B-1745 | | | | | |
| B-1746 | | | | | |
| B-1747 | | | | | |
| B-1748 | | | | | |

10024780-120701















Example#


 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1749 |  |  | | | |
| B-1750 |  |  | | | |
| B-1751 |  |  | | | |
| B-1752 |  |  | | | |
| B-1753 |  |  | | | |
| B-1754 |  |  | | | |
| B-1755 |  |  | | | |
| B-1756 |  |  | | | |
| B-1757 |  |  | | | |
| B-1758 |  |  | | | |

Example#

 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1759 |  |  | | | |
| B-1760 |  |  | | | |
| B-1761 |  |  | | | |
| B-1762 |  |  | | | |
| B-1763 |  |  | | | |
| B-1764 |  |  | | | |
| B-1765 |  |  | | | |























Examples B-1766 through B-1789 are prepared from Scaffold C-71

| Example# | R ² | R ^L | | | |
|----------|----------------|----------------|--|--|--|
| B-1766 | | | | | |
| B-1767 | | | | | |
| B-1768 | | | | | |
| B-1769 | | | | | |
| B-1770 | | | | | |
| B-1771 | | | | | |
| B-1772 | | | | | |















Example#

 R^2 R^L


| | | | | | |
|--------|---|---|--|--|--|
| B-1773 |  |  | | | |
| B-1774 |  |  | | | |
| B-1775 |  |  | | | |
| B-1776 |  |  | | | |
| B-1777 |  |  | | | |
| B-1778 |  |  | | | |
| B-1779 |  |  | | | |
| B-1780 |  |  | | | |
| B-1781 |  |  | | | |
| B-1782 |  |  | | | |

Example#

 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1783 |  |  | | | |
| B-1784 |  |  | | | |
| B-1785 |  |  | | | |
| B-1786 |  |  | | | |
| B-1787 |  |  | | | |
| B-1788 |  |  | | | |
| B-1789 |  |  | | | |

T02021-08422001



Examples B-1790 through B-1813 are prepared from Scaffold C-72

Example#





















R²















R¹


| | | | | | |
|--------|--|--|--|--|--|
| B-1790 | | | | | |
| B-1791 | | | | | |
| B-1792 | | | | | |
| B-1793 | | | | | |
| B-1794 | | | | | |
| B-1795 | | | | | |
| B-1796 | | | | | |

Example#

 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1797 |  |  | | | |
| B-1798 |  |  | | | |
| B-1799 |  |  | | | |
| B-1800 |  |  | | | |
| B-1801 |  |  | | | |
| B-1802 |  |  | | | |
| B-1803 |  |  | | | |
| B-1804 |  |  | | | |
| B-1805 |  |  | | | |
| B-1806 |  |  | | | |

| Example# | R ² | R ^L | | | |
|----------|---|---|--|--|--|
| B-1807 |  |  | | | |
| B-1808 |  |  | | | |
| B-1809 |  |  | | | |
| B-1810 |  |  | | | |
| B-1811 |  |  | | | |
| B-1812 |  |  | | | |
| B-1813 |  |  | | | |



Examples B-1814 through B-1837 are prepared from Scaffold C-73

Example#





















R²

R⁴

| | | | | | |
|--------|--|--|--|--|--|
| B-1814 | | | | | |
| B-1815 | | | | | |
| B-1816 | | | | | |
| B-1817 | | | | | |
| B-1818 | | | | | |
| B-1819 | | | | | |
| B-1820 | | | | | |















Example#


 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1821 |  |  | | | |
| B-1822 |  |  | | | |
| B-1823 |  |  | | | |
| B-1824 |  |  | | | |
| B-1825 |  |  | | | |
| B-1826 |  |  | | | |
| B-1827 |  |  | | | |
| B-1828 |  |  | | | |
| B-1829 |  |  | | | |
| B-1830 |  |  | | | |

Example#

 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1831 |  |  | | | |
| B-1832 |  |  | | | |
| B-1833 |  |  | | | |
| B-1834 |  |  | | | |
| B-1835 |  |  | | | |
| B-1836 |  |  | | | |
| B-1837 |  |  | | | |



Examples B-1838 through B-1861 are prepared from Scaffold C-33

Example#

R²





















R¹

| | | | | | |
|--------|--|--|--|--|--|
| B-1838 | | | | | |
| B-1839 | | | | | |
| B-1840 | | | | | |
| B-1841 | | | | | |
| B-1842 | | | | | |
| B-1843 | | | | | |
| B-1844 | | | | | |















10034990-100704

Example#


 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1845 |  |  | | | |
| B-1846 |  |  | | | |
| B-1847 |  |  | | | |
| B-1848 |  |  | | | |
| B-1849 |  |  | | | |
| B-1850 |  |  | | | |
| B-1851 |  |  | | | |
| B-1852 |  |  | | | |
| B-1853 |  |  | | | |
| B-1854 |  |  | | | |

100480 43001-0872001

| Example# | R ² | R ^L | | | |
|----------|---|---|--|--|--|
| B-1855 |  |  | | | |
| B-1856 |  |  | | | |
| B-1857 |  |  | | | |
| B-1858 |  |  | | | |
| B-1859 |  |  | | | |
| B-1860 |  |  | | | |
| B-1861 |  |  | | | |

1004380-100701























Examples B-1862 through B-1885 are prepared from Scaffold C-45

| Example# | R^2 | R^L | | | |
|----------|-------|-------|--|--|--|
| B-1862 | | | | | |
| B-1863 | | | | | |
| B-1864 | | | | | |
| B-1865 | | | | | |
| B-1866 | | | | | |
| B-1867 | | | | | |
| B-1868 | | | | | |















Example#


 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1869 |  |  | | | |
| B-1870 |  |  | | | |
| B-1871 |  |  | | | |
| B-1872 |  |  | | | |
| B-1873 |  |  | | | |
| B-1874 |  |  | | | |
| B-1875 |  |  | | | |
| B-1876 |  |  | | | |
| B-1877 |  |  | | | |
| B-1878 |  |  | | | |

Example#

 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1879 |  |  | | | |
| B-1880 |  |  | | | |
| B-1881 |  |  | | | |
| B-1882 |  |  | | | |
| B-1883 |  |  | | | |
| B-1884 |  |  | | | |
| B-1885 |  |  | | | |























Examples B-1886 through B-1909 prepared from Scaffold C-42

| Example# | R ² | R ^L | | | |
|----------|----------------|----------------|--|--|--|
| B-1886 | | | | | |
| B-1887 | | | | | |
| B-1888 | | | | | |
| B-1889 | | | | | |
| B-1890 | | | | | |
| B-1891 | | | | | |
| B-1892 | | | | | |















Example#


 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1893 |  |  | | | |
| B-1894 |  |  | | | |
| B-1895 |  |  | | | |
| B-1896 |  |  | | | |
| B-1897 |  |  | | | |
| B-1898 |  |  | | | |
| B-1899 |  |  | | | |
| B-1900 |  |  | | | |
| B-1901 |  |  | | | |
| B-1902 |  |  | | | |

Example#

 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1903 |  |  | | | |
| B-1904 |  |  | | | |
| B-1905 |  |  | | | |
| B-1906 |  |  | | | |
| B-1907 |  |  | | | |
| B-1908 |  |  | | | |
| B-1909 |  |  | | | |























Examples B-1910 through B-1933 are prepared from Scaffold C-44

| Example# | R ² | R ^L | | | |
|----------|----------------|----------------|--|--|--|
| B-1910 | | | | | |
| B-1911 | | | | | |
| B-1912 | | | | | |
| B-1913 | | | | | |
| B-1914 | | | | | |
| B-1915 | | | | | |
| B-1916 | | | | | |















Example#

 R^2 R^L


| | | | | | |
|--------|---|---|--|--|--|
| B-1917 |  |  | | | |
| B-1918 |  |  | | | |
| B-1919 |  |  | | | |
| B-1920 |  |  | | | |
| B-1921 |  |  | | | |
| B-1922 |  |  | | | |
| B-1923 |  |  | | | |
| B-1924 |  |  | | | |
| B-1925 |  |  | | | |
| B-1926 |  |  | | | |

Example#

 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1927 |  |  | | | |
| B-1928 |  |  | | | |
| B-1929 |  |  | | | |
| B-1930 |  |  | | | |
| B-1931 |  |  | | | |
| B-1932 |  |  | | | |
| B-1933 |  |  | | | |

400480-4004



Examples B-1934 through B-1957 are prepared from Scaffold C-41

Example#

R²





















R¹

| | | | | | |
|--------|--|--|--|--|--|
| B-1934 | | | | | |
| B-1935 | | | | | |
| B-1936 | | | | | |
| B-1937 | | | | | |
| B-1938 | | | | | |
| B-1939 | | | | | |
| B-1940 | | | | | |















FOUOBT-08272001


Example#

 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-1941 |  |  | | | |
| B-1942 |  |  | | | |
| B-1943 |  |  | | | |
| B-1944 |  |  | | | |
| B-1945 |  |  | | | |
| B-1946 |  |  | | | |
| B-1947 |  |  | | | |
| B-1948 |  |  | | | |
| B-1949 |  |  | | | |
| B-1950 |  |  | | | |

10024380-40001

| Example# | R ² | R ^L | | | |
|----------|---|---|--|--|--|
| B-1951 |  |  | | | |
| B-1952 |  |  | | | |
| B-1953 |  |  | | | |
| B-1954 |  |  | | | |
| B-1955 |  |  | | | |
| B-1956 |  |  | | | |
| B-1957 |  |  | | | |





































Examples B-1958 through B-1981 are prepared from Scaffold C-43

| Example# | R ² | R ¹ | | | |
|----------|----------------|----------------|--|--|--|
| B-1958 | | | | | |
| B-1959 | | | | | |
| B-1960 | | | | | |
| B-1961 | | | | | |
| B-1962 | | | | | |
| B-1963 | | | | | |
| B-1964 | | | | | |


Example#

 R^2 R^L

| | | | | | |
|--------|---|---|--|--|--|
| B-1965 |  |  | | | |
| B-1966 |  |  | | | |
| B-1967 |  |  | | | |
| B-1968 |  |  | | | |
| B-1969 |  |  | | | |
| B-1970 |  |  | | | |
| B-1971 |  |  | | | |
| B-1972 |  |  | | | |
| B-1973 |  |  | | | |
| B-1974 |  |  | | | |

| Example# | R ² | R ^L | | | |
|----------|---|---|--|--|--|
| B-1975 |  |  | | | |
| B-1976 |  |  | | | |
| B-1977 |  |  | | | |
| B-1978 |  |  | | | |
| B-1979 |  |  | | | |
| B-1980 |  |  | | | |
| B-1981 |  |  | | | |

FOI 2004-1003780-100704

















Examples B-1982 through B-2005 are prepared from Scaffold C-30


| Example# | R ² | R ¹ | | | |
|----------|----------------|----------------|--|--|--|
| B-1982 | | | | | |
| B-1983 | | | | | |
| B-1984 | | | | | |
| B-1985 | | | | | |
| B-1986 | | | | | |
| B-1987 | | | | | |
| B-1988 | | | | | |

Example#

 R^2 R^L





















| | | | | | |
|--------|--|--|--|--|--|
| B-1989 | | | | | |
| B-1990 | | | | | |
| B-1991 | | | | | |
| B-1992 | | | | | |
| B-1993 | | | | | |
| B-1994 | | | | | |
| B-1995 | | | | | |
| B-1996 | | | | | |
| B-1997 | | | | | |
| B-1998 | | | | | |















| Example# | R ² | R ^L | | | |
|----------|---|---|--|--|--|
| B-1999 |  |  | | | |
| B-2000 |  |  | | | |
| B-2001 |  |  | | | |
| B-2002 |  |  | | | |
| B-2003 |  |  | | | |
| B-2004 |  |  | | | |
| B-2005 |  |  | | | |




Examples B-2006 through B-2029 are prepared from Scaffold C-60

| Example# | R ² | R ^J | | | |
|----------|----------------|----------------|--|--|--|
| B-2006 | | | | | |
| B-2007 | | | | | |
| B-2008 | | | | | |
| B-2009 | | | | | |
| B-2010 | | | | | |
| B-2011 | | | | | |
| B-2012 | | | | | |

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2013 |  |  | | | |
| B-2014 |  |  | | | |
| B-2015 |  |  | | | |
| B-2016 |  |  | | | |
| B-2017 |  |  | | | |
| B-2018 |  |  | | | |
| B-2019 |  |  | | | |
| B-2020 |  |  | | | |
| B-2021 |  |  | | | |
| B-2022 |  |  | | | |

| Example# | R ² | R ^J | | | |
|----------|---|---|--|--|--|
| B-2023 |  |  | | | |
| B-2024 |  |  | | | |
| B-2025 |  |  | | | |
| B-2026 |  |  | | | |
| B-2027 |  |  | | | |
| B-2028 |  |  | | | |
| B-2029 |  |  | | | |





































Examples B-2030 through B-2053 are prepared from Scaffold C-36


| Example# | R ² | R ^J | | | |
|----------|----------------|----------------|--|--|--|
| B-2030 | | | | | |
| B-2031 | | | | | |
| B-2032 | | | | | |
| B-2033 | | | | | |
| B-2034 | | | | | |
| B-2035 | | | | | |
| B-2036 | | | | | |

Example#

 R^2 R^1





















| | | | | | |
|--------|---|---|--|--|--|
| B-2037 |  |  | | | |
| B-2038 |  |  | | | |
| B-2039 |  |  | | | |
| B-2040 |  |  | | | |
| B-2041 |  |  | | | |
| B-2042 |  |  | | | |
| B-2043 |  |  | | | |
| B-2044 |  |  | | | |
| B-2045 |  |  | | | |
| B-2046 |  |  | | | |

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2047 |  |  | | | |
| B-2048 |  |  | | | |
| B-2049 |  |  | | | |
| B-2050 |  |  | | | |
| B-2051 |  |  | | | |
| B-2052 |  |  | | | |
| B-2053 |  |  | | | |

















Examples B-2054 through B-2077 are prepared from Scaffold C-34


| Example# | R ² | R ^J | | | |
|----------|----------------|----------------|--|--|--|
| B-2054 | | | | | |
| B-2055 | | | | | |
| B-2056 | | | | | |
| B-2057 | | | | | |
| B-2058 | | | | | |
| B-2059 | | | | | |
| B-2060 | | | | | |

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2061 |  |  | | | |
| B-2062 |  |  | | | |
| B-2063 |  |  | | | |
| B-2064 |  |  | | | |
| B-2065 |  |  | | | |
| B-2066 |  |  | | | |
| B-2067 |  |  | | | |
| B-2068 |  |  | | | |
| B-2069 |  |  | | | |
| B-2070 |  |  | | | |

10034780-1004

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2071 |  |  | | | |
| B-2072 |  |  | | | |
| B-2073 |  |  | | | |
| B-2074 |  |  | | | |
| B-2075 |  |  | | | |
| B-2076 |  |  | | | |
| B-2077 |  |  | | | |

T06031-08212001



Examples B-2078 through B-2101 are prepared from Scaffold C-57

Example#



















R²

R^J

| | | | | | |
|--------|--|--|--|--|--|
| B-2078 | | | | | |
| B-2079 | | | | | |
| B-2080 | | | | | |
| B-2081 | | | | | |
| B-2082 | | | | | |
| B-2083 | | | | | |
| B-2084 | | | | | |

















Example#


 R^2 R^1

| | | | | | |
|--------|---|---|--|--|--|
| B-2085 |  |  | | | |
| B-2086 |  |  | | | |
| B-2087 |  |  | | | |
| B-2088 |  |  | | | |
| B-2089 |  |  | | | |
| B-2090 |  |  | | | |
| B-2091 |  |  | | | |
| B-2092 |  |  | | | |
| B-2093 |  |  | | | |

Example#





















 R^2 R^1















| | | | | | |
|--------|---|---|--|--|--|
| B-2094 |  |  | | | |
| B-2095 |  |  | | | |
| B-2096 |  |  | | | |
| B-2097 |  |  | | | |
| B-2098 |  |  | | | |
| B-2099 |  |  | | | |
| B-2100 |  |  | | | |
| B-2101 |  |  | | | |




Examples B-2102 through B-2125 are prepared from Scaffold C-52

| Example# | R ² | R ¹ | | | |
|----------|----------------|----------------|--|--|--|
| B-2102 | | | | | |
| B-2103 | | | | | |
| B-2104 | | | | | |
| B-2105 | | | | | |
| B-2106 | | | | | |
| B-2107 | | | | | |
| B-2108 | | | | | |

| Example# | R ² | R ³ | | | |
|----------|---|---|--|--|--|
| B-2109 |  |  | | | |
| B-2110 |  |  | | | |
| B-2111 |  |  | | | |
| B-2112 |  |  | | | |
| B-2113 |  |  | | | |
| B-2114 |  |  | | | |
| B-2115 |  |  | | | |
| B-2116 |  |  | | | |
| B-2117 |  |  | | | |
| B-2118 |  |  | | | |















| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2119 |  |  | | | |
| B-2120 |  |  | | | |
| B-2121 |  |  | | | |
| B-2122 |  |  | | | |
| B-2123 |  |  | | | |
| B-2124 |  |  | | | |
| B-2125 |  |  | | | |




Examples B-2126 through B-2149 are prepared from Scaffold C-56

| Example# | R ² | R ^J | | | |
|----------|----------------|----------------|--|--|--|
| B-2126 | | | | | |
| B-2127 | | | | | |
| B-2128 | | | | | |
| B-2129 | | | | | |
| B-2130 | | | | | |
| B-2131 | | | | | |
| B-2132 | | | | | |





















| Example# | R ² | R ¹ | | | |
|----------|----------------|----------------|--|--|--|
| B-2133 | | | | | |
| B-2134 | | | | | |
| B-2135 | | | | | |
| B-2136 | | | | | |
| B-2137 | | | | | |
| B-2138 | | | | | |
| B-2139 | | | | | |
| B-2140 | | | | | |
| B-2141 | | | | | |
| B-2142 | | | | | |















| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2143 |  |  | | | |
| B-2144 |  |  | | | |
| B-2145 |  |  | | | |
| B-2146 |  |  | | | |
| B-2147 |  |  | | | |
| B-2148 |  |  | | | |
| B-2149 |  |  | | | |




Examples B-2150 through B-2173 are prepared from Scaffold C-32

| Example# | R ² | R ^J | | | |
|----------|----------------|----------------|--|--|--|
| B-2150 | | | | | |
| B-2151 | | | | | |
| B-2152 | | | | | |
| B-2153 | | | | | |
| B-2154 | | | | | |
| B-2155 | | | | | |
| B-2156 | | | | | |





















| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2157 |  |  | | | |
| B-2158 |  |  | | | |
| B-2159 |  |  | | | |
| B-2160 |  |  | | | |
| B-2161 |  |  | | | |
| B-2162 |  |  | | | |
| B-2163 |  |  | | | |
| B-2164 |  |  | | | |
| B-2165 |  |  | | | |
| B-2166 |  |  | | | |















| Example# | R ² | R ^J | | | |
|----------|---|---|--|--|--|
| B-2167 |  |  | | | |
| B-2168 |  |  | | | |
| B-2169 |  |  | | | |
| B-2170 |  |  | | | |
| B-2171 |  |  | | | |
| B-2172 |  |  | | | |
| B-2173 |  |  | | | |




Examples 2174 through B-2197 are prepared from Scaffold C-64

| Example# | R^2 | R^J | | | |
|----------|-------|-------|--|--|--|
| B-2174 | | | | | |
| B-2175 | | | | | |
| B-2176 | | | | | |
| B-2177 | | | | | |
| B-2178 | | | | | |
| B-2179 | | | | | |
| B-2180 | | | | | |





















| Example# | R ² | R ^J | | | |
|----------|---|---|--|--|--|
| B-2181 |  |  | | | |
| B-2182 |  |  | | | |
| B-2183 |  |  | | | |
| B-2184 |  |  | | | |
| B-2185 |  |  | | | |
| B-2186 |  |  | | | |
| B-2187 |  |  | | | |
| B-2188 |  |  | | | |
| B-2189 |  |  | | | |
| B-2190 |  |  | | | |















| Example# | R ² | R ^J | | | |
|----------|---|---|--|--|--|
| B-2191 |  |  | | | |
| B-2192 |  |  | | | |
| B-2193 |  |  | | | |
| B-2194 |  |  | | | |
| B-2195 |  |  | | | |
| B-2196 |  |  | | | |
| B-2197 |  |  | | | |




Examples B-2198 through B-2221 re prepared from Scaffold C-22

| Example# | R ² | R ^J | | | |
|----------|----------------|----------------|--|--|--|
| B-2198 | | | | | |
| B-2199 | | | | | |
| B-2200 | | | | | |
| B-2201 | | | | | |
| B-2202 | | | | | |
| B-2203 | | | | | |
| B-2204 | | | | | |

| Example# | R ² | R ^J | | | |
|----------|---|---|--|--|--|
| B-2205 |  |  | | | |
| B-2206 |  |  | | | |
| B-2207 |  |  | | | |
| B-2208 |  |  | | | |
| B-2209 |  |  | | | |
| B-2210 |  |  | | | |
| B-2211 |  |  | | | |
| B-2212 |  |  | | | |
| B-2213 |  |  | | | |
| B-2214 |  |  | | | |

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2215 |  |  | | | |
| B-2216 |  |  | | | |
| B-2217 |  |  | | | |
| B-2218 |  |  | | | |
| B-2219 |  |  | | | |
| B-2220 |  |  | | | |
| B-2221 |  |  | | | |



Examples B-2222 through B-2245 are prepared from Scaffold C-29

Example#



















R²

















R^J


| | | | | | |
|--------|--|--|--|--|--|
| B-2222 | | | | | |
| B-2223 | | | | | |
| B-2224 | | | | | |
| B-2225 | | | | | |
| B-2226 | | | | | |
| B-2227 | | | | | |
| B-2228 | | | | | |

Example#

 R^2 R^1





















| | | | | | |
|--------|---|---|--|--|--|
| B-2229 |  |  | | | |
| B-2230 |  |  | | | |
| B-2231 |  |  | | | |
| B-2232 |  |  | | | |
| B-2233 |  |  | | | |
| B-2234 |  |  | | | |
| B-2235 |  |  | | | |
| B-2236 |  |  | | | |
| B-2237 |  |  | | | |















| Example# | R ² | R ^J | | | |
|----------|---|---|--|--|--|
| B-2238 |  |  | | | |
| B-2239 |  |  | | | |
| B-2240 |  |  | | | |
| B-2241 |  |  | | | |
| B-2242 |  |  | | | |
| B-2243 |  |  | | | |
| B-2244 |  |  | | | |
| B-2245 |  |  | | | |



Examples B-2246 through B-2269 are prepared from Scaffold C-35

| Example# | R ² | R ^J | | | |
|----------|----------------|----------------|--|--|--|
| B-2246 | | | | | |
| B-2247 | | | | | |
| B-2248 | | | | | |
| B-2249 | | | | | |
| B-2250 | | | | | |
| B-2251 | | | | | |
| B-2252 | | | | | |

| Example# | R ² | R ¹ | | | |
|----------|---|---|--|--|--|
| B-2253 |  |  | | | |
| B-2254 |  |  | | | |
| B-2255 |  |  | | | |
| B-2256 |  |  | | | |
| B-2257 |  |  | | | |
| B-2258 |  |  | | | |
| B-2259 |  |  | | | |
| B-2260 |  |  | | | |
| B-2261 |  |  | | | |
| B-2262 |  |  | | | |

| Example# | R ² | R ^J | | | |
|----------|---|---|--|--|--|
| B-2263 |  |  | | | |
| B-2264 |  |  | | | |
| B-2265 |  |  | | | |
| B-2266 |  |  | | | |
| B-2267 |  |  | | | |
| B-2268 |  |  | | | |
| B-2269 |  |  | | | |

5

10



Examples B-2270 through B-2317

15

In a parallel array reaction block containing 48 fritted vessels, each reaction vessel was charged with 250 mg of polymer bound carbodiimide **B48** (1.0 mmol/g resin) and a solution of the acid-containing scaffold **C-49** in dimethylformamide (0.1 M, 500 uL). To each slurry was added a solution of pyridine in dichloromethane (0.2 M, 1000 uL) followed by a solution of a unique amine **B47** (0.2 M, 375 uL) in dimethylformamide. The reaction mixtures were agitated on a Labline benchtop orbital shaker at 250 RPM for 16-20 h at ambient temperature. The reaction mixtures were filtered into conical vials and the polymer was washed with 1.5 mL of dimethylformamide and 2.0 mL of dichloromethane. The filtrates were evaporated to dryness in a Savant apparatus and dimethylformamide (350 uL) was added to each conical vial to dissolve the residue. A solution of tetrafluorophthalic anhydride (1.0 M, 150 uL) in

dimethylformamide was added to the reconstituted conical vials and the mixture incubated for 2 hours at ambient temperature. Polyamine polymer B33 (4.0 meq N/g resin, 250 mg) and 1.0 mL dichloromethane was then added to the reaction mixture in each conical vial. After agitating the reaction mixtures for 16 h at 250 RPM on an orbital shaker at ambient temperature, the mixtures were filtered through a polypropylene syringe tube fitted with a porous frit. The polymers were washed twice with dimethylformamide (1.0 mL each) and the filtrates and washings collected in conical vials. The filtrates were evaporated to dryness and weighed to afford the desired amide products B-2270 through B-2317 as oils or solids. The analytical data and yields for the products prepared in this manner are listed below.






















10024780-120701






















R²






















Yield






















Calcd. Mass
Spec.Observed
Mass Spec
M+H




| | | | | | |
|--------|--|--|----|-----|-----|
| B-2270 | | | 12 | 352 | 353 |
| B-2271 | | | 39 | 432 | 433 |
| B-2272 | | | 26 | 400 | - |
| B-2273 | | | 14 | 396 | 397 |
| B-2274 | | | 30 | 434 | 435 |
| B-2275 | | | 43 | 443 | - |
| B-2276 | | | 35 | 364 | 365 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|---------------------------------------|
| B-2277 |  |  | 33 | 490 | - |
| B-2278 |  |  | 53 | 460 | 461 |
| B-2279 |  |  | 10 | 420 | - |
| B-2280 |  |  | 7 | 435 | 436 |
| B-2281 |  |  | 18 | 401 | 402 |
| B-2282 |  |  | 22 | 390 | 413 ^a ^a M+Na |
| B-2283 |  |  | 10 | 394 | 417 ^a ^a M+Na |
| B-2284 |  |  | 7 | 423 | - |
| B-2285 |  |  | 23 | 450 | - |
| B-2286 |  |  | 4 | 506 | - |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|---------------------------|
| B-2287 |  |  | 5 | 437 | 438 |
| B-2288 |  |  | 8 | 435 | 436 |
| B-2289 |  |  | 4 | 450 | 451 |
| B-2290 |  |  | 9 | 456 | 457 |
| B-2291 |  |  | 9 | 415 | 416 |
| B-2292 |  |  | 5 | 368 | 369 |
| B-2293 |  |  | 5 | 366 | 367 |
| B-2294 |  |  | 5 | 381 | 382 |
| B-2295 |  |  | 16 | 410 | 411 |
| B-2296 |  |  | 4 | 483 | - |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|---------------------------|
| B-2297 |  |  | 7 | 490 | - |
| B-2298 |  |  | 4 | 537 | - |
| B-2299 |  |  | 4 | 507 | 508 |
| B-2300 |  |  | 7 | 442 | - |
| B-2301 |  |  | 20 | 396 | 397 |
| B-2302 |  |  | 30 | 459 | - |
| B-2303 |  |  | 6 | 482 | - |
| B-2304 |  |  | 5 | 395 | 396 |
| B-2305 |  |  | 10 | 460 | - |
| B-2306 |  |  | 11 | 466 | 467 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2307 |  |  | 5 | 421 | 422 |
| B-2308 |  |  | 26 | 470 | - |
| B-2309 |  |  | 24 | 424 | 425 |
| B-2310 |  |  | 9 | 348 | - |
| B-2311 |  |  | 21 | 338 | 339 |
| B-2312 |  |  | 28 | 398 | 399 |
| B-2313 |  |  | 6 | 410 | - |
| B-2314 |  |  | 15 | 363 | 364 |
| B-2315 |  |  | 11 | 444 | - |
| B-2316 |  |  | 11 | 418 | - |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2317 |  |  | 36 | 428 | - |

5

10

By analogy to the procedure identified above for the preparation of Examples B-2270 through B-2317, the following examples B-2318 through B-2461 were prepared.


15

20




















25




















30




















FOI b7 - D

































| | R ² | | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|----------------|--|-------|-------------------|------------------------|
| B-2318 | | | 23 | 426 | 427 |
| B-2319 | | | 23 | 394 | - |
| B-2320 | | | 50 | 490 | 491 |
| B-2321 | | | 49 | 426 | 427 |
| B-2322 | | | 40 | 366 | 367 |
| B-2323 | | | 68 | 410 | 411 |
| B-2324 | | | 57 | 456 | 457 |



| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2325 |  |  | 41 | 382 | 383 |
| B-2326 |  |  | 71 | 440 | 441 |
| B-2327 |  |  | 36 | 464 | 465 |
| B-2328 |  |  | 32 | 467 | 468 |
| B-2329 |  |  | 34 | 465 | 466 |
| B-2330 |  |  | 26 | 364 | 365 |
| B-2331 |  |  | 38 | 464 | 465 |
| B-2332 |  |  | 33 | 483 | 484 |
| B-2333 |  |  | 36 | 378 | 379 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2334 |  |  | 44 | 428 | 429 |
| B-2335 |  |  | 27 | 406 | 407 |
| B-2336 |  |  | 41 | 428 | 429 |
| B-2337 |  |  | 27 | 423 | 424 |
| B-2338 |  |  | 33 | 469 | 470 |
| B-2339 |  |  | 52 | 518 | 519 |
| B-2340 |  |  | 64 | 442 | 443 |
| B-2341 |  |  | 41 | 350 | 351 |
| B-2342 |  |  | 34 | 414 | 415 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2343 |  |  | 29 | 424 | 425 |
| B-2344 |  |  | 33 | 492 | 493 |
| B-2345 |  |  | 30 | 420 | 421 |
| B-2346 |  |  | 35 | 474 | 475 |
| B-2347 |  |  | 34 | 392 | 393 |
| B-2348 |  |  | 51 | 458 | 459 |
| B-2349 |  |  | 73 | 517 | 518 |
| B-2350 |  |  | 22 | 448 | 449 |
| B-2351 |  |  | 64 | 486 | 487 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2352 |  |  | 41 | 482 | 483 |
| B-2353 |  |  | 57 | 438 | 439 |
| B-2354 |  |  | 63 | 484 | 485 |
| B-2355 |  |  | 28 | 536 | 537 |
| B-2356 |  |  | 29 | 408 | 409 |
| B-2357 |  |  | 41 | 436 | 437 |
| B-2358 |  |  | 41 | 451 | 452 |
| B-2359 |  |  | 57 | 502 | 503 |
| B-2360 |  |  | 46 | 496 | 497 |




















| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|--|--|-------|-------------------|------------------------|
| B-2361 |  |  | 13 | 476 | 477 |
| B-2362 |  |  | 46 | 493 | 494 |
| B-2363 |  |  | 57 | 396 | 397 |
| B-2364 |  |  | 61 | 438 | 439 |
| B-2365 |  |  | 72 | 424 | 425 |




















R²




















Yield




















Calcd. Mass
Spec.Observed
Mass Spec
M+H












| | | | | | |
|--------|--|--|----|-----|-----|
| B-2366 | | | 34 | 380 | 381 |
| B-2367 | | | 52 | 480 | 481 |
| B-2368 | | | 35 | 407 | 407 |
| B-2369 | | | 31 | 435 | 436 |
| B-2370 | | | 33 | 414 | 415 |
| B-2371 | | | 28 | 366 | 367 |
| B-2372 | | | 37 | 422 | 423 |


| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2373 |  |  | 50 | 432 | 433 |
| B-2374 |  |  | 29 | 382 | 383 |
| B-2375 |  |  | 35 | 395 | 396 |
| B-2376 |  |  | 36 | 428 | 429 |
| B-2377 |  |  | 68 | 438 | 439 |
| B-2378 |  |  | 55 | 446 | 447 |
| B-2379 |  |  | 33 | 364 | 365 |
| B-2380 |  |  | 51 | 421 | 422 |
| B-2381 |  |  | 52 | 429 | 430 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|---------------------------|
| B-2382 |  |  | 48 | 407 | 408 |
| B-2383 |  |  | 53 | 382 | 383 |
| B-2384 |  |  | 38 | 447 | 448 |
| B-2385 |  |  | 59 | 498 | 450 |
| B-2386 |  |  | 45 | 429 | 430 |
| B-2387 |  |  | 74 | 558 | - |
| B-2388 |  |  | 53 | 475 | - |
| B-2389 |  |  | 33 | 493 | 494 |
| B-2390 |  |  | 53 | 487 | 488 |




















| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|---------------------------|
| B-2391 |  |  | 30 | 435 | 436 |
| B-2392 |  |  | 57 | 464 | 465 |
| B-2393 |  |  | 50 | 418 | 419 |
| B-2394 |  |  | 65 | 488 | 489 |
| B-2395 |  |  | 59 | 437 | 438 |
| B-2396 |  |  | 34 | 534 | 535 |
| B-2397 |  |  | 32 | 516 | 517 |
| B-2398 |  |  | 81 | 533 | 534 |
| B-2399 |  |  | 55 | 502 | - |




















| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|---------------------------|
| B-2400 |  |  | 34 | 381 | 382 |
| B-2401 |  |  | 32 | 378 | 379 |
| B-2402 |  |  | 71 | 519 | 520 |
| B-2403 |  |  | 68 | 527 | 528 |
| B-2404 |  |  | 62 | 447 | 448 |
| B-2405 |  |  | 71 | 536 | 537 |
| B-2406 |  |  | 47 | 394 | 395 |
| B-2407 |  |  | 65 | 508 | 509 |
| B-2408 |  |  | 34 | 495 | 496 |




















| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|--|-------|-------------------|------------------------|
| B-2409 |  |  | 47 | 448 | 449 |
| B-2410 |  |  | 73 | 542 | 543 |
| B-2411 |  |  | 81 | 489 | 490 |
| B-2412 |  |  | 54 | 409 | 410 |
| B-2413 |  |  | 37 | 493 | 494 |

































| | R ² | | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|----------------|--|-------|-------------------|---------------------------|
| B-2414 | | | 14 | 473 | 474 |
| B-2415 | | | 19 | 421 | 422 |
| B-2416 | | | 13 | 386 | 387 |
| B-2417 | | | 29 | 414 | 415 |
| B-2418 | | | 6 | 420 | 421 |
| B-2419 | | | 10 | 454 | - |
| B-2420 | | | 5 | 442 | 443 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2421 |  |  | 28 | 454 | 455 |
| B-2422 |  |  | 47 | 420 | 421 |
| B-2423 |  |  | 53 | 400 | 401 |
| B-2424 |  |  | 15 | 400 | 401 |
| B-2425 |  |  | 18 | 522 | 523 |
| B-2426 |  |  | 38 | 464 | 465 |
| B-2427 |  |  | 26 | 468 | 469 |
| B-2428 |  |  | 22 | 432 | 433 |
| B-2429 |  |  | 41 | 404 | 405 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2430 |  |  | 15 | 476 | 477 |
| B-2431 |  |  | 6 | 446 | 447 |
| B-2432 |  |  | 37 | 404 | 405 |
| B-2433 |  |  | 8 | 428 | 429 |
| B-2434 |  |  | 13 | 476 | 477 |
| B-2435 |  |  | 23 | 442 | 443 |
| B-2436 |  |  | 5 | 486 | 487 |
| B-2437 |  |  | 4 | 492 | 493 |
| B-2438 |  |  | 58 | 422 | 423 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2439 |  |  | 12 | 454 | 455 |
| B-2440 |  |  | 8 | 521 | 522 |
| B-2441 |  |  | 6 | 443 | 444 |
| B-2442 |  |  | 37 | 514 | 515 |
| B-2443 |  |  | 15 | 518 | - |
| B-2444 |  |  | 52 | 520 | - |
| B-2445 |  |  | 33 | 517 | 518 |
| B-2446 |  |  | 70 | 500 | 501 |
| B-2447 |  |  | 56 | 488 | 489 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|---|-------|-------------------|------------------------|
| B-2448 |  |  | 51 | 522 | 523 |
| B-2449 |  |  | 19 | 512 | 513 |
| B-2450 |  |  | 16 | 538 | 539 |
| B-2451 |  |  | 71 | 511 | 512 |
| B-2452 |  |  | 71 | 500 | 501 |
| B-2453 |  |  | 61 | 470 | - |
| B-2454 |  |  | 15 | 472 | 473 |
| B-2455 |  |  | 39 | 520 | - |
| B-2456 |  |  | 51 | 533 | 534 |

| | R^2 |  | Yield | Calcd. Mass Spec. | Observed Mass Spec M+H |
|--------|---|--|-------|-------------------|---------------------------|
| B-2457 |  |  | 55 | 540 | - |
| B-2458 |  |  | 22 | 488 | 489 |
| B-2459 |  |  | 8 | 486 | 487 |
| B-2460 |  |  | 13 | 534 | 535 |
| B-2461 |  |  | 13 | 542 | - |


5

10

Example C-1

15

5-AMINOMETHYL-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



20

1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone. 4-picoline (40 g, 0.43 mol) was added to a LiHMDS solution (0.45 mol, 450 mL of a 1.0 M solution in THF) over 30 minutes at room temperature (a slight exotherm was observed). The resulting solution was stirred for 1 h. This solution was added to ethyl 4-fluorobenzoate (75.8 g, 0.45 mol, neat) over 1 h. The mixture was stirred overnight (16 h). Water (200 mL) was added and the mixture was extracted with EtOAc (2x200 mL). The organic layer was washed with brine (1x200 mL) and dried over

25

Na₂SO₄. The organic layer was filtered and the solvent was removed to leave oily solid. Hexane was added to the oil and the resulting solid was filtered and washed with hexane (cold). A yellow solid was isolated (50 g, 54%):

5 ¹H NMR (CDCl₃) δ 8.58 (d, J = 5.7 Hz, 2H), 8.02 (dd, J = 5.5, 8.0, 2H), 7.12-7.21 (m, 4H), 4.23 (s, 2H); ¹⁹F NMR (CDCl₃) δ -104.38 (m); LC/MS, t_r = 2.14 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), M+H = 216; High Resolution MS Calcd for

10 C₂₃H₂₀N₄O₂F (M+H): 216.0825. Found: 216.0830 (Δ mmu = 0.5).

N-benzyloxycarbonyl-5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. A 3L round bottom flask

15 fitted with a mechanical stirrer, N₂ inlet and an addition funnel was charged with 557 mL (0.56 mol) of 1 M t-BuOK in THF and 53 mL (0.56 mol) of t-BuOH. The ketone, 1 (60 g, 0.28 mol) was dissolved in 600 mL of THF and added to the stirred mixture at room temperature. A yellow

20 precipitate formed and the mixture was stirred for 1 h. N-benzyloxycarbonyl-glycinyll N-hydroxysuccinimide (128.6 g, 0.42 mol) was dissolved in 600 mL of THF and added dropwise at r.t. over 1h. The mixture was stirred for another 5 minutes and 150 mL of water was added. the pH

25 was adjusted to 6.7 with 70 mL of AcOH. Hydrazine monohydrate (41 mL in 100 mL of water) was added via an addition funnel. The mixture was stirred for 1 h and was diluted with 500 mL of water and 500 mL of ethyl acetate. The biphasic mixture was transferred to a sep funnel and

30 the layers were separated. The aqueous layer was extracted with EtOAc (3x300 mL). The organic layer was

dried (Na_2SO_4), filtered and evaporated to leave 157 g of a crude reddish oil.

The oil was suspended in CH_2Cl_2 and filtered to remove any insoluble material (DCU, hydrazone of the monoketone). The solution was split into two portions and each portion was chromatographed (Biotage 75L, 3% $\text{EtOH}/\text{CH}_2\text{Cl}_2$ then 6% $\text{EtOH}/\text{CH}_2\text{Cl}_2$). The appropriate fractions were concentrated (some contamination from the monoketone and the hydrazone) from each portion to leave a yellow solid. The solid was suspended in ethyl acetate and heated to boiling for 10 minutes. The solution was allowed to cool to R.T. overnight. The precipitate was filtered to give 30 g of a white solid (27% yield of 2): ^1H NMR ($\text{DMF}-d_7$) δ 13.36 (s, 1H), 8.57 (d, $J = 5.8$ Hz, 2H), 7.16-7.52 (m, 11H), 5.11 (s, 2H), 4.48 (d, $J = 5.4$ Hz, 2H); ^{19}F NMR ($\text{DMF}-d_7$) δ -114.9 (m), -116.8 (m) (split fluorine signal is due to the pyrazole tautomers); LC/MS, $t_r = 3.52$ minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), $M+H = 403$; High Resolution MS Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_4\text{O}_2\text{F}$ ($M+H$): 403.1570. Found: 403.1581 (Δ mmu = 1.1).

5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl)

pyrazole. To a 1L Parr bottle was added 7 g (17.4 mmol) of 2 and 180 mL of MeOH and 90 mL of THF to give a clear solution. The bottle was purged with nitrogen and 1.5 g of 10% Pd/C (wet Degussa type E101) was added. The Parr bottle was pressured to 40 psi (H_2) and was agitated. Hydrogen uptake was 5 psi after 5 h. The bottle was repressured to 42 psi and was agitated overnight. The bottle was purged with N_2 and was filtered through Celite. The Celite was washed with MeOH (3x50 mL) and


the filtrate was concentrated to give 4.5 g of an off-white solid (94%). ^1H NMR (DMSO- d_6) δ 8.52 (d, J = 4.63 Hz, 2H), 7.36 (dd, J = 5.64, 8.1 Hz, 2H), 7.16-7.30 (m, 4H), 3.79 (s, 2H); ^{19}F NMR (DMSO- d_6) δ -114.56 (m); LC/MS, t_r = 1.21 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), $M+H$ = 269 m/z; High Resolution MS Calcd for $\text{C}_{15}\text{H}_{14}\text{N}_4\text{F}$ ($M+H$): 269.1202. Found: 269.1229 (Δ mmu = 2.7).

10






The following pyridylpyrazoles (C-2 through C-21, Table C-1) were prepared according to the experimental procedure described above for example C-1.







15

Table C-1.

| Example No. | Structure | MW, $M + H$ Calculated Found | ^1H NMR (solvent), ppm |
|-------------|---|------------------------------------|---|
| C-2 |  | 323.1672 323.1670 | (DMF- d_7): 8.77 (t, J = 4.4 Hz, 2H), 7.60 (m, 2H), 7.44 (t, J = 4.4 Hz, 2H), 7.35 (m, 2H), 3.22 (bd, 2H), 3.01 (septet, J = 5.3 Hz, 1H), 2.74 (m, 2H), 1.95 (m, 4H) |

| | | | |
|-----|--|---------------------------------------|--|
| C-3 | | 282.127 (M) 282.1245 (M, EI) | (DMF-d ₇): 8.77 (br s, 2H), 7.64-7.62 (m, 2H), 7.50 (br s, 2H), 7.38-7.34 (m, 2H), 4.40-4.37 (m, 1H), 1.56 (br s, 3H) |
| C-4 | | 282.127 (M) 282.1147 (M, EI) | (DMF-d ₇): 8.77 (br s, 2H), 7.64-7.62 (m, 2H), 7.50 (br s, 2H), 7.38-7.35 (m, 2H), 4.40-4.37 (m, 1H), 1.57 (br s, 3H) |
| C-5 | | 323.1672 323.1687 | (DMSO-d ₆): 8.56 (br, 2H), 7.32 (m, 2H), 7.18 (m, 4H), 2.91 (m, 2H), 2.71 (m, 2H) 1.88 (m, 1H), 1.65 (m, 2H), 1.40 (m, 2H) |
| C-6 | | 359 359 | (DMSO-d ₆): 8.46 (d, J = 4.6 Hz, 2H), 7.32-7.13 (m, 7H), 6.98-6.96 (m, 4H), 4.06 (t, J = 7.0 Hz, 1H), 2.98-2.95 (m, 2H) |
| C-7 | | 359 359 | (DMSO-d ₆): 8.46 (d, J = 5.4 Hz, 2H), 7.32-7.28 (m, 2H), 7.20-7.12 (m, 5H), 6.98-6.96 (m, 4H), 4.06 (t, J = 7.0 Hz, 1H), 2.98-2.94 (m, 2H) |
| C-8 | | 313.1465 313.1492 | (DMSO-d ₆): 13.83 (bs, 1H), 8.61 (d, J = 5.7 Hz, 2H), 8.33 (bs, 1H), 7.33 (m, 6H), 4.44 (m, 1H), 3.63 (m, 2H), 3.27 (s, 3H) |

| | | | |
|------|---|----------------------|---|
| C-9 |  | 313.1465 313.1457 | (DMSO-d ₆): 8.55 (dd, J = 1.5, 4.4 Hz, 2H), 7.37-7.32 (m, 2H), 7.26 (dd, J = 1.6, 4.4 Hz, 2H), 7.22-7.16 (m, 2H), 4.06 (t, J = 6.5 Hz, 1H), 3.49 (d, J = 6.6 Hz, 2H), 3.20 (s, 3H) |
| C-10 |  | 354 354 | (DMSO-d ₆): 13.03 (bs, 1H), 8.50 (dd, J=1.6, 2.7 Hz, 2H), 7.58 (bq, J=4.3 Hz, 1H), 7.3 (m, 2H), 7.12-7.21 (m, 4H), 3.77 (t, J= 6.3 Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J= 7.4 Hz, 2H), 1.85 (dt, J=7.3, 7.1 Hz, 2H) |
| C-11 |  | 354 354 | (DMSO-d ₆): 13.03 (bs, 1H), 8.50 (dd, J=1.6, 2.7 Hz, 2H), 7.58 (bq, J=4.3 Hz, 1H), 7.3 (m, 2H), 7.12-7.21 (m, 4H), 3.77 (t, J= 6.3 Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J= 7.4 Hz, 2H), 1.85 (dt, J=7.3, 7.1 Hz, 2H) |
| C-12 |  | 283.1359 283.1363 | (DMSO-d ₆): 8.53 (d, J = 5.0 Hz, 2H), 7.37-7.32 (m, 2H), 7.21-7.17 (m, 4H), 2.83 (d, J = 6.0 Hz, 2H), 2.77 (d, J = 6.0 Hz, 2H) |
| C-13 |  | 297.1515 297.1515 | (DMSO-d ₆): 8.53 (d, J = 5.4 Hz, 2H), 7.34 (dd, J = 5.8, 8.2 Hz, 2H), 7.18 |

| | | | |
|------|---|----------------------|--|
| | | | (dd, $J = 5.8, 9.8$ Hz, 4H), 2.68 (t, $J = 7.3$ Hz, 2H), 2.52 (m, 2H), 1.64 (m, 2H) |
| C-14 |  | 284.0829 284.0806 | (CD_3OD): 8.74 (br, 2H), 7.77 (br, 2H), 7.45-7.58 (m, 3H), 7.30-7.40 (m, 1H), 4.43 (s, 2H) |
| C-15 |  | 285 285 | (DMSO- d_6): 8.53 (br, 2H), 7.56 (br, 2H), 7.26 (m, 4H), 3.75 (br, 2H) |
| C-16 |  | 329, 331 329, 331 | (DMSO- d_6): 8.53 (d, $J =$ 4.4 Hz, 2H), 7.42 (d, $J =$ 7.9 Hz, 2H), 7.34 (d, $J =$ 8.5 Hz, 2H), 7.24 (d, $J =$ 4.6 Hz, 2H), 3.76 (bs, 2H) |
| C-17 |  | 339 339 | (DMSO- d_6): 8.53 (t, $J =$ 4.3 Hz, 2H), 7.33 (m, 3H), 7.19 (t, $J = 4.6$ Hz, 2H), 7.14 (d, $J = 7.3$ Hz, 1H), 3.23 (m, 2H), 2.88, (m, 3H), 1.92, (m, 3H), 1.70 (m, 1H) |
| C-18 |  | 339 339 | (DMSO- d_6): 8.57 (d, $J =$ 4.6 Hz, 2H), 7.41 (d, $J =$ 8.3 Hz, 2H), 7.29 (d, $J =$ 8.5 Hz, 2H), 7.20 (d, $J =$ 4.8 Hz, 2H), 3.18 (bd, 2H), 2.88 (m, 1H), 2.76 (m, 2H), 1.82 (br, 4H) |
| C-19 |  | 383, 385 383, 385 | (DMSO- d_6): 8.56 (br, 2H), 7.52 (br, 2H), 7.14-7.29 (m, 4H), 2.99 (br, 2H), |




| | | | |
|--|--|--|---|
| | | | 2.71 (br, 1H), 2.51 (br, 2H), 1.68 (br, 4H) |
|--|--|--|---|










5












10





The following pyridylpyrazoles (C-22 through C-40, Table C-2) are prepared utilizing the general schemes C-1 and C-2 and the experimental procedure described for example C-1 above.

Table C-2


| Cmpd. No. | Structure |
|-----------|--|
| C-22 |  |
| C-23 |  |
| C-24 |  |

| | |
|------|--|
| C-25 |  <chem>NCC1=NN=C(C2=CC=CC=C2Br)C1c3ccncc3</chem> |
| C-26 |  <chem>NCC1=NN=C(C2=CC=C(C)C=C2)C1c3ccncc3</chem> |
| C-27 |  <chem>C1CCNCC1C2=CC=CC=C2BrC3=NN=C(C4=CC=CC=C4)C3c5ccncc5</chem> |
| C-28 |  <chem>C1CCNCC1C2=CC=C(C)C=C2C3=NN=C(C4=CC=CC=C4)C3c5ccncc5</chem> |
| C-29 |  <chem>NCC1=NN=C(C2=CC=CC=C2S)C1c3ccncc3</chem> |
| C-30 |  <chem>C1CCNCC1C2=CC=CC=C2SC3=NN=C(C4=CC=CC=C4)C3c5ccncc5</chem> |
| C-31 |  <chem>C1CCNCC1C2=CC=CC=C2C(F)(F)F=C3=CC=CC=C3C4=NN=C(C5=CC=CC=C5)C4c6ccncc6</chem> |
| C-32 |  <chem>NCC1=NN=C(C2=CC=C(F)C=C2)C1c3ccncc3</chem> |
| C-33 |  <chem>C1CCNCC1C2=CC=C(F)C=C2C3=NN=C(C4=CC=CC=C4)C3c5ccncc5</chem> |

| | |
|------|--|
| C-34 |  |
| C-35 |  |
| C-36 |  |
| C-37 |  |
| C-38 |  |
| C-39 |  |
| C-40 |  |
| C-41 |  |
| C-42 |  |
| C-43 |  |
| C-44 |  |

| | |
|------|--|
| C-45 |  |
| C-46 |  |
| C-47 |  |
| C-48 |  |

Example C-49



Step A

The pyrazole (2.60 g, 10.3 mmol) from **example C-4** was suspended in 52 mL of dichloroethane and 52 mL of 2.5 M


NaOH. Tetrabutylammonium hydroxide (0.5 mL of a 1 M aqueous solution) was added to the stirred mixture. To this mixture was added t-butyl bromoacetate (2.10 g, 10.8 mmol). The reaction mixture was stirred at room temperature for 4 h. The mixture was poured onto 200 mL of CH_2Cl_2 and 200 mL of H_2O . The phases were separated and the organic phase was washed with water (1x100 mL) and brine (1x100 mL). The organic layer was dried over Na_2SO_4 and was filtered. The solvent was removed to leave an off-white solid. This solid was triturated with hexane and the resulting solid isolated by filtration. The solid was washed with hexane to leave 3.4 g of a white solid (90%).

Step B

The alkylated pyrazole (3.7 g, 10.1 mmol) from Step A was treated with 57 mL of 4 N HCL in dioxane. The solution was stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the residue was dissolved in THF. The solution was treated with propylene oxide (10.3 mmol) and was stirred for 1h at room temperature. The solvent was removed to leave an oil. The residual solvent was chased with several portions of EtOH. The resulting solid was triturated with Et_2O and the title compound Example C-49 was isolated by filtration to afford 3.0 g of an off-white solid (95%). Mass spec: M+H calcd: 312; found 312. ^1H NMR (DMSO-d_6): 8.81 (d, J = 6.4 Hz, 2H), 7.73 (d, J =

5.8 Hz, 2H), 7.40 (m, 2H), 7.23 (t, J = 8.5 Hz, 1H), 5.16 (s, 2H), 2.40 (s, 3H).


5

Example C-50

According to the procedure described above in Example C-
 10 49, Example C-50 was also prepared starting from 4-[3-(4-fluorophenyl)-1H-pyrazole-4-yl]pyridine. Mass spec: M+H
 calcd: 298; found 298. ¹H NMR (DMSO-d₆): 8.75 (d, J =
 6.4 Hz, 2H), 8.68 (s, 1H), 7.78 (d, J = 6.6 Hz, 2H), 7.52
 (dd, J = 5.4, 8.5 Hz, 2H), 7.31 (t, J = 8.9 Hz, 2H),
 15 5.16 (s, 2H).

Example C-51


20



Starting with the N-Boc-piperidinyl analog of Example C-
 2, Example C-51 is also prepared according to the methods
 described in Scheme C-1.


Example C-52

5




Step A: Picoline is treated with a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH in an organic solvent such as THF, ether, t-BuOH or dioxane from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The picoline solution is then added to a solution of N-Cbz-(L)-phenylalaninyl N-hydroxysuccinimide. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from -20 °C to 120 °C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone is isolated as a crude solid which could be purified by crystallization and/or chromatography.

20




Step B: A solution of the pyridyl monoketone in ether, THF, tBuOH, or dioxane is added to a base chosen from but

not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. Formyl acetic anhydride is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between -50 °C and 50 °C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to several hours. The resulting pyridyl diketone intermediate is utilized without purification in Step C.




Step C: The solution containing the pyridyl diketone is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between -20 °C and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between -20 °C and 40 °C for a period of 30 minutes to several hours. The mixture is then poured into water and extracted with an organic solvent. The N-Cbz-protected pyridyl pyrazole is obtained as a crude solid which is purified by chromatography or crystallization.



5 Step: D

The CBZ protecting group is cleaved using hydrogen gas under pressure and Pd-C in an alcohol solvent, affording scaffold C-52 after filtration and concentration.









10

- 15 The following compounds C-53 through C-59 in Table C-3 are prepared according to the general procedure described above for the preparation of C-52.

Table C-3

| Example No. | Structure |
|-------------|-----------|
| C-53 | |

| | |
|------|--|
| C-54 |  |
| C-55 |  |
| C-56 |  |
| C-57 |  |
| C-58 |  |
| C-59 |  |


Example C-60

5 Step A:

A Boc protected pyridylpyrazole is treated with benzaldehyde in methylene chloride at room temperature in

the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine is used in step B without further purification.

5




Step B:

The pyridylpyrazole imine is dissolved in THF and stirred under nitrogen at temperatures ranging from -78 to -20 °C. A base such as LDA, n-BuLi, or LiHMDS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two equivalents of a methyl iodide are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give purified C-60.


911

Step B



5

Example C-61




10 Example C-61 is prepared according to the method described in example C-60, substituting 1,4-dibromobutane for methyl iodide.

15

20

Example C-62




Example C-62 is prepared according to the method described in example C-60, substituting 1,3-dibromoethane for methyl iodide.

5


Example C-63

The synthesis of compound C-63 starts with the condensation reaction of bromomaleic anhydride B77 with 2, 4-dimethoxybenzylamine in acetic acid and acetic anhydride. The maleimide B78 is then treated with 4'-fluoroacetophenone in the presence of catalytic amount $\text{Pd}_2(\text{dba})_3$ and sodium t-butoxide to form the fluoroacetophenone substituted maleimide B79. B79 is then treated with tert-butoxybis(dimethylamino)methane to yield the α -ketoenamine B80. The α -ketoenamine B80 is condensed with hydrazine to form the N-protected maleimide pyrazole B81. The 2,4-dimethoxybenzyl group is cleaved with ceric ammonium nitrate (CAN) to give the title compound C-63.

1004480-1004




Example C-64




Using the method described in Schemes C-6 and C-7,
 10 Example 64 is prepared.

Example C-65




Using the method described in Schemes C-6 and C-7, Example 65 is prepared.

Example C-66



Using the method described in Schemes C-6 and C-7, Example C-66 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78.


Example C-67



5

Using the method described in Schemes C-6 and C-7,
Example C-67 is synthesized, substituting N-2,4-
10 dimethoxybenzyl-4-bromopyridone for **B78**, and substituting
N-Boc-glycyl N-hydroxysuccinimide for **B82**.


Example C-68



15

Using the method described in Schemes C-6 and C-7,
20 Example C-68 is synthesized, substituting N-2,4-
dimethoxybenzyl-4-bromopyridone for **B78**.


25

Example C-69

5

Using the method described in Schemes C-6 and C-7, Example 69 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.


10

Example C-70

15 Using the method described in Schemes C-6 and C-7, Example 70 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.


Example C-71

20




Using the method described in Schemes C-6 and C-7, Example 71 is prepared, substituting N-methyl-3-bromomaleimide for B78.

5

Example C-72

10 Using the method described in Schemes C-6 and C-7, Example 72 is prepared, substituting N-methyl-3-bromomaleimide for B78, and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

15

Example C-73


20 Using the method described in Schemes C-6 and C-7, Example 73 is prepared, substituting N-methyl-3-bromomaleimide for B78 and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

25

10031790-12091

General Synthetic Procedures


Scheme C-8 illustrates a general method that can be used for the introduction of various groups on an unsubstituted nitrogen atom that is present as part of pyrazole (Cviii) with appropriately substituted aldehydes ($R_{302}\text{CHO}$) or ketones ($R_{302}\text{COR}_{303}$) in the presence of a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride affords the desired products (Cix). Typical conditions for the reductive alkylation include the use of an alcoholic solvent at temperatures ranging from 20 °C to 80 °C. In Scheme C-8, R_{302} and R_{303} are selected from but not limited to alkyl, benzyl, substituted benzyl, arylalkyl, heteroarylalkyl.



Scheme C-9 illustrates another method for introduction of substituents on the unsubstituted nitrogen atom present as part of the C-3 position of the pyrazole (Cviii). Treatment of the pyrazole (Cviii) with

a suitable alkylating agent ($R_{304}X$) such as an alkyl chloride, alkyl bromide, alkyl iodide or with an alkyl methanesulfonate or alkyl p-toluenesulfonate in the presence of a suitable base affords the desired alkylated pyrazoles (**Cx**). Examples of suitable bases include diisopropylethylamine, triethylamine, N-methylmorpholine, potassium carbonate and potassium bicarbonate.

Scheme C-9




Typical conditions for the alkylation include reaction with the suitable base in a polar aprotic solvent such as acetonitrile, dimethylformamide, dimethylacetamide or dimethyl sulfoxide at temperatures ranging from 20 °C to 150 °C. Typical R_{304} substituents are selected from but are not limited to alkyl, substituted benzyl, heteroaromatic, substituted heteroalkyl and substituted heteroarylalkyl groups.

Compounds containing acyl, sulfonyl or ureidyl groups at the nitrogen atom can be prepared as shown in Scheme C-10. Treatment of the pyrazole **Cviii** with a suitable acylating agent in the presence of a base such as N-methylmorpholine, triethylamine, diisopropylethylamine or dimethylamino pyridine in an

organic solvent such as dichloromethane, dichloroethane or dimethylformamide at temperatures ranging from 20 °C to 120 °C affords the desired acylated pyrazoles (**Cxi**). Suitable acylating agents include acid halides, activated esters of acids such as the N-hydroxysuccinimide esters, p-nitrophenyl esters, pentafluorophenyl esters, sulfonyl halides, isocyanates, and isothiocyanates.

Scheme C-10



A general synthesis of 2-substituted pyrimidinylpyrazole compounds of type **Cxv** is shown in Scheme C-11.

Step A:

4-Methyl-2-methylmercaptopyrimidine is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH in an organic solvent such as THF, ether, t-BuOH, dioxane from -78 °C to 50 °C for a period of time from 30 minutes to 5 hours. The resulting 4-methyl anion is then added to a solution of an appropriate ester **B88**. The reaction is allowed to stir from 30 minutes to 48 hours during which time the

temperature may range from 0 °C to 100 °C. The reaction mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the desired monoketone **B89** is isolated as a crude solid which can be recrystallized or purified by chromatography.

Step B:

Monoketone **B89** is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH, K₂CO₃ or Cs₂CO₃ in an organic solvent such as THF, ether, t-BuOH, dioxane, toluene or DMF from -78 °C to 50 °C for a period of time from 30 minutes to 5 hours. A solution of an appropriately activated ester of a carboxylic acid $\text{CbzNR}^{\text{H}}-(\text{CH}_2)_n\text{CR}^{\text{F}}(\text{R}^{\text{G}})-\text{COOH}$ or $\text{BocNR}^{\text{H}}-(\text{CH}_2)_n\text{CR}^{\text{F}}(\text{R}^{\text{G}})-\text{COOH}$, preferably but not limited to the N-hydroxysuccinimide ester **B90** is then added to the monoketone anion while maintaining the temperature between 0 °C to 100 °C. The reaction is allowed to stir at the specified temperature for a period of time ranging from 30 minutes to 48 hours. The resulting pyrimidine diketone intermediate **B91** is utilized without further purification in Step C.

Step C:

The solution or suspension containing the diketone intermediate **B91** is quenched with water and the pH adjusted to between 4 and 8 using an acid chosen from AcOH, H₂SO₄, HCl or HNO₃ while maintaining the temperature between 0 °C to 40 °C. Hydrazine or hydrazine monohydrate is then added to the mixture while maintaining the temperature between 0 °C to 40 °C. The mixture is stirred

for a period of 30 minutes to 16 hours maintaining the temperature between 20 °C to 50 °C, poured into water and extracted with an organic solvent. The pyrimidinyl pyrazole **CxiiBoc** or **CxiiCbz** is obtained as crude solid which is purified by chromatography or crystallization.

Step D:

The 2-methylmercapto group in the pyrimidinyl pyrazole (**CxiiBoc** or **CxiiCbz**) is oxidized to the 2-methylsulfone (where $n = 2$) or the 2-methylsulfoxide (where $n = 1$) using either Oxone or m-chloroperbenzoic acid as an oxidizing agent in a suitable solvent at temperatures ranging from 25 °C to 100 °C. Solvents of choice for the oxidation include dichloromethane, acetonitrile, tetrahydrofuran or hydroalcoholic mixtures. The 2-methylsulfone ($n = 2$) or the 2-methylsulfoxide ($n = 1$) (**CxiiiBoc** or **CxiiiCbz**) is purified by crystallization or chromatography.

Step E:


The 2-methylsulfone/2-methylsulfoxide group in **CxiiiBoc** or **CxiiiCbz** is conveniently displaced with various amines or alkoxides at temperatures ranging from 20 °C to 200 °C in solvents that include but are not limited to dimethylformamide, acetonitrile, tetrahydrofuran and dioxane. The alkoxides can be generated from their alcohols by treatment with a base selected from but not limited to sodium hydride, lithium hexamethyldisilazide, potassium tertiary-butoxide in solvents such as tetrahydrofuran, dimethylformamide and

dioxane at temperatures ranging from 0 °C to 100 °C. The resulting 2-amino or 2-oxo derivatives (**CxivBoc** or **CxivCbz**) are purified by either chromatography or crystallization.

Step F:

The carbamate protecting groups from **CxivBoc** or **CxivCbz** are removed to afford the desired compounds **Cxv** containing either a free primary amine (R^H is hydrogen) or a free secondary amine (R^H is not equal to hydrogen). The Boc protecting groups are cleaved utilizing either trifluoroacetic acid in methylene chloride or hydrochloric acid in dioxane at room temperature for several hours. The Cbz protecting groups are cleaved using hydrogen gas at atmospheric or higher pressures and a catalyst (palladium on charcoal) in an alcoholic solvent. The resulting amines **Cxv** are then crystallized or purified by chromatography.


SCHEME C-11



The following examples contain detailed descriptions of the methods of preparation of compounds that form part of the invention. These descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistent with their assigned structures.

Example C-74

5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glyciny l *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ¹HNMR (d₆-DMSO) δ 8.57 (d, *J* = 4.83 Hz, 2 H), 7.41 (d, *J* = 8.26 Hz, 2 H), 7.29 (d, *J* = 8.26 Hz, 2 H), 7.20 (d, *J* = 4.63 Hz, 2 H), 3.18 (bd, *J* =

12.08 Hz, 2 H), 2.88 (m, 1 H), 2.76 (m, 2 H), 1.82 (bs, 4 H). MS (M+H): 339 (base peak).


Example C-75

5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (25 g, 61 mmol) in 140 mL of formic acid (96%) was added 50 g of formaldehyde (37%). The solution was stirred at 75 °C for 48 h and was cooled to room temperature. The excess formic acid was removed under reduced pressure and the residue was dissolved in 100 mL of water. The solution was added to concentrated $\text{NH}_4\text{OH}/\text{H}_2\text{O}$ and the mixture was extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (1 x 250 mL) and was dried over Na_2SO_4 . The solution was filtered and concentrated to leave a white solid. The solid was triturated with ether and was filtered to afford the title compound: MS (M+H): 353 (base peak).

Example C-76

5-(N-ACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE


To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (1 g, 2.4 mmol) in 24 mL of CH_2Cl_2 , was added 4-dimethylamino pyridine (0.88 g, 7.2 mmol) and acetyl chloride (0.21 g, 2.6 mmol). The solution was stirred for 3 h and the solvent was removed under reduced pressure. The residue was treated with saturated NH_4OH (20 mL) and the suspension was extracted with ethyl acetate (3 x 30 mL). The combined extracts were washed with brine (1 x 50 mL), dried over MgSO_4 , filtered and concentrated to leave a solid. The solid was triturated with ether and was filtered to leave the title compound: MS (M+H): 381 (base peak).

Example C-77

5-(*N*-METHOXYACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE

By following the method of Example C-76 and substituting methoxy acetyl chloride for acetyl chloride the title compound was prepared: ^1H NMR (DMSO- d_6) δ 8.75 (d, J = 6.72 Hz, 2 H), 7.70 (d, J = 6.72 Hz, 2 H), 7.38 (d, J = 8.60 Hz, 2 H), 7.29 (dd, J = 6.72, 1.88 Hz, 2 H), 4.40 (d, J = 11.8 Hz, 1 H), 4.05 (m, 2 H), 3.70 (d, J = 12.70 Hz, 1 H), 3.25 (s, 3 H), 3.0 (m, 2 H), 2.55 (m, 1 H), 1.7 (m, 4 H). MS ($M+H$): 411 (base peak).


Example C-78

5-(*N*-METHYLSULFONYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE

By following the method of Example C-76 and substituting methylsulfonyl chloride (2.0 equivalents) for acetyl chloride the title compound was prepared: ¹HNMR (DMSO-d₆) δ 8.70 (d, J = 6.72 Hz, 2 H), 7.72 (d, J = 6.72 Hz, 2 H), 7.38 (d, J = 7.66 Hz, 2 H), 7.30 (dd, J = 6.72, 1.88 Hz, 2 H), 3.58 (bd, J = 11.8 Hz, 2 H), 2.87 (m, 1 H), 2.82 (s, 3 H), 2.72 (m, 2 H), 1.85 (m, 4 H). MS (M+H): 417 (base peak).

Example C-79

5-[N-METHOXYETHYL-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (500 mg, 1.2 mmol) in 12 mL of DMF was added Hunig's base (790 mg, 6.1 mmol) and 2-bromoethyl methyl ether (850 mg, 6.1 mmol). The solution was stirred at room temperature for 5 days. The solution was poured onto 2.5 N NaOH and was extracted with ethyl acetate (3 x 100 mL). The combined extracts were washed with water (3 x 100 mL) and brine (1 x 100 mL). The organic phase was dried over Na₂SO₄ and was filtered. The

solvent was removed under reduced pressure to leave a solid. The solid was triturated and filtered to leave the title compound: $^1\text{H NMR}$ (CDCl_3) δ 8.63 (d, $J = 4.23$ Hz, 2 H), 7.28 (m, 4 H), 7.14 (d, $J = 4.43$ Hz, 2 H), 3.57 (t, $J = 5.24$ Hz, 2 H), 3.38 (s, 3 H), 3.14 (bd, $J = 10.1$ Hz, 2 H), 2.79 (m, 1 H), 2.68 (t, $J = 5.04$, 2 H), 2.08 (m, 4 H), 1.92 (m, 2 H). MS ($\text{M}+\text{H}$): 397 (base peak).

Example C-80


5-(*N*-ALLYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE



By following the method of example C-79 and substituting allyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS ($\text{M}+\text{H}$): 379 (base peak)

Example C-81


5-(N-PROPARGYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-
CHLOROPHENYL) PYRAZOLE



By following the method of example C-79 and substituting propargyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS (M+H): 377 (base peak)

Example C-82

5-[N-(2-METHYLTHIAZOLYL)-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-
CHLOROPHENYL) PYRAZOLE




To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) in 12 mL of MeOH was added trimethyl orthoformate (2.6 g,

24.4 mmol) and 2-thiazolecarboxaldehyde (1.4 g, 12.2 mmol). The suspension was stirred at room temperature for 2 h. To this mixture was added NaCNBH₃ (1.5 g, 24.4 mmol) and the resulting suspension was stirred at room temperature for 7 days. The mixture was poured onto 2.5 N NaOH and was extracted with ethyl acetate (2 x 100 mL). The combined extracts were washed with brine (1 x 100 mL), dried over Na₂SO₄, filtered and concentrated to leave a solid. This solid was triturated with ether and filtered to afford the title compound: MS (M+H): 436 (base peak).

Example C-83

5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE




By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benzyloxycarbonyl-glyciny l *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate

was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 373 (base peak).

Example C-84


5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole hydrochloride (Example C-83) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak).

Example C-85


5-[N-(2-PROPYL)-4-PIPERIDYL]-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole (Example C-83) (300 mg, 0.7 mmol) in 50 mL of acetone was added 1 mL of AcOH and $\text{NaBH}(\text{OAc})_3$ (15 g, 70.8 mmol). The mixture was warmed to reflux and was stirred for 5 days. The reaction mixture was poured onto 100 mL of 2.5 N NaOH and was extracted with ethyl acetate (2 x 100 mL). The extracts were combined and washed with brine (1 x 100 mL). The organic phase was dried over Na_2SO_4 , filtered, and concentrated to afford the title compound: MS (M+H): 415 (base peak).

Example C-86

5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE




By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the

title compound as its hydrochloride salt: MS (M+H): 373 (base peak).the pyrazole C-3 substituent (Cviii). Treatment of the

Example C-87

5-(*N*-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE




By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl)phenyl] pyrazole hydrochloride (Example C-86) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak).

1004001 08212001


Example C-88

5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 339 (base peak).


Example C-89

5-(*N*-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL) PYRAZOLE

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole hydrochloride (Example C-88) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 353 (base peak).

Example C-90

5-(3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting *N*-*t*-butoxycarbonyl-nipecotyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glyciny *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 323 (base peak).

T06021-08212004

Example C-91


5-(*N*-METHYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE



By following the method of Example C-75 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole hydrochloride (Example C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).

Example C-92

5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-
CHLOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-

fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glyciny l *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: ¹HNMR (d₆-DMSO) δ 8.56 (d, *J* = 6.04 Hz, 2 H), 7.39 (d, *J* = 8.66 Hz, 2 H), 7.31 (d, *J* = 8.46 Hz, 2 H), 7.17 (d, *J* = 5.84 Hz, 2 H), 3.05 (m, 1 H), 2.62 (m, 1 H), 1.99 (m, 2 H), 1.53 (m, 6 H). MS (M+H): 353 (base peak).

Example C-93


5-*cis*-(4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).

Example C-94


5-[*cis*-4-*N*-(2-PROPYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



To a slurry of 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) (1.0 g, 2.8 mmol, 1.0 eq) in methylene chloride (28 mL) was added acetone (0.5 mL), acetic acid (0.5 mL) and solid sodium triacetoxyborohydride. The slurry was stirred for 5 h and the volatiles were removed. The residue was partitioned between 2.5 M NaOH (25 mL) and ethyl acetate (25 mL) and the aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined organic layer was washed with brine (50 mL), dried over MgSO₄ and evaporated. The residue was triturated with ether to yield the title compound as a white powder: ¹HNMR (d₆-DMSO) δ 8.56 (d, *J* = 5.84 Hz, 2H), 7.40 (d, *J* = 8.26 Hz, 2H), 7.30 (d, *J* = 8.66 Hz, 2H), 7.18 (d, *J* = 5.64 Hz, 2H), 2.95 (m, 2H), 2.72 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H), 1.55 (m, 4H), 1.07 (d, *J* = 5.64 Hz, 6H). MS (M+H): 395 (base peak).

Example C-95


5-*cis*-[4-*N*-(ACETYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 395 (base peak).

Example C-96

5-*cis*-[4-*N*-(METHOXYACETYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




By following the method of Example C-76 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-

(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 425 (base peak).

Example C-97


5-*cis*-[4-N-(METHYLSULFONYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 431 (base peak).

Example C-98


5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-
FLUOROPHENYL) PYRAZOLE



By following the method of Example C-1 and substituting *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 337 (base peak).

Example C-99


5-(*cis*-4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-
FLUOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-98) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 365 (base peak).

Example C-100


5-*cis*-[4-*N*-(2-PROPYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-94 and substituting *cis*-5-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-98) for 5-(*cis*-4-*N*-(2-propyl)aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) the title compound was prepared: MS (M+H): 379 (base peak).

Example C-101


5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

Example C-102


5-*cis*-(4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole (Example C-101) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

Example C-103

5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE




By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

1002031-08272001

Example C-104


5-*cis*-(4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-(trifluoromethyl)phenyl) pyrazole (Example C-103) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

Example C-105

5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-

10024380-120701
T0202T-084T00T

fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 353 (base peak).

Example C-106


5-*cis*-(4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole hydrochloride (Example C-105) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).


1004180-1004

Example C-107

5-(*N*-ACETIMIDO-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE

To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) (0.11 g, 0.35 mmol) in 2 mL EtOH was added ethyl acetamidate hydrochloride (0.065 g, 0.53 mmol) and the mixture was refluxed for 30 minutes. The solution was left at 5-10 °C for 16 h and filtered to obtain the title compound as a white solid: MS (M+H): 364 (base peak).

Example C-108


5-(*N*-CARBOXAMIDINO-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-2) (1.5 g, 4.7

mmol) in 47 mL of DMF was added Hunig's base (0.60 g, 4.7 mmol) and pyrazole carboxamide hydrochloride (0.68 g, 4.7 mmol). The slurry was allowed to stir at room temperature for 4 days. The reaction mixture was poured onto 300 mL of ether. The resulting precipitate was filtered to leave the title compound as the hydrochloride salt: MS (M+H): 365 (base peak).

Example C-109


5-(N-CYCLOPROPANOYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting cyclopropanoyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 407 (base peak).

Example C-110


5-[N-(2-FLUORO)BENZOYL-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 2-fluorobenzoyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 461 (base peak).

Example C-111

5-(N-METHYLSULFONYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-74)

and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 401 (base peak).

Example C-112


5-(*N*-METHOXYACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

Example C-113


5-(*N*-ACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole Example (C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole Example (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

Example C-114


5-[2-(1,1-DIMETHYL)AMINOETHYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-1 and substituting *N*-*t*-butoxycarbonyl-2-amino-2,2-dimethylpropanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glyciny *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 327 (base peak).

Example C-115


5-(METHOXYMETHYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE



By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2-methoxyacetyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glyciny *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 300 (base peak).

Example C-116

5-(4-AMINOBENZYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE




By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-4-aminophenyl

acetyl *N*-hydroxysuccinimide for *N*-benzyloxycarbonyl-glyciny *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 361 (base peak).

Example C-117

5-[4-(*N,N*-DIMETHYL)AMINO BENZYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




By following the method of Example C-75 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-116) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 389 (base peak).

1002180-120701

Example C-118


5-[4-(*N*-ACETYL)AMINO BENZYL]-4-(4-PYRIDYL)-3-(4-
CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-116) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 403 (base peak).

Example C-119

5-(*N*-METHYLAMINOMETHYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE




5-(*N*-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a suspension of 5-aminomethyl-

4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) (8.04 g, 30 mmol) in 120 mL dichloromethane was added p-nitrophenylformate (6.01 g, 36 mmol) as a solid. The suspension was stirred for 24 h at room temperature and the solvents removed under reduced pressure. The residue was triturated with ether and filtered to obtain the desired 5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole derivative as a white solid: MS (M+H): 297 (base peak).

5-(N-methylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a suspension of 5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (8.74 g, 29.5 mmol) in 90 mL anhydrous tetrahydrofuran was added a 1.0 M solution of borane in tetrahydrofuran (90 mL, 90 mmol) and the mixture was stirred at room temperature for 24 h. 1 N aqueous hydrochloric acid (100 mL) was then added to this mixture and the solution was refluxed for 5 hours and cooled to room temperature. The solution was extracted with ether (2 x 250 mL) and the pH of the aqueous layer adjusted to 9 by addition of concentrated ammonium hydroxide. The aqueous layers (pH ~ 9) were then extracted with ethyl acetate (4 x 150 mL). The organic extracts were dried over sodium sulfate, filtered and evaporated to dryness under reduced pressure. The residue was triturated with acetonitrile and filtered to obtain the title compound as a white solid: MS (M+H): 283 (base peak).

Example C-120

5-[*N*-(2-AMINO-2,2-DIMETHYLACETYL)AMINOMETHYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




5-(*N*-*t*-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a solution of 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) (0.27 g, 1 mmol) in anhydrous dimethylformamide (4 mL) was added *N*-tert-butoxycarbonyl aminoisobutyric acid *N*-hydroxysuccinimide ester (0.33 g, 1.1 mmol) and the mixture stirred at 40 °C for 24 h. The resulting solution was evaporated to dryness under reduced pressure. The residue was dissolved in dichloromethane (30 mL) and washed with a saturated solution of sodium bicarbonate (2 x 20 mL) and brine (20 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure to dryness to afford 5-(*N*-*t*-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole as a white solid.

5-(*N*-(2-amino-2,2-dimethylacetyl)aminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a solution of the above compound in acetonitrile (2 mL) was added 1 mL of a 4.0 M solution of hydrochloric acid in dioxane. The

reaction mixture was stirred at room temperature for 6 hours. The suspension was evaporated to dryness under reduced pressure. The resulting residue was stirred in acetonitrile (5 mL), filtered and dried in a vacuum dessicator to afford the title compound as a hydrochloride salt: MS (M+H): 354 (base peak).

Example C-121


5-[N-(2-AMINO-2,2-DIMETHYLACETYL)AMINOMETHYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-120 and substituting 5-aminomethyl-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-15) for 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) the title compound was prepared: MS (M+H): 370 (base peak).

Example C-122


5-[4-N-(2-DIMETHYLAMINOACETYL)PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



To a solution of N,N-dimethylglycine hydrochloride (0.28 g, 2 mmol) in dimethylformamide (4 mL) was added hydroxybenzotriazole (0.27 g, 2 mmol), N,N-diisopropylethyl amine (0.7 mL, 4 mmol) and polymer supported ethyl carbodimide (Example B-49) (1 g, 2.39 mmol). To this solution after 30 minutes at room temperature was added 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74), 0.41 g, 1 mmol). The suspension was agitated on a labtop orbital shaker for 24 h. The suspension was filtered, washed with dimethylformamide (2 x 5 mL) and the filtrates evaporated under high pressure. The residue was dissolved in dichloromethane (30 mL), washed with a saturated solution of sodium bicarbonate (50 mL) and brine (50 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under high vacuum to afford the title compound as a white solid: MS (M+H): 424 (base peak).

Example C-123


(S)-5-(2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE



By following the method of Example C-1 and substituting (S)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glyciny N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

Example C-124

(S)-5-(N-METHYL-2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-
FLUOROPHENYL) PYRAZOLE




Example C-125

Fc1ccc(cc1)-c2nc3c(c[nH]3c2-c4cccnc4)C[C@H]5CCNCC5

By following the method of Example C-1 and substituting (R)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glyciny N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

Example C-126


(R)-5-(N-METHYL-2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-
FLUOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting (R)-5-(2-pyrrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 323 (base peak).

Example C-127

(R)-5-(3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE




By following the method of Example C-1 and substituting (R)-N-t-butoxycarbonyl-nipecotyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glyciny l N-

hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 323 (base peak).

Example C-128

(*R*)-5-(*N*-METHYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-75 and substituting (*R*)-5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).

1002430-12001
T02021-0812001

Example C-129


2,2-DIMETHYL-4-[4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLYL] BUTYRIC ACID



By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2,2-dimethyl glutaric anhydride for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 370 (base peak).

Example C-130


4-[4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLYL] BUTYRIC
ACID



By following the method of Example C-1 and substituting glutaric anhydride for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 326 (base peak).

Example C-131

4-[4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLYL] BUTYRAMIDE




Methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate. To a solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyric acid (Example C-130) (40 g, 123 mmol) in 650 mL of MeOH was added 20 mL of concentrated H_2SO_4 . The solution was stirred overnight at room temperature. The solution was concentrated and diluted with 200 mL of water. The solution was cooled with an ice/water bath and to the solution was added 150 mL of saturated $NaHCO_3$. The solution was neutralized further with 50% NaOH to pH 7. The resulting slurry was extracted with CH_2Cl_2 (3 x 250 mL). The combined extracts were washed with water (1 x 300 mL) and saturated $NaHCO_3$ (1 x 500 mL). The organic phase was dried over Na_2SO_4 , filtered and concentrated to afford methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate: MS (M+H): 340 (base peak).

4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyramide. A solution of methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate (39 g, 120 mmol) in 600 mL of MeOH was saturated with NH_3 . The solution was

periodically treated with additional NH_3 over a 24 h period. The solution was degassed with a stream of nitrogen and the solution was concentrated to leave a yellow solid. The solid was slurried in ether and filtered to leave the title compound: MS (M+H): 325 (base peak).

Example C-132

5-[4-(1-HYDROXY)BUTYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




A stirred suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyric acid (Example C-130) (2 g, 6.15 mmol) in 100 ml of anhydrous ether was cooled to 0 °C under nitrogen. Lithium aluminum hydride (467 mg, 12.3 mmol) was added to this suspension slowly. After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched slowly with 1N KHSO_4 (80 ml). The mixture was transferred to a separatory funnel and the aqueous layer was removed. The aqueous layer was then made basic with K_2CO_3 (pH 8). The aqueous solution was extracted with ethyl acetate (2 x 100 mL). The combined ethyl acetate extracts were washed with water (1 x 100

1004801004

mL), dried over MgSO_4 , filtered and concentrated to give the title compound: MS (M+H): 312 (base peak).

Example C-133


5-[4-(1,1-DIMETHYL-1-HYDROXY)BUTYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



A solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyric acid (Example C-130) (200 mg, 0.615 mmol) in 50 ml of MeOH was treated with 10 ml of 4 N HCl/dioxane. The reaction mixture was stirred for 5 hours and evaporated to dryness. To this residue was added 15 ml of 1N methyl magnesium bromide in butyl ether and 5 ml of anhydrous THF. The reaction was heated to reflux under nitrogen for 64 h.

The reaction was quenched with 20 ml of saturated ammonium chloride. This mixture was transferred to a separatory funnel and was extracted with 100 ml ethyl acetate (2 x 100 mL). The combined ethyl acetate extracts were washed with water (1 x 100 mL), dried over MgSO_4 , filtered and concentrated to afford a crude oil. The crude oil was subjected to column chromatography by using 3.5 % MeOH/ CH_2Cl_2 , followed by 6 % MeOH/ CH_2Cl_2 , to give the title compound: MS (M+H): 340 (base peak).


Example C-134

5-(4-(1-AMINO)BUTYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE

To a suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyramide (Example C-131) (2 g, 6.2 mmol) in 100 ml of anhydrous ether was added lithium aluminum hydride (467 mg, 12.3 mmol). After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched with 20 mL of ethyl acetate and was poured onto 100 mL of 2.5 N NaOH. The mixture was extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with brine (1 x 100 mL), dried over Na₂SO₄, filtered and concentrated to afford the title compound: MS (M+H): 311 (base peak).

Example C-135


4-(4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLYL) PROPIONIC
ACID



By following the method of Example C-1 and substituting succinic anhydride for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 312 (base peak).

Example C-136

5-(4-PIPERIDYL)-4-(4-PYRIMIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE




By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate, *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide and 4-methylpyrimidine for 4-picoline

the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ^1H NMR (CDCl_3) δ 9.2 (s, 1 H), 8.48 (d, $J = 5.19$ Hz, 1 H), 7.31 (m, 4 H), 6.94 (d, $J = 4.79$ Hz, 1 H), 3.69 (m, 3 H), 3.12 (m, 2 H), 2.3 (m, 3 H), 1.24 (m, 2 H). MS ($\text{M}+\text{H}$): 340 (base peak).

Example C-137


5-(*N*-METHYL-4-PIPERIDYL)-4-(4-PYRIMIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-136) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: ^1H NMR (CDCl_3) δ 9.2 (d, $J = 1.2$ Hz, 1 H), 8.48 (d, $J = 5.59$ Hz, 1 H), 7.31 (m, 4 H), 6.95 (dd, $J = 1.2$, 5.6 Hz, 1 H), 3.39 (m, 1 H), 3.03 (d, $J = 11.6$ Hz, 2 H), 2.38 (s, 3 H), 2.06 (m, 4 H), 1.24 (m, 2 H). MS ($\text{M}+\text{H}$): 354 (base peak).

Example C-138


5-(*N*-ACETYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE



By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

Example C-139

5-(*N*-METHOXYACETYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-
FLUOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (C-74) and methoxy


973

acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:


Example C-140

5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole



Example C-141


5-(4-piperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole



TOC-0031063-0001


Example C-142

5-(4-*N*-methylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-143

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-144

5-(4-piperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-145

5-(4-N-methylpiperidiny1)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-146

5-(4-N-t-butoxycarbonylpiperidiny1)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-147

5-(4-piperidiny1)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-148

5-(4-*N*-methylpiperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-149

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-150

5-(4-piperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-151

5-(4-*N*-methylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-152

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-153

5-(4-piperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-154

5-(4-*N*-methylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-155

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-156

5-(4-piperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-157

5-(4-*N*-methylpiperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-158

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-159

5-(4-piperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-160

5-(4-N-methylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-161

5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-162

5-(4-piperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-163

5-(4-*N*-methylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-164

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-(2-*N,N*-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-165

5-(4-piperidinyl)-4-[4-(2-(2-*N,N*-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-166

5-(4-*N*-methylpiperidinyl)-4-[4-(2-(2-*N,N*-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-167

5-(*N*-acetylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-168

5-(*N*-benzylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-169

5-(*N*-phenylacethydroxylimido-4-piperidyl)-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole




Example C-170

5-[*N*-methyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-
chlorophenyl)pyrazole




Example C-171

5-[*N*-isopropyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-
chlorophenyl)pyrazole




Example C-172

5-[N-benzyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-173

5-[N-methyl-4-(4-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-174

5-[N-methyl-4-(4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-175

5-[N-methyl-4-(4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-176

5-[N-methyl-4-(2,5-tetramethyl-4-fluoropiperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-177

5-[N-methyl-4-(2,5-tetramethyl-4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-178

5-[*N*-methyl-4-(2,5-tetramethyl-4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-179

5-[4-(3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-180

5-[4-(*N*-methyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-181

5-[4-(*N*-isopropyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-182

5-[4-(*N*-benzyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-183

5-[4-(*N*-acetyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-184

5-[4-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-185

5-[4-(N-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-186

5-[4-(*N*-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-187

5-[4-(*N*-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-188

5-[4-(*N*-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-189

5-[5-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-190

5-[5-(*N*-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-191

5-[5-(*N*-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-192

5-[5-(*N*-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-193

5-[5-(*N*-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-194

5-(*N*-acethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-195

5-(*N*-benzhydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-196

5-(*N*-phenacethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-197

5-(2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-198

5-(*N*-methyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-199

5-(*N*-isopropyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-200

5-(*N*-benzyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-201

5-(*N*-acetyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-202

5-[*trans*-4-(*N*-*t*-butoxycarbonylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-203

5-(*trans*-4-aminomethylcyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-204

5-[trans-4-(*N*-isopropylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-205

5-[trans-4-(*N,N*-dimethylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-206

5-[trans-4-(*N*-acetylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-207

5-[*trans*-4-(*N*-*t*-butoxycarbonylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-208

5-(*trans*-4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-209

5-[*trans*-4-(*N,N*-dimethylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-210

5-[*trans*-4-(*N*-isopropylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-211

5-[*trans*-4-(*N*-acetylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-212

5-[*cis*-4-(*N*-*t*-butoxycarbonyl)methylaminocyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-213

5-(*cis*-4-methylaminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-214

5-[*cis*-4-(*N,N*-dimethyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-215

5-[*cis*-4-(*N*-isopropyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-216

5-[*cis*-4-(*N*-acetyl)methylaminocyclohexyl)]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole




Example C-217

5-[3-(1,1-dimethyl-1-(*N*-*t*-butoxycarbonylamino)propyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-218

5-[3-(1,1-dimethyl-1-amino)propyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-219

5-[3-(1,1-dimethyl-1-(*N,N*-dimethylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-220

5-[3-(1,1-dimethyl-1-(*N*-isopropylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-221

5-[3-(1,1-dimethyl-1-(*N*-acetylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-222

5-[4-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-223

5-[4-(1-N-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-224

5-[4-(1-N-benzylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-225

5-[3-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-226

5-[3-(1-N-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-227

5-[3-(1-N-benzylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-228

5-[3-(*N*-*t*-butoxycarbonyl)aminobenzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-229

5-(3-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-230

5-[3-(*N,N*-dimethylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-231

5-[3-(*N*-isopropylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-232

5-[3-(*N*-benzylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-233

5-[3-(*N*-acetylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-234

5-[4-(2-amino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-235

5-[4-(2-*N,N*-dimethylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-236

5-[4-(2-*N*-isopropylamino)methylimidazolyl]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole




Example C-237

5-[4-(2-*N*-benzylamino)methylimidazolyl]-4-(4-pyridyl)-3-(
(4-chlorophenyl)pyrazole




Example C-238

5-[4-(2-*N*-acetylamino)methylimidazolyl]-4-(4-pyridyl)-3-(
(4-chlorophenyl)pyrazole




Example C-239

5-[4-(2-amino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-240

5-[4-(2-*N,N*-dimethylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-241

5-[4-(2-*N*-isopropylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-242

5-[4-(2-*N*-benzylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-243

5-[4-(2-*N*-acetylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-244

5-[4-(2-amino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-245

5-[4-(2-*N,N*-dimethylamino)methylthiazolyl]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole




Example C-246

5-[4-(2-*N*-isopropylamino)methylthiazolyl]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole




Example C-247

5-[4-(2-*N*-benzylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole



Example C-248

5-[4-(2-*N*-acetylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole



Biological data from compounds of Examples B-0001 through B-1573 and of Examples B-2270 through B-2462 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

"P38 alpha kinase IC₅₀, uM or % inhib @ conc. (uM)"

10

In vitro whole cell assay for measuring the ability of the compounds to inhibit TNF production in human U937 cells stimulated with LPS are shown in the column identified as:

15

"U937 Cell IC₅₀, uM or % inhib @ conc., (uM)"

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the mouse is shown in the column identified as:

20

"Mouse LPS Model, % TNF inhib @ dose @ predose time"

wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

25

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

30

"Rat LPS Model, % TNF inhib @ dose @ predose time"

wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time

indicates the number of hours before LPS challenge when the compound is administered.

1004030001

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0001 | 53.0%@1.0uM | 40.0% @1.0uM | | |
| B-0002 | 71.0%@1.0uM | 28.0%@10.0uM | | |
| B-0003 | 70.0%@1.0uM | 76.0% 10.0uM | | |
| B-0004 | 80.0%@1.0uM | 4.61uM | | |
| B-0005 | 95.0%@1.0uM | 2.97uM | | |
| B-0006 | 82.0%@1.0uM | 80%@10.0uM | | |
| B-0007 | 74.0%@1.0uM | 85.0%@10.0uM | | |
| B-0008 | 42.0%@1.0uM | 65.0%@10.0uM | | |
| B-0009 | 0.04 uM | 0.72uM | | |
| B-0010 | 0.52 uM | 0.65uM | | |
| B-0011 | 0.03 uM | 4.47uM | | |
| B-0012 | 30.0%@1.0uM | 44.0% @1.0uM | | |
| B-0013 | 70.0%@1.0uM | 84.0%@10.0uM | | |
| B-0014 | 79.0%@1.0uM | 80.0%@10.0uM | | |
| B-0015 | 82.0%@1.0uM | 80.0%@10.0uM | | |
| B-0016 | 94.0%@1.0uM | 3.98uM | | |
| B-0017 | 56.0%@1.0uM | 79.0%@10.0uM | | |
| B-0018 | 60.0%@1.0uM | 59.0%@10.0uM | | |
| B-0019 | 84.0%@1.0uM | 100.0%@10.0uM | | |
| B-0020 | 73.0%@1.0uM | 81.0%@10.0uM | | |
| B-0021 | 68.0%@1.0uM | 76.0%@10.0uM | | |
| B-0022 | 69.0%@1.0uM | 44.0@1.0uM | | |
| B-0023 | 90.0%@1.0uM | 77.0%@10.0uM | | |
| B-0024 | 94.0%@1.0uM | 52.0%@1.0uM | | |
| B-0025 | 89.0%@1.0uM | 79.0%@10.0uM | | |
| B-0026 | 96.0%@1.0uM | 3.27uM | | |
| B-0027 | 94.0%@1.0uM | 11.0uM | | |
| B-0028 | 69.0%@1.0uM | 45.0%@10.0uM | | |
| B-0029 | 91.0%@1.0uM | 58.0%@10.0uM | | |
| B-0030 | 92.0%@1.0uM | 75.0%@10.0uM | | |
| B-0031 | 94.0%@1.0uM | 100.0%@10.0uM | | |
| B-0032 | 94.0%@1.0uM | 78.0%@10.0uM | | |
| B-0033 | 97.0%@1.0uM | 10.0uM | | |
| B-0034 | 95.0%@1.0uM | 10.0uM | | |
| B-0035 | 94.0%@1.0uM | 10.0uM | | |
| B-0036 | 92.0%@1.0uM | 8.24uM | | |
| B-0037 | 91.0%@1.0uM | 86.0%@10.0uM | | |
| B-0038 | 71.0%@1.0uM | 84.0%@10.0uM | | |
| B-0039 | 89.0%@1.0uM | 72.0%@10.0uM | | |
| B-0040 | 93.0%@1.0uM | 2.3uM | | |
| B-0041 | 65.0%@1.0uM | 66.0%@10.0uM | | |
| B-0042 | 94.0%@1.0uM | 2.76uM | | |

1004001-03272001

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0043 | 0.22 uM | 0.54uM | | |
| B-0044 | 0.14 uM | 0.19uM | | |
| B-0045 | 94.0%@1.0uM | 1.01uM | | |
| B-0046 | 96.0%@1.0uM | 54.0%@1.0uM | | |
| B-0047 | 94.0%@1.0uM | 74.0%@10.0uM | | |
| B-0048 | 94.0%@1.0uM | 76.0%@10.0uM | | |
| B-0049 | 88%@1.0uM | 33.0%@1.0uM | | |
| B-0050 | 73%@1.0uM | 34.0%@1.0uM | | |
| B-0051 | 3.3uM | 2.15uM | 47%@100mpk@-6h | 79%@3mpk@-4h |
| B-0052 | 92%@1.0uM | 15.0%@1.0uM | | |
| B-0053 | 95%@1.0uM | 34.0%@1.0uM | | |
| B-0054 | 90%@1.0uM | 30.0%@1.0uM | | |
| B-0055 | 93%@1.0uM | >1.0uM | | |
| B-0056 | 96%@1.0uM | 21.0%@1.0uM | | |
| B-0057 | 96%@1.0uM | 29.0%@1.0uM | | |
| B-0058 | 79%@1.0uM | 18.0%@1.0uM | | |
| B-0059 | 83%@1.0uM | 35.0%@1.0uM | | |
| B-0060 | 73%@1.0uM | 22.0%@1.0uM | | |
| B-0061 | 62%@1.0uM | 27.0%@1.0uM | | |
| B-0062 | 94%@1.0uM | 36.0%@1.0uM | | |
| B-0063 | 96%@1.0uM | 40.0%@1.0uM | | |
| B-0064 | 90%@1.0uM | 4.0%@1.0uM | | |
| B-0065 | 83%@1.0uM | 21.0%@1.0uM | | |
| B-0066 | 94%@1.0uM | 28.0%@1.0uM | | |
| B-0067 | 91%@1.0uM | 1.0%@1.0uM | | |
| B-0068 | 72%@1.0uM | 22.0%@1.0uM | | |
| B-0069 | 96%@1.0uM | 37.0%@1.0uM | | |
| B-0070 | 92%@1.0uM | 30.0%@1.0uM | | |
| B-0071 | 86%@1.0uM | 31.0%@1.0uM | | |
| B-0072 | 77%@1.0uM | 32.0%@1.0uM | | |
| B-0073 | 91%@1.0uM | 24.0%@1.0uM | | |
| B-0074 | 92%@1.0uM | 42.0%@1.0uM | | |
| B-0075 | 91%@1.0uM | 35.0%@1.0uM | | |
| B-0076 | 58%@1.0uM | 21.0%@1.0uM | | |
| B-0077 | 0.8uM | 10.0uM | | |
| B-0078 | 80%@1.0uM | 20.0%@1.0uM | | |
| B-0079 | 93%@1.0uM | 13.0%@1.0uM | | |
| B-0080 | 73%@1.0uM | 73.0%@1.0uM | | |
| B-0081 | 92%@1.0uM | 13.0%@1.0uM | | |
| B-0082 | 47%@1.0uM | 27.0%@1.0uM | | |
| B-0083 | 0.22uM | 6.51uM | | |
| B-0084 | 56%@1.0uM | 30.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0085 | 83%@1.0uM | 21.0%@1.0uM | | |
| B-0086 | 91%@1.0uM | 37.0%@1.0uM | | |
| B-0087 | 0.55uM | 2.26uM | 38%@30mpk@-6h | |
| B-0088 | 96%@1.0uM | 9.0%@1.0uM | | |
| B-0089 | 0.04uM | 3.33uM | | |
| B-0090 | 98%@1.0uM | 52.0%@1.0uM | | |
| B-0091 | 96%@1.0uM | 40.0%@1.0uM | | |
| B-0092 | 97%@1.0uM | 34.0%@1.0uM | | |
| B-0093 | 3.18 uM | 1.25uM | 30%@30mpk@-6h | |
| B-0094 | 96%@1.0uM | 52.0%@1.0uM | | |
| B-0095 | 98%@1.0uM | 38.0%@1.0uM | | |
| B-0096 | 91%@1.0uM | 22.0%@1.0uM | | |
| B-0097 | 72.0%@10.0uM | 38.0%@1.0uM | | |
| B-0098 | 66.0%@10.0uM | 12.0%@1.0uM | | |
| B-0099 | 43.0% @1.0uM | >1.0uM | | |
| B-0100 | 75.0% @1.0uM | 5.0uM | | |
| B-0101 | 71.0% @1.0uM | 2.11uM | | |
| B-0102 | 81.0%@1.0uM | 15.0%@1.0uM | | |
| B-0103 | 71.0%@1.0uM | 6.0%@1.0uM | | |
| B-0104 | 56.0% @1.0uM | 2.78uM | | |
| B-0105 | 78.0%@1.0uM | 5.0uM | | |
| B-0106 | 62.0%@1.0uM | 5.0uM | | |
| B-0107 | 0.27uM | 5.0uM | | |
| B-0108 | 61.0%@1.0uM | 4.85uM | | |
| B-0109 | 45.0%@1.0uM | 19.0%@1.0uM | | |
| B-0110 | 66.0%@1.0uM | 13.0%@1.0uM | | |
| B-0111 | 57.0%@1.0uM | >1.0uM | | |
| B-0112 | 97.0%@1.0uM | 1.12uM | | |
| B-0113 | 75.0%@1.0uM | 43.0%@1.0uM | | |
| B-0114 | 45.0%@1.0uM | 3.92uM | | |
| B-0115 | 47.0%@1.0uM | 2.0%@1.0uM | | |
| B-0116 | 73.0%@1.0uM | 35.0%@1.0uM | | |
| B-0117 | 0.46 uM | 1.78 uM | 30%@30mpk@-6h | |
| B-0118 | 1.18 uM | 1.29 uM | | |
| B-0119 | 89.0%@10.0uM | 2.78uM | | |
| B-0120 | 0.008 uM | 0.21 uM | 77%@100mpk@-6h | 70%@3mpk@-4h |
| B-0121 | 79.0%@1.0uM | 1.22uM | | |
| B-0122 | 79.0%@10.0uM | 2.0%@1.0uM | | |
| B-0123 | 59.0%@1.0uM | >1.0uM | | |
| B-0124 | 73.0%@1.0uM | 15.0%@1.0uM | | |
| B-0125 | 70.0%@10.0uM | 17.0%@1.0uM | | |
| B-0126 | 66.0%@1.0uM | 1.57uM | | |

T0202T-084200T

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0127 | 82.0%@1.0uM | 0.96uM | | |
| B-0128 | 78.0%@1.0uM | 1.81uM | | |
| B-0129 | 51.0%@1.0uM | 31.0%@1.0uM | | |
| B-0130 | 69.0%@1.0uM | 58.0%@1.0uM | | |
| B-0131 | 43.0%@1.0uM | 46.0%@1.0uM | | |
| B-0132 | 76.0%@1.0uM | 8.0%@1.0uM | | |
| B-0133 | 51.0%@1.0uM | 42.0%@1.0uM | | |
| B-0134 | 60.0%@1.0uM | 2.17uM | | |
| B-0135 | 78.0%@1.0uM | 58.0%@1.0uM | | |
| B-0136 | 77.0%@1.0uM | 44.0%@1.0uM | | |
| B-0137 | 41.0%@1.0uM | 37.0%@1.0uM | | |
| B-0138 | 50.0%@1.0uM | 32.0%@1.0uM | | |
| B-0139 | 54.0%@10.0uM | 17.0%@1.0uM | | |
| B-0140 | 67%@10.0uM | 9.0%@1.0uM | | |
| B-0141 | 78.0%@1.0uM | 10.0%@1.0uM | | |
| B-0142 | 86.0%@1.0uM | 12.0%@1.0uM | | |
| B-0143 | 42.0% @1.0uM | 3.63uM | | |
| B-0144 | 86.0% @1.0uM | 43.0%@1.0uM | | |
| B-0145 | 54.0% @10.0uM | 12.0% @1.0uM | | |
| B-0146 | 77.0% @10.0uM | 28.0% @1.0uM | | |
| B-0147 | 44.0% @1.0uM | 22.0% @1.0uM | | |
| B-0148 | 51.0% @1.0uM | >1.0uM | | |
| B-0149 | 1.15 uM | 10.0 uM | | |
| B-0150 | 27.0% @10.0uM | 35.0% @1.0uM | | |
| B-0151 | 43.0% @1.0uM | 30.0% @1.0uM | | |
| B-0152 | 51.0% @1.0uM | 24.0% @1.0uM | | |
| B-0153 | 57.0% @1.0uM | 21.0% @1.0uM | | |
| B-0154 | 65.0% @10.0uM | 14.0% @1.0uM | | |
| B-0155 | 40.0% @10.0uM | 26.0% @1.0uM | | |
| B-0156 | 42.0% @10.0uM | 13.0% @1.0uM | | |
| B-0157 | 48.0% @10.0uM | 9.0% @1.0uM | | |
| B-0158 | 58.0% @10.0uM | 39.0% @1.0uM | | |
| B-0159 | 54.0% @10.0uM | 5.0% @1.0uM | | |
| B-0160 | 59.0% @10.0uM | 26.0% @1.0uM | | |
| B-0161 | 72.0% @10.0uM | 13.0% @1.0uM | | |
| B-0162 | 23%@1.0uM | 2.05 uM | | |
| B-0163 | 20.0% @10.0uM | 10.0% @1.0uM | | |
| B-0164 | 37.0% @10.0uM | 20.0% @1.0uM | | |
| B-0165 | 70.0% @10.0uM | 19.0% @1.0uM | | |
| B-0166 | 45.0% @10.0uM | 37.0% @1.0uM | | |
| B-0167 | 40.0% @1.0uM | 37.0% @1.0uM | | |
| B-0168 | 44%@1.0uM | 2.36 uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0169 | 43.0% @1.0uM | 21.0% @1.0uM | | |
| B-0170 | 43.0% @1.0uM | 30.0% @1.0uM | | |
| B-0171 | 61.0% @10.0uM | 21.0% @1.0uM | | |
| B-0172 | 16.0% @10.0uM | 11.0% @1.0uM | | |
| B-0173 | 33.0% @10.0uM | 48.0% @1.0uM | | |
| B-0174 | 54.0% @10.0uM | 43.0% @1.0uM | | |
| B-0175 | 41.0% @10.0uM | 31.0% @1.0uM | | |
| B-0176 | 50.0% @1.0uM | 30.0% @1.0uM | | |
| B-0177 | 70.0% @10.0uM | 27.0% @1.0uM | | |
| B-0178 | 12.0% @10.0uM | 35.0% @1.0uM | | |
| B-0179 | 27.0% @10.0uM | 37.0% @1.0uM | | |
| B-0180 | 34.0% @10.0uM | 23.0% @1.0uM | | |
| B-0181 | 5.0% @1.0uM | 2.0% @1.0uM | | |
| B-0182 | 39.0% @10.0uM | 40.0% @1.0uM | | |
| B-0183 | 12.0% @10.0uM | 34.0% @1.0uM | | |
| B-0184 | 66.0% @10.0uM | 17.0% @1.0uM | | |
| B-0185 | 65.0% @10.0uM | 25.0% @1.0uM | | |
| B-0186 | 40.0% @1.0uM | 25.0% @1.0uM | | |
| B-0187 | 4.0% @10.0uM | 14.0% @1.0uM | | |
| B-0188 | 70.0% @10.0uM | 35.0% @1.0uM | | |
| B-0189 | 42.0% @10.0uM | 9.0% @1.0uM | | |
| B-0190 | 59.0% @10.0uM | 31.0% @1.0uM | | |
| B-0191 | 40.0% @1.0uM | 29.0% @1.0uM | | |
| B-0192 | 12.0% @10.0uM | 47.0% @1.0uM | | |
| B-0193 | 0.54 uM | 6% @1.0uM | | |
| B-0194 | 1.31 uM | 22% @1.0uM | | |
| B-0195 | 1.03 uM | 55% @1.0uM | | |
| B-0196 | 2.24 uM | >1.0uM | | |
| B-0197 | 2.0 uM | 14% @1.0uM | | |
| B-0198 | 1.2 uM | 2% @1.0uM | | |
| B-0199 | 1.34 uM | 3% @1.0uM | | |
| B-0200 | 1.31 uM | 16% @1.0uM | | |
| B-0201 | 0.29 uM | 59% @1.0uM | | |
| B-0202 | 0.55 uM | 2.26 uM | | |
| B-0203 | 0.16 uM | 65% @1.0uM | | |
| B-0204 | 0.21 uM | 48% @1.0uM | | |
| B-0205 | 0.096 uM | 54% @1.0uM | | |
| B-0206 | 5.76 uM | 14% @1.0uM | | |
| B-0207 | 0.12 uM | 52% @1.0uM | | |
| B-0208 | 0.067 uM | >1.0uM | | |
| B-0209 | 0.29 uM | 8% @1.0uM | | |
| B-0210 | 0.057 uM | 67% @1.0uM | | |

100494-0342004

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0211 | 0.25 uM | 30%@1.0uM | | |
| B-0212 | 0.12 uM | 28%@1.0uM | | |
| B-0213 | 0.31 uM | 39%@1.0uM | | |
| B-0214 | 0.16 uM | 50%@1.0uM | | |
| B-0215 | 0.11 uM | 51%@1.0uM | | |
| B-0216 | 0.56 uM | >1.0uM | | |
| B-0217 | 0.55 uM | >1.0uM | | |
| B-0218 | 0.53 uM | 18%@1.0uM | | |
| B-0219 | 0.91 uM | 18%@1.0uM | | |
| B-0220 | 0.13 uM | 40%@1.0uM | | |
| B-0221 | 2.4 uM | >1.0uM | | |
| B-0222 | 0.4uM | 29.0%@1.0uM | | |
| B-0223 | 0.2uM | 1.0%@1.0uM | | |
| B-0224 | <0.1uM | 93.0%@1.0uM | | |
| B-0225 | 0.047uM | 37.0%@1.0uM | | |
| B-0226 | 0.074uM | 20.0%@1.0uM | | |
| B-0227 | 0.045uM | 1.0%@1.0uM | | |
| B-0228 | 0.15uM | 44.0%@1.0uM | | |
| B-0229 | <0.1uM | 61.0%@1.0uM | | |
| B-0230 | 0.041uM | 30.0%@1.0uM | | |
| B-0231 | 0.055uM | 40.0%1.0uM | | |
| B-0232 | 0.048uM | 24.0%@1.0uM | | |
| B-0233 | 0.095uM | 43.0%@1.0uM | | |
| B-0234 | 0.11uM | 68.0%@1.0uM | | |
| B-0235 | 1.31uM | 90.0%@1.0uM | | |
| B-0236 | 0.077uM | 46.0%@1.0uM | | |
| B-0237 | 0.13uM | 60.0%@1.0uM | | |
| B-0238 | 0.47uM | 82.0%@1.0uM | | |
| B-0239 | 5.73uM | 84.0%@1.0uM | | |
| B-0240 | 0.2uM | 70.0%@1.0uM | | |
| B-0241 | 0.1uM | 45.0%@1.0uM | | |
| B-0242 | <0.1uM | 78.0%@1.0uM | | |
| B-0243 | 0.039uM | 53.0%@1.0uM | | |
| B-0244 | 0.02uM | 57.0%@1.0uM | | |
| B-0245 | 0.13uM | 24.0%@1.0uM | | |
| B-0246 | <0.1uM | >1.0uM | | |
| B-0247 | 0.082uM | 75.0%@1.0uM | | |
| B-0248 | <0.1uM | 11.0%@1.0uM | | |
| B-0249 | <0.1uM | 75.0%@1.0uM | | |
| B-0250 | 0.28uM | 36.0%@1.0uM | | |
| B-0251 | 0.31uM | 1.0%@1.0uM | | |
| B-0252 | 0.041uM | 54.0%@1.0uM | | |

100430-1004

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0253 | 0.061uM | 74.0%@1.0uM | | |
| B-0254 | 0.12uM | 59.0%@1.0uM | | |
| B-0255 | 0.32uM | 68.0%@1.0uM | | |
| B-0256 | <0.1uM | 88.0%@1.0uM | | |
| B-0257 | 1.71uM | 11.0%@1.0uM | | |
| B-0258 | 0.37uM | 63.0%@1.0uM | | |
| B-0259 | 0.35uM | 58.0%@1.0uM | | |
| B-0260 | 0.56uM | 23.0%@1.0uM | | |
| B-0261 | 0.49uM | 23.0%@1.0uM | | |
| B-0262 | 0.41uM | 89.0%@1.0uM | | |
| B-0263 | 0.62uM | 64.0%@1.0uM | | |
| B-0264 | 0.14uM | 18.0%@1.0uM | | |
| B-0265 | 0.92uM | 24.0%@1.0uM | | |
| B-0266 | 0.25uM | 24.0%@1.0uM | | |
| B-0267 | 0.48uM | 11.0%@1.0uM | | |
| B-0268 | 3.39uM | 19.0%@1.0uM | | |
| B-0269 | 9.81uM | 19.0%@1.0uM | | |
| B-0270 | 5.79uM | 13.0%@1.0uM | | |
| B-0271 | 7.55uM | 12.0%@1.0uM | | |
| B-0272 | 1.81uM | 48.0%@1.0uM | | |
| B-0273 | 5.03uM | 13.0%@1.0uM | | |
| B-0274 | 2.68uM | 25.0%@1.0uM | | |
| B-0275 | 2.67uM | 33.0%@1.0uM | | |
| B-0276 | 1.25uM | 26.0%@1.0uM | | |
| B-0277 | 0.68uM | 34.0%@1.0uM | | |
| B-0278 | 1.26uM | 36.0%@1.0uM | | |
| B-0279 | 1.39uM | 33.0%@1.0uM | | |
| B-0280 | 0.86uM | 18.0%@1.0uM | | |
| B-0281 | 7.37uM | 24.0%@1.0uM | | |
| B-0282 | 0.75uM | 38.0%@1.0uM | | |
| B-0283 | 6.66uM | 29.0%@1.0uM | | |
| B-0284 | 0.083uM | 65.0%@1.0uM | | |
| B-0285 | 4.57uM | 29.0%@1.0uM | | |
| B-0286 | 0.33uM | 50.0%@1.0uM | | |
| B-0287 | 4.0uM | 22.0%@1.0uM | | |
| B-0288 | 4.46uM | 26.0%@1.0uM | | |
| B-0289 | 0.15uM | 55.0%@1.0uM | | |
| B-0290 | 0.66uM | 44.0%@1.0uM | | |
| B-0291 | 1.33uM | 20.0%@1.0uM | | |
| B-0292 | 0.22uM | 28.0%@1.0uM | | |
| B-0293 | 0.66uM | 53.0%@1.0uM | | |
| B-0294 | 0.68uM | 45.0%@1.0uM | | |

10034390-40704

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0295 | 0.82uM | 45.0%@1.0uM | | |
| B-0296 | 8.03uM | 36.0%@1.0uM | | |
| B-0297 | 0.78uM | 30.0%@1.0uM | | |
| B-0298 | 0.58uM | 48.0%@1.0uM | | |
| B-0299 | 0.87uM | 54.0%@1.0uM | | |
| B-0300 | 0.78uM | 32.0%@1.0uM | | |
| B-0301 | 0.19uM | 50.0%@1.0uM | | |
| B-0302 | 4.02uM | 24.0%@1.0uM | | |
| B-0303 | 0.22uM | 10.0%@1.0uM | | |
| B-0304 | 0.56uM | 28.0%@1.0uM | | |
| B-0305 | | | | |
| B-0306 | | | | |
| B-0307 | | | | |
| B-0308 | | | | |
| B-0309 | | | | |
| B-0310 | | | | |
| B-0311 | | | | |
| B-0312 | | | | |
| B-0313 | | | | |
| B-0314 | | | | |
| B-0315 | | | | |
| B-0316 | | | | |
| B-0317 | | | | |
| B-0318 | | | | |
| B-0319 | | | | |
| B-0320 | | | | |
| B-0321 | | | | |
| B-0322 | | | | |
| B-0323 | | | | |
| B-0324 | | | | |
| B-0325 | | | | |
| B-0326 | | | | |
| B-0327 | | | | |
| B-0328 | | | | |
| B-0329 | | | | |
| B-0330 | | | | |
| B-0331 | | | | |
| B-0332 | | | | |
| B-0333 | | | | |
| B-0334 | | | | |
| B-0335 | | | | |
| B-0336 | | | | |

100480 0822004

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0337 | | | | |
| B-0338 | | | | |
| B-0339 | | | | |
| B-0340 | | | | |
| B-0341 | | | | |
| B-0342 | | | | |
| B-0343 | | | | |
| B-0344 | | | | |
| B-0345 | | | | |
| B-0346 | | | | |
| B-0347 | | | | |
| B-0348 | | | | |
| B-0349 | | | | |
| B-0350 | | | | |
| B-0351 | | | | |
| B-0352 | | | | |
| B-0353 | 1.37uM | 55%@1.0uM | | |
| B-0354 | 1.0uM | 0.66uM | 51%@30mpk@-6h | 54%@3mpk@-4h |
| B-0355 | 0.75uM | 40.0%@1.0uM | | |
| B-0356 | 0.66uM | 24.0%@1.0uM | | |
| B-0357 | 1.46uM | 0.66uM | | |
| B-0358 | 0.37uM | 17.0%@1.0uM | | |
| B-0359 | 0.45uM | 47.0%@1.0uM | | |
| B-0360 | 1.6uM | 19.0%@1.0uM | | |
| B-0361 | 0.33uM | 46.0%@1.0uM | | |
| B-0362 | 0.52uM | 27.0%@1.0uM | | |
| B-0363 | 4.67uM | 25.0%@1.0uM | | |
| B-0364 | 1.44uM | 27.0%@1.0uM | | |
| B-0365 | 0.96uM | 27.0%@1.0uM | | |
| B-0366 | 0.7uM | 46.0%@1.0uM | | |
| B-0367 | 1.0uM | 23.0%@1.0uM | | |
| B-0368 | 1.0uM | 0.64uM | 37%@30mpk@-6h | |
| B-0369 | 0.16uM | 57.0%@1.0uM | | |
| B-0370 | 0.65uM | 28.0%@1.0uM | | |
| B-0371 | 0.49uM | 28.0%@1.0uM | | |
| B-0372 | 0.35uM | 29.0%@1.0uM | | |
| B-0373 | 0.45uM | 18.0%@1.0uM | | |
| B-0374 | 1.38uM | 12.0%@1.0uM | | |
| B-0375 | 1.0uM | 19.0%@1.0uM | | |
| B-0376 | 2.99uM | 12.0%@1.0uM | | |
| B-0377 | 1.29uM | 36.0%@1.0uM | | |
| B-0378 | 1.1uM | 36.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0379 | 0.53uM | 24.0%@1.0uM | | |
| B-0380 | 1.41uM | 32.0%@1.0uM | | |
| B-0381 | 0.22uM | 47.0%@1.0uM | | |
| B-0382 | 0.41uM | 32.0%@1.0uM | | |
| B-0383 | 1.43uM | 10.0%@1.0uM | | |
| B-0384 | 4.02uM | 16.0%@1.0uM | | |
| B-0385 | 0.057uM | 0.9uM | 30%@30mpk@-6h | 0%@3mpk@-4h |
| B-0386 | 0.13uM | 54.0%@1.0uM | | |
| B-0387 | 0.41uM | 52.0%@1.0uM | | |
| B-0388 | <0.1uM | 36.0%@1.0uM | | |
| B-0389 | 0.01uM | 0.05uM | | 62%@3mpk@-4h |
| B-0390 | 0.089uM | 55.0%@1.0uM | | |
| B-0391 | 0.86uM | 18.0%@1.0uM | | |
| B-0392 | 0.13uM | 57.0%@1.0uM | | |
| B-0393 | 0.043uM | 66.0%@1.0uM | | |
| B-0394 | 0.13uM | 45.0%@1.0uM | | |
| B-0395 | 0.087uM | 48.0%@1.0uM | | |
| B-0396 | 0.097uM | 0.44uM | | |
| B-0397 | 0.17uM | 41.0%@1.0uM | | |
| B-0398 | 0.054uM | 66.0%@1.0uM | | |
| B-0399 | 0.14uM | 39.0%@1.0uM | | |
| B-0400 | 0.16uM | 25.0%@1.0uM | | |
| B-0401 | 0.46uM | 52.0%@1.0uM | | |
| B-0402 | 0.14uM | 1.51uM | | |
| B-0403 | 1.77uM | 2.42uM | | |
| B-0404 | 0.31uM | 48.0%@1.0uM | | |
| B-0405 | 0.79uM | 30.0%@1.0uM | | |
| B-0406 | 0.54uM | 35.0%@1.0uM | | |
| B-0407 | 0.76uM | 27.0%@1.0uM | | |
| B-0408 | 0.5uM | 50.0%@1.0uM | | |
| B-0409 | 0.53uM | 30.0%@1.0uM | | |
| B-0410 | 0.38uM | 44.0%@1.0uM | | |
| B-0411 | 0.62uM | 50.0%@1.0uM | | |
| B-0412 | 0.24uM | 48.0%@1.0uM | | |
| B-0413 | 0.18uM | 55.0%@1.0uM | | |
| B-0414 | 2.54uM | 25.0%@1.0uM | | |
| B-0415 | 0.42uM | 43.0%@1.0uM | | |
| B-0416 | 0.32uM | 34.0%@1.0uM | | |
| B-0417 | 0.91uM | 28.0%@1.0uM | | |
| B-0418 | 0.22uM | 27.0%@1.0uM | | |
| B-0419 | 0.85uM | 41.0%21.0uM | | |
| B-0420 | 0.83uM | 49.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0421 | 0.46uM | 57.0%@1.0uM | | |
| B-0422 | <0.1uM | 40.0%@1.0uM | | |
| B-0423 | 0.18uM | 33.0%@1.0uM | | |
| B-0424 | 0.083uM | 32.0%@1.0uM | | |
| B-0425 | 0.26uM | 54.0%@1.0uM | | |
| B-0426 | 0.055uM | 0.74uM | | 41%@3mpk@-4h |
| B-0427 | 0.63uM | 39.0%@1.0uM | | |
| B-0428 | 0.99uM | 27.0%@1.0uM | | |
| B-0429 | 0.27uM | 45.0%@1.0uM | | |
| B-0430 | 0.29uM | 75.0%@1.0uM | | |
| B-0431 | 0.21uM | 64.0%@1.0uM | | |
| B-0432 | <0.1uM | 89.0%@1.0uM | | |
| B-0433 | <0.1uM | 92.0%@1.0uM | | |
| B-0434 | 0.12uM | 65.0%@1.0uM | | |
| B-0435 | 0.3uM | 61.0%@1.0uM | | |
| B-0436 | 1.11uM | 71.0%@1.0uM | | |
| B-0437 | 0.58uM | 59.0%@1.0uM | | |
| B-0438 | <0.1uM | 91.0%@1.0uM | | |
| B-0439 | 2.12uM | 65.0%@1.0uM | | |
| B-0440 | 0.66uM | 63.0%@1.0uM | | |
| B-0441 | 0.8uM | 58.0%@1.0uM | | |
| B-0442 | <0.1uM | 91.0%@1.0uM | | |
| B-0443 | 2.01uM | 71.0%@1.0uM | | |
| B-0444 | 1.01uM | 51.0%@1.0uM | | |
| B-0445 | <0.1uM | 83.0%@1.0uM | | |
| B-0446 | 0.78uM | 80.0%@1.0uM | | |
| B-0447 | 0.19uM | 71.0%@1.0uM | | |
| B-0448 | 0.4uM | 79.0%@1.0uM | | |
| B-0449 | 0.83uM | 81.0%@1.0uM | | |
| B-0450 | 0.26uM | 81.0%@1.0uM | | |
| B-0451 | 0.071uM | 83.0%@1.0uM | 42%@30mpk@-6h | |
| B-0452 | 0.7uM | 75.0%@1.0uM | | |
| B-0453 | 0.47uM | 75.0%@1.0uM | | |
| B-0454 | 0.11uM | 80.0%@1.0uM | | |
| B-0455 | <0.1uM | 95.0%@1.0uM | | 36%@3mpk%-4h |
| B-0456 | 1.81uM | 67.0%@1.0uM | | |
| B-0457 | 0.089uM | 81.0%@1.0uM | | |
| B-0458 | 0.033uM | 70.0%@1.0uM | | |
| B-0459 | 0.099uM | 76.0%@1.0uM | | |
| B-0460 | 0.061uM | 92.0%@1.0uM | | |
| B-0461 | 0.025uM | 96.0%@1.0uM | | |
| B-0462 | <0.1uM | 97.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0463 | 0.052uM | 95.0%@1.0uM | | |
| B-0464 | <0.1uM | 91.0%@1.0uM | | |
| B-0465 | 0.084uM | 98.0%@1.0uM | | |
| B-0466 | <0.1uM | 98.0%@1.0uM | | 0%@3mpk@-4h |
| B-0467 | <0.1uM | 77.0%@1.0uM | | |
| B-0468 | 0.031uM | 93.0%@1.0uM | | |
| B-0469 | 0.056uM | 92.0%@1.0uM | | |
| B-0470 | 0.063uM | 92.0%@1.0uM | | |
| B-0471 | 0.027uM | 97.0%@1.0uM | | |
| B-0472 | 0.19uM | 54.0%@1.0uM | | |
| B-0473 | 0.004uM | 95.0%@1.0uM | | |
| B-0474 | 0.024uM | 86.0%@1.0uM | | |
| B-0475 | 0.21uM | 74.0%@1.0uM | | |
| B-0476 | 0.56uM | 69.0%@1.0uM | | |
| B-0477 | 1.48uM | 96.0%@1.0uM | | |
| B-0478 | 0.034uM | 87.0%@1.0uM | | |
| B-0479 | 0.031uM | 90.0%@1.0uM | | 15%@3mpk@-4h |
| B-0480 | 0.12uM | 88.0%@1.0uM | | |
| B-0481 | 0.014uM | 95.0%@1.0uM | | 56%@3mpk@-4h |
| B-0482 | 0.97uM | 68.0%@1.0uM | | |
| B-0483 | 0.57uM | 68.0%@1.0uM | | |
| B-0484 | 0.28uM | 62.0%@1.0uM | | |
| B-0485 | 0.04uM | 95.0%@1.0uM | | |
| B-0486 | 0.24uM | 80.0%@1.0uM | | |
| B-0487 | 0.11uM | 89.0%@1.0uM | | 54%@3mpk@-4h |
| B-0488 | 0.62uM | 88.0%@1.0uM | | |
| B-0489 | 0.3uM | 80.0%@1.0uM | | |
| B-0490 | 0.91uM | 74.0%@1.0uM | | |
| B-0491 | 0.43uM | 66.0%@1.0uM | | |
| B-0492 | 0.069uM | 42.0%@1.0uM | | |
| B-0493 | 0.3uM | 36.0%@1.0uM | | |
| B-0494 | 0.13uM | 30.0%@1.0uM | | |
| B-0495 | 0.12uM | 25.0%@1.0uM | | |
| B-0496 | 0.83uM | 16.0%@1.0uM | | |
| B-0497 | 0.44uM | 31.0%@1.0uM | | |
| B-0498 | 0.33uM | 11.0%@1.0uM | | |
| B-0499 | 0.39uM | 37.0%@1.0uM | | |
| B-0500 | 0.26uM | 41.0%@1.0uM | | |
| B-0501 | 0.049uM | 52.0%@1.0uM | | |
| B-0502 | 0.065uM | 48.0%@1.0uM | | |
| B-0503 | 0.16uM | 73.0%@1.0uM | | |
| B-0504 | 0.4uM | 43.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0505 | 0.28uM | 44.0%@1.0uM | | |
| B-0506 | 0.94uM | 43.0%@1.0uM | | |
| B-0507 | 0.18uM | 75.0%@1.0uM | | |
| B-0508 | 2.0uM | 48.0%@1.0uM | | |
| B-0509 | 0.1uM | 86.0%@1.0uM | | |
| B-0510 | 0.69uM | 61.0%@1.0uM | | |
| B-0511 | 0.007uM | 90.0%@1.0uM | | |
| B-0512 | 1.0uM | 53.0%@1.0uM | | |
| B-0513 | 0.72uM | 52.0%@1.0uM | | |
| B-0514 | 0.14uM | 87.0%@1.0uM | | |
| B-0515 | 0.42uM | 61.0%@1.0uM | | |
| B-0516 | 0.37uM | 84.0%@1.0uM | | |
| B-0517 | 0.094uM | 52.0%@1.0uM | | |
| B-0518 | 0.11uM | 64.0%@1.0uM | | |
| B-0519 | 0.043uM | 87.0%@1.0uM | | |
| B-0520 | 0.4uM | 67.0%@1.0uM | | |
| B-0521 | 1.37uM | 52.0%@1.0uM | | |
| B-0522 | 0.15uM | 75.0%@1.0uM | | |
| B-0523 | 0.19uM | 83.0%@1.0uM | | |
| B-0524 | 0.4uM | 77.0%@1.0uM | | |
| B-0525 | 0.16uM | 76.0%@1.0uM | | |
| B-0526 | 0.031uM | 87.0%@1.0uM | | |
| B-0527 | 1.09uM | 63.0%@1.0uM | | |
| B-0528 | 0.14uM | 70.0%@1.0uM | | |
| B-0529 | 0.11uM | 73.0%@1.0uM | | |
| B-0530 | 5.53uM | 45.0%@1.0uM | | |
| B-0531 | 0.5uM | 48.0%@1.0uM | | |
| B-0532 | 0.45uM | 1.01uM | 41% @30mpk@-6h | |
| B-0533 | 1.23uM | 47.0%@1.0uM | | |
| B-0534 | 0.41uM | 54.0%@1.0uM | | |
| B-0535 | 0.44uM | 0.87uM | | |
| B-0536 | 0.46uM | 0.15uM | | |
| B-0537 | 3.44uM | 51.0%@1.0uM | | |
| B-0538 | 1.13uM | 45.0%@1.0uM | | |
| B-0539 | 2.84uM | 21.0%@1.0uM | | |
| B-0540 | 3.62uM | 54.0%@1.0uM | | |
| B-0541 | 3.24uM | 28.0%@1.0uM | | |
| B-0542 | 1.55uM | 50.0%@1.0uM | | |
| B-0543 | 1.56uM | 43.0%@1.0uM | | |
| B-0544 | 1.12uM | 27.0%@1.0uM | | |
| B-0545 | 1.06uM | 41.0%@1.0uM | | |
| B-0546 | 1.04uM | 18.0%@1.0uM | | |
| B-0547 | 1.24uM | 21.0%@1.0uM | | |
| B-0548 | 1.77uM | 28.0%@1.0uM | | |
| B-0549 | 2.22uM | 22.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0550 | 2.41uM | 14.0%@1.0uM | | |
| B-0551 | 1.08uM | 56.0%@1.0uM | | |
| B-0552 | 0.13uM | 46.0%@1.0uM | | |
| B-0553 | 1.44uM | 47.0%@1.0uM | | |
| B-0554 | 2.58uM | 20.0%@1.0uM | | |
| B-0555 | 1.87uM | 34.0%@1.0uM | | |
| B-0556 | 0.49uM | 39.0%@1.0uM | | |
| B-0557 | 1.37uM | 32.0%@1.0uM | | |
| B-0558 | 0.85uM | 33.0%@1.0uM | | |
| B-0559 | 0.53uM | 49.0%@1.0uM | | |
| B-0560 | 2.57uM | 31.0%@1.0uM | | |
| B-0561 | 2.07uM | 40.0%@1.0uM | | |
| B-0562 | 0.22uM | 0.3uM | | 5%@3mpk@-4h |
| B-0563 | 0.18uM | 0.13uM | | |
| B-0564 | 0.82uM | 58%@1.0uM | | |
| B-0565 | 0.23uM | 0.59uM | | |
| B-0566 | <0.1uM | 0.17uM | | 0%@3mpk@-4h |
| B-0567 | 0.14uM | 0.28uM | | |
| B-0568 | 1.22uM | 46.0%@1.0uM | | |
| B-0569 | 0.15uM | 0.26uM | | |
| B-0570 | 0.27uM | 46.0%@1.0uM | | |
| B-0571 | 0.38uM | 44.0%@1.0uM | | |
| B-0572 | 0.27uM | 41.0%@1.0uM | | |
| B-0573 | 0.36uM | 1.7uM | | |
| B-0574 | 0.13uM | 0.66uM | | 37%@3mpk@-4h |
| B-0575 | 0.032uM | 0.17uM | | |
| B-0576 | 0.068uM | 0.39uM | | 65%@3mpk@-4h |
| B-0577 | 0.091uM | 66.0%@1.0uM | | |
| B-0578 | 1.88uM | 47.0%@1.0uM | | |
| B-0579 | 0.11uM | 79.0%@1.0uM | | |
| B-0580 | 2.23uM | 0.84uM | | |
| B-0581 | 0.26uM | 2.17uM | | |
| B-0582 | 1.03uM | 37.0%@1.0uM | | |
| B-0583 | 3.93uM | 26.0%@1.0uM | | |
| B-0584 | 0.66uM | 54.0%@1.0uM | | |
| B-0585 | 0.83uM | 79.0%@1.0uM | 50%@30mpk@-6h | |
| B-0586 | 0.81uM | 51.0%@1.0uM | | |
| B-0587 | 6.84uM | 38%@1.0uM | | |
| B-0588 | 12.8uM | 42%@1.0uM | | |
| B-0589 | 1.71uM | 42%@1.0uM | | |
| B-0590 | 1.57uM | 38.0uM | | |
| B-0591 | 3.59uM | 29.0%@1.0uM | | |
| B-0592 | 1.62uM | 45.0%@1.0uM | | |
| B-0593 | 1.22uM | 36.0%@1.0uM | | |
| B-0594 | - | 41.0%@1.0uM | | |
| B-0595 | 2.42uM | 22.0%@1.0uM | | |
| B-0596 | 20.0uM | 41.0%@1.0uM | | |
| B-0597 | 1.68uM | 63.0%@1.0uM | | |
| B-0598 | 2.12uM | 50.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0599 | 4.16uM | 21.0%@1.0uM | | |
| B-0600 | 0.002uM | 28.0%@1.0uM | | |
| B-0601 | 0.089uM | 1.31uM | | 43%@3mpk%-4h |
| B-0602 | 0.97uM | 61.0%@1.0uM | | |
| B-0603 | 0.09uM | 51.0%@1.0uM | | |
| B-0604 | 0.3uM | 20.0%@1.0uM | | |
| B-0605 | 0.18uM | 47.0%@1.0uM | | |
| B-0606 | 0.17uM | 53.0%@1.0uM | | |
| B-0607 | 2.79uM | 70.0%@1.0uM | | |
| B-0608 | 0.059uM | 73.0%@1.0uM | | |
| B-0609 | <0.1uM | 87.0%@1.0uM | | |
| B-0610 | <0.1uM | 88.0%@1.0uM | | |
| B-0611 | 0.65uM | 60.0%@1.0uM | | |
| B-0612 | 0.16uM | 60.0%@1.0uM | | |
| B-0613 | 0.17uM | 76.0%@1.0uM | | |
| B-0614 | 0.76uM | 70.0%@1.0uM | | 0%@3mpk@-4h |
| B-0615 | 0.08uM | 83.0%@1.0uM | | |
| B-0616 | 0.38uM | 87.0%@1.0uM | | |
| B-0617 | 0.045uM | 92.0%@1.0uM | | |
| B-0618 | 0.37uM | 80.0%@1.0uM | | |
| B-0619 | <0.1uM | 88.0%@1.0uM | | |
| B-0620 | 1.59uM | 58.0%@1.0uM | | |
| B-0621 | 0.36uM | 68.0%@1.0uM | | |
| B-0622 | 0.076uM | 78.0%@1.0uM | | |
| B-0623 | 0.12uM | 76.0%@1.0uM | | |
| B-0624 | 0.085uM | 54.0%@1.0uM | | |
| B-0625 | 0.023uM | 88.0%@1.0uM | | |
| B-0626 | <0.1uM | 85.0%@1.0uM | | |
| B-0627 | 0.25uM | 69.0%@1.0uM | | |
| B-0628 | 0.023uM | 72.0%@1.0uM | | |
| B-0629 | 0.2uM | 79.0%@1.0uM | | |
| B-0630 | 0.06uM | 77.0%@1.0uM | | |
| B-0631 | 0.065uM | 81.0%@1.0uM | | |
| B-0632 | <0.1uM | 79.0%@1.0uM | | |
| B-0633 | 0.6uM | 80.0%@1.0uM | | |
| B-0634 | 0.6uM | 40.0%@1.0uM | | |
| B-0635 | 0.15uM | 55.0%@1.0uM | | |
| B-0636 | <0.1uM | 86.0%@1.0uM | | |
| B-0637 | 0.11uM | 92.0%@1.0uM | | |
| B-0638 | 0.25uM | 89.0%@1.0uM | | |
| B-0639 | 0.051uM | 93.0%@1.0uM | | 50%@3mpk@-4h |
| B-0640 | 0.36uM | 94.0%@1.0uM | | |
| B-0641 | 0.58uM | 65.0%@1.0uM | | |
| B-0642 | 0.49uM | 90.0%@1.0uM | | |
| B-0643 | 0.069uM | 85.0%@1.0uM | | 0%@3mpk@-4h |
| B-0644 | 0.058uM | 89.0%@1.0uM | | |
| B-0645 | 0.58uM | 80.0%@1.0uM | | |
| B-0646 | 0.26uM | 94.0%@1.0uM | | |
| B-0647 | 1.61uM | 76.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0648 | <0.1uM | 83.0%@1.0uM | | |
| B-0649 | 0.83uM | 39.0%@1.0uM | | |
| B-0650 | 0.006uM | 95.0%@1.0uM | | 8%@3mpk@-4h |
| B-0651 | 1.78uM | 81.0%@1.0uM | | |
| B-0652 | 0.19uM | 83.0%@1.0uM | | |
| B-0653 | 2.01uM | 74.0%@1.0uM | | |
| B-0654 | 5.97uM | 78.0%@1.0uM | | |
| B-0655 | 1.25uM | 76.0%@1.0uM | | |
| B-0656 | 0.007uM | 95.0%@1.0uM | | 28%@3mpk@-4h |
| B-0657 | 0.17uM | 83.0%@1.0uM | | |
| B-0658 | 1.14uM | 91.0%@1.0uM | | |
| B-0659 | 2.64uM | 87.0%@1.0uM | | |
| B-0660 | 0.088uM | 92.0%@1.0uM | | |
| B-0661 | <0.1uM | 90.0%@1.0uM | | |
| B-0662 | <0.1uM | 95.0%@1.0uM | | |
| B-0663 | 0.88uM | 74.0%@1.0uM | | |
| B-0664 | 0.39uM | 80.0%@1.0uM | | |
| B-0665 | 0.47uM | 72.0%@1.0uM | | |
| B-0666 | 0.17uM | 73.0%@1.0uM | | |
| B-0667 | 0.83uM | 75.0%@1.0uM | | |
| B-0668 | 0.27uM | 78.0%@1.0uM | | |
| B-0669 | 0.89uM | 34.0%@1.0uM | | |
| B-0670 | 3.15uM | 32.0%@1.0uM | | |
| B-0671 | 6.38uM | 36.0%@1.0uM | | |
| B-0672 | 6.59uM | 32.0%@1.0uM | | |
| B-0673 | 8.54uM | 48.0%@1.0uM | | |
| B-0674 | 2.81uM | 42.0%@1.0uM | | |
| B-0675 | 5.42uM | 3.0%@1.0uM | | |
| B-0676 | 2.09uM | 22.0%@1.0uM | | |
| B-0677 | 1.63uM | 25.0%@1.0uM | | |
| B-0678 | 0.38uM | 52.0%@1.0uM | | |
| B-0679 | 0.062uM | 45.0%@1.0uM | | |
| B-0680 | 0.42uM | 67.0%@1.0uM | | |
| B-0681 | 1.96uM | 17.0%@1.0uM | | |
| B-0682 | 0.76uM | 39.0%@1.0uM | | |
| B-0683 | 13.0uM | 32.0%@1.0uM | | |
| B-0684 | 0.54uM | 68.0%@1.0uM | | |
| B-0685 | 15.4uM | 33.0%@1.0uM | | |
| B-0686 | 0.42uM | 59.0%@1.0uM | | |
| B-0687 | 10.1uM | 15.0%@1.0uM | | |
| B-0688 | 0.66uM | 58.0%@1.0uM | | |
| B-0689 | 14.6uM | 27.0%@1.0uM | | |
| B-0690 | 27.1uM | 36.0%@1.0uM | | |
| B-0691 | 0.16uM | 48.0%@1.0uM | | |
| B-0692 | 0.38uM | 29.0%@1.0uM | | |
| B-0693 | 0.39uM | 28.0%@1.0uM | | |
| B-0694 | 0.62uM | 21.0%@1.0uM | | |
| B-0695 | 0.23uM | 32.0%@1.0uM | | |
| B-0696 | 0.085uM | 35.0%@1.0uM | | |

1002130-1004

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0697 | 0.45uM | 44.0%@1.0uM | | |
| B-0698 | 2.33uM | 43.0%@1.0uM | | |
| B-0699 | 0.34uM | 31.0%@1.0uM | | |
| B-0700 | 0.24uM | 56.0%@1.0uM | | |
| B-0701 | 0.39uM | 45.0%@1.0uM | | |
| B-0702 | 0.036uM | 39.0%@1.0uM | | |
| B-0703 | 0.12uM | 39.0%@1.0uM | | |
| B-0704 | 2.19uM | 29.0%@1.0uM | | |
| B-0705 | 0.44uM | 21.0%@1.0uM | | |
| B-0706 | 0.44uM | 32.0%@1.0uM | | |
| B-0707 | 1.7uM | | | |
| B-0708 | 2.1uM | | | |
| B-0709 | 0.84uM | | | |
| B-0710 | 1.99uM | | | |
| B-0711 | 1.99uM | | | |
| B-0712 | 2.9uM | | | |
| B-0713 | 4.3uM | | | |
| B-0714 | 3.7uM | | | |
| B-0715 | 3.2uM | | | |
| B-0716 | 4.6uM | | | |
| B-0717 | 4.3uM | | | |
| B-0718 | 1.4uM | | | |
| B-0719 | 3.4uM | | | |
| B-0720 | 1.3uM | | | |
| B-0721 | 3.8uM | | | |
| B-0722 | 0.07uM | >1.0uM | | |
| B-0723 | 0.47uM | | | |
| B-0724 | 0.06uM | 17.0%@1.0uM | | |
| B-0725 | 9.7uM | | | |
| B-0726 | 1.4uM | | | |
| B-0727 | 0.51uM | | | |
| B-0728 | 20.0uM | | | |
| B-0729 | 0.87uM | | | |
| B-0730 | 0.25uM | 11.0%@1.0uM | | |
| B-0731 | 0.87uM | >1.0uM | | |
| B-0732 | 14.0uM | | | |
| B-0733 | 32.0uM | | | |
| B-0734 | 0.92uM | | | |
| B-0735 | 1.0uM | | | |
| B-0736 | 26.0uM | | | |
| B-0737 | 2.6uM | | | |
| B-0738 | 2.7uM | | | |
| B-0739 | 4.1uM | | | |
| B-0740 | 4.4uM | | | |
| B-0741 | 26.0uM | | | |
| B-0742 | 2.2uM | | | |
| B-0743 | 1.2uM | | | |
| B-0744 | 23.0uM | | | |
| B-0745 | 6.0uM | | | |

404301-0312001

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0746 | 0.01uM | 22.0%@1.0uM | | |
| B-0747 | 1.1uM | | | |
| B-0748 | 1.2uM | | | |
| B-0749 | 4.4uM | | | |
| B-0750 | 0.92uM | | | |
| B-0751 | 1.6uM | | | |
| B-0752 | 0.33uM | | | |
| B-0753 | 0.37uM | | | |
| B-0754 | 0.55uM | | | |
| B-0755 | 2.3uM | | | |
| B-0756 | 0.94uM | | | |
| B-0757 | 0.54uM | 16.0%@1.0uM | | |
| B-0758 | 1.5uM | | | |
| B-0759 | 0.3uM | | | |
| B-0760 | 0.01uM | 13.0%@1.0uM | | |
| B-0761 | <0.1uM | | | |
| B-0762 | 0.13uM | 5.0%@1.0uM | | |
| B-0763 | 0.015uM | 17.0%@1.0uM | | |
| B-0764 | 0.67uM | 26.0%@1.0uM | | |
| B-0765 | 0.3uM | 29.0%@1.0uM | | |
| B-0766 | 0.95uM | | | |
| B-0767 | 0.08uM | | | |
| B-0768 | 1.4uM | | | |
| B-0769 | 12.7uM | | | |
| B-0770 | 2.3uM | | | |
| B-0771 | 0.5uM | | | |
| B-0772 | 0.8uM | | | |
| B-0773 | 14.0uM | | | |
| B-0774 | 1.5uM | | | |
| B-0775 | 0.6uM | >1.0uM | | |
| B-0776 | 0.9uM | >1.0uM | | |
| B-0777 | 21.0uM | | | |
| B-0778 | 51.0uM | | | |
| B-0779 | 0.5uM | | | |
| B-0780 | 1.1uM | | | |
| B-0781 | 48.0uM | | | |
| B-0782 | 22.0uM | | | |
| B-0783 | 8.0uM | | | |
| B-0784 | 7.0uM | | | |
| B-0785 | 23.0uM | | | |
| B-0786 | 24.0uM | | | |
| B-0787 | 1.5uM | | | |
| B-0788 | 1.2uM | | | |
| B-0789 | 33.0uM | | | |
| B-0790 | 1.0uM | 4.0%@1.0uM | | |
| B-0791 | 0.3uM | >1.0uM | | |
| B-0792 | 1.1uM | | | |
| B-0793 | 0.3uM | | | |
| B-0794 | 2.9uM | 2.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0795 | 1.9uM | 11.0%@1.0uM | | |
| B-0796 | 1.4uM | | | |
| B-0797 | 1.04uM | - | | |
| B-0798 | 1.73uM | - | | |
| B-0799 | - | >1.0uM | | |
| B-0800 | 1.01uM | >1.0uM | | |
| B-0801 | 0.67uM | >1.0uM | | |
| B-0802 | - | >1.0uM | | |
| B-0803 | 0.057uM | 53.0%@1.0uM | | |
| B-0804 | 0.3uM | 32.0%@1.0uM | | |
| B-0805 | 0.71uM | >1.0uM | | |
| B-0806 | 3.28uM | >1.0uM | | |
| B-0807 | 10.8uM | - | | |
| B-0808 | 3.09uM | >1.0uM | | |
| B-0809 | 1.22uM | 7.0%@1.0uM | | |
| B-0810 | 1.11uM | >1.0uM | | |
| B-0811 | 2.79uM | 2.0%@1.0uM | | |
| B-0812 | 2.12uM | >1.0uM | | |
| B-0813 | 3.02uM | >1.0uM | | |
| B-0814 | - | >1.0uM | | |
| B-0815 | 2.11uM | >1.0uM | | |
| B-0816 | 3.46uM | >1.0uM | | |
| B-0817 | 3.07uM | 33.0%@1.0uM | | |
| B-0818 | 4.97uM | >1.0uM | | |
| B-0819 | 1.08uM | >1.0uM | | |
| B-0820 | 1.64uM | 3.0%@1.0uM | | |
| B-0821 | 1.44uM | - | | |
| B-0822 | 1.33uM | - | | |
| B-0823 | 2.39uM | >1.0uM | | |
| B-0824 | 3.41uM | - | | |
| B-0825 | - | - | | |
| B-0826 | 1.74uM | - | | |
| B-0827 | 15.6uM | - | | |
| B-0828 | 7.9uM | - | | |
| B-0829 | 0.61uM | 65.0%@1.0uM | | |
| B-0830 | 0.54uM | 34.0%@1.0uM | | |
| B-0831 | 0.9uM | >1.0uM | | |
| B-0832 | 1.49uM | - | | |
| B-0833 | 0.95uM | 23.0%@1.0uM | | |
| B-0834 | 1.25uM | - | | |
| B-0835 | - | - | | |
| B-0836 | 1.24uM | - | | |
| B-0837 | 1.96uM | >1.0uM | | |
| B-0838 | 3.1uM | - | | |
| B-0839 | 4.3uM | - | | |
| B-0840 | 0.63uM | 47.0%@1.0uM | | |
| B-0841 | 0.32uM | 36.0%@1.0uM | | |
| B-0842 | 0.74uM | 63.0%@1.0uM | | |
| B-0843 | 0.61uM | >1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0844 | 0.4uM | 25.0%@1.0uM | | |
| B-0845 | 1.78uM | - | | |
| B-0846 | 1.8uM | - | | |
| B-0847 | 0.73uM | 21.0%@1.0uM | | |
| B-0848 | 1.56uM | - | | |
| B-0849 | 1.25uM | - | | |
| B-0850 | 1.81uM | - | | |
| B-0851 | 0.91uM | 39.0%@1.0uM | | |
| B-0852 | 1.02uM | - | | |
| B-0853 | - | 38.0%@1.0uM | | |
| B-0854 | - | 25.0%@1.0uM | | |
| B-0855 | - | 8.0%@1.0uM | | |
| B-0856 | - | 38.0%@1.0uM | | |
| B-0857 | 6.25uM | - | | |
| B-0858 | 2.1uM | 48.0%@1.0uM | | |
| B-0859 | 39.5uM | - | | |
| B-0860 | 38.1uM | - | | |
| B-0861 | 1.32uM | 12.0%@1.0uM | | |
| B-0862 | 2.15uM | 4.0%@1.0uM | | |
| B-0863 | 0.81uM | 25.0%@1.0uM | | |
| B-0864 | 0.39uM | 40.0%@1.0uM | | |
| B-0865 | 0.66uM | 46.0%@1.0uM | | |
| B-0866 | 1.38uM | 28.0%@1.0uM | | |
| B-0867 | 0.62uM | >1.0uM | | |
| B-0868 | 3.28uM | 8.0%@1.0uM | | |
| B-0869 | 4.19uM | >1.0uM | | |
| B-0870 | 3.13uM | >1.0uM | | |
| B-0871 | 1.9uM | >1.0uM | | |
| B-0872 | 3.13uM | 3.0%@1.0uM | | |
| B-0873 | 6.92uM | >1.0uM | | |
| B-0874 | 1.92uM | >1.0uM | | |
| B-0875 | 2.13uM | 8%@1.0uM | | |
| B-0876 | 0.89uM | >1.0uM | | |
| B-0877 | 1.17uM | 13.0%@1.0uM | | |
| B-0878 | 0.65uM | 19.0%@1.0uM | | |
| B-0879 | 0.87uM | 1.0%@1.0uM | | |
| B-0880 | 0.15uM | 40.0%@1.0uM | | |
| B-0881 | 1.36uM | >1.0uM | | |
| B-0882 | 1.48uM | 9%@1.0uM | | |
| B-0883 | 1.06uM | >1.0uM | | |
| B-0884 | 1.89uM | - | | |
| B-0885 | | | | |
| B-0886 | | | | |
| B-0887 | | | | |
| B-0888 | | | | |
| B-0889 | | | | |
| B-0890 | | | | |
| B-0891 | | | | |
| B-0892 | | | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0893 | | | | |
| B-0894 | | | | |
| B-0895 | | | | |
| B-0896 | | | | |
| B-0897 | | | | |
| B-0898 | | | | |
| B-0899 | | | | |
| B-0900 | | | | |
| B-0901 | | | | |
| B-0902 | | | | |
| B-0903 | | | | |
| B-0904 | | | | |
| B-0905 | | | | |
| B-0906 | | | | |
| B-0907 | | | | |
| B-0908 | | | | |
| B-0909 | | | | |
| B-0910 | | | | |
| B-0911 | | | | |
| B-0912 | | | | |
| B-0913 | | | | |
| B-0914 | | | | |
| B-0915 | | | | |
| B-0916 | | | | |
| B-0917 | | | | |
| B-0918 | | | | |
| B-0919 | | | | |
| B-0920 | | | | |
| B-0921 | | | | |
| B-0922 | | | | |
| B-0923 | | | | |
| B-0924 | | | | |
| B-0925 | | | | |
| B-0926 | | | | |
| B-0927 | | | | |
| B-0928 | | | | |
| B-0929 | | | | |
| B-0930 | | | | |
| B-0931 | | | | |
| B-0932 | | | | |
| B-0933 | 47.0%@1.0uM | 37.0%@1.0uM | | |
| B-0934 | 67.0%@1.0uM | 36.0%@1.0uM | | |
| B-0935 | 69.0%@1.0uM | 54.0%@1.0uM | | |
| B-0936 | 69.0%@1.0uM | >1.0uM | | |
| B-0937 | 64.0%@1.0uM | 1.74uM | | |
| B-0938 | 51.0%@1.0uM | 29.0%@1.0uM | | |
| B-0939 | 78.0%@1.0uM | 14.0%@1.0uM | | |
| B-0940 | 56.0%@1.0uM | 22.0%@1.0uM | | |
| B-0941 | 81.0%@1.0uM | 25.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0942 | 82.0% @ 1.0uM | 2.0% @ 1.0uM | | |
| B-0943 | 63.0% @ 10.0uM | 24.0% @ 1.0uM | | |
| B-0944 | 45.0% @ 1.0uM | 27.0% @ 1.0uM | | |
| B-0945 | 96.0% @ 1.0uM | 0.93uM | | |
| B-0946 | 76.0% @ 1.0uM | 31.0% @ 1.0uM | | |
| B-0947 | 69.0% @ 1.0uM | 34.0% @ 1.0uM | | |
| B-0948 | 68.0% @ 1.0uM | 1.81uM | | |
| B-0949 | 90.0% @ 1.0uM | 17.0% @ 1.0uM | | |
| B-0950 | 81.0% @ 1.0uM | 0.58uM | | |
| B-0951 | 82.0% @ 1.0uM | 20.0% @ 1.0uM | | |
| B-0952 | 44.0% @ 1.0uM | 21.0% @ 1.0uM | | |
| B-0953 | 63.0% @ 1.0uM | 25.0% @ 1.0uM | | |
| B-0954 | 62.0% @ 1.0uM | 0.52uM | | |
| B-0955 | 49.0% @ 1.0uM | 0.54uM | | |
| B-0956 | 56.0% @ 1.0uM | 1.33uM | | |
| B-0957 | 79.0% @ 1.0uM | 22.0% @ 1.0uM | | |
| B-0958 | 74.0% @ 1.0uM | 0.38uM | | |
| B-0959 | 83.0% @ 1.0uM | 39.0% @ 1.0uM | | |
| B-0960 | 48.0% @ 1.0uM | 4.0% @ 1.0uM | | |
| B-0961 | 79.0% @ 1.0uM | 23.0% @ 1.0uM | | |
| B-0962 | 85.0% @ 1.0uM | 2.71uM | | |
| B-0963 | 76.0% @ 1.0uM | 39.0% @ 1.0uM | | |
| B-0964 | 94.0% @ 1.0uM | 5.0uM | | |
| B-0965 | 74.0% @ 1.0uM | 1.1uM | | |
| B-0966 | 50.0% @ 1.0uM | 5.0% @ 1.0uM | | |
| B-0967 | 80.0% @ 1.0uM | 29.0% @ 1.0uM | | |
| B-0968 | 35.0% @ 1.0uM | 26.0% @ 1.0uM | | |
| B-0969 | 63.0% @ 1.0uM | 35.0% @ 1.0uM | | |
| B-0970 | 76.0% @ 10.0uM | 0.88uM | | |
| B-0971 | 61.0% @ 1.0uM | 39.0% @ 1.0uM | | |
| B-0972 | 85.0% @ 1.0uM | 2.0% @ 1.0uM | | |
| B-0973 | 66.0% @ 10.0uM | 48.0% @ 1.0uM | | |
| B-0974 | 57.0% @ 1.0uM | 47.0% @ 1.0uM | | |
| B-0975 | 82.0% @ 1.0uM | 32.0% @ 1.0uM | | |
| B-0976 | 79.0% @ 1.0uM | 36.0% @ 1.0uM | | |
| B-0977 | 60.0% @ 1.0uM | 26.0% @ 1.0uM | | |
| B-0978 | 59.0% @ 1.0uM | 36.0% @ 1.0uM | | |
| B-0979 | 56.0% @ 10.0uM | 23.0% @ 1.0uM | | |
| B-0980 | 68.0% @ 1.0uM | 31.0% @ 1.0uM | | |
| B-0981 | 62.0% @ 1.0uM | 57.0% @ 1.0uM | | |
| B-0982 | 65.0% @ 1.0uM | 23.0% @ 1.0uM | | |
| B-0983 | 75.0% @ 1.0uM | 0.8uM | | |
| B-0984 | 60.0% @ 1.0uM | 51.0% @ 1.0uM | | |
| B-0985 | 86.0% @ 1.0uM | 0.75uM | | |
| B-0986 | 70.0% @ 1.0uM | 71.0% @ 1.0uM | | |
| B-0987 | 78.0% @ 1.0uM | 79.0% @ 1.0uM | | |
| B-0988 | 72.0% @ 1.0uM | 65.0% @ 1.0uM | | |
| B-0989 | 85.0% @ 1.0uM | 0.85uM | | |
| B-0990 | - | 26.0% @ 1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-0991 | 58.0%@1.0uM | 33.0%@1.0uM | | |
| B-0992 | 77.0%@1.0uM | 45.0%@1.0uM | | |
| B-0993 | 57.0%@1.0uM | 73.0%@1.0uM | | |
| B-0994 | 55.0%@1.0uM | 43.0%@1.0uM | | |
| B-0995 | 53.0%@1.0uM | 14.0%@1.0uM | | |
| B-0996 | 54.0%@1.0uM | 27.0%@1.0uM | | |
| B-0997 | 69.0%@1.0uM | 22.0%@1.0uM | | |
| B-0998 | 67.0%@1.0uM | 25.0%@1.0uM | | |
| B-0999 | 61.0%@1.0uM | 24.0%@1.0uM | | |
| B-1000 | 55.0%@1.0uM | 42.0%@1.0uM | | |
| B-1001 | 63.0%@1.0uM | 31.0%@1.0uM | | |
| B-1002 | 70.0%@1.0uM | 41.0%@1.0uM | | |
| B-1003 | 74.0%@1.0uM | 29.0%@1.0uM | | |
| B-1004 | 79.0%@1.0uM | 45.0%@1.0uM | | |
| B-1005 | 58.0%@1.0uM | 23.0%@1.0uM | | |
| B-1006 | 69.0%@1.0uM | 38.0%@1.0uM | | |
| B-1007 | 52.0%@1.0uM | 34.0%@1.0uM | | |
| B-1008 | 54.0%@1.0uM | 23.0%@1.0uM | | |
| B-1009 | 80.0%@1.0uM | 55.0%@1.0uM | | |
| B-1010 | 75.0%@1.0uM | 1.0uM | | |
| B-1011 | 72.0%21.0uM | 17.0%@1.0uM | | |
| B-1012 | - | 20.0%@1.0uM | | |
| B-1013 | 85.0%@1.0uM | 7.0%@1.0uM | | |
| B-1014 | 88.0%@1.0uM | 20.0%@1.0uM | | |
| B-1015 | 77.0%@1.0uM | 34.0%@1.0uM | | |
| B-1016 | 58.0%@1.0uM | 10.0%@1.0uM | | |
| B-1017 | 96.0%@1.0uM | 58.0%@1.0uM | | |
| B-1018 | 88.0%@1.0uM | 34.0%@1.0uM | | |
| B-1019 | 82.0%@1.0uM | 66.0%@1.0uM | | |
| B-1020 | 87.0%@1.0uM | 36.0%@1.0uM | | |
| B-1021 | 82.0%@1.0uM | 35.0%@1.0uM | | |
| B-1022 | 84.0%@1.0uM | 53.0%@1.0uM | | |
| B-1023 | 93.0%@1.0uM | 70.0%@1.0uM | | |
| B-1024 | 89.0%@1.0uM | 57.0%@1.0uM | | |
| B-1025 | 61.0%@1.0uM | 23.0%@1.0uM | | |
| B-1026 | 87.0%@1.0uM | 53.0%@1.0uM | | |
| B-1027 | 58.0%@1.0uM | 18.0%@1.0uM | | |
| B-1028 | 70.0%@1.0uM | 17.0%@1.0uM | | |
| B-1029 | 69.0%@1.0uM | 54.0%@1.0uM | | |
| B-1030 | 76.0%@1.0uM | 60.0%@1.0uM | | |
| B-1031 | 69.0%@1.0uM | 42.0%@1.0uM | | |
| B-1032 | 76.0%@1.0uM | 37.0%@1.0uM | | |
| B-1033 | 86.0%@1.0uM | 34.0%@1.0uM | | |
| B-1034 | 66.0%@1.0uM | 39.0%@1.0uM | | |
| B-1035 | 75.0%@1.0uM | 52.0%@1.0uM | | |
| B-1036 | 68.0%@1.0uM | 68.0%@1.0uM | | |
| B-1037 | - | 41.0%@1.0uM | | |
| B-1038 | 57.0%@1.0uM | 0.57uM | | |
| B-1039 | - | 1.33uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1040 | 72.0%@1.0uM | 0.38uM | | |
| B-1041 | 70.0%@1.0uM | 73.0%@1.0uM | | |
| B-1042 | 79.0%@1.0uM | 12.0%@1.0uM | | |
| B-1043 | 64.0%@1.0uM | 53.0%@1.0uM | | |
| B-1044 | 94.0%@1.0uM | 0.93uM | | |
| B-1045 | 78.0%@1.0uM | 25.0%@1.0uM | | |
| B-1046 | 72.0%@1.0uM | 66.0%@1.0uM | | |
| B-1047 | 72.0%@1.0uM | 58.0%@1.0uM | | |
| B-1048 | 67.0%@1.0uM | 19.0%@1.0uM | | |
| B-1049 | 67.0%@1.0uM | 65.0%@1.0uM | | |
| B-1050 | - | 0.54uM | | |
| B-1051 | 68.0%@1.0uM | 41%@1.0uM | | |
| B-1052 | 69.0%@1.0uM | 66%@1.0uM | | |
| B-1053 | 78.0%@1.0uM | 0.4uM | | |
| B-1054 | 79.0%@1.0uM | 55.0%@1.0uM | | |
| B-1055 | 89.0%@1.0uM | 63.0%@1.0uM | | |
| B-1056 | 89.0%@1.0uM | 0.76uM | | |
| B-1057 | 85.0%@1.0uM | 0.72uM | | |
| B-1058 | 0.66uM | 43.0%@1.0uM | | |
| B-1059 | 0.18uM | 24.0%@1.0uM | | |
| B-1060 | 0.11uM | 32.0%@1.0uM | | |
| B-1061 | 0.03uM | 19.0%@1.0uM | | |
| B-1062 | <0.1uM | 26.0%@1.0uM | | |
| B-1063 | 0.16uM | 44.0%@1.0uM | | |
| B-1064 | 0.39uM | 50.0%@1.0uM | | |
| B-1065 | 0.56uM | 40.0%@1.0uM | | |
| B-1066 | <0.1uM | 39.0%@1.0uM | | |
| B-1067 | 1.6uM | 32.0%@1.0uM | | |
| B-1068 | 0.48uM | 24.0%@1.0uM | | |
| B-1069 | 0.22uM | 27.0%@1.0uM | | |
| B-1070 | <0.1uM | 44.0%@1.0uM | | |
| B-1071 | <0.1uM | 48.0%@1.0uM | | |
| B-1072 | 0.38uM | 28.0%@1.0uM | | |
| B-1073 | <0.1uM | 21.0%@1.0uM | | |
| B-1074 | 0.23uM | 33.0%@1.0uM | | |
| B-1075 | 0.03uM | 29.0%@1.0uM | | |
| B-1076 | 0.08uM | 31.0%@1.0uM | | |
| B-1077 | <0.1uM | 38.0%@1.0uM | | |
| B-1078 | 0.26uM | 48.0%@1.0uM | | |
| B-1079 | <0.1uM | 40.0%@1.0uM | | |
| B-1080 | 0.19uM | 28.0%@1.0uM | | |
| B-1081 | <0.1uM | 37.0%@1.0uM | | |
| B-1082 | <0.1uM | 54.0%@1.0uM | | |
| B-1083 | <0.1uM | 23.0%@1.0uM | | |
| B-1084 | 0.43uM | 29.0%@1.0uM | | |
| B-1085 | <0.1uM | 29.0%@1.0uM | | |
| B-1086 | <0.1uM | 42.0%@1.0uM | | |
| B-1087 | 0.05uM | 32.0%@1.0uM | | |
| B-1088 | 0.73uM | 49.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1089 | <0.1uM | 39.0%@1.0uM | | |
| B-1090 | <0.1uM | 90.0%@1.0uM | | |
| B-1091 | <0.1uM | 73.0%@1.0uM | | |
| B-1092 | 0.27uM | 85.0%@1.0uM | | |
| B-1093 | 0.33uM | 36.0%@1.0uM | | |
| B-1094 | 0.013uM | 69.0%@1.0uM | | |
| B-1095 | <0.1uM | 70.0%@1.0uM | | |
| B-1096 | <0.1uM | 32.0%@1.0uM | | |
| B-1097 | <0.1uM | 44.0%@1.07uM | | |
| B-1098 | <0.1uM | 82.0%@1.0uM | | |
| B-1099 | 0.26uM | 74.0%@1.0uM | | |
| B-1100 | 0.22uM | 56.0%@1.0uM | | |
| B-1101 | 0.026uM | 82.0%@1.0uM | | |
| B-1102 | 0.035uM | 83.0%@1.0uM | | |
| B-1103 | 0.094uM | 90.0%@1.0uM | | |
| B-1104 | 0.12uM | 69.0%@1.0uM | | |
| B-1105 | <0.1uM | 84.0%@1.0uM | | |
| B-1106 | <0.1uM | 86.0%@1.0uM | | |
| B-1107 | 0.057uM | 84.0%@1.0uM | | |
| B-1108 | 0.22uM | 81.0%@1.0uM | | |
| B-1109 | 0.054uM | 80.0%@1.0uM | | |
| B-1110 | 0.47uM | 64.0%@1.0uM | | |
| B-1111 | 0.19uM | 64.0%@1.0uM | | |
| B-1112 | 0.58uM | 43.0%@1.0uM | | |
| B-1113 | <0.1uM | 72.0%@1.0uM | | |
| B-1114 | 0.069uM | 51.0%@1.0uM | | |
| B-1115 | 0.024uM | 89.0%@1.0uM | | |
| B-1116 | 0.41uM | 81.0%@1.0uM | | |
| B-1117 | 0.13uM | 73.0%@1.0uM | | |
| B-1118 | 0.33uM | 91.0%@1.0uM | | |
| B-1119 | 0.35uM | 80.0%@1.0uM | | |
| B-1120 | 0.47uM | 9.0%@1.0uM | | |
| B-1121 | 3.58uM | 29.0%@1.0uM | | |
| B-1122 | 1.84uM | 32.0%@1.0uM | | |
| B-1123 | 2.93uM | 27.0%@1.0uM | | |
| B-1124 | 1.49uM | 52.0%@1.0uM | | |
| B-1125 | 0.56uM | 41.0%@1.0uM | | |
| B-1126 | 1.5uM | >1.0uM | | |
| B-1127 | 0.71uM | 7.0%@1.0uM | | |
| B-1128 | 2.55uM | 26.0%@1.0uM | | |
| B-1129 | 1.07uM | 46.0%@1.0uM | | |
| B-1130 | 0.5uM | 29.0%@1.0uM | | |
| B-1131 | 0.076uM | 34.0%@1.0uM | | |
| B-1132 | 0.72uM | 11.0%@1.0uM | | |
| B-1133 | 0.38uM | 33.0%@1.0uM | | |
| B-1134 | 1.71uM | 33.0%@1.0uM | | |
| B-1135 | 0.23uM | 38.0%@1.0uM | | |
| B-1136 | 1.17uM | 40.0%@1.0uM | | |
| B-1137 | 0.038uM | 35.0%@1.0uM | | |

100430 03/2007

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1138 | 1.82uM | >1.0uM | | |
| B-1139 | 0.041uM | 29.0%@1.0uM | | |
| B-1140 | 1.68uM | 39.0%@1.0uM | | |
| B-1141 | 2.47uM | 32.0%@1.0uM | | |
| B-1142 | 0.11uM | 37.0%@1.0uM | | |
| B-1143 | 0.17uM | 40.0%@1.0uM | | |
| B-1144 | 0.44uM | 72.0%@1.0uM | | |
| B-1145 | 1.07uM | 71.0%@1.0uM | | |
| B-1146 | 0.47uM | 61.0%@1.0uM | | |
| B-1147 | 0.095uM | 53.0%@1.0uM | | |
| B-1148 | 0.43uM | 61.0%@1.0uM | | |
| B-1149 | 1.55uM | 48.0%@1.0uM | | |
| B-1150 | 0.47uM | 75.0%@1.0uM | | |
| B-1151 | 0.32uM | 72.0%@1.0uM | | |
| B-1152 | 0.73uM | 53.0%@1.0uM | | |
| B-1153 | 2.22uM | 52.0%@1.0uM | | |
| B-1154 | 0.085uM | 46.0%@1.0uM | | |
| B-1155 | 3.22uM | 30.0%@1.0uM | | |
| B-1156 | 0.27uM | 78.0%@1.0uM | | |
| B-1157 | 0.26uM | 66.0%@1.0uM | | |
| B-1158 | 74.0%@1.0uM | 0.68uM | 53.0%@30mpk@-6h | |
| B-1159 | 66.0%@1.0uM | 1.03uM | 60.0%@30mpk@-6h | |
| B-1160 | 79.0%@1.0uM | 0.38uM | | |
| B-1161 | 64.0%21.0uM | 0.93uM | 40.0%@30mpk@-6h | 45.0%@3mpk@-4h |
| B-1162 | 79.0%@1.0uM | 0.59uM | 40.0%@30mpk@-6h | |
| B-1163 | 74.0%@1.0uM | 0.37uM | | |
| B-1164 | - | 0.35uM | | |
| B-1165 | 66.0%@1.0uM | 0.99uM | | |
| B-1166 | 77.0%@1.0uM | 0.39uM | 50.0%@30mpk@-6h | 50.0%@3mpk@-4h |
| B-1167 | 70.0%@1.0uM | 1.06uM | | |
| B-1168 | 66.0%@1.0uM | 0.63uM | | |
| B-1169 | 80.0%@1.0uM | 0.11uM | | |
| B-1170 | 82.0%@1.0uM | 0.57uM | | |
| B-1171 | 78.0%@1.0uM | 0.23uM | | |
| B-1172 | 68.0%@1.0uM | 1.95uM | | |
| B-1173 | 65.0%@1.0uM | 62.0%@1.0uM | | |
| B-1174 | 80.0%@1.0uM | 0.86uM | | |
| B-1175 | 72.0%@1.0uM | 1.83uM | | |
| B-1176 | 67.0%@1.0uM | 67.0%@1.0uM | | |
| B-1177 | 70.0%@1.0uM | 1.16uM | | |
| B-1178 | 92.0%@1.0uM | 1.61uM | | |
| B-1179 | 86.0%@1.0uM | 0.41uM | | |
| B-1180 | 78.0%@1.0uM | 0.53uM | | |
| B-1181 | 79.0%@1.0uM | 66.0%@1.0uM | | |
| B-1182 | 72.0%@1.0uM | 0.65uM | | |
| B-1183 | 77.0%@1.0uM | 0.2uM | | |
| B-1184 | 69.0%@1.0uM | 0.63uM | | |
| B-1185 | 71.0%@1.0uM | 0.79uM | | |
| B-1186 | 83.0%@1.0uM | 60.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1187 | 76.0%@1.0uM | 1.89uM | | |
| B-1188 | - | 36.0%@1.0uM | | |
| B-1189 | 68.0%@1.0uM | 0.83uM | | |
| B-1190 | 78.0%@1.0uM | 62.0%@1.0uM | | |
| B-1191 | 74.0%@1.0uM | 57.0%@1.0uM | | |
| B-1192 | 84.0%@1.0uM | 0.47uM | | |
| B-1193 | 69.0%@1.0uM | 65.0%@1.0uM | | |
| B-1194 | 87.0%@1.0uM | 0.58uM | | |
| B-1195 | 52.0%@1.0uM | 60.0%@1.0uM | | |
| B-1196 | 74.0%@1.0uM | 68.0%@1.0uM | | |
| B-1197 | 77.0%@1.0uM | 45.0%@1.0uM | | |
| B-1198 | 92.0%@1.0uM | 0.46uM | | |
| B-1199 | 87.0%@1.0uM | 49.0%@1.0uM | | |
| B-1200 | 95.0%@1.0uM | 0.64uM | | |
| B-1201 | 84.0%@1.0uM | 0.51uM | | |
| B-1202 | 71.0%@1.0uM | 58.0%@1.0uM | | |
| B-1203 | 84.0%@1.0uM | 58.0%@1.0uM | | |
| B-1204 | 68.0%@1.0uM | 59.0%@1.0uM | | |
| B-1205 | 74.0%@1.0uM | 46.0%@1.0uM | | |
| B-1206 | 81.0%@1.0uM | 0.34uM | | |
| B-1207 | 90.0%@1.0uM | 58.0%@1.0uM | | |
| B-1208 | 82.0%@1.0uM | 51.0%@1.0uM | | |
| B-1209 | 86.0%@1.0uM | 55.0%@1.0uM | | |
| B-1210 | 82.0%@1.0uM | 57.0%@1.0uM | | |
| B-1211 | 88.0%@1.0uM | 59.0%@1.0uM | | |
| B-1212 | 90.0%@1.0uM | 57.0%@1.0uM | | |
| B-1213 | 84.0%@1.0uM | 0.62uM | | |
| B-1214 | 76.0%@1.0uM | 58.0%@1.0uM | | |
| B-1215 | 86.0%@1.0uM | 0.23uM | | |
| B-1216 | 88.0%@1.0uM | 0.18uM | | |
| B-1217 | 87.0%@1.0uM | 0.46uM | | |
| B-1218 | 88.0%@1.0uM | 76.0%@1.0uM | | |
| B-1219 | 85.0%@1.0uM | 37.0%@1.0uM | | |
| B-1220 | 81.0%@1.0uM | 53.0%@1.0uM | | |
| B-1221 | 82.0%@1.0uM | 44.0%@1.0uM | | |
| B-1222 | 65.0%@1.0uM | 9.0%@1.0uM | | |
| B-1223 | 80.0%@1.0uM | 61.0%@1.0uM | | |
| B-1224 | 82.0%@1.0uM | 74.0%@1.0uM | | |
| B-1225 | 89.0%@1.0uM | 73.0%@1.0uM | | |
| B-1226 | 89.0%@1.0uM | 0.18uM | | |
| B-1227 | 83.0%@1.0uM | 0.22uM | | |
| B-1228 | 90.0%@1.0uM | 0.72uM | | |
| B-1229 | 87.0%@1.0uM | 0.65uM | | |
| B-1230 | 90.0%@1.0uM | 0.25uM | | |
| B-1231 | 94.0%@1.0uM | 0.56uM | | |
| B-1232 | 81.0%@1.0uM | 54.0%@1.0uM | | |
| B-1233 | 85.0%@1.0uM | 0.36uM | | |
| B-1234 | 89.0%@1.0uM | 0.49uM | | |
| B-1235 | 0.04uM | 76.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1236 | 0.1uM | 53.0%@1.0uM | | |
| B-1237 | 0.22uM | 39.0%@1.0uM | | |
| B-1238 | 0.14uM | 16.0%@1.0uM | | |
| B-1239 | <0.1uM | 38.0%@1.0uM | | |
| B-1240 | <0.1uM | 59.0%@1.0uM | | |
| B-1241 | 0.04uM | 81.0%@1.0uM | | |
| B-1242 | 0.08uM | 83.0%@1.0uM | | |
| B-1243 | 0.04uM | 47.0%@1.0uM | | |
| B-1244 | 0.26uM | 44.0%@1.0uM | | |
| B-1245 | 0.49uM | 42.0%@1.0uM | | |
| B-1246 | 0.27uM | 40.0%@1.0uM | | |
| B-1247 | <0.1uM | 58.0%@1.0uM | | |
| B-1248 | <0.1uM | 68.0%@1.0uM | | |
| B-1249 | 0.24uM | 60.0%@1.0uM | | |
| B-1250 | 0.14uM | 18.0%@1.0uM | | |
| B-1251 | 0.41uM | 38.0%@1.0uM | | |
| B-1252 | 0.17uM | 46.0%@1.0uM | | |
| B-1253 | 0.15uM | 57.0%@1.0uM | | |
| B-1254 | 0.16uM | 68.0%@1.0uM | | |
| B-1255 | 12.9uM | 75.0%@1.0uM | | |
| B-1256 | 0.12uM | 41.0%@1.0uM | | |
| B-1257 | 1.48uM | 40.0%@1.0uM | | |
| B-1258 | 0.07uM | 56.0%@1.0uM | | |
| B-1259 | <0.1uM | 0.48uM | | |
| B-1260 | 0.11uM | 48.0%@1.0uM | | |
| B-1261 | 0.74uM | 44.0%@1.0uM | | |
| B-1262 | <0.1uM | 63.0%@1.0uM | | |
| B-1263 | 1.05uM | 57.0%@1.0uM | | |
| B-1264 | 0.32uM | 47.0%@1.0uM | | |
| B-1265 | 0.43uM | 51.0%@1.0uM | | |
| B-1266 | <0.1uM | 58.0%@1.0uM | | |
| B-1267 | <0.1uM | 73.0%@1.0uM | | |
| B-1268 | <0.1uM | 79.0%@1.0uM | | |
| B-1269 | 0.46uM | 84.0%@1.0uM | | |
| B-1270 | 0.47uM | 83.0%@1.0uM | | |
| B-1271 | 0.13uM | 74.0%@1.0uM | | |
| B-1272 | 0.014uM | 38.0%@1.0uM | | |
| B-1273 | <0.1uM | 36.0%@1.0uM | | |
| B-1274 | <0.1uM | 41.0%@1.0uM | | |
| B-1275 | <0.1uM | 50.0%@1.0uM | | |
| B-1276 | 0.062uM | 11.0%@1.0uM | | |
| B-1277 | <0.1uM | 47.0%@1.0uM | | |
| B-1278 | 0.12uM | 85.0%@1.0uM | | |
| B-1279 | <0.1uM | 79.0%@1.0uM | | |
| B-1280 | 0.039uM | 83.0%@1.0uM | | |
| B-1281 | <0.1uM | 85.0%@1.0uM | | |
| B-1282 | <0.1uM | 75.0%@1.0uM | | |
| B-1283 | <0.1uM | 64.0%@1.0uM | | |
| B-1284 | <0.1uM | 75.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1285 | 0.057uM | 80.0%@1.0uM | | |
| B-1286 | 0.15uM | 78.0%@1.0uM | | |
| B-1287 | 0.25uM | 55.0%@1.0uM | | |
| B-1288 | 0.15uM | 74.0%@1.0uM | | |
| B-1289 | 0.73uM | 35.0%@1.0uM | | |
| B-1290 | 0.26uM | 75.0%@1.0uM | | |
| B-1291 | 0.097uM | 55.0%@1.0uM | | |
| B-1292 | 0.01uM | 74.0%@1.0uM | | |
| B-1293 | 0.31uM | 48.0%@1.0uM | | |
| B-1294 | 0.013uM | 54.0%@1.0uM | | |
| B-1295 | 0.079uM | 74.0%@1.0uM | | |
| B-1296 | 0.038uM | 48.0%@1.0uM | | |
| B-1297 | 0.02uM | >1.0uM | | |
| B-1298 | 0.055uM | 20.0%@1.0uM | | |
| B-1299 | 0.091uM | >1.0uM | | |
| B-1300 | 0.071uM | 18.0%@1.0uM | | |
| B-1301 | 0.12uM | 15.0%@1.0uM | | |
| B-1302 | 0.023uM | 11.0%@1.0uM | | |
| B-1303 | 0.08uM | >1.0uM | | |
| B-1304 | 0.11uM | 10.0%@1.0uM | | |
| B-1305 | 0.64uM | 9.0%@1.0uM | | |
| B-1306 | 0.11uM | >1.0uM | | |
| B-1307 | 0.009uM | 16.0%@1.0uM | | |
| B-1308 | <0.1uM | >1.0uM | | |
| B-1309 | 0.045uM | >1.0uM | | |
| B-1310 | 0.12uM | 11.0%@1.0uM | | |
| B-1311 | 0.05uM | 57.0%@1.0uM | | |
| B-1312 | 0.35uM | >1.0uM | | |
| B-1313 | 0.035uM | 37.0%@1.0uM | | |
| B-1314 | 0.045uM | 24.0%@1.0uM | | |
| B-1315 | 0.055uM | 12.0%@1.0uM | | |
| B-1316 | 0.026uM | 36.0%@1.0uM | | |
| B-1317 | 0.019uM | 9.0%@1.0uM | | |
| B-1318 | <0.1uM | 1.0%@1.0uM | | |
| B-1319 | 0.24uM | >1.0uM | | |
| B-1320 | 0.047uM | 43.0%@1.0uM | | |
| B-1321 | 0.47uM | 66.0%@1.0uM | | |
| B-1322 | 0.12uM | 87.0%@1.0uM | | |
| B-1323 | 0.013uM | 85.0%@1.0uM | | |
| B-1324 | 0.16uM | 83.0%@1.0uM | | |
| B-1325 | 0.27uM | 95.0%@1.0uM | | |
| B-1326 | 0.092uM | 84.0%@1.0uM | | |
| B-1327 | 0.13uM | 65.0%@1.0uM | | |
| B-1328 | 0.032uM | 86.0%@1.0uM | | |
| B-1329 | 0.66uM | 54.0%@1.0uM | | |
| B-1330 | 0.053uM | 85.0%@1.0uM | | |
| B-1331 | 0.004uM | 85.0%@1.0uM | | |
| B-1332 | 0.007uM | 81.0%@1.0uM | | |
| B-1333 | 0.45uM | 76.0%@1.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1334 | 0.13uM | 73.0%@1.0uM | | |
| B-1335 | 0.097uM | 63.0%@1.0uM | | |
| B-1336 | 0.072uM | 83.0%@1.0uM | | |
| B-1337 | 0.4uM | 90.0%@1.0uM | | |
| B-1338 | 0.18uM | 73.0%@1.0uM | | |
| B-1339 | 0.12uM | 67.0%@1.0uM | | |
| B-1340 | 0.043uM | 63.0%@1.0uM | | |
| B-1341 | 0.42uM | 52.0%@1.0uM | | |
| B-1342 | 0.25uM | 59.0%@1.0uM | | |
| B-1343 | 0.065uM | 83.0%@1.0uM | | |
| B-1344 | 0.014uM | 86.0%@1.0uM | | |
| B-1345 | 0.27uM | 73.0%@1.0uM | | |
| B-1346 | 0.043uM | 86.0%@1.0uM | | |
| B-1347 | 0.021uM | 84.0%@1.0uM | | |
| B-1348 | 0.009uM | 69.0%@1.0uM | | |
| B-1349 | 0.037uM | 86.0%@1.0uM | | |
| B-1350 | 0.019uM | 78.0%@1.0uM | | |
| B-1351 | 0.068uM | 78.0%@1.0uM | | |
| B-1352 | 0.013uM | 76.0%@1.0uM | | |
| B-1353 | 0.062uM | 80.0%@1.0uM | | |
| B-1354 | 0.013uM | 83.0%@1.0uM | | |
| B-1355 | 0.07uM | 75.0%@1.0uM | | |
| B-1356 | 0.059uM | 91.0%@1.0uM | | |
| B-1357 | 0.18uM | 84.0%@1.0uM | | |
| B-1358 | 0.16uM | 76.0%@1.0uM | | |
| B-1359 | 0.005 | 84.0%@1.0uM | | |
| B-1360 | 0.11 | 0.15uM | | 54%@3mpk@-4h |
| B-1361 | 0.03 | 0.29uM | | |
| B-1362 | 0.003 | 0.29uM | | |
| B-1363 | 0.009 | 0.28uM | 51.0%@30pmk @-6H | 53%@3mpk@-4h |
| B-1364 | 0.009 | 0.27uM | 53.0%@30mpk@-6.0H | 17%@3mpk@-4h |
| B-1365 | 0.17 | 88.0%@1.0uM | | |
| B-1366 | 0.04 | 0.27uM | | |
| B-1367 | <0.1 | 0.22uM | | |
| B-1368 | 0.031 | 0.33uM | 44.0%@30mpk @- | |
| B-1369 | <0.1 | 0.29uM | | |
| B-1370 | <0.1 | 0.77uM | | |
| B-1371 | 0.06 | 83.0%@1.0uM | | |
| B-1372 | <0.1 | 0.41uM | 48.0%@30mpk @- | |
| B-1373 | 0.016 | 0.17uM | | |
| B-1374 | <0.1 | 0.28uM | | |
| B-1375 | 0.01 | 0.25uM | | |
| B-1376 | 0.009 | 0.26uM | 3.0%@30mpk @-6H | |
| B-1377 | 0.12 | 5.0uM | | |
| B-1378 | 0.02 | 1.04uM | | |
| B-1379 | <0.1 | 0.092uM | | |
| B-1380 | <0.1 | 0.26uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1381 | 0.055 | 0.73uM | | |
| B-1382 | <0.1 | 0.44uM | | |
| B-1383 | 0.0012 | 0.15uM | | |
| B-1384 | 0.57 | 0.37uM | | |
| B-1385 | <0.1 | 0.11uM | | |
| B-1386 | <0.1 | 0.25uM | | |
| B-1387 | <0.1 | 0.1uM | | |
| B-1388 | 0.57 | 1.38uM | | |
| B-1389 | 0.06 | 0.57uM | | |
| B-1390 | <0.1 | 71.0%@1.0uM | | |
| B-1391 | 0.016uM | 82.0%@1.0uM | | |
| B-1392 | 0.059uM | 82.0%@1.0uM | | |
| B-1393 | 3.17uM | 80.0%@1.0uM | | |
| B-1394 | 0.32uM | 78.0%@1.0uM | | |
| B-1395 | 1.48 | 61.0%@1.0uM | | |
| B-1396 | 1.55 | 73.0%@1.0uM | | |
| B-1397 | 0.92 | 85.0%@1.0uM | | |
| B-1398 | 0.67 | 83.0%@1.0uM | | |
| B-1399 | 0.14 | 74.0%@1.0uM | | |
| B-1400 | 0.024 | 83.0%@1.0uM | | |
| B-1401 | 0.033 | 75.0%@1.0uM | | |
| B-1402 | 0.12 | 76.0%@1.0uM | | |
| B-1403 | 4.54 | 71%@1.0uM | | |
| B-1404 | 0.6 | 70%@1.0uM | | |
| B-1405 | 0.28 | 70%@1.0uM | | |
| B-1406 | 1.39 | 56.0%@1.0uM | | |
| B-1407 | 0.4 | 71.0%@1.0uM | | |
| B-1408 | 0.27 | 69.0%@1.0uM | | |
| B-1409 | <0.1 | 72.0%@1.0uM | | |
| B-1410 | <0.1 | 69%@1.0uM | | |
| B-1411 | <0.1 | 81.0%@1.0uM | | |
| B-1412 | 0.097 | 80.0%@1.0uM | | |
| B-1413 | 0.016 | 78.0%@1.0uM | | |
| B-1414 | 0.025 | 83.0%@1.0uM | | |
| B-1415 | 1.41 | 79.0%@1.0uM | | |
| B-1416 | 0.14 | 81.0%@1.0uM | | |
| B-1417 | 0.069 | 69.0%@1.0uM | | |
| B-1418 | 1.01 | 82.0%@1.0uM | | |
| B-1419 | 0.3 | 84.0%@1.0uM | | |
| B-1420 | <0.1 | 82.0%@1.0uM | | |
| B-1421 | 0.014 | 75.0%@1.0uM | | |
| B-1422 | 0.58 | 68.0%@1.0uM | | |
| B-1423 | 1.58 | 84.0%@1.0uM | | |
| B-1424 | 0.86 | 76.0%@1.0uM | | |
| B-1425 | 0.09 | 83.0%@1.0uM | | |
| B-1426 | 0.19 | 80.0%@1.0uM | | |
| B-1427 | <0.1 | 84.0%@1.0uM | | |
| B-1428 | <0.1 | 86.0%@1.0uM | | |
| B-1429 | <0.1 | 87.0%@1.0uM | | |

FOUO = CONFIDENTIAL

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-1430 | 0.75uM | 35.0% @1.0uM | | |
| B-1431 | 0.36uM | 58.0% @1.0uM | | |
| B-1432 | 0.11uM | 51.0% @1.0uM | | |
| B-1433 | 0.26uM | 21.0% @1.0uM | | |
| B-1434 | 0.19uM | 28.0% @1.0uM | | |
| B-1435 | 1.8uM | 45.0% @1.0uM | | |
| B-1436 | 1.0uM | 20.0% @1.0uM | | |
| B-1437 | 0.3uM | 23.0% @1.0uM | | |
| B-1438 | 2.01uM | 27.0% @1.0uM | | |
| B-1439 | 1.7uM | 17.0% @1.0uM | | |
| B-1440 | 0.87uM | 3.0% @1.0uM | | |
| B-1441 | 1.95uM | 66.0% @1.0uM | | |
| B-1442 | 1.54uM | 18.0% @1.0uM | | |
| B-1443 | 0.014uM | 83.0% @1.0uM | | |
| B-1444 | 0.3uM | 24.0% @1.0uM | | |
| B-1445 | 0.43uM | 27.0% @1.0uM | | |
| B-1446 | 0.77uM | 36.0% @1.0uM | | |
| B-1447 | 0.5uM | 34.0% @1.0uM | | |
| B-1448 | 1.43uM | 22.0% @1.0uM | | |
| B-1449 | 1.61uM | 50.0% @1.0uM | | |
| B-1450 | 2.1uM | 49.0% @1.0uM | | |
| B-1451 | 2.88uM | 50% @1.0uM | | |
| B-1452 | 2.41uM | 47.0% @1.0uM | | |
| B-1453 | 2.53uM | 49.0% @1.0uM | | |
| B-1454 | 1.6uM | 12.0% @1.0uM | | |
| B-1455 | 1.21uM | 8.0% @1.0uM | | |
| B-1456 | 1.29uM | >1.0uM | | |
| B-1457 | 0.43uM | 43.0% @1.0uM | | |
| B-1458 | 0.95uM | 65.0% @1.0uM | | |
| B-1459 | 0.67uM | 46.0% @1.0uM | | |
| B-1460 | 0.96uM | 29.0% @1.0uM | | |
| B-1461 | 0.4uM | 39.0% @1.0uM | | |
| B-1462 | 0.22uM | 50.0% @1.0uM | | |
| B-1463 | 2.34uM | 26.0% @1.0uM | | |
| B-1464 | 1.18uM | 27.0% @1.0uM | | |
| B-1465 | 3.23uM | 31.0% @1.0uM | | |
| B-1466 | 1.69uM | >1.0uM | | |
| B-1467 | 1.22uM | 1.0% @1.0uM | | |
| B-1468 | 1.61uM | 10.0% @1.0uM | | |
| B-1469 | 0.37uM | 14.0% @1.0uM | | |
| B-1470 | 0.6uM | 28.0% @1.0uM | | |
| B-1471 | 0.85uM | 25.0% @1.0uM | | |
| B-1472 | 0.93uM | 12.0% @1.0uM | | |
| B-1473 | 1.24uM | 14.0% @1.0uM | | |
| B-1474 | 1.23uM | 31.0% @1.0uM | | |
| B-1475 | 2.1uM | 24.0% @1.0uM | | |
| B-1476 | 0.047uM | 42.0% @1.0uM | | |
| B-1477 | 2.5uM | 34.0% @1.0uM | | |
| B-1478 | | | | |

| | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| Example# | | | | |
| B-1479 | | | | |

1002180:100201

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-2270 | 0.72uM | 31%@10.0uM | | |
| B-2271 | 0.93uM | 38%@10.0uM | | |
| B-2272 | 0.26uM | 53.0%@10.0uM | | |
| B-2273 | 1.92uM | 39.0%@10.0uM | | |
| B-2274 | 0.26uM | 59.0%@10.0uM | | |
| B-2275 | 2.16uM | 53.0%@10.0uM | | |
| B-2276 | 11.5uM | 37.0%@10.0uM | | |
| B-2277 | 14.9uM | 44.0%@10.0uM | | |
| B-2278 | 0.8uM | 51.0%@10.0uM | | |
| B-2279 | 0.32uM | 36.0%@10.0uM | | |
| B-2280 | 0.4uM | 57.0%@10.0uM | | |
| B-2281 | 0.81uM | 60.0%@10.0uM | | |
| B-2282 | 0.91uM | 41.0%@10.0uM | | |
| B-2283 | 0.04uM | 53.0%@10.0uM | | |
| B-2284 | 4.61uM | 62.0%@10.0uM | | |
| B-2285 | 2.29uM | 49.0%@10.0uM | | |
| B-2286 | 0.017uM | 0.78uM | 25% @30mpk@-1h | |
| B-2287 | 2.56uM | 61.0%@10.0uM | | |
| B-2288 | 6.51uM | 46.0%@10.0uM | | |
| B-2289 | 3.0uM | 30.0%@10.0uM | | |
| B-2290 | 2.37uM | 59.0%@10.0uM | | |
| B-2291 | 0.019uM | 41%@10.0uM | | |
| B-2292 | 8.82uM | 57.0%@10.0uM | | |
| B-2293 | 2.11uM | 56.0%@10.0uM | | |
| B-2294 | 1.68uM | 50.0%@10.0uM | | |
| B-2295 | 1.79uM | 56.0%@10.0uM | | |
| B-2296 | 17.3uM | 63.0%@10.0uM | | |
| B-2297 | 3.59uM | 57.0%@10.0uM | | |
| B-2298 | 0.29uM | 4.22uM | | |
| B-2299 | 1.97uM | 62.0%@10.0uM | | |
| B-2300 | 0.07uM | 43.0%@10.0uM | | |
| B-2301 | 0.18uM | 44.0%@10.0uM | | |
| B-2302 | 1.0uM | 58.0%@1.0uM | | |
| B-2303 | 0.011uM | 54.0%@10.0uM | | |
| B-2304 | 1.41uM | 50.0%@10.0uM | | |
| B-2305 | 0.54uM | 60.0%@10.0uM | | |
| B-2306 | 5.88uM | 39.0%@10.0uM | | |
| B-2307 | 2.29uM | 69.0%@10.0uM | | |
| B-2308 | 0.66uM | 56.0%@10.0uM | | |
| B-2309 | 0.29uM | 47.0%@10.0uM | | |

1003450-120704

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-2310 | 0.12uM | 1.2uM | 50%@30mpk@-6h | |
| B-2311 | 7.18uM | 60.0%@10.0uM | | |
| B-2312 | 2.93uM | 43.0%@10.0uM | | |
| B-2313 | 42.3uM | 58.0%@10.0uM | | |
| B-2314 | 11.0uM | 66.0%@10.0uM | | |
| B-2315 | 0.49uM | 36.0%@10.0uM | | |
| B-2316 | 0.46uM | 58.0%@10.0uM | | |
| B-2317 | 1.0uM | 60.0%@10.0uM | | |
| B-2318 | 73.0%@10.0uM | 25.0%@10.0uM | | |
| B-2319 | 75.0%@10.0uM | 40.0%@10.0uM | | |
| B-2320 | 44.0%@10.0uM | 35.0%@10.0uM | | |
| B-2321 | 69.0%@10.0uM | 27.0%@10.0uM | | |
| B-2322 | 76.0%@10.0uM | 38.0%@10.0uM | | |
| B-2323 | 69.0%@10.0uM | 46.0%@10.0uM | | |
| B-2324 | 58.0%@10.0uM | 36.0%@10.0uM | | |
| B-2325 | 60.0%@10.0uM | 51.0%@10.0uM | | |
| B-2326 | 76.0%@10.0uM | 33.0%@10.0uM | | |
| B-2327 | 76.0%@10.0uM | 23.0%@10.0uM | | |
| B-2328 | 65.0%@10.0uM | 28.0%@10.0uM | | |
| B-2329 | 72.0%@10.0uM | 53.0%@10.0uM | | |
| B-2330 | 81.0%@10.0uM | 37.0%@10.0uM | | |
| B-2331 | 74.0%@10.0uM | 44.0%@10.0uM | | |
| B-2332 | 70.0%@10.0uM | 47.0%@10.0uM | | |
| B-2333 | 58.0%@10.0uM | 36.0%@10.0uM | | |
| B-2334 | 81.0%@10.0uM | 45.0%@10.0uM | | |
| B-2335 | 82.0%@10.0uM | 50.0%@10.0uM | | |
| B-2336 | 48.0%@10.0uM | 35.0%@10.0uM | | |
| B-2337 | 46.0%@10.0uM | 59.0%@10.0uM | | |
| B-2338 | 73.0%@10.0uM | 50.0%@10.0uM | | |
| B-2339 | 84.0%@10.0uM | >10.0uM | | |
| B-2340 | 35.0%@10.0uM | 12.0%@10.0uM | | |
| B-2341 | 75.0%@10.0uM | 50.0%@10.0uM | | |
| B-2342 | 83.0%@10.0uM | 46.0%@10.0uM | | |
| B-2343 | 43.0%@10.0uM | 27.0%@10.0uM | | |
| B-2344 | 71.0%@10.0uM | 50.0%@10.0uM | | |
| B-2345 | 64.0%@10.0uM | 38.0%@10.0uM | | |
| B-2346 | 45.0%@10.0uM | 48.0%@10.0uM | | |
| B-2347 | 49.0%@10.0uM | 50.0%@10.0uM | | |
| B-2348 | 76.0%@10.0uM | 48.0%@10.0uM | | |
| B-2349 | 75.0%@10.0uM | 27.0%@10.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-2350 | 38.0%@10.0uM | 56.0%@10.0uM | | |
| B-2351 | 77.0%@10.0uM | 1.0%@10.0uM | | |
| B-2352 | 37.0%@10.0uM | 19.0%@10.0uM | | |
| B-2353 | 38.0%@10.0uM | 33.0%@10.0uM | | |
| B-2354 | 65.0%@10.0uM | 25.0%@10.0uM | | |
| B-2355 | 84.0%@10.0uM | 50.0%@10.0uM | | |
| B-2356 | 77.0%@10.0uM | 45.0%@10.0uM | | |
| B-2357 | 47.0%@10.0uM | 41.0%@10.0uM | | |
| B-2358 | 17.0%@10.0uM | 52.0%@10.0uM | | |
| B-2359 | 76.0%@10.0uM | 35.0%@10.0uM | | |
| B-2360 | 45.0%@10.0uM | >10.0uM | | |
| B-2361 | 19.0%@10.0uM | 46.0%@10.0uM | | |
| B-2362 | 60%@100.0uM | 39.0%@10.0uM | | |
| B-2363 | 44.0%@10.0uM | 1.0%@10.0uM | | |
| B-2364 | 47.0%@10.0uM | 4.0%@10.0uM | | |
| B-2365 | 82.0%@10.0uM | 43.0%@10.0uM | | |
| B-2366 | 70.0%@10.0uM | 59.0%@10.0uM | | |
| B-2367 | 46.0%@10.0uM | 40.0%@1.0uM | | |
| B-2368 | 65.0%@10.0uM | 55.0%@10.0uM | | |
| B-2369 | 32.0%@10.0uM | >10.0uM | | |
| B-2370 | 73%@100.0uM | 20.0%@10.0uM | | |
| B-2371 | 54.0%@10.0uM | 36.0%@10.0uM | | |
| B-2372 | 55.0%@100.0uM | >10.0uM | | |
| B-2373 | 50.0%@100.0uM | 6%@10.0uM | | |
| B-2374 | 35.0%@10.0uM | 20.0%@10.0uM | | |
| B-2375 | 62.0%@100.0uM | >10.0uM | | |
| B-2376 | 32.0%@10.0uM | 17.0%@10.0uM | | |
| B-2377 | 34.0%@10.0uM | 17.0%@10.0uM | | |
| B-2378 | 48.0%@10.0uM | 61.0%@10.0uM | | |
| B-2379 | 73.0%@100.0uM | 45.0%@1.0uM | | |
| B-2380 | 81%@100.0uM | 53.0%@10.0uM | | |
| B-2381 | 68%@100.0uM | 2.0%@10.0uM | | |
| B-2382 | 51.0%@10.0uM | 24.0%@10.0uM | | |
| B-2383 | 63.0%@10.0uM | 35.0%@10.0uM | | |
| B-2384 | 49%@100.0uM | 10.0%@10.0uM | | |
| B-2385 | 79.0%@10.0uM | 19.0%@10.0uM | | |
| B-2386 | 38.0%@10.0uM | 19.0%@10.0uM | | |
| B-2387 | 50.0%@100.0uM | >10.0uM | | |
| B-2388 | 42.0%@10.0uM | 24.0%@10.0uM | | |
| B-2389 | 39.0%@10.0uM | 29.0%@10.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF Inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-2390 | 34.0% @ 10.0uM | 27.0% @ 1.0uM | | |
| B-2391 | 40.0% @ 10.0uM | 59.0% @ 10.0uM | | |
| B-2392 | 63.0% @ 10.0uM | 46.0% @ 10.0uM | | |
| B-2393 | 43.0% @ 10.0uM | >10.0uM | | |
| B-2394 | 37.0% @ 10.0uM | 22.0% @ 10.0uM | | |
| B-2395 | 32.0% @ 10.0uM | 28.0% @ 10.0uM | | |
| B-2396 | 75.0% @ 10.0uM | >10.0uM | | |
| B-2397 | 83.0% @ 10.0uM | 22.0% @ 10.0uM | | |
| B-2398 | 55% @ 100.0uM | 10.0% @ 10.0uM | | |
| B-2399 | 69.0% @ 10.0uM | 18.0% @ 10.0uM | | |
| B-2400 | 60.0% @ 10.0uM | 40.0% @ 10.0uM | | |
| B-2401 | 78.0% @ 10.0uM | 44.0% @ 10.0uM | | |
| B-2402 | 43.0% @ 10.0uM | 52.0% @ 10.0uM | | |
| B-2403 | 72% @ 100.0uM | 52.0% @ 10.0uM | | |
| B-2404 | 58% @ 100.0uM | 52.0% @ 10.0uM | | |
| B-2405 | 47% @ 100.0uM | >10.0uM | | |
| B-2406 | 45.0% @ 10.0uM | 24.0% @ 10.0uM | | |
| B-2407 | 47% @ 100.0uM | 27.0% @ 10.0uM | | |
| B-2408 | 39.0% @ 10.0uM | 10.0% @ 10.0uM | | |
| B-2409 | 78.0% @ 10.0uM | 26.0% @ 10.0uM | | |
| B-2410 | 33.0% @ 10.0uM | 32.0% @ 10.0uM | | |
| B-2411 | 26% @ 100.0uM | 13.0% @ 10.0uM | | |
| B-2412 | 40.0% @ 10.0uM | 31.0% @ 10.0uM | | |
| B-2413 | 75.0% @ 10.0uM | 37.0% @ 10.0uM | | |
| B-2414 | 86.0% @ 10.0uM | 38.0% @ 10.0uM | | |
| B-2415 | 94.0% @ 10.0uM | 50.0% @ 10.0uM | | |
| B-2416 | 85.0% @ 10.0uM | 43.0% @ 1.0uM | | |
| B-2417 | 83.0% @ 10.0uM | 18.0% @ 10.0uM | | |
| B-2418 | 88.0% @ 10.0uM | 34.0% @ 10.0uM | | |
| B-2419 | 86.0% @ 10.0uM | 66.0% @ 10.0uM | | |
| B-2420 | 70.0% @ 10.0uM | 34.0% @ 10.0uM | | |
| B-2421 | 89.0% @ 10.0uM | 38.0% @ 10.0uM | | |
| B-2422 | 90.0% @ 10.0uM | 17.0% @ 10.0uM | | |
| B-2423 | 85.0% @ 10.0uM | >10.0uM | | |
| B-2424 | 86.0% @ 10.0uM | 43.0% @ 10.0uM | | |
| B-2425 | 79.0% @ 10.0uM | 42.0% @ 10.0uM | | |
| B-2426 | 88.0% @ 10.0uM | 53.0% @ 10.0uM | | |
| B-2427 | 87.0% @ 10.0uM | 59.0% @ 10.0uM | | |
| B-2428 | 82.0% @ 10.0uM | 50.0% @ 10.0uM | | |
| B-2429 | 92.0% @ 10.0uM | 32.0% @ 10.0uM | | |

| Example# | P38 alpha kinase IC50,uM or % inhib@conc. (uM) | U937 Cell IC50,uM or % inhib@conc. (uM) | Mouse LPS Model % TNF inhib @ dose @predose time | Rat LPS Model % inhib @dose @predose time |
|----------|--|---|--|---|
| B-2430 | 90.0% @ 10.0uM | 61.0% @ 10.0uM | | |
| B-2431 | 85.0% @ 10.0uM | 68.0% @ 10.0uM | | |
| B-2432 | 86.0% @ 10.0uM | 40.0% @ 10.0uM | | |
| B-2433 | 94.0% @ 10.0uM | 84.0% @ 10.0uM | | |
| B-2434 | 92.0% @ 10.0uM | 63.0% @ 10.0uM | | |
| B-2435 | 84.0% @ 10.0uM | 4.0% @ 10.0uM | | |
| B-2436 | 80.0% @ 10.0uM | 54.0% @ 10.0uM | | |
| B-2437 | 82.0% @ 10.0uM | 41.0% @ 10.0uM | | |
| B-2438 | 75.0% @ 10.0uM | 40.0% @ 10.0uM | | |
| B-2439 | 81.0% @ 10.0uM | 44.0% @ 10.0uM | | |
| B-2440 | 77.0% @ 10.0uM | 78.0% @ 10.0uM | | |
| B-2441 | 86.0% @ 10.0uM | 46.0% @ 10.0uM | | |
| B-2442 | 86.0% @ 10.0uM | >10.0uM | | |
| B-2443 | 84.0% @ 10.0uM | 44.0% @ 10.0uM | | |
| B-2444 | 89.0% @ 10.0uM | 7.0% @ 10.0uM | | |
| B-2445 | 94.0% @ 10.0uM | 15.0% @ 10.0uM | | |
| B-2446 | 90.0% @ 10.0uM | 28.0% @ 10.0uM | | |
| B-2447 | 94.0% @ 10.0uM | >10.0uM | | |
| B-2448 | 75.0% @ 10.0uM | 30.0% @ 10.0uM | | |
| B-2449 | 86.0% @ 10.0uM | 42.0% @ 10.0uM | | |
| B-2450 | 87.0% @ 10.0uM | 46.0% @ 1.0uM | | |
| B-2451 | 87.0% @ 10.0uM | 45.0% @ 10.0uM | | |
| B-2452 | 89.0% @ 10.0uM | 33.0% @ 10.0uM | | |
| B-2453 | 91.0% @ 10.0uM | >10.0uM | | |
| B-2454 | 88.0% @ 10.0uM | 40.0% @ 10.0uM | | |
| B-2455 | 87.0% @ 10.0uM | 54.0% @ 10.0uM | | |
| B-2456 | 86.0% @ 10.0uM | 53.0% @ 10.0uM | | |
| B-2457 | 90.0% @ 10.0uM | 18.0% @ 10.0uM | | |
| B-2458 | 83.0% @ 10.0uM | 36.0% @ 10.0uM | | |
| B-2459 | 82.0% @ 10.0uM | 81.0% @ 10.0uM | | |
| B-2460 | 80.0% @ 10.0uM | 79.0% @ 10.0uM | | |
| B-2461 | 67.0% @ 10.0uM | 59.0% @ 10.0uM | | |
| | | | | |

FOUO - 08212001

Biological data from a number of compounds of Examples C-74 through C-139 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

"P38 alpha kinase IC50, μ M"

In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as:

"Human Whole Blood IC50, μ M or %Inhib@conc. (μ M)"

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

"Rat LPS Model % Inhibition@dose@predose time"

wherin the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

| Example# | P38 alpha kinase IC50, μ M | Human Whole Blood IC50, μ M or %Inhib@conc. (μ M) | Rat LPS Model % Inhibition@ dose@predose time |
|----------|-----------------------------------|--|--|
| C-74 | 0.037 | 0.56 | 54%@5mpk@-4h |
| C-75 | 0.045 | 0.4 | 71%@5mpk@-4h |
| C-76 | 0.07 | 3.24 | 66%@5mpk@-4h |
| C-77 | 0.071 | 8.2 | 92%@5mpk@-4h |
| C-78 | 0.068 | 10.5 | 87%@5mpk@-4h |
| C-79 | 0.045 | 0.52 | 83%@5mpk@-4h |

| Example# | P38 alpha kinase IC50, μ M | Human Whole Blood IC50, μ M or %Inhib@conc. (μ M) | Rat LPS Model % Inhibition@ dose@predose time |
|----------|-----------------------------------|--|--|
| C-80 | 0.008 | 51% @ 5 μ M | |
| C-81 | 0.037 | 40% @ 5 μ M | |
| C-82 | 0.15 | 7.31 | |
| C-83 | 0.24 | 1.23 | 25% @ 5mpk @ -4h |
| C-84 | 0.048 | 0.88 | 22% @ 5mpk @ -4h |
| C-85 | 0.57 | >25 | |
| C-86 | 0.007 | 0.19 | 66% @ 5mpk @ -4h |
| C-87 | 0.027 | 0.34 | |
| C-88 | 0.012 | 0.3 | 59% @ 5mpk @ -4h |
| C-89 | 0.039 | 0.12 | 27% @ 5mpk @ -4h |
| C-90 | 0.037 | 0.48 | |
| C-91 | 0.054 | 2.31 | 63% @ 5mpk @ -4h |
| C-92 | 0.024 | 0.28 | 66% @ 5mpk @ -4h |
| C-93 | 0.009 | 0.38 | 50% @ 5mpk @ -4h |
| C-94 | 0.02 | 0.27 | 73% @ 5mpk @ -4h |
| C-95 | 0.13 | 3.91 | 32% @ 5mpk @ -4h |
| C-96 | 0.077 | 2.1 | 38% @ 5mpk @ -4h |
| C-97 | 0.025 | 3.83 | 21% @ 5mpk @ -4h |
| C-98 | 0.016 | 0.64 | 78% @ 5mpk @ -4h |
| C-99 | 0.062 | 0.38 | 36% @ 5mpk @ -4h |
| C-100 | 0.027 | 0.27 | 44% @ 5mpk @ -4h |
| C-101 | 0.083 | 3.71 | 52% @ 5mpk @ -4h |
| C-102 | 0.29 | 7.56 | 72% @ 5mpk @ -4h |
| C-105 | 0.033 | 0.13 | 46% @ 5mpk @ -4h |
| C-106 | 0.026 | 0.44 | 23% @ 5mpk @ -4h |
| C-107 | 0.014 | 0.38 | 11% @ 5mpk @ -4h |
| C-108 | 0.02 | 0.73 | 0% @ 5mpk @ -4h |
| C-111 | 0.21 | 6.05 | 39% @ 5mpk @ -4h |
| C-112 | 0.54 | 6.36 | 89% @ 5mpk @ -4h |
| C-113 | 0.082 | 2.72 | 77% @ 5mpk @ -4h |
| C-114 | 0.11 | 1.73 | 39% @ 5mpk @ -4h |
| C-115 | 0.042 | 10.2 | 39% @ 5mpk @ -4h |
| C-116 | 0.429 | 0.50 | 53% @ 5mpk @ -4h |
| C-117 | 3.42 | 7.26 | 71% @ 5mpk @ -4h |
| C-118 | 0.298 | >25 | 39% @ 5mpk @ -4h |
| C-120 | 0.7 | 18.6 | 26% @ 5mpk @ -4h |
| C-121 | 0.11 | 15.3 | 39% @ 5mpk @ -4h |
| C-122 | 0.025 | | 55% @ 5mpk @ -4h |
| C-123 | 0.67 | >25.0 | |


| Example# | P38 alpha kinase IC50, μM | Human Whole Blood IC50, μM or %Inhib@conc. (μM) | Rat LPS Model % Inhibition@ dose@predose time |
|----------|---|---|--|
| C-124 | 0.17 | 4.56 | 51%@20mpk@-4h |
| C-125 | 7.22 | >25.0 | |
| C-126 | 0.71 | >25.0 | 6%@20mpk@-4h |
| C-127 | 0.038 | 0.27 | 53%@5mpk@-4h |
| C-128 | 0.09 | 2.22 | 63%@5mpk@-4h |
| C-132 | 0.086 | 44%@ 5 μM | |
| C-133 | 0.16 | 4.54 | 55%@5mpk@-4h |
| C-135 | 6.0 | | |
| C-136 | 0.032 | | |
| C-137 | 0.051 | | 58%@5mpk@-4h |
| C-138 | 0.28 | 0.68 | 26%@5mpk@-4h |
| C-139 | 0.2 | 3.66 | 46%@5mpk@-4h |

1004180-1004180

Additional compounds of interest can be prepared as set forth above and as described below in Scheme D-1, wherein the R_1 and R_2 substituents are as defined previously.

5

Scheme D-1



The synthesis begins with the treatment of 4-methylpyrimidine 2 with a base such as LiHMDS, LDA or tBuOK in an organic solvent such as THF or ether which is cooled in an ice bath (0-10 °C). To the resulting 4-methylanion is added a solution of a suitably protected (Boc is shown) ethyl ester of isonipecotic acid 1 in THF or ether. The reaction is allowed to warm to room


temperature and stirred for a period of 4 hours to 20 hours at which time the desired ketone 3 is isolated after aqueous work up. Condensation of the ketone 3 with tosylhydrazide in toluene or benzene as a solvent at
5 refluxing temperatures for a period of 1 hour to 5 hours affords the hydrazone 4. The hydrazone 4 is reacted with a suitably substituted benzoyl chloride 5, in the presence of a base such as LiHMDS or LDA or tBuOK or triethylamine at temperatures ranging from 0 °C to 70 °C. The reaction
10 is stirred for a period of 3-6 hours. Acidic hydrolysis of the protecting groups with an aqueous acid such as HCl or H₂SO₄ and subsequent neutralization with an aqueous base such as NaOH or KOH affords the desired pyrazole 6. Treatment of the pyrazole 6 with an acid chloride 7 in the
15 presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC or PyBrOP with an additive such as HOBT or HATU and base such as N-methylmorpholine or diisopropylethylamine or triethylamine) affords the desired pyrazole amide 9. In most instance the desired
20 products can be obtained pure by direct trituration with solvents such as methanol, ethyl acetate, acetonitrile or ether and/or recrystallization from suitable solvents.

The following examples contain detailed descriptions of the methods of preparation of these additional
25 compounds that form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistent with their assigned structures.


30

Example D-1

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole




5




Step 1: A 5 L 4-necked round bottom flask fitted
 10 with an overhead mechanical stirrer, N₂ inlet and a
 thermocouple was charged with 600 g (2.75 mol) of di-tert-
 butyl-dicarbonate and 1.5 L of CH₂Cl₂. The solution was
 cooled to 0 °C and 428 g (2.73 mol) of ethyl isonipecotate
 was added dropwise via an addition funnel. The addition
 15 took 45 minutes and the temperature rose from 0 °C to 17.4
 °C. The reaction mixture was stirred for an additional 2
 hours at ambient temperature. The solvent was removed *in*
vacuo to afford 725 g of a yellow oil (residual solvent
 remained).

20



Step 2: A 3 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂ inlet, an addition
 5 funnel and a thermocouple was charged with 1850 mL (1.85 mol) of a 1.0 M solution of LiHMDS in THF. The flask was cooled to 5 °C and 68 mL (0.74 mol) of 4-methylpyrimidine was added (neat) to the stirred solution. To this solution was added 198 g (0.77 mol) of Ethyl-N-t-
 10 butylcarboxyl isonipecotate dissolved in 160 mL of THF. The ice bath was removed and the reaction was allowed to stir for 18 hours. The reaction was quenched with 500 mL of saturated NH₄Cl and was extracted with 500 mL of ethyl acetate. The organic phase was washed with 500 mL of
 15 brine, dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford 235 g of a brown oil.




20 Step 3: A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a Dean-Stark trap and

a thermocouple was charged with 1.5 L of toluene, 226 g (0.742 mol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone and 138.4 g (0.743 mol) of tosyl hydrazide. The mixture was warmed to reflux. The solution was allowed to reflux for 2 hours and was cooled to ambient temperature. The reaction was allowed to stand overnight. A fine precipitate formed and was removed by filtration. The filtrate was concentrated *in vacuo* to afford a brown solid. The solid was suspended in 500 mL of ethyl acetate and the resulting mixture was placed in a sonication bath for 5 hours. The mixture was cooled in an ice bath and was filtered to afford 310 g of a wet solid. The solid was dried in a vacuum oven (40 °C, 5 mm) overnight to afford 248 g of the desired hydrazone (71%).


¹H NMR (CDCl₃) δ 9.03 (d, *J* = 1.2 Hz, 1H), 8.72 (d, *J* = 5.2 Hz, 2H), 7.89 (d, *J* = 8.3 Hz, 2H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.26 (dd, *J* = 5.2, 1.0 Hz, 1H), 4.03 (d, *J* = 12.1 Hz, 2H), 3.76 (s, 2H), 2.71 (t, *J* = 12.1 Hz, 2H), 2.43 (s, 3H), 2.34 (m, 1H), 1.66 (d, *J* = 13.5 Hz, 2H), 1.47 (s, 9H), 1.38 (m, 2H); MS (*M* + *H*): 474 (base peak).

Step 4:



Method A. A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂ inlet, an addition funnel and a thermocouple was charged with 400 mL (400 mmol) of a 1.0 M solution of LiHMDS in THF. The solution was cooled to -21.9 °C and a solution of 62 g (131 mmol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone p-toluenesulfonyl hydrazone in 400 mL of THF was added slowly. The temperature never exceeded -11 °C throughout the addition. The solution was re-cooled to -19.6 °C and 23.0 g (131 mmol in 250 mL of THF) of p-chlorobenzoylchloride was added slowly. The temperature never exceeded -13 °C throughout the addition. The cooling bath was removed and the reaction was allowed to warm to ambient temperature. After 3 hours the reaction was quenched with 600 mL of 3 N HCl. The reaction was warmed to reflux and was held at reflux for 2 hours. The reaction was allowed to cool to ambient temperature overnight. The reaction mixture was washed with 1.4 L of Et₂O and the aqueous phase was neutralized with 1 L of 2.5 N NaOH. The aqueous phase was extracted with ethyl acetate (2 x 1000 mL). The combined organic phases were washed with brine (1 x 500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford 21 g of a yellow solid. The solid was suspended in 500 mL of 2:1 Et₂O/hexane. After sonication the solid was isolated by filtration to leave a wet solid. The solid was dried in a vacuum oven to afford 13.8 g of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole. ¹H NMR (DMSO-d₆) 9.18 (s, 1H), 8.65 (d, J = 5.2, 1H), 7.44 (d, J = 8.5, 2H), 7.37 (d, J = 7.7 Hz, 2H), 7.15 (d,

$J = 5.2$ Hz, 1H), 3.16 (m, 1H), 3.00 (d, $J = 11.9$ Hz, 2H), 2.52 (m, 2H), 1.69 (m, 4H); MS ($M + H$): 340 (base peak).




5

Method B: To a solution of 200 g (423 mmol) of *N*-*t*-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone *p*-toluenesulfonyl hydrazone in 800 mL THF was added 70 mL (500 mmol) of triethylamine in a 3 L three necked flask. The solution was cooled in an ice/salt/water bath to 0-5 °C. To this cold solution was added a solution of 4-chlorobenzoyl chloride (74 g, 423 mmol) in 100 mL THF dropwise, maintaining the temperature below 10 °C. After the addition was complete the ice-bath was removed and replaced with a heating mantle. 4-*N*, *N*-dimethylaminopyridine (5 g, 40 mmol) was added and the reaction mixture was heated to 50 °C for 15-30 minutes. The reaction mixture was filtered and the residue washed

with THF (100 mL). The combined filtrates were evaporated under reduced pressure to a semisolid.

The semisolid residue was dissolved in 450 mL THF and 180 mL of 12 N HCl was added to this solution rapidly. The reaction mixture was heated to 65 °C for 1.5-2 hours and transferred to a separatory funnel. The organic layer was discarded and the aqueous phase was washed twice with 200 mL of THF. The aqueous phase was transferred back to a 2 L flask and cooled to 0-10 °C in an ice bath. The pH of the solution was adjusted to between ~ 9-10 by dropwise addition of 15 N ammonium hydroxide (~ 180 mL). This mixture was transferred back to a separatory funnel and extracted with warm n-butanol (3 X 150 mL). The combined n-butanol phases were evaporated under reduced pressure to dryness. The residue was then stirred with methanol (200 mL), filtered and dried to obtain 129 g (90%) of the desired 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole as a off-white solid. This material was identical in all respects to the material prepared by Method A.



Step 5: A 1 L round bottom flask was charged with 34.2 g (102 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole, 500 mL of CH₂Cl₂ and 26.6 mL (153 mmol) of Hunig's base. To this suspension was added 16.5

g (122 mmol) of 1-hydroxybenzotriazole and 8.1 g (106 mmol) of glycolic acid. The addition of glycolic acid was followed by the addition of 23.7 g (122 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.

5 The reaction was allowed to stir at ambient temperature overnight. The reaction was concentrated *in vacuo* to leave an oily residue. The residue was dissolved in 400 mL of methanol and 50 mL of 2.5 N NaOH. The reaction mixture was stirred at ambient temperature for 1 hour.

10 The mixture was acidified to pH 5 with 2 N HCl and was extracted with CH₂Cl₂ (6 x 200 mL). The combined organic phases were filtered through phase paper and the filtrate was concentrated *in vacuo* to leave a yellow residue. The residue was treated with 75 mL of acetonitrile. A


15 precipitate formed. The solid was filtered and washed with additional acetonitrile and Et₂O to afford 31.4 g of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole. ¹H NMR (DMSO-d₆) 9.20 (s, 1H), 8.67 (d, *J* = 4.8, 1H), 7.40 (m, 4H), 7.17 (d, *J* = 4.0, 1H), 4.53 (m, 2H), 4.13 (s, 2H), 3.77 (m, 1H), 3.05 (t, *J* = 12.7 Hz, 1H), 2.69 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H); MS (M + H): 398 (base peak).

20

Example D-2

25

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride




A 25 mL round bottom flask was charged with 65 mg
 5 (0.164 mmol) of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-
 pyrimidyl)-3-(4-chlorophenyl) pyrazole and 2.5 mL of
 dioxane. To this suspension was added 0.082 mL of 4 N HCl
 in dioxane. The mixture was stirred for 2 hours. The
 mixture was diluted with 5 mL of Et₂O and filtered. The
 10 solid was dried over solid CaSO₄ under vacuum for 12 h to
 afford 68 mg of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-
 pyrimidyl)-3-(4-chlorophenyl) pyrazole hydrochloride. ¹H
 NMR (DMSO-d₆) 9.18(s, 1H), 8.63(d, J=5.37 Hz, 1H),
 7.40(d, J=8.59 Hz, 2H), 7.33(d, J=8.59 Hz, 2H), 7.15(m,
 15 1H), 4.40(m, 1H), 4.06(m, 2H), 3.72(m, 1H), 3.33(m, 1H),
 2.97(m, 1H), 2.62(m, 1H), 1.83(m, 2H), 1.64(m, 2H); MS
 (M+H): 398

Example D-3

20

N-(2-Methoxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-
 chlorophenyl)pyrazole (fumarate salt)




To a suspension of 250 mg (0.74 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-1, Step 3) and 180 mg (1.48 mmol) of N,N-dimethylamino pyridine in 20 mL of CH_2Cl_2 , was added 88 mg (0.81 mmol) of 2-methoxyacetyl chloride. The reaction was stirred for 5 hours. The reaction was quenched with 20 mL of saturated NH_4Cl . The mixture was extracted with n-butyl alcohol and the organic layer was washed with brine. The solvent was removed to afford 72 mg of an oil. This oil was dissolved in 1 mL of warm MeOH. This solution was combined with a warm solution of 1 equivalent of fumaric acid in warm MeOH. The solution was cooled to ambient temperature and the reaction was allowed to stir for 1 hour. The solvent was removed *in vacuo* and the residue was triturated with Et_2O . The resulting solid was isolated by filtration to yield 56 mg of an off-white powder. ^1H NMR ($\text{DMSO}-d_6$) 13.23 (bs, 1H), 9.19 (d, J = 1.2 Hz, 1H), 8.65 (d, J = 5.1 Hz, 1H), 7.41 (m, 4H), 7.16 (dd, J = 5.4, 1.2 Hz, 1H), 4.45 (bd, J = 11.1 Hz, 1H), 4.11 (q_{AB} , J = 39.0, 13.8 Hz, 2H), 3.86 (bd, J = 12.9 Hz, 1H), 3.32 (m, 4H), 3.04 (bt, J = 12.3 Hz, 1H), 2.63 (bt, J = 12.0 Hz, 1H), 1.77 (m, 4H); MS ($M + H$): 411 (base peak).

Example D-4

N-(2-Hydroxy-2-methylpropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

5




Step 1: To a suspension of 2.05 g (6.1 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-1, Step 3) and 3.7 g (30.5 mmol) of N,N-dimethylamino pyridine in 30 mL of CH_2Cl_2 was added 1.06 mL (7.3 mmol) of 2-acetoxy-2-methylpropionyl chloride. The reaction was allowed to stir overnight at ambient temperature. The reaction was quenched with saturated NH_4Cl and water. The resulting aqueous phase was extracted with CH_2Cl_2 . The combined organic layers were concentrated in vacuo to leave an oily solid. The residue was treated with CH_3CN and allowed to stand for 15 minutes. The resulting suspension was diluted with Et2O and was filtered to afford 2.2 g of a solid. Analysis by LC/MS indicated that the solid was a mixture of the hydroxy derivative and the acetoxy derivative. This solid was carried on to the next step without further purification.

Step 2: A solution of 1 g of the solid from step 1 in 10 mL of MeOH was treated with 500 mg of solid K_2CO_3 . The mixture was allowed to stir overnight at ambient

temperature. The suspension was treated with water and the resulting solution was extracted with ethyl acetate. The organic phase was filtered through phase separation paper (to remove the residual water) and was concentrated in vacuo to leave an oily solid. The solid was dried under vacuum and was treated with CH₃CN. The suspension was filtered to afford 825 mg of an off-white solid. This solid was suspended in 5 mL of dioxane and 0.5 mL of 4 N HCl in dioxane was added. The suspension was stirred for 1 hour and the suspension was filtered to leave a solid. The solid was washed with Et₂O and the resulting suspension was filtered to give 900 mg of the title compound. ¹H NMR (DMSO-d₆) 9.23 (s, 1H), 8.69 (s, 1H), 7.45 (m, 4H), 7.19 (s, 1H), 4.8 (br m, 4H), 3.85 (m, 2H), 3.38 (m, 1H), 1.89 (m, 2H), 1.72 (m, 2H), 1.37 (s, 6H); MS (M + H): 426 (base peak).

Example D-5

(S)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride



By following the method of Example C-1 and substituting (S)-lactic acid for glycolic acid the title compound was prepared. ¹H NMR (DMSO-d₆) 13.15(s, br, 1H), 9.12(d, J=1.07 Hz, 1H), 8.59(d, J=5.37Hz, 1H),


7.39(d, $J=7.79\text{Hz}$, 2H), 7.31(d, $J=8.33$, 2H), 7.10(dd, $J=1.34$, 5.1Hz, 1H), 4.76(m, 1H), 4.41(m, 2H), 3.99(m, 1H), 2.97(m, 1H), 2.45(m, 1H), 1.83(m, 2H), 1.64(m, 2H), 1.15(m, 3H); MS (M+H): 412 (base peak).

5

Example D-6

(R)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

10




By following the method of Example C-1 and substituting (R)-lactic acid for glycolic acid the title compound was prepared. ^1H NMR (CDCl_3) 9.24(s, 1H), 8.52(d, $J = 5.0$ Hz, 1H), 7.32-7.36(m, 4H), 6.98(d, $J = 5.3$ Hz, 1H), 4.72(d, $J = 10.5$ Hz, 1H), 4.55(br, 1H), 3.88(d, $J = 13.1$ Hz, 1H), 3.66(br, 1H), 3.19(br, 1H), 2.82(t, $J = 12.4$ Hz, 1H), 2.10(br, 2H), 1.37(d, $J = 6.2$ Hz, 3H), 1.81-1.90(m, 2H); MS (M + H): 412 (base peak).

20

Example D-7

(R)-N-(2-Hydroxy-2-phenylacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole


25



By following the method of Example C-1 and substituting (R)-phenylacetic acid for glycolic acid the title compound was prepared. ¹H NMR (DMSO-d₆) 9.15 (d, *J* = 0.9 Hz, 1H), 8.63 (d, *J* = 5.4 Hz, 1H), 7.40 (m, 9H), 7.13 (t, *J* = 6.6 Hz, 1H), 5.43 (d, *J* = 19.5 Hz, 1H), 4.51 (s, 1H), 4.04 (m, 1H), 3.33 (m, 4H), 2.8 (m, 2H), 1.68 (m, 3H); MS (M + H): 474 (base peak).

Example D-8

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-fluorophenyl)pyrazole




By following the method of Example C-1 and substituting 4-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₂) 13.48 (s, 1H), 9.40 (s, 1H), 8.86 (d, *J* = 5.1 Hz, 1H), 7.71 (br, 2H), 7.42 (bd, *J* = 5.2 Hz, 3H), 4.78 (br, 1H), 4.43 (s, 2H), 4.04 (br, 1H), 3.79 (br, 1H), 3.70 (s, 1H),

3.34 (t, $J = 12.2$ Hz, 1H), 3.0 (br, 1H), 2.21 (d, $J = 10.9$ Hz, 2H), 2.08 (br, 1H); MS (M + H): 382 (base peak).

Example D-9

5

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethylphenyl)pyrazole




10

By following the method of Example C-1 and substituting 4-trifluoromethylbenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ^1H NMR (DMF- d_7) 13.47 (s, 1H), 9.24 (s, 1H), 8.73 (d, $J =$
 15 4.0 Hz, 1H), 7.77 (bd, $J = 13.3$ Hz, 4H), 7.34 (d, $J = 4.3$ Hz, 1H), 4.61 (br, 1H), 4.26 (s, 2H), 3.87 (br, 1H), 3.52 (s, 2H), 3.17 (t, $J = 12.0$ Hz, 1H), 2.8 (br, 1H), 2.02 (br, 2H), 1.91 (br, 1H); MS (M + H): 432 (base peak).

20

Example D-10


N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethoxyphenyl)pyrazole



By following the method of Example C-1 and substituting 4-trifluoromethoxybenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.55(s, 1H), 9.40(s, 1H), 8.88(d, J = 4.6 Hz, 1H), 7.81(d, J = 7.7 Hz, 2H), 7.64(br, 2H), 7.47(d, J = 4.4 Hz, 1H), 4.75(br, 1H), 4.42(s, 2H), 4.04(d, J = 12.5 Hz, 1H), 3.69(br, 2H), 3.34(t, J = 12.0 Hz, 1H), 3.0(br, 1H), 2.20(d, J = 11.7 Hz, 2H), 2.05(br, 1H); MS (M + H): 448 (base peak).

Example D-11

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(3-chlorophenyl)pyrazole



By following the method of Example C-1 and substituting 3-chlorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.41(s, 1H), 9.24(s, 1H), 8.73(d, J = 4.9 Hz, 1H), 7.56(s, 1H), 7.49(br, 2H), 7.41(br, 1H), 7.32(d, J = 4.2


Hz, 1H), 4.60(d, J = 11.7 Hz, 1H), 4.25(s, 2H), 3.87(d, J = 12.7 Hz, 1H), 3.52(bs, 2H), 3.17(t, J = 12.1 Hz, 1H), 2.84(d, J = 12.5 Hz, 1H), 2.03(d, J = 11.9 Hz, 2H), 1.87(br, 1H); MS ($M + H$): 398 (base peak).

5

Example D-12

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-fluorophenyl)pyrazole

10



By following the method of Example C-1 and substituting 3-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ^1H NMR (DMF-d_7)


13.38(s, 1H), 9.24(s, 1H), 8.72(d, J = 5.2 Hz, 1H), 7.49(dd, J = 8.0 and 6.2 Hz, 1H), 7.24-7.32(m, 4H), 4.60(d, J = 13.1 Hz, 1H), 4.25(s, 2H), 3.87(d, J = 13.3 Hz, 1H), 3.55-3.60(m, 1H), 3.52(s, 1H), 3.17(t, J = 12.2 Hz, 1H), 2.82(d, J = 12.9 Hz, 1H), 2.03(d, J = 10.9 Hz, 2H), 1.83-1.96(m, 1H); MS ($M + H$): 382 (base peak).

20

Example D-13

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-trifluoromethylphenyl)pyrazole

25




By following the method of Example C-1 and substituting 3-trifluoromethylbenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared.

¹H NMR (DMF-d₇) 13.76(s, 1H), 9.41(s, 1H), 8.91(d, *J* = 5.3 Hz, 1H), 8.02(s, 1H), 7.95(t, *J* = 6.5 Hz, 2H), 7.85(t, *J* = 7.5 Hz, 1H), 7.53(d, *J* = 4.6 Hz, 1H), 4.78(d, *J* = 11.9 Hz, 1H), 4.45(d, *J* = 16.3 Hz, 2H), 4.06(d, *J* = 12.5 Hz, 1H), 3.69(bs, 2H), 3.34(t, *J* = 11.3 Hz, 1H), 3.01(d, *J* = 13.1 Hz, 1H), 2.20(d, *J* = 11.1 Hz, 2H), 2.12(br, 1H); MS (M + H): 432 (base peak).

The following examples can be prepared in a manner similar to that described above for the synthesis of Examples C1-C13.

Example D-14


5-[4-*N*-(2-hydroxy-2-(2-chlorophenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole



Example D-15


5- [4-*N*- (2-hydroxy-2- (3-chlorophenyl) acetyl) piperidyl] -4-
 (4-pyrimidyl) -3- (4-chlorophenyl) pyrazole

5



Example D-16


10 5- [4-*N*- (1-hydroxy-1-cyclohexylacetyl) piperidyl] -4- (4-
 pyrimidyl) -3- (4-chlorophenyl) pyrazole



15

Example D-17


15 5- [4-*N*- (2-hydroxy-1-cyclohexylacetyl) piperidyl] -4- (4-
 pyrimidyl) -3- (4-chlorophenyl) pyrazole



20


Example D-18

5- [4-N- (3-hydroxy-1-cyclohexylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-19

5- [4-N- (4-hydroxy-1-cyclohexylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-20

5- [4-N- (1-hydroxy-1-cyclopentylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-21

5- [4-*N*- (2-hydroxy-1-cyclopentylacetyl)piperidyl] -4- (4-
 5 pyrimidyl) -3- (4-chlorophenyl)pyrazole



Example D-22


10 5- [4-*N*- (3-hydroxy-1-cyclopentylacetyl)piperidyl] -4- (4-
 10 pyrimidyl) -3- (4-chlorophenyl)pyrazole



15


Example D-23

20 5- [4-*N*- (3-hydroxypropionyl)piperidyl] -4- (4-pyrimidyl) -3-
 20 (4-chlorophenyl)pyrazole




Example D-24

5- [4-*N*- (2-hydroxy-3,3,3-trifluoropropionyl)piperidyl] -4-
 (4-pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-25

5- [4-*N*- (2-hydroxy-3-methylbutyryl)piperidyl] -4- (4-
 pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-26

5- [4-*N*- (2-hydroxyisocaproyl)piperidyl] -4- (4-pyrimidyl) -3-
 (4-chlorophenyl)pyrazole




Example D-27

5- [4-*N*- (2-hydroxy-2-cyclohexylacetyl)piperidyl] -4- (4-
 5 pyrimidyl) -3- (4-chlorophenyl)pyrazole



Example D-28

10 5- [4-*N*- (2-hydroxy-2- (4-methoxyphenyl) acetyl)piperidyl] -4-
 (4-pyrimidyl) -3- (4-chlorophenyl)pyrazole




15

Example D-29

5- [4-*N*- (2-hydroxy-2- (3-methoxyphenyl) acetyl)piperidyl] -4-
 (4-pyrimidyl) -3- (4-chlorophenyl)pyrazole


20

1078




Example D-30

5 5-[4-N-(2-hydroxy-2-(4-trifluoromethylphenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole



Example D-31

5-[4-N-(2-hydroxy-3-phenylpropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole




15

Example D-32


5- [4-*N*-(2-hydroxy-3-(4-hydroxyphenyl)propionyl)piperidyl]-
4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

5



Example D-33

10 5- [4-*N*-(2-hydroxy-3-imidazolpropionyl)piperidyl]-4-(4-
pyrimidyl)-3-(4-chlorophenyl)pyrazole




15

The synthesis of 2-substituted pyrimidinyl pyrazoles is shown in Scheme 2. Reaction of 2-methylmercapto-4-methyl pyrimidine 10 with *N*-Boc methyl ester of isonipecotic acid (1) under basic (base selected from
20 LiHMDS or LDA or *t*BuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether affords the desired ketone 11. Condensation of the ketone 11 with tosyl hydrazine under refluxing conditions in either toluene or

benzene affords the hydrazone 12. The hydrazone 12 is deprotonated under basic (base selected from LiHMDS or LDA or tBuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether and the anion is reacted in situ
5 with a suitably substituted benzoyl chloride 5 to afford, after mild aqueous work up, the desired and fully protected pyrazole 13. Oxidation of the 2-mercaptomethyl group present in 13 with oxidants selected from but not limited to Oxone[®], H₂O₂ or mCPBA in solvents such as
10 dichloromethane, acetonitrile or tetrahydrofuran affords the 2-methanesulfonyl pyrazole 14. The 2-methanesulfonyl group in 14 is conveniently displaced with various amines, aryloxides or alkoxides in solvents such as tetrahydrofuran, dioxane, dimethylformamide or
15 acetonitrile at temperatures ranging from 20 °C to 200 °C. Under these reaction conditions the tosyl protecting group on the pyrazole is also simultaneously deprotected. Aqueous workup affords the desired tosyl deprotected, 2-alkoxy, or 2-aryloxy or 2-amino substituted pyrazoles 15.
20 The alkoxides or aryloxides are generated from their respective alcohols or phenols with suitable bases such as LiHMDS, NaH, LDA or tBuOK in solvents such as tetrahydrofuran, dioxane or dimethylformamide. Deprotection of the remaining N-Boc group in 15 is
25 accomplished with trifluoroacetic acid or hydrochloric acid in solvents such as dichloromethane or dioxane to afford the pyrazole 16. Treatment of the pyrazole 16 with an acid chloride 7 in the presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC
30 or PyBrop with an additive such as HOBT or HATU and base

such as N-methylmorpholine or diisopropyl ethylamine) affords the desired final products 17.

Scheme D-2




The following 2-substituted pyrimidine compounds can be prepared as set forth above, particularly in a manner similar to that outlined above in Scheme D-2.

5

Example D-34

5 - [4-*N*-(2-hydroxyacetyl)piperidyl]-4-[4-(2-thiomethyl)pyrimidyl]-3-(4-chlorophenyl)pyrazole


10



Example D-35

15

5 - [4-*N*-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methanesulfonyl)pyrimidyl]-3-(4-chlorophenyl)pyrazole




Example D-36

20


5 - [4-*N*-(2-hydroxyacetyl)piperidyl]-4-[4-(2-amino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

1083




Example D-37

5 5- [4-*N*- (2-hydroxyacetyl)piperidyl] -4- [4- (2-
methylamino)pyrimidyl] -3- (4-chlorophenyl)pyrazole



10 Example D-38


5- [4-*N*- (2-hydroxyacetyl)piperidyl] -4- [4- (2-
isopropylamino)pyrimidyl] -3- (4-chlorophenyl)pyrazole



15 Example D-39


20 5- [4-*N*- (2-hydroxyacetyl)piperidyl] -4- [4- (2-*S*-
methylbenzylamino)pyrimidyl] -3- (4-chlorophenyl)pyrazole

1084




Example D-40

5 5 - [4-*N*-(2-hydroxyacetyl)piperidyl] -4 - [4-(2-*R*-
methylbenzylamino)pyrimidyl] -3-(4-chlorophenyl)pyrazole




Example D-41

10 5 - [4-*N*-(2-hydroxyacetyl)piperidyl] -4 - [4-(2-
methoxy)pyrimidyl] -3-(4-chlorophenyl)pyrazole



Example D-42

5- [4-*N*- (2-hydroxyacetyl)piperidyl] -4- [4- (p-fluorophenoxy)pyrimidyl] -3- (4-chlorophenyl)pyrazole




5

Example D-43

5- [4-*N*- (2-hydroxyacetyl)piperidyl] -4- [4- (p-fluoroanilino)pyrimidyl] -3- (4-chlorophenyl)pyrazole

10




In a manner similar to that outlined above in Scheme D-1, for the synthesis of the piperidine analogs 6, the aminocyclohexane analogs are prepared by substitution of 1 in Scheme D-1 with a suitably protected (Boc is shown) methyl or ethyl ester of *cis*-aminocyclohexane carboxylic acid 10 or *trans*-aminocyclohexane carboxylic acid 11 or *trans*-aminomethylcyclohexane carboxylic acid 12, which

affords the cis-aminocyclohexane **13**, or trans-aminocyclohexane **14** or the trans-aminomethylcyclohexane **15** respectively (Scheme 3). Suitable reductive alkylations on **13**, **14** or **15** with 1-1.5 equivalents of aldehydes or ketones in the presence of a reducing agent like sodium cyanoborohydride or sodium triacetoxyborohydride in solvents such as methanol, ethanol, acetic acid, tetrahydrofuran or dichloromethane lead to the desired mono-alkylated derivatives **16**, **17** or **18** respectively.




10

Scheme 3



The dimethyl derivatives **19**, **20** or **21** can be prepared by heating a solution of the aminocyclohexanes **13**, **14** or **15**




respectively in a mixture of formaldehyde and formic acid at temperatures ranging from 40 °C to 110 °C.



5

An additional group of compounds of interest includes the following:

10



15

Biological data for a number of compounds are shown in the following table. In vitro p38 alpha kinase inhibitory data are shown in the column identified as "p38 alpha IC_{50} (μM)". In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as: "HWB IC_{50} (μM)". In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF-release in the rat is shown in the column identified as: "ratLPS/%Inh@dose(mg/kg)" wherein the dose is in milligram per kilogram (mg/kg) administered by oral gavage, 4 hours before LPS challenge.

| Example | p38 alpha IC_{50} (μM) | HWB IC_{50} (μM) | ratLPS/%Inh @1.0 (mg/kg) | ratLPS/%Inh @5.0 (mg/kg) | ratLPS/%Inh @20.0 (mg/kg) |
|---------|------------------------------------|------------------------------|-----------------------------|-----------------------------|------------------------------|
| D-1 | 0.17 | | 83.0 | | |
| D-2 | 0.084 | 1.79 | 89.0 | 95.0 | |
| D-3 | 0.095 | 0.46 | 69.0 | 88.0 | 91.0 |
| D-4 | 0.91 | 1.55 | 42.3 | 83.0 | 99.0 |
| D-5 | 0.14 | 4.09 | 65.0 | 78.5 | 83.0 |
| D-6 | 0.083 | 1.33 | 82.0 | 96.0 | 100 |
| D-7 | 0.44 | >25.0 | | 0 | |
| D-8 | 0.18 | 1.3 | 65 | 85 | |
| D-9 | 1.63 | 15.8 | 5 | 86 | |
| D-10 | 3.95 | 14.8 | | 80 | |
| D-11 | 0.16 | 1.5 | 43 | 86 | |
| D-12 | 0.82 | 7.06 | 71 | 91 | |
| D-13 | 0.33 | 8.36 | 53 | 87 | |